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ABSTRACT 
Mycalamides A and B, isolated recently from a marine sponge of the 
genus Mycale, show strong in vitro and in vivo antiviral and antitumour 
properties. In this research, the chemistry of the mycalamides was explored 
and structure-activity relationships were determined, with the overall objective 
of producing analogues with better, or more selective biological activities. 
Along with this, the conformational behaviour of the mycalamides and a 
related compound, pederin, was examined. 
Simple esters, silyl and alkyl ethers of the hydroxyl and amide 
functionalities were prepared during initial studies. While many of these 
proved to be inactive, they were still useful as protected intermediates for use 
in acid and base catalysed hydrolysis reactions. In the course of the acid 
catalysed reactions, the acetal groups were partially or completely hydrolysed, 
eliminated, or exchanged and cleavage fragments were isolated. The 
exocyclic double bond was hydrogenated, epoxidised and rearranged in 
further studies. Base catalysed hydrolysis, elimination and rearrangement 
reactions were examined extensively and many interesting and unexpected 
products were obtained, including epimers and further cleavage fragments. 
Reduction and oxidation reactions also provided a source of important and 
potentially useful derivatives. 
In all, more than one hundred and ten derivatives of mycalamides A 
and B were prepared, characterised and tested for biological activity. The 
central portion of the structure, including the a-hydroxy amide and 
neighbouring groups, was shown to be crucial for the biological activity. A 
simple model structure was prepared containing some of these elements. The 
structure-activity relationships described in this work, combined with a better 
knowledge of the chemistry and conformational behaviour of these 
ix 
compounds, should together provide renewed stimulus for the ongoing study 
and development of these potential antitumour compounds. 
1 
INTRODUCTION 
0.1 OVERVIEW 
Nature, particularly terrestrial plants and animals, has long been 
realised to be the source of substances exhibiting various medicinal 
properties for the treatment of disease in mankind. However, the isolation and 
structure determination of the active constituents of various plants and animals 
has occurred only comparatively recently in our history. In particular, the 
treatment of diseases with specific drugs, chemotherapy, has made 
substantial progress only over the past fifty years 1-3, partly as a result of this 
expanding natural products research. Of the large number of antibiotics and 
other drugs available in today's society, a high proportion arise from natural 
sources or represent a modification of compounds from such sources4,5. An 
interesting feature of most naturally occurring biologically active compounds is 
that they are secondary metabolites, that is, they have no clearly recognisable 
function for the host organism, although there are cases where they could 
serve as weapons of defence6-12. 
The search for new and effective antiviral and anticancer agents has 
recently been extended to the consideration of marine sources, which 
represent a vast, new and relatively untapped resource. Prominent amongst 
the organisations involved in such investigations is the National Cancer 
Institute (NCI) in the United States of America, which has initiated large scale 
systematic bioactivity-directed screening programs of extracts and natural 
products worldwide, in an attempt to discover new compounds for the 
development of anti-H IV and anticancer drugs 1,13. The success of these and 
other initiatives worldwide can, at least to some extent, be measured by the 
large numbers of novel compounds reported in marine natural products 
2 
reviews 7-13, some of which are notable as much for the uniqueness or 
complexity of their chemical structure as for their cytotoxicity. (Note that the 
terms 'antitumour' or 'antineoplastic' refer to in vivo biological activity and the 
term 'cytotoxicity' is best used to describe similar activities against cells 
cultured in vitro13). These include such compounds as palytoxin, a complex 
polyhydroxy structure containing sixty-four chiral centres, the didemnins, cyclic 
peptides with varying potency as anticancer and immunosuppresive agents, 
the bryostatins, containing a unique bryopyran ring structure, and the 
halichondrins, to name a few13. 
Unfortunately, the limited natural abundance of some compounds has 
limited their further investigation and evaluation, at least until synthetic routes 
can be established. Furthermore, while many compounds show some in vitro 
biological activity, few have shown significant in vivo antitumour or antiviral 
activity, and it is of course the latter which is vital if the compound is to be 
clinically usefuJ1. Moreover, even those that show good in vivo activity may be 
relatively unselective in their action. This illustrates an important aspect, that 
to be an effective drug the compound must display selective toxicity against 
the tumour or virus, yet leave the normal cells of the host organism 
unaffected2. In particular, few antiviral agents have been developed because 
of the similarity between cells infected by a virus and normal ceJis3. 13, 14. 
Most success in the anticancer field has been confined to inhibiting the 
cell growth or cell division of tumours with rapidly dividing cells and to the 
treatments of various leukemias2. This may reflect the extensive early use of 
primary screening assays based on the mouse leukemia models, L 1210 and 
P388, and similar models, which represent rapidly dividing cell lines. These 
systems have some advantages, as they are fast and convenient in the in vitro 
stage, and results for the P388 assay can be readily compared with in vivo 
results, while the P388 test has been found to be predictive of over 95% of all 
3 
the known, clinically effective antitumour drugs13. However, less progress has 
been made against solid tumours containing slowly dividing cells, which 
develop in the lungs, colon, breast and brain1 .2. A recently developed 
screening protocol by the NCI, involving a large panel of various human 
tumour cell lines cultured in vitro, places more emphasis on solid tumour 
growth inhibition, so that progress in this area is expected in the future2,13. 
Compounds displaying selective in vivo activity against any one tumour may 
be advanced for human clinical trials, where both maximum and optimum 
. 
dosages are determined. Didemnin B was the first marine natural product to 
be tested in such trials13, but, in reality, few compounds ever reach this stage. 
Evidence from the pharmaceutical industry has shown that the most 
effective drug may not be the isolated compound, but some analogue of it4. 
This highlights the importance of performing chemical modifications on such 
compounds to obtain the therapeutically most useful derivatives, which may, 
for example, be more potent, more selective, less toxic, or give less side 
effects. In this process structure-activity relationships1,15 may be elucidated, 
which can provide some insight into the essential structural and 
conformational requirements 16 for the biological activity of the natural 
compound. This can ultimately lead to the design of more simple analogues4 
and an understanding of the active site geometry. 
0.2 STUDIES AT THE UNIVERSITY OF CANTERBURY AND 
BACKGROUND TO THE ISOLATION OF THE MYCALAMIDES 
0.2.1 GENERAL APPROACHES AND EARLY RESULTS OF THE MARINE 
CHEMISTRY GROUP 
Since its founding in 1975, the Marine Chemistry Group at the 
University of Canterbury has been involved in the search for new, biologically 
4 
active molecules. From 1982, in conjunction with the NCI and various 
pharmaceutical companies, this group has been involved in the collection of 
organisms from a variety of locations around New Zealand and other places, 
ranging from Western Samoa to Antarctica6, 17. These organisms were 
identified, and small extracts tested for antifungal, antibacterial and antiviral 
activity and for cytotoxicity (P388 antileukemic assay). An additional useful 
outcome of these collections was the generation of information on the 
incidence and disposition of biological activity within the marine phyla. A 
. 
marine natural products literature database was also set up to allow fast and 
convenient access to information on various organisms and compounds. 
The most interesting and suitable candidates from this screening 
programme were extracted in larger quantity, leading to the isolation and 
structure determination of their active constituents. More recently, a second, 
chemical prescreening method has been implemented prior to this step, to 
reduce the chance of re-isolating known compounds. One early lead led to a 
series of antiviral compounds from an ascidian, Rittere/la sigiflinoides, that 
were the same or similar to the eudistomins and also proved to have effective 
antitumour activity6. A series of cytotoxic sponge pigments, named the 
discorhabdins A (0.1) to E, were isolated from various species of Latrunculia, 
and one of these had significant antitumour activity6. 17. Other recently 
isolated compounds included some new ~-carboline (0.2) derivatives and a 
cytotoxic trithiane 17 (0.3). 
HO 
Discorhabdin A (0.1) ~-Carboline (0.2) Trithiane A (0.3) 
5 
One of the most significant discoveries, however, arose from the 
investigation of a sponge of the genus Mycale, which led to the isolation and 
structural determination of two new compounds, mycalamides A 18 (0.4) and 
B 19 (0.5). These compounds were found to have potent antiviral and 
antitumour activity and a collaborative effort was set up, involving this group 
and two pharmaceutical agencies in the United States, Harbor Branch 
Oceanographic Institution {Incorporated) and SeaPharm Incorporated, to 
develop the potential of these compounds. An investigation of these novel 
. 
compounds and their derivatives forms the major basis for the work described 
in this thesis and outlined in following sections. Before considering these 
compounds further, the biological assay systems employed in this work will be 
discussed, along with a review of compounds isolated from Mycale sponges 
worldwide. 
OH 
H 
§ CH3 
OCH3 
OR 
CH3 
R=H: Mycalamide A (0.4) 
R=CH3: Mycalamide B (0.5) 
0.2.2 BIOLOGICAL ASSAY SYSTEMS 
Three in vitro biological assay systems have been employed in the 
initial screening of extracts from marine organisms, as well as for testing 
routine samples. These include antifungal/antibacterial, antileukemic and 
antiviral assays, and enzyme inhibition assays have also recently become 
available, although these will not be discussed here. 
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0.2.2.1 ANTIFUNGAL/ANTIBACTERIAL ASSAYS 
Three bacteria were available for testing in this assay, Bacillus subtilis, 
Pseudomonas aeruginosa and Escherichia coli, along with three fungi, 
Candida albicans, Trichophyton mentagrophytes and Cladosporium resinae. 
The antibacterial or antifungal activity of compounds is tested by placing a 
paper disc (6 mm diameter), impregnated with the test solution, onto the 
surface of an agar plate which has been incubated with the microorganism in 
question. Solvent and antibiotic controls are prepared in a similar manner 
and the set of dishes incubated at 37oc for at least 24 hours. Antibacterial or 
antifungal activity is determined by measuring the size (in mm) of any 
inhibition zone from the edge of the central sample disc. 
0.2.2.2 P388 ANTILEUKEMIC ASSAY 
The in vitro P388 mouse leukemia assay system is used as an 
indication of potential antitumour activity, as discussed above. The sample 
solution, and up to eight successive two-fold sample dilutions, are added to 
wells containing the leukemia cells and these, along with media, solvent, cell 
and positive controls, are incubated at 35oc for three days. The number of 
healthy leukemia cells present in each well is determined by the addition of a 
yellow dye, MTT tetrazolium (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazo!ium bromide), which is reduced to a purple MTT formazan 
derivative by such cells. The amount of MTT formazan is then determined 
spectrophotometrically, by recording the absorbance at 540 nm, and this 
absorbance is then expressed as a percentage of the absorbance of the cell 
control. By plotting these percentages against the logarithm of the sample 
concentration, the concentration at which the number of healthy cells is 
reduced by 50% over the control (the ICso) may be interpolated. For crude 
7 
extracts, an ICso of less than 30 Jlg/ml is considered to represent an active 
sample and thus to be of potential interest13. 
0.2.2.3 ANTI VI RAL!CYTOTOXICITY ASSAY 
The antiviral/cytotoxicity assay system was employed on a BSC 
monkey kidney cell line, using two viruses, Herpes simplex virus Type I (a 
DNA virus) and Poliovirus Type I (an RNA virus}. Assay wells (13 mm 
diameter) were prepared, containing a cellular monolayer infected with virus 
. 
and overlaid with methyl cellulose, and sample-impregnated paper discs (6 
mm diameter} were introduced to lie directly upon the virus-infected cells. 
Following incubation at 35oc for 24 hours, the sizes of the viral inhibition 
and/or cytotoxic zones (measured from the central disc) were determined by 
microscopic examination. 
The antiviral assay result was presented on a scale, ranging from no 
discernible antiviral effect (-) to an effect over the whole well (WW), with 
intermediate zone sizes being classified as + (1-2 mm), ++ (2-4 mm) and +++ 
(4-6 mm). The cytotoxic effect of the sample on the BSC cells was also 
recorded on the same scale. This effect was further described according to 
the appearance of the affected cells, which would generally fall into one of 
twelve categories (C1-C12). All the compounds discussed in later chapters of 
this thesis displayed a single light cytotoxicity, type C7*, in which there were 
indistinct individual cells throughout the antiviral zone, with a misty 
appearance. The antiviral/cytotoxicity results will be reported in the form x 
(HSV result), y (PV result), z (cytotoxicity result), m (mass of the sample loaded 
onto the disc, in nanograms). 
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0.2.3 COMPOUNDS ISOLATED FROM MYCALE SPONGES 
Marine sponges of the genus Mycale have been the source of several 
diverse structures (selected structures from each class of compounds have 
been depicted below). Extracts of the sponge Mycale rota/is, from the 
Mediterranean Sea, yielded two diterpenoid compounds20, which were given 
the trivial names, rotalin A (0.6) and rotalin B. A Japanese Mycale sponge 
yielded two nucleosides21, mycalisines A (0. 7) and B, which inhibited the cell 
division of fertilised starfish eggs (an in vitro assay determining antitumour 
potential13), although it was asserted that these compounds were likely to be 
produced by symbiotic microorganisms. Three trisoxazole macrolides, 
mycalolides A (0.8), 8 and C, which were isolated from another Japanese 
Myca/e sponge22, were cytotoxic and antifungal, although possibly also of 
microbial origin. An Australian sponge, Mycale ancorina, was the source of a 
norsesterterpene cyclic peroxide (0.9), displaying antimicrobial activity23. 
Further investigations of this sponge also gave two more isomers of this 
compound24. Finally, various steroid glycosides (structures not given) were 
found from a Russian sponge, Myca/e purpurea25. 
As an appendix to this review, it should be noted that amongst the most 
recent work in our group was the further study of Mycale sponges, this time in 
the Fiordland area, which yielded another new biologically active compound 
and no mycalamides. This compound, a macrolide containing thiazole and 
amine functionalities and named pateamine (0.1 0), was also very cytotoxic 
and had other very promising biological activities26. The local regional 
variation in the active constituents of Mycale sponges of the same species is 
not yet understood and will be the subject of further investigations in the future. 
9 
H 
N:::?' ~I 
N N 
CN H 
.. -~'''' H,C~ 
H H3CO OH 
Rotalin A (0.6) Mycalisine A (0.7) 
H 
O~N 0 ;::::? ~t I CH3 OAc 0 OCH3 0 
Nx 0 
:::::,..._ 
0 OCH3 
Mycalolide A (0.8) 
C02H 
H 
Cyclic peroxide (0.9) 
Pateamine (0.1 0) 
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0.3 THE ANTIVIRAL AND ANTITUMOUR AGENTS, MYCALAMIDES 
A AND B, PEDERIN AND ONNAMIDE A 
0.3.1 ISOLATION OF MYCALAMIDES A AND B 
The routine screening of extracts of marine organisms determined that 
an extract of a marine sponge of the genus Mycale, collected from the Otago 
Harbour, had significant in vitro antiviral activity. Subsequent bioactivity-
. 
directed chromatography on a larger extract (reproduced from reference 18 in 
the Experimental section) led to the isolation of mycalamide A (0.4), a new 
compound with strong antiviral and antileukemic activity18. In our assay 
system, mycalamide A gave a whole-well antiviral zone at 5 ng/disk for both 
test viruses, with only very light cytotoxicity, and had a P388 ICso of 0.5 ng/ml 
(Table 0.1 ). By comparison, mycalamide A showed no antibacterial activity 
against the three bacteria listed above at 30 J.Lg/disk, and only weak growth 
reductions in the fungi Candida albicans and Trichophyton mentagrophytes 
for the same sample loading. 
The structure of mycalamide A was solved primarily using results from 
one- and two-dimensional NMR spectroscopy experiments, supported by 
infrared and high resolution mass spectroscopic analyses. It was also 
facilitated by a Chemical Abstracts on-line substructure search, which 
retrieved references to a remarkably similar structure, pederin (0.11 ), and its 
derivatives27,28. Pederin was isolated from a terrestrial blister beetle29,30 
(see below) and was initially the only known compound with comparable 
structure to mycalamide A. However, within weeks of the characterisation of 
mycalamide A, the isolation and structure of onnamide A (0.12), a closely 
related structure from a Japanese sponge of the genus Theone/la, was 
independently established31. 
1 1 
OH 
H 
• 
CH2 ~H CH3 
Pederin (0.11) 
Onnamide A (0.12) 
Further extractions of Myca/e sponge, in order to obtain a larger 
quantity of mycalamide A for extensive biological testing, led to the isolation 
and structure determination of mycalamide 8 (0.5), the 17-0-methyl derivative 
of mycalamide A19. Mycalamide 8 was a less abundant compound than 
mycalamide A (3-4 times less abundant), but displayed stronger biological 
activities, giving a whole-well antiviral response at between 1 and 2 ng/disk 
and having a P388 ICso of about 0.1 ng/ml in our assays (Table 0.1 ). Recently 
a sample of pederin (0.11) was also obtained and assayed for comparative 
purposes. This was found to give a whole-well antiviral response at between 
0.5 and 1 ng/ml and a P388 ICso of 0.07 ng/ml (Table 0.1 ), so that it was 
possibly slightly more active than mycalamide 8 (0.5). In view of the similar 
structures and in vitro biological activities of mycalamides A and 8 and 
pederin, it is useful to review the extensive amount of literature describing the 
known biological properties of pederin. 
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0.3.2 THE BIOLOGICAL ACTIVITY OF PEDERIN 
Pederin (0.11) was the active constituent of an East African beetle, 
Paederus fuscipes (known as the Nairobi eye fly), which secretes a vesicating 
fluid causing eye closure and red weals followed by severe blisters on the skin 
of human sufferers32. Although first isolated in 195229,33, the structure of 
pederin was not solved conclusively until 196834. To albino mice, pederin 
was reported to cause permanent hair loss, swelling to the head, and 
dermititis to the back33. However, by 1962 the first therapeutic uses of pederin 
had been reported35, including its use in the treatment of human bed sores, 
ulcers and gangrene, as well as its use against parasites. Several recent 
reports have been published36-38 which record the success of these 
dermatological applications, with 35% complete cures and 46% partial 
improvements reported in the treatment of human ulcers to the skin38. 
Pederin was found to be remarkably toxic to animals and plants. The 
L Dso (lethal dose for 50% of animals) for mice, rats and guinea pigs was 
about 2 J.tg per 100 g of body weight32,39. On in vitro cultures of He La (mouse 
tumoural) cells, concentrations around 1 ng/ml caused marked inhibition of 
cellular growth and severe cytological alterations40. Minimum inhibitory 
concentrations (MIG) of 1.5 ng/ml were later reported for a wider range of 
different strains and cell lines39. Also, levels of 0.5 J.tg/ml of pederin inhibited 
the germination of seeds of Lupinus a/bus and blocked cell division in root-tip 
meristems of Allium cepa35,39. The growth of tumours, induced by chemical 
agents in Lupinus a/bus and in Sarcoma 180 (mice), was also slowed or 
prevented40,41. However, pederin had no antibacterial power41. 
This striking toxicity of pederin prompted numerous studies into its 
mechanism of action. An analysis of DNA, RNA and protein synthesis in 
cellular systems, using radioactive precursors, established that pederin 
caused an almost immediate block in protein and DNA synthesis, without such 
13 
an effect on RNA synthesis39. In cell-free systems, the compound inhibited 
protein synthesis only, so that this was its major mechanism of action and the 
effect on DNA synthesis was secondary39. More detailed studies42-45 
strongly suggested that pederin inhibits the translocation of the peptidyl-tRNA 
from the amino-acyl (A) site to the peptidyl (P) site on the ribosome46-49. It 
was proposed that pederin binds to a ribosomal site42,47, causing inhibition of 
protein synthesis by steric hindrance, or by the inactivation of a specific protein 
involved in the translocation, or the inactivation of some other ribosomal 
functionSO. Further studies44,51 showed that pederin did not affect peptide 
bond formation or the binding of the aminoacyl-tRNA to the ribosome. 
The site of action of pederin and other protein synthesis inhibitors has 
been further investigated52. There is evidence that inhibitors such as 
cryptopleurine, emetine (0.13) and tubulosine may have a common or 
overlapping binding site, differing from the action and binding sites of pederin 
and cycloheximide (0.14) (a glutarimide antibiotic), which are believed to be 
more similar but non-identical47,52,53. 
0 
0 
OCH3 CH3 
Emetine (0.13) Cycloheximide (0.14) 
Pederin has been reported to induce cell fusion in human skin 
fibroplasts54, but this did not occur in ascidian eggs55. The cytological action 
14 
of pederin has also been studied41 .sa. Thus a great deal of information on the 
biological properties and action of pederin has been amassed. 
0.3.3 THE BIOLOGICAL ACTIVITIES OF MYCALAMIDES A AND BAND 
ONNAMIDEA 
0.3.3.1 ANTITUMOUR PROPERTIES 
The antiproliferative effects of mycalamides A and B (0.4, 0.5), pederin 
(0.11) and onnamide A (0.12) against four in vitro cell lines57 have been 
compared in Table 0.1. Note that P388 and HL-60 are mouse and human 
leukemia cell lines, respectively, HT-29 is a human colon carcinoma cell line 
and A549 is a human lung carcinoma cell line. The results show that 
mycalamide B is the most potent inhibitor, although the mycalamide A results 
were also in the nanomolar range. Onnamide A (0.12) showed strong P388 
activity, but reduced activity in the other assays. A sample of pederin was 
about twice as active as mycalamide B in the same assay58. 
These compounds were also tested for in vivo P388 antileukemic 
activity57, using tumour-infected mice. Mycalamides A and B showed 
moderate activity, giving 40% and 50% increases in lifespan after applying a 
schedule of daily injection for nine days at doses of 10 Jlg/kg and 2.5 Jlg/kg, 
respectively. Onnamide A was inactive in the in vivo P388 assay. Since 
mycalamide A displayed significant in vivo activity against P388 leukemia, it 
was also tested against other in vivo tumour models57. Good responses were 
observed against the models B16 melanoma and M5076 ovarian carcinoma 
(Table 0.2), but less activity was shown against colon 26 carcinoma, although 
this activity was still considered to be significant. Mycalamide A was also 
particularly active against solid tumour cultures. The growth of Lewis lung, 
M5076 and Burkitt's lymphoma tumours were markedly inhibited by 
administration of mycalamide A and moderate activity was observed against 
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MX-1 and CX-1 human tumour xenografts. Thus mycalamide A was active 
against nine of the eleven tumour models tested. Mycalamide B was active 
against six of eight tumour models, with similar levels of response to 
mycalamide A, but onnamide A was active in only three of seven such assays. 
In view of this impressive in vitro and in vivo antitumour activity, further 
work was performed to establish the mechanism of action of these 
compounds57. It was found that these compounds were potent inhibitors of 
protein synthesis, with DNA synthesis but not RNA synthesis also being 
. 
affected in cellular systems, just as was found for pederin. (It was noted that 
mycalamide A did not intercalate into DNA or disrupt deoxynucleoside 
synthesis). Thus inhibition of protein synthesis was a probable cytotoxic 
mechanism for this class of compounds. 
0.3.3.2 ANTIVIRAL ACTIVITY 
Further testing of the in vitro antiviral properties of mycalamides A and 
B6 showed that mycalamide B was more active than mycalamide A against 
Vesicular stomatitis virus (VSV) and against Coronovirus A59, a mouse 
hepatitis (RNA) virus (Table 0.2). Mycalamide A was quite active against 
human Cytomegalovirus14 (CMV), without any associated cytotoxicity59. 
However mycalamides A and B displayed no anti-HIV (anti-AIDS) activity58. 
A partially purified extract of mycalamide A {"'2%) was also found to 
have significant in vivo activity against Coronovirus Asg6,18. All infected mice 
which had been administered 0.1 mg/kg of this sample daily for nine days 
remained alive after fourteen days, whereas the control group had died after 
eight days. However, it was noted that the toxicity level of this sample was not 
ideal and no result was obtained with pure mycalamide A. 
Mycalamides A and B were also able to cause Harvey sarcoma virus-
transformed60 NRK (mouse) cells to change their morphology from the 
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transformed shape to the normal one61 (at concentrations of 10 and 1 ng/ml, 
respectively). Cycloheximide (0.14) and its acetyl derivative also showed this 
type of activity62 and all four compounds were found to inhibit the biosynthesis 
of a p21 protein preferentially61,62. The concentrations required for 
morphological change were similar or higher than those required for inhibition 
of protein synthesis so that this was probably the mechanism of action. 
However some other protein synthesis inhibitors did not display this 
activity61,62. 
0.3.3.3 OTHER BIOLOGICAL ACTIVITIES 
Mycalamides A and B were both found to be strongly 
immunosuppressive. (There is current interest in new immunosuppressants 
such as FK50663-66 for use use in preventing graft rejection, following bone 
marrow and organ transplants). This immunosuppressive property was 
observed in skin grafting experiments on mice58, where mycalamide A 
appeared to be more useful than mycalamide B in that it gave good 
acceptance of grafts with less toxicity. In one animal treated with mycalamide 
A, complete graft tolerance was achieved, resulting in hair growth from the 
grafted skin. However, there was significant reduction in bone marrow cell 
numbers and there were some additional complications. Mycalamide A did 
not have activity in topical skin models such as wound healing or burns58. 
Mycalamide A was also active in vitro against a strain of malarial 
parasite Plasmodium falciparum with an ICso of 0.9 ng/ml, but apparently did 
not have any in vivo activity58. Other protein synthesis inhibitors, including 
emetine (0.13), cycloheximide (0.14 ), anisomycin and pederin also show 
some activity against various parasites35,53,58,67. 
Thus the biological activities of mycalamides A and B, along with 
pederin and onnamide A, are evidently related to their inhibition of protein 
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synthesis. The antiviral and antitumour properties of protein synthesis 
inhibitors have been known for some time. In particular, Grollman53 stated 
that all inhibitors of protein synthesis in eukaryotes possessed some degree of 
in vivo antitumour activity, but that the chemotherapeutic usefulness of these 
compounds was always limited by their cytotoxic action. Emetine (0.13), for 
example, which has been successfully used for over three hundred years in 
the treatment of amoebiasis, has a cardiotoxic action53, as has diptheria toxin. 
Protein synthesis inhibitors were also noted to manifest antiviral activity in cell 
. 
cultures, and in some cases in vivo, by inhibiting the formation of enzymes 
used by the virus, or by inhibiting the synthesis of proteins required for the 
synthesis of viral RNA53. However, protein synthesis in the host cell is also 
usually affected, which is certainly not ideal for an antiviral agent2. 13. Thus 
protein synthesis inhibitors in general have not been useful as antiviral 
agents, although several are either in use, or remain of interest as antitumour 
agents. Therefore, although mycalamides A and B were originally isolated as 
antiviral agents18, they have also been patented as potential antitumour 
agents68,69, which probably reflects the more likely property considered for 
their ongoing development and possible therapeutic usefulness. 
0.4 SYNTHETIC STUDIES ON MYCALAMIDES A AND 8 
0.4.1 OVERALL OBJECTIVES AND PROPOSALS 
The work in this thesis will describe primarily the synthetic modifications 
of mycalamides A and B, including an exploration of the chemistry of these 
compounds and the preparation and characterisation of a range of derivatives 
to be tested for their biological activity. There were several specific aims to be 
considered in this work. Firstly, the ultimate aim was to produce analogues 
with better antitumour properties, that is, compounds which could be 
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therapeutically more useful, whether for their improved potency, reduced 
toxicity, or reduced side effects2.4. Secondly, it was hoped to discover the 
structural requirements for antitumour activity by determining overall structure-
activity relationships1,15. Another, third, important consideration was to 
determine the conformational features of the active compounds16,70,71. A 
fourth objective was to obtain a crystalline heavy atom mycalamide derivative 
for x-ray structural analysis, since this would enable a confirmation of the 
absolute stereochemistry and a comparison of the solid state and solution 
. 
conformations70,72. The potential to incorporate isotopic labels, such as 
deuterium, was also a consideration for possible future pharmacokinetic 
studies73. Finally, the data obtained from these investigations would be used 
in the synthesis of some simple model compounds, which would incorporate 
some essential structural features of the mycalamides. 
There are numerous examples in the literature74,75 of the derivatisation 
of biologically active molecules to elucidate structure-activity relationships, 
and these will not be discussed here. However, in considering the structure of 
the mycalamides, it is apparent that these are quite complex compounds, 
containing several functional groups. Thus it was proposed that initial 
reactions should concentrate on the preparation of simple ethers and esters 
for the protection of the hydroxyl groups76-78 of mycalamides A and B. The 
size, polarity, stability and position of these substituents were factors which 
could be varied in initial studies75,76. These protected intermediates would 
then become the substrates for acid and base catalysed substitution, 
elimination, rearrangement and hydrolysis reactions, as required. The 
potential cleavage of the molecule into various fragments79, which could be 
tested for their biological activities was a further aim of this work. Reduction 
and oxidation reactions would also be considered in this investigation and, 
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where possible, the results compared with those from similar studies on 
pederin. 
0.4.2 MATERIALS AND METHODS 
A limited supply of purified mycalamides A and B ( ~250 mg mycalamide 
A, 120 mg mycalamide B) was available from a large scale commercial 
extraction of Mycale sponge (mycalamide A was present at about 5 mg/kg of 
sponge). This supply was both very valuable and very toxic (adverse skin 
. 
reactions, including acute dermatitis- rashes to the skin which led to extensive 
blistering and swelling to the eyes, were encountered several times during this 
work with the mycalamides). Therefore most reactions were performed on the 
milligram scale, typically 0.5-5 mg, using small scale equipment. High-
yielding and accurate chromatographic separation techniques were also 
employed, including analytical and preparative silica gel thin layer 
chromatography (TLC) and reverse phase high performance liquid 
chromatography (HPLC). 
A strong emphasis was placed on the use of one- and two-dimensional 
nuclear magnetic resonance (NMR) spectroscopy experiments for the 
structure determination and characterisation of derivatives, supported by high 
resolution mass spectroscopy measurements wherever possible. In particular, 
homonuclear correlation spectroscopy (COSY) experiments80,81 were 
routinely performed to unambiguously assign the coupled resonances in the 
1 H NMR spectra, together with nuclear Overhauser enhancement (NOE) 
experiments82 to determine the stereochemistry and solution conformations of 
derivatives in various solvents19,72,83,84. (Some molecular modelling 
techniques were also investigated as methods to probe the conformational 
behaviour of various mycalamide derivatives and related compounds). A 1 H-
detected heteronuclear multiple quantum coherence (HMQC) experiment85, a 
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1 H-detected heteronuclear multiple bond connectivity (HMBC) 
experiment86,87, and a reverse detection probe, were recent additions to the 
software and hardware of the Varian XL-300 NMR spectrometer available in 
this department and these proved invaluable for the correlation of 1 H and 13C 
resonances for several mycalamide derivatives. The main advantage of these 
experiments over the analogous 13C-detected HETCOR88 and XCORfE87,89 
(long range HETCOR) experiments was the large increase in sensitivity, 
enabling successful results for only 1-3 mg of sample. In some cases these 
experiments even enabled the accumulation of 13C NMR spectral data where 
the sample was too small to record a 13C NMR spectrum directly. 
In all, more than 110 derivatives of mycalamides A or 8 were 
synthesised during the course of this research and each was characterised 
and tested for its biological activity, enabling some useful structure-activity 
relationships to be elucidated. Part of the structure of mycalamides A and B 
which seemed to be essential for the biological activity was then targeted for 
synthesis, based on procedures developed for the synthesis of pederin90. 
This led to the synthesis of some simple model compounds. Unfortunately no 
x-ray crystal structure determination of a mycalamide derivative was achieved 
during the course of this work. However, the recently reported total synthesis 
of mycalamides A and 891 has enabled the relative and absolute 
stereochemistries of these structures to be verified. Hopefully this 
achievement and the work described here will stimulate a more complete 
assessment of the potential of these compounds and their derivatives as 
antitumour agents. 
Table 0.1 Biological activitiesa of mycalamides A and B, onnamide A and 
pederin against various in vitro cell lines. 
Compound 
Mycalamide A 
Mycalamide B 
Onnamide A 
Pederin 
P388 (UOC) 
0.5 
0.1 
0.07 
P388 
2.6 
0.7 
1.9 
0.3 
ICso (nglml) 
HL-60 
1.5 
0.8 
20 
HT-29 
1.4 
0.8 
140 
A549 
1.8 
0.3 
140 
aResults from reference 47, except UOC values (results from our assays). 
Table 0.2 Antitumour activities of mycalamide A (in vivo)a. 
Tumour type Site Dose schedule Best response Dose (w,g!kg) 
P388 leukemia . b daily (9 doses)c 56% ILSd 10 l.p. 
B16 melanoma i.p. every 4 days (9 doses) 145% ILS (40%d) 30 
M5076 reticulum cell i.p. every 4 days (3 doses) 133% ILS (40%) 60 
Colon 26 carcinoma i.p. every 4 days (3 doses) 49% ILS (20%) 60 
B16 melanoma s.c.b every 4 days (9 doses) 0.77 TIC TWid 3.8 
B16 melanoma S.C. every 4 days (9 doses) 43% ILS 7.5 
Lewis lung S.C. daily (9 doses) 0.15 TIC TWI 20 
M5076 reticulum cell S.C. every 4 days (3 doses) 0.15 TIC TWI 120 
MX-1 mammary xeno. S.C. every 4 days (3 doses) 0.21 TIC TWI 80 
CX-1 colon xenograft S.C. every 4 days (3 doses) 0.29 TIC TWI 60 
LX-1 lung xenograft S.C. every 4 days (3 doses) 0.76 TIC TWI 7.5 
Burkitt's lymphoma S.C. every 4 days (3 doses) 0.19 TIC TWI 20 
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aResults from reference 57. bsite of tumour, i.p.=intraperitoneal , s.c=subcutaneous, injected 
one day prior to treatment, except the last four tumours, inoculated 2-3 days prior to treatment 
csite of injection of mycalamide A was i.p. except M5076 s.c. tumour when it was i.v. 
diLS=increase in life span compared to control experiment. Values in brackets refer to% cures 
TIC TWI=tumour weight index, based on a ratio of tumour volumes of test versus control 
samples. 
Table 0.3 Antiviral activitiesa of mycalamides A and B and pederin (in vitro) 
and their cytotoxicities. 
Compound mass (ng) PV1 (UOC) HSV (UOC) A 59 HSV VSV CMY 
Mycalamide A 10 ++,+ 
5 WW,+ WW,+ 
2 +,+ +,+ ++,- +,+ 
0.5 +++,-
Mycalamide B 2 WW,+ WW,+ ++,- ++,- ++,+ 
1 +++,+ +++,+ 
Pederin 1 WW,+ WW,+ 
0.5 +++,+ 
aResults listed in the order antiviral result, cytotoxicity, where -,+,++,+++,WW=antiviral zone 
size or cytotoxic effect (see text) for a given sample mass loaded onto an assay disk. Note that 
UOC refers to a result in our assays, the remaining results were from references 6, 58 and 59. 
For a description of the viruses, see text. 
CHAPTER 1 
STRUCTURES AND SOLUTION 
CONFORMATIONS OF MYCALAMIDES 
A ·AN.D B, PEDERIN AND 
PEDERIN DIBENZOATE 
1.1 INTRODUCTION 
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The structural similarities between mycalamides A and B, onnamide A 
and pederin were noted in the Introduction. These compounds are all strong 
inhibitors of protein synthesis47,57, a property which is thought to be the basis 
of the biological activities of these compounds. Therefore it is likely that some 
common substructure in these compounds is involved in interactions with the 
same active site15. These structures consist of various flexible chains and six-
membered rings which would appear to permit many different conformations. 
However, it is likely that only one conformer is involved in specific receptor 
binding to generate the biological response70,71. This is important because 
conformationally restricted analogues of biologically active compounds can 
show higher levels of activity or selectivity than the original compound70,92. 
The main aim of this study was to establish the major solution conformations of 
mycalamides A and Band pederin, using a combination of NMR spectroscopic 
techniques with molecular mechanics calculations, to determine whether there 
were similarities in overall shape. The solid state conformation of pederin di-
p-bromobenzoate (1.1 ), as found by x-ray crystallography93, has also been 
compared with the major solution conformations of pederin dibenzoate (1.2) 
to illustrate the influence of intermolecular forces. 
OR 
H 
OCH3 
= 
CH3 
OR 
R=COCsH4Br: Pederin di-p-bromobenzoate (1.1) 
R=COCsHs: Pederin dibenzoate (1.2) 
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The isolation and structure determination of my calami des A and B 18,19 
were not part of this research. However, the assignment of the 1 H and 13C 
NMR spectra of both compounds in various solvents, using two-dimensional 
correlation and NOE experiments, forms an important part of the 
conformational analysis described here and is therefore considered in detail. 
This also serves as a useful background to the use of molecular modelling 
and various NMR spectroscopic techniques, and in particular to the results 
obtained for mycalamides A and B, which form some basis for work performed 
on various derivatives, as described in subsequent chapters. Infrared (IR) and 
mass spectroscopic (MS) results for mycalamides A and B are also analysed 
in this chapter. 
The structure of pederin27,94,95 was initially based simply on the 
analysis of signals in the 1 H NMR spectrum, coupled with chemical evidence, 
and on the results from various other analyses, such as infrared and mass 
spectroscopies and elemental analysis. The structure was later completely 
solved by an x-ray crystallographic study34. However, there had not been a 
complete assignment of the 1 H NMR spectral data, nor had any assignment of 
the 13C NMR spectral data been reported. These assignments are described 
here as the first step in analysing the solution conformations of pederin and 
pederin dibenzoate (a collaborative effort), which complemented work on 
mycalamides A and B. 
24 
1.2 STRUCTURE OF MYCALAMIDES A AND 8 
1.2.1 INFRARED AND MASS SPECTROSCOPIC ANALYSES 
1.2.1.1 INFRARED SPECTRA OF MYCALAMIDES A AND B 
The infrared (IR) spectrum of mycalamide A was recorded initially18 as 
a film. The major features of this spectrum were:-
i) a carbonyl stretching band at 1690 cm-1, and a weaker band at 1540cm-1 
. 
indicative of a (secondary) amide group96, 
ii) a broad band between 3100 and 3700 cm-1 indicating NH and OH stretches 
broadened by hydrogen bonding, and 
iii) several bands from 1040 to 1100 cm-1, representing C-0-C stretches. 
There were also bands around 2960, 1470 and 1390 cm-1, indicative of 
various C-H stretching and bending vibrational modes, respectively96. The 
film IR spectrum of mycalamide B19 was almost identical, as expected from the 
similarity of their structures. 
The IR spectra of mycalamides A and B were also recorded in 
chloroform solution. The spectrum of mycalamide A showed a sharper peak at 
3420 cm-1, probably due to the amide NH stretch, superimposed on a broader 
band, and the amide carbonyl stretch was at 1680 cm-1. Otherwise this 
spectrum was similar to the one described above. Similarly, the solution IR 
spectrum of mycalamide B showed a sharp peak at 3380 cm-1, superimposed 
on a broader band. Note that in both spectra the characteristic C=C band for 
the terminal alkene was not observed, being weak and hidden by the large 
amide carbonyl band. 
Thus the major focus of these IR spectra of mycalamides A and B was 
the position of the amide carbonyl stretch. This was of reasonably high 
frequency in both the solution and film IR spectra, and this could be caused by 
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the presence of neighbouring oxygenated carbons, competing for some 
electron density from this group96. 
1.2.1.2 MASS SPECTRA OF MYCALAMIDES A AND B 
Mycalamides A and B were analysed by several modes of mass 
spectroscopy. High resolution electron impact mass spectroscopy (HREIMS) 
of mycalamide A gave a weak molecular ion at m/z 503.27220 daltons, 
corresponding to a molecular formula of C24H41 N01 O· However, under these 
. 
ionisation conditions there was a facile loss of 32 mass units, corresponding to 
a loss of methanol from the C6 acetal (Scheme 1.1 ), as reported for pederin 
and its derivatives97. This elimination, forming a double bond between C5 
and C6, would be assisted by the presence of the exocyclic double bond. 
Thus for mycalamide A the peak at m/z 471 was dominant. Similarly, for 
mycalamide B, a strong ion at m/z 485.2634 daltons was the dominant high 
mass peak under these conditions, giving a molecular formula for the parent 
compound of C2sH4sN01 O· 
Although an analysis of the fragmentation pattern of pederin under 
analogous ElMS conditions was reported97, this was rather complex, and so a 
complete analysis of the mycalamide A and B spectra was not attempted. 
However, there was a common dominant peak at m/z 155 in the spectra of all 
three compounds, corresponding to a fragment obtained by a cleavage of the 
C6-C7 bond, and a smaller peak at mlz 123, corresponding to a loss of 
methanol from this fragment (Scheme 1.1 ). Another common peak in these 
spectra was at mlz 208, reported to represent a rearranged fragment, involving 
the left hand portion to C1 0 and containing an oxazolidinone ring. In the 
DEIMS spectrum of mycalamide A, there were other significant low mass ions 
at m/z 147, 215 and 226 which were not assigned, and an m/z 229 ion in the 
spectrum of mycalamide B. 
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Scheme 1.1 El mass spectroscopy fragmentation of mycalamides A and B. 
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The fragmentation pattern near to the parent ion was better understood, 
being assigned on the basis of high resolution results and by comparison with 
similar results for pederin97. For mycalamide A, there were peaks at mlz 440 
and 422, which probably represented successive cleavages along the C16-
C18 sidechain (Scheme 1.1) from the major M+-CHaOH ion (m/z 471 ). In 
particular, cleavage of C17-C18 would give an m/z440 ion, then a loss of H20 
across C16-C17 could give rise to the m/z 422 ion. Similarly, for mycalamide 
B, peaks at m/z 454 and 422 would correspond to a cleavage of the C17 -C 18 
. 
bond from the major M+-CHaOH ion (m/z 485), then a loss of CHaOH across 
C16-C17, as above. There were also further peaks for mycalamide Bat m/z 
396, 366 and 348, which could be accounted for by cleavages of the C15-C16 
bond and cleavages of the C1 0-C12 methylene acetal. However, there were 
also likely to be other combinations which could account for some of these 
smaller ions, so that these fragmentations were not studied further. 
The mass spectrum of mycalamide A under DCI (desorption chemical 
ionisation) conditions, using ammonia (NHa) as the reagent gas, gave an 
adduct peak of low intensity at m/z 521 (MNH4+) and a much stronger peak at 
m/z 489, corresponding to a loss of methanol, as above (MNH4+-CHaOH). If 
the reagent gas was deuterated ammonia (NDa), then the adduct ions 
maximised in intensity at m/z 529 and 497, so that this indicated the presence 
of four exchangeable protons in mycalamide A. For mycalamide B, DCIMS, 
using NHa as the reagent gas, gave peaks at m/z 535 (MNH4+), 503 (MNH4+-
CHaOH) and 486 (MH+-CHaOH). With ND3 as the reagent gas these peaks 
shifted to m/z 542, 510 and 490, requiring the presence of three exchangeable 
protons for this compound. If the reagent gas was methane (CH4) then little 
low mass material was obtained and no adduct ions were observed, so that 
the MH+-CHaOH peak was dominant in the spectra of mycalamides A and B. 
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Mass spectroscopy under fast atom bombardment (FAB) ionisation 
conditions seemed to be most useful for these compounds, since sodium or 
potassium adduct ions (MNa+, MK+) were found in good intensity, in addition 
to other peaks showing loss of methanol. Therefore FABMS was probably the 
method of choice for the mass spectroscopic analysis of mycalamide 
derivatives. 
1.2.2 ASSIGNMENT OF THE 1 H NMR SPECTRA OF MYCALAMIDES A AND 
BINDEUTEROCHLOROFORM 
The 1 H NMR spectrum of mycalamide A, as recorded in CDCI3, is 
shown in Figure 1.1, while the data obtained are listed in Table 1.1. The 
broad doublet at o7.49 ppm was assignable to the proton attached to the 
secondary amide nitrogen, since this resonance was removed slowly on 
addition of D20 to the sample98. The remaining three exchangeable protons 
were necessarily hydroxyl protons from the molecular formula, but their 
resonances were not observed in this 1 H NMR spectrum. 
A homonuclear correlation spectroscopy (COSY) experiment80,81 was 
performed to assign the coupled resonances, and the spectrum obtained is 
shown in Figure 1.2. There was a connectivity from the amide NH resonance 
to the triplet at o5.87 ppm, and from the latter to a doublet of doublets at o3.86 
ppm, so that these were assignable to the H1 0 and H11 protons respectively. 
This series of connectivities continued through to H12 and H13. A similar 
series of connectivities established the linkage of resonances from H15 to 
H 18, and the assignment of the H16 resonances was obvious from their 
chemical shifts, thus locating the remaining resonances in this chain. There 
were three remaining coupled networks in the COSY spectrum. One involved 
the methyl doublets at o1.19 and 0.99 ppm, being coupled to resonances at 
o3.98 and 2.23 ppm respectively. These represented the C2 and C3 methyl 
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groups being coupled to the H2 and H3 protons, but the expected correlation 
between the H2 and H3 resonances was absent in the COSY spectrum, 
probably because the coupling constant was small (2.7 Hz)81 ,99. A second 
spin system involved the multiplets at o4.84 and 4.72 ppm, which were weakly 
coupled to a two proton multiplet at o2.36 ppm. These multiplets were 
assigned to the exocyclic methylene and C5 methylene protons respectively, 
which were in an allylic relationship. The remaining isolated spin system 
involved the coupled resonances at o5.13 and 4.87 ppm, which corresponded 
. 
to signals for the methylene acetal protons contained in the C1 O-C12 dioxan 
ring. 
The assignments of the two methoxyl resonances and the 
stereochemistry associated with the exocyclic methylene resonances were 
achieved by NOE experiments. In particular, irradiation of the H7 resonance 
(the singlet at o4.31 ppm) enhanced the methoxyl resonance at o3.29 ppm, 
whereas irradiation of one of the two methyl singlets (assigned to groups at 
C14) enhanced the resonance at o3.55 ppm, so that these resonances could 
be assigned to groups at C6 and C13, respectively (Table 1.2). Similarly, 
irradiation of the H3 resonance gave an enhancement of the more downfield 
4=CH resonance, at o4.84 ppm, and irradiation of the H2S multiplet enhanced 
the resonance at o4. 72 ppm, so that these were designated Z and E, 
respectively. (These assignments represent an application of the sequence 
rules for prochirality to the double bond substituents 1 OO). The stereochemistry 
associated with the C14 methyl and 1 O-OCH2 methylene proton resonances is 
discussed in a following subsection describing the solution conformations of 
the trioxadecalin ring system. Thus the complete assignments of the 1 H NMR 
spectrum of mycalamide A have been listed in Table 1.1. 
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The 1 H NMR spectrum of mycalamide B was similar to that of 
mycalamide A, but contained three methoxyl resonances. A COSY 
experiment was performed, which enabled assignments of all the coupled 
resonances (Table 1.1 ), and this indicated that there were significant shifts (in 
ppm) in the HS (-0.1 ), H15 (-0.2) and H17 (-0.5) proton resonances, compared 
to data for mycalamide A. However, the observed chemical shifts of the other 
resonances were all within 0.1 ppm of data recorded for mycalamide A. These 
chemical shifts were consistent with the location of the third methoxyl group at 
C17, since methylation of an hydroxyl group is known to cause an upfield shift 
in the a-proton resonance 1 o 1. The assignments of the three methoxyl 
resonances were obtained from the results of NOE experiments, as described 
above for mycalamide A. Irradiation of the third methoxyl resonance, at 83.24 
ppm, in an NOE experiment gave enhancements of the H216 and H18 
resonances (Table 1.2), further confirming the location of this methoxyl group 
in the mycalamide B structure. Interestingly, the resonances for the two HS 
methylene protons were resolved in the 1 H NMR spectrum of mycalamide B, 
and only one of the two protons showed allylic coupling to the exocyclic 
methylene protons. These points will be considered further in the following 
conformational analysis. 
1.2.3 ANALYSIS OF THE SOLUTION CONFORMATIONS OF MYCALAMIDES 
A AND B BY 1H NMR SPECTROSCOPY 
The solution conformations of mycalamides A and B (in CDCI3) have 
been examined initially by combining an analysis of the vicinal proton-proton 
coupling constants with the results of extensive NOE experiments. The basis 
for the former analysis stems from the well known relationship relating the size 
of the three-bond coupling constants to the dihedral angle between the 
protons, as documented in the Karplus equation102. Recently, the precision of 
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this equation has been enhanced by an empirical generalisation, which 
includes correction terms for the electronegativities of substituents in the a and 
~ positions and for the orientations of these substituents103. This calculation 
lends itself to computer programming and is a feature of many molecular 
modelling programs. 
The solution conformation of the 01-C6 tetrahydropyran ring of 
mycalamides A and B was elucidated mainly from the results of NOE 
experiments (Table 1.2). In particular, irradiation of the H2 resonance of 
. 
mycalamide A caused an enhancement of the C6 methoxyl resonance and 
irradiation of the C3 methyl resonance enhanced the H2S multiplet, and vice 
versa. These NOE interactions suggested that H2, 6-0CHa, 3-CHa and one 
HS proton were axial substituents, so that this ring was required to be in a 
chair conformation, as shown in Figure 1.3. 
Figure 1.3 1 H-1 H NOE interactions and solution conformation of the 01-C6 
tetrahydropyran ring in mycalamides A and B 
Other NOE interactions between substituents of this 01-C6 ring in both 
mycalamides A and B were supportive of this proposed conformation (Table 
1.2). In mycalamide B, where the two HS resonances were resolved, it was 
the more upfield HS resonance which was enhanced on irradiation of the C3 
methyl resonance, so that this could be assigned to the axial HS proton (H5a). 
Only H5a showed significant coupling to the 4=CH protons, and this was 
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consistent with the dependence of the size of the allylic coupling constant1 02 
on the angle <j> in Figure 1.4. In particular, the magnitude of this coupling 
constant is zero for <j>=O or 1aoo, and maximum (~3Hz) for <j>=90o, since it is 
related to the degree of cr-n orbital overlap, and is similar for both the cisoid 
and transoid coupling paths1 04. 
Figure 1.4 Angular dependence of the allylic coupling constant 
The proposed chair conformation for the 01-C6 ring is favoured by two 
factors. Firstly, the bulky C7 sidechain is in the favoured equatorial position to 
minimise unfavourable steric interactions and, secondly, the C6 acetal 
methoxyl oxygen is axial, as favoured by the anomeric effect1 05,106. The 
anomeric effect is the unexpected preference displayed by polar substituents, 
X, at the 2 position of tetrahydropyran ring systems, to adopt an axial 
orientation, and is believed to result mainly from unfavourable polar effects 
operating in the equatorial form which destabilise that orientation 106. 
However, there is also believed to be significant stabilisation of the axial form 
by overlap of the antibonding orbital of the C-X bond with the lone pair orbital 
on the ring oxygen atom105,106. The exo-anomeric effect105, which describes 
the general preference for a methoxyl group in this position to adopt a 
conformation in which the O-CH3 bond lies anti-coplanar to the C2-C3 bond of 
a general tetrahydropyran ring, is probably also effective in the present 
system. There is evidence for such a conformation of the C6 methoxyl group 
(Figure 1.5a) from the observed strong NOE interactions between this 
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methoxyl group and both H2 and H7, whereas there was only a very weak 
interaction between this group and the equatorial HS proton. 
Figure 1.5 Newman projections for the major staggered conformers about 
the C6-C7 bond in mycalamides A and B 
CH3 T CH3 
o~~'H HW' ~CH30 H'~ H HO O. H) H ~N o-..........OH 
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The conformations of the C7-N9 chain portion were less clearly defined. 
However, there was a strong NOE interaction between the H7 and NH protons 
which suggested that these protons were mainly in a gauche relationship and 
that the conformation about the amide C-N bond was mainly Z (a trans 
relationship of the alkyl substituents)1DO. In fact, this Z conformation about the 
amide bond has been reported to be strongly preferred over the E 
conformation for N-monosubstituted amides in generaPD7. The conformations 
about the C6-C7 bond could also be deduced from NOE interactions. It was 
noted above that there was a strong interaction between the H7 and C6 
methoxyl protons. Irradiation of H5a (in mycalamide B) gave enhancements of 
the H7 and NH resonances, whereas these resonances were not significantly 
enhanced on irradiation of H5e. These data required the presence of two of 
the three staggered rotamers about the C6-C7 bond, as shown in Figure 1.5. 
At the other end of this chain, the N9-C1 0 bond was required to be 
approximately fixed, with the NH and H1 0 protons in an anti relationship, since 
the H10-H11 vicinal coupling constant was sufficiently large (9.8 Hz)102,1D8. 
There was no significant NOE interaction between these protons. Therefore, 
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although this portion of the structure was potentially rather flexible, this study 
has shown that it consists of only a few major solution conformations. 
The trioxadecalin ring system of mycalamides A and B was required to 
be cis-fused109-111, with the two rings in chair conformations, as in Figure 
1.6a, in order to satisfy the observed NOE interactions across these rings, 
Hi 0-1 0-0CH, Hi 0-H13, Hi 0-H15, 1 O-OCH-H13, H12-14-CH3 and H13-H15 
(Table 1.2). · These NOE interactions required that the downfield 1 0-0CH 
resonance (enhanced) be assigned to the axial pro-R proton and that the 
. 
more upfield 14-CHa resonance be assigned to the axial pro-S methyl 
group 112. These assignments were confirmed by further NOE interactions, 
such as from H13, 13-0CHa and H15 to the 14-CHaR group only. Also, 
irradiation of 1 0-0CHS gave an enhancement of the 1 0-0CHR resonance 
only. Irradiation of H11 gave strong enhancements of the NH and H12 proton 
resonances, but not H1 0 or H16, consistent with the proposed anti 
relationships between NH and H1 0 and between H1 0 and Hi 1 and the 
proposed chair conformation of the C11-C16 ring. 
Figure 1.6 1 H-1 H NOE interactions and possible chair-chair conformations 
of the trioxadecalin ring system in mycalamide A 
These results were in good agreement with the geometric requirements 
obtained from an analysis of the vicinal proton-proton coupling constants 
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between C1 0 and C13. In particular, the values (in Hz) for H1 0-H11 (9.8), 
H11-H12 (6.7) and H12-H13 (10.3) (Table 1.1) required that there be anti, 
gauche, and anti relationships102, repectively, between these proton pairs, as 
found in the proposed conformation (Figure 1.6a). 
Significantly, in the stated conformation of the trioxadecalin ring system 
(Figure 1.6a) both the N9 and C16 sidechains (at C1 0 and C15 respectively) 
were equatorial substituents, and this preference appeared to be reasonable, 
since it would minimise unfavourable steric interactions involving these 
chains. However, while the C12 and C13 oxygen substituents were equatorial 
to the C11-C15 ring, C1 0 was axial, so that there were unfavourable gauche 
interactions between C1 0 and C13, C1 0 and C15, and 1 O-OCH2 and C13. 
Such a conformation has been described as an '0-outside' conformation for 
derivatives of cis 1 ,3-dioxadecalane 109,111, and the alternate chair-chair 
conformation is termed '0-inside'. An alternate chair-chair conformation for 
the trioxadecalin ring system of mycalamide A has been depicted in Figure 
1.6b. This conformation has the N9 and C16 chain atoms axial (introducing 
unfavourable gauche interactions between C11 and C16, and C13 and C16 
for example) and the C12 and C13 oxygen substituents axial to the C11-C15 
ring. There was no evidence from NOE experiments or from an analysis of the 
vicinal coupling constants to suggest the presence of this second chair-chair 
conformation for mycalamides A or B in CDCI3 solution. However, various 
studies describing the chemical and conformational equilibration of 
derivatives of cis 1 ,3-dioxadecalane 109,111 and related compounds 113 have 
been reported, and in one case109 both 1H and 13C NMR spectroscopy were 
used to probe their conformations. There have also been several studies of 
the conformational behaviour of various cis-decalins using 13C NM R 
spectroscopy114, 115. Therefore this discussion is continued in a following 
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subsection, where the results from 13C NMR spectroscopy on mycalamides A 
and B are presented. 
The conformations of the C16-C18 chain portion of mycalamides A and 
B were not able to be determined from these data, due to the overlap of the 
two H16 resonances and the close proximity of the H15, H17 and H18 and 
other resonances in the 1 H NMR spectra. However, there was clearly a 
difference in· the relative populations of various rotamers about the C15-C16 
bonds in these two compounds, based on the observed coupling constants 
. 
recorded for their respective H15 resonances (Table 1.1 ). These values were 
not consistent with the presence of a single conformation about the C15-C16 
bond, although those for mycalamide B suggested that there was one major 
conformation, probably having C17 anti to C14102,116. The coupling 
constants recorded for the two H18 resonances were similar for mycalamides 
A and B, but also indicative of some combination of rotamers about the C17-
C 18 bond. Thus this substructure appeared to be quite conformationally 
flexible. 
There were several long range NOE interactions which were indicative 
of major overall solution conformations of the mycalamide A and B structures. 
There were NOE interactions between the C3 methyl protons and the NH and 
H11 protons (strong for mycalamide B), and possibly from the C3 methyl 
protons to H17 {weak), in addition to an interaction between the HS axial 
proton and Hi 7 {strongest for mycalamide B). These results suggested that 
the mycalamide molecule was folded around in a roughly circular shape, and 
this possibility will be discussed in more detail in relation to molecular 
modelling results, presented in a subsequent section. 
Therefore, to summarise the results of these analyses, it has been 
shown that the three rings of mycalamides A and B were almost entirely in 
single chair conformations, that the central amide chain portion C7-N9 has 
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some conformational rigidity, but that the C15-C18 sidechain was rather 
flexible. 
1.2.4 ASSIGNMENT OF THE 13C NMR SPECTRA OF MYCALAMIDES A AND 
B IN' DEUTEROCHLOROFORM 
The 13C NMR spectrum of mycalamide A is shown in Figure 1.7, while 
the data obtained are listed in Table 1.3. The resonance at 8171.82 ppm 
clearly belonged to the C8 amide carbonyl, and resonances at 8145.65 and 
~ 
. 11 0.55 ppm were assignable to the carbons of the exocyclic double bond117. 
A coupled 1 H-detected heteronuclear multiple quantum coherence (HMQC) 
experiment85 was performed to assign the protonated carbon signals of 
mycalamide A. The increased sensitivity of this HMQC experiment over the 
standard 13C-detected HETCOR experiment88 was very apparent, in that a 2.5 
hour acquisition on a 9 mg sample of mycalamide A gave an almost complete 
set of correlations, whereas a HETCOR experiment on the same sample for an 
equivalent time period gave almost no real correlations. Of interest from the 
13C assignments obtained (Table 1.3) was the chemical shift of the C1 0 
resonance, 873.74 ppm, which was lower than expected for a methine carbon 
having oxygen and nitrogen substituents 117. This carbon was therefore 
probably affected by shielding affects associated with the adjacent carbonyl 
oxygen functionality117,118. Also, the methyl groups at C14 were of quite 
different chemical shift, but the upfield position of the 14-CH3S resonance was 
entirely consistent with standard gauche shielding effects for axial ring 
substituents 117,119,120, and was similarly observed for the 3-CH3 and, 
possibly, the 6-0CH3 resonances. 
Figure 1.7 13C NMR spectrum of mycalamide A in CDCI3 solution 
Figure 1.8 Heteronuclear multiple bond correlation (HMBC) spectrum of 
mycalamide A in CDCia solution 
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A 1 H-detected heteronuclear multiple bond connectivity (HMBC) 
experiment86 was performed to assign the quaternary carbon signals of 
mycalamide A and to provide further evidence for the above assignments. 
This experiment was effective for obtaining two or three bond 1 H- 13C 
correlations and was found to be much more sensitive than the corresponding 
13C-detected long range HETCOR (XCORFE) experiment87,89. Results 
obtained from the two experiments have been compared in Table 1.4, and the 
HMBC spectrum has been reproduced in Figure 1.8. It can be seen that many 
. 
more correlations were observed in the HMBC experiment, although this was 
performed on a larger sample. Both experiments were less sensitive in 
detecting correlations involving proton resonances of high multiplicity, 
because the correlation was spread over a greater frequency range, leading 
to a poorer signal to noise ratio in the two-dimensional spectrum. Here both 
experiments provided effective assignment of the quaternary carbon 
resonances, C4, C6, C8 and C14, and proved the location of the C6 and C13 
methoxyl groups. 
The 13C NMR spectrum of mycalamide B was similar to that of 
mycalamide A, but there was a third methoxyl resonance at 856.65 ppm, and 
there were shifts in the C7 (-1.2), C15 (+3.5), C16 (-2.3), C17 (+7.2) and C18 (-
3.0) carbon resonances, as previously assigned by a HETCOR experiment19. 
The shifts in the C15-C18 resonances were in accordance with standard 
substituent effects117 for the methylation of the C17 hydroxyl group of 
mycalamide A, providing further strong evidence for the structure of 
mycalamide B. 
1.2.5 VARIABLE TEMPERATURE 13C NMR STUDY ON MYCALAMIDE A 
Further to the above analyses, it was noticed that the linewidths of some 
of the 13C NMR signals in the spectra of mycalamides A and B that were 
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assigned to substituents of the trioxadecalin ring system were larger than 
normally obseNed. The C11 and 14-CH3S resonances appeared to be most 
affected. (A similar line broadening behaviour was also obseNed in the 13C 
NMR spectrum of onnamide A 19). This behaviour was suggestive of the 
occurrence of some conformational exchange 121, although the evidence from 
analyses of NOE interactions and proton-proton coupling constants for 
mycalamides A and 8 required the presence of one major solution 
conformation for this trioxadecalin ring system. 
The line broadening of the 13C NMR signals of some cis-
decalins 114,115 has been extensively studied and is reported to arise from 
conformational exchange between two chair-chair conformations. The line 
broadening of such signals is a function of the temperature and the spacing (in 
Hz) between resonances for the same carbons in the two conformations, and 
these data can be used to calculate thermodynamic parameters for the 
conformational inversion process 114,121. In considering the exchange 
process, there are three key spectral forms114 and these have been simulated 
in Figure 1.9 for two conformations in a population ratio of 95:5. Firstly, at low 
temperature, the kinetic exchange is slowed to the extent that separate, 
reasonably sharp signals are observed for individual carbons in the two 
conformations {Figure 1.9a}. Secondly, at the coalescence temperature, 
peaks for the two conformations merge (due to kinetic averaging on the NMR 
time scale), but the peak widths may be very broad (Figure 1.9b). Thirdly, at 
temperatures above coalescence, the merged peaks also become reasonably 
sharp (Figure 9.1 c). However, neither the low temperature nor the high 
temperature resonances are as sharp as those resonances not involved in the 
exchange process due to residual kinetic effects 114. 
Figure 1.9 Computer simulation of the three key spectral forms for 
conformational exchange involving two conformations in a 
population ratio of 95:5. 
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A variable temperature 13C NMR study was therefore performed to 
investigate the nature of this proposed conformational exchange in 
mycalamide A. 13C NMR spectra were recorded at intervals of 25oc, for a 
temperature range of -sooc to +5ooc. The spectrum at 5ooc contained 
resonances for substituents of the trioxadecalin ring system that were 
significantly sharper than those recorded at 23oc, and this was particularly 
obvious for the C11 and 14-CH3S resonances. At ooc these resonances 
were broader, as was the C16 resonance, and this was even more 
. 
pronounced at -250C. However, at -5ooc, the 14-CH3R, 14-CH3S and some 
resonances of the trioxadecalin ring system were again sharper, although the 
C 16 resonance was broad. 
To account for this behaviour, it is proposed that the trioxadecalin ring 
system is undergoing conformational exchange between two chair-chair 
conformations114,115,121, where the coalescence temperature for the C14 
methyl resonances must lie between -sooc and -25oc. The fact that the C16 
and other resonances did not necessarily show similar linewidths at particular 
temperatures merely reflects the dependence of the coalescence temperature 
on the o separation of a particular pair of resonances from a single carbon in 
the two conformations114. Note also that the slight variation of the chemical 
shifts of some resonances with temperature did not allow unambiguous 
assignment of all the resonances between o70 to 80 ppm in these spectra. 
The spectrum at -50°C did not seem to contain any new resonances, so that 
the proportion of the proposed alternate chair-chair conformation of the 
trioxadecalin ring system was comparatively small, probably less than 10% 
from the signal to noise ratio of this spectrum. In fact, the simulation in Figure 
1.9 shows that as little as 5% of the alternate chair-chair conformation could 
give rise to the observed line broadening behaviour of the 14-CH3 S 
resonance. (This simulation was constructed with a o separation of 10 ppm 
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between the two resonances and an activation energy of 54 kJ mol-1, which 
are reasonable values for such systems114, 121 ). This population distribution 
was consistent with the lack of direct evidence for the minor conformation from 
NOE experiments or analyses of the vicinal proton-proton coupling constants. 
1.3 SOLUTION CONFORMATIONS OF MYCALAMIDES A AND B IN 
OTHER SOLVENTS AND MOLECULAR MODELLING 
. 
It has been shown above that, despite the potential flexibility of the 
mycalamide A and B structures, there were a limited number of major solution 
conformations present in chloroform solution. One probe for the variation in 
the population distributions of these and other conformations with changes in 
their environment is to observe the distribution of conformations in a range of 
solvents of varying polarity by 1 H NMR spectroscopy72. The conservation of 
shape for particular structural portions has been considered to be some 
indication that similar conformations may be involved in binding to a 
receptor15, since every conformational change must be repaid by binding 
energy70. (This obviously still allows higher energy conformations to be 
considered16,70, 122). Therefore it was of interest to study the conformations of 
mycalamides A and B in a range of other solvents, and to attempt to model the 
resulting conformations, in order to obtain some insights into their overall 
shape. 
1.3.1 SOLUTION CONFORMATIONS OF MYCALAMIDE A IN D4-METHANOL 
The 1 H NMR spectrum of mycalamide A in CD30D was very similar to 
that recorded in CDCI3 and the spectral assignments (Table 1.1) were 
confirmed by the results of a COSY experiment. (These data were also similar 
to those recorded for onnamide A31 in the same solvent (Table 1.7)). The 
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major differences between the data recorded for mycalamide A in this solvent, 
compared with those in CDCI3, were in the chemical shifts of the H2 (-0.1 ), 
H11 (+0.1), H13 (+0.2), H15 (-0.1) and H16 (+0.1) proton resonances. The 
two HS and two H16 resonances were also resolved in this solvent. Analysis 
of the vicinal proton-proton coupling constants showed that the only significant 
differences between data in the two solvents were in the magnitude of the 
H15-H16 constants, although the H16-H17 values could not be extracted from 
data recorded in CDCI3 due to the overlap of the H16 resonances. These 
. 
results suggested that the solution conformations of the ring structures of 
mycalamide A were similar in the two solvents, but that those of the C16-C18 
sidechain could be different. 
This was investigated further by a series of NOE experiments and the 
results of these have been listed in Table 1.5. Irradiation of HSa gave an 
enhancement of the 3-CH3, HSe and H7 resonances, but irradiation of H5e 
gave only a very weak enhancement of H7, along with stronger 
enhancements of the 4=CHE and H5a resonances. There was also a strong 
NOE interaction between 6-0CH3 and both H2 and H7. Therefore the 
conformations of the 01-C6 ring and the C6 methoxyl group were the same in 
both solvents, as were the conformations about the C6-C7 bond. No data 
regarding the conformations about the C7-C8 and N9-C1 0 bonds could be 
obtained since the NH proton was fully exchanged in this solvent. 
As indicated above, the two H16 resonances were resolved in this 
solvent, enabling some analysis of the solution conformations of the C16-C18 
portion of mycalamide A. Irradiation of the more downfield H16 resonance 
gave an enhancement of the 14-CH3R, H15 and H17 resonances, whereas 
irradiation of the upfield H16 resonance enhanced the 14-CH3S and H17 
resonances. These results suggested that there was only one major 
conformation about the C 15-C16 bond of mycalamide A in this solvent, such 
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that C17 was anti to C14116, as shown in Figure 1.10. Also, the observed 
vicinal coupling constants between Hi 5 and the two H16 protons, of 2.3 and 
10.3 Hz, were indicative of gauche and anti relationships, respectively, 
between these protons102, consistent with the proposed conformation. The 
coupling constants between the two H16 protons and H17, of 5.6 and 7.0 Hz, 
and those between H17 and the two H18 protons, of 3.8 and 6.3 Hz, were 
suggestive of combinations of several conformations about the C16-C17 and 
C17-C18 bonds, so that the solution conformations of this portion of the 
. 
structure were not well defined. Therefore the only detected difference in the 
solution conformations of mycalamide A in CDaOD, compared to those in 
CDCia, was in the conformation about the C15-C16 bond. This difference was 
probably indicative of the different properties of these solvents, where CDCis 
is relatively non-polar and favours intramolecular hydrogen bonding, whereas 
methanol is more polar and is itself a good hydrogen bond donor and 
acceptor, so that intramolecular hydrogen bonding is disrupted. (The hydroxyl 
groups would also be more solvated in CDaOD). 
Figure 1.10 1 H-1 H NOE interactions and proposed solution conformation 
about the C15-C16 bond of mycalamide A in CDaOD solution 
The 13C NMR spectrum of mycalamide A in CDaOD was also similar to 
that recorded in CDCis, although many of the resonances were slightly more 
downfield. The C11, C12, C13, 14-CHaR and 14-CHaS resonances were also 
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broader, so that a similar conformational exchange process was occurring for 
the trioxadecalin ring system to that found in CDCI3. 
1.3.2 SOLUTION CONFORMATIONS OF MYCALAMIDE A IN DMSO 
The 1 H NMR spectrum of mycalamide A in DMSO showed the presence 
of all four exchangeable protons. The NH and 7-0H doublets were located at 
o8.37 and 5.76 ppm respectively, suggesting that these protons were involved 
in intramolecular hydrogen bonding interactions98, 101. The 18-0H and 17-
. 
OH resonances appeared as broad singlets at o4.37 and 3.27 ppm, or as a 
triplet and doublet, respectively, depending on the temperature and state of 
the sample. Unfortunately, the large H20 peak, at o3.4 ppm, obscured some 
of the C15-C18 proton resonances. A COSY experiment was performed, 
which was very useful in locating these hidden resonances and in assigning 
the remainder of the 1 H NMR data (Table 1.1 ). 
Compared to data recorded in CD30D, there were significant shifts in 
only the H13 (+0.1 ), H17 (-0.1) and H18 (-0.1) proton resonances. However, 
the vicinal proton-proton coupling constants, H1 O-H11 (8.9), H11-H12 (6.1) 
and H12-H13 (9.5) were significantly less than those recorded in CDCI3 
solution, suggesting that there was a higher proportion of the alternate chair 
conformation of the trioxadecalin ring system of mycalamide A in this solvent. 
Furthermore, the H11, H13 and H16 resonances were broad in the 1 H NMR 
spectrum. A variable temperature 1 H NMR study was therefore performed to 
investigate these results. 
The 1 H NMR spectra at 45, 65 and 850C showed successively sharper 
resonances for the H11, H13 and H16 protons, but the exchangeable proton 
resonances became broader due to an increased rate of exchange. Also the 
H 20 peak was shifted to higher fields in these spectra, enabling the 
resonances between o3.3 and 3.5 ppm to be directly observed. Thus the H15 
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resonance was a doublet of doublets (2.2, 9.8), as were the H18 resonances 
(3.8, 11.3) and (5.7, 11.1 ), and the upfield H16 resonance became a doublet 
of doublet of doublets (5.1, 9.8, 14.2) (coupling constants in Hz). Note that the 
couplings between H15 and the two H16 protons were indicative of the 
presence of one major C15-C16 rotamer, having C17 anti to C14 (Figure 
1.1 0), as for mycalamide A in CD30D. 
NOE experiments were performed to further analyse the solution 
conformations of mycalamide A in this solvent. There were weak NOE 
interactions between the NH and the 1 0-0CHS and H12 protons, between the 
H1 0 and H11 protons, between the H13 and 14-CH3S protons and between 
the H11 and one of the H16 protons (Table 1.5), giving direct evidence for the 
presence of the minor chair-chair conformation for the trioxadecalin ring 
system of mycalamide A. The remaining NOE interactions were similar to 
those observed in CDCI3 and CD30D solution so that, overall, the major 
solution conformations of mycalamide A were conserved in all three solvents. 
A 13C NMR spectrum was also recorded and assigned with the 
assistance of an HMQC experiment (Table 1.3). Even greater linewidths were 
observed for some of these 13C resonances than those found above, 
consistent with earlier proposals of a higher proportion of the minor chair-chair 
conformation of the trioxadecalin ring system114. To illustrate this point, the 
largest linewidths were (in Hz), C1 O/C12 (8), C11 (>>20), C13 (1 0), 14-CH3R 
(16) and 14-CH3S (>>20), whereas those of 'normal' 13C resonances were 2-
2.5 Hz. Thus this conformational exchange process was most obvious in 
DMSO, due to the different population distribution of the two chair-chair 
conformations in this solvent. 
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1.3.3 NMR ASSIGNMENTS OF MYCALAMIDE B IN D6-BENZENE 
The 1 H NMR spectrum of mycalamide Bin d6-benzene displayed some 
very different chemical shifts to those recorded in CDCI3, which was expected, 
due to the anisotropic shielding effects associated with aromatic rings98,123. 
A COSY experiment was performed which enabled complete assignments to 
be performed (Table 1.1 ). Despite the unusual chemical shifts, the vicinal 
proton-proton coupling constants were very similar in both solvents, except for 
the magnitude of the NH-H1 0 constant (6.5 Hz), which was significantly 
smaller than that normally observed (-9.8 Hz), and was suggestive of a 
mixture of conformations having gauche and anti relationships between these 
protons 102,1 os. However, no NOE experiments were performed to investigate 
these conformations further. The 13C NMR spectral data (Table 1.3) appeared 
to very similar to those recorded in CDCI3, including both the chemical shifts 
and the linewidths of the observed resonances. Thus it was likely that the 
conformations of the ring structures of mycalamides A and B, at least, were the 
same in all these solvents, with only minor changes in the conformations of the 
flexible chain portions. 
1.3.4 MOLECULAR MODELLING STUDIES 
The major aim of initial molecular modelling studies on the structure of 
mycalamide A was to produce model structures for the proposed solution 
conformations discussed in previous sections, which could be crudely 
minimised in energy. Note that there were too many rotatable bonds in 
mycalamide A to perform a full conformational search to find global energy 
minima122,124. The starting structure of mycalamide A was derived from the 
structure of pederin di-p-bromobenzoate (1.1 ), which was specified by its x-
ray crystal structure coordinates93. This was achieved by modifying the 
substituents at C7, C1 0, C12, C13, C17 and C18, setting the H1 0 and H11 
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protons and the N-C1 0 and O-CH2 bonds in anti relationships, and then 
introducing the third ring19. This gave a structure in which the trioxadecalin 
ring system was in the major observed chair-chair conformation discussed 
above, and which had H7 anti to C5 and gauche to the C6 methoxyl group 
about the C6-C7 bond and had C17 anti to C14 about the C15-C16 bond. 
Energy minimisation, using a modified MODEL program125 with MM2 
parameters, gave the conformation displayed in Figure 1.11 a, which, as stated 
above, was not necessarily a global minimum, since rotations had not been 
. 
periormed about other bonds in the molecule. However, note that in this 
conformation the H17 proton was only 2.2 A from the H5a proton and 2.5 A 
from the closest C3 methyl proton, and that the NH and H11 protons were both 
only 3.6 A from the closest C3 methyl proton, consistent with long range NOE 
interactions specified earlier for mycalamides A and B and shown on this 
figure, suggesting that this was a valid low energy conformation of 
mycalamide A This conformation also displayed hydrogen bonds between 
the NH proton and 01 and between the C7-0H proton and the CS carbonyl 
oxygen. 
Rotation about the C6-C7 bond and reminimisation gave a second 
conformation, of 3.5 kJ mol-1 higher energy (Figure 1.11 b), which satisfied the 
observed NOE interaction between H7 and H5a and between H5a and NH. 
This structure contained a single hydrogen bond only, between the C7-0H 
proton and the ca carbonyl oxygen. Note that the energies of these 
conformations could not be used to predict relative populations since the 
remaining rotatable bonds had not been considered. 
Figure 1.11 Long range 1 H-1 H NOE interactions and proposed overall 
solution conformations of mycalamide A as derived from 
molecular modelling (methyl protons are not shown) 
a) H7 anti to C5 (gauche to 6-0CH3) 
b) H7 anti to 6-0CHa 
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The two chair-chair conformations of the trioxadecalin ring system were 
modelled independently, by entering the two simplified structures 1.3A and 
1.38 (shown in Figure 1.12), having N9 terminating as NH2 and Cl6 
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terminating as CH3. Energy minimisation was performed and the resulting 
structure, containing the alternate chair-chair conformation, was only 1.7 kJ 
mol-1 higher in energy than the minimised structure containing the normal 
chair-chair conformation. Thus both conformations were relatively similar in 
energy and were therefore both likely to be accessible for mycalamides A and 
B. The coupling constants for the two conformations were calculated using 
Haasnoot's generalisation of the Karp Ius equation 103 and have been shown 
in Table 1.6. Those for the alternate chair conformation were (in Hz), H1 O-H11 
. 
(1.7), H11-H12 (1.4) and H12-H13 (2.2). The values for structure 1.3A were 
closest to the experimental values recorded for mycalamides A and B, 
agreeing with other NMR evidence that this was the major solution 
conformation of the trioxadecalin ring system. However, these calculated 
values were all significantly lower than the experimental values102, so that 
these results were not sufficiently accurate to allow the calculation of a precise 
ratio of the two conformations. 
Figure 1.12 Starting structures for preliminary molecular modelling of the 
trioxadecalin ring system of mycalamides A and B 
H 
H-\-OH 
0 ~ 
" 
H H 
OCH3 
1.3A 1.38 
Thus these molecular modelling results were clearly useful in providing 
further support for the proposed major solution conformations of mycalamide A 
and in depicting the overall shape of the molecule, in agreement with NOE 
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results. The following sections describe similar studies on pederin and 
pederin dibenzoate which will be compared with the results above. (The 
collaboration of Dr F. Matsuda in supplying samples of these compounds and 
of Dr N. Perry in performing some of the NMR and molecular modelling work84 
is specifically acknowledged here). 
1.4 NMR ASSIGNMENTS AND SOLUTION CONFORMATIONS OF 
PEDERIN 
1.4.1 ASSIGNMENT OF THE 1 HAND 13C NMR SPECTRA OF PEDERIN 
The 1 H NMR spectrum of pederin in CDCI3 showed some similarities to 
those of mycalamides A and B, as expected, and the coupled resonances 
were unambiguously assigned using the results obtained from a COSY 
experiment (Table 1.7). Interestingly, the C7 hydroxyl proton resonance was 
observed in this spectrum, at 83.92 ppm, coupled to H7 (2.2 Hz), but the C13 
hydroxyl proton resonance was not observed. The NH resonance was also 
shifted slightly upfield of its position in mycalamides A and B, possibly 
reflecting the different environment at C1 0. The assignments of two of the four 
methoxyl resonances were obtained from the results of selective NOE 
experiments. Irradiation of the H1 0 signal gave a strong enhancement of the 
methoxyl resonance at 83.380 ppm, whereas irradiation of the H7 signal 
enhanced the resonance at 83.326 ppm, so that these resonances could be 
assigned to the methoxyl groups at C10 and C6, respectively. The remaining 
two methoxyl resonances were due to the groups at C17 and C18, but NOE 
experiments could not distinguish these because of the similarity in the 
chemical shifts of these and the H17 and H 18 resonances. The 
stereochemistries associated with the two 4=CH resonances and the two C14 
methyl resonances were assigned by comparison with data obtained for 
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mycalamides A and 8 and were confirmed by NOE experiments as discussed 
below. (Note that, because of the different substituents at C12 and C13 in 
mycalamides A and 8, pederin and pederin dibenzoate, the true prochiral 
assignments112 for the C14 methyl groups would be different only for pederin. 
To avoid confusion, this has been disregarded, so that the C14 methyl groups 
have been assigned the same labels as for mycalamides A and 8 in all 
cases). Similar assignments for the two H12 and H16 methylene proton 
resonances are also presented in a following analysis of the solution 
conformations of pederin. Note that the complete 1 H NMR spectral 
assignments for pederin presented here agreed well with previous partial 
assignments94,95,126-128, and that the data for the left hand portion to the 
amide were very similar for mycalamides A and 8 and pederin, as expected. 
The 13C NMR spectral data of pederin had been reported128, 129, but 
not assigned. Hence a 13C NMR spectrum was recorded on this sample and 
HMQC and HMBC experiments were performed to permit an assignment of 
the data obtained. The HMQC experiment gave correlations for all the 
protonated carbon resonances but could not allow an assignment of the C17 
and C18 methoxyl resonances since the 1 H NMR signals were not yet 
assigned. However, results from the HMBC experiment resolved this 
ambiguity, since there were three-bond correlations between all the methoxyl 
protons and the chain or ring carbon atoms bonded to the methoxyl oxygen 
atoms, including from 17-0CH3 to C17 and from 18-0CH3 to C18 (Table 1.4). 
The HMBC experiment also allowed the assignment of the four quaternary 
carbon resonances, but these were obvious from their chemical shifts and by 
comparison with data for mycalamides A and B. The 13C NMR data for the C2 
to C8 portion of pederin were all within 0.4 ppm of those recorded for 
mycalamide A and the differences for the remaining data were consistent with 
normal substituent effects117 (Table 1.3). The 14-CH3S (axial) and C11 
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resonances were broad, as in mycalamide A, suggesting that a similar 
conformational exchange process was occurring in this compound. This is 
investigated further in the following conformational analysis. 
1.4.2 CONFORMATIONAL ANALYSIS OF PEDERIN 
The results of all the NOE experiments on pederin are listed in Table 
1.8. The NOE interactions between H5a and 3-CH3, H7 and 6-0CH3 and 
between the H5a and H7 protons, indicated that the 01-C6 ring was in the 
. 
same chair conformation and that the same two staggered rotamers about C6-
C7 as found for mycalamide A (Figure 1.5) were present for pederin, as 
expected. There were additional NOE interactions between C7-0H and the 
H5e, 6-0CH3, H7 and NH protons, as well as between the NH proton and both 
the H5a and H7 protons, which supported these conformations and required 
the presence of at least two conformations about C7-C8 which had the H7 
and/or C7-0H protons in gauche relationships with the NH proton. 
The observed vicinal proton-proton coupling constants, NH-H1 0 (9.7) 
and H1 O-H11 (8.0), required that these protons be in predominantly anti 
relationships (Figure 1.13a), although the 8 Hz value also suggested the 
presence of a minor conformation having the H1 0 and H11 protons in a 
gauche relationship102, such as in Figure 1.13b. These conformations were 
supported by a strong NOE interaction between the H11 and NH protons, and 
weaker interactions between NH and H1 0 and between H1 0 and H11. The 
interaction between 1 O-OCH3 and both NH and H1 0, but not H11 or H12, 
indicated that the C1 0 methoxyl group was anti to C11 and gauche to H1 0, as 
shown in Figure 1.13. Therefore, despite the absence of the C1 O-C12 dioxan 
ring of mycalamides A and B in the structure of pederin, it was apparent that 
the major conformation of the N9-C11 chain portion was similar in these 
compounds. 
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Figure 1.13 1 H-1 H NOE interactions and proposed solution conformations 
for the N9-C16 portion of pederin 
H 
(S) H CH3 (S) 
a) Major conformation b) Minor conformation 
There were NOE interactions between H1 0 and both H13 and H15 and 
between H13 and H15 which required the C11-C15 ring to be the same major 
chair conformation as observed for mycalamides A and B (Figure 1.13). 
Irradiation of H13 caused an enhancement of the more downfield H12 and 14-
CH3 resonances, so that these could be assigned to the equatorial H12R and 
14-CH3R protons, respectively. Other NOE interactions between H12S and 
14-CH3S and between H15 and 14-CH3R supported the proposed major 
chair conformation. However, there were weaker interactions between 14-
CH3S and the H13 and H15 protons which indicated the presence of a minor 
alternate chair conformation, although the 11.2 Hz vicinal coupling constant 
between the H12S and H13 protons required that the normal chair 
conformation be very dominant1 01,102. Thus this portion of the structure of 
pederin was also displaying very similar conformational behaviour to that 
found for mycalamides A and B, despite the different substituents at C12 and 
C13. 
The coupling constants between H15 and the two H16 protons, of 2.0 
and 10.1 Hz, required predominantly gauche and anti relationships between 
these protons, so that there was one major staggered rotamer about the C15-
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C16 bond having C17 anti to C14 (compare Figure 1.1 0). This was supported 
by the observation of NOE interactions between the H16S proton (which had 
the smaller coupling constant to H15) and the 14-CH3R protons, and between 
the H16R and the 14-CH3S protons (Figure 1.13). This behaviour was similar 
to that found for mycalamide B, but not mycalamide A, in CDCI3 solution, and 
was also similar to that found for various C-glycosides116. The coupling 
constants from H17 to H16R (3.4) and H16S (9.4) were also indicative of 
mainly gauche and anti relationships, respectively, between these protons, 
. 
although there were probably also other minor conformations contributing to 
these values. The remainder of this sidechain portion was not analysed. 
Thus it was found that the major solution conformations of pederin and 
mycalamide B, and, to a slightly lesser extent, mycalamide A, were very 
similar. This was consistent with the similarity in the chemical shifts of 
resonances in their NMR spectra which corresponded to equivalent structural 
features. This was also further supported by comparing molecular mechanics 
models of the two major C6-C7 rotamers of pederin (not shown) with those 
obtained for mycalamide A, and noting the similarities in the overall shape of 
the proposed major conformations of the two molecules58,84. The differences 
in the substituents at the C1 0, C12, C13, C17 and C18 positions in these 
compounds evidently did not affect the (unknown) active conformation, or 
interactions at the active site, since these molecules displayed such similar 
biological activities. The synthesis of analogues of these structures could lead 
to a better understanding of the essential structural and conformational 
features required for these biological activities and such is the aim of work in 
subsequent chapters. 
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1.5 SOLID STATE CONFORMATION OF PEDERIN DI-P-BROMO-
BENZOATE AND SOLUTION CONFORMATIONS OF PEDERIN 
DIBENZOATE 
The aim of this study was to determine the solution conformations of 
pederin dibenzoate (1.2) and to compare them, firstly with those of pederin 
and the mycalamides, and secondly with the solid state conformation of 
pederin di-p-bromo benzoate (1.1 ). The rationale behind these comparisons 
. 
was to illustrate the relative influences of intermolecular forces, in addition to 
those of intramolecular forces, on the (low energy) conformations of these 
molecules70,84. In particular, conformational studies of some other 
biologically active molecules, including cyclosporin72 and cycloheximide83 
(0.14) have revealed distinct differences between their solid and solution 
state conformations, which have been considered to be important for the 
potential understanding of the binding of these molecules to their receptors. 
Such studies also form a basis for observing correlations between the 
conformations of derivatives of these molecules and their biological 
activity16,70,71, in addition to comparing differences in structure1,15. 
1.5.1 CRYSTAL STRUCTURE OF PEDERIN 01-P-BROMOBENZOATE 
Two independent x-ray crystallographic studies were reported for 
pederin di-p-bromobenzoate34,93 (1.1 ). The crystal structure of this 
compound is displayed in Figure 1.14. In this conformation, the 01-C6 ring 
had the usual chair conformation, as found for the mycalamides and pederin, 
and H7 was gauche to the C6 methoxyl group. The central amide chain, C7-
C1 0, was planar, with some n-delocalisation of the amide reported. The C1 0 
methoxyl group was anti to the C1 O-C11 bond, with NH anti to H1 0, as in a 
proposed solution conformation of pederin (Figure 1.13 above). However, the 
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conformation about the C1 O-C11 bond was such that the H1 0 and H11 
protons were in a gauche relationship, rather than the mainly anti relationship 
which was the proposed major solution conformation of pederin130. The C11-
C15 ring was in the usual chair conformation, having the ester and sidechain 
substituents at C13 and C15 equatorial, and the amide chain axial at C11. 
The latter caused some considerable distortion in the dihedral angles about 
the C11-0 and C11-C12 bonds93, a fact which is illustrated by the calculated 
vicinal coupling constants1 03 between the H11-H12R (0.9) and H11-H12S 
I (8.3) protons, which are in distorted gauche relationships. The C16-C18 
sidechain was such that C17 was anti to C14 and 17-0 was anti to C15, about 
the C15-C16 and C16-C17 bonds, respectively. The space group was P21. 
and the structure contained two molecules in the unit cell, which were linked 
together by a single co-crystallised alcohol molecule (methanol or ethanol) via 
hydrogen bonds involving the amide NH and C=O groups, to form a zig-zag 
chain. 
Figure 1.14 X-ray crystal structure of pederin di-p-bromobenzoate (1.1 ). 
Note that no hydrogen atoms were located so these have not 
been shown. 
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Thus the only unusual feature of this structure was the conformation 
about the C1 O-C11 bond. This conformation was reported to be favoured by 
an attractive 0/0 gauche effect130. However, it was likely that intermolecular 
forces, including Van der Waals and hydrogen bonding interactions between 
molecules packed in the crystal, were important factors in this solid state 
conformation 70. It was therefore of interest to determine whether such a 
conformation was present in solution. 
1.5.2 ASSIGNMENT OF THE.1 HAND 13C NMR SPECTRA OF PEDERIN 
DIBENZOATE IN DEUTEROCHLOROFORM 
The 1 H NMR spectrum of a sample of pederin dibenzoate (1.2) in 
CDCI3 showed large downfield shifts (>i ppm) in the H7 and H13 proton 
resonances, compared to data recorded for pederin, consistent with this 
esterification of the C7 and C13 hydroxyl groups of pederin98, 101. The 
coupled resonances were unambiguously assigned with the assistance of a 
COSY experiment (Table 1. 7). There were further shifts in the HSa (+0.4), NH 
(-0.4), H11 (+0.2), H15 (+0.4) and H16 (+0.4) proton resonances, which 
suggested that the solution conformations of this derivative could be slightly 
different from those of pederin. NOE experiments enabled an assignment of 
the C6 and C1 0 methoxyl proton resonances, but not the C17 and C18 
methoxyl resonances. Assignments of the stereochemistries associated with 
the C12 and C16 methylene and the C14 methyl resonances were also 
achieved by NOE experiments, but these are described with an analysis of the 
solution conformations below. 
A 13C NMR spectrum of pederin dibenzoate (1.2) was recorded and 
the protonated carbon resonances were assigned by an HMQC experiment 
(Table 1.3). The C17 and C18 methoxyl resonances and the quaternary 
carbon resonances were assigned by comparison with data recorded for 
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pederin. There were shifts in the C8 (-4.3), C10 (+2.3), C11 (-2.5), C12 (-3.0), 
C13 (+3.1), C14 (-1.5), 14-CH3R (+1.8), 14-CH3S (+4.4), C16 (-1.0) and C18 (-
1.0) carbon resonances, compared to data recorded for pederin, which were 
also suggestive of changes in the solution conformations, since, of these, only 
the C8 and C12-C14 carbons would be appreciably affected by the 
esterification117. The C11 and 14-CH3S resonances were also significantly 
broader than those in pederin, suggestive of the occurrence of some 
conformational exchange process for the C11-C15 tetrahydropyran ring. 
1.5.3 SOLUTION CONFORMATIONS OF PEDERIN DIBENZOATE IN 
DEUTEROCHLOROFORM 
An extensive series of NOE experiments was performed to examine the 
solution conformations of pederin dibenzoate (1.2) and the results of these 
have been detailed in Table 1.8. The solution conformations of the left hand 
portion of the structure to the amide were found to be the same as for pederin 
and mycalamides A and B, as evidenced by the similarity in the chemical shifts 
and NOE interactions for these structures. The observed vicinal coupling 
constant between the NH and Hi 0 protons, of 9.8 Hz, was also indicative of a 
predominantly anti relationship between these protons102,108, as in pederin. 
The coupling constants (in Hz) between H1 0 and Hi i (4.2), H11 and 
the two H12 protons (5.6, 6.1 ), and between H13 and the two H12 protons 
(4.1 ,7.9), were rather different to those recorded for pederin. The small Hi O-
H11 constant was also noted for derivatives of pederin dibenzoate during 
synthetic studies127,130 and had been ascribed to the presence of a similar 
conformation to that observed for pederin di-p-bromobenzoate in the solid 
state. However, this conformation could not explain the differences in the 
sizes of the C11 to C13 vicinal proton-proton coupling constants for the 
benzoates compared to those of pederin (Table 1.9), nor the observed 
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broadening of the 14-CH3S and the C11 carbon resonances. It was therefore 
more likely, based on results for mycalamide A, that there was a significant 
population of both chair conformations of the C11-C15 ring. 
This proposal was confirmed by NOE results (Table 1.8). There were 
strong NOE interactions between H1 0 and H15 and between H13 and H15 
suggestive of a significant contribution from the major chair conformation 
observed for pederin to the overall conformations of this C11-C15 ring. 
Irradiation of the more downfield H12 resonance gave strong enhancements 
. 
of the NH, H11 and H13 resonances, whereas irradiation of the more upfield 
H12 resonance strongly enhanced the H11 and the more downfield 14-CH3 
resonances. This provided further support for this chair conformation and 
allowed an assignment of the stereochemistry associated with the two H12 
and 14-CH3 resonances. However, irradiation of H 11 gave strong 
enhancements of the H1 0 and the more downfield H16 resonances, and there 
were weak interactions between H12R and 14-CH3R, H12S and H13, H13 
and 14-CH3S, for example, which required the (minor) presence of an 
alternate chair conformation for the C11-C15 ring. Thus it is proposed that this 
ring was involved in conformational exchange between these two chair 
conformations. Molecular mechanics calculations to determine approximate 
relative proportions of these conformations are described in a following 
subsection. 
The vicinal proton-proton coupling constants from C15 to C18 were 
very similar to those observed for pederin, implying a similar mixture of 
solution conformations for this substructure in both compounds. Thus C17 
was predominantly anti to C14 about the C15-C16 bond, so that the 
stereochemistry associated with the H16 resonances could also be assigned, 
as for pederin. 
1.5.4 SOLUTION CONFORMATIONS OF PEDERIN DIBENZOATE IN 
D4-METHANOL 
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In order to compare the conformations above more conclusively with 
the solid state conformation of pederin di-p-bromobenzoate (1.1 ), it was 
appropriate to also consider the conformations of pederin dibenzoate (1.2) in 
methanol, which was the crystallisation solvent in the first reported crystal 
structure analysis34. The 1 H NMR spectrum of pederin dibenzoate in CD30D 
was readily assigned by comparison with the data recorded in CDCI3 and 
these assignments were confirmed by the results of a COSY experiment 
(Table 1.7). A 13C NMR spectrum was also recorded and assigned by 
comparison with the data recorded in CDCI3 (Table 1.3). Note that the C11 
and 14-CH3S resonances were slightly broad in this spectrum also. 
Selected NOE experiments were performed and the results are shown 
in Table 1.8. There were similar NOE interactions observed to those found 
above for CDC Is solution, including H1 O-H15, H13-H15, H11-H16R and H1 O-
H11. These results indicated that the same two chair conformations of the 
C11-C15 ring were also present in this solvent as in GDCI3. This was 
confirmed by an analysis of the vicinal proton-proton coupling constants from 
C1 0 to C13. The H1 O-H11 constant, 3.4 Hz, was smaller than in CDCI3, 
suggesting a higher contribution from a conformer having the H1 O-H11 
protons in a gauche relationship1 02,127. By comparison, the remaining 
coupling constants for this portion of the structure were all within 0.5 Hz of the 
values recorded in CDCI3, so that there was likely to be a similar ratio of the 
chair conformations of this ring in both solvents. Also the coupling constants 
for the C15-C18 portion were fairly similar. Thus it appeared that a similar set 
of solution conformations of this compound were present in both CDCI3 and 
CD30D. 
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1.5.5 MOLECULAR MECHANICS CALCULATIONS AND CONCLUSIONS 
Modification of the x-ray structure of pederin di-p-bromobenzoate (1.1), 
by removal of the bromine atoms and adding hydrogen atoms throughout the 
structure, provided a starting structure of pederin dibenzoate (1.2). Energy 
minimisation thus gave a conformation which had the H1 0 and Hi 1 protons in 
a gauche relationship. Rotation about the C10-C11 bond and reminimisation 
gave a slightly higher energy conformation58, having the H1 0 and Hi 1 
protons in an anti relationship, as shown in Figure 1 .15a. An alternate chair 
conformation was also generated84 and the minimised conformation is shown 
in Figure 1.15b. The calculated coupling constants for these conformations 
(designated 1.2A and 1.28, respectively) have been listed in Table 1.9, and it 
is readily apparent that the experimental values required a combination of the 
two proposed conformations. Equal contributions from these conformations 
gave averaged values that were all within 2 Hz of the experimental values, so 
this would seem to a reasonable approximation given the inevitable 
inaccuracies in the calculated values102,103. This result was not quite in 
accordance with the observed NOE results, which appeared to indicate a 
major 'normal' chair conformation, but was reasonable. Note that the 
calculated energies could not be used to predict ratios of these conformations 
since a full conformational search involving all the rotatable bonds in the 
molecule had not been performed. 
Thus it has been shown that the solution state conformations of pederin 
dibenzoate (1.2) were indeed different to the solid state conformations of 
pederin di-p-bromobenzoate (1.1 ). This illustrates the importance of 
intermolecular forces, as well as intramolecular forces, in determining the 
favoured conformation, and similar forces are likely to be involved in 
interactions with the unknown active site. Therefore any one of several low 
energy solution conformations may be the active conformation16,70,71,122. 
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With large flexible structures such as pederin and the mycalamides, the 
design and biological testing of conformationally restricted analogues70,92 
could lead to a more conclusive understanding of the active site geometry. 
The synthetic modifications of the mycalamides are a first step in such a 
direction. 
Figure 1.15 Alternate chair conformations (1.2A and 1.28, respectively) for 
the C11-C15 ring of pederin dibenzoate (1.2), as calculated by 
molecular modelling (methyl and aromatic protons not shown). 
a) 'Normal' chair 
conformation 
b) Alternate chair conformation 
Table 1.1 1H NMR dataa for mycalamides A and Bin various solvents. 
Protonb Typicalc Mycalamide A Mycalamide A Mycalamide A Mycalamide B Mycalamide B 
IJJ!JttiQiiQ~ (CI)(}.tl (C[bQ)) (Qs-OMSO) (QCCG) ~ 
H2 dq 3.98 (2.7,6.6) 3.88 (2.6,6.6) 3.83 (2.4,6.5) 4.02 (2.8,6.6) 3.98 (2.8,6.6} 
2-CH3 d 1.19 (6.6} 1.16(6.6) 1.16 (6.6) 1.19(6.6) 0.99 (6.6} 
H3 dq 2.23 (2.7,7.0) 2.19 (2.7,7.1) 2.24 (2.1 ,6.9) 2.25 (2.8,7.0) 2.04 (2.7,7.3) 
3-CH3 d 0.99 (7.0) 0.96 (7.1) 0.97 (7.0) 1.01 (7.1) 1.10 (7.2) 
4:CHZ torm 4.84 (m) 4.79 (2.1) 4.84 (m) 4.85 (1.9) 4.89 (2.0) 
4:CHE torm 4.72 (m) 4.65 (2.2) 4.67 (m) 4.71 (1.8) 4.84 (2.1) 
H5a td 2.36 (m) 2.41 (2.1 1 14.3) 2.49 (m, 14.5) 2.23 (1.9, 14.0) 2.59 (2.0, 14.1) 
H5e d 2.36 (m) 2.30 (14.2) 2.29 (14.4) 2.36 (14.0) 2.78 (14.0) 
6-0CH3 s 3.29 3.24 3.22 3.29 3.34 
H7 sord 4.31 4.29 4.20 (4.4) 4.28 4.37 
7-0H s ord 5.76 (4.5) 
NH9 d 7.51 (9.7) 8.37 (9.3) 7.53 (9.6) 6.91 (6.5) 
H10 t ordd 5.87 (9.7) 5.81 (9.5) 5.80 (9.0) 5.78 (9.6) 6.03 (6.5, 1 0.0) 
10-0CHR d 5.13 (6.9) 5.21 (6.9) 5.24 (7.0) 5.11 (7.0) 4.77 (6.9) 
1 0-0CHS d 4.87 (6.9) 4.80 (6.9) 4.85 (6.9) 4.84 (6.9) 4.71 (6.9) 
H11 dd 3.86 (6.8,9.7) 3.98 (6.5,9.4) 4.02 (6.0,8.8)d 3.78 (6.8,9.7) 3.87 (6.9, 10.1) 
H12 dd 4.22 (6.8, 1 0.3) 4.17 (6.6,9.9) 4.14 (6.2,9 .5) 4.20 (6.8,1 0.4) 4.41 (7.0,1 0.6) 
H13 d 3.46 (1 0.3) 3.66 (10.1) 3.77 (9.4)d 3.43 (10.3) 3.17 (1 0.6) 
13-0CH3 s 3.55 3.56 3.54 3.54 3.41 
14-CH3R s 0.97 1.00 1.03 0.97 0.97 
14-CH3S s 0.87 0.86 0.86 0.85 0.94 
H15 d 3.62 (5.5,7 .1) 3.49 (2.4, 1 0.6) 3.47 (m) 3.41 (3.3,8.7) 3.58 (m) 
H16 ddd or m 1.54 (m) 1.66 (2.3,7.0,14.2) 1.68 (1.9,8.1,14.3) 1.54 (m) 1.73 (m) 
H16 ddd or m 1.54 (m) 1.49 (5.6,1 0.4,14.2) 1.41 (m)d 1.54 (m) 1.73 (m) 
H17 m 3.74 (m) 3.69 (m) 3.56 (m) 3.20 (m) 3.51 (m) 
11-0CH3 s 3.24 3.21 
H18 dd 3.57 (3.5, 11.3) 3.50 (3.8, 11.3) 3.39 (4.0,11.4) 3.65 (3.3,11.9) 4.00 (3.6, 11.9) 
H18 dd 3.38 (6.2, 11.3) 3.38 (6.3, 11.4) 3.32 (5.2,11.4) 3.46 (5.7,11.9) 3.88 (5.3, 11.8) 
aAII data were recorded in the stated solvents, with chemical shifts in ppm relative to CHCI3, o7.25, CHD20D, o3.30, CHD2SOCD3, o2.60, CsHDs, 
o7.27 (coupling constants in Hz). bMethylene proton or methyl grouft prochiral stereochemistries were assigned by NOE experiments. (J) 
cAppearance of signal: s=singlet, d=doublet, t=triplet, m=multiplet Resonances showed unusual line broadening. co 
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Table 1.2 1 H-1 H NOE interactionsa for my calami des A and B. 
Compound 
Mycalamide A 
Mycalamide 8 
Signal(s) 
Irradiated 
H2 
2-CH3 
H3 
3-CH3 (14-CHsR) 
4=CHZ 
4=CHE 
H2S 
6-0CH3 
H7 
Signals enhanced 
(% enhancement) 
2-CHs(2), H3(7), 6-0CHs(2} 
H2(9}, H3{2) 
H2(9}, 3-CH3(2), 4=CHZ(6) 
H3(6), H25{1}, NH(1}, H11(1), H13(4)b, 13-0CH3(0.8)b, 
H15(3)b, H216(3)b 
H3(6), 4=CHE(21), 10-0CHR(6)b 
4=CHZ(21), H25(1) 
3-CH3{0.9), 4=CHE(6)b, 6-0CH3(0A), H7(2), NH(3) 
H17(1) 
H2(7), H2S(O.S), H7(7) 
6-0CH3(3), NH(2) 
NH • H7(3), H11 (6) 
H10 
10-0CHR 
10-0CHS (4=CH2) 
H11 
H12 
H13 (H18u0) 
13-0CH3 (H18d0) 
14-CHsR (3-CH3) 
14-CH3S 
H15 (13-0CHs, 
H18cJC) 
H216 
H17 
H18d0 (H15, 
13-0CHs) 
H18u0 
3-CHs (14-CHsR) 
H5a (H3) 
H5e 
6-0CH3 (H13, H15) 
H7 (H12} 
NH 
H10 
H11 
14-CH3R (3-CHs) 
H17 (17-0CHs) 
17-0CHs (H17, 
6-0CHs) 
10-0CHR(4), H13(3), H15(6) 
H10(5), 10-0CH$(19), H13(5), 13-0CH3(0.7) 
H3(3)b, 4=CHE(7)b, 10-0CHR(14) 
NH(4), H12(10) 
H11 (9), 14-CHsS(1) 
H10(5), 10-0CHR(S), 13-0CH3(1 ), 14-CHsR(0.9), 
H15(4), H18d(4)b,c 
10-0CHR(2), H12(1), H13(3), 14-CH3R(0.5), H17(4)b, 
H18u(3)b,c 
H3(3)b, H5(1)b, H13(5), 13-0CH3(1), H15(4), H216{3) 
H12(10), H216(2) 
H10(10), H13(3}, 14-CH3R(1), H216{2), H17(6), 
H18u(8)b,c 
14-CH3R(2), 14-CHs${1), H15(2), H17(5), H18u(1)0 
H216(1) 
H10(10)b ,H13(3)b, 14-CH3R(1)b, H216(2), H17(6), 
H18u(8)0 
H216(1), H17(2), H18d(1)c 
2-CH3(1 }, H3(5}, H5a(3}, NH(2), H11 (3), H13(1 )b, 
H15(1)b, H216(0.5}b, H17(0.8), 17-0CH3 (0.5) 
H2(5)b, 2-CH3 (0.4}b, 3-CH3(2), 4=CHZ(4)b, H5e(14), 
H7(2), NH(1), H17(3} 
4=CHE(5}, H5a(12), H7(0.4) 
H2(5), H7(9), H10(0.9)b, 10-0CHR(O.S)b 
H5a(0.4}, 6-0CH3(3), NH(3), H11 (0.8)b 
H5a(0.8), H7(4), H11(7) 
NH(1), 10-0CHR(4), H13(5), H15(5) 
3-CHs(0.7), NH(5}, H10(1), H12(10) 
H3(2)b, H5a(1)b, H13(6}, 13-0CH3(1), H15(6), H216(3), 
17-0CH3(0.3) 
H12(4), H216(2) 
14-CH3R(2}, 14-CH3S(2}, H15/H18u(5)0 , H17(5}, 
H18d(2)C 
H5a(2), H216(1}, H18d(2)0 
H5a(0.5)b, H7(0.8)b, H216(2), H18d(1)0 
aAn were data recorded in CDCis bEnhancement interpreted as being due to the irradiation of 
an overtapping signal CHigher field (u) or lower field (d) signal of a geminal pair. 
Table 1.3 13C NMR dataa.b for mycalamides A and B, pederin, and pederin dibenzoate in various solvents. 
Myc.A Myc.A Myc.A Myc.B Myc.B Pederin Pederin dibenzoate (1.2} 
(QOCh) (Qf.:OOO) £d6:DMSO) (QI:&B) (P6Q)) (QDCb,) (CDC8) (CQ:3QD) 
C2 69.81 71.14 69.09 69.63 69.93 69.57 69.68 71.03 
2-CH3 17.88 18.40 18.61 19.94 18.36 17.92 17.91 18.56 
C3 41.37 43.33 41.86 41.27 42.25 41.32 41.35 43.12 
3-CH3 12.02 12.59 12.50 12.15 12.89 12.07 11.98 12.66 
C4 145.65 148.51 148.24 145.10 146.33 145.72 145.67 147.98 
4:CH2 11 0.55 110.32 109.88 111.03 111.24 110.62 110.48 110.70 
C5 33.75 34.80 34.21 33.66 34.74 34.14 34.09 34.90 
C6 99.83 101.67 100.58 99.92 100.94 99.74 99.36 110.84 
6-0CH3 48.94 ? 48.53 48.59 48.86 49.04 48.62 ? 
C7 72.92 73.93 72.97 71.75 72.80 72.84 72.64 74.42 
C8 171.82 175.11 172.31 171.79 172.75 171.77 167.44 170.60 
C10 73.74 75.24 74.28 73.93 74.70 79.43 81.71 84.70 
10-0CH2 86.84 88.02 86.69 86.49 86.94 
1 O-OCH3 56.41 56.43 56.95 
C11 71.26 71.32c 69.23c 70.94 72.42 72.77 70.25c 71.52c 
C12 74.42 75.95 74.28 74.44 75.68 29.59 26.62 26.86 
C13 79.15 80.88 79.77 79.30 79.32 71.98 75.07 77.00 
13-0CH3 61.81 62.25 61.59 61.77 61.86 
C14 41.66 42.63 ? 41.46 42.15 38.60 37.10 38.43 
14-CH3R 23.11 23.82 24.13 23.17 23.40 23.00 24.75 25.63 
14-CH3S 13.49 14.50C 15.20C 13.35 13.78 12.93 17.36C 18.29C 
C15 78.99 78.67 76.54 75.51 76.15 75.85 76.72 78.31 
C16 31.99 33.68 33.31 29.68 31.00 30.09 29.14 30.75 
C17 71.64 72.32 70.24 78.80 79.62 77.69 77.53 79.72 
11-0CH3 56.65 57.08 56.81 56.88 57.58 
C18 66.49 66.62 65.24 63.45 64.41 73.81 72.82 74.02 
18-0CH3 59.17 59.21 59.75 
aAII data were recorded in the stated solvents, with chemical shifts in ppm relative to CDCI3, 877.01, CD30D, 849.30, (CD3)2SO, 840.5, or C6D6. 8128.40. 
bsenzoate ester carbon resonances are listed in the Experimental section. cThese signals were unusually broad. 
'-l 
0 
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Table 1.4 2JcH and 3JcH HMBC and XCORFE correlationsa for mycalamide 
A and pederin. 
Compound <Exptl Detected signal 
Mycalamide A (HMBC) H2 
2-CH3 
H3 
3-CH3 
4=CHBZ 
H2S 
6-0CH3 
H? 
NH9 
H10 
10-0CHR/S 
H11 • 
H12 
H13 
13-0CH3 
14-CH3R 
14-CH3S 
H15 
H216 
H18 
Mycalamide A (XCORFE) C2 
C4 
4=CH2 
C6 
C8 
C10 
10-0CH2 
13-0CH3 
C14 
14-CH3R 
Pederin (HMBC) H2 
2-CH3 
H3 
3-CH3 
4=CHBZ 
H5a/e 
6-0CH3 
H? 
NH 
H10 
10-0CH3 
H11 
H12R/S 
14-CH3R 
14-CH3S 
H16R/S 
18-0CH3 
aAII data were recorded in CDCI3 
Correlated resonances 
3-CH3 
C2,C3 
3-CH3,C4, 4=CH2 
C2, C3, C4 
C3,C5 
C3, C4, 4=CH2, C6 
C6 
C6,C8 
C8, C10 (weak) 
C8 (weak) 
C1 0, C12 
C10, C12, C13 
C10, 10-0CH2, C11, C13 
C12, 13-0CH3, C14, 14-CH3R, 14-CH3S 
C13 
C13, C14, 14-CH3S, C15 
C13, C14, 14-CH3R, C15 
14-CH3S, C16 
C14,C15,C17, C18 
C16 
2-CH3, 3-CH3 
3-CH3, H2S 
H2S 
H2, H2S, 6-0CH3, H? 
H?, H10 
NH9 
H12 
H13 
14-CH3S 
14-CH3S 
3-CH3 
C2,C3 
3-CH3,C4, 4=CH2, C5 
C2, C3, C4 
C3,C5 
C3, C4, 4=CH2, C6 
C6 
C6, C8 
C8 (weak) 
C8, 10-0CH3 
C10 
C10, C12, C13, C15 
C10, C13, C14 
C13, C14, 14-CH3S, C15 
C13, C14, 14-CH3R, C15 
C17, C18 
C18 
Table 1.5 1 H-1 H NOE interactionsa for mycalamide A in other solvents. 
Compound 
Mycalamide A 
(CD30D) 
Signal(s) 
Irradiated 
H2 
H3 
3-CH3 (14-CHsR) 
4=CHE 
H5a 
H5e 
6-0CH3 
H7 
13-0CH3 
Signals enhanced 
(% enhancement} 
2-CH3(2), H3(8), 6-0CH3(2) 
H2(8), 2-CH3(l), 3-CH3(2), 4=CHZ(6) 
2-CH3(2), H3{8), H5a(4), H11 (1) 
4=CHZ(19), H5e(4) 
3-CH3(2), H5e{15), H7(4) 
4=CHE{7), H5a{18), H7(0.8) 
H2{8), H7(1 0) 
6-0CH3(3) 
14-CHsR(1) 
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H16dc 14-CH3R(2), 14-CHsS(0.6), H15/H18d(2)c, H16u(8)c, 
H17(3), H18u(1)C 
Mycalamide A 
(da-DMSO) 
H16uc 
H18uc 
H5a 
H5e (H3) 
H7 
NH 
H10 (7-0H) 
H11 
H12 (H7) 
H13 (H2) 
14-CHsR 
14-CHsS 
H16dc 
H16uc 
14-CH3S(1), H16d(12)c, H17(3) 
H17(5), H18d(9)C 
3-CH3(1), H5e(9), H7(2), NH(0.9) 
H2(5)b, 2-CH3(0.3)b, 3-CHs(O.S)b, 4=CHE(3), 
4=CHZ(3}b, H5a(10), H7(0.3), 7-0H(O.S) 
H5a(0.9), 6-0CHs{2), 7-0H(1), NH(2) 
H5a(0.9}, H7 (3), 10-0CH$(0.9), H11 (4), H12(0.8) 
H7(3)b, NH(2)b, 10-0CHR{2), H11(0.8), H13(2) 
NH(3), H1 0(0.7) 
6-0CH3 (0.4)b, NH(1)b, 10-0CH$(0.8), 13-0CH3(0.5), 
14-CHsS(1) 
2-CH3(0.6)b, H3(2)b, 6-0CHs(0.6)b, H10(2), 
10-0CHR(4), 14~CH3R(1), 14-CHsS(0.3) 
H13(3), 13-0CH3(1), 14-CH3S(0.8), H16d(3)c 
H12(4), 13-0CH3(0.4), 14-CHsR(O.S), H16u(1)c 
14-CHsR(O.S), 14-CHs$(0.3), H16u(4)c, H17(2) 
H11 (1), 14-CH3S(0.4), H16d(6)c, H17(3) 
aAII data were recorded in the stated solvents, CDsOD and ds-DMSO 
bEnhancement interpreted as being due to the irradiation of an overlapping signal 
cHigher field (u) or lower field (d) signal of a geminal pair. 
Table 1.6 Comparison of calculated vicinal proton-proton coupling constants 
for the model structures, 1.3A and 1.38, with experimental 
values recorded for mycalamide Aa. 
H10-H11 
H11-H12 
H12-H13 
Experimental 
(tvWA) 
9.7 
6.8 
10.3 
Calculated values (dihedral angles) 
1.3A 1.38 
8.4(176) 1.7(71) 
6.1 (45) 1.4 (53) 
9.1 (172) 2.2 (73) 
acoupling constants measured in Hz; experimental values recorded in CDCI3 solution. 
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Table 1.7 1 H NMR dataa,b for onnamide A, pederin and pederin dibenzoate. 
H2 
2-CHa 
H3 
3-CHa 
4:CHZ 
4:CHE 
H5a 
H5e 
6-0CH3 
H7 
7-0H 
NH9 
H10 
10-0CHa 
1 0-0CHR 
1 0-0CHS 
H 11 
H12R 
H12S 
H13 
13-0CHa 
14-CH3R 
14-CH3S 
H15 
H16R 
H16S 
H17 
11-0CH3 
H18 
H18 
18-0CHa 
Onnamide A 
3.87 (2.4,6.5) 
1.17 (6.5) 
2.18(m) 
0.96 (6.9) 
4.79 (m) 
4.63 (m) 
2.40 (m, 14.4) 
2.32 (14.4) 
3.22 
4.23 
5.79 (9.3) 
5.18 (6.9) 
4.80 (6.9) 
3.98 (6.5,9.3) 
Pederin 
3.99 (2.7,6.6) 
1.18 (6.6) 
2.24 (2.6,7.1) 
1.00 (7.1) 
4.85 (1.8) 
4.73 (1.8) 
2.32 (1.9, 14.3) 
2.43 (14.2) 
3.33 
4.30 (2.2) 
3.92 (2.3) 
7.15 (9.7) 
5.38 (8.0,9.7) 
3.38' 
Pederin dibenzoate (1.2) 
(C£X;h) (C£b00) 
3.96 (2.6,6.6) 3.81 (2.5,6.5) 
1.11 (6.6) 0.94 (6.6) 
2.21 (2.5,7.3) 2.12 (2.4,7.1) 
0.96 (7.3) 0.86 (7.0) 
4.86 (1.8) 4.80 (7.0) 
4.79 (1.8) 4.71 (2.2) 
2.76 (1.8, 14.4) 2.87 (2.2, 14.5) 
2.49 (14.4) 2.39 (14.6) 
3.24 3.21 
5.50 5.47 
6.78 (9.8) 
5.34 (4.3,9.7) 
3.45 
5.30 (3.4) 
3.47 
3.78 (2.3,6.2,8.0) 3.95 (4.0,5.8) 
2.04 (2.4,4.6, 13.4) 2.15 (4.3,6.2, 13.8) 
4.16 (6.5,9.7)" 1.76 (6.2,11.2,13.3) 1.81 (5.6,7.7,13.6) 
3.97 (3.4,5.5,6.5) 
2.30 (4.3,6.6, 14.0) 
1.85 (5.5,7.3,14.0) 
5.25 (4.3,7.3) 3.62 (9.6) 3.63 (4.8, 11.1) 5.14 (4.1 ,7.8) 
3.55 
1.00 
0.85 
3.47 (3.6,8.1) 
1.53 (m) 
1.53 (m) 
3.64 (m) 
1.49 (m) 
1.28 (m) 
0.93 0.98 1.05 
0.86 1.00 1.01 
3.23 (2.0,10.1) 3.63 (2.4,11.2) 3.76 (2.4,11.2) 
1.68 (3.4, 1 0.0, 14.2) 2.05 (2.4, 11.2, 13.5) 2.09 (3.6, 11.3, 14.6) 
1.57 (2.1 ,9.4, 14.2) 1.79 (2.4,8.6, 13.6) 1.82 (2.4,8.6, 14.5) 
3.38 (m) 3.48 (m) 3.54 (m) 
3.32 3.35 3.37 
3.44 (1.8,9.5) 3.53 (2.5,9.1) 3.57 (2.4,8.7) 
3.32 (5.9,9.5) 3.43 (3.6,9.1) 3.51 (5.2,8.9) 
3.36 3.35 
aoata for onnamide (in CDsOD) were reproduced from reference 31, omitting data beyond C18. 
Data for pederin were measured in CDCis, with chemical shifts in ppm relative to CHCis, o7.25 
(coupling constants in Hz). Data for pederin dibenzoate were measured in the stated solvents, 
where chemical shifts in CDsOD were relative to CHD20D, 03.30 ppm. 
bAromatic proton resonances are listed in the Experimental section. 
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Table 1.8 1 H-1 H NOE interactions for pederin and pederin dibenzoate (1.2). 
Slgnal(s) Signals enhanced 
QQmr;ulun(j Jrragl~!~d ( 0.11 ~nhan~~m~nn 
Pederin H2 2-CHs(2), H3(6) 
H5a (H3) H2(1)b, 3-CHs(1), H5e(11), H7(3), NH(0.8) 
H5e 4=CHE(6), H5a(1 0), H7(0.5) 
H7 H5a(2), H5e(0.5), 6-0CHs(2), 7-0H(1), NH(3) 
10-0CHs(O.S) 
7-0H (H2, H12S, 2-CHs(0.7)b, H3(2)b, H5e(0.8), 6-0CH3(0.8), H7(6), 
2x H16) NH(3), 10-0CHs(O.S), H13(1)b, 14-CHsR(O.S)b, 
14-CHsS(O.S)b 
NH 3-CHs(O.S), H5a(0.5), 6-0CHs(O.S), H7(4), H10(2}, 
1 0-0CHs(O.S), H11 (6) 
H10 NH(1), 10-0CH3(2}, H11(3), H13(6), H15(7) 
H11 NH(4), H10(1), H12R(2), H12S(3) 
H12R H10(1), H11(2), H12S(15), H13(4) 
H12S(H16R) H11(6), H12R(16}, 14-CHg$(2), H16S(4) 
H13 H10(6), H12R(4), 14-CHgR(2}, 14-CHsS(O.S), 
H15(4) 
14-CHsR H13(6), H15(6), H16S(3) 
14-CHsS ( 14-CHsR) H12S(5), H13(2)b, H15(1)b, H16R(2), H16S(1) 
H15 (6-0CHs, H10(8), H13(6), 14-CHsR(2), H16S(1), H18d(3)c 
17 -OCHg, H 18uc) 
Pederin 2-CHs H2(1 0), H3(4) 
dibenzoate (1.2) H3 {H12R) H2/H11 (4), 2-CH3(0.6), 3-CHg(2), 4=CHZ(6), NH(1 }b 
H 12S(7)b, H13(3)b 
4=CHZ H3(9), 4=CHE(9} 
4=CHE 4=CHZ(13), H5e{5) 
H5a 3-CHs(1 ), H5e(24), H7(2) 
6-0CHs H2(6), H7(11) 
H7 6-0CHs(4), NH(6) 
NH H7(11), H10(2), 10-0CH3(0.3), H11 (3) 
H10 NH(1), 10-0CH3(3), H11(3), H15(4) 
10-0CH3 (H17, H7(0.6), NH(1), H10(4), H15(2)b 
H18uC) 
2-CH3(2)b, H3(7)b, 6-0CHs(2)b, NH(3), H10(5), H11 (H2} 
H12S(2), H16R(3) 
H12R(H3) H2/H11(4), 2-CHs(0.6)b, 3-CHs(0.7)b, 4=CHZ(3)b, 
NH(3), H12S(12), H13(6), 14-CH3R(0.7} 
H12S (H16S) H10(1), H11(3), H12R(16), H13(1), 14-CH3S(2), 
H15(4)b, H16R(13)b, H17(2)b 
H13 H12R(3), H12S(1), 14-CH3R(1 ), 14-CHs$(0.7), 
H15(4) 
H15 H10(5), H13(4), 14-CH3R(0.8), H16S(1) 
H16R(H12R) H11(4), H13(1)b,14-CH3S(0.6), H16S(9), H17(2}, 
17-0CH3(1) 
Pederin H10 (H13) 10-0CH3(3), H11(6), 14-CH3R(0.6)b, H15(4) 
dibenzoate (1.2) H11 H10(8), H12S(3}, H16R(2) 
(CDsOD) H12R(H5e) H5a(4)b, H12S(10), H13(5) 
H13 (H10) 10-0CHs(1)b, H11(4)b, H12R(4), 14-CH3R(1), H15(5} 
H15 (H2) 2-CHs(O.a)b, H3(3)b, H10(3}, H13(4), 14-CH3R(1) 
8 AII data were recorded in CDCI3 unless otherwise stated. bEnhancement interpreted as due to 
the irradiation of an overlapping signal. cHigher field {u) or lower field (d) signal of a geminal pair. 
Table 1.9 Comparisons of calculated vicinal proton-proton coupling 
constants for pederin di-p-bromobenzoate (1.1) and model 
conformations of pederin dibenzoate (1.2A, 1.28) with 
experimental values for pederin dibenzoate (1.2)a. 
Experimental Calculated values (dihedral angles) 50% 
Probns 12 1.1 1.2A 1.28 1.2A/1.2B 
H10-H11 4.1 1.7 8.1 1.5 4.8 
H11-H12R 5.9 0.9 1.2 11.4 6.3 
H11-H12S 5.7 8.3 5.8 1.6 3.7 
H12R-H13 4.1 5.0 4.3 3.6 4.0 
H12S-H13 7.8 10.9 11.2 2.7 7.0 
acoupling constants measured in Hz; experimental values recorded in CDCI3 solution. 
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CHAPTER 2 
ESTERS, SIL YL AND ALKYL ETHERS 
OF MYCALAMIDES A & 8 
2.1 INTRODUCTION 
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The overall aims of this research project, as defined in the Introduction, 
were to explore the chemistry of the mycalamides and to determine structure-
activity relationships which ·would assist in the design of analogues. In 
particular, it was desirable to produce mycalamide derivatives with better or 
more selective antiviral or antitumour activity. Another objective was to obtain 
a crystalline heavy atom derivative for examination by x-ray crystallography, to 
confirm the stereochemistry, and to compare the solid state and solution 
conformations, as described in Chapter 1. 
The mycalamide structure has many potentially reactive functional 
groups. As a first step towards achieving the above goals, the syntheses of a 
number of esters, silyl ethers and alkyl ethers were undertaken, to provide 
protected intermediates for use in further reactions. This work was also 
performed to establish the relative reactivity of the individual hydroxyl groups 
so that particular groups could be protected, as required, thus allowing more 
selective reactions to be performed. This relative reactivity depends on a 
combination of steric and electronic factors76 and could provide important 
information about the structure. The requirements for effective protection of a 
particular hydroxyl group are that the derivatisation reaction be high yielding 
and specific, that the protecting group be stable to the desired sequence of 
chemical reactions and, usually, that the original hydroxyl group be readily 
regenerated, specifically and in high yield76, 131. The protecting groups 
presented in this chapter represent a range of size and polarity and a range of 
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stabilities and methods of cleavage. Note that acetals were not considered 
because of potential problems with acid stability of existing groups in the 
mycalamide structure, as found for pederin95,130,132,133. Acid catalysed 
reactions of mycalamide A and derivatives will be considered in Chapter 3. 
This study also represents an introduction to the application of microscale 
reaction chemistry for working on the milligram scale, which included the use 
of small scale . equipment, high yielding and accurate analytical 
chromatographic techniques and sensitive spectroscopic methods . 
. 
There was little work of this kind performed on pederin. No ethers of 
pederin were reported, but various esters and acetals of fragments were 
prepared during its total synthesis127,134,135. Pederin and various derivatives 
were commonly acetylated as a means of structural identification in an early 
study27,94. This acetate group was removed by reduction with lithium 
aluminium hydride. The only other reported esters of pederin were the di-p-
bromobenzoate ester {1.1 ), which was successfully examined by xray 
crystallography34,93, and the related dibenzoate ester127,129,132 (1.2}, used 
for NMR spectroscopic analysis, as described in Chapter 1. 
2.2 SIL YLATION OF MYCALAMIDES A AND 8 
2.2.1 PREPARATION AND CHARACTERISATION OF MYCALAMIDE A AND B 
TRIMETHYLSIL YL ETHERS 
Silyl ethers have found wide use in synthetic organic chemistry for the 
protection of active hydrogen functionalities and a large series of silyl groups 
and reagents have become available78. As protecting groups, they have the 
advantages of being formed and cleaved readily, in high yield and under mild 
reaction conditions136, while possessing a range of stabilities, which also 
allows the selective addition or removal of different silyl ethers137. The most 
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simple of all these are the trimethylsilyl (TMS) ethers, which are also the least 
stable 138, but have found good use in gas chromatography and mass 
spectroscopy to give improved volatility, thermal stability and chromatographic 
behaviour76, and limited use in carbohydrate chemistry??. 137. 
The reaction of mycalamide A with N,O-bis-trimethylsilyl acetamide in 
pyridine at room temperature readily yielded a less polar derivative (by TLC), 
which was a mycalamide A tris-TMS ether (2.1) by HREIMS. The 1 H NMR 
spectrum, recorded in CDCI3, showed the presence of three new signals 
between 80.0 and 0.2 ppm, of correct intensity for TMS ether groups at the 
three hydroxyl sites of mycalamide A. The amide nitrogen was not silylated, 
consistent with the lower reactivity of such groups to silylation78. The 
chemical shift changes on silylation were relatively minor and the spectrum 
was easily assigned using the observed spin multiplicities, coupling constants 
and chemical shifts, compared with those of mycalamide A (Table 2.1 ). In 
particular, the a-protons were almost unaffected, with the largest differences 
occurring in the HSe (+0.2), H15 (-0.3) and H16 (+0.2) signals, and smaller 
differences in signals assigned to H2, NH, H1 0, H11 and H16. These are best 
explained by steric interactions123 involving the new, bulky TMS ethers, which 
may have caused changes in the solution conformations of the chain portions. 
This derivative was not stable in CDCI3 solution, probably due to the 
trace acidity associated with this solvent95, 139, which is considered more fully 
in a later chapter. However, the reprepared derivative was stable in CD2CI2, 
allowing both 1 H and 13C NMR spectra to be recorded. The 1 H NMR data 
were almost identical in the two solvents, therefore to avoid repetition, where 
data in both solvents were recorded, only data in CDCI3 solution have been 
reported. The 13C NMR data were assigned by comparison with those for 
mycalamide A, although some assignments remained uncertain at this point 
(Table 2.2). The CS, C7 and C15 resonances were shifted most, with C16-
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C18 also slightly affected. These shifts117 would also result from changes in 
conformation and shielding effects associated with the proximity of the new 
TMS ether groups. A noticeable feature was the selective broadening of the 
1 4-C H3S and C11 resonances (and the other C12-C15 resonances to a 
lesser extent), and this was found to be a general feature of the 13C NMR 
spectra of all the mycalamide A and B esters and silyl ethers. This may 
indicate a slightly different rate of exchange of chair-chair conformations of the 
trioxadecalin ring system, as discussed in Chapter 1, or a marginal change in 
the relative populations of the conformations 114,115. (Note that the 
magnitudes of the C1 O-C13 vicinal proton-proton coupling constants were 
similar to those found in data recorded for mycalamide A). 
R1=R3=R4=Si(CH3)3, R2=H: Mycalamide A tris-TMS ether (2.1) 
R1=R4=Si(CH3)3, R2=H, R3=CH3: Mycalamide B bis-TMS ether (2.2) 
R1=R2=H, R3=CH3, R4=Si(CH3)3: Mycalamide B 18-mono-TMS ether (2.3) 
R1=R2=H, R3=R4=Si(CH3)3: Mycalamide A 17,18-bis-TMS ether (2.4) 
R1=R2=R3=H, R4=Si(CH3)2C(CH3)3: Myc.A 18-mono-TBDMS ether (2.5) 
R1=R2=H, R3=R4=Si(CH3)2C(CH3)3: Myc.A 17,18-bis-TBDMS ether (2.6) 
R1=R3=R4=Si(CH3)2C(CH3)3, R2=H: Mycalamide A tris-TBDMS ether (2.7) 
R1=R2=H, R3=CH3, R4=Si(CH3)2C(CH3)3: Myc.B 18-mono-TBDMS ... (2.8) 
R1=R4=Si(CH3)2C(CH3)3, R2=H, R3=CH3: Myc.B bis-TBDMS ether (2.9) 
R 1 =R2=R3=H, R4=COC6H4Br: Myc.A 18-mono-p-bromobenzoate (2.1 0) 
R1=COC6H4Br, R2=R3=R4=H: Myc.A 7-mono-p-bromobenzoate (2.11) 
R1=R4=COC6H4Br, R2=R3=H: Myc.A 7,18-di-p-bromobenzoate (2.12) 
R 1 =R2=H, R3=R4=COC6H4Br: Myc.A 17, 18-di-p-bromobenzoate (2.13) 
R1=R3=R4=COC6H4Br, R2=H: Mycalamide A tri-p-bromobenzoate (2.14) 
R1=COC6H4Br, R2=R4=H, R3=CH3: Myc.B 7-mono-p-bromobenzoate (2.15) 
R1=R2=H, R3=CH3, R4=COC6H4Br: Myc.B 18-mono-p-bromobenzoate (2.16) 
R1=R4=COCsH4Br, R2=H, R3=CH3: Myc.B di-p-bromobenzoate (2.17) 
R1=R3=R4=COCH3, R2=H: Mycalamide A triacetate (2.18) 
R1=R4=COCH3, R2=H, R3=CH3: Mycalamide B diacetate {2.19) 
R1=R2=H, R3=CH3, R4=COCH3: Mycalamide B 18-monoacetate (2.20) 
R1=COCH3, R2=R4=H, R3=CH3: Mycalamide B 7-monoacetate (2.21) 
R1=R3=R4=COCH2CH3, R2=H: Mycalamide A tripropanoate {2.22) 
R1=R2=H, R3=CH3, R4=S02CH3: Mycalamide B 18-monomesylate {2.23) 
R1=R2=CH3, R3=R4=H: 7-Q..Methyl, N-methyl mycalamide A (2.24) 
R1=R2=R4=CH3, R3=H: 7,18-di-Q..Methyl, N-methyl mycalamide A (2.25) 
R1 =R2=R3=R4=CH3: 7, 17, 18-tri-Q..Methyl, N-methyl mycalamide A (2.26) 
R1 =R2=R3=CH3, R4=H: 7, 17:di-Q..Methyl, N-methyl mycalamide A (2.27) 
R1=R3=R4=CH3, R2=H: 7,17,18-tri-0-Methyl mycalamide A (2.31) 
R1=R4=CH3, R2=R3=H: 7, 18-di-0-Methyl mycalamide A (2.32) 
R1 =R3=CH3, R2=R4=H: 7, 17-di-Q..Methyl mycalamide A {2.33) 
R1=CH3, R2=R3=R4=H: 7-Q..Methyl mycalamide A (2.34) 
R1=R2=R3=H, R4=CH3: 18-Q..Methyl mycalamide A (2.35) 
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R1=COCH3, R2=H, R3=R4=CH3: 17,18-di-Q..Methyl myc.A 7-monoacet. {2.36) 
R1=R3=CH3, R2=H, R4=COCH3: 7,17-di-Q..Methyl myc.A 18-monoacet. (2.37) 
R1=R2=H, R3=R4=CH3: 17, 18-di-Q..Methyl mycalamide A (2.38) 
R1=CH2Ph, R2=R3=R4=H: 7-Q..Benzyl mycalamide A (2.39) 
R1=R4=CH2Ph, R2=R3=H: 7,18-di-Q..Benzyl mycalamide A (2.40) 
R1=R2=CH2Ph, R3=R4=H: 7,18-di-Q..Benzyl mycalamide A (2.41) 
R1 =R2=R4=CH2Ph, R3=H: 7, 18-di-Q..Benzyl, N-benzyl mycalamide A {2.42) 
R1=CH2Ph, R2=R4=H, R3=CH3: 7-0-Benzyl mycalamide B (2.43) 
R1 =R4=CH2Ph, R2=H, R3=CH3: 7, 18-di-0-Benzyl mycalamide B (2.44) 
R1=R2=CH2Ph, R3=CH3, R4=H: 7-Q..Benzyl, N-benzyl mycalamide B (2.45) 
R1 =R2=R4=CH2Ph, R3=CH3: 7, 18-di-Q..Benzyl, N-benzyl myc.B (2.46) 
The reaction of mycalamide B with the same reagent gave mycalamide 
B bis-TMS ether (2.2) by HREIMS. The 1 H NMR spectrum showed the 
presence of two TMS signals between 80.0 and 0.2 ppm, consistent with this 
formulation, with similar chemical shift changes on silylation to those noted 
above (Table 2.1 ). Irradiation of the signal at 80.2 ppm, in an NOE 
experiment, gave an enhancement of the H7 and 6-0CH3 resonances (Table 
2.3), so this was assigned to the TMS ether group located at C7. The 13C 
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NMR spectrum also showed a similar pattern of chemical shifts to those 
observed above, but with less effect at C15 and C16 (Table 2.2). 
2.2.2 SELECTIVE TRIMETHYLSIL YLATIONS OF MYCALAMIDES A AND B 
It was clear that silylation of mycalamides A and B proceeded very 
readily, but it was proposed that cooling of the reaction might introduce some 
selectivity in the site of silylation. The reaction of mycalamide B with the 
reagent in an ice-cooled system for five minutes gave a single product by TLC 
which was more polar than the bis-TMS ether above, but less polar than 
mycalamide B. HREIMS confirmed that this was a mycalamide B mono-TMS 
ether. The 1 H NMR spectrum showed a single TMS resonance at 80.13 ppm, 
and comparison of all the chemical shifts (Table 2.1) with those for the bis-
TMS ether and mycalamide B suggested that the silyl group was attached to 
the C18 oxygen. This was confirmed by an observed broadening of the H7 
resonance due to coupling to the underivatised C7 hydroxyl group, which was 
removed on addition of 020 and by selective proton decoupling. The 13C 
NMR data (Table 2.2) were also consistent with mono-silylation at the C18 
oxygen, and were similar to those recorded for mycalamide B. Therefore this 
derivative was assigned the structure 2.3. 
The reaction of mycalamide A under similar conditions also gave a 
single product by TLC, of intermediate polarity, and HREIMS showed that it 
was a mycalamide A bis-TMS ether. The 1 H NMR spectrum showed the 
presence of two TMS signals between 80.0 and 0.2 ppm, and the H7 
resonance appeared as a doublet, implying the presence of the C7 hydroxyl 
group. This was confirmed by addition of 020, which removed this coupling, 
and the doublet at 83.95 ppm, so the latter was assigned to this hydroxyl 
proton. This required that the product be a mycalamide A 17, 18-bis-TMS 
ether (2.4) and the chemical shift data (Table 2.1) were consistent with this. 
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There was insufficient sample to record a 13C NMR spectrum and attempts to 
repeat this reaction were unsuccessful due to the formation of either tris- or 
mixed mono-silylated products. Therefore the initial clean formation of this 
bis-TMS ether was actually rather fortuitous. 
2.2.3 CLEAVAGE OF TMS ETHERS AND DISCUSSION 
The removal of these TMS ether groups from mycalamide A tris-TMS 
ether was attempted using tetra-n-butyl ammonium fluoride in tetrahydrofuran 
. 
{THF} at room temperature78. TLC and 1 H NMR spectroscopy showed 
complete hydrolysis to mycalamide A within minutes. The mechanism for this 
cleavage involves an attack of fluoride ion on the central silicon atom and 
displacement of the alkoxy group in an SN2 reaction. The driving force for this 
cleavage is the preferential formation of the very stable silicon-fluorine bond, 
and is general for silyl ethers136. 
The mechanism of formation of these silyl ethers is also SN2, with attack 
of the hydroxy oxygen on the silyl electrophile, as activated in the reagent. 
This explains the preferred silylation of the C18 hydroxyl group in mycalamide 
8, since there is an expected steric effect in such reactions which favours 
reaction of primary over secondary hydroxyl groups76,140,141. The favoured 
silylation of both C17 and C18 hydroxyl groups in mycalamide A over the C7 
hydroxyl group was slightly more surprising, and some synergistic effect may 
be involved. 
An example of the use of the TMS ether group as a protecting group in 
an acylation reaction will be given later in the chapter. However, it became 
apparent that this group was too readily hydrolysed to be of much use in 
mycalamide modifications, as the derivatives were too unstable to storage and 
to mild acid and base 138. Therefore a more versatile silyl ether was 
considered and the t-butyldimethylsilyl ether was chosen, since it was 
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reported to show good acid and base stability136, 138. This group, being of 
larger size, also allows greater selectivity in reaction and can be used for the 
selective protection of primary hydroxyl groups 142,143, as well as for 
secondary and tertiary groups78, 136. 
2.2.4 PREPARATION AND CHARACTERISATION OF MYCALAMIDE A AND B 
T-BUTYLDIMETHYLSIL YL ETHERS 
The reaction of mycalamide A with t-butyldimethylchlorosilane 
(TBDMCS) and triethylamine in chloroform was very slow at room 
temperature. Silylation reactions were expected to be more rapid in polar 
aprotic solvents136,142 so in this case the solvent was changed to pyridine, 
which could also act as a co-catalyst142. Also dimethylaminopyridine142,143 
(DMAP) has been reported to be an excellent catalyst for difficult silylation and 
acylation reactions, so this was incorporated into the present reaction. These 
modifications were highly successful, with two less polar derivatives being 
readily obtained from mycalamide A, as monitored by TLC. These products 
were well resolved on silica gel and were cleanly separated and purified from 
reagents using a small pipette column (see Experimental). HRFABMS of 
these products showed that the major one was a mycalamide A mono-TBDMS 
ether and the other a mycalamide A bis-TBDMS ether derivative. 
The 1 H NMR spectrum of the mono-silylated derivative showed the 
presence of two new signals, at 80.9 and 0.1 ppm, which were assigned to the 
t-butyl methyl and the two methyl groups attached to silicon, respectively. The 
H7 resonance was coupled to a signal at 83.8 ppm, which was assigned to the 
C7 hydroxyl proton, and there was a second hydroxyl resonance at 82.8 ppm, 
which appeared as a doublet, so this had to arise from the hydroxyl group at 
C17. Both resonances were removed on addition of D20. Therefore this was 
a mycalamide A 18-mono-TBDMS ether (2.5), as expected, based on the 
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preferential silylation of primary hydroxyl groups by this reagent, discussed 
above. Full 1 H NMR spectral assignments are shown in Table 2.4. The major 
chemical shift changes occurred for the H15, two H16, H17 and H18 proton 
resonances, consistent with this assignment. A 13C NMR spectrum was also 
recorded for this derivative, and this showed the presence of new signals at 
825.8 and -5.5 ppm for the new methyl resonances, which were similar to 
those shown in model compounds144, but few chemical shift changes 
compared with data recorded for mycalamide A (Table 2.5). 
Similarly the 1 H NMR spectrum of the bis-TBDMS ether derivative, 
recorded in CD2CI2, showed two sets of signals for the TBDMS ether groups, 
and the presence of the coupled H7-C7-0H system required that these silyl 
ether groups be at C17 and C18, as in structure 2.6. By adding a trace of 
pyridine to the sample, the compound was also found to be stable in CDCI3, 
and the 1 H NMR spectrum was readily assigned to give the data in Table 2.4. 
The addition of a TBDMS ether at C17 had an effect on the chemical shifts of 
some protons which appeared to be remote, including the NH, H1 0, H11, H13, 
H15, H5a and H5e protons. This suggested that there were some changes to 
the solution conformations of the chain portions due to longer range steric 
effects. NOE experiments established the assignment of the dimethyl silyl 
ether resonances at C17 and C18 (Table 2.3) but the solution conformations 
were not investigated. The 13C NMR spectrum of a larger sample showed 
shifts in the C15-C18 resonances, in addition to the new signals for the 
TBDMS ether groups (Table 2.5). 
A second reaction of mycalamide A with the same reagents, but at 6ooc 
for two days, gave a mixture of the mycalamide A 17, 18-bis-TBDMS ether 
(2.6) above and a less polar derivative. These were separated by silica gel 
column chromatography and the new product was found to be the 
corresponding mycalamide A tris-TBDMS ether (2.7) by HRFABMS. The 1 H 
85 
NMR spectrum showed shifts in the H2, two H5 and NH resonances (Table 
2.4), and the new dimethyl silyl signals were resolved, suggesting a more 
chiral neighbouring environment98. Irradiation of H7 in an NOE experiment 
gave a strong enhancement of the H5e and 6-0CH3 resonances, as well as 
the new dimethyl silyl signals (Table 2.3). The strong H5e-H7 interaction 
represents a larger population of this C6-C7 rotamer than in mycalamide A or 
8, as discussed in Chapter 1, and could be caused by steric effects involving 
the new bulky silyl ether group at C7. The 13C NMR spectrum reflected these 
. 
changes, with shifts in the C5, 6-0CH3, C7 and C8 resonances (Table 2.5}. 
Similar results were obtained for mycalamide 8, where the mycalamide 
B 18-mono-TBDMS ether derivative {2.8} was obtained from a reaction at 
room temperature, but the bis-TBDMS ether {2.9) was obtained only under 
forcing conditions. HRFABMS, 1H and 13C NMR spectra were obtained for 
both derivatives and assignments of the NMR data are shown in Tables 2.1 
and 2.5. The 13C NMR spectral assignments were confirmed by an HMQC 
experiment, particularly the assignment of the downfield C7 resonance, which 
was uncertain in other derivatives until this result144. The remaining shifts in 
both mycalamide B derivatives were similar to those observed for the 
mycalamide A TBDMS ethers. 
2.2.5 CONCLUSIONS AND BIOLOGICAL ACTIVITY 
In summary, the order of silylation of the hydroxyl groups in mycalamide 
A was C18, C17 then C7, and this was more pronounced in reactions with the 
more bulky TBDMCS reagent. This order of substitution would therefore allow 
a selective reaction at the C7 hydroxyl group, if desired. Biological assay 
results on these derivatives are shown in Table 2.6. It is apparent that the 
mycalamide A and B TMS ethers were of similar activity to the parent 
compounds, but this may simply reflect the ease of hydrolysis and instability of 
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these derivatives138. However, the mycalamide A and B TBDMS ethers, 
which were much more stable (reportedly 1 o4 times more stable to 
hydrolysis136), displayed a rapid decline in activity with increasing substitution 
of the hydroxyl groups of mycalamides A and B. In particular, substitution at 
the C18 group caused a 50-fold loss in the activity of mycalamide A and a 
200-fold loss in the activity of mycalamide B. Further substitution led to 
effectively inactive derivatives in both assay systems. One possible factor in 
the loss of biological activity could be the reduced polarity of these derivatives, 
. 
which could decrease their solubility1. Another factor could be the size 16 of 
these TBDMS ether groups as it has been indicated from the NMR 
spectroscopic work above that the solution conformations of some of the 
derivatives have been altered from those of mycalamides A and B. It is 
possible that at least some of the hydroxyl groups of mycalamides A and B are 
important for favourable interactions with an active site 15, although the 
structure of pederin and mycalamide B suggests that the C17 and C18 
hydroxyl groups of mycalamide A are not essential, and this is investigated 
more completely in a later section of this chapter. Therefore, although these 
compounds could be useful protected intermediates, they did not appear to be 
useful analogues for their biological activity. 
2.3 ESTERIFICATION OF MYCALAMIDES A AND B 
2.3.1 PREPARATION AND CHARACTERISATION OF P-BROMOBENZOATE 
ESTERS OF MYCALAMIDES A AND B 
The overall aim of this investigation was to determine the optimum 
conditions for the preparation of larger quantities of a mycalamide A or B p-
bromobenzoate ester, which could be crystallised and subjected to analysis 
by x-ray crystallography. Therefore it was important to investigate the relative 
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reactivities of the various hydroxyl groups in mycalamides A and B under the 
reaction conditions required for this esterification, and to examine the physical 
properties of the products obtained. 
Mycalamide A reacted with p-bromobenzoyl chloride and triethylamine 
in dichloromethane at room temperature to give a mixture of two products and 
starting material by TLC. This mixture was separated by reverse phase HPLC 
and the two products, which were white solids from methanol-water mixtures 
but oils from less polar solvents, were found to be mycalamide A mono-p-
bromobenzoate isomers by HRFABMS. UV spectra were recorded which also 
confirmed the presence of this aromatic ester group. 
The 1 H NMR spectrum of the major product showed two new doublets, 
at 87.89 and 7.57 ppm, due to the aromatic protons of a p-bromobenzoate 
ester group1 01, and two hydroxyl proton doublets, at 83.76 and 3.20 ppm, 
which were removed on addition of D20. The multiplicity of these latter 
resonances required that the underivatised hydroxyl groups be those at C7 
and C17, and the complete spectrum of this mycalamide A 18-p-
bromobenzoate (2.1 0) was assigned using results from a COSY experiment 
(Table 2.7). Note that there were shifts in the H15 (+0.1), H16 (+0.1), H17 
(+0.3), H18 (+0.7) and H18 (+0.9) proton resonances which also required that 
the esterification be at the C18 oxygen 101. 
The 1 H NMR spectrum of the minor product contained aromatic proton 
resonances for the new ester group and showed a large downfield shift in the 
H7 resonance ( + 1.4 ppm), consistent with a mycalamide A 7-mono-p-
bromobenzoate ester (2.11 ). There were also shifts in many of the 
resonances belonging to protons on the 01-C6 ring or its substituents (Table 
2. 7), whereas those resonances for the rest of the structure were relatively 
unchanged in chemical shift from those observed for mycalamide A. No 13C 
NMR spectra were recorded for either of these derivatives. 
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As with the silylation of mycalamide A using the bulky TBDMCS 
reagent, this p-bromobenzoylation reaction was slow. Therefore the reaction 
conditions were modified to include dimethylaminopyridine as a catalyst143, 
pyridine as the solvent and a higher reaction temperature, in order to favour 
the formation of more substituted derivatives. This modified reaction on 
mycalamide A was successful by TLC and three new derivatives were 
separated by reverse phase HPLC, along with more of the 18-mono ester 
derivative (2.1 0). HRFABMS showed that these new products, which were 
. 
white solids from methanol-water mixtures but oils from less polar solvents, 
were two mycalamide A di-p-bromobenzoates and one tri-p-bromobenzoate 
ester. 
The 1 H NMR spectrum of the new compound, which had the shortest 
retention time on reverse phase HPLC, contained H7 and H18 proton 
resonances which were shifted downfield by more than 0.6 ppm, in addition to 
two pairs of aromatic resonances. There were also smaller shifts in the 
resonances of protons near to C7 and C18 (Table 2. 7}, consistent with a· 
mycalamide A 7,18-di-p-bromobenzoate ester (2.12). A 13C NMR spectrum 
was recorded which showed significant shifts in the C8 (-4.3}, C17 (-2.7) and 
C18 (+2.0) carbon resonances (Table 2.2), consistent with normal substituent 
effects for acylation 117 at C7 and C18 (the C6 and C7 resonances may be 
otherwise influenced by changes in the solution conformations). The 1 H NMR 
spectrum of the second mycalamide A di-p-bromobenzoate showed the 
presence of the coupled H7-C7-0H system, in addition to the new aromatic 
signals, so that the two ester groups had to be at C17 and C18, as in structure 
2.13. The downfield shifts in the C16-C18 sidechain proton resonances were 
consistent with this (Table 2.7), as assigned by a COSY experiment. The 1 H 
NMR spectrum of the remaining tri-substituted product showed three sets of 
aromatic signals and large downfield shifts in the H7, H17 and H18 proton 
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resonances (Table 2.7), as expected for this structure (2.14). Some 
resonances were broadened, such as those assigned to H 12, H15 and the 
two H16 protons, suggesting some conformational averaging. This was not 
surprising with the presence of three bulky ester groups and the high 
molecular weight (1052 daltons). The H10-H11, H11-H12 and H12-H13 
coupling constants were significantly smaller, suggesting a higher proportion 
of the alternate chair-chair conformation of the trioxadecalin ring system than 
in mycalamides A and B, as proposed in Chapter 1, but this was not 
investigated further. 
It was apparent that although there was a progressive reaction at the 
three hydroxyl groups in mycalamide A, there was no great selectivity in the 
reaction, so this was not ideal for the preparation of larger amounts of a single 
derivative. Therefore the reaction of mycalamide B was considered, since this 
compound had only two hydroxyl groups. The reaction of mycalamide B 
under the modified conditions above, at ssoc for one week, gave a mixture of 
unreacted material and the three possible product esters, although one was 
minor. Preparative reverse phase HPLC separated these compounds, which 
were also white solids from methanol-water mixtures, and HRFABMS 
confirmed that there were two mono-p-bromobenzoates (2.15, 2.16) and one 
di-p-bromobenzoate ester (2.17) of mycalamide B. 
The 1 H NMR spectrum of the minor product, which had eluted first by 
HPLC, showed that the single ester group was positioned at C7 (structure 
2.15), since there were the usual shifts in the H7 and nearby proton 
resonances (Table 2.4), whereas other signals were not affected. The major 
product, eluting second by HPLC, was mycalamide B 18-mono-p-
bromobenzoate (2.16) by 1 H NMR spectroscopy, with the assignments (Table 
2.4) being confirmed by a COSY experiment. A 13C NMR spectrum was also 
recorded for this derivative, which showed only the expected shifts in the C16 
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(+0.9), C17 (-2.4} and C18 (+ 1.0) carbon resonances (Table 2.2). The 1 H and 
13C NMR spectra of the remaining product, the mycalamide B di-p-
bromobenzoate ester (2.17}, were similarly assigned (Tables 2.4 and 2.2) 
Biological activity results on all these esters will be discussed in a later 
section. 
2.3.2 ATTEMPTS TO CRYSTALLISE MYCALAMIDE A AND B P-BROMO-
BENZOATE ESTERS 
Large quantities of pederin and some of its derivatives were readily 
crystallised from benzene-hexane mixtures, giving, invariably, needles, plates 
or elongated prisms94. Pederin di-p-bromobenzoate (1.1) was examined in 
two independent x-ray crystallographic investigations34,93. The crystals 
required for these studies were grown from methanol-ether and ethanol 
solutions, respectively, and were described as colourless plates or prisms34. 
Initial attempts to crystallise the small amounts of the mycalamide A and 
B p-bromobenzoate esters prepared above did not produce encouraging 
results. The samples were first dissolved in small amounts of methanol-water 
mixtures in Craig tubes and set aside at 40C. Slow evaporation of these 
solutions eventually yielded only oils. Similar results were obtained from 
methanol-ether solutions, also benzene-heptane, ether-petroleum ether, and 
ethanol-ether-petroleum ether mixtures. One sample, mycalamide A 7-mono-
p-bromobenzoate (2.11 ), gave fine, hair-like needles after slow evaporation 
from benzene-ether, but these were unsuitable for x-ray examinations. 
The best derivative to direct a large scale reaction towards appeared to 
be the mycalamide B di-p-bromobenzoate ester (2.17), since, based on the 
work above, this derivative would be favoured with higher temperatures and 
longer reaction times, and was also the most similar in structure and polarity to 
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pederin di-p-bromobenzoate (1.1 ). Such a reaction was performed to give 
about 17 mg of this derivative after purification on silica gel. Several attempts 
were then made to obtain suitably crystalline material, but all were 
unsuccessful. From alcoholic solvents, including methanol, ethanol and iso-
propyl alcohol, the material slowly oiled out of solution. From hot hexane 
solution the material precipitated slowly as a white, non-crystalline solid. With 
a few drops of ethanol added to this sample, a mixture of white solid, fine 
fibrous material and oil was obtained. Other solvent mixtures were also tried, 
but all were ineffective in producing single crystals, despite the high purity of 
the sample, and, regrettably, this work was eventually abandoned. 
2.3.3 PREPARATION AND CHARACTERISATION OF MYCALAMIDE A AND B 
ACETATE ESTERS 
The mycalamide A and B p-bromobenzoate esters were not ideal 
protected intermediates, since the formation reactions were slow and 
generally gave mixtures of several products which required chromatographic 
separation, while the cleavage reaction would require the use of fairly strong 
bases 78,138. In contrast, acetylation was a derivatisation reaction used 
extensively in an early chemical and structural study of pederin94, and was 
expected to be fast and high yielding, while giving products that had some 
mild acid stability, but would be easily removed by bases78,138. 
The reaction of mycalamide A with pyridine and acetic anhydride 
proceeded readily at room temperature, to give a single product by TLC, and 
HREIMS showed that this was mycalamide A triacetate (2.18). The IR 
spectrum, recorded in chloroform solution, showed a major carbonyl stretching 
band96 at 1740 cm-1, with shoulders at 1705 and 1690 cm-1, while the FTIR 
spectrum, recorded as a film, showed these bands at 1741, 1705 and 1680 
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cm-1. Also distinctive was the sharp N-H stretch at 3380 and 3370 cm-1 in the 
solution and film I R spectra, respectively96. 
The 1H NMR spectrum of mycalamide A triacetate (2.18) showed three 
new methyl resonances between <52.0 and 2.2 ppm, being those for the 
acetate esters, and shifts in many signals as assigned by a COSY experiment 
(Table 2.7). In particular, the H7 (+ 1.2), NH (-0.2), H15 (-0.2), H16 (+0.2), H17 
(+1.2), H18 (+0.7) and H18 (+0.8) resonances were shifted most, with smaller 
shifts in H5a, 6-0CH3 and H16, consistent with acetylation of the three 
hydroxyl groups101. However, the H10, 10-0CHR, H11, H12 and H13 
resonances were also affected, and the vicinal proton-proton coupling 
constants for the trioxadecalin ring system protons were slightly smaller, 
suggesting some changes in the relative proportions of various solution 
conformations. This was also found for the mycalamide A tri-p-
bromobenzoate ester (2.14) above, but was not investigated further. A 13C 
NMR spectrum showed shifts in some resonances (Table 2.2), for example 
those assigned to C7 (-1.1 ), C8 (-4.5), C11 (-1.3), C15 (-3.4), C16 (-1.9), C17 (-
1.5) and C18 (-2.8), in addition to the new methyl and carbonyl resonances, 
consistent with acetylation 117,145 and conformational changes. Note that the 
shielding effect at the ~ carbons is stronger than the deshielding effect at the 
carbons a to the new acetate groups. This effect is apparently general for 
aliphatic esters, and is thought to arise in part from steric perturbations 
involving the carbonyl oxygen118. 
When the mycalamide A acetylation reaction was left for a shorter time, 
a 1 :1 mixture of two products was obtained, including mycalamide A triacetate 
(2.18) and a more polar derivative. The 1 H NMR spectrum of the mixture 
showed that the second product was probably mycalamide A 7, 18-diacetate, 
since there were large downfield shifts in the H7 and H18 proton resonances, 
two new acetyl methyl resonances between <52.0 and 2.2 ppm, and also a new 
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doublet at o3.0 ppm, which was probably the C17 hydroxyl proton resonance. 
However no attempt was made to isolate this product. 
The acetylation of mycalamide B under analogous conditions readily 
gave a diacetyl derivative (2.19) by HREIMS and HRFABMS. The 1 H NMR 
spectrum was consistent with this, since there were similar shifts in the various 
resonances on acetylation to those found above (Table 2.8), as assigned by a 
COSY experiment, in addition to the two new acetyl methyl resonances. 
Irradiation of the three methoxyl resonances in an NOE experiment proved the 
assignment of these resonances, with known interactions being observed 
(Table 2.3). Of interest was the obseNed NOE interaction between the 17-
0CH3/H17 and the H5 protons, as found for mycalamide B (Chapter 1 ), which 
suggests that these compounds share a similar major overall solution 
conformation. The 13C NMR spectrum of mycalamide B diacetate (2.19) was 
similar to that of mycalamide B, except for the new reso~ances, a large upfield 
shift in the C8 resonance, as above, and a smaller shift in C17 (Table 2.9). 
2.3.4 SELECTIVE CLEAVAGE OF ACETATE ESTERS IN MYCALAMIDE A 
AND B ACETYL DERIVATIVES 
The most common method for the cleavage of ester groups is base 
hydrolysis77,78, although lithium aluminium hydride was successfully used to 
selectively remove the acetate groups of pederin diacetate94. Note that the 
standard mechanism for base catalysed ester hydrolysis is almost the reverse 
of the formation mechanism, and involves the attack of hydroxide ion on the 
carbonyl group of the ester to give a tetrahedral intermediate, then a loss of 
the alkoxy group to regenerate the starting alcohol and the carboxylate of the 
ester group146. Mycalamides A and B were expected to be stable to the mildly 
basic conditions required for such hydrolysis, which seemed preferable to 
reductive cleavage. 
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Mycalamide A triacetate (2.18) was stirred with a dilute solution of 
potassium carbonate in aqueous methanol at room temperature78. After two 
hours, TLC showed complete hydrolysis to mycalamide A. The same reaction 
was attempted on mycalamide 8 diacetate (2.19), monitoring by TLC. The 
reaction was observed to give a compound of intermediate polarity, probably a 
mycalamide 8 monoacetate, within minutes, which decomposed slowly to give 
mycalamide 8, by TLC and 1 H NMR spectroscopy, after twelve hours. 
In order to determine the nature of this partial hydrolysis product, the 
reaction was repeated, but quenched after one hour. Preparative TLC purified 
the major product, which was a mycalamide 8 mono-acetate by DCIMS and 
HREIMS. The 1 H NMR spectrum of this derivative showed a single methyl 
resonance at 82.08 ppm, and H18 resonances that were downfield of their 
position in the spectrum of mycalamide 8, as assigned by a COSY experiment 
(Table 2.8), whereas the chemical shifts of the H7 resonance and resonances 
of nearby protons were relatively similar for the two compounds. The H7 
resonance was also broadened by coupling to the C7 hydroxyl resonance, as 
shown by a selective proton decoupling experiment. A 13C NMR spectrum 
was also recorded and this showed very similar chemical shifts to those of 
mycalamide 8, except at C16, C17 and C18, along with the expected new 
acetyl methyl and carbonyl resonances (Table 2.9). Therefore this was 
mycalamide 8 18-monoacetate (2.20). 
The faster rate of hydrolysis of the acetate group at C7, compared with 
that at C18, probably reflects the greater stability of primary acetate esters over 
secondary ones, due to steric factors??. However, the presence of 
neighbouring electron-withdrawing entities at C6 and C8 may also cause 
some destabilisation of esters at C7140, making them more susceptible to 
hydrolysis. Therefore it has been shown that acetyl esters of mycalamides A 
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and B could be easily formed and cleaved under mild reaction conditions and 
in high yields, making this a potentially useful protecting group76,78. 
2.3.5 PREPARATION OF MYCALAMIDE B 7-MONOACETATE USING A TMS 
ETHER PROTECTING GROUP 
It was expected that the partial acetylation of mycalamide B would 
favour the formation of a C18 ester, as found for the p-bromobenzoylation 
reaction above. In order to prepare a C7 mono-acetyl derivative in good yield 
for use in structure-activity comparisons it was therefore considered necessary 
to use a protecting group, and this seemed to be a good opportunity to test the 
stability of the mycalamide TMS ethers. Therefore mycalamide B 18-mono-
TMS ether (2.3) was reacted with acetic anhydride and pyridine for three 
hours at room temperature, before quenching by the addition of water. After 
workup, TLC and mass spectroscopy showed that desilylation had occurred 
and that there was one mono-acetyl product, along with a small amount of 
mycalamide B diacetate (2.19). Silica gel column chromatography purified 
this product and the 1 H NMR spectrum confirmed that this was mycalamide B 
7-monoacetate (2.21 ), as shown by the characteristic shifts in the signals 
assigned to H7 and nearby protons, and the presence of a single new methyl 
resonance at 82.20 ppm (Table 2.8). Partial 13C NMR spectral data were 
obtained on the crude product (Table 2.9) and the molecular formula was 
confirmed by HRFABMS. 
Therefore the TMS ether group was clearly useful in giving a good yield 
of the desired derivative, although it was not completely stable to the 
conditions138 as shown by the presence of up to 25% mycalamide B diacetate 
in the product mixture. The observed desilylation of the major product 
evidently occurred during the aqueous workup procedure, and was an 
unexpected bonus, in that it saved an extra deprotection step. The use of the 
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corresponding TBDMS ether derivative would probably have eliminated the 
presence of mycalamide B diacetate due to the enhanced stability of these 
ethers136,138, but this was not attempted. 
2.3.6 PREPARATION AND CHARACTERISATION OF OTHER ESTERS OF 
MYCALAMIDES A AND B 
Two other esters were also prepared, which would add to the limited 
structure-activity data already obtained and to the existing range of esters 
above, of varying size, polarity, and reactivity. Mycalamide A tripropanoate 
(2.22) was readily prepared from the reaction of mycalamide A with pyridine 
and propionic anhydride at room temperature, as shown by HRFABMS and 
NMR spectroscopy. The 1 H NMR spectrum showed very similar chemical 
shifts to those of mycalamide A triacetate (2.18) (Tables 2. 7 and 2.8), but was 
more complex in the alkyl region, due to the presence of a small amount of 
reagent and the non-equivalence of the methylene protons on one of the ester 
groups, indicative of the chiral environment98. The 13C NMR spectrum 
showed three carbonyl resonances between 8173 and 174 ppm for the 
propanoate ester groups 117, so that the assignment of the C8 resonance at 
8167.2 ppm was unambiguous, and all the 13C NMR chemical shifts for the 
mycalamide structure were close to those observed for mycalamide A 
triacetate (Table 2.2). 
The preparation of methane sulphonate esters of mycalamide B was 
also investigated, as these were potentially reactive intermediates for 
substitution reactions147. The reaction of mycalamide B with methane 
sulphonyl chloride (mesyl chloride) in pyridine overnight at room temperature 
gave predominantly one product by TLC, with some unreacted mycalamide B. 
Preparative TLC purified this product and HRFABMS showed that this was a 
mycalamide 8 mono-mesylate. The 1 H NMR spectrum was assigned with the 
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assistance of a COSY experiment (Table 2.8), and this showed a new methyl 
signal at 83.06 ppm, being the methyl group of the new sulphonate ester1 01, 
and large downfield shifts in the H18 proton resonances. Also the C7 hydroxyl 
proton resonance was present, coupled to the H7 resonance, so that this 
product was mycalamide B 18-monomesylate (2.23). As expected, the 1 H 
NMR chemical shifts were close to those observed for mycalamide B 18-
monoacetate (2.20). The 13C NMR spectral data (Table 2.9) were also 
similar, except for the appearance of the new methyl resonance, at 837.6 ppm, 
and for the chemical shift of the C18 carbon resonance, which was almost 6 
ppm further downfield in the spectrum of the mesylate than in the data 
recorded for mycalamide B. This large downfield shift in the a carbon 
resonance on forming the sulphonate ester is, however, well documented for 
various model compounds. For example, the 13C NMR data for both 2-
mesyloxy adamantane 148 and 1-mesyloxy cyclohexane 145 show a + 10-11 
ppm downfield shift in the a carbon resonance, compared to data for the 
corresponding alcohols, whereas the shift on acetylation is only +2-3 
ppm 145,148. Therefore these data were consistent with the structures stated. 
However, the mycalamide B 18-mesylate derivative was unstable on storage, 
decomposing to a large mixture of compounds by 1 H NMR spectroscopy. 
2.3.7 BIOLOGICAL ACTIVITY OF MYCALAMIDE A AND B ESTERS 
The biological activity results obtained for the various mycalamide A 
and B esters described above are listed in Table 2.6. The series of p-
bromobenzoates, in particular, provided some interesting results, where 
substitution at the C18 oxygen was significantly more deactivating for 
mycalamide B than for mycalamide A (the derivatives 2.16 and 2.10 were 
respectively 200 times and 2 times less active than the starting compounds). 
Assuming that this is a valid result, this therefore represents a significant 
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selectivity in either the size, polarity or potential conformations of the C16-C18 
sidechain. Substitution at the C17 and C18 hydroxyl groups of mycalamide A 
gave a derivative (2.13) that was at least 50 times less active than the 18-
mono ester (2.1 0}, which was a similar pattern to that found for the 
mycalamide A TBDMS ethers. Mono-substitution at the C7 oxygen was 
strongly deactivating for both mycalamide A and 8 (50- and 200-fold 
reductions in activity). The remaining disubstituted and trisubstituted 
mycalamide A and B esters were even less active, but the relatively similar 
results observed may represent a limit in the purity achieved, rather than true 
activity. 
Analogous results were found for the remaining esters of mycalamides 
A and B. Mycalamide A triacetate (2.18) was about 1 00 times less active than 
mycalamide A and mycamide B diacetate (2.19) was about 200 times less 
active than mycalamide B. A similar result was found for pederin dibenzoate 
(1.2) compared to data for pederin (Table 2.6). The mycalamide B 7- and 18-
monoacetates (2.21, 2.20) were, respectively, about 20 and 10 times less 
active than mycalamide B. Mycalamide A tripropanoate (2.22) appeared to 
be slightly less active than mycalamide A triacetate and mycalamide 8 18-
mesylate (2.23) only slightly less active than mycalamide B. The latter result 
was also interesting, since it appeared that having a methane sulphonate 
ester at this position was more tolerable than similar substitution with an 
acetate ester, but the significance of this result is uncertain. 
Therefore some useful overall trends were observed in the biological 
activities of these esters, which would suggest that the C7 hydroxyl group is 
quite important for the biological activity, but that the C17 and C18 hydroxyl 
groups are less essential, although the size and polarity of the substituents at 
these positions also appeared to be important. 
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The above esters and silyl ethers all suffered from one major 
disadvantage in that they were not stable to strongly acidic or basic 
conditions138. Therefore alkylation reactions were considered as a method of 
further protecting the hydroxyl groups for more vigorous reaction conditions 
and to extend the structure-activity correlations found so far. 
2.4 METHYLATION OF MYCALAMIDES A AND B 
Mycalamides A and l3 have structures which are rather similar to 
pederin and it was shown in Chapter 1 that these compounds have very 
similar solution conformations. The only differences between these structures 
occur in the substituents at C1 0, C12, C13, C17 and C18. In particular, the 
interchange of hydroxyl and methoxyl groups at C13, C17 and C18 in these 
structures was of interest, in view of their similarly potent biological activities. 
A methylation study on mycalamides A and B was initiated to consider this, 
together with the effects of methylation of the C7 hydroxyl group and the 
amide. 
2.4.1 REVIEW OF METHODS FOR THE METHYLATION OF HYDROXYL 
GROUPS 
The formation of methyl ethers from hydroxyl groups can be 
accomplished by several methods76-78. The most general is the reaction of a 
nucleophilic oxygen group, usually an alkoxide ion formed under basic 
conditions, with a reagent, CHsX, where X is usually halide, sulphate, or 
sulphonate, in an SN2 reaction on the reagent. Earliest methylation methods 
involved the reaction of a carbohydrate with sodium in liquid ammonia, then 
treatment of the salt with methyl iodide. A more recent method generated the 
alkoxide ion with sodium hydride in aprotic solvents. Another established 
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method is to treat an aqueous solution of a carbohydrate with strong alkali and 
dimethyl sulphate (the Haworth procedure). Selective methylations have 
been described using two phase systems149. Another alternative was to use 
silver oxide and methyl iodide (the Purdie method). The Kuhn modification of 
this method uses N,N-dimethylformamide (DMF) as the solvent and replaces 
silver oxide by barium or strontium oxides or hydroxides150. Recently, the use 
of dimethylsulphoxide (DMSO) and powdered potassium hydroxide has been 
reported by Johnstone and coworkers151 as a mild, rapid technique for the 
permethylation of hydroxyl and amide groups. 
The synthesis of particular partially methylated compounds can be a 
problem since many protecting groups are not stable to the alkaline reaction 
conditions76. An alternative approach is the nucleophilic displacement of 
sulphonate esters by methoxide ion, in an SN2 reaction on the substrate, or a 
similar ring-opening reaction on epoxides77. A third method of forming methyl 
ethers in base sensitive compounds is to use diazomethane activated by an 
acid catalyst, such as boron trifluoride or wet silica gel, as the methylating 
agent76,78. 
2.4.2 PREPARATION AND CHARACTERISATION OF PRODUCTS FROM THE 
METHYLATION OF MYCALAMIDES A AND BUSING THE METHOD 
OF JOHNSTONE 
The title reaction was chosen for initial investigation because of the mild 
reaction conditions, rapid reactions and high yields of permethylated products 
reported from reactions of alcohols and am ides at room temperature 151. It 
was found that none of the protecting groups above were stable to these 
reaction conditions, but selectivity was not a requirement for this study since 
the biological activities of all products were of interest, and the reaction 
conditions could be optimised or modified as required. 
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The reaction of mycalamide A Vl(ith powdered potassium hydroxide and 
methyl iodide in DMSO for four hours at room temperature gave a mixture of 
two major products and a third minor product by TLC, but only two resolved 
peaks were apparent by reverse phase HPLC. Preparative HPLC in fact 
yielded only one pure fraction, representing the major, most polar product, and 
a second fraction, which was a mixture of two components in a 4:1 ratio, by 1 H 
NMR spectroscopy. DCIMS and HREIMS showed that the first fraction 
consisted of a mycalamide A derivative with two new methyl groups, while the 
second contained tri-methylated compounds. 
The 1 H NMR spectrum of the major product showed two new CH3-X 
resonances, at o3.45 and 3.19 ppm. The more upfield resonance was likely to 
be attached to the amide nitrogen1 01, as indicated by the absence of an NH 
resonance and the appearance of the H1 0 resonance as a doublet, instead of 
the usual triplet. There were also shifts in some resonances (Table 2.1 0), 
particularly those assigned to H5a (+0.3), H1 0 (+0.5) and H11 (+0.3), which 
suggested that the new methyl groups be located on the C7 oxygen and 
amide nitrogen atoms (structure 2.24 ). Irradiation of H7 in an NOE 
experiment gave an enhancement of both of the new resonances and the C6 
methoxyl resonance (Table 2.3), in accordance with this assignment. It is 
therefore proposed that the absence of a significant shift in the H7 resonance 
on methylation of the C7 hydroxyl group represents the fortuitous cancellation 
of two opposing effects:-
i) an expected upfield shift due to methylation of the C7 group 101, and 
ii) a downfield shift due to steric deshielding effects associated with the 
presence of a methyl group rather than a hydrogen atom at the amide 
nitrogen 123. 
A 13C NMR spectrum was recorded, which showed two new 
resonances, at o28.8 and 58.9 ppm, which were assigned to the new N-methyl 
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and C7 methoxyl groups respectively. There were also large shifts in the C7 
(+9.8), C10 (+3.6) and C11 (-4.1) resonances (Table 2.11), consistent with 
methylation at the positions stated117. Most of the resonances in the 1 H and 
13C NMR spectra were broadened, an effect which will be discussed in a 
conformational analysis, described below. 
In order to determine the identity of the more highly substituted 
products, the methylation reaction was repeated on a slightly larger scale and 
the reaction continued until TLC showed that these products were dominant. 
. 
Preparative TLC gave two fractions, where the minor one contained a tri-
methylated derivative, and the major one a tetra-methylated mycalamide A, by 
DCIMS and HREIMS. The 1 H NMR spectrum of the more polar, tri-methylated 
derivative showed that this was the same compound as found in the earlier 
reaction, but was now pure. There. were many similar features to that of the 7-
0-methyl, N-methyl mycalamide A derivative (2.24) above, but, in addition, 
there was a new methoxyl resonance, at 83.35 ppm, and further shifts in the 
two H16 (+0.1, -0.1), H17 (<0.1), and H18 (-0.3) proton resonances (Table 
2.1 0), as assigned by a COSY experiment. A 13C NMR spectrum also showed 
shifts in the C16 (+1.4), C17 (-1.9) and C18 (+10.0) resonances (Table 2.11). 
Therefore this was a 7, 18-di-0-methyl, N-methyl mycalamide A derivative 
(2.25), which was also the next most likely derivative on mechanistic grounds, 
since the C18 primary hydroxyl group would be expected to undergo an SN2 
reaction faster than the secondary C17 hydroxyl group 140 (assuming prior 
methylation of the C7-0H and amide NH groups, as observed above). 
The 1 H NMR spectrum of the major, less polar derivative was consistent 
with complete methylation of the amide and .hydroxyl groups in mycalamide A 
(2.26), having the new N-methyl and methoxyl resonances of the derivative 
above and a new methoxyl resonance at 83.27 ppm, which was assigned to 
the group at C17. There were also shifts in the H17 (-0.5) and H18 (+0.2) 
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resonances (Table 2.1 0), compared to those for the 7, 18-di-0-methyl, N-
methyl derivative (2.25), as assigned by a COSY experiment, that were 
indicative of this methylation101. Again many resonances were broad and 
there appeared to be some minor signals present, but this will be discussed 
with the results of further experiments below. The 13C NMR spectrum was 
assigned with the assistance of an HMQC experiment, and this also confirmed 
previous assignments of the C7, N-CH3 and C1 0 resonances. The observed 
shifts in the C17 and C18 resonances (+7.7 and -4.0 ppm respectively, relative 
to those of the 7, 18-di-0-methyl, N-methyl derivative) were also in line with 
normal substituent effects 117 (Table 2.11 ). 
Similarly, methylation of mycalamide B gave two products by TLC, 
which were separated by reverse phase HPLC. The less polar, minor product 
was identical by TLC, HPLC and 1H NMR spectroscopy to that of the 7,17,18-
tri-0-methyl, N-methyl mycalamide A derivative (2.26) above, giving further 
evidence that mycalamide B was the 17-0-methyl derivative of mycalamide A. 
The major, more polar derivative was therefore the expected 7-0-methyl, N-
methyl myc~lamide B (or 7, 17-di-0-methyl, N-methyl mycalamide A, 2.27) as 
shown by DCIMS, HREIMS and NMR spectroscopy. To avoid confusion in the 
naming of these compounds, the mycalamide B methyl ethers will be referred 
to as 17-0-methyl mycalamide A derivatives throughout this chapter. The 1 H 
NMR spectrum showed the same features noted above for 7-0-methyl, N-
methyl mycalamide A (2.24), but with the usual mycalamide B C16-C18 
sidechain resonances. NOE experiments were performed to confirm the 
assignment of the methoxyl resonances (Table 2.3). Of interest was the 
observation of a strong NOE interaction between the N-methyl and H11 
protons, so that the H1 0 and N-methyl groups were in an anti relationship, just 
as the NH and H1 0 protons of mycalamide A. The 13C NMR spectral data 
(Table 2.11) were also similar to those of 7-0-methyl, N-methyl mycalamide A 
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(2.24), except in the chemical shifts of the C16 sidechain resonances, as 
expected. 
2.4.3 CONFORMATIONAL EXCHANGE INN-METHYL MYCALAMIDES 
An analysis of the vicinal proton-proton coupling constants and 
selected NOE interactions for all these derivatives showed that the major 
solution conformations of the ring structures were the same as for mycalamide 
A. However, the 1 H and 13C NMR spectra of all the 7-0-methyl, N-methyl 
derivatives, recorded at 23·oc, contained many broadened resonances, 
suggesting that some slow conformational exchange process was 
occurring98,114,121. A variable temperature 1H NMR study, between -soc and 
ssoc, was conducted to investigate the broadening of signals for 7, 17, 18-tri-
0-methyl, N-methyl mycalamide A (2.26). Compared to the spectrum at 23°C, 
the spectra recorded at successive increments of 1 ooc higher showed an 
increased broadening of many signals. However, on cooling to 60C all 
signals sharpened to normal resolution and linewidths, while some new 
signals were also observed on the baseline, which were small and broad. 
These new signals must arise from the presence of a minor conformation 
involved in an exchange process, since some saturation transfer of irradiation 
was observed between pairs of major and minor resonances in NOE 
experiments performed at room temperature 152. For example, irradiation of 
the H10 resonance, at 36.26 ppm, caused some saturation of a broad, minor 
signal at 35.5 ppm, which was therefore assigned to the minor H1 0' 
resonance. The HSa', H7' and N-CH3' resonances were also located in this 
way and integration of the resonances showed that the ratio of conformers 
was about 5:1. The observed NOE interaction between H7 and H1 0 (Table 
2.3), not normally observed, required that this minor conformation involve an E 
conformation about the C-N amide bond1 oo, 107, as shown in Figure 2.1 b. 
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Note that the minor H10' resonance was a doublet (8.9 Hz}, so that the H10 
and H11 protons were in an anti relationship1 02, suggesting that the 
trioxadecalin ring system had the same major solution conformation in both 
amide forms. The full 1 H NMR data for the major conformer, recorded at soc, 
are listed in the Experimental section, and limited data for the minor conformer 
are shown in Figure 2.1 b. The observed chemical shift differences between 
resonances· for the two conformations, which was largest for the H1 0 
resonance, could be readily explained by dipolar, anisotropic shielding effects 
involving the amide carbonyl,~ and by smaller steric effects123. 
Figure 2.1 1 H-1 H NOE interactions and partial solution conformations of 
7-Q-methyl, N-methyl mycalamide A derivatives. 
a) Major conformation 
b) Minor conformation 
This amide isomerism is due to the partial double bond character of the 
C-N bond which causes a substantial energy barrier to rotation (~so kJ mol-1) 
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and is well known in N ,N-dialkyl am ides and formamides79,98, 107. 
Significantly, there appeared to be an increasing contribution from the minor 
conformation with methylation at the C17 and C18 hydroxyl groups for these 
7-0-methyl, N-methyl mycalamide A derivatives. This may suggest that the 
sidechain substituents are sufficiently close in solution to interact with the 
central hydroxy amide system. 
2.4.4 FURTHER DERIVATIVES FROM METHYLATIONS IN DMSO 
Methylation experiments performed with undried DMSO were 
significantly slower than those with dry DMSO, as could be expected153. In 
such an experiment with mycalamide A, powdered potassium hydroxide and 
methyl iodide, a new product was observed in the reaction mixture, which 
moved faster on silica gel TLC than the tetra-methylated derivative (2.26) 
above. Preparative TLC was performed to purify this compound and DCIMS 
and HREIMS showed that it was an isomer of 7, 17, 18-tri-0-methyl, N-methyl 
mycalamide A (2.26). The 1 H NMR spectrum showed shifts in the H5a (+0.2), 
H5e (+0.4), H7 (-0.1), 7-0CH3 (+0.1), N-CH3 (-0.1), H16 (+0.1), H16 (-0.1) and 
H17 (-0, 1) proton resonances (Table 2.1 0), as assigned by COSY and NOE 
experiments (Table 2.3). The 13C NMR spectrum also showed shifts in the C6 
(+1.0), 6-0CH3 (+1.5) and C7 (-3.0) resonances (Table 2.11). These data 
suggested the formation of an epimer at C7 (2.28), which could occur through 
an enolisation reaction at C7-CS154, involving the adjacent amide carbonyl 
group155. 
Two further experiments were performed in an attempt to prove this. 
Firstly, 7, 17-di-0-methyl, N-methyl mycalamide A (2.27) was treated with a 
solution of sodium methoxide in methanol in a sealed vial at gooc, monitoring 
by TLC. After three days, silica gel TLC showed that there was a mixture, 
including a minor amount of starting material and a product of higher Rt, so, 
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after workup, these were separated by preparative TLC. DCIMS and HREIMS 
confirmed that this was an isomer of 7,17-di-0-methyl, N-methyl mycalamide A 
(2.27), and the 1 H and 13C NMR spectra for this derivative (Tables 2.10 and 
2.11) showed similar shifts to those observed for the C7 epimer of the 
tetramethylated mycalamide derivative above. Therefore this was 7 S, 17-di-0-
methyl, N-methyl mycalamide A (structure 2.29). NOE experiments also 
showed the same interactions between the H7 proton and both the 6-0CH3 
and N-CH3 protons (Table 2.3). 
R1=H, R2=R3=CH3: 78,17,18-tri-0-Methyl N-methyl mycalamide A (2.28) 
R1=R3=H, R2=CH3: 7S,17-di-O-Methyl N-methyl mycalamide A (2.29) 
R1=D, R2=R3=H: 7-Deutero, ?S-O-methyl N-methyl mycalamide A (2.30) 
In a second experiment, 7-0-methyl, N-methyl mycalamide A (2.24) 
was treated with a solution of fully deuterated sodium methoxide in methanol 
at 7ooc, to give a similar mixture of epimers by TLC. DCIMS and HREIMS 
showed that a quantitative incorporation of one deuterium atom had occurred 
in the purified product, which was the C7 epimer of 7-0-methyl, N-methyl 
mycalamide A by 1 H NMR spectroscopy (structure 2.30), having no H7 proton 
resonance (Table 2.1 0). Therefore the proposed structures of these 
derivatives had been confirmed. 
Significantly, the observed signals in the 1 H and 13C NMR spectra of 
these epimers were sharp, with no indication of conformational exchange, and 
no NOE interactions were observed between the H7 and H1 0 protons to 
suggest the presence of an E conformation of the amide. This suggests that 
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the normal amide conformation (Z) was very dominant for these C7 epimers, 
as for mycalamides A and B. It is possible that one factor in the different 
populations of the two· amide conformations for these isomers could be 
unfavourable steric interactions107. The different chromatographic mobilities 
may also be associated with the different conformational effects, arising from 
the epimerisation at C7106. 
Another methylation experiment was performed on mycalamide A using 
barium oxide as the base 150 in place of the powdered potassium hydroxide, in 
a reaction conducted at ssoc. The single product obtained was found to be 
7, 17, 18-tri-0-methyl, N-methyl mycalamide A (2.26) by TLC and 1 H NMR 
spectroscopy. This demonstrated that the amide anion was still formed in 
sufficient concentration to permit amide methylation, despite the use of an 
apparently weaker base156. 
Finally, a reaction was performed on mycalamide B in which the 
amount of methyl iodide added was slightly less than usual, but still in excess. 
This gave an almost 1 :1 ratio of 7, 17-di-0-methyl, N-methyl mycalamide A 
(2.27) and a more polar compound by HPLC and 1 H NMR spectroscopy, 
where the latter was not mycalamide B. The H7 resonance of the new 
compound was shifted upfield1 01 (-0.4 ppm), whereas the H1 0 resonance 
appeared as a triplet, with a chemical shift close to that observed for the same 
resonance in mycalamide B, suggesting that this was a 7,17-di-0-methyl 
mycalamide A derivative (2.33). However, there was insufficient material from 
this reaction to purify this compound and, rather than repeat this reaction, it 
was decided to concentrate on finding alternative methods of methylation 
which would not affect the amide, nor be so biased towards methylation of the 
C7 hydroxyl group. 
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2.4.5 PREPARATION AND CHARACTERISATION OF PRODUCTS FROM THE 
METHYLATION OF MYCALAMIDES A AND BUSING METHYL IODIDE 
AND SILVER OXIDE IN BENZENE 
Silver(l) oxide, which is a milder base than potassium hydroxide, has 
been used in conjunction with methyl iodide in methylation reactions for many 
years76,77 (Purdie method). It has been reported156 that silver salts promote 
the 0-alkylation of amides, which was potentially useful, although really no 
amide alkylation was desiredt In a study on the alkylation of 2-pyridones157 it 
was obseNed that the choice of the solvent, as well as the base, had a major 
effect on the methylation product obtained. For example, non-polar solvents, 
such as benzene, favoured 0-alkylation. In the present study, it was reasoned 
that the preferential methylation of the C7 hydroxyl group for the reactions in 
DMSO could be a reflection of a greater ease of ionisation of this group, due to 
the presence of neighbouring electron-withdrawing entities at C6 and C8. A 
non-polar, low-ionising solvent, such as benzene 140,158, could reduce the 
importance of this effect, and possibly also reduce formation of the amide 
anion 156, so that new methylated products might be obtained. Therefore the 
methylation of mycalamide A was attempted with this new combination of 
silver oxide and methyl iodide in benzene. 
2.4.5.1 PRODUCTS DERIVED FROM MYCALAMIDE A 
The reaction of mycalamide A with the above reagents, in a sealed vial 
at sooc for three days, gave a mixture of three products of higher Rt by silica 
gel TLC, which gave light orange-brown chars on visualisation with 
anisaldehyde (see Experimental), similar to mycalamides A and B, whereas 
darker brown chars were obtained for the N-methylated derivatives above. A 
1 H NMR spectrum of the mixture showed that there were apparently no 
products arising from methylation of the amide group, since the H1 0 
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resonances were of similar chemical shift to those observed for mycalamide A 
and appeared as triplets, indicating the presence of coupling between the H1 0 
protons and the adjacent NH and H11 protons. However, there were several 
new methoxyl resonances, confirming that methylation of some of the hydroxyl 
groups had occurred. Preparative TLC gave three pure fractions, which 
represented one trimethylated mycalamide A derivative and two dimethylated 
derivatives by DCIMS and HREIMS. A 1 H NMR spectrum of the least polar, 
major fraction showed three new methoxyl resonances, at o3.55, 3.37 and 
3.28 ppm, and there were shifts in the H7 (-0.4), NH (-0.4), H15 (-0.3), H17 (-
0.4) and H18 (-0.1) proton resonances (Table 2.12), consistent with 
methylation of the three hydroxyl groups of mycalamide A101 (2.31 ). 
Irradiation of H7 in an NOE experiment gave an enhancement of the NH 
resonance and the methoxyl resonances at o3.55 and 3.28 ppm (Table 2.13), 
which were therefore assigned to the groups at C7 and C6, respectively, by 
reference to the mycalamide A data. The remaining methoxyl resonances 
could be assigned by comparison with data for the N-methylated derivatives 
above. The 13C NMR spectrum of this derivative (2.31) also showed three 
new methoxyl resonances, at o60.2, 59.19 and 56.81 ppm, which were 
assigned by comparison with data for derivatives above. There were also 
shifts in the C7 (+10.2), C8 (-1.5), C15 (-3.1), C16 (-2.1), C17 (+6.2) and C18 
(+6.5) resonances (Table 2.14) which were indicative of this methylation117. 
The 1 H NMR spectrum of the second fraction showed some similar 
features to those discussed above for compound 2.31, but the resonance 
assigned to the C17 methoxyl group was absent. Furthermore, the H15 and 
H17 proton resonances were shifted much less, compared to the mycalamide 
A data, whereas the H18 resonances were shifted further upfield (Table 2.12), 
as shown by a COSY experiment. The same NOE interactions were observed 
on irradiation of H7 as above. Therefore this evidence suggested that this 
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derivative was 7, 18-di-0-methyl mycalamide A (2.32). The 13C NMR 
spectrum confirmed this117, since the ~15 and C16 resonances were similar 
to those observed for mycalamide A, whereas there was a small upfield shift in 
the C17 resonance (-1.5) and a large downfield shift in the C18 resonance 
(+9.8 ppm) (Table 2.14). 
The final fraction was too small to perform a full NMR spectroscopic 
analysis. However, a 1H NMR spectrum suggested that this was a 7,17-di-Q-
methyl derivative (2.33), based on the chemical shifts of the H7 and new 
. 
methoxyl resonances (Table 2.12) and the otherwise similarity of the spectrum 
to that of mycalamide B. The preparation of this compound from mycalamide 
B is described below. 
In an attempt to prepare the remaining, less highly substituted methyl 
ethers, the reaction of mycalamide A with silver oxide and methyl iodide in 
benzene (in a sealed vial at 950C) was stopped after 1.5 hours, when TLC 
showed the presence of at least two compounds of similar Rt to mycalamides 
A and B. Careful preparative TLC separated four fractions, of which the most 
polar was unreacted mycalamide A by 1 H NMR spectroscopy. The remaining 
fractions contained only compounds that were isomeric with mycalamide B by 
DCIMS and HREIMS. 
The 1 H NMR spectrum of the second, most polar fraction contained a 
new methoxyl resonance at 83.56 ppm, which was enhanced on irradiation of 
H7 in an NOE experiment. The observed upfield shift in H7, and the large 
downfield shift of C7 in a 13C NMR spectrum (Tables 2.12 and 2.14), were 
further evidence that this was 7-Q-methyl mycalamide A (2.34). 
The 1 H NMR spectrum of the least polar, major fraction contained a new 
methoxyl resonance at 83.35 ppm, while the H18 resonances were shifted 
upfield, as confirmed by a COSY experiment. Similarly, the 13C NMR 
spectrum showed similar shifts in the C16-C18 sidechain resonances to those 
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of the 7, 18-di-0-methyl derivative, but was otherwise similar to that of 
mycalamide A Therefore this was 18-0-methyl mycalamide A (2.35). 
The 1 H NMR spectrum of the remaining fraction showed it to be a 
mixture of 17-0-methyl mycalamide A and 18-0-methyl mycalamide A (2.35), 
in a ratio of about 3:2. Hence mycalamide A had been partially converted into 
mycalamide B, but in rather poor yield, since the major product of the reaction 
was clearly the 18-0-methyl derivative. Based on the product masses, the rate 
of methylation at the three hydroxyl groups, C18, C17 and C7 was about 3:1 :1, 
which illustrates only the expected steric effect which causes SN2 reactions at 
primary hydroxyl groups to be favoured over those at secondary hydroxyl 
groups140. Therefore this reaction had been entirely successful in obtaining a 
different priority for methylation of mycalamide A and thus a wider range of 
derivatives. 
2.4.5.2 PRODUCTS DERIVED FROM MYCALAMIDE BAND THE USE OF AN 
ACETYL PROTECTING GROUP FOR OPTIMISED SEPARATIONS 
The remaining derivative not obtained from the methylation of 
mycalamide A was the 17, 18-di-0-methyl derivative, which was of most 
interest due to the similarity with pederin. Methylation of mycalamide B would 
seem to provide a good route to this, and the reaction of mycalamide B under 
analogous conditions did give a mixture of at least two components by TLC. 
To overcome the problem of the similarity in Rt values for the different 
derivatives, it was decided to derivatise prior to separation. An acetylation 
reaction was easily performed on the crude product mixture, to give three 
clearly resolved components by silica gel TLC. These were separated by 
preparative TLC and examined by 1 H NMR and mass spectroscopies. The 1 H 
NMR spectrum of the least polar fraction showed that this was mycalamide B 
diacetate (2.19), arising from the presence of unreacted mycalamide B in the 
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product mixture. The remaining two fractions contained mycalamide B 
monoacetates, each with a new methyl group, by DCIMS and HREIMS. 
The 1 H NMR spectrum of the major monoacetate clearly showed that 
the ester group was at C7, since there was a large downfield shift in the H7 
proton resonance and a new acetate methyl resonance at o2.20 ppm. There 
was also a new methoxyl resonance at o3.37 ppm and an upfield shift in the 
H 18 proton resonances, consistent with methylation at the C 18 hydroxyl 
group, giving the structure 2.36. The 1 H NMR spectral data were fully 
assigned with the assistance of a COSY experiment (Table 2.8). The 13C 
NMR spectral data (Table 2.9) were also consistent with these substitutions. 
The 1 H NMR spectrum of the minor monoacetate similarly showed the 
expected downfield shifts in the H18 proton resonances, due to acetylation of 
the C18 hydroxyl group, and an upfield shift in the H7 resonance with 
methylation at the C7 group, along with the new methoxyl and acetate 
resonances (Table 2.8). COSY and NOE experiments were performed to 
prove the assignments of the 1H NMR data and a 13C NMR spectrum was also 
obtained for this compound, 7, 17-di-0-methyl mycalamide A 18-monoacetate 
(2.37). 
The pure 7, 17-di-0-methyl (2.33) and 17, 18-di-0-methyl (2.38) 
mycalamide A derivatives were obtained by deacetylation of the 
monoacetates (2.37 and 2.36) in mild base, using conditions described 
earlier in this chapter. TLC, DCIMS, HREIMS, 1 H and 13C NMR spectroscopy 
showed complete deacetylation and the NMR data for both derivatives (Tables 
2.12 and 2.14) were readily assigned by comparison with those of other 
derivatives. Therefore a full set of all possible partially and fully methylated 
derivatives of mycalamide A had been obtained from these reactions. 
It was observed that, on storage, the 7, 17-di-D-methyl derivative (2.33) 
began to form fine rosettes from the solvent evaporated oil, suggesting a 
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tendency towards crystallisation which none of the previous derivatives had 
shown. Indeed, slow evaporation from ether/petroleum ether mixtures gave 
fine, clear needles. Preliminary x-ray analysis of one crystal showed weak 
diffraction, but the size of the crystal was unfortunately too small to permit a full 
analysis using equipment in this department. Further crystallisation attempts 
from other solvent mixtures or from cooled solutions gave non-crystalline 
solids or oils, respectively. A subsequent attempt to repeat the results above 
also failed, probably because of the small sample size and contamination from 
. 
solvent impurities after many attempts. It was possible that an x-ray 
crystallographic analysis could be performed on needles like those above on 
equipment not available here. However, unfortunately, there was insufficient 
time to repeat the synthesis and purification of this derivative for such an 
analysis. 
2.4.6 BIOLOGICAL ACTIVITIES OF MYCALAMIDE METHYL ETHERS 
The results obtained from tests in our assay system of the biological 
activities of the mycalamide methyl ethers have been listed in Table 2.6. Note 
that, in order to present accurate data, several derivatives were subjected to a 
further stage of chromatography, since the presence of trace amounts of more 
active derivatives may otherwise have distorted many of the results. For 
comparative purposes, the results for mycalamides A and B and pederin have 
also been listed. 
It is readily apparent that alkylation of the C7 hydroxyl group leads to 
the greatest change in biological activity, that is a substantial deactivation by a 
factor of at least 102-1 Q3. This loss in activity due to substitution of the C7 
hydroxyl group appeared to be less dramatic for the esters, discussed in an 
earlier section, but just as significant for the t-butyldimethylsilyl ethers. These 
results confirm that the C7 hydroxyl group has a very important role in the 
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activity of the mycalamides. It is possible that this functionality is directly 
involved in binding with a receptor15 (on a ribosome49) which leads to an 
inhibition of protein synthesis, since the latter is a known mechanism of action 
of the mycalamides57 and pederin46,47 (see Introduction). It has been shown 
from methylations performed in DMSO that the C7 hydroxyl group is the most 
nucleophilic entity in mycalamides A and B under basic conditions. This is 
probably due to the presence of neighbouring electron-withdrawing groups 
(the amide carbonyl at C8 and the acetal at C6), which may inductively 
promote ionisation of this hydroxyl group. 
Methylation of the amide nitrogen also occurred readily, but the 7-0-
methyl, N-methyl derivatives obtained appeared to be even less active than 
the 7-0-methyl derivatives above and could be considered inactive within the 
limits of purity attained. This result suggests the probable importance of 
neighbouring functional group systems to C7 for the biological activity. 
Of particular interest was the biological activity of derivatives in which 
the C7 hydroxyl group was not methylated. Methylation of either, or both of the 
C17 and C18 hydroxyl groups in mycalamide A gave three different 
derivatives which were significantly more active than mycamide A and almost 
equally as potent as pederin. However, since the 17-0-methyl derivative 
(mycalamide B) is also a natural product, and the other two derivatives were 
approximately equal in activity to this compound, then overall this somewhat 
difficult sidechain methylation seems to represent no major improvement for 
potential analogues. 
One possible factor in the increased biological activities of these 
derivatives, compared with mycalamide A, could be the changes in the 
distributions of solution conformations of this C16-C18 sidechain portion on 
methylation of the hydroxyl groups, as observed by 1 H NMR spectroscopy. In 
particular, the H15-H16 coupling constants are 5.5 and 7.1 Hz in mycalamide 
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A in CDCI3 solution, but 3.3 and 8.3 Hz in mycalamide 8, and the smaller 
value is 2.9 Hz in 18-0-methyl mycala.mide A (2.35). However, this portion of 
the molecule is undoubtedly flexible and various hydrogen bonding effects are 
possible. The close spatial interaction of the sidechain of mycalamide 8 with 
the 01-C6 tetrahydropyran ring has previously been shown by the obseNation 
of various NOE interactions (Chapter 1) and results from the N-methyl 
derivatives also suggest that the substituents on this sidechain have some 
effect on interactions at the amide site. Further reactions on this sidechain will 
be reported in Chapter 7. 
The remaining structural differences between the mycalamides and 
pederin occur in the substituents at C1 0, C12 and C13. Evidently methylation 
of the C13 hydroxyl group of pederin would have no major effect on the 
activity, since the C13 methoxyl group is present in all the mycalamides. Also, 
the extra ring in mycalamides A and 8 and onnamide A has the effect of fixing 
the conformation of the C1 0 methoxyl group of pederin, but this too evidently 
has little effect on the biological activity, as illustrated by the similarity of the 
results for 17, 18-di-0-methyl mycalamide A (2.38) and pederin. Thus these 
changes were not significantly affecting the active conformation70,71 or 
interactions at the active site15,16. 
Further work is in progress to test these derivatives in a variety of assay 
systems. The mycalamide A and 8 methyl ethers were tested against a wide 
range of tumour cell lines at the National Cancer Institute (NCI) in the U.S.A. 
Although some were not tested at appropriate concentrations it appeared that 
the compounds were relatively non-selective in their action. However, the NCI 
has expressed further interest in some of these derivatives. 
2.5 BENZYLATION AND RELATED ATTEMPTED ALKYLATIONS 
OF MYCALAMIDES A AND 8 
117 
The preparation of mycalamide A and 8 benzyl ethers arose from the 
need for a protecting group that would be stable to strongly basic conditions 
and yet be easily added or removed under relatively neutral conditions. The 
methyl ethers prepared above could not be selectively cleaved, since the 
favoured reagent for their removal, boron trichloride76, also attacks all ether 
. 
and acetal bonds77. Also, the preparation and purification of these ethers was 
not trivial. In contrast, benzyl ethers can be cleaved under conditions in which 
most other groups are stable, namely by hydrogenolysis over palladium 
catalysts77,78. The reactions of mycalamides A and B under such conditions 
will be reported in Chapter 4, but these did not exclude this possibility. 
Alternatively, some substituted benzyl ethers are also removable under mild 
oxidising conditions78, 159. (The lability of the benzyl group and related 
derivatives is due to the stability of the benzyl radical). Other advantages of 
benzyl ethers were their base stability138, potential selectivity in formation, 
and the expected larger difference in polarity for the variously substituted 
mycalamide derivatives, based on results for the p-bromobenzoate esters, so J 
that reaction products could be more easily separated and purified. 
2.5.1 PREPARATION AND CHARACTERISATION OF MYCALAMIDE A 
BENZYL DERIVATIVES 
Modification of the method of Johnstone 151, described for the 
methylation reactions above, provided a convenient starting point for 
preparing derivatives with a benzyl ether group at the important C7 position. 
Thus benzylation of mycalamide A, using benzyl bromide and potassium 
hydroxide in DMSO at room temperature, yielded a mixture of derivatives 
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within minutes by TLC. Preparative TLC gave four fractions, which consisted 
of one mono-benzylated, two di-benzylated, and one tri-benzylated 
mycalamide A derivatives by DCIMS and either HREIMS or HRFABMS. 
The 1 H NMR spectrum of the most polar, mono-benzylated derivative 
showed the presence of a new pair of doublets, at 84.77 and 4.68 ppm, and 
aromatic resonances, which were assigned to the new benzyl group. The 
obseNed shifts in the H2 (-0.1 ), H5a (+0.1 ), 6-0CH3 (-0.2), H7 (-0.2) and NH (-
0.3) resonances (Table 2.15), as assigned by a COSY experiment, were 
indicative of substitution at the C7 oxygen1 01 (structure 2.39). This 
substitution was confirmed by the obseNation of an NOE interaction between 
H7 and the new methylene protons of the benzyl ether group (Table 2.13). A 
13C NMR spectrum showed a large downfield shift in the C7 resonance (+8.0 
ppm), consistent with this substitution117, in addition to new resonances at 
873.24 and 128-129 ppm for the benzyl ether group (Table 2.16). 
The 1 H NMR spectrum of a second fraction suggested that it was 7,18-
di-0-benzyl mycalamide A (2.40), since there were additional shifts in the 
H16 (+0.1), H17 (+0.1) and H18 (-0.1) resonances to those obseNed above 
and there was a second set of benzyl ether proton resonances (Table 2.15). 
Irradiation of the H18 signals in an NOE experiment caused an enhancement 
of these new benzyl methylene resonances, which were also non-equivalent. 
The 13C NMR spectrum further confirmed this substitution, since there was a 
downfield shift in the C18 resonance of 7 ppm, and there were new benzyl 
resonances, as expected (Table 2.16). 
The 1 H NMR spectra of the remaining two derivatives contained 
resonances that were very broad and it was evident that both compounds 
contained an N-benzyl group, since the H1 0 resonances were shifted 
downfield and appeared as doublets. The 1 H NMR spectrum of the more 
polar derivative suggested that the two benzyl groups be located on the C7 
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oxygen and the amide nitrogen (structure 2.41 ), since there were shifts in the 
H5a (+0.3), H5e (-0.1), 6-0CH3 (-0.3), H10 (+0.5) and H11 (+0.1) proton 
resonances, as assigned by a COSY experiment, while the methylene 
resonances of the two benzyl groups were spread over a range of 1 .3 ppm 
(Table 2.15), indicating that some shielding interactions must be involved123. 
The 1 H NMR spectrum of the tribenzylated derivative contained similar shifts, 
but the H18 resonances were shifted upfield and one of the H16 resonances 
downfield, as shown by a COSY experiment, so that the third benzyl ether 
group was located at C18 (structure 2.42). The broadening of resonances 
was also apparent in a 13C NMR spectrum of this tribenzylated derivative, 
which suggested that a similar conformational exchange process was 
occurring to that observed for the N-methylated derivatives above 107,121. This 
was supported by the results of NOE experiments (Table 2.13), where signals 
for a minor conformation were saturated when the related signals for the major 
conformation were irradiated. This exchange is investigated in more detail 
below for a mycalamide B derivative. 
2.5.2 PREPARATION, CHARACTERISATION AND SOLUTION 
CONFORMATIONS OF MYCALAMIDE B BENZYL DERIVATIVES 
The benzylation of mycalamide B under analogous conditions gave a 
mixture of three products by TLC. Preparative TLC yielded three fractions, 
which represented one mono- and two di-benzylated mycalamide B 
derivatives by HRFABMS and DC I MS. The 1 H NMR spectra of these 
derivatives showed that these were 7-0-benzyl mycalamide B (2.43), 7,18-di-
0-benzyl mycalamide B (2.44), and 7-0-benzyl, N-benzyl mycalamide B 
(2.45), according to the observed chemical shifts of resonances assigned by 
COSY experiments (Table 2.17). These structures were further confirmed by 
recording 13C NMR spectra for the first two derivatives, which showed similar 
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substituent effects to those of the mycalamide A compounds above (Table 
2.16). An NOE experiment on mycalamide 8 7-0-benzyl ether (2.43) also 
showed the expected interaction between H7 and the new benzyl methylene 
protons (Table 2.13). 
The benzylation of mycalamide 8 for longer reaction times (3 hours at 
room temperature) gave a mixture of two new products by TLC. Significantly, 
there was a difference in the colour of the spots on visualisation, with the lower 
Rt compound giving a darker brown char and the higher Rt compound an 
orange brown char. Preparative TLC yielded two fractions which both 
contained tribenzylated mycalamide 8 derivatives by DCIMS and HRFA8MS. 
The 1 H NMR spectrum of the major fraction, which was of lower Rt on 
silica gel TLC, showed that it contained an N-benzyl group, but the 
resonances were broad and the multiplets poorly resolved, while there 
appeared to be some minor signals. The data for this derivative (2.46) were 
partially assigned using results from a COSY experiment (Table 2.17). 
Similarly a 13C NMR spectrum showed weak, broad resonances, but was not 
fully assignable. A variable temperature study, from -10 to +SSOC, was 
conducted to investigate this probable conformational exchange98, 114,121. 
The 1 H NMR spectra showed increased broadening of most resonances with 
increasing temperature, although some resonances of protons on the 01-C6 
tetrahydropyran ring were sharper. However, on cooling to ooc, the 1 H NMR 
spectrum showed two distinct sets of sharpened resonances, in a ratio of 
about 5:2. Difference NOE experiments were performed which assigned 
some of the signals for the minor conformation. NOE interactions were 
observed between the H7 and H1 0 protons and between H7 and both sets of 
benzyl methylene protons (Table 2.13) which required the presence of both E 
and Z conformations about the C8-N amide bond1 07,79, as observed for the N-
121 
methylated derivatives above. The 1 H NMR data for these two conformations, 
recorded at -1 ooc, are listed in the Experimental section. 
An HMQC experiment was also performed at -1 ooc, which enabled the 
13C NMR data to be assigned (Table 2.16), and, by comparison, the 13C NMR 
data for 7, 18-di-0-benzyl, N-benzyl mycalamide A (2.42). Some features of 
these data were the observed shielding of the 6-0CH3, C7, 7-0CH2, C11 and 
C18 carbon resonances on N-benzylation, along with the expected downfield 
shift of the C1 0 resonance 117. The new N-CH2 carbon resonance was 
. 
observed at 846.3 ppm and was correlated in the HMQC spectrum to the pair 
of methylene proton doublets at 85.1 and 4.7 ppm, which had an unusually 
large geminal coupling constant of 17 Hz. This suggests that these N-benzyl 
methylene protons are influenced by the amide n system 102,160. This 
assignment also required that the C7-0-benzyl methylene proton resonances 
be those at 84.4 and 3.9 ppm, shifted upfield by shielding effects involving the 
new N-benzyl group123. Therefore the 1 H and 13C NMR data were able to be 
completely assigned. 
The 1 H NMR spectrum of the minor fraction from the benzylation of 
mycalamide B showed resonances of normal linewidths, with three sets of 
methylene resonances for the benzyl ethers, all with typical geminal coupling 
constants of about 12 Hz1 02. Therefore this compound was probably 0-
benzylated at the amide, having a double bond between C8 and the new 
imidate nitrogen, as in structure 2.47. The formation of an Q-alkylated amide 
derivative under these reaction conditions is unusual, since normally silver 
salts or strong alkylating agents under neutral conditions are required to 
promote 0-alkylation of amides156. Here the initial preference for benzylation 
of the C7 hydroxyl group may leave the amide nitrogen partially hindered to 
benzylation, allowing some 0-benzylation to occur. 
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7,8,18-tri-Q.-Benzyl mycalamide B (2.47) 
The observed 1 H NMR chemical shifts for many resonances, 
particularly those relating to substituents of the trioxadecalin ring system, were 
very different from those observed for mycalamide B and other derivatives. To 
illustrate this, there were shifts (in ppm) in the H2 (-0.2), 2-CH3 (-0.2), 3-CH3 (-
0.2), H5a (+0.8), 6-0CH3 (-0.2), H7 (+0.4), H1 0 (-0.8), 1 0-0CHR (-0.4), 10-
0CHS (+0.3), H11 (-0.3), H12 (-0.2), H13 (-0.6), 13-0CH3 (-0.2), 14-CH3R 
(+0.2), H15 (+0.1), H16 (+0.8) and H16 (+0.2) proton resonances (Table 2.17), 
as assigned by a combination of COSY and NOE experiments, described 
below. Also the vicinal proton-proton coupling constants for the C1 0-C13 
portion were (in Hz), H1 O-H11 (1.5), H11-H12 (1.4) and H12-H13 (2.8), which 
required that the trioxadecalin ring system be in a different major solution 
conformation. There were certain NOE interactions, in particular H1 O-H11, 10-
OCHS-H12, H12-H13, H13-14-CH3S and H16-H11 (Table 2.13), which 
required that this new conformation be the alternate chair-chair conformation. 
Also, there was a strong NOE interaction between the H7 and H1 0 protons 
which required that the stereochemistry about the new C8=N imidate double 
bond be mostly E, and these conformations are depicted in Figure 2.2. 
In this observed conformation, the new imidate nitrogen is axial to the 
C1 O-C12 dioxan ring at C1 0. This may suggest that the anomeric 
effect1 05,106 is a significant factor influencing the ring conformation. However, 
steric effects are probably also important, since in the predominant solution 
conformation of mycalamide A the amide nitrogen is equatorial to this ring at 
C1 018,19. Molecular modelling of the two chair-chair conformations of the 
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trioxadecalin ring system (Chapter 1) showed that the energy minima for both 
conformations were within 2 kJ moJ-1. Hence it is possible that small 
electronic or steric preferences may account for this change in conformation. 
This work thus demonstrates the availability of both chair-chair conformations 
for the trioxadecalin ring system, this derivative being the first to have the 
alternate chair-chair conformation as a major solution conformation. 
The 13C NMR spectrum also showed large changes in chemical shift for 
carbons involved in these new solution conformations, as assigned by an 
HMQC experiment. In particular, the C1 0 (+8.6), C11 (-6.1 ), C12 (-5.7), C13 
(+4.7), 13-0CHa (-2.5), C14 (-5.0}, 14-CH3 R (+4.5}, 14-CH3S (+8.9) and C15 
( +3.1) resonances were most affected {Table 2.16). This explains the 
observed broadening of many of these resonances in mycalamide A and B 
and derivatives, where there is some conformational exchange with this 
alternate chair-chair conformation, since the chemical shift differences for 
carbons in the two conformations are substantial, especially for the 14-CHaS 
resonance (C1 0 may be affected by the new imidate system here}. The 
chemical shift of the new 8-0CH2 resonance, at 867.4 ppm, was consistent 
with the structure proposed, rather than an N-benzyl derivative 117, but the C8 
resonance was not observed. 
Figure 2.2 1 H-1 H NOE interactions and partial solution conformation of 
7,8, 18-tri-G-benzyl mycalamide B (2.47} 
H 
OCH3 
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2.5.3 BIOLOGICAL ACTIVITY AND FURTHER ALKYLATION ATTEMPTS 
The biological activity results for all the benzyl derivatives above are 
listed in Table 2.6. Not surprisingly, all were relatively inactive since they 
contained an ether group at C7. However, these derivatives were important 
as protected intermediates, as will be described in Chapter 6. 
The presence of the double bond in mycalamides A and B meant that 
any attempted hydrogenolysis of the benzyl group in the derivatives above 
would be non-selective. An alternative method of protection was a 4-methoxy 
benzyl or a 3,4-dimethoxy benzyl group159, which could be removed by very 
mild oxidation using 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ) 161. 
Before attempting the formation of these ethers, the reaction of mycalamide A 
with DDQ was checked by 1 H NMR spectroscopy. Mycalamide A was 
observed to undergo slow decomposition in the presence of DDQ, over a 
period of a few hours at room temperature. This was ascribed to the known 
decomposition of DDQ in the presence of water and alcohols to give the acid 
hydrogen cyanide 161. It was therefore of interest to note that a recent 
publication of the total synthesis of mycalamides A and B made successful use 
of this dimethoxy benzyl group for protection of the C7 hydroxyl and removed it 
with DDQ in a key final step91. This work was not pursued further. 
Several attempts were made to prepare a trityl ether of mycalamide A. 
Trityl ethers are commonly used in carbohydrate and steroid chemistry for the 
selective substitution of primary hydroxyl groups76,78. Various methods were 
tried, including the use of dimethylaminopyridine (DMAP) as a catalyst in 
various solvents162,143, in the presence of base and trityl chloride, but none 
appeared to be successful. The bulky size of both the reagent and the 
mycalamide A molecule may be a factor since a reaction with propan-1 ,2-diol 
was successful58. Therefore this reaction was also abandoned, many useful 
derivatives having been already synthesised above. 
Table 2.1 1 H NMR dataa for mycalamide A and B trimethylsilyl (TMS) and t-butyldimethylsilyl (TBDMS) ethers. 
Myc.A 17, 18-bis- Myc.A tris- Myc.B 18-mono- Myc.B bis- Myc.B 18-mono- Myc.B bis-
TMS etb~r (2.4) IMS etb~r (2.1) IMS etb~r (2.~) TMS etb~r (2.2) I6QMS ~tb~r (2.~,!) I6QMS ~tb~r (2.~U 
H2 3.99 (2.8,6.6) 3.88 (2.7,6.6) 4.05 (2.9,6.5) 3.90 (2.7,6.6) 4.03 (2.9,6.6) 3.87 (2.8,6.5) 
2-CH3 1.21 (6.6) 1.18 (6.6) 1.20 (6.6) 1.18 (6.6) 1.21 (6.6) . 1.17 (6.6) 
H3 2.27 (2.3,6.9) 2.19 (2.6,6.8) 2.26 (2.6, 7.1) 2.20 (2.6,7.1) 2.27 (2.6,7.0) 2.19 (2.9,7.1) 
3·CH3 1.02 (7.2) 1.00 (7.0) 1.02 (7.2) 1.00 (7.1) 1.02 (7.2) 0.99 (7.0) 
4:CHZ 4.87 (1.8) 4.81 (2.0) 4.86 (1.8) 4.81 (1.9) 4.86 (2.0) 4.81 (2.0) 
4:CHE 4.71 (1.8) 4.71 (2.1) 4.73 (1.8) 4.71 (2.0) 4.70 (2.0) 4.71 (2.0) 
H5a 2.24 (2.0, 14.0) 2.35 (1.9, 14.7) 2.18 (2.0, 13.9) 2.34 (2.0, 14.5) 2.15 (2.1 '14.2) 2.36 (2.0, 14.6) 
H5e 2.34 (14.0) 2.58 (14.5) 2.34 (13.8) 2.50 (14.5) 2.30 (13.8) 2.51 (14.4) 
6-0CH3 3.28 3.28 3.31 3.27 3.28 3.29 
H7 4.22 (2.6) 4.25 4.26 4.26 4.24 (2.7) 4.22 
7-0H 3.94 (2.6) 3.98 3.86 (2.7) 
NH9 7.54 (9.3) 7.38 (9.6) 7.52 (9.6) 7.35 (9.9) 7.51 (9.4) 7.27 (9.9) 
H10 5.72 (9.1) 5.76 (9.6) 5.79 (9.4) 5.78 (9.8) 5.78 (9.4) 5.76 (8.8,9.8) 
10-0CHR 5.12 (7.0) 5.11 (6.9) 5.13 (6.9) 5.13 (7.0) 5.12 (7.0) 5.10 (7.0) 
1 0-0CHS 4.83 (7.0) 4.81 (6.9) 4.85 (6.9) 4.82 (6.9) 4.84 (7.0) 4.82 (7.0) 
H 11 3.82 (6.5,9.0) 3.77 (6.4,9.5) 3.79 (6.6,9.3) 3.79 (6.6,9.6) 3.79 (6.3,9.0) 3.74 (6.1,8.7) 
H12 4.14 (6.5,9.8) 4.17 (6.4, 1 0.2) 4.19 (6.4,10.2) 4.20 (6.5, 1 0.3) 4.14 (6.3,9.5) 4.14 (6.2,9.2) 
H13 3.42 (1 0.0) 3.42 (1 0.3) 3.41 (1 0.3) 3.43 (1 0.3) 3.41 (9.3) 3.38 (9.3) 
13-0CH3 3.53 3.54 3.55 3.55 3.53 3.52 
14-CH3R 1.01 0.98 1.00 0.98 1.02 1.00 
14-CH3S 0.86 0.86 0.87 0.87 0.87 0.87 
H15 3.35 (2.1,10.1) 3.34 (1.7,9.9) 3.33 (m) 3.25 (m) 3.36 (1.5,9.8) 3.35 (2.0,9.6) 
H16 1.71 (2.0,9.7, 14.4) 1.74 (2.0,10.3,13.8) 1.72 (1.8,9.8,13.8) 1. 74 (1.8,9.9, 14.0) 1.76 (2.0,9.5, 14.2) 1.79 (2.0,9.8, 14.2) 
H16 1.43 (m) 1.42 (m) 1.48 (m) 1.52 (m) 1.50 (m) 1.53 (m) 
H17 3.73 (m) 3.72 (m) 3.14(m) 3.18 (m) 3.12(m) 3.16 (m) 
11-0CH3 3.23 3.27 3.21 3.26 
H18 3.50 (4.5) 3.53 (2.6, 11.4) 3.64 (2.6, 11.4) 3.66 (2.5, 11.5) 3.67 (2.8, 11.5) 3.70 (2.8, 11.5) 
H18 3.50 (4.5) 3.47 (4.4, 11.3) 3.51 (4.2, 11.6) 3.50 (4.1,11.5) 3.57 (4.1,11.5) 3.57 (3.7, 11.6) 
-OSI(CH3)3 0.14,0.06 0.21 ,0.1 0,0.06 0.13 0.20,0.12 
-OSIC(CH3)3 0.91 0.94,0.88 
-OSI(CH3)2 0.09,0.08 0.16,0.14,0.06 
...... 
I\) 
aoata for compounds 2.4 and 2.8 were recorded in CD2CI2. All other data were recorded in CDCI3, with chemical shifts in ppm relative to CHCI3, 87.25, or (J1 
to CHDCI2, 85.33 (coupling constants in Hz). 
Table 2.2 13C NMR dataa for mycalamide A and B TMS ethers and various estersb. 
Myc.A tris- B 18-mono- Myc.B bis- A 7,18-di- B 18-mono- B 7,18-di- Myc.A Myc.A 
TMS ether TMS ether TMS ether p-bromoBz p-bromoBz p-bromoBz triacetate tripropanoate 
(2.:1) (2.3) (2.2) (2.:12) (2.16) (2.l:l,} !2.lal (2.22) 
C2 69.66 69.69 69.69 70.18 69.55 70.04 69.73 69.61 
2-CH3 17.85 17.89 17.85 17.89 18.00 17.93 17.87 17.88 
C3 41.59 41.57 41.58 41.23 41.31 41.22 41.24 41.25 
3-CH3 11.78 12.31 11.90 12.14 12.20 12.19 12.04 12.03 
C4 147.37 145.95 147.32 144.67 145.01 144.74 145.08 145.15 
4:CH2 109.57 110.69 109.61 111.24 111.19 111.37 110.85 110.77 
C5 36.11 33.75 35.76 34.24 33.58 34.54 34.18 34.26 
C6 99.51 100.14 99.60 99.43 99.93 99.27 99.26 99.32 
6-0CH3 50.05 48.48 49.83 48.61 48.57 48.62 48.60 48.60 
C7 77.70 71.71 77.38 72.10 71.31 72.30 71.66 71.50 
C8 167.95 171.98 170.90 167.23 171.69 166.63 167.01 167.16 
C1 0 73.37 74.19 73.34 74.31 74.00 74.08 73.72 73.78 
1 O-OCH2 86.48 86.59 86.64 86.88- 86.40 86.52 86.53 86.52 
C11 70.67 70.38 70.72 71.58 70.70 70.50 69.90 69.90 
C12 74.35 74.36 74.54 74.54 74.19 74.10 74.06 74.03 
C13 79.75 79.82 79.72 79.06 79.33 79.52 79.93 79.70 
13-0CH3 61.57 61.60 61.64 61.80 61.73 61.67 61.55 61.56 
C14 41.37 41.51 41.58 41.62 41.50 41.16 40.90 ? 
14·CH3R 23.41 23.45 23.31 23.20 23.39 23.56 23.69 23.65 
14-CH3S 13.89 13.93 13.70 13.66 13.78 14.03 14.40 14.40 
C15 75.99 76.25 76.02 79.03 75.67 75.78 75.53 75.45 
C16 33.36 29.67 29.59 32.81 30.49 30.51 30.08 30.10 
C17 70.27 78.92 78.94 68.82 76.46 76.48 70.01 69.96 
17-0CH3 56.69 56.61 57.09 57.01 
C18 65.28 62.17 62.20 68.45 64.48 63.68 63.57 63.25 
-OTMS/-OAc 0.31 ,0.03, -0.55 0.29,-0.53 170.60,21.06, 
-0.39 169.85,20.80, 
169.64,20.65 
aoata for compounds 2.1, 2.2 and 2.3 were recorded in CD2CI2. All other data were recorded in CDCI3, with chemical shifts in ppm relative to 
CDCI3, 877.01, or CD2CI2, 853.60 boata for p-brornobenzoate and propanoate ester groups are listed in the Experimental section. ....... 1\.) 
0'> 
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Table 2.3 1 H-1 H NOE interactionsa for compounds in Sections 2.2-2.4. 
Compound 
A tris-TMS ether (2.1) 
B bis-TMS ether (2.2) 
A bis-TBDMS ether 
.(2.6) 
A tris-TBDMS et.(2.7) 
Myc.B diacetate 
(2.19) 
B 18-acetate (2.20) 
7-G-Methyl, N-methyl 
(2.24) 
7, 18-di-G-Methyl, 
N-methyl (2.25) 
7, 17-di-G-Methyl, 
N-methyl (2.27) 
7, 17, 18-tri-G-Methyl, 
N-methyl (2.26) 
Signal(s) 
irradiated 
7-0Si(CHs)s 
17/18-0Si(CHs)s 
7-0Si(CHs)s 
17/18-0Si(CHs)3 
H17 
17 -OSi(CH3)2 
H18 (13-0CHs) 
18-0Si(CHs)2 
H7 
6-0CHs 
13-0CHs 
17-0CH3 {H17) 
H7 
H7 (H12) 
H10 
H7 (H12) 
H10 
H15 
H2 
6-0CHs {17-0CHs) 
H7 (H11 I H12) 
7-0CHs (H13, H18) 
N-CHs 
H10 
H2 
H5a (H5a', N-CHs')d 
H5e 
H7 (H7',H12)d 
H7' (H7)d 
N-CH3 {H5a', N-CHs') 
N-CHs' (H5a', N-CHs} 
H10 (H10')d 
H10' (H10)d 
H11 (H7,H12) 
H216 
7$,17-di-G-Methyl, H2 
N-methyl (2.29) H7 
N-CH3 (H17) 
H10 
H12 
14-CHsR 
7 S, 17, 18-tri-G-Methyl, H7 
N-methyl (2.28) H 1 0 
Signals enhanced 
(% enhancement) 
H7(2), 6-0CHs(0.2) 
none 
H7(2), 6-0CHs(0.6) 
17-0CHs(0.3) 
H16u(3), 17-0Si(CHs}2(0.3) 
H17(2), 17-0SiC(CH3)3(0.4), H18d(1)c 
14-CH3R(0.4}b, 17-0Si(CH3)2(0.2) 
18-0SiC(CHs)s(0.4) 
H5e(3), 6-0CHs(2), 7-0Si(CHs)2(1} 
H2(2), H7(8) 
1 O-OCHR(2), 14-CH3R(0.5) 
H2S(1 )b, H18d(2)b,c 
6-0CHs(2) 
6-0CHs(2), 7-0CHs(2), N-CHs(2), 
14-CH3S(0.7)b 
H7(1), 10-0CHR(4), H13(3), H15(7) 
6-0CHs(1}, 7-0CHs(2), N-CHs(3), H10(2), 
14-CHsS(1)b 
H7(1), 10-0CHR(4}, H13(2), H15(5) 
H1 0(2), 14-CH3R(1} 
2-CHs(1 }, H3(5}, 6-0CHs(0.9) 
H2(3), H7(4), H18d(4)b,c 
6-0CH3(2), 7-0CH3(2), N-CH3(2), 14-CH3S(1)b 
H7(3), H10(5)b, 10-0CHR(4}b, H18d(5)b,c 
H7(3), H11 (7) 
H7(3), 10-0CHR(3), H13/H15(4) 
2-CH3(1 ), H3(5), 6-0CHs(0.9) 
3-CHs(1), H5e(19), H7(0.8) 
4=CHE(6), H5a(24), H5a'(20)d, 6-0CHs(0.4), 
H7(0.7) 
6-0CHs(2), 7-0CHs(2), N-CHs(2), H10(3), 
14-CHsS(1)b 
6-0CHs(1), 7-0CHs(1), N-CHs(0.8), 
N-CHs'(0.9)d, H 1 0(2) 
H5e(5)b, H7(2), H11 (4) 
3-CHs(0.4)b, H5e(4)b, H7(2), H7'(3), H11(2) 
H7(3), 10-0CHR(4), H13(3), H15(10) 
H7(1), H7'(3)d, 10-0CHR(2), H13(1), H15(3) 
N-CHs(2), N-CHs'(3)d, H10(1), 14-CH3S(1)b 
14-CHsR(1), 14-CH3S(0.7), H15(4), H17(8) 
2-CHs(1), 6-0CHs(1) 
6-0CHs(1), 7-0CHs(2}, N-CHs(3) 
H7(9), H11(9}, 17-0CH3(0.5}b 
10-0CHR(4), H13(4), H15(6} 
14-CH3S(1) 
H13(5}, 13-0CHs(1), H15(3) 
6-0CHs(1), 7-0CHs(2), N-CHs(4} 
10-0CHR(3), H13(3), H15(4) 
a All data were recorded in CDCis bEnhancement interpreted as being due to the irradiation of 
an overlapping signal cu and d have been used to designate the upfield and downfield 
resonances of a geminal pair d ' used to designate signals for a minor conformation 
Table 2.4 1 H NMR dataa for mycalamide A t-butyldimethylsilyl ethers and mycalamide B p-bromobenzoate esters. 
A 18-mono- A 17,18-bis- A tris- Myc.B 7-rnono- Myc.B 18-mono- Myc.B 7,18-di-
I6QMS etber (2,Q) I6QMS etber (2.2) I6QMS etber (2.Zl Q-Q[QIIJQ6Z:.(2.l Q) Q-Q[QIIJQ6Z:. (2,12) Q-Q[QIIJQ6Z:.(2.lZ) 
H2 3.99 (2.8,6.6) 4.03 (2.9,6.6) 3.86 (2.6,6.5) 4.09 (2.9,6.3) 4.06 (2.8,6.5) 4.05 (2.6,6.6) 
2-CH3 1.20 (6.6) 1.21 (6.5) 1.17(6.6) 1.28 (6.5) 1.21 (6.6) 1.23 (6.6) 
H3 2.26 (2.6,7.1) 2.26 (2.9,7.0) 2.19 (2.5,7.0) 2.33 (2.5,6.9) 2.29 (2.9,7.2) 2.30 (2.7,6.9) 
3-CH3 1.01 (7.1) 1.02 (7.0) 0.99 (7.1) 1.10 (7.1) 1.03 (7.1) 1.07 (7.1) 
4:CHZ 4.85 (m) 4.88 (1.8) 4.81 (1.9) 4.94 (m) 4.88 (1.7) 4.91 (m) 
4:CHE 4.71 (m) 4.75 (1.8) 4.71 (1.9) 4.63 (m) 4.73 (1.9) 4.79 (m) 
H5a 2.30 (m) 2.17 (1.8,14.4) 2.36 (2.0,14.4) 2.59 (m,14.0) 2.17 (1.8,14.1) 2.52 (m,13.5) 
H5e 2.30 (m) 2.38 (14.1) 2.55 (14.4) 2.53 (13.8) 2.36 (14.1) 2.45 (13.9) 
6-0CH3 3.28 3.31 3.29 3.20 3.30 3.19 
H7 4.25 (2.6) 4.23 4.20 5.74 4.24 (2.1) 5.63 
7-0H 3.79 (2.6) 3.83 (2.4) 
NH9 7.46 (9.7) 7.58 (9.9) 7.30 (9.7) 7.48 (9.8) 7.51 (9.7) 7.28 (9.6) 
H10 5.83 (9.7) 5.74 (9.1) 5.74 (8.5,9.7) 5.79 (9.5) 5.82 (9.5) 5.79 (9.4) 
10-0CHR 5.14 (7.0) 5.11 (6.9) 5.09 (6.9) 5.11 (7.1) 5.13 (7.0) 5.08 (6.7) 
10-0CHS 4.86 (7.0) 4.84 (6.8) 4.81 (6.8) 4.89 (7.0) 4.87 (6.9) 4.87 (6.9) 
H 11 3.84 (6.4,9.7) 3.77 (6.3,8.8) 3. 71 (6.1,8.5) 3.78 (7.0,9.5) 3.82 (6.7,9.5) 3.80 (6.3,8.9) 
H12 4.17 (6.6,1 0.2) 4.15 (6.3,9.7) 4.11 (6.0,9.3) 4.24 (7 .0, 1 0.5) 4.21 (6.6,1 0.2) 4.17 (6.5,9.8) 
H13 3.46 (10.1) 3.38 (9.5) 3.36 (9.2) 3.42 (10.7) 3.44 (1 0.0) 3.38 (9.7) 
13-0CH3 3.54 3.54 3.52 3.56 3.56 3.53 
14-CH3R 1.01 1.01 1.01 0.95 0.98 0.96 
14-CH3S 0.88 0.86 0.87 0.86 0.88 0.87 
H15 3.53 (2.3, 1 0.0) 3.41 (1.3,10.0) 3.41 (1.6, 1 0.2) 3.41 (m) 3.47 (m) 3.46 (9.1) 
H16 1. 73 (2.1 ,5.2, 14.0) 1.80 (1.7,9.9,14.1) 1.83 (1.7,10.2,13.8) 1.55 (m) 1.69 (2.0,9.6,14.8) 1.72 (m) 
H16 1.44 (m) 1.39 (3.9,10.1,14.2) 1.42 (4.5,10.3,13.6) 1.55 (m) 1.61 (m) 1.64 (m) 
H17 3.62 (m) 3.66 (m) 3.71 (m) 3.20 (m) 3.45 (m) 3.45 (m) 
17-0CH3 3.28 3.31 3.31 
H18 3.53 (m) 3.59 (4.2,10.8) 3.64 (3.8, 11.3) 3.65 (1.9,12.2) 4.48 (2.3, 12.5) 4.54 (3.0,12.3) 
H18 3.47 (m) 3.51 (2.5, 1 0.7) 3.53 (2.2, 11.3) 3.36 (6.8,12.4) 4.36 (5.0,12.2) 4.28 ( 4.2, 12.4) 
·OSIC(CH3)3 0.90 0.89,0.83 0.94,0.88,0.84 
-OSI(CH3)2 -0.08 0.06,-0.02 0.17,0.13,0.05,-0.01 
7-0Bz 7.62,7.98 (8.6) 7.90,7.57 (8.5) 
18-0Bz 7.91,7.59 (8.6) 7.85,7.54 (8.5) 
__.._ 
aoata for compound 2.5 were recorded in CD2CI2. All other data were recorded in CDCh. with chemical shifts in ppm relative to CHCh. 87.25, or CHDCI2. 1\) co 
85.33 (coupling constants in Hz). 
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Table 2.5 13C NMR dataa for mycalamide A and B TBDMS ethers. 
A 18-mono- A 17, 18-bis- Myc.A tris- B 18-mono- Myc.B bis-
TBDMS TBDMS TBDMS TBDMS TBDMS 
mtl~r (2.5) etber (2.§) ruber (2.7) m!Je[ (2.8) etber (2.~!) 
C2 69.82 69.71 69.54 69.70 69.56 
2-CH3 17.81 17.98 17.86 17.90 17.85 
C3 41.60 41.10 41.36 41.57 41.32 
3-CH3 12.09 11.97 11.77 12.34 11.85 
C4 ? 144.91 146.65 145.88 146.62 
4:CH2 110.19 111.35 109.96 110.74 109.97 
C5 33.83 33.49 35.79 33.70 35.59 
C6 99.99 99.93 99.58 100.14 99.59 
6·0CH3 48.76 48.71 50.10 48.46 50.00 
C7 72.61 71.80 77.13 71.59 77.00 
ca ? 171.34 170.58 ? 170.69 
C10 74.08 74.17 73.54 74.23 73.38 
10-0CH2 86.88 86.28 86.13 86.53 86.34 
C11 ? 70.10 70.03 ? 70.01 
C12 74.40 74.05 73.76 74.23 73.92 
C13 79.57 79.86 80.12 79.96 80.07 
13·0CH3 61.66 61.58 61.44 61.53 61.51 
C14 ? 41.10 40.89. ? 41.04 
14·CH3R 23.27 23.86 24.06 23.70 23.89 
14-CH3S 13.90 14.25 14.60 ? 14.30 
C15 79.07 76.15 76.20 76.49 76.31 
C16 32.36 33.31 33.05 29.91 29.70 
C17 71.37 70.38 70.38 79.09 78.87 
17-0CHa 56.74 56.69 
C18 66.54 65.81 65.60 62.48 62.03 
·OSIC ? 18.45,18.05 18.40,18.27 ? 18.29 
18.04 
-OSIC(CH3)3 25.84 26.03,25.89 26.02,25.90 25.89 25.97,25.87 
·OSI(CH3)2 -5.48 -5.22,-4.67 -5.27,-5.13 -5.43 -5.28,-4.88 
-4.32 -4.84,-4.74 -4.74 
-4.43,-4.27 
aoata for compounds 2.5 and 2.8 were recorded in CD2CI2. All other data were recorded 
in CDCI3, with chemical shifts in ppm relative to CDCI3, o77.01, or CD2CI2, 053.6 ppm. 
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Table 2.6 Biological assay results for compounds in Chapter 2. 
CQmJ2Q!.Jnd P~ee tQsoa Antivir£!1 R~suttsb (ngLdisk) 
Mycalamide A 0.5 WN ww +* 5 + + +* 2 
Mycalamide B 0.1 WN ww +* 2 +++ +++ +* 1 
Pederin 0.07 WN ww +* 1 +++ +* 0.5 
Pederin dibenzoate (1.2) 9 WN +++ +* 500 + - +* 200 
A 17,18-bis-TMS ether (2.4) 1.2 WN ww +* 20 ++ +++ +* 5 
A tris-TMS ether (2.1) 1.3 WN ww +* 20 5 
B 18-mono-TMS ether (2.3) 0.1 WN ww +* 0.5 
B bis-TMS ether (2.2) 0.2 WN ww +* 2 0.5 
A 18-TBDMS ether (2.5) 28 WN ww +* 50 20 
A 17, 18-bis-TBDMS eth.(2.6) 1200 WN ww +* 20000 - 10000 
A tris-TBDMS ether (2.7) >12500 40000 
B 18-TBDMS ether (2.8) 23 WN ww +* 50 20 
B bis-TBDMS ether (2.9) 600 WN ww +* 10000 5000 
A 7 -mono-p-bromobenz.(2.11) 23 WN ww +* 200 + +* 50 
A 18-mono-p-bromobenz.(2.1 0) 1 +++ ww +* 2 0.5 
A 7, 18-di-p-bromobenz.(2.12) 140 WN ww +* 2000 + ++ +* 500 
A 17, 18-di-p-bromobenz.(2.13) 57 WN ww +* 1000 + + +* 250 
A tri-p-bromobenzoate (2.14) 115 WN ww +* 500 200 
B 7 -mono-p-bromobenz.(2.15) 24 WN ww +* 50 20 
B 18-mono-p-bromobenz.(2.16) 20 +++ ww +* 20 + +* 5 
B di-p-bromobenzoate (2.17) 350 WN ww +* 4000 +++ +++ +* 2000 
Myc.A triacetate (2.18) 45 WN ww +* 500 +++ +++ +* 200 
B 7 -mono acetate (2.21) 2 WN ww +* 200 ++ +++ +* 50 
B 18-monoacetate (2.20) 0.9 WN ww +* 20 ++ +++ +* 10 
Myc.B diacetate (2.19) 20 WN ww +* 200 50 
17, 18-di-0-Me, 7-acet.(2.36) 1 WN ww +* 50 20 
7, 17-di-0-Me, 18-acet.(2.37) 500 +++ ww +* 5000 
Myc.A tripropanoate (2.22) 85 WN ww +* 500 + - +* 200 
B 18-monomesylate (2.23) 0.13 ww +* 5 2 
7-o-Methyl, N-methyl A (2.24) 1000 ww +* 20000 +++ +* 10000 
7,17 -di-D-Methyl, N-Me (2.27) 2500 5000 
7, 18-di-D-Methyl, N-Me (2.25) 1500 WN ww +* 10000 ++ + +* 5000 
7,17, 18-tri-0-Me, N-Me (2.26) 2000 WN ww +* 20000 +++ ++ +* 10000 
7-D, 7$-0-Methyl, N-Me (2.30) 1100 WN ww +* 20000 ++ ++ +* 10000 
7 S, 17, 18-tri-0-Me, N-Me (2.28) 5000 WN ww +* 40000 ++ +++ +* 20000 
7-o-Methyl myc.A (2.34) 80 WN ww +* 1000 +++ +* 500 
18-0-Methyl myc.A (2.35) 0.1 ww +* 1 + +* 0.5 
7,17 -di-0-Methyl A (2.33) 95 ww +* 2000 ++ +* 1000 
7, 18-di-0-Methyl A (2.32) 105 ww +* 2000 500 
17, 18-di-O-M ethyl A (2.38) 0.07 ww +* 1 ++ +* 0.5 
7, 17, 18-tri-0-Methyl A (2.31) 85 ww +* 2000 +++ +* 1000 
7-0-8enzyl myc.A (2.39) 90 WN ww +* 1000 500 
7, 18-di-0-8enzyl A (2.40) 170 WN ww +* 5000 ++ +++ +* 2000 
7-Q-8enzyl, N-benzyl A (2.41) 800 +++ ww +* 5000 + + +* 2000 
7, 18-di-0-8en. N-ben.A (2.42) 4000 WN ww +* 40000 ++ ++ +* 20000 
7-0-8enzyl myc.B (2.43) 45 WN ww +* 500 200 
7, 18-di-0-8enzyl 8 (2.44) 75 WN ww +* 2000 +++ +++ +* 1000 
7-Q-8enzyl, N-benzyl 8 (2.45) 170 WN ww +* 2000 WN ++ +* 1000 
7, 18-di-0-8en. N-ben.8 (2.46) 1900 WN ww +* 20000 + + +* 10000 
7,8, 18-tri-0-8enzyl B (2.47) 1200 WN +++ +* 40000 - 20000 
a In ng/ml. The derivatives are estimated to be better than 95% pure, having been subjected to 
at least two steps of chromatographic purification in most cases. 
b -,+,++,+++,WW=antiviral zone size. Resu~s are listed in the order of Herpes simplex virus, 
Polio virus, cytotoxicity, loaded sample mass. 
Table 2.7 1 H NMR data a for mycalamide A p-bromobenzoate and acetate esters. 
Myc.A 18-mono- Myc.A 7-mono- Myc.A 17,18-di- Myc.A 7,18-di- Myc.A 7,17 ,18-tri- Mycalamide A 
Q:Q[Q[]]Q!2Z.(2.10) Q-Q(QffiQI2t:.(2.11) Q-Q(QffiQElZ.(2.1~) Q:Q[QffiQElZ. (2.12) Q-Q[Q[]]Q6Z.{2.14} tria~etate (2.1~) 
H2 3.98 (2.7,6.6) 4.05 (2.7,6.4) 4.00 (2.9,6.6) 4.04 (2.7,6.7) 4.03 (2.8,6.6) 3.99 {2.8,6.6) 
2·CH3 1.18 (6.6) 1.24 (6.5) 1.19 (6.7) 1.23 (6.6) 1.23 {6.6) 1.20 (6.6) 
H3 2.23 {2.6,6.9) 2.30 (2.8,6.9) 2.22 (2.4,7.1} 2.30 (2.8,7.0) 2.28 (2.7,6.9) 2.25 (2.7,7.0) 
3-CH3 0.98 (7.0) 1.06 (7.1) 0.98 (7.1) 1.05 (7.1) 1.05 (7.0) 1.03 (7.1) 
4:CHZ 4.83 (m) 4.90 (1.8) 4.82 (1.9) 4.88 {1.9) 4.87 (1.8) 4.87 {1.8) 
4:CHE 4.68 (m) 4.82 (1.8) 4.70 (1.7} 4.72 {1.8) 4.75 (1.8) 4.76 {1.9) 
H5a 2.36 {m, 14.3) 2.64 (1.8, 14.4) 2.26 (1.8,14.2) 2.69 (1.8,14.4} 2.58 (1.7, 14.2) 2.45 (1.8, 14.4) 
H5e 2.31 (14.3) 2.46 (14.4) 2.39 (14.3) 2.42 (14.4) 2.51 (14.3} 2.38 (14.4) 
6·0CH3 3.27 3.21 3.28 3.20 3.20 3.18 
H7 4.28 (2.6} 5.70 4.27 (2.9) 5.70 • 5.64 5.47 
7-0H 3.76 (2.6) 3.93 (2.9) 
NH9 7.49 (9.9) 7.40 (9.5) 7.55 (9.6} 7.45 (9.2) 7.45 (9.2) 7.32 (9.4) 
H10 5.88 (9.8) 5.83 {9.6) 5.85 (9.2) 5.85 (9.4} 5.80 (8.2,9.1) 5.76 (9.0) 
10-0CHR 5.14 (6.9) 5.10 (6.9) 5.12 (6.9) 5.11 (6.9) 5.10 (7.0) 5.06 (6.9) 
10-0CHS 4.88 {6.9) 4.89 {7.0) 4.86 (6.8) 4.90 (6.9} 4.89 (7.0) 4.86 (7.0) 
H11 3.86 (6.6,9.8) 3.79 (7.0,9.6) 3.87 (6.1,8.8) 3.82 (6.6,9.6) 3.86 (5.7,8.0) 3.79 (6.0,8.7) 
H12 4.23 (6.5, 1 0.5) 4.21 (7.1 '10.4) 4.15 (6.0,9.5) 4.21 (6.7, 1 0.6) 4.11 (5.8,8.7) 4.10 (6.0,9.4) 
H13 3.47 (10.3) 3.41 (1 0.4) 3.41 (9.5) 3.44 (10.5) 3.38 (9.0) 3.36 (9.4) 
13-0CH3 3.56 3.54 3.53 3.55 3.51 3.52 
14·CH3R 1.00 0.93 1.01 0.96 1.03 1.01 
14·CH3S 0.90 0.85 0.88 0.88 0.88 0.86 
H15 3.71 (2.1 ,9.7} 3.60 (5.9,6.9) 3.59 (2.2,9.9} 3.76 (2.7,9.7) 3.62 (1.4,1 0.2) 3.45 (2.4,9.8) 
H16 1. 70 {2.4,3.8, 14.5) 1.49 (m) 1.97 (2.1,9.0, 14.6) 1.68 (3.0,3.0, 14.7) 2.03 (m) 1.77 (2.5,9.1,14.5) 
H16 1.58 (7.9,9.5,14.7) 1.49 (m) 1.85 (3.6, 1 0.4,14.5) 1.55 (m) 1.88 (m) 1.62 (4.5,9.5,14.5) 
H17 4.03 (m) 3.70 (m) 5.42 (m) 4.02 (m) 5.33 (m) 4.98 (m) 
H18 4.23 (5.5) 3.57 (2.9, 11.5) 4.56 (4.5) 4.23 { 4.6, 11.3) 4.61 {2.6, 12.5} 4.27 (2.7,12.4) 
H18 4.23 (5.5) 3.29 (7.1,11.5) 4.56 (4.5) 4.17 {6.0,11.4) 4.54 (4.9, 12.6) 4.14 (5.2,12.4) 
7-0Bz 7.96,7.62 (8.8} 7.91 ,7.56 (8.5) 7.97,7.59 (8.7) 
17·0Bz 7.83,7.54 (8.7) 7.84,7.58 (8.7) 
18-0Bz 7.89,7.57 (8.8} 7.82,7.54 {8.7) 7.89,7.51 (8.6) 7.84,7.56 (8.7) 
·OCOCH3 2.20,2.05,2.00 
...... 
aoata for compound 2.14 were recorded in CD2CI2. All other data were recorded in CDCI3, with chemical shifts in ppm relative to CHC(s, 67.25, or w ....... 
CHDCl2. 55.33 (coupling constants in Hz). 
Table 2.8 1 H NMR dataa for mycalamide B acetate and mesylate esters and a mycalamide A propanoate esterb. 
Mycalamide B Mycalamide B Mycalamide B 7,17-di-Q-Me, 17,18-di-0-Me, Mycalamide B Mycalamide A 
7-mono- 18-mono- diacetate myc.A 18-mono- myc.A 7-mono- 18-mesylate tripropanoate 
acetat~ (2.21) gQtllat~ (2.20) (2.liD iaQ~tat~ (2,37) aQetat~ (2,36) (2.23) {2.22) 
H2 4.04 {2.8,6.6) 4.05 {2.9,6.5) 4.02 {2.8,6.7} 3.94 {2.8,6.6} 4.03 (2.8,6.7} 4.05 {2.9,6.6) 3.99 {2.8,6.6) 
2·CHa 1.24 (6.7} 1.21 {6.6} 1.22 {6.5) 1.17 (6.6) 1.22 {6.6) 1.21 {6.6} 1.19 {6.6) 
H3 2.29 {2.9,7.1) 2.27 {2.7,7.1) 2.28 (2.7,7.3} 2.21 (2.9,7.1) 2.28 (2.9,7.2} 2.27 (3.1,7.1) 2.25 (m} 
3-CHa 1.07 (7.1) 1.02 (7.1) 1.04 (7.2) 0.98 (7.1} 1.05 (7.1) 1.02 {7.1} 1.02{7.1) 
4:CHZ 4.88 (m) 4.87 (2.0) 4.88 (m) 4.82 (1.7} 4.88 (1.7) 4.87 (1.8) 4.85 {1.7} 
4:CHE 4.77 (m) 4.73 (1.9) 4.75 (m) 4.71 (1.8} 4.76 (1.7) 4.73 (1.9) 4.75 (1.7) 
H5a 2.43 (m) 2.17 (2.1 '14.1) 2.40 (m} 2.41 (2.0,14.1) 2.43 (1.8, 14.2) 2.14 (1.9,14.0) 2.46 (m) 
H5e 2.43 (m) 2.36 (14.0) 2.40 (m) 2.30 (14.3) 2.36 {14.2) 2.36 {13.9) 2.38 (m) 
6·0CHa 3.17 3.31 3.17 3.27 3.17 . 3.31 3.17 
H7/7·0H 5.52 4.26 5.45 3.85 5.48 4.29/3.86 (2.3) 5.48 
NH9 7.46 (9.5) 7.50 (9.6) 7.27 (9.4) 7.11 (9.9) 7.38 {9.4) 7.49 (9.4) 7.34 (9.2) 
H10 5.77 {9.5) 5.78 (9.5) 5.75 (9.4) 5.79 (9.7) 5.78 (9.5) 5.77 (9.5) 5.77 (9.0) 
10-0CHR 5.09 (7.1) 5.11 (7.0) 5.07 (7.0) 5.11 {6.9) 5.08 {6.9) 5.11 {7.0) 5.06(7.0) 
10·0CHS 4.87 (7.1) 4.85 {7.0) 4.85 (6.9) 4.83 (6.9) 4.85 (6.9) 4.86 (7.0) 4.85 (6.9) 
H 11 3.75 (6.6,9.6) 3.78 (6.7,9.5) 3.77 (6.5,9.4) 3.81 (6.8,9.6) 3.75 (6.4,9.3) 3.79 (6.8,9.4) 3.79 (6.1,8.7} 
H12 4.22 (7.1 '1 0.2) 4.20 (6.5, 1 0.0) 4.17 (6.6, 1 0.0) 4.20 (6.7, 10.2) 4.18 (6.5, 1 0.0) 4.20 (6.6, 1 0.1) 4.12 (6.0,9.4) 
H13 3.42 (10.4) 3.42 (10.1) 3.39 (9.8) 3.43 (1 0.2) 3.39 (10.1) 3.43 (10.0) 3.37 {9.4) 
13·0CHa 3.55 3.55 3.53 3.54 3.54 3.55 3.52 
14-CH3R 0.96 0.97 0.97 0.97 0.98 1.01 0.99 
14-CHaS 0.85 0.86 0.86 0.87 0.86 0.87 0.85 
H15 3.44 (1.7, 1 0.0} 3.38 {m) 3.38 (2.5,9.2) 3.36 {4.5,7.6) 3.34 (m) 3.41 (3.0,9.1} 3.45 (2.5,9.8) 
H16 1.54 (m) 1.60 (m} 1.63 (m) 1.63 (m} 1.65 (m} 1.67 (m) 1. 78 (2.4,9.3, 14.3) 
H16 1.38 (m) 1.60 (m) 1.63 (m) 1.63 (m) 1.60 (m) 1.63 (m) 1.62 (m) 
H17 3.14 (m) 3.30 (m) 3.33 {m) 3.37 (m) 3.24 (m) 3.35 (m} 4.97 (m) 
17-0CHa 3.26 3.24 3.25 3.28 3.26 3.25 
H18 3.71 (2.1,12.3) 4.20 (2.6, 12.3} 4.28 (2.5, 12.3) 4.27 (2.5,12.1} 3.46 (2.4, 1 0.5) 4.34 (2.2,11.1) 4.28 (2.8, 12.4) 
H18 3.41 (6.7,12.3) 4.09 (5.3, 12.2) 4.07 { 4. 7, 12.5} 4.03 (5.3,12.1) 3.32 (5.0, 1 0.5) 4.26 (4.8,11.2) 4.16 {5.2,12.4} 
-OCOCH3 2.21 2.08 2.20,2.08 2.08 2.20 
7/18-0CH3 3.54 /3.37 
18-0S02CHa 3.06 
....... 
8 AII data were recorded in CDCI3, with chemical shifts in ppm relative to CHCI3, 87.25 (coupling constants in Hz). bpropanoate ester resonances are (..) 1'\) 
listed in the Experimental section. 
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Table 2.9 13C NMR dataa for mycalamide B acetate and mesylate esters. 
Myc.B Myc.B Myc.B 7,17-di- 17,18-di- Myc.B 
7-mono- 18-mono- 7,18-di- 0-Me A 18- 0-Me A 7- 18-mono-
acetate acetate acetate acetate acetate mesylate 
(2.21) (2.20) (2.19) (2.m (2.36) (2.2~) 
C2 70.30 69.54 69.95 69.45 70.00 69.57 
2-CH3 17.84 18.01 17.92 17.87 17.94 18.00 
C3 41.37 41.31 41.16 41.38 41.17 41.28 
3-CH3 12.20 12.22 12.19 11.87 12.26 12.20 
C4 145.17 144.95 144.75 145.95 144.73 144.94 
4:CH2 111.11 111 .25 111.26 11 0.25 111.31 111 .25 
C5 34.73 33.59 34.39 34.15 34.36 33.61 
C6 99.46 100.00 99.15 99.91 99.26 99.97 
6-0CHa 48.50 48.51 48.49 48.94 48.50 48.58 
C7 71.45 71.11 71.48 82.72 71.45 71.26 
CB ? 171 .69 166.67 170.87 166.79 171.68 
C10 74.29 74.05 74.02 73.31 73.79 74.12 
1 O-OCH2 86.78 86.43 86.53 86.45 86.48 86.51 
C11 ? 70.80 70.64 70.75 70.58 70.91 
C12 74.75 74.26 74.18 74.31 74.22 74.12 
C13 79.40 79.27 79.43 79.42 79.55 79.20 
13-0CHa 61.75 61.76 61.70 61.77 61.71 61.78 
C14 41.50 41.40 41.24 41.43 41.32 ? 
14-CHaR 23.13 23.28 23.38 23.21 23.46 23.34 
14-CHaS 13.32 13.60 13.80 13.55 13.81 13.60 
C15 75.86 75.61 75.68 75.53 76.08 75.34 
C16 30.18 30.29 30.33 30.20 30.00 29.73 
C17 79.91 76.26 77.93 ? 77.34 76.01 
11-0CH3 56.67 56.98 56.88 56.91 56.84 56.97 
C18 63.81 64.14 63.47 64.12 72.21 69.40 
?-OCOCH3 ? 169.68 169.60 
20.54 20.65 20.63 
18-0COCH3 171 .04 170.85 169.69 
20.97 20.97 20.95 
7-0CHa 60.06 
18-0CHa 59.11 
18-0S02CH3 37.63 
aoata for compound 2.21 were recorded in CD2CI2. All other data were recorded in CDCI3, 
with chemical shifts in ppm relative to CDCI3, 877.01, or CD2CI2, 853.60 ppm. 
Table 2.10 1H NMR dataa for mycalamide A and B methyl ethers. 
7-Q-Methyll 7-D~7S-Q-Mel 7,18-di-Q-Me, 7,17-di-Q-Me, 75, 17-di-Q-Me, 7,171 18-tri-Q-Me, 75,171 18-tri-Q-Mel 
N-methyl A N-methyl A N-methyl A N-methyiA N-methyl A N-methyiA N-methyl A 
(2.24) (2.3J) ~ (221) (2.29} (2.26) (2.28) 
H2 3.93 {2.616.3) 3.94 (2.716.5) 3.92 (2.816.5) 3.94 (2.7,6.3) 3.94 (2.6,6.6) 3.91 (2.8,6.6) 3.94 (2.616.6) 
2·CH3 1.14 {6.5) 1.13 (6.6) 1.13 (6.4) 1.14 (6.5) 1.14 (6.5} 1.12 (6.6) 1.14 (6.6) 
H3 2.20 (2.416.8) 2.21 (2.616.8) 2.19 (3.0,6.9) 2.20 (2.9,7.0) 2.20 {2.3,7.0) 2.18 (2.8,7.0) 2.21 (2.4,7.2) 
3·CH3 1.01 {7.0) 1.03 {7.0} 1.00 (6.8) 1.00 (7.0) 1.02 (7.0) 0.97 (7.0) 1.04 {7.0) 
4:CHZ 4.83 (2.0) 4.84 (2.0) 4.82 (2.0) 4.83 (2.0) 4.83 (2.0) 4.81 (2.0) 4.82 (2.0) 
4:CHE 4.73 {2.0) 4.74 {2.0) 4.72 (2.0) 4.74 (2.0) 4.73 (2.1) 4.70 (2.0) 4.73 (2.0) 
H5a 2.68 (2.0,14.5) 2.84 (2.0, 14.6) 2.70 (2.0,14.4) 2.71 {2.01 14.2) 2.84 (2.0,14.9) 2.65 (2.0 1 14.2) 2.80 (2.0,14.6) 
H5e 2.29 (14.3) 2.51 (14.5) 2.29 (14.5) 2.28 {14.1) 2.54 (15.0) • 2.26 (14.2) 2.63 (14.7) 
6·0CH3 3.31 3.31 3.31 3.30 3.29 3.29 3.26 
H7 4.27 4.25 4.25 4.22 4.25 4.16 
7·0CH3 3.45 3.58 3.46 3.46 3.61 3.44 3.56 
N-CH3 3.19 3.14 3.19 3.22 3.14 3.20 3.11 
H10 6.34 (9.9) 6.40 (1 0.3) 6.35 (9.5) 6.26 (10.2) 6.32 (1 0.3) 6.26 (10.1) 6.33 (1 0.2) 
10-0CHR 5.17 (6.6) 5.15 (6.7) 5.16 (6.7) 5.16 {6.7} 5.13 (6.8) 5.15 (7.0} 5.13 (6.7) 
10-0CHS 4.89 (6.7) 4.86 (6.8) 4.88 (6.6) 4.87 (6.7) 4.85 (6.8) 4.85 (7.0) 4.85 {6.7} 
H 11 4.15 (7.21 1 0.0) 4.14 (7.0110.4) 4.19 (7.1 ,9.5) 4.16 (6.8,9.8) 4.09 (7.1, 1 0.2) 4.18 (6.8,10.1) 4.12 (6.9,10.2) 
H12 4.28 (7.1 '1 0.6) 4.27 {7.01 1 0.7) 4.29 (7.2, 1 0.0) 4.29 {7.01 1 0.0) 4.28 (7.0,10.7) 4.26 (6.81 1 0.5) 4.27 (6.9,1 0.6) 
H13 3.53 {10.7) 3.53 {1 0.7) 3.54 (10.1) 3.48 (10.0} 3.50 (10.8) 3.49 (10.5) 3.52 (10.7) 
13-0CH3 3.58 3.56 3.57 3.57 3.55 3.55 3.55 
14-CHgR 0.99 0.96 0.99 0.99 0.96 0.97 0.97 
14·CH3S 0.88 0.87 0.90 0.87 0.85 0.87 0.86 
H15 3.70 (3.2,9.8) 3.68 (m) 3.69 (2.51 1 0.0) 3.50 (m) 3.47 (1.6,8.6) 3.38 (1.8,8.7) 3.33 (9.2) 
H16 1.56 (m} 1.53 (m) 1.71 (m) 1.54 (m) 1.58 (m) 1.70 (1.8,9.6,14.1) 1.83 (9.4,14.3) 
H16 1.56 (m) 1.53 {m) 1.47 (m) 1.54 {m) 1.45 {m} 1.51 (2.218.9,14.2) 1.42 (2.6,9.21 14.3) 
H17 3.74 (m} 3.67 {m) 3.81 (m) 3.30 (m) 3.12 (m) 3.33 (m) 3.23 (m) 
17-0CH3 3.31 3.36 3.27 3.30 
H18 3.60 (3.1 1 11.0) 3.64 (3.31 11.0) 3.28 (m) 3.72 (2.71 11.8) 3.72 (2.5, 11.8) 3.53 (m) 3.49 (3.0110.1) 
H18 3.34 (6.5,11.0} 3.26 (6.9,11.0) 3.28 (m} 3.52 (5.91 11.3) 3.54 (m) 3.36 (m) 3.37 (3.6, 10.0) 
18-0CH3 3.35 3.37 3.35 
...... 
aAII data were recorded in CDCI3, with chemical shifts in ppm relative to CHCis, 37.25 (coupling constants in Hz}. w ~ 
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Table 2.11 13C NMR dataa for mycalamide A and B methyl ethers. 
7-Q-Methyl, 7,18-di- 7,17-di- 7S, 17-di- 7, 17, 18-tri- 7 S, 17, 18-tri-
N-methyl A Q-Me, N-Me Q-Me, N-Me Q-Me, N-Me Q-Me, N-Me Q-Me, N-Me 
(2.24) A (2.25) A (2.27) A (2.29) A (2.26) A (2.28) 
C2 69.39 69.36 69.52 69.63 69.40 69.18 
2-CH3 17.66 17.65 17.64 18.00 17.68 17.99 
C3 41.39 41.43 41.38 41.35 41.35 41.41 
3-CH3 12.16 12.12 11.94 11.96 11.97 12.08 
C4 146.76 147.01 146.62 146.98 146.76 ? 
4:CH2 109.76 109.52 109.93 110.10 109.75 109.72 
C5 33.88 33.83 33.98 32.34 34.06 33.24 
C6 100.82 100.87 100.86 102.04 100.74 1 01.78 
6-0CH3 48.90 48.90 48.96 50.55 48.93 50.48 
C7 82.56 83.39 83.15 81.09 84.10 81.15 
7-0CH3 58.89 58.90 58.86 60.39 58.83 ? 
ca ? 171.24 ? ? 170.75 ? 
N-CH3 28.75 28.70 28.74 29.09 28.79 28.90 
C10 77.26 ? 77.27 ? 77.30 ? 
1 O-OCH2 86.49 86.68 86.15 86.85 86.37 87.00 
C11 67.09 67.01 66.95 67.24 66.78 67.27 
C12 74.40 74.40 74.37 74.74 74.31 74.69 
C13 79.16 79.15 79.32 79.05 79.35 79.11 
13-0CH3 61.86 61.83 61.83 61.88 61.76 61.85 
C14 41.84 41.90 41.55 41.66 41.64 ? 
14-CH3R 22.98 22.95 23.20 23.00 23.15 23.01 
14-CH3S 13.11 13.20 13.09 12.94 13.21 12.97 
C15 78.14 78.64 75.49 75.84 75.82 76.10 
C16 32.97 33.34 30.59 30.83 30.43 30.06 
C17 71.07 69.58 79.00 79.73 77.30 
17-0CH3 56.46 56.94 56.36 56.42 
C18 66.86 76.44 64.25 65.70 72.49 72.01 
18-0CH3 59.12 59.07 59.22 
aAII data were recorded in CDCI3, with chemical shifts in ppm relative to CDCis, 877.01 ppm. 
Table 2.12 1H NMR dataa for mycalamide A and B methyl ethers. 
7-0-Methyl 18-0-M ethyl 7,18-di-0-Me 7,17-di-0-Me 17,18-di-0-Me 7,17,18-tri-0-Me 
IIJ'iC A (2,34) r:JliC A (2.35) II.J'iQ A (2.32) IIJ'i.Q.A (2.33) rnvc,A (2,38) J::ruQ.A (2.31 l 
H2 3.90 (2.6,6.7) 4.00 (2.7,6.5) 3.89 (2.7,6.6) 3.94 (2.7,6.6) 4.05 (2.9,6.6) 3.91 (2.7,6.5) 
2-CH3 1.17 (6.6) 1.19 (6.6} 1.16 (6.6) 1.17 (6.6} 1.21 (6.6) 1.16 (6.6} 
H3 2.19 (2.6,7.0} 2.24 (2.6,7.1} 2.18 (2.6,7.2} 2.21 (2.5,7.0) 2.27 (2.5,7.2} 2.19 (2.6,7.2) 
3-CH3 0.96 (7.0} 1.01 (7.1} 0.96 (7.2} 0.98 (7.0} 1.03 (7.1} 0.97 (7.0} 
4:CHZ 4.82 (1.9) 4.84 (1.6} 4.81 (1.8} 4.83 (1.9} 4.86 (1.8) 4.82 (1.9) 
4:CHE 4.71 (1.8) 4.74 (1.5) 4.70 (1.9} 4.71 (2.0) 4.74 (1.8} 4.71 (1.9) 
H5a 2.43 (2.0, 14.3} 2.31 (1.7,14.0} 2.44 (1.9,14.3} 2.41 (1.9' 14.3} 2.20 (1.9,14.1} 2.43 (2.0, 14.2) 
H5e 2.32 (14.1) 2.38 (13.9} 2.31 (14.5) 2.32 (14.4) 2.37 (14.3) 2.30 (14.2) 
6-0CH3 3.28 3.30 3.28 3.27 3.32 3.28 
H7/7-0H 3.88 4.29 3.88 3.89 4.28/3.92 (2.5) 3.87 
7-0CH3 3.56 3.54 3.57 3.55 
NH9 7.18 (10.0) 7.49 (9.8) 7.13 (9.9} 7.25 (9.7} 7.55 (9.5) 7.13 (9.6) 
H10 5.91 (10.0} 5.85 (9.6} 5.90 (10.0} 5.82 (9.7) 5.81 (9.6) 5.81 (9.8) 
10-0CHR 5.14 (6.9} 5.13 (6.9) 5.14 (7.0} 5.13 (6.9} 5.13 (6.9) 5.13 (7.0) 
10-0CHS 4.85 (6.9) 4.87 (6.9) 4.83 (7.0} 4.85 (7.0) 4.86 (6.8) 4.82 (7.0) 
H11 3.87 (6.9, 1 0.0) 3.84 (6.6,9.6) 3.88 (6.7,9.8) 3.80 (6.8,10.0) 3.79 (6.6,9.6) 3.84 (6.6,9.9) 
H12 4.24 (6.9, 1 0.6) 4.21 (6.6, 1 0.2) 4.23 (6.8, 1 0.5} 4.23 (6.8,10.5} 4.20 (6.6, 1 0.2} 4.21 (6.6,10.4) 
H13 3.48 (10.6} 3.44 (10.1} 3.47 (10.7} 3.45 (1 0.5} 3.44 (10.3} 3.44 (1 0.2} 
13-0CH3 3.56 3.55 3.55 3.56 3.56 3.55 
14-CH3R 0.97 0.99 0.97 0.97 0.99 0.97 
14-CH3S 0.88 0.87 0.88 0.86 0.87 0.87 
H15 3.64 (5.1 ,6.5} 3.54 (m} 3.58 (m} 3.43 (1.7, 1 0.0) 3.37 (m} 3.32 (m} 
H16 1.56 (m} 1.60 (m} 1.60 (m} 1.57 (m} 1.62 (m) 1.62 (m) 
H16 1.56 (m) 1.54 (m) 1.52 (m) 1.46 {m) 1.57 (m) 1.62 (m) 
H17 3.75 (m} 3.79 (m} 3.82 (m} 3.22 (m} 3.24 (m) 3.29 (m} 
17-0CH3 3.30 3.25 3.29 
H18 3.60 (3.4, 11.0) 3.32 (4.2,9.5} 3.30 (4.6,9.6} 3.69 (3.0, 12.0} 3.46 (2.2, 1 0.3} 3.45 (m} 
H18 3.38 (6.0, 11.0) 3.23 (6.2,9.6) 3.26 (5.7,9.7} 3.45 (m} 3.31 (5.2, 1 0.3) 3.31 (m) 
18-0CH3 3.35 3.35 3.37 3.37 
aAII data were recorded in CDCh, with chemical shifts in ppm relative to CHCI3, 87.25 (coupling constants in Hz}. _... w 
(J) 
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Table 2.13 1 H-1 H NOE interactions for compounds in Sections 2.4-2.5. 
Compound 
7-0-Methyl myc.A (2.34) 
18-0-Methyl myc.A (2.35) 
7, 18-di-0-Methyl A (2.32) 
7, 17 -di-G-Methyl A (2.33) 
17, 18-di-0-Me.A (2.38) 
17, 18-di-0-Me, 7-.. (2.36) 
7,17-di-0-Me, 18-.. (2.37) 
7, 17, 18-tri-0-Me A (2.31) 
Signal(s) 
Irradiated 
H7 
H7 
H7 (H11) 
H7 
H7 
H7 
H7 
H7 
7-0-Benzyl myc.A (2.39) 6-0CH3 
H7 
7 ,18-di-0-Benzyl A (2.40) H7 
7-0-Benzyl, 
N-benzyl A (2.41) 
7,18-di-Q-Benzyl, 
N-benzyl A (2.42) 
7-0-Benzyl myc.B (2.43) 
H218 (H13) 
H7 (H71, H12)d 
H10 (H101)d 
H11 (7-0CHu)c 
H7 (H7', H12)d 
N-CH (10-0CHR) 
H10 (H101)d 
H7 
Signals enhanced 
C% enhancement) 
6-0CH3(2)1 7-0CH3(1)~ NH(2) 
6-0CH3(2)1 NH(2) 
6-0CH3(2}, 7-0CH3(1)1 H12(4)b 
6-0CH3(2), 7-0CH3(2) 
6-0CH3(2)1 7-0H(2}, NH(1) 
6-0CH3(3), NH(3) 
6-0CH3(2), 7-0CH3(2), NH(2) 
6-0CH3(2), 7-0CH3(2), NH(1) 
H7(6) 
6-0CH3(2), 7-0CHd(2)0 , 7-0CHu(2)0 
6-0CH3(2), 7-0CHu(1)0 
H10(2)b, 10-0CHR(3)b, H17(6), 18-0CHd(3)0 
18-0CHu(4)0 
6-0CH3(2), Hi 0(2), 14-CH3S(2)b 
H7(6), 10-0CHR(3), H13(2), H15(6) 
H7(2)b, N-CHu(2), H12(4) 
6-0CH3(3), 6-0CH3'(2)d, 14-CH3S(1 )b 
10-0CHS(4)b, H13(3)b 
H7(3), 10-0CHR(2), H13(2), H15(7) 
7,18-di-Q-Benzyl, 
N-benzyl B (2.46) 
H2S(1), 6-0CH3(2), 7-0CHd(2)0 , 7-0CHu(3)0 , 
NH(2) 
HSe' (H5e)d H5a(2), H5a'(5)d 
6-0CH3 (H5a, H5a') H2(4), H5e(6)b, H5e'(5)b,d, H7(6) 
7 ,8,18-tri-Q-Benzyl B 
(2.47) 
H7 (H7')d 6-0CH3(1), 6-0CH3'(1)d, 7-0CHd(0.8)0 , 
H10 (H101)d 
H131 (H13, H5a1)d 
H2 
3-CH3 
H5e (H16d0 ) 
6-0CH3 (H5a) 
H7 (4=CHE, 
10-0CHR) 
8-0CHd0 
8-0CHu0 
H10 
10-0CHS 
H12 
H13 
14-CH3R 
14-CH3S 
H16u0 
H18d0 
H18u0 (H11 I H15) 
7-0CHu(2)0 , N-CHd(2)0 , N-CHu(0.8)0 , 
H10(0.8) 
H7(0.9), 10-0CHR(2), H13(2), H15(5) 
H5e'(1)b,d, 10-0CHR(O.G), 13-0CH3(0.5) 
2-CH3(1), H3(3), 6-0CH3(0.S) 
H3(6), H5a(3) 
4=CHE(5), H5a(23), H11 (7)b, H16u(11 )b,c 
H2(4), H5e(2)b, H7(6) 
4=CHZ(1)b, 6-0CH3(2), 7-0CHd(1)0 , 
7-0CHu(2)0 , H10(8), 10-0CHS(S)b 
8-0CHu(10)0 
8-0CHd(3)0 
H7(4), H11(2) 
10-0CHR(G), H12(1) 
10-0CHS(2), H11(4), H13(3), 13-0CH3(1) 
H12(4), 13-0CH3(2), 14-CH3R(1), 
14-CH3S(0.3) 
H13(7), 14-CH3S(1), H15(5) 
H13(3), 13-0CH3(0.3), 14-CH3R(1), H16d(4)0 
14-CH3S(0.6), H15(3), H16d(10)c 
H18u(6)0 
H10(2)b, H12(3)b, 14-CH3R(0.5)b, 
H16u(2)b,c, H16d(3)b,c, H18d(4)0 
aAII data were recorded in CDCis. bEnhancement interpreted as being due to the irradiation of 
an overlapping signal. 0 u and d have been used to designate the upfield and downfield 
resonances of a geminal pair. d I has been used to designate signals for a minor conformation. 
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Table 2.14 13C NMR dataa for mycalamide A and B methyl ethers. 
7-mono- 18-mono- 7,18-di- 7, 17-di- 17, 18-di- 7,17,18-tri-
O-M ethyl O-M ethyl O-M ethyl O-M ethyl O-M ethyl O-M ethyl 
A (2.34) A (2.35) A (2.32) A (2.33) A (2.38) A (2.31) 
C2 69.40 69.48 69.32 69.52 69.58 69.39 
2-CH3 17.81 17.93 17.80 17.85 18.01 17.82 
C3 41.40 41.35 41.45 41.36 41.30 41.42 
3-CH3 11.77 12.07 11.73 11.88 12.28 11.80 
C4 146.27 145.50 146.45 145.77 145.00 146.20 
4:CH2 109.95 110.71 109.79 110.37 111.23 110.02 
C5 34.14 33.72 34.20 34.19 33.61 34.16 
C6 100.02 99.85 99.97 100.00 100.01 99.91 
6-0CH3 49.18 48.86 49.14 48.98 48.56 49.01 
C7 82.99 72.52 83.16 82.39 71.45 82.98 
7-0CH3 60.50 60.45 60.39 60.20 
ca 170.56 171.73. 170.43 170.33 171.78 170.06 
C10 73.22 73.83 73.07 73.51 73.94 73.11 
10-0CH2 86.83 86.72 86.74 86.61 86.47 86.49 
C11 71.60 70.87 71.26 71.41 70.62 70.59 
C12 74.55 74.31 74.47 74.64 74.33 74.41 
C13 79.22 79.34 79.38 79.27 79.43 79.48 
13·0CH3 61.89 61.77 61.86 61.86 61.76 61.80 
C14 41.81 41.54 41.81 41.59 41.47 41.57 
14-CH3R 22.98 23.25 23.03 23.12 23.34 23.18 
14-CH3S 13.24 13.72 13.35 13.18 13.66 13.45 
C15 78.99 78.56 79.08 75.49 75.99 75.81 
C16 32.03 32.49 32.48 29.94 29.95 29.83 
C17 71.65 69.71 69.96 79.72 ? 77.66 
11-0CH3 56.87 56.87 56.81 
C18 66.68 76.05 76.19 64.69 72.63 72.87 
18-0CH3 59.05 59.10 59.20 59.19 
aAII data were recorded in CDCis, with chemical shifts in ppm relative to CDCis, 877.01 ppm. 
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Table 2.15 1 H NMR dataa,b for mycalamide A benzyl ethers. 
7-Q-Benzyl 7,18-di-0-Benz. 7-Q-Benzyl, 7,18-di-Q-Benzyl, 
m¥Q,8 (2.39) m!ic.A (2.40) ~-benz,8 (2.41) N-beoz.8 (2.42) 
H2 3.88 (2.7,6.6) 3.86 (2.9,6.6) 3.91 (2.9,6.5) 3.88 
2-CHa 1.17(6.6) 1.16 (6.6) 1.19 (6.5) 1.16 (6.2) 
H3 2.19 (2.5,7.0) 2.18 (2.9,7.1) 2.19 (2.5,7.0) 2.16 (2.2,7.0) 
3-CHa 0.97 (7.0) 0.95 (7.0) 1.01 (7.0) 1.01 (7.0) 
4:CHZ 4.82 (1.8) 4.80 (m) 4.78 (1.9) 4.76 (m) 
4:CHE 4.72 (1.9) 4.70 (m) 4.69 (1.8) 4.66 (m) 
HSa 2.48 (1.9,14.4) 2.47 (m,14.5) 2.64 (1.9,14.4) 2.86 (m) 
HSe 2.41 (14.3) 2.40 (14.4) 2.28(14.1) 2.33 (14.0) 
6·0CHa 3.14 3.10 2.96 2.90 
H7 4.10 4.08 4.24 4.27 
7-0CH 4.77 (11.2) 4.75 (11.2) 4.33 (12.0) 4.36 (11.5) 
7-0CH 4.68 (11.2) 4.63 (1 0.8) 3.86 (12.5) 3.90 (11.5) 
NH9 7.24 (10.0) ~.22 (10.0) 
N-CH 5.14 (17.0) 5.11 (17.1) 
N-CH 4.63 (17.1) 4.65 (17.2) 
H10 5.93 (10.1) 5.92 (1 0.0) 6.40 (9.2) 6.33 (9.1) 
1 0-0CHR 5.13 (7.0) 5.13 (7.1) 5.21 (7.0) 5.19 (6.0) 
1 0-0CHS 4.84 (7.0) 4.82 (7.0) 4.90 (6.9) 4.91 (6.0) 
H 11 3.80 (6.8,1 0.0) 3.81 (6.7,10.1) 4.00 (7.0,9.2) 4.03 (7.1,8.7) 
H12 4.23 (6.8, 1 0.5) 4.22 (6.8,1 0.5) 4.24 (6.8,1 0.0) 4.24 (6.9,1 0.0) 
H13 3.49 (1 0.5) 3.46 (1 0.3) 3.48 (1 0.0) 3.47 (1 0.0) 
13-0CHa 3.56 3.55 3.56 3.55 
14·CH3 R 0.98 0.97 1.00 1.00 
14-CHaS 0.88 0.88 0.87 0.87 
H15 3.68 (5.8,6.9) 3.60 (1.8,10.4) 3.78 (m) 3.77 (m) 
H16 1.55 (m) 1.70 (m) 1.55 (m) 1.83 (m,14.0) 
H16 1.50 (m) 1.55 (m) 1.55 (m) 1.50 (m) 
H17 3.82 (m) 3.92 (m) 3.80 (m) 3.92 (m) 
H18 3.62 (3.5, 11.3) 3.44 (4.7,9.6) 3.69 (2.8, 11.1) 3.44 (m) 
H18 3.39 (6.0, 11.2) 3.39 (5.6,9.6) 3.29 (6.5, 11.0) 3.36 (5.1,9.1) 
18-0CH 4.59 (11.7) 4.56 (12.4) 
18-0CH 4.52(12.1) 4.52 (12.0) 
aAII data were recorded in CDCis, with chemical shifts in ppm relative to CHCis, o7.25 (coupling 
constants in Hz). bAll aromatic resonances (not listed) appeared as unresolved multiplets 
between 87.5-7.2 ppm. 
Table 2.16 13C NMR dataa.b for mycalamide A and B benzyl ethers. 
7-mono- 7,18-di- 7,18-di- 7-mono- 7,18-di- 7,18-di- 7,8,18-tri-
Q-Benzyl Q-Benzyl Q-Benzyl, Q-Benzyl Q-Benzyl Q-Benzyl, Q-Benzyl 
8(2.39) 8 (2,40) N-b~o.8 (2.12) 12 (2,43) 6 (2,44) N-b~o.6 (2,46) 6(2.11) 
C2 69.38 69.29 69.11 69.50 69.34 69.45 69.09 
2-CH3 17.80 17.80 17.70 17.84 17.83 17.76 17.67 
C3 41.38 41.41 41.48 41.35 41.41 41.53 41.59 
3-CH3 11.76 11.74 12.46 11.86 11.82 12.18 11.73 
C4 146.48 146.62 ? 146.00 146.40 146.97 147.53 
4:CH2 109.91 109.77 109.52 110.30 109.94 109.65 109.11 
C5 34.61 34.65 34.29 34.53 34.42 33.46 33.83 
C6 100.09 100.03 ? 100.10 99.95 101.44 101.32 
6-0CH3 49.22 49.15 47.92 48.95 48.94 • 47.81 48.24 
C7 80.81 80.91 76.22 80.15 80.73 75.98 73.29 
1-0CH2P h 73.24 73.20 73.32 73.48 73.25 71.91 71.71 
ca 170.59 170.43 ? 170.52 170.17 171.63 ? 
N-CH2Ph/8-0CH 45.96 46.32 /67.43 
C10 74.19 74.07 77.80 74.22 73.98 79.60 82.56 
1 O-OCH2 86.86 86.76 86.23 86.58 86.42 86.04 86.40 
C11 71.66 71.29 68.44 71.38 ? 69.05 64.79 
C12 74.56 74.48 74.35 74.62 74.33 73.41 68.70 
C13 79.24 79.23 79.84 79.29 79.55 80.69 84.03 
13-0CH3 61.88 61.84 61.67 61.85 61.75 61.39 59.32 
C14 41.82 41.78 ? 41.59 41.46 40.46 36.44 
14-CH3R 22.98 23.06 23.32 23.14 23.22 24.11 27.68 
14-CH3S 13.26 13.41 13.70 13.22 13.60 14.84 22.25 
C15 78.98 79.13 78.68 75.45 75.84 76.33 78.65 
C16 32.02 32.58 33.60 29.85 30.11 30.66 28.46 
C17 71.70 70.09 69.28 79.71 77.79 77.19 78.30 
11-0CH3 56.86 57.10 56.44 56.98 
C18 66.74 73.78 71.79 64.69 70.54 67.66 69.77 
18-0CH2P h 73.12 74.16 73.13 73.30 73.32 
aAII data were recorded in CDCI3, with chemical shifts in ppm relative to CDCI3, 877.01 ppm. bAromatic carbon resonances are listed in the ....... 
Experimental section. .f:>. 
0 
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Table 2.17 1 H NMR dataa,b for mycalamide B benzyl ethers. 
7-mono-
0-Benzyl B 
(2.43) 
7,18-di-
0-Benzyl B 
(2.44) 
7-0-Benzyl, 7,18-di-0-Ben, 
~benzyiB ~benzyiB 
(2.45) (2.46) 
7,8,18-tri-
0-Benzyl B 
(2.47) 
H2 
2-CH3 
H3 
3-CH3 
4:CHZ 
4:CHE 
HSa 
HSe 
6-0CH3 
H7 
7-0CH 
7-0CH 
8-0CH 
8-0CH 
3.91 (2.8,6.6) 
1.17 (6.6) 
2.20 (2.7,7.0) 
0.98 (7.0) 
4.82 (m) 
4.72 (m) 
2.43 (m) 
2.43 (m) 
3.10 
4.11 
4.81 (11.5) 
4.64 (11.3) 
3.87 (2.7,6.6) 
1.16 (6.6) 
2.18 (2.9,7.2) 
0.95 (7.1) 
4.80 (1.8) 
4.69 (1.8) 
2.43 (1.8, 14.3) 
2.35 (14.3) 
3.06 
4.01 
4.72 (11.3) 
4.52 (11.3) 
N H9 7.35 (9.8) 7.22 (9.8) 
3.89 (2.7,6.5) 3.85 (m) 
1.18(6.4) 1.14(7.0) 
2.17 (2.3,6.8) 2.15 (m) 
0.98 (6.7) 0.98 (7.0) 
4.78 (1.9) 4.77 (m) 
4.68 (m) 4.66 (m) 
2.59 (1.9,14.1) 2.86 (m,14.7) 
2.23 (14.2) 2.28 (14.5) 
2.96 2.89 
4.21 4.23 
4.39 (11.5) 4.37 (11.6) 
3.97 (11. 7) 3.93 (11.5) 
N -CH 5.11 (17.2) 5.07 (17.3) 
N-CH 4.61 (17.4) 4.65 (16.8) 
3.75 (2.6,6.5) 
1.02 (6.6) 
2.12 (2.1 ,6.8) 
0.84 (6.9) 
4.76 (1.9) 
4.68 (1.9) 
3.07 (2.0, 14.7) 
2.34 (14.5) 
3.13 
4.67 
4.51 (12.1) 
4.39 (12.2) 
5.28 (12.5) 
5.09 (12.7) 
H 1 0 5.85 (9.8) 5.81 (9.8) 6.26 (8.9) 6.10 (7.8) 4.99 (1.5) 
1 0-0CH R 5.13 (6.9) 5.11 (6.9) 5.20 (6.8) 5.15 (6.2) 4.68 (6.1) 
10-0CHS 4.84 (7.1) 4.81 (6.7) 4.87 (6.6) 4.89 (6.2) 5.13 (6.1) 
H 11 3.77 (6.7,9.9) 3.80 (6.7,9.7) 4.03 (7.6,8.9) 4.07 (m) 3.50 (1.5) 
H 1 2 4.23 (6.9,1 0.6) 4.19 (6.5, 1 0.2) 4.25 (7.4,9.9) 4.25 (m) 3.97 (1.4,2.8) 
H 13 3.46 (10.4) 3.38 (10.2) 3.42 (9.7) 3.31 (m) 2.86 (2.8) 
13·0CH3 3.56 3.54 3.54 3.51 3.36 
14-CH3R 0.98 0.93 1.02 0.98 1.20 
14-CH35 0.88 0.87 0.87 0.85 0.91 
H 15 3.45 (10.0) 3.44 (m) 3.69 (8.4) 3.50 (m) 3.51 (2.5,12.5) 
H 1 6 1.55 (m) 1.65 (m) 1.62 (m) 1.85 (m) 2.31 
H 1 6 1.45 (m) 1.65 (m) 1.56 (m) 1.65 (m) 1. 71 
H 17 3.27 (m) 3.28 (m) 3.46 (m) 3.47 (m) 3.37 
17·0CH3 3.27 3.27 3.34 3.30 3.33 
H18 3.71 (2.9,12.1) 3.61 3.86 (3.0,11.8) 3.71 (1.7,10.0) 3.63 (2.8,11.2) 
H 1 8 3.48 (6.6, 11.9) 3.45 3.60 (5.5, 11.8) 3.61 (3.2, 1 0.9) 3.52 (4.3, 11.1) 
18-OC H 4.62 (12.1) 4.59 (12.0) 4.60 (12.2) 
18-0CH 4.54(12.0) 4.53(12.0) 4.47(12.1) 
aAn data were recorded in CDCI3, with chemical shifts in ppm relative to CHCI3, o7.25 (coupling 
constants in Hz). bAn aromatic resonances (not listed) appeared as unresolved multiplets 
between o7.5-7.2 ppm. 
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CHAPTER 3 
ACID CATALYSED REACTIONS OF 
MYCALAMIDES A & 8 AND DERIVATIVES 
3.1 INTRODUCTION 
Early chemical studies on pederin27,94, which has a structure similar to 
mycalamides A and B, involved largely degradative chemistry, aimed at 
. 
structural determination and proof of the presence of the various functional 
groups. These workers noted the instability of their compound to mineral 
acids since interaction with these gave a large number of products of 'unclear 
meaning' which were difficult to isolate94. However, some products were 
characterised in this and later studies and these are described briefly below 
as a background to similar studies on mycalamides A and B. 
Hydrolysis of pederin27 with sulphuric acid in the presence of hexane 
(a two-phase system) gave an a,~-unsaturated aldehyde fragment, pederenal 
(3.1 ), in good yield. This fragment arose from complete hydrolysis of the C1 0 
aza-acetal functionality and involved an unusual elimination and 
rearrangement163. No other products were obtained from this reaction. Later 
studies of the sulphuric acid catalysed hydrolysis of pederin in methanol164, 
conducted in an oxygen atmosphere, were able to show that an unusual 
cyclised fragment derived from the 01-C8 portion was formed, 
pederinolactone (3.2), along with a dimethyl acetal fragment from C1 0 
onwards, meropederinacetal (3.3). Matsumoto126 also gave data for an intact 
01-N H9 fragment, pede ram ide (3.4), obtained by 'mild acid hydrolysis' of 
pederin, although the exact reaction conditions and yields were not reported. 
The most useful and high-yielding modification of pederin was the 
hydrolysis of the C6 acetal to give a hemiacetal. The hydrolysis product, 
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pseudopederin (3.5), was obtained simply by heating pederin in water94, so 
that this reaction was very facile. The reverse reaction was similarly facile, 
being achieved simply by heating pseudopederin in methanol164. 
Pseudopederin (3.5), which was also isolated during the initial extractions of 
pederin29,30, probably as a degradation product165, was itself degraded by 
prolonged heating in water, but into a number of products which were not 
isolable94. Partial 1 H NMR data were reported for pseudopederin, along with 
other spectroscopic and analytical results, and some biological assay results 
were also published for this ·and other derivatives in a subsequent paper40. 
The assays performed measured the cytotoxicity of pederin and some of its 
derivatives on cultured mammalian cells, both normal and tumoural (Hela 
mouse tumoural cells), and pseudopederin (3.5) was found to be 10-100 
times less active than pederin. 
0 
H 0 
Pederenal (3.1) Pederinolactone (3.2) 
OH 
OH 
Meropederinacetal (3.3) Pederamide (3.4) 
OH 
OH 
Pseudopederin (3.5) 
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The sensitivity of the pederin structure to acid was noted during various 
attempts at its total synthesis. For example, the acid catalysed removal of an 
acetonide protecting group for a C6, C7 dial was not possible in the presence 
of the exocyclic double bond because of an observed decomposition of the 
products 133. Similarly, acid catalysed epimerisations at C1 0 required 
protection of the double bond, and exchange at C6 was always found to be 
faster than exchange at C10130. Jarowicki and coworkers132, who performed 
a recent novel synthesis of pederin, summarised these results by noting that 
. 
the acid lability of the homoallylic C6 acetal and N-(1-alkoxy-1-alkyl)-amide 
groups had necessitated delaying their introduction until the latest possible 
stage in the synthesis. 
These same structural features are present in mycalamides A and B 
and preliminary work with these compounds had demonstrated their extreme 
acid sensitivity. Samples of mycalamides in CDCI3 solution decomposed 
unless some base was deliberately added and this was ascribed to the 
presence of trace amounts of acid from the decomposition of this solvent139. 
Thus all samples for NMR spectroscopic studies in this solvent were routinely 
prepared and stored in the presence of pyridine (0.1 %) to prevent this 
occurring. Note that other workers had found that a similar technique was 
necessary in dealing with pederin and its derivatives95, 126. 
The following study summarises attempts to monitor the acid catalysed 
decomposition of mycalamide A, with the aim of being able to isolate products 
from rearrangement, cleavage or hydrolysis, which could provide further 
insights into the chemistry of this compound and yield some new structure-
activity correlations. By careful control of the conditions it was hoped to 
perform acetal exchange reactions, particularly at C6. The use of an acetate 
protecting group in these studies is also detailed. 
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3.2 ACID CATALYSED DECOMPOSITIONS OF MYCALAMIDE A ~ 
PRELIMINARY STUDIES 
3.2.1 EFFECT ON THE BIOLOGICAL ACTIVITY 
A small amount of mycalamide A was dissolved in 1 0% methanol/water 
( 1 ~g/ml) as a control sample. A second sample of mycalamide A was 
prepared in a similar manner and then heated on a steam bath for 20 minutes. 
A third sample of mycalamide A was dissolved in 10% methanol/aqueous 
hydrochloric acid (0.1 M). All three samples were then assayed in the P388 
system, after 2 hours and after 3 days at ambient temperature. Samples 1 and 
2 showed about 90% inhibition (4+) after 3 days, but fraction 3 showed only 
50% inhibition (2+) in the first assay and had no detectable activity in the 
second assay. Thus mycalamide A was probably fairly stable to heating in 
water, whereas treatment with dilute acids gave products which were 
substantially less active. 
3.2.2 REACTION MONITORED BY HPLC -ISOLATION OF 
PEDEROLACTONE 
A larger sample of mycalamide A was reacted with hydrochloric acid in 
methanol, as above, at ambient temperature. Aliquots were taken for analysis 
by reverse phase HPLC immediately after mixing, then after 10 minutes, 60 
minutes, and finally 240 minutes. HPLC showed the disappearance of 
mycalamide A with time, and the appearance of one major new peak, which 
was more polar, with another minor one. Note that there was no change 
between one and four hours, despite the continued presence of a small 
amount of mycalamide A. 
This reaction was repeated on a larger scale for NMR spectroscopic 
analysis. However, after workup, the 1 H NMR spectrum of the product showed 
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the presence of mycalamide A signals superimposed on broad humps, 
suggesting substantial decomposition, and one new major component which 
appeared to be a mycalamide fragment. The corresponding signals for this 
new fragment consisted simply of three methyl doublets, 81.06 (7.2), 1.35 
(6.6), 1.98 (1.5) ppm (couplings in Hz), coupled to single proton resonances at 
82.08 (doublet of quartets, 3.2, 7 .2), 4.54 (doublet of quartets, 3.1, 6.6) and 
5.74 (quartet, 1.5), respectively, as shown by selective decoupling 
experiments on the mixture. Attempts to purify this fragment were not very 
. 
successful, apart from the removal of mycalamide A. However, the 1 H NMR 
data obtained closely matched those reported94,166 for pederolactone (3.6), a 
decomposition fragment of pseudopederin (3.5). An FTIR spectrum, also 
showed a strong carbonyl stretch at 1720 cm-1, with a weak C=C stretch at 
about 1645 cm-1, indicative of an a,~-unsaturated lactone96 and in good 
agreement with published data for this derivative94. This suggested that a 
pseudomycalamide derivative may have been formed early in the hydrolysis, 
which decomposed, possibly during workup procedures. The mechanism of 
formation of pederolactone probably involves an allylic (air) oxidation of the 
C6 hemiacetal, following an acid catalysed rearrangement of the exocyclic 
double bond into the C4-C5 position of the 01-C6 tetrahydropyran ring, with 
cleavage occurring between C6 and C7. This product was later observed to 
be a common acid catalysed degradation product for other mycalamide 
derivatives. 
Pederolactone (3.6) 
3.2.3 REACTION MONITORED BY 1 H NMR SPECTROSCOPY-
FORMATION OF PSEUDOMYCALAMIDE A? 
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The results of some early attempts by Perry58 to monitor the reaction of 
mycalamide A with trifluoroacetic acid (0.01 M) in CDCI3 by 1 H NMR 
spectroscopy were not very encouraging. In particular, a 1 H NMR spectrum 
, recorded after two hours showed a complete loss of the signals for the C6 
methoxyl group and many other protons, and a rather complex mixture of 
components. 
In a new approach, a few drops of D20 containing trifluoroacetic acid 
(0.01 M) were added to a sample of mycalamide A in CDCI3 in an NMR sample 
tube. The phases were mixed by shaking the sample tube vigorously, after 
which the sample was allowed to stand at room temperature. After one hour 
there was little change, but after one day there was a mixture of components. 
The major component was new, and appeared to have appropriate signals by 
1 H NMR spectroscopy for a pseudomycalamide A derivative (3.7), based on 
data reported for pseudopederin94 (3.5). These included loss of the C6 
methoxyl group resonance and shifts in the signals of some nearby protons. 
However, there were also other components present in this sample, including 
minor amounts of mycalamide A and some new compound ('UNKNOWN 1'), 
so that further analysis was impossible. Clearly a cleaner method of preparing 
pseudomycalamide A (3.7) was required, although the above method was the 
best preparation found so far. 
NH 
lb. 
H 
R1=R2=R3=R4=H: Pseudomycalamide A (3.7) 
R1=R2=R4=H, R3=CH3: Pseudomycalamide B {3.8) 
R1=CD3, R2=R3=R4=H: 6-Trideuteromethoxy A (3.9) 
R1=CH2CH3, R2=R3=R4=H: 6-Ethoxy myc.A (3.10) 
R1=H, R2=R3=R4=COCH3: Pseudo A triacetate (3.15) 
3.3 PREPARATION AND CHARACTERISATION OF PSEUDO-
MYCALAMIDES A AND B 
3.3.1 TWO-PHASE HYDROLYSIS REACTION 
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Earlier work on pederin94, and the work above, clearly suggested that a 
two-phase hydrolysis system was the best method for the isolation of acid-
sensitive mycalamide degradation products. The use of p-toluene sulphonic 
acid as a fairly mild, water soluble acetalisation catalyst110, 167 is common in 
synthetic chemistry. Here an aqueous solution of p-toluene sulphonic acid 
(O.OSM) was stirred rapidly with a solution of mycalamide A in CH2CI2 at room 
temperature. Reverse phase HPLC showed the gradual disappearance of 
mycalamide A and a slow buildup of a single, more polar peak with time, 
which was complete after about eight hours. Careful workup procedures gave 
almost pure pseudomycalamide A (3.7) by 1 H NMR and mass spectroscopies. 
A notable feature of the mass spectroscopy results was the ready loss of H20 
from the parent or parent adduct ions in the ElMS and DCIMS spectra, 
consistent with the proposed structure (see Chapter 1 ). The reaction was 
successfully repeated on a larger scale and an analogous reaction on 
mycalamide B gave pseudomycalamide B (3.8). 
3.3.2 NMR SPECTROSCOPIC CHARACTERISATIONS OF PSEUDO-
MYCALAMIDES A AND B 
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Pseudomycalamides A and B (3.7, 3.8) were first analysed by 1 H NMR 
spectroscopy in CDC Is (with 0.1% pyridine added to prevent acid catalysed 
decomposition139) and these spectra were assigned with the aid of COSY 
and difference NOE experiments (described below) to give the data in Table 
3.1. (Data for mycalamide A have also been listed for comparative purposes). 
The major changes in the 111 NMR spectrum of pseudomycalamide A (3.7), 
compared with that of mycalamide A, were an absence of the C6-0CHs signal, 
a large separation in chemical shift for the two HS proton resonances {0.6 
ppm}, which were coincident in mycalamide A, and minor chemical shift 
changes (in ppm) in the signals assigned to H2 (+0.2), 2-CHs (-0.1 ), H7 (-0.2), 
and the 4=CH2, NH, H1 0 and H11 protons (<0.1 ). In the 1 H NMR spectrum of 
pseudomycalamide B (3.8), there were additional minor shifts in the signals 
assigned to the H17, 17-0CH3 and H18 protons, suggesting that these 
protons were spatially close to the left hand portion of the molecule in solution, 
as for mycalamide B (Chapter 1 ), or that the conformations of the C16-C18 
sidechain had been affected. 
The separation in the two HS signals was also found for pseudopederin 
(3.5), where it was noted that such differences were normal for structures 
containing different oxygenated functions whose actions were 
superimposed94. The downfield shift in the H2 resonance may result from 
different anisotropic long range shielding interactions123 on replacement of 
the C6 methoxyl by a hydroxyl group (note that the C6-0H group is still axial, 
as favoured by the anomeric effect1 05,106, and because the C7 chain is 
preferentially equatorial). However, other shifts cannot be accounted for in 
this way and it is more likely that these are the result of changes in the solution 
conformations, particularly about C6-C7, since the C8 carbonyl group, for 
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example, has large shielding and deshielding zones 123. The solution 
conformations of mycalamides A and 8 have been described in detail 
(Chapter 1 ), but in the pseudomycalamides there exist new hydrogen bonding 
possibilities involving the new C6-0H group, which could have a significant 
effect on these conformations. This proposal is considered more fully in the 
following subsection. 
The 13C NMR spectrum of pseudomycalamide A (3.7) was assigned by 
an HMQC experiment, and the results also used to assign data for 
. 
pseudomycalamide 8 (3.8) (Table 3.2). There were shifts in the signals 
assigned to C6 (-2), and C5, C7 and C8 (all +2 ppm), which were broadly 
indicative of the C6 acetal hydrolysis by the direction of the substituent 
effects117 (C5, C6 and C7), although conformational changes in this area 
could also have some effect on the chemical shifts. 
3.3.3 SOLUTION CONFORMATIONS OF PSEUDOMYCALAMIDES A AND B 
The 1 H NMR spectrum of pseudomycalamide 8 (3.8) in CD2CI2 
solution showed that the signal assignable to the axial H5 proton was split into 
a broad quartet of doublets (2.0, 14 Hz) and was coupled to a broad doublet at 
o4.95 ppm (2 Hz) as shown by selective proton decoupling. The latter signal 
was removed on addition of D20 and was therefore assigned to the C6-0H 
proton, which by its chemical shift must be involved in some hydrogen 
bonding interaction101. This coupling of 6-0H to the axial H5 proton was also 
observed for pseudopederin (3.5) in d6-acetone94, and requires a planar 'W' 
orientation of the protons for maximum long-range coupling to occur1 02,104. 
Several examples of such long range couplings through oxygen have been 
reported, including an hydroxyl proton in cycloheximide83 (0.14) and 
hemiacetal protons in elaiophylin 152,168 and bafilomycin 169. The latter two 
examples have some structural features similar to pseudomycalamides A and 
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B and their conformations have been studied by both x-ray crystallography 
and 1 H NMR spectroscopy. In particular, the hemiacetal proton of elaiophylin 
is hydrogen bonded to an oxygen on a nearby carbon, to form a 6-membered 
ring chair conformation. This 'locks' its position in a plane, involving the chain 
atoms H-0-C-C-H of the hemiacetal and an adjacent axial methylene proton, 
accounting for the observed 'W' coupling (1.5 Hz), as shown in Figure 3.1. 
The same situation occurs in bafilomycin and it was noted that the strong 'W' 
coupling (2.2 Hz) implied 'little or no motional freedom around the C-O(H) 
bond'169. 
Figure 3.1 Structure and conformation of elaiophylin, illustrating the 'W' 
geometry of the hydrogen bonded hemiacetal proton with an 
adjacent methylene proton. 
HO 
HO~ 
H 
0 
H ~OH 
OH 
Newman projections for the three staggered conformers about the C6-
C7 bond of pseudomycalamides A and B are shown in Figure 3.2. The data 
obtained from difference NOE experiments are shown in Table 3.3 and, where 
relevant, as arrows in Figure 3.2. There were NOE interactions between the 
C3 methyl group and H5a, which confirmed the proposed chair conformation 
for the 01-C6 ring, and between both H5a and H5e and H7. It is thus likely 
that there is some contribution from all three conformers in Figure 3.2a-c, 
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which each offer many hydrogen bonding possibilities, and also possibly from 
other conformations. In particular, the conformations in Figures 3.2c, and 
possibly 3.2b, are required by the observed NOE interactions between HSa 
and H7 and between H5e and H7, where the latter appeared to be stronger. 
Note, however, that the conformer in Figure 3.2c appears to be the most 
favoured, since it allows the C6-0H proton to be hydrogen bonded to the C8 
carbonyl group in a 6-membered ring, with the hemiacetal proton anti to C5 
about the C6-0 bond, giving the observed 'W' coupling, while H7 is closest to 
H5e, in accordance with the strong NOE interaction observed between these 
protons. In the conformation depicted by Figure 3.2a, the hemiacetal proton 
has to be shifted out of the C5-C6-0 plane to allow the same hydrogen bond 
with the C8 carbonyl group, which is not favourable for the observed long 
range coupling. This result is therefore very different from that found for 
mycalamide A, where the conformations in Figures 3.2a, and to a lesser extent 
3.2b, were the proposed major solution conformations (Chapter 1 ). 
Figure 3.2 Newman projections for the staggered conformers about C6-C7 
in pseudomycalamides A and B (3.7, 3.8) 
CH3 "'t 
N-.... O~o H 
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3.3.4 MECHANISM AND STEREOCHEMISTRY OF ACETAL HYDROLYSIS 
The 01-C6 tetrahydropyran ring system of mycalamides A and B and 
pederin, containing the C6 acetal group, is analogous to that found in various 
glycosides. The acid catalysed hydrolysis of glycosides is known to occur with 
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fission of the glycosyl-oxygen bond170, 171 (shown by 180 labelling), and 
involves protonation of the alkoxyl oxygen (not the ring oxygen) and cleavage 
to give a cyclic carbonium ion. This ion is resonance stabilised by electron 
donation from the ring oxygen, so that the positive charge lies mainly on the 
oxygen, with the acetal carbon sp2 hybridised170. This carboxonium ion 
intermediate171 is then readily attacked by H20, to give the cyclic hemiacetal 
in an SN1 fashion 172 (Scheme 3.1 ). 
Scheme 3.1 Mechanism for .C6 acetal hydrolysis (R=H) and exchange 
(R=alkyl) in mycalamide A. 
The geometry of the cyclic carboxonium ion intermediate derived from 
glycosides resembles a half-chair100, 170. In mycalamide A, this conformation 
is only slightly modified by the presence of the exocyclic double bond (Figure 
3.3). An attack of H20 from below the ring gives a product with retention of 
configuration at C6, whereas attack from above gives inversion. The C6 
inversion product would be in a new chair conformation, having the C6-0H 
group axial (as favoured by the anomeric effect) and the C7 sidechain 
equatorial at C6 (as favoured by steric factors) (Figure 3.4). However, it would 
also have a 1 ,3-diaxial steric interaction between an axial methyl group at C2 
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and the C6-0H group making it less thermodynamically favourable. This 
thermodynamic effect causes both a stereospecific hydrolysis and a 
stereospecific methanolysis of the product, since these reactions are 
reversible. Similar results were also found for pederin94, 133,164. 
Figure 3.3 Conformation of the carboxonium ion intermediate generated 
from mycalamide A by acid catalysed hydrolysis. 
Figure 3.4 Chair conformations for pseudomycalamides A and B (3.7, 3.9) 
and a C6 epimer. 
H 
a) b) 
3.3.5 REARRANGEMENT AND DECOMPOSITION OF HEMIACETALS 
In the presence of H20, free sugars (cyclic hemiacetals) undergo 
isomerisation between the a and ~ forms (mutarotation). The mechanism for 
this reaction 106 involves a ring opening of the hemiacetal to give an acyclic 
intermediate (Scheme 3.2), as shown by 180 labelling, since the hemiacetal 
oxygen atoms are retained. The presence of acid-base catalysts is known to 
speed up this isomerisation. 
Scheme 3.2 Mechanism of epimerisation of hemiacetals, as shown for 
pseudomycalamide A (3.7). 
H3C H3C 
H3C H3C 
' 
H3C 
............. 
~0 H 
OH +6) OH ~ HaC HaC 
/ 
H3C H3C 
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Pseudomycalamides A and B (3. 7, 3.8) were not very stable, as 
illustrated in earlier acid catalysed reactions. Attempts to purify an old sample 
of pseudomycalamide B (containing a new component) by preparative silica 
gel TLC gave two fractions which were similar, containing both 
pseudomycalamide B (3.8) and another, related compound. It is likely that the 
new compound was the C6 epimer, which was interconverting with 
pseudomycalamide B on silica gel, as discussed above. Several 1 H NMR 
resonances for this epimer were significantly different in chemical shift from 
those observed for pseudomycalamide B. In particular, the 2-CH3 {+0.1 ), H5a 
(-0.3), H5e (+0.1), H10 (+0.1) and H11 (-0.1) resonances were most affected, 
with smaller shifts occurring in many other resonances throughout the 
spectrum. These shifts would be consistent with a 'flipping' of the chair 
conformation of the 01-CB ring on epimerisation at C6, thereby allowing the 
C6-0H group to remain in an axial orientation as favoured by the anomeric 
effect1 06, since the remaining substituents would be in different spatial and 
chemical environments (Figure 3.4). Further changes in the solution 
conformations about the C6-C7 and C7-C8 bonds could also occur as a result. 
However, the separation of these isomers could not be achieved readily, and, 
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furthermore, these pseudomycalamide derivatives were rather unstable, so 
that this work was not pursued further. 
3.3.6 CONVERSION OF PSEUDOMYCALAMIDES A AND B TO 
MYCALAMIDES A AND B. 
Pseudomycalamide A (3.7) was successfully converted to mycalamide 
A by a reaction in methanol containing a trace of p-toluene sulphonic acid 
(5x1 o-4M) as the acid catalyst. The reaction was monitored by reverse phase 
. 
HPLC, which showed a gradual decrease in the amount of the starting 
compound and an increase in the intensity of a peak with an elution time 
identical to mycalamide A. The reaction was about 50% complete after 2 
hours and at least 90% complete after 1 day at room temperature. 
Pseudomycalamide B (3.8) was treated in a similar manner to give complete 
reaction to mycalamide B after four hours, as determined by HPLC. TLC of the 
product also gave a single spot with an identical Rt to that of pure mycalamide 
B. 
This reaction occurs by an attack of CHsOH on the carboxonium ion170, 
generated by loss of H20 from the protonated hemiacetal in an SN1 fashion 
(see Scheme 3.1 ). Therefore this conversion of mycalamides A and B to 
pseudomycalamides A and B was reversible, as for pseudopederin (3.5). 
However, the reaction of pseudopederin was apparently more facile, in that it 
did not require the presence of an added acid catalyst164, whereas the 
analogous reaction of pseudomycalamides A and B did not occur without such 
a catalyst. 
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3.4 C6 ALKOXY EXCHANGE AND ELIMINATION REACTIONS 
3.4.1 04-METHANOL EXCHANGE 
The incorporation of CD30 at C6 in mycalamide A was monitored by 
observing changes in the 1 H NMR spectrum of a sample of mycalamide A in 
CD30D solution containing a trace of trifluoroacetic acid (0.01 M). After 45 
minutes the exchange was about 40% complete, as shown by the appearance 
in the spectrum of a new Cf-lsOH resonance, decrease in the intensity of the 
signals assigned to the 6-0CH3 and H7 protons, and the appearance of a new 
H7 resonance, shifted slightly upfield ( -2 Hz). After 15 hours the exchange 
was complete to give 6-trideuteromethoxy mycalamide A (3.9), but there 
appeared to be a very minor product as well, previously .referred to as 
UNKNOWN 1. HRFABMS confirmed the quantitative inclusion of OCD3 into 
mycalamide A at C6, in place of the OCH3 group, since CD30H was readily 
lost under DCI and DEl mass spectroscopy conditions. Further treatment of 
this product under the same reaction conditions, but using CH30 H, 
regenerated mycalamide A. The mechanism for this and other alkoxy 
exchange reactions at C6 is also SN1, as in Scheme 3.1, with the alcohol 
being the attacking nucleophile. 
3.4.2 ETHANOL EXCHANGE 
Initial attempts were made to prepare a 6-ethoxy derivative of 
mycalamide A by adding a trace of trifluoroacetic acid (0.01 M) to a sample of 
mycalamide A in ethanol. However, the 1 H NMR spectrum of the crude 
product showed a mixture containing mostly pseudomycalamide A (3.7), with 
a smaller amount of a new compound, which was possibly 6-ethoxy 
mycalamide A (3.1 0), along with unreacted mycalamide A and a minor 
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amount of UNKNOWN 1. Thus hydrolysis, due to traces of H20 in the solvent, 
was the favoured reaction path. 
A second attempt, using pyridinium p-toluene sulphonate 167,173 as the 
catalyst in dry ethanol, was more successful. The reaction was best monitored 
by reverse phase TLC or HPLC, since the new compound found above had a 
longer retention time than mycalamide A and pseudomycalamide A a shorter 
retention time, whereas on silica gel both compounds had shorter retention 
times than mycalamide A. The reaction was very slow, but after four days at 
. 
room temperature the reaction mixture consisted of a ratio of about 2:1 in 
favour of a more retained product over mycalamide A, with another very minor 
product. Preparative HPLC was performed to purify the new major product, 
which was similar to mycalamide A by 1 H NMR spectroscopy, but lacked the 
C6-methoxyl group and contained a new ethoxy system (Table 3.1 ). These 
new -OCH2 proton resonances were non-equivalent, with each appearing as 
a doublet of quartets. The more downfield -OCH resonance was enhanced 
most on irradiation of H7 in an NOE experiment (Table 3.3), whereas the 
upfield -OCH resonance was enhanced most on irradiation of H2, so that this 
compound was clearly 6-ethoxy mycalamide A (3.1 0). The 13C NMR 
spectrum was also similar to that of mycalamide A, but contained no C6 
methoxyl signal, and there were two new carbon resonances at 856.7 and 
15.2 ppm, assignable to the new ethoxy substituent (Table 3.2). The C7 
resonance was only slightly shifted (+0.8 ppm) and all other signals in the 13C 
NMR spectrum were within 0.2 ppm of those for mycalamide A. These results 
suggested that the distributions of solution conformations of this C6-ethoxy 
derivative were almost identical to those of mycalamide A. HRFABMS 
confirmed the molecular formula of this compound, which was isomeric with 
mycalamide B, and showed a ready loss of CH3CH20H from the MH+ ion, as 
expected. 
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3.4.3 ATTEMPTED EXCHANGE WITH ISOPROPYL ALCOHOL 
Little or no reaction was observed by TLC for a sample of mycalamide A 
in isopropyl alcohol, containing a small amount of pyridinium p-toluene 
sulphonate, after a period of 16 hours at room temperature, so the reaction 
was heated for 1 hour at 55oc. Reverse phase TLC showed the presence of 
some unreacted mycalamide A and other, less retained products only, so the 
reaction was stopped. After workup, 1 H NMR spectroscopy showed the 
presence of at least fqur compounds, including mycalamide A, 
pseudomycalamide A (3.7), pederolactone (3.6), and the compound earlier 
designated as UNKNOWN 1. Preparative HPLC gave four fractions, but on 
evaporation and examination by 1 H NMR spectroscopy only two of the four 
purified fractions contained recognisable signals, which belonged to 
mycalamide A and the unknown compound respectively. 
3.4.4 STRUCTURE OF 'UNKNOWN 1' 
The lH NMR spectrum of this compound was similar to that of 
mycalamide A but there were no C6 methoxyl or H5 resonances apparent, 
although there was a new single proton singlet at 85.64 ppm. There were also 
shifts in the H2 (+0.2), H3 (+0.2), 4=CHZ (-0.2), H7 (+0.3) and NH (-0.3) proton 
resonances, compared to data recorded for mycalamide A (Table 3.1 ). 
Irradiation of the new resonance in an NOE experiment gave an enhancement 
of the downfield 4=CHE and H7 signals (Table 3.3). Similarly, irradiation of 
these signals enhanced the singlet at 85.64 ppm. This evidence suggested 
that this singlet was due to a single H5 proton on a double bond, which must 
be located between C5 and C6, as in structure 3.11. 
Note that the chemical shifts of the 4=CH2 protons had 'swapped', 
compared to data for mycalamide A, with the 4=CHE signal now being the 
more downfield resonance, consistent with shielding effects due to this double 
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bond123. The shifts in the remaining signals probably also resulted from a 
combination of electronic factors 101 and steric effects, and also from the new 
conformation of the 01-C6 tetrahydropyran ring, depicted in Figure 3.5. Here 
the atoms C3, 4=CH2, C4, C5, C6, C7 and 01 all lie approximately in a plane, 
giving an envelope shape, with C2 preferentially below this plane so that the 
C2 methyl group is approximately equatorial. The conformations about the 
C6-C7 bond were not fixed, but the NOE results above suggested that H7 was 
close to H5 in a major solution conformation, and this is reasonable, in order 
to minimise steric interactions. 
OH 
NH 
"''· 
H 
R1=R2=H: 5,6-Dehydromethoxy mycalamide A (3.11) 
R1=R2=COCHs: 5,6-Dehydromethoxy A 17,18-diacetate (3.16) 
Figure 3.5 1 H-1 H NOE interactions and partial solution conformation of 
5,6-dehydromethoxy mycalamide A (3.11 ). 
There was insufficient sample of this 5,6-dehydromethoxy mycalamide 
A derivative (3.11) to enable further NMR spectroscopic characterisations, 
although HRFABMS was achieved, which indicated a molecular formula of 
C2sHs7NOg, in accordance with the proposed structure. The reaction above 
did not seem to be a good method to reprepare this derivative, particularly as 
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same decomposition had been observed on silica gel and in a stared NMR 
sample. However, a new route was discovered subsequently from 
investigations of mycalamide A in mild bases at high temperature. This 
method will be described briefly here, since it was high yielding and allowed 
further characterisat_ians an this same derivative. Fallowing this, mechanisms 
far bath acid and base catalysed reactions will be proposed. 
3.4.5 HIGH TEMPERATURE ELIMINATION REACTION, CATALYSED BY 
WEAK BASES 
The elimination of methanal at C6 in mycalamides A and B occurs 
readily at high temperatures, as observed under all mass spectroscopy 
conditions. During high temperature 1 H NMR studies of mycalamide A in 
DMSO, it was observed that mycalamide A was stable to temperatures of at 
least 15ooc in solution. However, upon the addition of only a few microliters 
of pyridine or triethylamine, there occurred a clean reaction, which was almost 
complete within twa hours at 13QOC in the sealed sample tube. A 1 H NMR 
spectrum of the product showed the presence of the same signals described 
above far 5,6-dehydramethaxy mycalamide A (3.11) and a methanal signal 
was observed as well. To confirm the identity of this product, the 1 H NMR 
spectral data in DMSO were also fully assigned (Table 3.1 ). Nate that in this 
solvent the signals far the C7-0H and NH protons were observed at quite law 
fields, suggesting that these protons were involved in strang hydrogen 
banding interactians101. This reaction was then repeated and the combined 
product separated from DMSO by elution an a reverse phase pipette column. 
Full NMR spectroscopic characterisations were then performed in CDCI3, 
containing a trace of pyridine as usual. 
The 1 H NMR spectrum was conclusively assigned by using the results 
of COSY and NOE experiments (Tables 3.1 and 3.3). A 13C NMR spectrum 
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was recorded and both HMQC and HMBC experiments were performed to 
assign these signals. The strong HMBC correlations from the C2 and C3 
methyl and the 4=CH methylene proton signals (Table 3.4) were used to 
confirm the assignments of C2 and C3, which had shown only weak 
correlations in the HMQC spectrum, and to locate C4 (8142.9 ppm). Note that 
the C5 resonance, 8103.6 ppm, had been located by the HMQC experiment, 
and was of typical chemical shift for the structure 117. The C6 resonance, at 
8149.8 ppm, was located by a strong HMBC correlation from H7, and was also 
similar in chemical shift to those of other enol ethers117,174,175. 
Comparing these 13C NMR data with those recorded for mycalamide A 
(Table 3.2), the largest shifts had occurred in the C5 and C6 resonances due 
to the presence of the new double bond. However, the chemical shifts of 
signals assigned to the remaining 01-C6 ring carbons and substituents had 
also changed significantly, with shifts in the C2 (+6.8), 2-CH3 (-2.0), C3 (-3.6), 
3-CH3 (+1.2), C4 (-2.8) and 4=CH2 (-2.5) carbon resonances. These changes 
were also consistent with the presence of a double bond between C5 and 
C6117, and with changes in the ring conformation, as shown in Figure 3.5 
above. 
3.4.6 ELIMINATION MECHANISMS 
3.4.6.1 ACID CATALYSED ELIMINATION MECHANISM 
The 5,6-dehydromethoxy mycalamide A derivative (3.11) was present 
at a low level in most of the acid catalysed C6 hydrolysis or alkoxy-exchange 
attempts described above, as indicated. This was not surprising since the 
intermediate carboxonium ion is in a homoallylic relationship to the terminal 
alkene and the ~ (allylic) H5 proton is therefore slightly acidic. Thus the 
elimination reaction to give 5,6-dehydromethoxy mycalamide A could be 
expected to compete with substitution reactions under acidic conditions, 
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especially with poorer nucleophiles and a partially hindered carboxonium 
ion 170,176. The mechanism of such an elimination reaction is likely to be 
E1176 (Scheme 3.3a), since the reaction conditions were fairly polar, with a 
good leaving group being present under acidic conditions (eg CH30H), and 
the carboxonium ion intermediate was reasonably stable. 
Scheme 3.3 Acid and base catalysed elimination mechanisms for the 
formation of 5,6-dehydromethoxy mycalamide A (3.11 ). 
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3.4.6.2 BASE CATAL YSED ELIMINATION MECHANISM 
The mechanism for the base catalysed elimination reaction is likely to 
lie somewhere in the range E2 to E1 cB176. The solvent, DMSO, is dipolar and 
aprotic, but simply applying a high temperature to a solution of mycalamide A 
in DMSO was insufficient to induce elimination. Pyridine is a relatively poor 
nucleophile and a weak base 140,177. In the mycalamide structure, the HSa 
proton is antiperiplanar to the C6-0CH3 group, which is the preferred 
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arrangement for an E2 anti elimination reaction176 (Scheme 3.3b). However, 
CH 30- is a poor leaving group140 and the H5 protons are slightly acidic so 
that the transition state may have substantial carbanion character, as in the 
E1 cB mechanism176 (Scheme 3.3c). The difference between the two 
extremes is whether H+-Base leaves before (E1 cB), or at the same time as 
(E2) the CH3o- group, but this is not essential to the present discussion. 
3.5 ANALYSIS OF BIOLOGICAL ASSAY RESULTS 
The antiviral and P388 assay results for the above derivatives have 
been listed in Table 3.5. The conversion of mycalamides A and 8 to 
pseudomycalamides A and 8 (3. 7, 3.8), having a C6-0H group, has a 
deactivating effect of 20-40 fold, which is in good agreement with the 
published results for pederin and pseudopederin40 (see the introduction to 
this chapter). Detailed analysis of the solution conformations of 
pseudomycalamides A and 8 showed that there were significant differences 
from those found for mycalamides A and 8, particularly in the relative 
populations of the C6-C7 rotamers. In addition, the higher polarity of 
pseudomycalamides A and 8, due to the extra hydroxyl group, and the 
potentially different interactions of this group with the unknown active site 15, 
could be factors involved in the observed drop in the biological activities of 
these derivatives. 
By comparison, the biological activities of 6-ethoxy mycalamide A 
(3.1 0) were almost the same as those of mycalamide A. The distribution of 
solution conformations appeared to be the same in both, despite the polarity of 
the 6-ethoxy compound being slightly less than mycalamide A, as measured 
by the relative mobilities of these compounds on C18 and silica gel. 
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The 5,6-dehydromethoxy mycalamide A derivative (3.11) was 
significantly less active than even pseudomycalamide A (3.7) and at least 200 
times less active than mycalamide A. Again there were probably some 
changes to the distribution of solution conformations about C6-C7, but also 
there were different electronic and steric effects caused by the presence of the 
new C5-C6 double bond and the 01-C6 ring conformation was considerably 
different. Note that the mobilities of this derivative on both C18 and silica gel 
lay between those of pseudomycalamide A and mycalamide A, so that the loss 
in activity would not seem to be associated entirely with different solubility 
characteristics 1,15. 
In summary, it appears that the C6 acetal is very important for the 
biological activities of mycalamide A. The observation of changes to the 
solution conformations of this portion of the molecule on derivatisation may be 
useful in probing the active conformation or site. Such work has not been 
considered in this study. 
3.6 ACID CATALYSED DECOMPOSITION STUDIES OF 
MYCALAMIDE A TRIACETATE 
The instability of the mycalamides A and Band pederin to contact with 
acids has so far been shown to arise mainly from the presence of a 
homoallylic acetal functionality132 at C6. Indeed the only products isolated 
from such reactions have so far involved acid catalysed exhange at C6, 
elimination across C5-C6, and cleavage of the C6-C7 bond. In an attempt to 
follow the decomposition further, it was considered desirable to use an acetate 
protecting group78 for the hydroxyl groups, since the resulting acetate esters 
would be stable to mild acid138, and would increase the mass and reduce the 
polarity of potential fragments. Furthermore, potential enols at C7 or other 
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centres would be partially trapped as the vinyl esters. Also, various other 7-0-
substituted derivatives, including mycalamide B bis-TMS ether (2.2) and 
mycalamide A 7, 18-di-p-bromobenzoate (2.12), had shown a tendency to 
undergo a facile elimination-rearrangement reaction in acidic CDCI3 and it 
was therefore desirable to investigate this reaction further. The results for the 
above derivatives will be discussed briefly following a presentation of the 
results obtained in the current study, since this will assist in their interpretation. 
3.6.1 INITIAL INVESTIGATION, MONITORED BY 1 H NMR SPECTROSCOPY 
A sample of mycalamide A triacetate (2.18) was dissolved in CDCI3 
containing a trace of trifluoroacetic acid (0.1 M) and placed in an NMR sample 
tube. 1 H NMR spectroscopy showed a slow reduction in the intensity of 
signals belonging to mycalamide A triacetate, and the appearance of new 
signals over several days. After two days at ambient temperature there was 
about 40% conversion to one major rearranged product, but other minor 
products were also observed. After five days there were still more 
components, but there was still residual mycalamide A triacetate present in the 
mixture. Of particular interest in the 1 H NMR spectrum of this mixture was a 
strong singlet at about <59.16 ppm, suggesting the presence of an aldehyde 
group 101. Therefore the reaction products were recovered, washed with 
water, and then analysed by HPLC. Preparative HPLC initially separated two 
fractions from a mixture of more polar components, and the latter was then 
further chromatographed to yield two further fractions, giving four fractions 
overall, which have been ordered according to increasing polarity. 
The 1 H NMR spectrum of the first fraction showed that it consisted 
entirely of unreacted mycalamide A triacetate (2.18) and the second fraction 
was similarly found to be a rearranged product ('UNKNOWN 2'). The third 
fraction was also almost pure by 1 H NMR spectroscopy, but very small, and 
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was evidently a cleavage fragment derived from the right-hand portion of 
mycalamide A triacetate ('UNKNOWN 3'). The final fraction was a complex 
mixture, with few recognisable signals. The small sample size of the two new 
compounds required that the reaction be repeated to obtain sufficient sample 
for accurate NMR spectroscopic characterisation. This was done, but the 
system was modified by using the milder two-phase technique, developed 
above for the hydrolysis of mycalamide A, in an attempt to improve the yields, 
and, possibly, to isolate further degradation products. 
3.6.2 TWO-PHASE HYDROLYSIS MONITORED BY TLC 
A larger sample of mycalamide A triacetate (2.18), dissolved in 
C H2CI2, was stirred rapidly with an aqueous p-toluene sulphonic acid solution 
(0.1 M) at 75-aooc in a sealed vial. After one day, silica gel TLC showed that 
most of the starting material had disappeared, and that there were several 
products. Following neutralisation and other workup procedures, preparative 
TLC was performed, which yielded four fractions. These fractions were then 
examined by 1 H NMR spectroscopy, in order of decreasing polarity. 
The major fraction (1) was an almost pure sample of UNKNOWN 2 by 
1 H NMR spectroscopy, so these samples were combined for analysis. The 
second fraction contained a compound similar to that contained in fraction 1, 
possibly an isomer ('UNKNOWN 4'), with a small amount of UNKNOWN 2. 
The third fraction was a mixture and so it was set aside for HPLC separation, 
while the final fraction was also a mixture, containing the aldehyde fragment, 
UNKNOWN 3. These 'unknowns' are chacterised below. 
3.6.3 STRUCTURE OF UNKNOWNS 2 AND 4 
Mass spectroscopy showed that the compounds described above as 
UNKNOWNS 2 and 4 were isomers, of molecular formulae C29H43N012, 
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which corresponded to a loss of CHaOH from mycalamide A triacetate (2.18). 
An FTIR spectrum of these isomers showed a small decrease in the frequency 
of the amide carbonyl stretch (1 0-14 cm-1 ), compared to similar data for 
mycalamide A triacetate, which is consistent with further conjugation of this 
group96. There was also evidence for a vinyl (C7) acetate group96, since 
there were carbonyl stretching bands at 1765 and 177 4 cm-1 for the two 
isomers, in· addition to the normal 1740 cm-1 acetate band found in 
mycalamide A triacetate (2.18). The 1 H NMR spectrum of both compounds 
. 
also showed a loss of the signals for the 6-0CH3, H7, H2S, and 4=CH2 
protons, and the appearance of new sign·als for an allylic methyl-methine 
system. These data are consistent with a rearrangement of the exocyclic 
double bond into the C4-C5 position of the 01-C6 tetrahydropyran ring and an 
elimination of methanol across C6-C7, to give two isomers about the C6-C7 
bond of a fully conjugated, planar dienone from C4 to C8 (3.12, 3.13). These 
structures were called 'neomycalamides' for ease of reference. 
NH h,, H 
R1=R2=R3=COCH3: ZNeomycalamide A triacetate (3.12) 
R1=R3=COCsH4Br, R2=H: ZNeomyc.A 7,18-di-p-bromobenzoate (3.18) 
R1=R2=Ra=COCHa: E Neomycalamide A triacetate (3.13) 
R1=R3=COCsH4Br, R2=H: E Neomyc.A 7, 18-di-p-bromobenzoate (3.19) 
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The complete 1 H NMR spectrum of each isomer was assigned with the 
aid of COSY and proton decoupling experiments (Table 3.6). The two isomers 
differed most in the chemical shifts of the H2, 2-CH3, H5 and NH resonances, 
with the shifts for the latter two being very large (> 1 ppm). The large downfield 
shift in the H5 proton resonance of UNKNOWN 4, relative to that of 
UNKNOWN 2, is consistent with a Z geometry at the C6-C7 double bond 
(3.12), since the H5 proton is then close to the C8 carbonyl oxygen, and in the 
plane of the dienone (Figure 3.6a), thus giving the anomalous chemical 
shift123. Examples of this ·deshielding by carbonyl groups abound in the 
literature. 
Figure 3.6 1 H-1 H NOE interactions and possible conformations of the 
neomycalamide A triacetate isomers (3.12, 3.13). 
CH3 
a) Zisomer, cis enone 
CH3 
T 
N, 
H 
OAc 
c) E isomer, cis enone 
OAc 
CH3 
b) Zisomer, trans enone 
The C6-C8 enone for this Z isomer (3.12) can only be cisoid, otherwise 
unfavourable steric interactions occur between the ring substituents and the 
NH9 chain (Figures 3.6a and b). In contrast, the E isomer (3.13) can be either 
cisoid or transoid at the C6-C8 enone (Figures 3.6c and d respectively). If the 
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enone is trans, then the NH proton is close to the ring oxygen, 01, and can 
form an almost planar 6-membered ring by hydrogen bonding. The chemical 
shift of this proton resonance (88.1 0 ppm) suggested that it was strongly 
hydrogen bonded1 01, much more so than in the Z isomer (3.12) or 
mycalamide A triacetate (2.18). This proposal was further supported by the 
different chemical shifts of the H2 and 2-CH3 proton resonances for the two 
isomers and by the observation of NOE interactions between these protons 
and the NH proton (Table 3.3 and Figure 3.6d). Further evidence for the 
. 
proposed C6-C7 double bond stereochemistry of this E isomer was obtained 
from the observation of NOE interactions between H5 and the C7 acetate 
methyl protons. 
13C NMR spectra were also recorded for the two isomers and, in 
addition, HMQC and HMBC experiments were performed on the major isomer 
(E, 3.13) to enable unambiguous 13C NMR spectral assignments (Table 3.2). 
The HMBC correlations obtained have been listed in Table 3.4. The C8 
carbon resonance was shifted upfield, compared to its position in mycalamide 
A triacetate, consistent with a,~-unsaturation 117. Many of the other 01-C6 ring 
carbons were also shifted considerably, as expected, due both to electronic 
factors and to changes in the conformation of this ring. 
The chemical shifts of the carbons directly involved in the new dienone 
system (Table 3.2) were close to those observed in model 
compounds174,175,178. However, either the quaternary C6 or C7 resonance 
was not observed in the 13C NMR spectrum, unless the two were coincident, 
and only one of the two possible HMBC correlations from H5 were observed. 
It was assumed that the 13C resonance for C7 was less likely to be observed 
because it could have a longer relaxation time, since the quaternary C7 is 
itself located between two quaternary carbon atoms. Therefore the signal at 
8151.8 ppm, which also showed the HMBC correlation to H5, was tentatively 
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assigned to C6. Note, however, that this value would be an equally 
acceptable chemical shift for C7174,175. 
3.6.4 STRUCTURE OF 'UNKNOWN 3' 
In the introduction to this chapter, it was noted that the hydrolysis of 
pederin in sulphuric acid/hexane94 gave an aldehyde fragment, pederenal 
(3.1 ). This was formed by hydrolysis of the Ci 0 aza acetal of pederin and 
elimination of H20 across C12~C13, followed by rearrangement of the new 
. 
double bond into the C11-C12 position (the C13-0H had originally been 
incorrectly placed at C12 in the pederin structure because of this result27,94). 
Mycalamide A, which contains many structural features similar to those of 
pederin, could undergo a similar cleavage reaction. 
The ElMS and DCIMS results on UNKNOWN 3 indicated a molecular 
formula of C1sH2407. An FTIR spectrum showed the presence of a carbonyl 
stretch at about 1700 cm·1, on the shoulder of the carbonyl band for the two 
acetate groups (1741 cm-1}, along with a weak C=C stretching band at 1637 
cm-1, which were indicative of an a,~-unsaturated aldehyde96, and were 
almost identical to theIR bands reported for pederenal94 (3.1). The 1H NMR 
spectrum contained a singlet at o9.16 ppm, which was assigned to a Ci 0 
aldehyde proton, and a doublet at o5.84 ppm coupled to a doublet at o3.61 
ppm (2.6 Hz), which were assigned to the H12 and H13 protons, respectively 
(Table 3.6). There were also resonances for the 13-0CH3, two 14-CHa, H15-
H18, and two acetate methyl groups, although there were small shifts in these 
resonances compared to those recorded for mycalamide A triacetate (2.18). 
These data are all consistent with the structure 3.14. Note that there was 
insufficient sample to obtain a 13C NMR spectrum. 
Difference NOE experiments were performed to analyse the 
conformation of the C11-C15 ring, and the results listed in Table 3.3 have 
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been summarised in Figure 3.7. In particular, strong NOE interactions were 
observed between H1 0 and H12, and weaker interactions between H13 and 
H15, and from both H13 and H15 to the equatoriai14-CH3 group, confirming 
that the relative stereochemistries of the ring carbons had not changed. The 
conformation of this C11-C15 ring could thus be described as a half-chair100, 
with the C16 sidechain substituent in the preferred equatorial position at C15. 
Figure 3.7 Structure and 1 H-1 H NOE interactions for the 1 a-aldehyde 
fragment (3.14) .• 
OAc 
3.6.5 OTHER PRODUCTS FROM THE HYDROLYSIS OF MYCALAMIDE A 
TRIACETATE 
3.6.5.1 PRODUCTS FROM TLC FRACTION 3 
The 1 H NMR spectrum of the third TLC fraction above had indicated a 
mixture of at least four major components, so this was further analysed by 
reverse phase HPLC. Three compounds were isolated after preparative 
chromatography, including a very small amount of unreacted mycalamide A 
triacetate (2.18). 
Of the remaining two HPLC fractions, one was assumed to be 
pseudomycalamide A triacetate (3.15), based on certain features of the 1 H 
NMR spectrum. These included the absence of the C6 methoxyl resonance, 
together with the presence of the two 4=CH, two H5 and H7 resonances, 
although the latter had shifted considerably from their positions in the 1 H NMR 
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spectrum of mycalamide A triacetate (2.18) in the same manner as they had 
in the spectrum of pseudomycalamide A (3.7) compared to that of mycalamide 
A. However, on comparison of the 1 H NMR spectrum of the original mixture 
with the 1 H NMR spectrum of this fraction, it became apparent that substantial 
decomposition had occurred during purification, a property which was also 
characteristic of the pseudomycalamides, as described above. 
The remaining HPLC fraction was also a compound related to one 
observed earlier. The 1 H NMR spectrum contained signals that were similar to 
. 
those observed for 5,6-dehydromethoxy mycalamide A (3.11), and there were 
two acetate signals, positioned at C17 and C18, as shown by the downfield 
chemical shifts of the a proton resonances101. The C7-0H proton resonance 
was also observed, coupled to H7, and being exchanged on addition of D20. 
A COSY spectrum was recorded to confirm the 1 H NMR assignments (Table 
3.6), but there was insufficient sample to record a 13C NMR spectrum. 
However, HRFABMS confirmed the molecular formula of this 5,6-
dehydromethoxy mycalamide A 17, 18-diacetate derivative (3.16). 
3.6.5.2 PRODUCTS FROM TLC FRACTION 4 
The 1 H NMR spectrum of the fourth TLC fraction above had indicated a 
mixture of at least two major components, so this was also further analysed by 
reverse phase HPLC. Preparative HPLC yielded a small amount of the 
aldehyde fragment (3.14) above, along with another related fragment. The 
1 H NMR spectrum of this compound showed that the signals for the two C14 
methyl groups were now superimposed, at 81.09 ppm, and those for H15 and 
the C13 methoxyl had also shifted downfield (+0.4, +0.3 ppm, respectively), 
relative to those in the aldehyde fragment (Table 3.6). There was no aldehyde 
resonance, and only one other signal apart from those relating to the C16-C18 
sidechain, a singlet at 85.05 ppm. When this was irradiated in an NOE 
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experiment, the C13 methoxyl resonance was weakly enhanced. Hence this 
singlet was assigned to an H12 proton, and the presence of a double bond 
between C12 and C13 was proposed, in order to account for the chemical shift 
of H12 and the downfield shifts in the C13 methoxyl and C14 methyl signals, 
compared to data recorded for mycalamide A triacetate (2.18). There was 
evidently no proton at C11 since H12 was a singlet, so that an exocyclic 
double bond was required at C11. One possibility was that this was a 
carbonyl group, so that the compound was an a,~-unsaturated lactone (3.17) . 
. 
FTIR showed a carbonyl stretching band at about 1720 cm-1, on the shoulder 
of the 1740 cm-1 C=O acetate band, and weaker C=C stretching bands at 
1665 and 1614 cm-1 which would arise from this unsaturated lactone96. 
Further evidence was obtained from HRFABMS, which indicated a compound 
of molecular formula C1sH2207, consistent with this proposed structure. 
0 
H 
H 
CH3 
OCH3 
OAc 
11-Lactone fragment (3.17) 
3.6.6 MECHANISMS OF FORMATION 
3.6.6.1 NEOMYCALAMIDE A TRIACETATE ISOMERS 
The mechanism of formation of the neomycalamide A triacetate isomers 
(3.12, 3.13) may include two possible pathways (Scheme 3.4). In the first 
pathway (Scheme 3.4a), an acid catalysed elimination of the C6 methoxyl 
group and H5 is proposed, in an E1 process176 as described earlier, to give a 
5,6-dehydromethoxy mycalamide A triacetate derivative. This diene could 
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then undergo an acid catalysed rearrangement, with elimination of H7, to give 
both isomers of the observed conjugated dienone. The isolation of a small 
amount of the diene (3.16), with no C7 acetate, could arise from a competing 
acid catalysed hydrolysis of the C7 acetate, which would trap the diene. An 
alternative pathway (Scheme 3.4b) is the acid catalysed rearrangement of the 
exocyclic double bond into the ring and then elimination of the C6 methoxyl 
group and H7 in an E1 process. 
Scheme 3.4 Mechanism of formation of the neomycalamide A triacetate 
isomers (3.12, 3.13) from mycalamide A triacetate (2.18). 
H'( (1) 
H + OAc 
H_poH ~ 
·a~' w} ; 
(2) 
Route a): 1, 3, 5, 6 
Route b): 1, 2, 4, 6 
Route c): 1, 2, 6 
Neomycalamide A triacetate 
E and Zisomers (6) 
~ OAc 
The most stable isomer of neomycalamide A triacetate was the E 
isomer (3.13), since there was evidence of some rearrangement of the Z 
isomer to the E isomer on silica gel TLC, but not the reverse. Under more 
forcing acidic conditions, such as in the initial experiment monitored by 1 H 
NMR spectroscopy, only the E isomer was observed. However, under very 
mildly acidic conditions, and with a relatively non-polar solvent, there is some 
evidence that the reactions shown in Scheme 3.4b occur, but with the 
elimination reaction proceeding by an E2 anti mechanism176 (Scheme 3.4c). 
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For example, various 7-0-substituted ethers, such as mycalamide B bis-TMS 
ether (2.2), and esters, such as mycalamide A 7,18-di-p-bromobenzoate 
(2.12}, underwent this elimination and rearrangement in CDCI3 solution, to 
give the Z isomers of the neomycalamide derivatives almost quantitatively and 
stereospecifically, as shown by the distinctive downfield allylic HS resonances. 
1 H NMR data for Z neomycalamide A 7,18-di-p-bromobenzoate (3.18) are 
listed in the Experimental section, with the assignments being verified by the 
results of a COSY experiment. Note that the Z isomer is the expected anti 
.. 
elimination product from elimination of H7 and 6-0CH3 groups. In the latter 
example, this sample slowly, and quantitatively, rearranged to the E isomer 
(3.19) on standing overnight at ambient temperature (data for this isomer are 
also recorded in the Experimental section only). The intermediate in this 
rearrangement reaction could be the conjugated dienol, shown in Scheme 
3.4. This would be formed by protonation of the carbonyl and rearrangement 
of the double bonds, and allows for free rotation about C6-C7, as required. 
These neomycalamide derivatives can only be formed when the C7 
hydroxyl group is substituted, as an ether or ester, since enols are not the most 
stable tautomer and readily convert to ketones154. An attempted 
deacetylation of the major neomycalamide A triacetate isomer (3.13), using 
potassium carbonate in aqueous methanol, gave a complex mixture of 
decomposition products. This was not considered further. 
3.6.6.2 DIACETYL a,~-UNSATURATED ALDEHYDE FRAGMENT 
Under acidic conditions both the C1 0 aza acetal and the C1 0-0, C12-0 
methylene acetal can be hydrolysed to give an aldehyde at C1 0 and an 
alcohol at C12. The mechanism for this dual hydrolysis is not shown, since 
there is more than one possible route, depending on which acetal is more acid 
stable, involving various hemiacetals and carboxonium ion intermediates, and 
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this standard chemistry has been indicated earlier with the conversion of 
mycalamide A to pseudomycalamide A (3. 7). Note, however, that the 
remaining products of this hydrolysis are formaldehyde and a primary amide. 
The aldehyde product contains an a-proton and a I)-hydroxyl, and is thus an 
ideal structure for an elimination reaction 176,179, which is assisted by the 
acidic reaction conditions and elevated temperature, to give the observed a,j)-
unsaturated aldehyde (3.14). 
3.6.6.3 OTHER PRODUCTS ~ 
The mechanism of formation of the pseudomycalamide (3.7, 3.8) and 
5,6-dehydromethoxy mycalamide (3.11) derivatives has been discussed in 
earlier sections. The remaining product to account for is the diacetyl a,j)-
unsaturated C11 lactone fragment (3.17). It is assumed that this unsaturated 
lactone is formed by an allylic oxidation on the enol form of the· aldehyde 
(3.14) (having double bonds between C12-C13 and C1 O-C11 ), or some 
similarly conjugated derivative, in a fashion similar to the proposed formation 
of pederolactone (3.6). This follows from the known acid catalysed addition 
reactions of water with enol ethers, such as the one at C11, to give 
hemiacetals172. In the present case, addition of H20 across C10-C11 would 
give an allylic hemiacetal, which could then undergo air oxidation to give the 
observed lactone (3.17). 
3.7 BIOLOGICAL ASSAY RESULTS FOR MYCALAMIDE A 
TRIACETATE DEGRADATION PRODUCTS AND 
CONCLUSIONS 
The assay results for the compounds discussed above have been listed 
in Table 3.5. For the products with low sample mass (all except the E isomer 
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of neomycalamide A triacetate (3.13) and the starting triacetate (2.18)), the 
biological activity stated may be caused by traces of more active impurities. It 
is readily apparent that all these compounds were relatively inactive. The 
neomycalamide derivatives were potentially useful in terms of reducing the 
number of solution conformations of mycalamide A, but were inactive, 
probably due mainly to the C7-0 substitution, although loss of the C6 acetal 
may also be' a factor. The cleavage fragments isolated from the right hand 
portion of the molecule (3.14, 3.17) were also inactive, as was pederolactone 
(3.6). 
The main aim of the study was to investigate the acid decomposition 
pathway of the mycalamides and, in particular, look at the biological activities 
of the fragments. From this viewpoint the study was a success, although the 
isolation of more fragments from the left hand portion would have been useful. 
It has been shown that the acid instability problems of the mycalamides arise 
primarily from the presence of the homoallylic C6 acetal functionality, but also 
from the unusual C1 0 acetal systems. Acid catalysed hydrolyses, 
eliminations, rearrangements and, probably, allylic oxidations could therefore 
account for the rapid decomposition of the mycalamide skeleton on contact 
with acids. 
The earlier work of substitution and elimination reactions at the C6 
acetal gave some useful structure-activity correlations which have 
considerably added to information reported from studies on pederin. It has 
also given some clear experimental guidelines if any further acid catalysed 
reactions of mycalamide A or its derivatives are attempted in future studies. 
Table 3.1 1 H NMR dataa for compounds described in Sections 3.2-3.4. 
Mycalamide A Pseudomyc.A Pseudomyc.B 6-Ethoxy myc.A 5,6-Dehydromethoxy myc.A (3.11) 
(~ @m @1Ql (Q~ (j)'yS2) 
H2 3.98 (2.7,6.6) 4.20 (2.6,6.7) 4.21 (2.5,6.5) 3.99 (2.7,6.6) 4.18 (3.1 ,6.5) 4.16 (2.5,6.6) 
2-CH3 1.19 (6.6) 1.08 (6.6) 1.09 (6.6) 1.17 (6.5) 1.21 (6.5) 1.19 (6.5) 
H3 2.23 (2.7,7.0) 2.22 (2.6,7.0) 2.22 (2.8,7.0) 2.23 (2.6, 7.1) 2.45 (2.6,7.0) 2.49 (2.6,7.0) 
3·CH3 0.99 (7.0) 0.99 (7.0) 1.00 (7.1) 1.00 (7.1) 1.01 (7.0) 1.03 (7.0) 
4:CHZ 4.84 (m) 4.89 (2.0) 4.89 (2.0) 4.83 (m) 4.67 (m) 4.70 (m) 
4:CHE 4.72 (m) 4.77 (1.9) 4.76 (2.0) 4.73 (m) 4.79 (m) 4.80 (m) 
H5a 2.36 (m) 2.81 (1.9,13.8) 2.81 (2.0, 13.8) 2.38 (m) 
H5e 2.36 (m) 2.17 (13.8) 2.16 (14.0) 2.38 (m) 5.64 5.54 
6·0CH3 3.29 
H7 4.31 4.08 4.06 4.26 4.57 • 4.43 (5.3) 
7-0H 6.16 (5.3) 
NH9 7.51 (9.7) 7.59 (9.8) 7.57 (9.1) 7.50 (9.6) 7.23 (9.8) 8.46 (9.3) 
H10 5.87 (9.7) 5.82 (9.9) 5.67 (9.1 ,9.9) 5.87 (9.7) 5.86 (10.0) 5.80 (9.3) 
10-0CHR 5.13 (6.9) 5.15 (7.0) 5.15 (7.0) 5.13 (7.0) 5.15 (6.8) 5.27 (6.9) 
10-0CHS 4.87 (6.9) 4.89 (6.9) 4.88 (6.8) 4.87 (7.0) 4.88 (6.9) 4.83 (6.9) 
li11 3.86 (6.8,9.7) 3.93 . (6.6, 1 0.0) 3.91 (6.7, 1 0.0) 3.85 (6.8,9.6) 3.85 (6.9,10.1) 4.10 (6.7,9.5) 
H12 4.22 (6.8, 1 0.3) 4.24 (6.8, 1 0.5) 4.23 (6.7,10.5) 4.22 (6.7, 10.2) 4.24 (6.7, 1 0.6) 4.15 (6.8,8.9) 
H13 3.46 (10.3) 3.47 (10.4) 3.46 (1 0.4) 3.46 (1 0.3) 3.48 (1 0.6) 3.86 (9.0) 
13-0CH3 3.55 . 3.56 3.56 3.56 3.56 3.56 
14·CH3R 0.97 0.97 0.96 0.98 0.97 1.00 
14·CH3S 0.87 0.87 0.88 0.87 0.86 0.84 
H15 3.62 (5.5,7.1) 3.58 (m) 3.30 (m) 3.62 (5.5,7.0) 3.56 (m) ? 
H16 1.54 (m) 1.56 (m) 1.58 (m) 1.56 (m) 1.53 (m) 1.68 (1.4,7.6,14.3) 
H16 1.54 (m) 1.56 (m) 1.58 (m) 1.56 (m) 1.53 (m) 1.34 (m) 
H17 3.74 (m) 3.75 (m) 3.37 (m) 3.74 (m) 3.73 (m) 3.56 (m) 
17·0CH3 3.31 
H18 3.57 (3.5, 11.3) 3.56 (m) 3.53 (3.9, 11.4) 3.57 (m) 3.56 (3.5, 11.3) ? 
H18 3.38 (6.2, 11.3) 3.41 (5.6, 11.4) 3.47 (6.0, 11.5) 3.38 (6.7, 11.2) 3.37 (6.1,11.4) ? 
6-0CH . 3.60 (7.0,9.0) 
6-0CH 3.51 (7.0,9.0) 
6-0CH2CH3 1.18 (7.0) 
..... 
a All data were recorded in CDCI3 (except 3.11 in DMSO), with chemical shifts in ppm relative to CHCI3, o7.25 (coupling constants in Hz), or to '-l (0 
CH D2SOCD3, o2.60 ppm. 
Table 3.2 13C NMR dataa for compounds described in Chapter 3. 
Mycalamide A Pseudomyc.A Pseudomyc.B 6-Ethoxy A 5,6-Dehydro- Myc.A triacetate ENeomyc.A ZNeomyc.A 
(3.1.) (3.8) (3.10) me!hQx:t 8 (3.11) (2.18) 1oa~e1. (3.13) lria!::el. (3.12) 
C2 69.81 68.95 68.90 69.83 76.59 69.73 76.15 ? 
2·CH3 17.88 17.87 17.87 17.92 15.88 17.87 17.40 17.21 
C3 41.37 41.43 41.46 41.41 37.72 41.24 38.13 38.14 
3·CH3 12.02 11.75 11.80 12.07 13.17 12.04 10.27 10.31 
C4 145.65 146.49 146.63 145.67 142.90 145.08 150.77 ? 
4:CH2 110.55 110.41 110.31 110.47 108.03 110.85 
4·CH3 22.32 22.69 
C5 33.75 35.72 35.65 33.89 103.63 34.18 112.60 114.60 
C6 99.83 97.54 97.41 99.75 149.80 99.26 151.85 ? 
6·0CH3 48.94 48.'60 
C7 72.92 74.89 73.74 72.57 71.66 ? ? 
C8 171.82 174.08 174.83 171.73 171.91 167.01 162.55 ? 
C10 73.74 73.26 73.53 73.67 73.59 73.72 74.09 73.56 
10·0CH2 86.84 87.03 86.75 86.83 87.04 86.53 86.61 86.68 
C11 71.26 71.22 70.47 71.27 71.51 69.90 70.75 ? 
C12 74.42 74.50 74.51 74.42 74.62 74.06 74.38 74.44 
C13 79.15 78.90 79.24 79.18 78.96 79.93 79.34 79.17 
13·0CHa 61.81 61.93 61.89 61.82 61.91 61.55 61.81 61.86 
C14 41.66. 41.91 41.72 41.65 41.84 40.90 41.54 ? 
14-CHaR 23.11 22.93 22.99 23.13 22.92 23.69 23.08 22.94 
14·CH3S 13.49 13.22 13.18 13.52 13.17 14.40 13.58 13.24 
C15 78.99 79.45 75.15 78.97 78.64 75.53 74.64 74.53 
C16 31.99 31.55 28.76 32.02 31.79 30.08 29.60 29.36 
C17 71.64 72.21 78.79 71.52 71.72 70.01 69.89 70.28 
17·0CH3 56.92 
C18 66.49 66.47 64.01 66.51 66.42 63.57 63.58 63.80 
6·0CH2CH3 56.71,15.17 
7·0COCH3 169.64,20.65 169.52,20.38 ?,20.44 
17·0COCH3 170.60,20.80 170.48,20.81 ?,20.76 
18-0COCH3 169.85,21.06 170.07,21.06 ?,21.02 
_... 
aAn data were recorded in CDCJa, with chemical shifts measured in ppm, relative to CDCI3, o77.01 ppm. co 
0 
Table 3.3 1 H-1 H NOE interactionsa for compounds in Chapter 3. , 
Compound 
Pseudomyc.A 
(3.7) 
Pseudomyc.B 
(3.8) 
6-Ethoxy myc.A 
(3.1 0) 
5,6-Dehydromethoxy 
myc.A (3.11) 
E Neomyc.A triacetate 
(3.13) 
1 0-Aidehyde fragment 
(3.14) 
Slgnal(s) 
Irradiated 
H5a 
H5e (H3) 
H7 
H5a 
H5e 
H7 
H2 
H7 (H12) 
4=CHZ 
4=CHE 
H5 
H7 
H2 (H18d0 ) 
2-CH3 (H16u0 ) 
4-CH3 
H5 
?-OCOCH3 
NH 
H10 
H12 
H13 
H15 
Signals enhanced 
C% enhancement> 
3-CH3(1), H5e(14), H7(2) 
H2(2)b, 3-CH3(0.5)b, 4=CHZ(2)b, 4=CHE(4), 
H5a(16), H7(2) ' 
H5e(1) 
3-CH3(1), H5e(21), H7(2) 
4=CHE(6), H5a(25), H7 (4) 
H5a (1 ), H5e(2) 
2-CH3(1), H3(3), H6u(1)c 
H~(0.8), H6d(2)c, NH(2), H11(2)b, 
14-CH3S(0.4)b 
H3(3), 3-CH3(0.6), 4=CHE(14) 
4=CHZ(14), H5(6) 
4=CHE(4), H7(3) 
H5(4) 
2-CH3(2), H3(5), H5(0.8), NH(0.6), H17(1)b, 
H18u(8)b,c 
H2(8), H3(3), 3-CH3(2), NH(2), H17(0.7)b 
H3(3), 3-CH3(0.8), H5(1 0) 
4-CH3(1), 7-0COCH3(0.2) 
H5(2) 
H2(1 ), 2-CH3(0.S), H11 (8) 
H12(6) 
H10(12), H13(3), 13-0CH3(1) 
H12(1), 14-CH3R(1), H15(2) 
H13(1), 14-CH3R(0.5) 
aAII data were recorded in CDCI3, except for compound 3.8, where the solvent was CD2CI2 
bEnhancement interpreted as being due to the irradiation of an overlapping resonance 
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cu and d have been used to designate the upfield and downfield resonances of a geminal pair 
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Table 3.4 2JcH and 3JcH HMBC correlationsa for compounds in Chapter 3. 
Gamru1d proton Carbon signal correlated (chemical shittbL 
E Neomyc.A triacetate 
(3.13) 
5,6-Dehydromethoxy myc.A 
(3 .11) 
2-CH3 C2, C3 
3-CH3 C2, C3, C4 (o150.75) 
4-CH3 C3, C4, CS 
H5 C3, 4-CH3, C6 or C7 (o151.85) 
7-0COCH3 7 -OCO 
10-0CHR C10, C12 
10-0CHS C10, C12 
H11 C12, C13 
H12 C10, 10-0CH2 
H13 C12, 13-0CH3, C14, 14-CH3S 
13-0CH3 C13 
14-CH3R C13, C14, 14-CH3S, C15 
14-CH3S C13, C14, 14-CH3R, C15 
H15 C16 
2-CH3 
3-CH3 
4=CH2 
. H7 
10-0CHR 
10-0CHS 
H12 
13-0CH3 
14-CH3R 
14-CH3S 
C2,C3 
C2, C4 (o142.9) 
C3,C5 
C6 (o149.8), C8 
C10, C12 
C10, C12 
C10 
C13 
C13, C14, 14-CH3S, C15 
C13, C14, 14-CH3R, C15 
8AII data were recorded in CDCI3 (chemical shifts in ppm relative to CDCI3, o77.01) 
Table 3.5 Biological assay results for compounds in Chapter 3 
Comgound P38~ ICsoa Anlfvlral R~sult~b (oaldisls) 
Mycalamide A 0.5 WN WN +* 5 + + +* 
Pederolactone (3.6) 120 WN +++ +* 1000 ++ +++ +* 
Pseudomycalamide A (3.7) 9 WN WN +* 100 +++ +++ +* 
Pseudomycalamide B (3.8) 4 WN +++ +* 50 + + +* 
6-Ethoxy mycalamide A (3.1 0) 1 WN WN +* 20 +++ +++ +* 
5,6-Dehydromethoxy A (3.11) 120 WN WN +* 5000 
Mycalamide A triacetate (2.18) 45 WN WN +* 500 +++ +++ +* 
ZNeo A triacetate (3.12) 220 WN WN +* 20000 ++ ++ +* 
E Neo A triacetate (3.13) 1300 +++ ++ +* 20000 -
1 0-Aidehyde fragment (3.14) 500 WN +++ +* 10000 
5,6-Dehyd.A 17,18-diac.(3.16) 270 WN WN +* 10000 
11-Lactone fragment (3.17) 125 WN ++ +* 1000 + + +* 
ENeo A 7,18-di-p-brBz.(3.19) 600 WN WN +* 2000 
2 
500 
50 
20 
10 
2000 
200 
10000 
10000 
5000 
5000 
500 
500 
a In ng/ml. The derivatives are estimated to be better than 95% pure, having been subjected 
to at least two steps of chromatographic purification in most cases. · 
b -,+,++,+++,WW=antiviral zone size. Results are listed in the order of Herpes simplex virus, 
Polio virus, cytotoxicity, loaded sample mass. 
Table 3.6 1 H NMR dataa for compounds described in Section 3.6. 
Mycalamide A ENeomyc.A ZNeomyc.A 5,6-Dehydro. 1 0-Aidehyde 11-Lactone 
triacetate triacetate triacetate A 17, 18-diacet. fragment fragment 
!2.la.l Q.lal (3.121 (3.16) Q.Hl Q,ll) 
H2 3.99 (2.8,6.6) 4.30 (2.8,6.5) 4.14 (2.8,6.6) 4.19 (2.8,6.5) 
2-CH3 1.20 (6.6) 1.42 (6.5) 1.23 (6.5) 1.20 (6.5) 
H3 2.25 (2.7,7.0) 2.07 (2.3,6.8) 2.01 (m) 2.44 (2.7,6.9) 
3-CH3 1.03 (7.1} 1.02 (7.1) 0.96(7.1) 1.00 (7.1) 
4:CHZ 4.87 (1.8) 4.76 (m) 
4:CHE 4.76 (1.9) 4.64 (m) 
4-CH3 1.92 (1.4} 1.93 (1.4) 
HS 6.01 (1.5) 7.35 (1.4) 5.61 
H5a 2.45 (1.8,14.4) 
Hse 2.38 (14.4) 
6·0CH3 3.18 
H7/7·0H 5.47 4.56/4.29 (4.4) 
NH9 7.32 (9.4) 8.10 (8.6) 6.54 (9.0) ? 
H10 5.76 (9.0) 5.84 (8.7,9.8) 5.82 (9.9,9.9) 5.76 {9.7) 9.16 
10·0CHR 5.06 (6.9) 5:14 (6.8) 5.16 (6.8) 5.13 (7.0) 
10·0CHS 4.86 (7.0) 4.85 (6.9) 4.85 (7.0) 4.85 {7.0) 
H 11 3.79 (6.0,8.7) 3.86 (6.5,9.8) 3.92 {6.7,9.9) 3.83 (6.6,9.6) 
H12 4.10 (6.0,9.4) 4.19 (6.6,10.2) 4.19 (6.7,10.3) 4.20 (6.7,10.5) 5.84 {2.6) 5.05 
H13 3.36 (9.4) 3.47 {10.2) 3.53 (10.4) 3.46 (10.4) 3.61 (2.6) 
13·0CH3 3.52 3.55 3.56 3.55 3.45 3.71 
14·CH3R 1.01 0.95 0.94 0.95 0.99 1.09 
14·CH3S 0.86 0.87 0.85 0.85 0.85 1.09 
H15 3.45 (2.4,9.8) 3.39 (2.0,10.4) 3.36 (1.9, 1 0.2) 3.36 {2.2,9.8) 3.83 (2.5,9.7) 4.18 (2.5,9.6) 
H16 1. 77 (2.5,9. 1 '14.5) 1.75 {2.2,9.6, 13.9) 1.77 (2.0,9.0, 14.5) 1.79 {m} 2.02 (6.6,9.8, 14.8) 2.02 {m) 
H16 1.62 (4.5,9.5, 14.5) 1.64 (3.9, 1 0.3,13.9) 1.57 (m) 1.53 (m) 1.91 {2.5,5.6,14.9) 1.93 (m} 
H17 4.98 (m) 5.07 (m) 5.03 (m) 5.04 {m) 5.31 (m) 5.34 (m} 
H18 4.27 {2.7,12.4) 4.26 (2.5, 12.4) 4.23 (3.4,12.2) 4.10 (m) 4.27 (3.3,12.1) 4.31 (3.2,12.3) 
H18 4.14 (5.2, 12.4) 4.09 (5.5,12.7) 4.01 (5.6,12.3) 4.10 (m) 4.18 (6.1 '12.2) 4.22 (5.8,12.4) 
7-0COCH3 2.20 2.24 2.21 
17/18-0COCH3 2.05,2.00 1.99,1.98 2.01 '1.99 2.05,2.03 2.10,2.06 2.09,2.06 
..... 
a All data were recorded in CDCis, with chemical shifts in ppm relative to CHCia, o7.25 (coupling constants in Hz) 0) c.> 
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CHAPTER 4 
HYDROGENATION AND OTHER ADDITIONS 
TO THE DOUBLE BOND OF 
MYCALAMIDES A & B AND DERIVATIVES 
4.1 INTRODUCTION 
The hydrogenation of pederin over Adams catalyst and over palladium 
. 
on charcoal was reported as part of an early study investigating the structure 
of pederin27,94. It was found that crystallisation of the product obtained from 
the hydrogenation of pederin over Adams catalyst yielded only one isomer of 
dihydro pederin (4.1 ), as determined by 1 H NMR spectroscopy, melting point 
and chromatography94. However, a complete analysis of the 1 H NMR spectral 
data was not reported, so that the stereochemistry at C4 was undefined. Also 
no NMR data were given for dihydro pseudopederin (4.2), prepared from 
pseudopederin (3.5). The hydrogenation of pederin over palladium on 
charcoal gave about equal amounts of dihydro pederin (4.1) and dihydro 
deoxy pseudopederin (4.3), the latter being obtained by hydrogenolysis of the 
acetal after a rearrangement of the exocyclic double bond94. Again only one 
isomer was reported, although a complete analysis of the 1 H NMR spectral 
data was not performed. 
The biological activity data reported for these compounds40, which 
measured their in vitro activity against Hela tumour cell cultures, showed that 
dihydro pederin (4.1) and dihydro pseudopederin (4.2) were less cytotoxic 
than the parent compounds. This result was interpreted as being of 
considerable interest, since the 'high antimitotic activity' appeared to be 
associated with 'negligible vesicatory effects•40,180. However, the dilution 
series used to establish the relative activities used steps of ten in 
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concentration, so that this result needed further investigation. Dihydro deoxy 
pseudopederin (4.3) was also reported as showing antimitotic activity181, 
although this was not quantified. 
R1=0CH3, R2=R3=H: Dihydro pederin (4.1) 
R1=0H, R2=R3=H: Dihydro pseudopederin (4.2) 
R1=H, R2=R3=H: Dihydro deoxy pseudopederin (4.3) 
R1=0CH3, R2=R3=Ac: Dihydro pederin diacetate (4.8) 
R1=H, R2=R3=Ac: Dihydro deoxy pseudopederin diacetate (4.14) 
These results for dihydro pederin (4.1) provided a good basis for a 
similar investigation into the hydrogenation of the mycalamides, which would 
aim to solve the stereochemistry of the products and determine quantitative 
structure-activity relationships. It was also hoped that the apparently different 
cytotoxicity of dihydro pederin would provide a useful lead for synthesising 
mycalamide derivatives which would be more selective in their action2. The 
work in this chapter describes the results of this study and an extension to 
other double bond addition reactions, such as epoxidation. 
4.2 HYDROGENATION OF MYCALAMIDES A AND B OVER ADAMS 
CATALYST 
4.2.1 PREPARATION OF DIHYDRO MYCALAMIDE A AND B ISOMERS 
Mycalamide A reacted readily with hydrogen, in the presence of Adams 
catalyst (Pt02), to give a mixture of two dihydro mycalamide A isomers (4.4, 
186 
4.5), in a ratio of about 3:2 by 1 H NMR spectroscopy and analytical HPLC (no 
order intended). This was repeated using mycalamide B as the substrate, to 
give two isomers of dihydro mycalamide B (4.6, 4.7). Mass spectroscopy of 
the products confirmed the addition of H2 to mycalamides A and B. The 
isomers obtained from these reactions were not fully resolved by either 
reverse phase HPLC or silica gel TLC. However, by collecting three fractions 
from preparative HPLC, corresponding to cuts on either side of the observed 
double peak, and recycling the central mixture, it was possible to obtain 
. 
fractions which were 85-90% rich in one isomer by 1 H NMR spectroscopy. 
These fractions were then subjected to an extensive investigation by NMR 
spectroscopy, to assign their 1 H and 13C NMR spectra and to determine their 
stereochemistries and solution conformations. 
R1=0CH3, R2=R3=R4=H: 4a-Dihydro mycalamide A (4.4) 
R1=0CH3, R2=R4=H, R3=CH3: 4a-Dihydro mycalamide B (4.6) 
R1=0H, R2=R3=R4=H: 4a-Dihydro pseudomycalamide A (4.10) 
R1=H, R2=R3=R4=H: 4a-Dihydro, 6-deoxy pseudomycalamide A (4.13) 
R1=H, R2=R3=R4=Ac: 4a-Dihydro, 6-deoxy pseudomyc.A triacetate (4.15) 
OH 
R=H: 4~-Dihydro mycalamide A (4.5) 
R=CH3: 4~-Dihydro mycalamide B (4.7) 
OH 
4.2.2 1 H NMR SPECTRAL ASSIGNMENTS, STEREOCHEMISTRY AND 
SOLUTION CONFORMATION OF THE MAJOR DIHYDRO ISOMER 
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The 1 H NMR spectrum of the major dihydro mycalamide A isomer 
showed the loss of the signals due to the C4 exocyclic methylene protons and 
the appearance of a third methyl doublet, consistent with hydrogenation at C4. 
There were large shifts in the 01-C6 ring proton resonances, as expected, and 
the 1 H NMR spectrum was assigned with the aid of COSY and NOE 
experiments, as detailed below, to give the data in Table 4.1. 
There were three methyl doublets in the 1 H NMR spectrum, at o1.17 
(6.6), 1.16 (7.1) and 0.93 (7.1) ppm (coupling constants in Hz). The signal at 
o1.17 ppm was almost certainly due to the C2 methyl group since it had the 
smaller coupling constant, being adjacent to oxygen102. The COSY spectrum 
confirmed this assignment, since this signal showed a correlation to a doublet 
of quartets at o4.11 ppm, which was assignable to H2. The methyl doublet at 
o1.16 ppm was coupled to a multiplet at o1.70 ppm, while the remaining 
doublet, at o0.93 ppm, was coupled to a multiplet at o1.33 ppm. There were 
also two doublet of doublets, at o1.76 (5.6, 13.8) and o1.53 (2.9, 14.0} ppm, 
which could be assigned to the two geminal H5 protons (D20 was added to 
exchange out the H20 signal at o1.5-1.6 ppm}. 
These signals were further assigned by an analysis of the results of 
NOE experiments, performed on both the mycalamide A and B isomers (Table 
4.2}. These results are summarised as arrows in Figure 4.1 a. Irradiation of 
the H2 resonance gave a strong enhancement of the multiplet at o1.33 ppm, 
the methyl doublet at o1.16 ppm, the C2 methyl resonance and the C6 
methoxyl resonance. The observed NOE interaction between H2 and the C6 
methoxyl protons suggested that the preferred solution conformation of the 
01-C6 tetrahydropyran ring was still a chair conformation, as in mycalamides 
A and B, with the C6 methoxyl group axial, as favoured by the anomeric 
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effect1 05,106, and the C7 sidechain equatorial as favoured by steric factors. 
The observed coupling constant between H2 and H3 was almost the same as 
in mycalamides A and B, so that this assumption appeared to be reasonable, 
and is further confirmed below. Therefore the H2 and C3 methyl substituents 
were in an anti relationship, so that the methyl doublet at o1.16 ppm, which 
was enhanced by irradiation of H2, was required to be an axial C4 methyl 
group. Therefore the multiplet at o1.33 ppm was H3, and the remaining 
methyl doublet, at 80.93, must be assigned to the C3 methyl group. Irradiation 
of the latter enhanced the H3 resonance, the multiplet at o1.70 ppm (H4) and 
the signal at o1.76 ppm, which was therefore assignable to the axial H5 
proton, and this could only occur if the 01-C6 ring was in a chair conformation. 
Other NOE interactions (Table 4.2) supported these assignments, the 
stereochemistry at C4, and the proposed 01-C6 ring conformation. The 
complete 1 H NMR data for both 4j3-dihydro mycalamides A and B (4.5, 4.7) 
have been listed in Table 4.1. (Throughout this chapter, the nomenclature a. 
and J3 follows the IUPAC recommendations for the naming of substituents in 
steroids 182, where the hydrogen (or oxygen for epoxides) is the new ring 
substituent at C4). 
Figure 4.1 1 H-1 H NOE interactions and solution conformations for the 01-C6 
. ring of the C4-dihydro mycalamide A and B epimers (4.4-4.7). 
a) Major isomer (4~) b) Minor isomer (4a) 
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The C2-C5 vicinal proton-proton coupling constants (Table 4.1) were 
well within the expected ranges for the stereochemistry and ring conformation 
stated above. In particular, the magnitudes of the H3-H4, H4-H5e and H4-H5a 
coupling constants, 2.7, 2.9, and 5.6 Hz, respectively, were in accordance with 
the equatorial-equatorial relationships for the protons in the first two cases, 
and the equatorial-axial relationship of the protons for the latter, as predicted 
by the Karplus equation98,102. 
4.2.2 1 H NMR SPECTRAL ASSIGNMENTS, STEREOCHEMISTRY AND 
SOLUTION CONFORMATION OF THE MINOR DIHYDRO ISOMER 
The 1 H NMR spectrum of the minor dihydro mycalamide A isomer (4.4) 
had the same overall features as that of the major isomer, but with substantial 
chemical shift differences for some resonances. There were three methyl 
doublets, at 81.18 (6.6), 0.88 (7.0) and 0.73 (7.1) ppm, which were correlated 
to signals at 83.97 (2.3, 6.6), 2.14 and 1.47 ppm, respectively, in a COSY 
spectrum. Of these methyl doublets, the first could be assigned to the C2 
methyl group, but the remaining two could not be distinguished on this 
evidence. The HS proton resonances, at 81.23 and 1.62 ppm were distinctive 
by their large geminal coupling constant and the resulting strong correlation in 
the COSY spectrum. The upfield one was coupled to the multiplet at 82.14 
ppm with a coupling constant of around 13 Hz, which could only be satisfied if 
the protons were in an anti relationship98. This geometry required that the 
upfield HS resonance be assigned to the axial HS proton and that the multiplet 
at 82.14 be assigned to an axial H4 proton. This, combined with the COSY 
data above, then enabled direct assignment of the signals for the remaining 
ring substituents, and hence of the complete 1 H NMR data for both 4a.:dihydro 
mycalamides A and B (4.4, 4.6) (Table 4.1 ). 
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Various NOE experiments were performed to check the 1 H NMR 
assignments, the designated stereochemistry, and the solution conformation 
of the 01-C6 ring, and the results of these (Table 4.2) have been summarised 
as arrows in Figure 4.1 b. In particular, observed NOE interactions between 
the 1 ,3-diaxial substituents, H2 and H4, H2 and 6-0CH3, and 3-CH3 and H5a, 
confirmed the solution conformation and the stereochemistry at C4. The other 
vicinal coupling constants, H3-H4 and H4-H5, were both about 3.9 Hz, which 
is typical for an axial-equatorial relationship of the protons in a 6-membered 
.. 
ring98. 
There were no major differences between the 1 H NMR data for the 
mycalamide A and mycalamide B compounds, except for the C16-C18 
sidechain resonances, as expected. However, there were significant chemical 
shift differences noted on comparing data for the two isomers, particularly for 
H4, 4-CH3 and H5a, with smaller differences in data for the remaining 01-C6 
ring and substituent protons. This is consistent with the difference in 
stereochemistry at C4, and different shielding and deshielding effects98,123. 
In particular, the signals for axial substituents at C4 were deshielded by the 
presence of the axial C6 methoxyl group, as was the H2 resonance by an 
axial methyl group at C4, due to a combination of steric and anisotropic 
effects. Also the C3 methyl resonance was slightly shielded by an equatorial 
C4 methyl group, an effect which has been noted in substituted cyclohexane 
systems123. 
4.2.3 13C NMR ASSIGNMENTS FOR THE DIHYDRO MYCALAMIDE A AND B 
ISOMERS 
13C NMR spectra were recorded for all four compounds. An HMQC 
experiment was performed on both the dihydro mycalamide B isomers (4.6, 
4.7), and an HMBC experiment was performed on the major one (4.7), to 
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enable unambiguous assignments of the 13C NMR data to be obtained. The 
HMBC experiment was required to clearly distinguish the C4, C5 and C16 
resonances, since the proton signals were overlapping. The strong HMBC 
correlations observed between the C4 methyl proton resonance and the C4 
and C5 carbon signals, and between the C3 methyl resonance and the C2 
and C4 signals (Table 4.3) were useful for these assignments. The HMQC 
correlations ·to the C3, C4 and C16 signals were also weak for the minor 
isomer (4.6). However, the C5 resonance was clearly located and the C16 
. 
resonance could be assigned on the basis of its chemical shift. The only 
remaining ambiguity was then in the assignment of the C3 and C4 
resonances, which were given the values closest to those in the major isomer 
(4.7), since it was reasonably expected that these particular ring carbons 
would not change in chemical shift by more than 4 ppm with an epimerisation 
at C4. The 13C NMR data for 4a- and 4~-dihydro mycalamide A (4.4, 4.5) 
were then assigned by comparison with the dihydro mycalamide B results 
(Table 4.4). 
On comparing the 13C NMR data for the two dihydro isomers, it was 
apparent that the largest chemical shift differences occurred for C2 and the C3 
methyl group. The observed shielding of the C3 methyl carbon resonances in 
the two 4a isomers (4.4, 4.6), due to the presence of the new equatorial C4 
methyl group, and the shielding of the C2 (and C6) resonances in the 4~ 
isomers (4.5, 4.7), due to the presence of the new axial C4 methyl group, is 
ascribed to the steric compression of a gauche interaction117. This effect is 
well documented for substituted cyclohexanes120 and tetrahydropyrans119. 
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4.2.4 STEREOSELECTIVITY·IN THE HYDROGENATION OF MYCALAMIDES 
A AND B AND PEDERIN 
The hydrogenation of mycalamides A and B over Adams catalyst gave 
an approximately 3:2 ratio of the two isomers, and favoured the 4P isomer, 
although this may not necessarily be preferred thermodynamically. The 
mechanism of this heterogeneous catalytic hydrogenation reaction will be 
discussed in detail later in this chapter. However, it is well known183 that the 
addition of hydrogen to double bonds is cis, so that the stereochemistry of the 
major isomer (4.4, 4.6) implies that an attack of hydrogen from above the face 
of the double bond is slightly favoured over an attack from below, as shown in 
Figure 4.2. Note that both faces would have some steric hindrance, with the 
top re face having the adjacent axial C3 methyl group, and the bottom si face 
having the axial C6 methoxyl group nearby. The chair conformation of the 01-
C6 tetrahydropyran ring, which has the exocyclic double bond in a pseudo-
equatorial orientation, may allow slightly easier access to the top face, 
although this may also be influenced by the conformations of the rest of the 
molecule, especially the C7 sidechain. 
Figure 4.2 The approach of reagents in additions to the exocyclic double 
bond of mycalamides A and B. 
Pederin was hydrogenated under similar experimental conditions, but 
apparently gave only one isomer94. The partial 1 H NMR data reported for 
dihydro pederin (4.1) were recorded in ds-benzene, which is known to cause 
193 
unusual chemical shift effects98,123. However, partial1 H NMR data were also 
reported for dihydro pederin diacetate (4.8) in d6-acetone94, which could be 
directly compared with data for pederin diacetate (4.9) in the same solvent. 
Note that the reported data for pederin in d6-acetone did not differ 
considerably from the data recorded in CDCI3 (Chapter 1 ), so that solvent 
effects could reasonably be ignored. Similarly acetylation had little effect on 
data for the 01-C6 ring and, in particular, data for the C2 and C3 methyl 
resonances in pederin diacetate (4.9), <51.15 (6.5) and 0.97 (7.0) ppm, were 
. 
similar to data for these resonances in mycalamides A and 8 in CDCI3. 
Therefore a comparison of such data for compound 4.8 with those recorded 
for the dihydro mycalamide derivatives could enable the stereochemistry at C4 
of dihydro pederin to be determined. 
OAc 
= : 
' H 
c~ ! c~ 
OAc 
Pederin diacetate (4.9) 
The three methyl resonances in dihydro pederin diacetate (4.8) were 
observed at <51.12 (6.5), 0.88 (7.0), and 0.69 (7.0) ppm. The chemical shifts of 
these methyl groups in dihydro pederin diacetate (4.8) were very close to 
those recorded for 4a-dihydro mycalamides A and 8 (4.4~ 4.6), and could not 
reasonably arise from a 4~ isomer, since this would have substantially less 
shielded signals for both the the C3 and C4 methyl groups 123, as described 
above. Therefore the major product from the hydrogenation of pederin with 
Adams catalyst was probably the 4a isomer, a point which will be referred to in 
a discussion of the biological assay data in a later section. It is possible that 
this difference in stereoselectivity occurred because of some longer range 
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effects associated with the different solution conformations and substituents in 
pederin compared with the mycalamides, or because of some variation in the 
exact experimental conditions 183-185. 
4.3 HYDROLYSIS OF DIHYDRO MYCALAMIDES A AND B 
The above NMR spectroscopy experiments on the dihydro mycalamide 
isomers were performed in CDCia with added pyridine and under these 
.. 
conditions the compounds were quite stable. However, in the absence of 
pyridine, samples of both dihydro mycalamide isomers in CDCia solution 
changed within a few minutes at room temperature, to give new derivatives 
almost quantitatively. Characteristics of the 1 H NMR spectra of the products 
included the loss of the C6 methoxyl signal, and chemical shift changes in the 
signals assigned to the H2, 2-CHa, two HS and H7 protons. There were no 
new signals, therefore the most likely explanation was that the C6 acetal had 
been hydrolysed to a hemiacetal under these slightly acidic conditions 139. 
HRFABMS confirmed that this was so, and the ready loss of H20 from the 
parent ion was also observed in the DCI and DEl mass spectra. Thus the 
products were isomers of dihydro pseudomycalamide A or 8, but only the 
mycalamide A derivatives (4.10, 4.11) will be described here. 
The 1 H NMR spectrum of 4a-dihydro pseudomycalamide A (4.1 0} was 
assigned by comparison with the corresponding data for 4a-di hydro 
mycalamide A (4.4) and by using the results of COSY and selective proton 
decoupling experiments (Table 4.1 ). There were shifts observed in the signals 
assigned to H2 (+0.2), 2-CHa (-0.1 ), H4 (+0.1 ), H5a (+0.4}, H5e (-0.2), and H7 
(-0.2), which were very similar to those observed on comparison of data for 
pseudomycalamide A (3.7) with data for mycalamide A. The 13C NMR 
spectrum was also directly assignable by noting the shifts in the 13C signals 
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between mycalamide A and pseudomycalamide A (3. 7) and applying these to 
the data for 4a.-dihydro mycalamide A (4.4) (Table 4.4). 
OH 
H 
, CH3 
~ CH3 
OCH3 
OH 
OH 
4(3-Dihydro 6S pseudomycalamide A (4.11) 
However, the 1 H NMR spectrum of '4(3-dihydro pseudomycalamide A' 
{ 4.11) was not interpretable in the same way, since the chemical shift 
differences between these data and those recorded for 4(3-di hydro 
mycalamide A (4.5) were quite different from those found above. The 
spectrum was also less clean, with at least one minor component being 
evident. The 1 H NMR spectral data were assigned by using the results of 
COSY and selective proton decoupling experiments (Table 4.1 ). These 
results showed that the H2 and 2-CH3 resonances had hardly shifted with this 
C6 hydrolysis, whereas other signals. H3 (+0.1 ), H4 {+0.2), 4-CH3 (-0.1 ), H7 
(+0.2) and NH (-0.2), displayed unusual shifts. Similarly, those signals in the 
13C NMR spectrum which related to the left hand portion of the molecule (C2-
C8) were also of quite different in their chemical shifts to those in the parent 
compound (4.5), so that these data could not be directly assigned. 
Two possibilities exist to explain these observations. Firstly, the 
conformation of the 01-C6 ring could have changed, for example, from a chair 
to a boat conformation. However, this would probably significantly modify the 
H2-H3 coupling constant102, which was not observed, and such alternate 
conformations would also be expected to be of higher energy1 06. 
Furthermore, the parent 4(3-dihydro mycalamide A derivative (4.5} existed in 
the usual chair conformation, so that reducing the size of the C6 axial 
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substituent should make this conformation more favourable. Finally, this 
possibility would not explain the shifts in all the proton and carbon 
resonances, as listed above. A second possibility is that there had been an 
inversion of configuration at C6 on hydrolysis of the acetal. Note that in the 
chair conformation of the 01-C6 tetrahydropyran ring of 4~-dihydro 
mycalamide A (4.5) there are three axial substituents. If inversion had 
occurred at C6, and the hydrolysed product were in the opposite chair 
conformation, then there would be only two axial substituents to this ring, one 
. 
being the C6 hydroxyl group, as favoured by the anomeric effect1 05. This 
would place most substituents in a different environment (compare Figure 3.4) 
and thus better explain the observed chemical shift differences. 
The mechanism for the hydrolysis of the C6 acetal was discussed in 
Chapter 3. The mechanism for the formation of the hydrolysed C6 epimer may 
involve either a rearrangement of the hemiacetaP 06, as discussed in Section 
3.3.5, or the occurrence of some inversion in the hydrolysis mechanism itself, 
since the reversibility of such reactions cause the more thermodynamically 
stable product to be formed. Neither compound was stable to long term 
storage and both contained small amounts of non-hydrolysed dihydro 
mycalamide A, so that the biological assay results for these derivatives, 
described in a later section, are unreliable. Therefore a full NMR 
spectroscopic investigation on these compounds, to complete assignments of 
the 1 H and 13C NMR spectra and to determine the solution conformations, did 
not appear to be warranted. 
However, it is useful to note that removal of the double bond by 
hydrogenation does not appear to make mycalamides A and 8 significantly 
more acid stable. This is shown by the fact that the hydrolysis of the C6 acetal 
in the dihydro derivatives appeared to be more facile than in mycalamides A 
and B, which required the use of p-toluene sulphonic acid in a two-phase 
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hydrolysis system (Chapter 3). It is possible that this is partly caused by the 
presence of new steric interactions across the tetrahydropyran ring system 
between axial C4 sustituents and the C6 oxygen, which are absent in 
mycalamides A and B. However, the extreme ease of hydrolysis of 
glycosides170, and other similar ring acetals, is well known186, since this 
property is the basis for the use of tetrahydrofuranyl (THF) and 
tetrahydropyranyl (THP) ethers as protecting groups for hydroxyl 
functionalities78, 11 o, 187. 
4.4 HYDROGENATION OF MYCALAMIDE A OVER PALLADIUM ON 
CARBON CATALYST 
4.4.1 PREPARATION AND PURIFICATION OF PRODUCTS 
The aim of this study was to prepare and characterise a C6 reduction 
product analogous to compound 4.3, derived from pederin, and then to 
determine its biological activity. Although there were alternative methods for 
reducing such acetals to catalytic hydrogenation, these generally involved 
acidic conditions 188-190, and did not seem to be very selective or high-
yielding. Thus a reaction similar to that reported for pederin27 ,94 was 
performed on mycalamide A, using 10% palladium on carbon as the catalyst 
for an hydrogenation reaction. Reverse phase HPLC of the crude reaction 
product showed that at least five components were present, including the two 
dihydro mycalamide A isomers (4.4, 4.5), a small amount of unreacted 
mycalamide A, and two new components. Preparative HPLC thus gave six 
fractions, including three containing various mixtures of the dihydro 
mycalamide A isomers and one which was unreacted mycalamide A by 1 H 
NMR spectroscopy. Of the remaining fractions, numbers 1 and 3, fraction 1 
was quite pure, but fraction 3 was a mixture with one dominant component 
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and a minor amount of mycalamide A. The major compounds in these two 
fractions were new derivatives and the structure determinations of these are 
outlined below. 
4.4.2 STRUCTURE OF THE COMPOUND IN HPLC FRACTION 1 
A HRFABMS measurement on this fraction indicated that the compound 
had the sam·e molecular formula as mycalamide A. The 1 H NMR spectrum 
showed the loss of the signals assigned to both the exocyclic methylene 
. 
system and also either H2 or H3, since only one of the methyl groups was a 
clean doublet (the other was a broad singlet). There was also a new, broad 
methyl singlet at about 81 .6 ppm. A COSY spectrum showed that the methyl 
doublet was coupled to a multiplet at 84.19 ppm (6.6 Hz), suggesting that this 
was due to the methyl group at C2. These results could therefore only be 
satisfied if there was a double bond between C3 and C4, as in Figure 4.3, so 
that the compound was A3 mycalamide A (4.12). Note that the conformation 
of the 01-C6 ring in this derivative is restricted, since C2-C5 must be planar. 
Therefore 01 is drawn above, and C6 below the plane, in a half chair 
conformation100, to allow the C7 sidechain to remain equatorial and the C6 
methoxyl to remain axial, as preferred. 
Figure 4.3 1 H-1 H NOE interactions and proposed solution conformation for 
the 01-C6 ring of A3 mycalamide A (4.12). 
OH 
= ::: 
i H 
, CH3 
~ CH3 
OCH3 
.!\3 Mycalamide A (4.12) 
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The 1 H NMR data could therefore be fully assigned (Table 4.5), with the 
exceptions of the distinction between the C3 and C4 methyl signals and of 
determining the stereoch~mistries associated with the geminal H5 
resonances. These methyl signals were assigned by analysing the results of 
various NOE experiments (Table 4.2), which are depicted in Figure 4.3. In 
particular, NOE interactions were observed between H2 and the protons of the 
methyl resonance at <51.58 ppm, and between both H5 protons and the 
protons of the methyl resonance at <51.63 ppm. Thus these methyl signals 
could be assigned to the groups at C3 and C4, respectively. 
The H2 and two H5 protons are in a homoallylic relationship, as are the 
H2 and C4 methyl protons, the C5 methylene and C3 methyl protons, and the 
C3 and C4 methyl protons. The presence of long range homoallylic 
coupling102,104 (typically in the range 1-3Hz) was indicated by the broadness 
of all these resonances in the 1 H NMR spectrum. These couplings were 
partially resolved by selective proton decoupling experiments. Irradiation of 
the signal assigned to H2 sharpened the two H5 resonances and the C4 
methyl resonance and vice versa. Irradiation of the signal assigned to the C3 
methyl group sharpened both H5 resonances, and the upfield one became a 
sharp doublet of doublets (2.2, 17.3 Hz), whereas the downfield one was a 
broader doublet of doublets (-2.7, 17.3 Hz). The smaller coupling constants 
(2.2, 2.7 Hz) were evidently from the two H5 protons to H2 and, of the two 
values, the larger homoallylic coupling constant is known to be associated 
with a transoid relationship of the protons involved102, 104. Thus the downfield 
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H5 resonance was assignable to the 'axial' H5 proton (above the ring as 
depicted in Figure 4.3). Irradiation of this resonance in an NOE experiment 
enhanced the H7 signal, whereas irradiation of the other H5 resonance did 
not, as found for mycalamide 8 (the H5 resonances were not resolved in 
mycalamide A). Homoallylic coupling between two vinyl methyl groups in a 
cis relationship is usually of the order of 1 Hz1 04 and this is consistent with 
only the slight broadening of both the C3 and C4 methyl resonances observed 
here. 
The geminal coupling~ constant for the H5 protons, of 17.3 Hz, was 
about 3 Hz larger than that observed for mycalamide B. This is because, in 
this derivative (4.12), the two H5 protons are almost symmetrically above and 
below the plane of the adjacent double bond, which maximises the 1t 
contribution to the coupling constant1 02,160. The geometry was less 
favourable for this effect in mycalamide 8, where the C5 protons were 
adjacent to an exocyclic double bond. 
There was insufficient sample to obtain a 13C NMR spectrum. 
However, the above evidence leaves little doubt as to the structure of this 
derivative. The mechanism for its formation will be discussed later in this 
chapter. Other experiments performed to obtain rearranged double bond 
isomers will also be described in a subsequent section. 
4.4.3 STRUCTURE OF THE MAJOR COMPOUND IN HPLC FRACTION 3 
The 1 H NMR spectrum of fraction 3 had indicated that it contained a 
mixture of at least three components, including unreacted mycalamide A. 
However, signals for the new major component were dominant by at least a 
3:1 ratio. The major features of the 1 H NMR spectrum were the loss of the 
exocyclic methylene signals, loss of the C6 methoxyl signal and the 
appearance of a new methyl doublet. There were also shifts in the signals for 
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the 01-C6 ring protons and H7. The latter resonance appeared as a doublet 
(4 Hz) and an addition of D20 to the sample did not alter this, so that this 
coupling could not arise from the C7 hydroxyl proton. This evidence was 
consistent with the formation of a 4-dihydro, 6-deoxy pseudomycalamide A 
derivative (4.13), analogous to that obtained from pederin. HRFABMS 
indicated a molecular formula of C23H41 NOg in support of this structure. 
As further evidence, the sample was acetylated, so that the chemical 
shift and coupling constant of the H7 proton could be clearly distinguished and 
compared directly with reported data for the pederin equivalent94 (such data 
were only reported for the pederin diacetate derivative, 4.14). The 1H NMR 
spectrum of the acetylated mycalamide derivative (4.15) showed a large 
downfield shift in the H7 resonance, as expected, and the chemical shift and 
coupling constant data for this resonance (o5.28 ppm, 3.0 Hz) were very 
similar to those reported for the pederin derivative, 4.14 (o5.23 ppm, 2.5 Hz). 
The 1 H NMR spectrum of 4-dihydro, 6-deoxy pseudomycalamide A triacetate 
(4.15) was then fully assigned using results from a combination of COSY, 
NOE and proton decoupling experiments (Table 4.5). 
The results from various NOE experiments (Table 4.2) have been 
illustrated in Figure 4.4. In particular, irradiation of the H7 signal gave an 
enhancement of a multiplet at o3.86 ppm and this multiplet was also 
enhanced on irradiation of the signal assigned to H2. Therefore this multiplet 
was assigned to the new C6 proton, which was then required to be axial to the 
01-C6 ring, as expected, in order that the bulky C7 sidechain be equatorial to 
this ring at C6. Irradiation of the H2 resonance also gave an enhancement of 
multiplets at o1.41 and 1.82 ppm, which were assigned to H3 and H4 on the 
basis of their COSY connectivities. Irradiation of the H6 resonance gave an 
enhancement of the multiplet at o1.82 ppm, as well as the H2 and H7 
resonances, so that this multiplet had to be assigned to an axial H4 proton. 
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Thus the conformation of the 01-C6 ring was the usual chair conformation. 
The two H5 proton resonances were located at about 81.2 ppm, as shown by 
a strong correlation in the COSY spectrum from the H6 resonance, and by a 
selective proton decoupling experiment, irradiating at 81.2 ppm, which 
reduced the H6 resonance to a doublet (3 Hz). Thus the stereochemistries at 
C4 and C6 were clearly defined and the chemical shifts of the C3 and C4 
substituents were similar to those in 4a-dihydro mycalamide A (4.4). 
Figure 4.4 1 H-1 H NOE interactions and solution conformation for the 01-C6 
ring of 4a-dihydro 6-deoxy pseudomycalamide A (4.13). 
The 1 H NMR spectrum of the non-acetylated compound (4.13) was 
partially assigned by comparison with the data above. However, there was 
insufficient sample to enable a complete spectroscopic characterisation, or to 
allow further purification for analysis of its biological activity. Therefore it was 
desirable to find an alternative preparation of this derivative which would give 
a better (purified) yield. The almost quantitative conversion of mycalamide A 
to 5,6-dehydromethoxy mycalamide A (3.11 ), described in Section 3.4.5, 
appeared to provide a better starting point, since complete hydrogenation of 
this diene could give the required derivative directly, although possibly with 
other isomers. This attempt is described below. 
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4.5 HYDROGENATION OF 5,6-DEHYDROMETHOXY MYCALAMIDE 
A OVER ADAMS CATALYST 
4.5.1 PREPARATION AND PURIFICATION OF PRODUCTS 
A sample which was about 90% 5,6-dehydromethoxy mycalamide A 
(3.11) was hydrogenated over Adams catalyst to give a mixture of 
components by 1 H NMR spectroscopy. Preparative reverse phase HPLC was 
then performed to give five tractions, which were analysed by 1 H NMR and 
mass spectroscopies. Fraction 1 was a small sample of a pure, new 
derivative, as judged by 1 H NMR spectroscopy. The structure of this 
compound will be described later in this section. Fraction 2 was a very small 
sample of a mixture, which contained a small amount of the compound in 
fraction 1, together with another compound, by 1 H NMR spectroscopy. The 
latter, new compound gave rise to signals in the 1 H NMR spectrum which 
suggested the presence of a C4-C5 double bond, but was not considered 
further due to the poor purity and small size of this sample. Fraction 3 was a 
pure sample of 4a-dihydro, 6-deoxy pseudomycalamide A (4.13) and further 
NMR spectroscopic characterisations on this sample will be described below. 
Fractions 4 and 5 were the 4a- and 4~-dihydro mycalamide A isomers (4.4, 
4.5). 
4.5.2 FURTHER CHARACTERISATIONS OF 4a-DIHYDRO, 6-DEOXY 
PSEUDOMYCALAMIDE A 
The complete 1 H NMR spectrum of 4a-dihydro, 6-deoxy pseudo-
mycalamide A (4.13) was assigned with the assistance of COSY, selective 
proton decoupling, and NOE experiments (Table 4.5). Irradiation of a multiplet 
at 83.7 4 ppm in a proton decoupling experiment reduced the multiplicity of the 
H25, H7 and H18 resonances, so that this multiplet had to include the H6 and 
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H17 resonances. Similarly, irradiation of a multiplet at B1.4 ppm reduced the 
multiplicity of the H6 resonance (to a doublet, 4 Hz), as well as the 
multiplicities of the H4 and C3 methyl resonances, so that it contained both the 
two H5 and H3 resonances. An NOE interaction was observed between H4 
and H6 (Table 4.2), so that the 01-C6 ring conformation was the same as 
determined above for the acetylated derivative (4.15). The overlap of 
resonances and the multiplicity of the signals meant that further analysis of the 
solution conformations was not practical for this derivative. 
A comparison of the chemical shifts of this compound (4.13) with those 
of 4a-dihydro mycalamide A (4.4), revealed shifts in the signals assigned to 
H2 (-0.3), H4 (-0.3), H5a (+0.2), H5e (-0.2) and H7 (-0.2). These shifts could 
be ascribed to the removal of anisotropic and steric deshielding effects 
associated with the axial C6 methoxyl group123, which were observed with 
several derivatives above. The partial data reported for the pederin 
derivative94 (4.3) compared well with those found here, suggesting that this 
pederin equivalent had the same C4 stereochemistry. 
Although there was still insufficient sample to obtain a 13C NMR 
spectrum by direct acquisition, the 13C resonances were obtained indirectly, 
by means of HMQC and HMBC experiments performed at higher field strength 
(500 MHz). The resolution of the 13C signals was lower (0.4 ppm), so the 
results contained an error of± 0.2 ppm. These 13C data are listed in Table 
4.4, with the HMBC correlations detailed in Table 4.3. Comparison of these 
13C NMR chemical shifts with those of 4a-dihydro mycalamide A (4.4) 
showed that there were shifts in the signals assigned to C2 (+7), C4 (+5), C5 (-
2), C6 (-22), C7 (+2) and CB (+2). The direction of these shifts is consistent 
with standard substituent effects117 (except the C7 resonance, which is 
sensitive to the conformations about the C6-C7 and C7-C8 bonds). Note, 
however, that the removal of shielding effects associated with the C6 methoxyl 
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group is undoubtedly also important in the large downfield shifts of the C2 
and, to a lesser extent, C4 and C7 resonances. Such effects were also noted 
in other derivatives above, and are well documented119,120. 
4.5.3 STRUCTURE OF THE COMPOUND IN HPLC FRACTION 1 
The 1 H NMR spectrum of fraction 1 showed the loss of the signals for 
the exocyclic met,hylene protons and the appearance of a new methyl doublet, 
consistent with hydrogenation at C4. However, the C5-C6 double bond of the 
starting diene was still present, as shown by the chemical shifts of the signals 
for H5 and H7 (the H5 resonance was almost 1 ppm upfield of its chemical 
shift in the starting compound due to the reduction at C41 01 ). Hence this 
compound was likely to be 4-dihydro, 5,6-dehydromethoxy mycalamide A 
(4.16). The 1H NMR spectrum was assigned using results from COSY, proton 
decoupling and NOE experiments (Table 4.5). 
OH 
=  ; 
H 
! CH3 
OCH3 
OH 
CH3 
OH 
4a-Dihydro, 5,6-dehydromethoxy mycalamide A (4.16) 
Selective proton decoupling experiments showed that there was an 
appreciable homoallylic coupling between H4 and H7 (1.5 Hz) and the H5 
resonance was also broadened by allylic and long range W couplings104 to 
H7 and H3, respectively. The NOE results (Table 4.2) have been illustrated in 
Figure 4.5. The strong NOE interactions between H2 and H4 required that 
these protons be in a 1,3 diaxial relationship, so that the C4 stereochemistry 
was 4a-dihydro. The 01-C6 ring conformation would be slightly distorted from 
that of 4a-dihydro mycalamide A (4.4), since C4-C7 and 01 are all in a plane, 
206 
and is best described as a half chair1 oo (Figure 4.5). There was insufficient 
sample to obtain a 13C NMR spectrum. However, HRFABMS indicated a 
compound of molecular formula C23H3gNOg, consistent with the proposed 
structure. 
Figure 4.5 1 H-1 H NOE interactions and proposed solution conformation for 
the 01-C6 ring of 4a-dihydro, 5,6-dehydromethoxy mycalamide 
A(4.16). 
This derivative (4.16) represents a partial hydrogenation of the starting 
diene (3.11 ). Note that the exocyclic double bond has fewer (non-hydrogen) 
substituents than the C5-C6 double bond and would therefore be 
preferentially hydrogenated185. The method of preparing 4a-dihydro 6-deoxy 
pseudomycalamide A (4.13) from the diene was slightly better in yield than 
the first reaction, but it was also evident that some decomposition had 
occurred during the reaction. This was not surprising since the starting 
material itself was somewhat unstable, having an allylic hydroxyl group, and 
side reactions could be expected183,191. There was no sign of a C4 isomer in 
either preparation, which does agree with the pederin result, and this 
observation will be further discussed further, along with the mechanisms of 
these reactions, in the following section. 
4.6 MECHANISM OF HETEROGENEOUS CATALYTIC 
HYDROGENATIONS 
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The mechanism of the heterogeneous catalytic hydrogenation of 
double bonds is not thoroughly understood183 because it is difficult to study. 
Kinetic data are difficult to interpret because of hydrogen exchange between 
the substrate and catalyst, even for protons not on a double bond192, in 
addition to double bond migrations185 and isomerisations. The accepted 
. 
mechanism 183,192 (Scheme 4.1) has the olefin adsorbed onto the surface of 
the metal, with its less hindered side attached to the catalyst surface. 
Hydrogen is cleaved into atoms on being adsorbed onto the catalyst surface. 
In a second step, one hydrogen atom becomes bonded to a carbon atom of 
the alkene, leaving a catalyst-bound alkyl radical. This radical combines with 
a second hydrogen atom to give the free alkane in the final step. Hydrogen 
addition is syn, and occurs from the least hindered side of the alkene. 
This mechanism explains the possible side reactions of hydrogen 
exchange, double bond rearrangement and isomerisation, since the catalyst-
bound alkyl radical can lose a hydrogen atom from an adjacent carbon to 
regenerate a catalyst-bound alkene. This is also shown in Scheme 4.1 and 
will be discussed further below. 
Hydrogenation of mycalamides A and B and pederin over Adams 
catalyst proceeded without rearrangement of the double bond (Scheme 4.1 a), 
and this is consistent with the known properties of this catalyst185. However, 
hydrogenation of mycalamide A over palladium on carbon (1 0%) gave 
considerable double bond rearrangement, as observed by the formation of the 
C3-C4 isomer (4.12) and the 4a-dihydro 6-deoxypseudomycalamide A 
derivative (4.13). The rearrangement to the C3-C4 and the C4-C5 positions 
of the 01-C6 ring appeared to be equally likely, based on the relative masses 
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of these two products. The favoured position would be expected to be C3-C4, 
since the double bond is then more substituted, but there are statistical and 
steric factors to consider also185. The mechanism for this rearrangement183, 
shown in Scheme 4.1 b, is consistent with the observation that the reaction 
only occurs in the presence of hydrogen193. The rearrangement of double 
bonds on palladium catalysts is well known185,194. 
Scheme 4.1 Mechanisms of hydrogenation (a), double bond rearrangement 
(b) and hydrogenolysis (c) in mycalamides A and B. (An 
asterisk indicates a binding site on the catalyst surface). 
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The transposition of the exocyclic double bond into the C4-C5 position 
of the 01-C6 ring places the C6 acetal in an allylic position, and 
hydrogenolysis of the methoxyl group is possible, and evidently occurs readily 
(Scheme 4.1 c). Although the exact mechanism is uncertain 191,195, it is 
evident that the hydrogen atom attacks from the same side as the methoxyl 
group, since only one C6 isomer was obtained, with the H6 and H2 atoms 
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both axial. Furthermore, the reduction of the C4-C5 double bond must be 
more facile than reduction of the C3-C4 double bond, since no ~4(5) derivative 
was obtained, and this is reasonable as it has one less alkyl substituent185. 
The reduction of the C4-C5 double bond appeared to be 
stereoselective in giving the 4a-dihydro isomer (4.13) only. This would 
require that the addition of hydrogen occur almost exclusively from below the 
double bond, which is reasonable, since the axial C3 methyl group, and 
possibly the C7 substituents, could hinder access from above the 01-C6 ring, 
. 
whereas the bottom face would have much less steric hindrance with the 
replacement of the axial C6 methoxyl group by a hydrogen atom. The same 
selectivity occurred in the hydrogenation of the diene (3.11) to give the 4a 
isomer (4.13) only, since again there was no axial C6 group, so that attack 
from below the 01-C6 ring was favoured. 
In view of the above, it was a little surprising that no hydrogenolysis at 
C6 or C7 was detected from hydrogenation of the diene over Adams 
catalyst183, 191. It is possible that this required either more forcing conditions 
or a better leaving group. Thus if a C7-deoxy derivative was desired, it would 
be better to convert the C7 hydroxyl group to an acetate or sulphonate ester 
prior to reduction195. However this was not investigated. 
4.7 OTHER ATTEMPTS TO REARRANGE THE EXOCYCLIC 
DOUBLE BOND OF MYCALAMIDE A 
There are several other reagents available for performing double bond 
rearrangements which do not require the presence of hydrogen, which 
necessarily reduces the yield of such products. Strong bases cause 
rearrangement of double bonds 196 and these reactions on mycalamide A will 
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be described in a later chapter (5). Rearrangements also occur with acids196, 
but such reactions would obviously not be useful for the mycalamides. 
Another common method is the use of various metal ions (Pd, Pt, Rh, 
Ru), or metal carbonyl catalysts (eg Fe3(C0)12), which involve the formation of 
a 1t-allyl complex194,196. Many of these seem to require the presence of acid 
as a co-catalyst, or are also potentially oxidising. RhCI3 and Pd(CsHsCN)2CI2 
are two reagents which allow double bond rearrangements under neutral 
conditions197, so both were tried in small scale reactions with mycalamide A. 
. 
The reaction with RhCI3 gave a very large number of products by TLC and the 
1 H NMR spectrum suggested decomposition. The second reagent was 
equally unsuccessful, so this work was abandoned. 
4.8 BIOLOGICAL ASSAY RESULTS FOR MYCALAMIDE 
HYDROGENATION PRODUCTS · 
The biological assay results for all the mycalamide derivatives 
described in this chapter have been listed in Table 4.6. It is apparent that the 
dihydro mycalamide isomers (4.4, 4.5, 4.6, 4.7} have levels of biological 
activity that are similar to those of mycalamides A and B, as was found for 
dihydro pederin40 {4.1 ). However, there appeared to be a consistent 
difference in biological activity between the dihydro isomers themselves, with 
the 4J3 isomer, the major product in the mycalamide reactions, being at least 4-
8 times more active than the 4a isomer. The 4J3-dihydro mycalamide A 
isomer (4.5) was possibly more active than mycalamide A, but the 4J3-dihydro 
mycalamide B derivative (4.7) was of similar activity to mycalamide B. The 
hydrolysis products, the isomers of dihydro pseudomycalamide A (4.10, 
4.11 ), were 10-20 times less active than the dihydro mycalamide A isomers 
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(4.4, 4.5), which was consistent with earlier results for C6 acetal hydrolysis 
(Chapter 3). 
There was no apparent difference in the cytotoxicity or selectivity of 
these dihydro mycalamide isomers. It is likely that the early assay results for 
the pederin derivatives (4.1, 4.2)40,180 merely reflected the reduced activities 
of the 4a-dihydro isomers, compared with those of pederin and 
pseudopederin (3.5), as found above for dihydro mycalamides A and B and 
also for the corresponding C6 hydrolysis products. The use of 1 0-fold steps in 
concentration for this early study could not give a true indication of the ICso, or 
the minimum inhibitory dose39, which would be better points at which to 
compare the relative cytotoxicities of pederin and its derivatives. However, the 
main point of note from these results is that the exocyclic double bond is not 
essential for the biological activities of the mycalamides and pederin. 
The other mycalamide hydrogenation reaction products were less 
active. Surprisingly, the C3-C4 double bond isomer (4.12) was about 100 
times less active than mycalamide A, although none of the other functional 
groups had been changed and the polarity was not very different from that of 
mycalamide A. The conformation of the 01-C6 tetrahydropyran ring was 
slightly different, the major difference being at C3, where the C3 methyl group 
was no longer axial. Electronic effects associated with the double bond in the 
ring could also be significant. 
It is also useful to compare the biological activity of 4a-dihydro 
mycalamide A (4.4) with that of 4a-dihydro, 6-deoxy pseudomycalamide A 
(4.13). The latter is at least 300 times less active than the same dihydro 
isomer with a C6 methoxyl group, and probably substantially less active than 
the compound with a C6 hydroxyl group. {The latter derivative, 4.10, was 
impure so that the comparison was not quantitative. However, compound 
4.13 was about 25 times less active than pseudomycalamide A). No data 
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were reported for the pederin equivalent (4.3}, although antimitotic activity 
was claimed181. The 4a-dihydro, 5,6-dehydromethoxy mycalamide A 
derivative {4.16) was similarly relatively inactive, as expected, based on 
results discussed in Chapter 3. 
Thus it appears that the C6 acetal is required for the biological activity 
of the mycalamides, since having a double bond between C5 and C6, or a 
hydrogen atom to replace the methoxyl group, caused the compounds to 
become almost inactive. Also the conformation of the 01-C6 tetrahydropyran 
~ 
ring must also be important, although the double bond at C4 is not required for 
this activity. Therefore other double bond additions were considered in the 
following studies. 
4.9 EPOXIDATION OF MYCALAMIDES A AND B 
4.9.1 PREPARATION AND CHARACTERISATION OF EPOXIDES 
Mycalamides A and B were each converted into a mixture of epimeric 
epoxides using m-chloroperbenzoic acid198 in CH2CI2. These isomers were 
in a 3:2 ratio, and were separated by preparative silica gel TLC. HRFABMS 
results indicated the inclusion of one extra oxygen in mycalamides A and B, 
consistent with this epoxidation. The 1 H NMR spectra of both epoxide isomers 
showed a large upfield shift in the C4' exocyclic methylene resonances and 
shifts in signals for the remaining 01-C6 ring protons. Results from a COSY 
experiment were used to assign these spectra for both mycalamide A and B 
isomers (Table 4.7}, with the exception of assigning the stereochemistries 
associated with the C4' and C5 methylene resonances and determining the 
C4 stereochemistry. These ambiguities were resolved by considering the 
results of NOE experiments and from an analysis of the chemical shifts and 
proton-proton coupling constants. Note that for ease of reference the C4' 
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methylene resonances will still be given the designations E and Z, in order to 
indicate their relationships in space to the other 01-C6 ring substituents, 
although it is recognised that there is no longer a double bond present. 
The observed NOE interactions for both compounds are listed in Table 
4.8 and depicted in Figure 4.6. Irradiation of the signal assigned to H2 caused 
an enhancement of the C6 methoxyl resonance and irradiation of the C3 
methyl reson·ance caused an enhancement of the downfield H5a resonance in 
both isomers. Therefore the 01-C6 tetrahydropyran ring was in the usual 
chair conformation, as expected, and the stereochemistry associated with the 
two H5 signals was assigned. Also, irradiation of the H3 resonance resulted 
in an enhancement of the more upfield C4' methylene resonance (4-CHZ), 
whereas irradiation of the H5e resonance enhanced the more downfield 
resonance (4-CHE), thus assigning the stereochemistry of these proton 
resonances. There were no major differences in the NOE data for the isomers, 
although the major isomer had a 3-CHa- 4-CHZ NOE interaction, suggesting 
that this was the 4a. isomer (4.17, 4.19). 
Figure 4.6 1 H-1 H NOE interactions and solution conformations for the 01-C6 
ring of the mycalamide A and B epoxide isomers (4.17-4.20). 
a) Major isomer (4a) b) Minor isomer (4~) 
The stereochemistry at C4 was further elucidated from an analysis of 
the observed long range couplings. As noted in earlier examples, coupling 
across four bonds in alkanes is maximised for a planar 'W' relationship of the 
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protons102,104. Such a 'W' coupling was observed between the H3 and HSe 
protons in both isomers, which is consistent with their geometrical 
relationships (Figure 4.6). However, in the 1 H NMR spectrum of the minor 
isomer, predicted to be 4~ from the NOE results, there was a long range 
coupling of 1.5 Hz between the HSa and 4-CHZ resonances. In neither isomer 
do the geometrical relationships between these protons seem to satisfy the 
requirements for 'W' coupling, although it is best approached in the 4~ isomer 
(4.18, 4.20). Long range coupling in exocyclic epoxides has been 
investigated for various steroidal derivatives and has been found to always 
involve one of the pseudo-axial methylene (4~) protons and an adjacent axial 
methylene proton199,200. This common geometrical arrangement has been 
described as being more like that required for allylic coupling than the 'W' 
configuration and has been ascribed to favourable cr orbital overlap with a 
de localised electron density system above the C-C bond of the epoxide200. It 
is also known that long range couplings across strained ring systems are often 
unusually large104. Thus the stereochemistry of the minor mycalamide 
epoxide must be 4~, as suggested above. 
An analysis of the 1 H NMR chemical shifts for the 01-C6 ring 
substituents of the two isomers suggested that similar diaxial deshielding 
effects 123 were involved as were observed for the dihydro mycalamide 
derivatives. In particular, the pseudo-axial C4 methylene protons in the 4~ 
isomers (4.18, 4.20) were deshielded by the axial C6 methoxyl group and 
the H2 proton was deshielded in both isomers by the pseudo-axial C4 
substituents, but more by oxygen (4a isomers, 4.17, 4.19). 
13C NMR spectra were recorded for all four epoxides and an HMQC 
experiment was performed on the major isomer to confirm the assignments 
(Table 4.9). Shielding effects were also found here, similar to those observed 
for the dihydro mycalamide A and 8 isomers above 117,119,120. In particular, 
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C2 was shielded by axial C4 substituents in both epoxide isomers but the C4-
oxygen (4a isomer) appeared to have the most influence. Similarly, the C3 
methyl group was shielded in both isomers by equatorial substituents at C4, 
but more by oxygen (4~ isomer). The chemical shifts of the C4 and C4' 
resonances compared well with those found for another exocyclic epoxide201, 
with the pseudo-equatorial methylene carbon resonance (4a isomer) 
appearing more shielded due to a combination of electronic and steric 
factors117. These results were therefore also consistent with the designated 
~ 
stereochemistries of the epoxide isomers, as determined above. 
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R=CHa: Mycalamide 8 4~-epoxide (4.20) 
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4.9.2 MECHANISM AND STEREOCHEMISTRY OF THE EPOXIDATION 
REACTION 
According to 8artlett198, epoxidation occurs by a one step mechanism, 
involving the addition of one oxygen atom from the peracid to the alkene, as 
shown in Scheme 4.2. In the epoxidation of mycalamides A and 8, the 
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observed ratio of the two isomers, about 3:2, favoured the 4a. isomer. This 
corresponds to a favoured path of attack (for the peracid) from the bottom face 
of the exocyclic double bond, the axial side (Figure 4.2b), which is the reverse 
of that found for hydrogenation. However, it is known that axial attack is 
generally favoured in epoxidation reactions202. Axial substituents on the 
homoallylic carbon (C6) reverse this preference, whereas an axial methyl 
group on the allylic carbon (C3) increases it, and both are present in 
mycalamides A and B. It is also known that hydroxyl groups have a strong 
syn-directing influence by hydrogen bonding to the peracid in the transition 
state202. However, it is unlikely that the latter occurs in the mycalamides, 
since there are no such groups sufficiently close by. The stereochemical 
preference in this epoxidation reaction with mycalamides A and B is not 
strong, although steric effects are known to be more important than in 
hydrogenation, which could explain this observed difference for the two 
reactions. 
Scheme 4.2 Mechanism of epoxidation in mycalamides A and B. The 
reagent can attack from above or below the double bond, giving 
two isomers. 
Cl 
Cl 
4.9.3 BIOLOGICAL ASSAY RESULTS 
The biological assay results for these four epoxide derivatives are 
recorded in Table 4.6. It is interesting to note that the difference in activity 
between the two C4 dihydro mycalamide isomers is accentuated for the two 
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mycalamide epoxide isomers, with the 4a isomer being 7-20 times less active 
than the 4~ isomer. Even the 4~ epoxide isomer was 30-40 times less active 
than the corresponding parent compound (mycalamides A or 8). The polarity 
of these epoxides is slightly higher than the starting compounds. However, 
the stereoselectivity and the loss of biological activity shown by these products 
is difficult to explain without a knowledge of the active site. These results 
therefore follow the pattern of earlier results, where relatively small changes to 
the structure or conformation of the 01-C6 ring appeared to cause large 
changes to the observed activity. 
4.10 OTHER ADDITIONS TO TijE EXOCYCLIC DOUBLE BOND 
4.10.1 ADDITION OF HYDROGEN CHLORIDE WITH ETHYLCHLORO-
FORMATE 
The reactivity of mycalamides A and 8 to acids prevented the direct 
addition of hydrogen halides to the double bond. However, ethyl 
chloroformate203 is less reactive than acetyl chloride, which is known to be a 
good source of 'anhydrous HCI'. Besides being good for acylation, ethyl 
chloroformate is known to alkylate imides204 and amides156. With the latter in 
mind, this reagent was reacted with mycalamide B, in the presence of 
potassium carbonate, to give mostly one product (TLC). However, after 
workup the product became coloured, and was found to be a mixture by 1 H 
NMR spectroscopy and TLC. Preparative TLC gave a pure product by 1 H 
NMR spectroscopy, which had two ethyl carbonate esters at C7 and C18, as 
shown by large downfield shifts in the a-proton signals 101, no change to the 
amide, and a double bond between CS and C6 (due to an acid catalysed 
elimination of the C6 methoxyl group). The latter was shown by the loss of the 
C6 methoxyl and the usual CS proton resonances, and the appearance of a 
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new singlet at o5.15 ppm, assigned to a single H5 proton, as in previous 
derivatives (3.11, 4.16), which showed a small long range coupling to the H7 
resonance. Also the spectrum showed a loss of the exocyclic methylene 
signals and contained a new methyl singlet at o1.58 ppm, which must be 
assigned to a group at C4. Furthermore, H3 (o2.53 ppm) was strongly 
deshielded relative to the dihydro derivatives (+0.9 ppm compared with 4.16), 
suggesting the presence of a heteroatom. A COSY spectrum was performed 
to assign the data for this compound which was given the proposed structure 
"4.21. 
H 
! CH3 
OCH3 
OCH3 
CH3 
4-Hydrochloro, 5,6-dehydromethoxy mycalamide B bis-ethylcarbonate (4.21) 
This structure is consistent with an addition of HCI to the exocyclic 
double bond of the diene (3.11) in Markovnikov fashion205. The HCI would 
originate from excess reagent reacting with H20 in the workup solvents, and 
would first catalyse an elimination of methanol across C5-C6 in mycalamide B, 
as observed in earlier work (Chapter 3). To obtain maximum deshielding123 
of the H3 proton, the chlorine atom at C4 must be axial to the ring. This is also 
consistent with an attack of Cl- from the less hindered face of the intermediate 
carbocation, which is from below, because of the adjacent axial C3 methyl 
group. Note that the allylic tertiary carbocation at C4 could be resonance 
stabilised using the tetrahydropyran ring oxygen. 
Unfortunately this compound was insufficiently stable to enable further 
spectroscopic characterisations to be performed. However, on the basis of 
earlier work it would be expected to be inactive. Attempts to cleave the ester 
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groups with mild base gave mostly decomposition, which was not surprising, 
since the product would have reactive allylic alcohol (C7) and allylic halide 
(C4) functionalities. If the C6 acetal could have been easily regenerated, such 
as by mild acid catalysed addition of methanol to the enol110, and the hydroxyl 
groups protected in some way, then this might be a useful reagent for studying 
addition of HCI at C4, although it is possible that this derivative would still be 
unstable and formed in low yield. Therefore this work was not pursued further. 
4.10.2 ATIEMPTED BROMINATION OF MYCALAMIDE A 
Mycalamide A is only slightly soluble in CCI4. Addition of a dilute 
bromine solution in CCI4 to a sample of mycalamide A, stabilised by a trace of 
pyridine206, gave, after workup, an approximately 1 :1 mixture of unreacted 
mycalamide A and possibly a major C4 dibromo isomer, with minor 
components. Attempts to complete the reaction or repeat it, using added 
C H2CI2 and triethylamine, were unsuccessful, since TLC and a 1 H NMR 
spectrum of the products indicated that decomposition had occurred. The 
mycalamide structure may have been reacting further with bromine in the 
presence of base, such as in oxidation reactions207, although care was taken 
to exclude light. The bromination of mycalamide A could probably have been 
eventually achieved under optimised conditions. However, the time and 
' 
material required for the preparation and purification of such a derivative was 
not considered worthwhile, since some trends in the biological activity of 
double bond addition products had been determined above. 
Table 4.1 1 H NMR dataa for compounds described in Sections 4.2 and 4.3. 
4a-Dihydro 4p-Dihydro 4a-Dihydro 4P-Dihydro 4a-Dihydro 4P-Dihydro, 6$ 
mycalamide A mycalamide A mycalamk:le B mycalamide B pseudomyc.A pseudomyc.A 
Wl (4.5) (4.6) (4,1) ~.:10) (4.11) 
H2 3.97 (2.3,6.6) 4.11 (2.7,6.7) 3.99 (2.4,6.6) 4.13 (2. 7 ,6.6) 4.20 (2.4,6.6) 4.08 (3.0,6.5) 
2-CH3 1.18 (6.6) 1.17 (6.6) 1.19 (6.6) 1.18 (6.5) 1.06 (6.6) 1.19 (6.6) 
H3 1.47 (2.5,3.9,6.9) 1.33 (2.7,7.1) 1.49 (m} 1.35 (2.4,7.2) 1.44 (m) 1.47 (m) 
3-CH3 0.73 (7.1) 0.93 (7.1) 0.75 (7.1) 0.95 (7.1) 0.72 (7.0) 0.88 (7.0) 
H4 2.14 (3.7,7.0,12.8) 1.70 (m) 2.18 (m) 1.67 (m) 2.23 (m) 1.92 (m) 
4·CH3 0.88 (7.0) 1.16 (7.1) 0.86 (7.0) 1.18 (7.1) 0.90 (7.0) 1.04 (7.0) 
H5a 1.23 (13.0) 1.76 (5.6,13.8) 1.17 (13.2) 1.66 (4.4,14.0) 1.67 (13.3) 1.58 (m) 
H5e 1.62 (3.9, 13.9) 1.53 (2.9,14.0) 1.63 (3.8,13.9) 1.50 (2.3,14.2) 1.42 ( 4.2,13.3) 1.52 (m) 
6·0CH3 3.30 3.28 3.30 3.28 
H7 4.23 4.21 4.22. 4.20 3.99 4.44 
NH9 7.46 (9.6} 7.45 (9.7) 7.52 (9.7) 7.49 (9.5) 7.49 (9.8) 7.25 (10.0) 
H10 5.84 (9.6) 5.85 (9.7) 5.76 (9.4) 5.76 (9.6) 5.83 (9.9) 5.84 (10.0) 
10-0CHR 5.13 (6.9) 5.13 (7.0) 5.11 (6.9) 5.12 (7.0) 5.15 (7.0) 5.17 (7.0) 
'10-0CHS 4.87 (6.9) 4.87 (7.0) 4.86 (6.9) 4.85 (7.0) 4.89 (7.0) 4.87 (7.0) . 
H 11 3.84 (6.7,9.7) 3.86 (6.7,9.7) 3.80 (6.5,9.3) 3.81 (6.6,9.6) 3.91 (6.8,1 0.2) 3.88 (6.9,1 0.0) 
H12 4.22 (6.8,10.1) 4.22 (6.7,1 0.1) 4.19 (6.5,10.0) 4.20 (6.7,10.3) 4.24 (6.8, 1 0.5) 4.22 (6.9, 1 0.5) 
H13 3.45 (10,2) 3.46 (1 0.3) 3.41 (9.9) 3.43 (1 0.3) 3.48 (10.5) 3.52 (10.4) 
13-0CH3 3.56 3.56 3.55 3.55 3.56 3.56 
14-CH3R 0.98 0.98 0.99 0.98 0.97 0.98 
14-CH3S 0.88 0.88 0.87 0.87 0.87 0.87 
H15 3.63 (6.6) 3.63 (6.3) 3.44 (2.3, 1 0.3) 3.42 (2.5, 10.1) 3.58 (m) 3.55 (m) 
H16 1.57 (m) 1.56 (m) 1.59 (m) 1.57 (m) 1.55 (m) 1.56 (m) 
H16 1.57 (m) 1.56 (m) 1.55 (m) 1.57 (m) 1.55 (m) 1.50 (m) 
H17 3.74 (m) 3.74 (m) 3.26 (m) 3.24 (m) 3.74 (m) 3.71 (m) 
17-0CH3 3.31 3.29 
H18 3.58 (3.5, 11.4) 3.57 (3.5, 11.2) 3.66 (3.3, 12.0) 3.63 (3.3, 11.9) 3.54 (3.6, 11.3) 3.53 (m) 
H18 3.37 (6.1 '11.2) 3.38 (5.9,11.3) 3.48 (5.8, 12.0) 3.47 (5.9,12.0) 3.40 (5.6, 11.3) 3.35 (6.5, 11.3) 
aAII data were recorded in CDCI3, with chemical shifts in ppm relative to CHCI3, <57.25 (coupling constants in Hz) 
1\) 
1\) 
0 
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Table 4.2 1 H-1 H NOE interactionsa for compounds in Sections 4.2-4.5. 
Slgnal(s) Signals enhanced 
ComgQyn~ lrra~la~~d ( 0{Q ~nhan~em~nU 
4~-Dihydro myc.A H2 2-CHs(1 ), H3(3), 4-CHs(O.S), 6-0CHs(0.3) 
(4.5) 3-CHs (2x14-CHs) H3(5), H4(3), H5a(2), H216(2)b 
HSe (H16) H4(1), H5a(15), H17(4)b 
HSa 3-CHs(1), H5e(11), H7(2) 
H7 (H12) 6-0CH3(2), H11(6)b, 14-CH3S(1) 
4~-Dihydro myc.B H2 2-CHs/4-CHs(1), H3(3), 6-0CHs(O.S) 
(4.7) 2-CHs (4-CHs) H2(6), H3(3), 3-CHs(0.6), H4(3)b 
H3 H2(4), 3-CHs(1), H4(1) 
3-CHs H3(4), H4/H5a(2) 
HSe (H16) H4/H5a(4), 14-CHsS(0.4)b, 14-CHsR(O.?)b 
6-0CHs H2(1), H7(4) 
H7 (H12) 6-0CH3(1), H11(4)b, 14-CHsS(0.4)b 
4a.-Dihydro myc.B H2 2-CHs(2), H3(4), H4(5), 6-0CHs(1) 
(4.6) 2-CHs (HSa) H2(5), 3-CHs(2)b, H5e(12)b, H7(2)b 
H3 (H216) H2(3), 3-CH3(2), H4(3), 4-CH3(0.7), 14-CHsR(O.S)b 
3-CHs H3(5), 2-CH3(0.7), H5a(3) 
H4 H2(4), H3(3), 4-CH3(1), H5e(1) 
4-CHs (14-CHsS) H3(3), H4(6), H5e(3), H12(6)b, 13-0CH3(0.3)b, 
HSe (H216) 
H216(3)b 
H4(3), 4-CHs(O.S), H5a(18), 14-CHsS(1)b, 
14-CH3R(0.3)b, H17(3)b 
H7 (H12) 6-0CH3(2), H11(4)b, 14-CHsS(0.9)b 
A.3 Mycalamide A H2 (H12) 2-CHs(2), 3-CH3(0.8), 6-0CH3(1 ), H11 (7)b, 
(4.12) 14-CHsS(1)b 
2-CHs H2(7) 
3-CHs (H216) H2(3), 14-CH3S(2)b, 14-CHsR(1)b, H17(7)b 
HSa 4-CHs(O.S), H5e(10), H7(2) 
H7 6-0CHs(1) 
4a.-Dihydro, 6-deoxy H2 (13-0CHs) 2-CH3(2), H3(4), H4(3), H6(3), 10-0CHR(1)b, 
pseudo A triacetate 14-CHsR(0.6)b 
(4.15) H6 (H11) H2(4), H4(2), H7(8), NH(S)b, H12(4)b 
H7 H6(3) 
4a.-Dihydro 6-deoxy H2 (13-0CHs, 2-CHs(2), H4(3), H10(8)b, H12(7)b, 14-CH3R(1)b, 
mycalamide A H15, H1&JC) H18u(7)b,c 
(4.13) 3-CHs (14-CHsS) H3(4), H12(8) 
H6 (H17) H4(6) 
H7 (H11) H12(8)b 
4a.-Dihydro 5,6- H2 (H12) 2-CHs(1), H3(5), H4(6), H11 (3)b, 14-CH3S(0.8)b 
dehydromethoxy A H3 H2(6), 3-CH3(2), H4(6) 
(4.16) 3-CHs (14-CHsS) H3(5), H12(5)b 
H4 H2(5), H3(7), 4-CH3(2), H5(4) 
H5 H4(2), 4-CH3(1) 
aAII data were recorded in CDCis 
bEnhancement interpreted as being due to the irradiation of an overlapping signal 
cu and d have been used to designate the upfield and downfield resonances of a geminal pair 
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Table 4.3 2JcH and 3JcH HMBC correlationsa for compounds in Chapter 4. 
4~-Dihydro mycalamide B 
(4.7) 
4a-Dihydro 6-deoxy ps.A 
(4.13) 
Proton 
3-CHs 
4-CHs 
6-0CHs 
H7 
10-0CHR 
10-0CHS 
H11 
H12 
H13 
13-0CHs 
14-CHsR 
14-CHsS 
17-0CHs 
2-CHs 
H3/H25 
3-CHs 
4-CHs 
H7 
10-0CHR 
10-0CHS 
H13 
13-0CHs 
14-CHsR 
14-CHsS 
H216 
aAn data were recorded in CDCis 
Carbon signal correlated 
C2,C4 
C4,C5 
C6 
C6,C8 
C10, C12 
C10, C12 
C10, C12, C13 
C10, C13 
13-0CHs 
C13 
C13, C14, C15 
C13, C14, 14-CH3R 
C17 
C2,C3 
C2/C6, C3, C4 
C2,C3,C4 
C3, C4, C5 
C5,C8 
C10 
C10, C12 
C 12, 13-0CHs, 14-CH3R, 14-CHsS 
C13 
C13, C14, 14-CH3 S, C15 
C13, C14, 14-CH3R, C15 
C15, C17 
Table 4.4 13C NMR dataa for compounds described in Sections 4.2 and 4.3. 
4a-Dihydro 4~-Dihydro 4a-Dihydro 4~-Dihydro 4a-Dihydro 4~-Dihydro, 6S 4a-Dihydro 
mycalamide A mycalamide A mycalamide B mycalamide B pseudomyc.A pseudomyc.A 6-deoxy ps.A 
(4A} ~ ~ (4:n (4,10,) (4.11} (4Ja) 
C2 70.88 64.92 70.80 64.79 69.83 73.02° 77.6 
2-CH3 18.46 18.28 18.49 18.40 18.48 15.41 b 18.7 
C3 37.09 37.45 37.06 37.35 37.00 37.62 37.4 
3·CH3 4.36 13.04 4.49 13.07 4.04 13.20 4.8 
C4 28.94 32.11 28.83 32.19 29.00 ? 34.0 
4·CH3 18.85 20.81 19.00 20.87 19.21 21.01b 19.2 
C5 31.10 29.51 31.09 29.22 32.68 32.03b 29.6 
C6 99.30 100.05 99.42 100.18 97.09 ? 77.2 
6·0CH3 48.47 48.11 48.31 47.87 
C7 72.93 73.32 72.37 72.63 75.04 73.79 74.6 
C8 171.82 171.72 171.82 ? 167.95 173.3 
C10 73.77 73.80 74.14 74.02 73.11 73.44 73.5 
10·0CH2 86.80 86.81 86.55 86.56 87.04 87.18 87.0 
C11 71.12 71.23 70.69 71.24 71.64 71.4 
C12 74.37 74.40 74.32 74.42 74.51 74.83b 74.6 
C13 79.20 79.15 79.60 79.49 79.50 79.12 79.1 
13·0CH3 61.81 61.82 61.72 61.77 61.94 61.84 61.8 
C14 41.59 41.63 41.40 41.79 41.91 41.7 
14·CH3R 23.16 23.15 23.41 23.30 22.94 22.83 22.9 
14·CH3S 13.59 13.56 13.80 13.62 13.22 13.73 13.2 
C15 78.80 79.09 75.64 75.52 78.89 78.65 79.1 
C16 32.01 32.05 29.75 29.66 31.54 31.78 31.7 
C17 71.21 71.48 79.00 78.99 72.06 71.83 71.8 
17-0CH3 56.71 56.71 
C18 66.37 66.56 63.57 63.74 66.35 66.60 66.5 
aAII data were recorded in CDCI3, with chemical shifts in ppm relative to CDCJs, o77.01 
bAssignments uncertain. 
1\) 
1\) 
w 
Table 4.5 1 H NMR data a for compounds described in Sections 4.4-4.1 0. 
a3 Mycalamide A 4cx-Dihydro, 4cx-Dihydro, 4cx-Dihydro, 4-HCI,5,6-dehydrometh. 
6-deoxy ps.A 6-deoxy ps.A 5,6-dehydrometh. B bis-ethyl carbonate 
(4.12) (g,1al ldacet, (~.15) rwc.A £4,12l (4.21) 
H2 4.19 (m) 3.64 (2.2,6.4) 3.56 (2.4,6.6) 4.13 (1.7,6.5) 4.18 (2.8,6.5) 
2-CH3 1.30 (6.6) 1.11 (6.4) 1.10 (6.5) 1.26 (6.6) 1.30 (6.5) 
H3 1.41 (m) 1.42 (m) 1.66 (1.7,5.9,7.1) 2.53 (2.8,6.9) 
3-CH3 1.58 (m) 0.74 (7.0) 0.74 (7.1) 0.76 (7.0) 1.03 (7.0) 
H4 1.84 (m) 1.82 (m) 2.63 (1.4,5.8,7.3) 
4-CH3 1.63 (m) 0.93 (6.8) 0.91 (6.8) 0.95 (7.4) 1.58 (m) 
H5a 2.24 (m, 17.6) 1.40 (m) 1.24 (m) 
H5e 2.08 (m,17.6) 1.40 (m) 1.17(m) 4.70 (m) . 5.15(1.1) 
H6 3.74 (4.0,5.1,8.8) 3.86 (3.0, 10. 7) 
6-0CH3 3.37 
H7 4.30 4.00 (4.0) 5.28 (3.0) 4.48 (1.5) 5.35 (1.0) 
NH9 ? 7.41 (9.9) 6.95 (9.7) 7.23 (9.8) ? 
H10 5.82 (9.7) 5.83 (10.0) 5.74 (9.4) 5.85 (9.8) 5.67 (9.5) 
10-0CHR 5.12 (6.9) 5.15 (7.0) 5.10 (6.8) 5.15 (6.7) 5.14 (7.0) 
10-0CHS 4.86 (6.9) 4.88 (7.0) 4.84 (6.9) 4.89 (6.9) 4.88 (6.9) 
H11 3.79 (6.7,9.7) 3.88 (6.7,10.1) 3.85 (6.3,9.1) 3.82 (6.8,10.1) 3.94 (6.6,9. 7) 
H12 4.21 (6.8,10.3) 4.24 (6.8,1 0.4) 4.16 (6.4,10.1) 4.23 (6.9,1 0.5) 4.22 (6.7,10.5) 
H13 3.44 (1 0.3) 3.48 (10.4) 3.42 (9.9) 3.47 (10.6) 3.44 (1 0.4) 
13-0CH3 3.55 3.56 3.54 3.56 3.56 
14·CH3R 0.98 0.98 0.97 0.97 0.99 
14·CH3S 0.87 0.87 0.85 0.87 0.87 
H15 3.61 (4.3,8.5) 3.61 (6.4,8.5) 3.37 (2.1, 1 0.0) 3.57 (m) 3.35 (2.4,8.1) 
H16 1.57 (m) 1.55 (m) 1.76 (m) 1.54 (m) 1.72 (m) 
H16 1.57 (m) 1.55 (m) 1.62 (m) 1.54 (m) 1.62 (m) 
H17 3.71 (m) 3.73 (m) 4.98 (m) 3.74 (m) 3.36 (m) 
17-0CH3 3.26 
H18 3.57 (3.4, 11.0) 3.54 (3.5,11.3) 4.22 (2.8,12.4) 3.56 (3.6,11.4) 4.19 (3.2,11.7) 
H18 3.38 (5.8,11.1) 3.39 (5.9,11.3) 4.05 (5.5,12.4) 3.36 (6.1, 11.3) 4.04 (5.1,11.7) 
·OCH2CH3 4.15,1.27 (7.0) 
1\.) 
aAII data were recorded in CDCI3, with chemical shifts in ppm relative to CHCI3, b7.25 (coupling constants in Hz). 1\.) ~ 
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Table 4.6 Biological assay results for compounds in Chapter 4. 
CQmgauod ~388 ICsoa AoUvl[al B~sult~zb (ogldisk) 
Mycalamide A 0.5 WN vwv +* 5 + + +* 2 
Mycalamide B 0.1 WN vwv +* 2 +++ +++ +* 1 
4a-Dihydro mycalamide A (4.4) 0.8 vwv +* 10 +++ +* 5 
4~-Dihydro mycalamide A (4.5) 0.2 vwv +* 5 + + +* 2 
4a-Dihydro mycalamide B (4.6) 0.8 Vffl +* 10 +++ +* 5 
4~-Dihydro mycalamide B (4.7) 0.1 ww +* 5 ++ ++ +* 2 
4a-Dihydro pseudo A (4.10) 11 WN Vffl +* 200 ++ + +* 50 
4 Vffl Vffl +* 20 ++ ++ +* 5 4~-Dihydro pseudo A (4.11) 
A Mycalamide A (4.12) 58 WN Vffl +* 1000 +++ ++ +* 500 
4a-Dihydro, 6-deoxy ps.A (4.13) 250 WN Vffl +* 2000 1000 
4a-Dihydro, 5,6-dehyd.A (4.16) 650 +++ +++ +* 2000 + ++ +* 1000 
Myc.A 4a-epoxide (4.17) 115 Vffl +* 500 200 
Myc.A 4~-epoxide (4.18) 16 Vffl +* 100 + +* 50 
Myc.B 4a-epoxide (4.19) 90 Vffl +* 500 200 
Myc.B 4~-epoxide (4.20) • 4 Vffl +* 40 ++ +* 20 
a1n ng/ml. The derivatives are estimated to be better than 95% pure, having been subjected 
to at least two steps of chromatographic purification in most cases. 
b -,+,++,+++,WW=antiviral zone size. Results are listed in the order of Herpes simplex virus, 
Polio virus, cytotoxicity, loaded sample mass. 
Table 4.7 1 H NMR dataa for mycalamide A and B epoxides. 
H2 
2-CH3 
H3 
3-CH3 
4-CHZ 
4-CHE 
Hsa 
Hse 
6-0CHa 
H7 
NH9 
H10 
10-0CHR 
10-0CHS 
H 11 
H12 
H13 
13-0CHa 
14-CH3R 
14-CHaS 
H15 
H16 
H16 
H17 
17-0CHa 
H18 
H18 
Mycalamide A 
4a-epoxide 
(4.17) 
4.34 (2.5,6.6) 
1.21 (6.6) 
1.12 (1.3,2.5,7.1) 
1.00 (7.1) 
2.55 (4.5) 
2.52 (4.5) 
2.22 (14.7) 
1.43 (1.3,14.7) 
3.37 
4.31 
7.41 (10.0) 
5.88 (9.9) 
5.14 (6.9) 
4.88 (6.9} 
3.86 (6.8,9.9) 
4.23 (6.8, 1 0.4) 
3.47 (10.4) 
3.56 
0.98 
0.88 
. 3.62 (5.3,6.9) 
1.57 (m) 
1.57 (m) 
3.74 (m) 
3.56 (m) 
3.38 (5.8, 11.2) 
Mycalamide A Mycalamide B Mycalamide B 
4~-epoxide 4a-epoxide 4~-epoxide 
(4.18) (4.19) (4.20) 
4.15 (2.6,6.6) 4.35 (2.4,6.6) 4.18 (2.6,6.5) 
1.23 (6.6) 1.22 (6.6) 1.23 (6.6) 
1.26 (1.2,2.6,7.0) 1.11 (1.2,2.5,7.0) 1.25 (1.2,2.6,7.0) 
1.02 (7.0) 1.01 (7.0) 1.04 (7.0) 
2.80 {5.0) 2.53 (4.5} 2.79 (4.9} 
2.71 (1.5,5.0) 2.51 (4.6) 2.69 (1.5,5.0) 
2.10 (1.5,13.4) 2.13 (14.6) 2.03 (1.6,13.4) 
1.43 (1.1,13.4) 1.44 (1.2,14.6) 1.42 (1.2,13.3) 
3.31 3.37 3.32 
4.32 4.30 4.31 
7.33 (9.9) 7.45 (9.4) 7.43 (9.6) 
5.88 (9.8) 5.77 (9.6) 5.80 (9.6) 
5.14 (6.9) 5.13 (7.0) 5.13 (7.0) 
4.88 (6.9) 4.85 {7.0) 4.86 (7.0) 
3.86 (6.7,9.8} 3.82 {6.7,9.7) 3.81 (6.8,9.6) 
4.24 (6.7,10.4} 4.22 (6.7,10.3) 4.23 (6.6,10.4) 
3.46 (10.4) 3.44 {10.3) 3.45 (10.7) 
3.56 3.55 3.56 
0.98 0.98 0.99 
0.88 0.87 . 0.88 
3~60 (3.2,9.1) 3.38 (2.4,9.6) 3.42 (1.9,9.9} 
1.63(m) 1.59 (3.3,9.7,14.2) 1.65 (4.1,10.0,14.2) 
1.57 (m) 1.50 (2.3,9.4,14.1) 1.52 (2.0,9.6,14.1) 
3.73 (m) 3.25 (m) 3.24 (m) 
3.30 3.32 
3.56 (m) 3.62 (3.1, 12.0) 3.67 (3.3, 11.8) 
3.39 (6.1 '11.1) 3.46 (6.3, 12.0) 3.44 (5.8,11.9) 
aAn data were recorded in CDCI3, with chemical shifts in ppm relative to CHCI3, 87.25 
(coupling constants in Hz). 
Table 4.8 1 H-1 H NOE interactionsa for mycalamide A and B epoxides. 
Compound 
Mycalamide A 
4a-epoxide (4.17) 
Mycalamide A . 
4~-epoxide (4.18) 
Slgnal(s} 
Irradiated 
H2 
H3 (2-CH3) 
3-CH3 
4-CHE 
4-CHZ 
H5a 
H5e 
H2 (H7) 
2-CH3 
H3 
Signals enhanced 
C% enhancement> 
2-CH3(2), H3(2), 6-0CH3(0.7) 
H2(8), 3-CH3(2), 4-CHZ(4) 
H3(3), H5a(3) 
4-CHZ(15), H5e(3) 
H3(2), 4-CHE(12) 
3-CH3(0.8), H5e(16), H7(1) 
4-CHE(4), H5a(21) 
2-CH3(0.9), 6-0CH3(0.8) 
H2(6) 
H2(6), 4-CHZ(2) 
3-CH3 (14-CH3R) 
4-CHE 
4-CHZ(2), H5a(2), H13(3)b, H15(2)b, H216(2)b 
H5e(5) 
4-CHZ 
H5a 
H5e 
H7 (H2) 
aAu data were recorded in CDCI3 
H3(3) 
3-CH3(0.6), H5e(20), H7(3) 
4-CHE(3), H5a(19), H7(0.6) 
6-0CH3(3), H5a(1) 
bEnhancement interpreted as being due to the irradiation of an overlapping signal 
Table 4.9 13C NMR dataa for mycalamide A and B epoxides. 
Mycalamide A Mycalamide A Mycalamide B Mycalamide B 
4a-epoxide 4~-epoxide 4a-epoxide 4~-epoxide (4.rn (4.18) (4.19) (4.2Q) 
C2 67.17 68.78 67.17 68.83 
2-CHa 17.55 17.72 17.57 17.78 
C3 39.72 39.95 39.75 40.08 
3-CHa 9.76 7.93 9.82 8.04 
C4 58.42 58.59 58.32 58.42 
4-CH20 50.69 56.90 50.51 56.58 
C5 31.40 32.23 31.39 31.99 
C6 99.65 100.47 99.69 100.73 
6-0CH3 49.03 48.60 48.88 48.36 
C7 73.25 72.60 72.81 71.63 
ca 171.36 171.53 171.32 171.43 
C10 73.61 73.76 73.78 73.96 
10-0CH2 86.89 86.83 86.61 86.52 
C11 71.40 71.27 70.83 70.88 
C12 74.48 74.46 74.49 74.47 
C13 79.17 79.11 79.37 79.35 
13-0CH3 61.86 61.86 61.82 61.81 
C14 41.74 41.71 41.53 41.74 
14-CH3R 23.05 23.07 23.17 23.18 
14-CH3S 13.39 13.40 13.38 ? 
C15 79.02 78.75 75.38 75.58 
C16 31.94 32.23 29.48 29.73 
C17 71.66 71.14 79.25 78.78 
17-0CH3 56.74 56.72 
C18 66.56 66.44 63.95 63.36 
aAu data were recorded in CDC's. with chemical shifts in ppm relative to CDCI3, 577.01. 
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CHAPTER 5 
REACTIONS OF MYCALAMIDES A & 8 
AND DERIVATIVES UNDER BASIC 
CONDITIONS 
PART I 
5.1 INTRODUCTION 
. 
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During early chemical degradations on pederin, it was noted that 
pederin was not affected by heating with a dilute solution of barium methoxide 
in methanol27. This base stability of pederin was utilised in its synthesis. An 
example of this was the removal of the benzoate ester protecting group with 
(1M) lithium hydroxide at either room temperature90,127 or at sooc129,132 in a 
final step. However, pseudopederin (3.5) was readily attacked by a barium 
methoxide solution at room temperature27,94 and gave pederolactone (3.6) 
and meropederoic acid (5.1) as major products, especially when performed in 
an oxygen atmosphere. (This reaction occurred by cleavage of the C6-C7 
bond in a retro-aldol process, followed by oxidation at C7). The same 
products were also formed when ,pseudopederin was treated with 
piperidine27,94. Unfortunately, no biological activity data were reported for 
these cleavage products. 
H 
OH 
Meropederoic acid (5.1) 
The treatment of mycalamides A and B with mild bases has been 
indirectly described in previous chapters. In Chapter 2, both structures were 
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shown to be stable to pyridine and other amine bases during esterification and 
silylation reactions, even at aooc. This stability was extensively utilised for 
buffering CDCI3 solutions of mycalamide derivatives with pyridine or 
triethylamine, to prevent acid catalysed decomposition139, as had been 
performed for pederin95 and its derivatives 126. However, at higher 
temperatures (130-1500C) in DMSO, it was found that these bases catalysed 
an elimination of methanol at C5-C6 in mycalamide A, as described in 
Chapter 3. Mycalamides A and B were also stable to other mild bases at room 
temperature, as illustrated by the successful removal of acetate ester groups 
from acetylated derivatives, using solutions of potassium carbonate in 
aqueous methanol (Chapter 2). 
The current investigation of the reactivity of mycalamides A and B to 
various bases in different solvents and at different temperatures was 
conducted, initially, for two reasons. Firstly, it was desirable to determine how 
stable these structures were to base, for use infuture synthetic modifications. 
A second, more direct aim was the base hydrolysis of the amide functionality, 
which was assumed to be the most base sensitive functional group, apart from 
the possibility of rearrangement of the exocyclic double bond196. In particular, 
the acetal functionalities, which were most acid sensitive, were expected to be 
base stable, as in pederin. This chapter describes the first part of this 
investigation, which yielded some surprising results. 
5.2 INITIAL INVESTIGATIONS ON MYCALAMIDE A 
5.2.1 EFFECT OF 0.1 M SODIUM HYDROXIDE ON THE P388 ACTIVITY OF 
MYCALAMIDEA 
A small sample of mycalamide A, dissolved in a solution of sodium 
hydroxide in 90% water/methanol (0.1 M), was assayed after two hours and 
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three days at ambient temperature. Both results were the same as for the 
control sample, suggesting that mycalamide A was stable to these conditions. 
5.2.2 SMALL SCALE REACTIONS MONITORED BY TLC AND HPLC 
A sample of mycalamide A was treated with a 3mM solution of sodium 
methoxide in methanol. No reaction was observed by TLC after 5 days at 
room tempe·rature. Similarly, treatment with a 30mM solution at room 
temperature and at 40°C for several hours gave no reaction, as monitored by 
. 
reverse phase HPLC. Finally, mycalamide A was treated with a 1M solution of 
sodium methoxide at room temperature. There was no evidence of reaction 
after three hours, but, after 1 day, the starting material had disappeared and 
there was at least one, more polar product by HPLC. TLC confirmed this in an 
unusual way, since the observed products were of similar Rt to mycalamide A, 
but gave a bright blue char following treatment with the usual anisaldehyde 
reagent (see Experimental) and heating, instead of the usual orange-brown 
colour. Further preparations and spectroscopic characterisations of these 
products are therefore described below. 
5.3 PREPARATION AND CHARACTERISATION OF COMPOUNDS 
FROM THE REACTION OF MYCALAMIDES A AND B IN THE 
PRESENCE OF SODIUM METHOXIDE AND OTHER BASES 
5.3.1 PREPARATION AND SEPARATION OF PRODUCTS 
The above reaction was successfully repeated on a larger scale, but 
this time required gentle heating to achieve complete reaction. TLC of the 
product clearly showed two distinct spots, not quite resolved, and a 1 H NMR 
spectrum confirmed that there were indeed two similar compounds, in a ratio 
230 
of about 4:3. Analysis by reverse phase HPLC showed that there was almost 
baseline resolution of the two products so preparative HPLC was performed to 
separate them for spectroscopic analysis. 
5.3.2 SPECTROSCOPIC CHARACTERISATIONS 
HRFABMS spectra of these products showed that they were isomers, 
with molecular formulae C23H3gNOg, which represented a loss of CH20 from 
mycalamide A. The 1 H NMR spectra of both products showed a loss of the 1 O-
OCH2 doublets of mycalamide A, loss of the coupling between the H10 and 
amide NH protons and the appearance of a new long range coupling between 
the H7 and H1 0 protons. These data could only be satisfied if there was a 
new 5-membered oxazolidinone ring, arising from a substitution of C?-O- at 
C10, with a loss of formaldehyde from the C1 O-C12 methylene acetal of 
mycalamide A, to leave an hydroxyl group at C12 (structures 5.2 and 5.3). In 
particular, the long range coupling between H7 and H1 0 could only occur if 
they were fixed in a ring, and such couplings in 2,5-substituted 1 ,3-oxazolidin-
4-ones are well documented208,209, as discussed below. Furthermore, theIR 
spectra of both isomers contained an amide carbonyl stretch at 1715-1720 
cm-1, which represented a 25-30 cm-1 increase in frequency over the value 
recorded for mycalamide A. This result is consistent with the constrained cis 
geometry of a 5-membered lactam ring96,210, compared with a normal open 
chain secondary amide, which would be predominantly trans (Z) in 
conformation107. Also, preliminary NOE experiments showed that there was 
an NOE interaction between the H7 and H1 0 protons in one of the isomers 
only. This isomer was therefore cis (5.2), and was the major compound in the 
initial 1 H NMR spectrum of the mixture. Further NOE results are described 
below in an analysis of the solution conformations of these compounds. 
R1=R2=R3=H: Mycalamide A cis oxazolidinone (5.2) 
R1=R3=H, R2=CH3: Mycalamide B cis oxazolidinone (5.9) 
R1=R2=R3=R4=H: Mycalamide A trans oxazolidinone (5.3) 
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R1=R2=R4=H, R3=CH3: Mycalamide B trans oxazolidinone (5.10) 
R1=R2=R3=R4=COCH3: N-Acetyl myc.A trans oxazolidinone triacetate (5.13) 
R1=R2=R3=R4=CH3: 12,17,18-tri-0-Methyl, N-methyl myc.A trans oxaz.(5.14) 
The 1 H NMR spectra of both compounds were therefore assigned using 
results obtained from COSY experiments, to give the data in Table 5.1. A 
comparison of the data for the cis and trans isomers, respectively, with those 
for mycalamide A, showed that the largest chemical shift differences (in ppm) 
occurred in the signals assigned to H7 (+0.1 ), NH (-0.9, +0.4), H1 0 (-0.3), H12 
(-0.2) and H13 (-0.5). These shifts cannot be explained entirely by the usual 
substituent effects101. However, it is likeiy that the shifts in H1 0, H12 and H13 
partly reflect the release of steric deshielding effects123, associated with the 
1 0112-0CH2 group in the cis-fused trioxadecalin ring system of mycalamide A. 
The observed chemical shifts for both isomers were similar, except for those of 
the NH proton, reflecting its different hydrogen bonding environments in the 
two compounds101. Note that, in general, the C2 and C5 oxazolidinone ring 
protons in a cis relationship are reported to be slightly shielded relative to 
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those in a trans relationship209, which is also consistent with results found 
here for the H7 and H1 0 proton resonances (Table 5.1 ). 
A long range coupling of between 1 and 3 Hz is commonly observed 
between protons at C2 and C5 in 1 ,3-oxazolidin-4-ones and is reported to 
arise from a mechanism through 5 bonds which involves the partially 
developed 1t system of the amide C-N bond209. The magnitude of such 
couplings in ·various ring systems209 appears to depend on the degree of x 
character in this bond between the ring atoms 3 and 4, since a full double 
bond {such as in a lactone)' gives large couplings {5.7 Hz in furanomycin), 
whereas the absence of a x system gives virtually no such coupling. The 
magnitude of this coupling is also typically larger for the trans isomer209, 
which was the result found for these mycalamide derivatives. Similar long 
range couplings between protons in a trans relationship have been observed 
across lactone groups in 1 ,3-dioxolan-4-ones211,212 and have been 
explained by a similar mechanism. 
A 13C NMR spectrum was recorded for each isomer and the signals 
assigned by HMQC experiments, to give the data in Table 5.2. An HMBC 
experiment was also performed on the trans isomer, which confirmed the 
assignments of the quaternary carbon resonances, but did not add any new 
information (Table 5.3): Compared with the mycalamide A data, there were 
sizeable shifts in the signals assigned to C7 (+2.9, +4.4), C1 0 (+7.2, + 12.8), 
C11 (+6.4, +3.0), C12 (-5.4, -5.4) and C13 (+9.0, +7.9) for the cis and trans 
isomers, respectively. The direction of these shifts at C11, C12 and C13 were 
consistent with the usual a and ~ substituent effects associated with 
converting C12-0R (R=alkyl) into C12-0H117. However, the downfield shifts 
for the C1 0, C11 and C13 resonances must also have a sizeable contribution 
from the loss of gauche shielding interactions with the 10112-0CH2 group117, 
as observed for the 1 H NMR data above. The differences between the 
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isomers were largest for the C1 0 resonance (5.6 ppm), in accordance with a 
change in stereochemistry at this position, although most of the other C7-C15 
resonances also showed significant differences. Also the linewidths of most of 
the C11-C16 resonances were considerably larger for the trans isomer only 
{Table 5.2), an effect which is discussed further in the following subsection. 
5.3.3 SOLUTION CONFORMATIONS BY NMR SPECTROSCOPY 
The 01-C6 tetrahydropyran rings of both isomers were found to have 
. 
the same solution conformation as that observed for mycalamides A and B, as 
expected. (This was shown by the observed NOE interactions between the C3 
methyl and H5a protons (Table 5.4) and by the similar proton-proton coupling 
constants in these compounds). There also appeared to be a similar 
distribution of solution conformations about C6-C7 in both isomers as 
discussed for mycalamide B (Chapter 1 ), as indicated by the strong H7-6-
0CH3 and weaker H5a-H7 NOE interactions (Table 5.4). 
For the cis isomer (5.2), there were NOE interactions between the H7 
and H1 0 protons and between the two H5 protons and H11 which clearly 
demonstrated the stereochemistry of the oxazolidinone ring (Figure 5.1 a). For 
the trans isomer (5.3), there were NOE interactions between the two H5 
protons and H1 0 and between the H7 and H11 protons, which further 
confirmed the relative stereochemistries. These NOE results ·also required 
that a major solution conformation of both isomers have H7 gauche to 6-0 and 
anti to C5, and that H1 0 be anti to H11 (Figure 5.1 b), as in mycalamide A. The 
latter is almost certainly the case in the cis isomer, since the H1 O-H11 
coupling constant is about 9 Hz, but a considerably smaller value was 
observed in the trans isomer (5.4 Hz). However, there were strong NOE 
interactions between the H1 0 and both the H13 and H15 protons in both 
isomers, showing that a major solution conformation does have this anti 
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relationship between H1 0 and H11. Note, however, that these NOE 
interactions appeared to be significantly weaker for the trans isomer, and that 
there was a small NOE interaction between H1 0 and H11 in both isomers, 
suggesting the presence of another, minor rotamer, having H1 0 and H11 
gauche. 
Figure 5.1 1 H-1 H NOE interactions and partial solution conformations for 
mycalamide A cis and trans oxazolidinones (5.2 and 5.3). 
a) Cis isomer 
b) Trans isomer, major conformation c) Trans isomer, minor conformation 
The vicinal proton-proton coupling constants for the C11-C15 
tetrahydropyran ring substituents in the cis isomer (5.2) were similar to those 
in mycalamides A and B. There were also similar NOE interactions between 
the axial substituents, such as between H13 and H15, and between H12 and 
14-CH3S, suggesting that this C11-C15 ring had the same chair conformation 
in these compounds. The trans isomer (5.3) also showed similar NOE 
interactions to those above, but had additional weaker NOE interactions 
between the H1 0 and H12, H12 and H13, H13 and 14-CH3S, and H11 and 
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H16 protons, suggesting the presence of an alternate chair conformation for 
this ring (Figure 5.1c). The H10-H11, H11-H12 and H12-H13 coupling 
constants were also significantly lower for the traps isomer than for the cis 
isomer. Conformational averaging between the two chair conformations 102 is 
proposed to account for all these results on the trans isomer. Such exchange 
was earlier investigated for mycalamide A 19, pederin and pederin 
dibenzoate84 (1.2) in Chapter 1. 
A known method of probing such exchange is to observe the linewidths 
of affected signals in th·e 13C NMR spectrum as a function of 
temperature114,115,121. Although this was not feasible in the present case 
due to the small sample size, the spectrum at 23oc did show significant line 
broadening for several signals assigned to carbon atoms from C1 0 to C16, 
particularly those for C11 and 14-CH3S, where the linewidths were 10.2 and 
8.4 Hz, respectively, compared with the normal 2 Hz (Table 5.2). Such 
exchange could also account for changes in chemical shift for many of these 
resonances, since these would be a weighted average of those in the two 
conformations. 
The effect of the solvent on this exchange was considered by recording 
the 1 H NMR spectra of both isomers in CD30D (Table 5.1 ). Allowing for slight 
changes in chemical shift with solvent, the data for the cis isomer (5.2) were 
almost identical to those recorded in CDCI3. An exception was that some 
different coupling constants were observed for those resonances 
corresponding to protons on the C16-C18 sidechain, as expected from earlier 
studies on mycalamide A (Chapter 1 ). (An analysis of the coupling constant 
data for this portion will be presented in a later section). The 1 H NMR data in 
CD30D for the trans isomer (5.3) were also similar to those in CDCI3; except 
for differences noted above, and importantly, the vicinal proton-proton 
coupling constants for the H1 0-H13 portion, which were even smaller than 
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those observed in CDCI3. This suggested a higher proportion of the alternate 
chair conformation for the C11-C15 ring of the trans isomer in this solvent, 
and, possibly, the presence of other C10~C11 rotamers. However, the results 
of some NOE experiments for this isomer in CD30D were comparable to those 
recorded in CDCI3. This was the first mycalamide derivative to have a 
significant proportion of both chair conformations for this ring in solution. 
Therefore, in· order to investigate this more thoroughly, a molecular mechanics 
modelling approach was considered. 
5.3.4 SOLUTION CONFORMATIONS BY MOLECULAR MODELLING 
There were three main aims for the investigation of the solution 
conformations of the mycalamide A oxazolidinone isomers using molecular 
modelling:-
i) to show that both the C11-C15 tetrahydropyran ring chair conformers were 
similar in energy, and thus were accessible solution conformations; 
ii) to determine the influence of the configuration at C1 0, and the different 
hydrogen bonding possibilities on the populations of various conformations; 
iii) to calculate averaged coupling constants for the various structures which 
could be compared with the experimental results. 
The computer program used for this work was a modified MODEL 
program125, which used MM2 parameters and allowed either grid or statistical 
conformational searches to be performed, in order to generate a set of lowest 
energy conformations122 (conformers having minimised energies within 12.6 
kJ mol-1 of the lowest energy conformer would be accepted). These were 
analysed using another computer program213 to calculate vicinal proton-
proton coupling constants, using Haasnoot's generalisation of the Karplus 
equation 103, and dihedral angles for all the MM2 calculated geometries . 
. These calculated coupling constants could be weighted according to the 
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minimised energies (and thus the relative populations) of the various 
conformers. 
5.3.4.1 GRID SEARCH FOR CONFORMATIONS OF THE C11-C15 RING 
SUBSTITUENTS 
The structures of the mycalamide A oxazolidinone isomers (5.2, 5.3) 
were too conformationally flexible to perform a complete grid search124 
analysis on the entire molecules122. Therefore the structures were simplified 
. 
to concentrate on interactions between the oxazolidinone and the C11-C15 
tetrahydropyran rings, by initially setting a methyl group at C7 in place of the 
01-C6 ring and a methyl group at C15 in place of the C16-C18 sidechain. 
This gave two model structures representing the cis and trans isomers, 
differing in the configuration at C1 0, but having C1 0 axial to the C11-C15 ring, 
in the normal chair conformation (structures 5.4A and 5.5A - see Figure 5.2). 
A further two structures for these isomers were also generated, having C1 0 
equatorial to the C11-C15 ring, in the alternate chair conformation (structures 
5.48 and 5.58 - see Figure 5.2). Grid searches were then performed on all 
four starting structures, allowing 1200 rotations124,214 about the C10-C11, 
C12-0 and C13-0 bonds in the first instance, so that minimised energies 
could be calculated for all combinations of the three staggered rotamers of 
these bonds. 
The results of this search and a subsequent analysis are summarised in 
Table 5.6. The conformations obtained have been listed in order of increasing 
energy for each of the four structures, 5.4A, 5.48, 5.5A and 5.58, 
respectively, and described by the dihedral angles of the three rotatable 
bonds. An abbreviated notation for this large set of angles, described in a 
recent publication215, has been introduced as a useful method of classifying 
and comparing the conformers. Here 'A' represents an anti, '-' a (-) gauche, 
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and '+' a (+) gauche conformation for a particular dihedral angle, in the order 
C1 O-C11, C12-0 and C13-0, as described in Table 5.5. (The typical bounds 
for such classifications214 are ( +) gauche 1-1190, (-) gauche -1-(-1190), and 
anti 121-(-1200)). Vicinal proton-proton coupling constants from C1 0 to C13 
have been calculated for each conformer and the presence of hydrogen 
bonds has also been noted. 
Figure 5.2 Structures of the model conformers 5.4A, 5.48, 5.5A, 5.58, 
5.5C and 5.50 used for a grid search, showing the rotatable 
bonds considere"d (in bold). 
H CH3 
H 
;P 
HIYNH OCH3 
5.48 H3C. 
CH3 
~Hb•· 
H3C 0 
H 
H 5.58 
5.5C 
CH3 
CH3 
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The results show that the lowest energy conformers of the 5.4A, 5.48, 
5.5A and 5.58 structures were all within 12 kJ mo1~1, but that the alternate 
chair conformers (of 5.48 and 5.58) were energetically favoured in each 
case, contrary to the experimental evidence. The position of the C13 methoxyl 
group was almost the same in each of the low energy conformers, whereas all 
rotamers of the C12 hydroxyl group were represented, often with a significant 
effect on the· energy (see conformers 2 and 7 for structure 5.4A). All rotamers 
about C1 O-C11 were also represented and the lowest energy conformers of 
5.5A did not have H10-H11 anti, as required by the observed NOE 
interactions between H10 and H13 and H15 above. In several cases 
hydrogen bonds were noted between the amide NH proton and C12-0 and 
between C12-0H and one or more of the C10, C11 and C13 oxygen atoms. 
The conformers with these hydrogen bonds seemed to fit the NOE results 
better, since anti H1 O-H11 conformers were better represented. It has been 
reported215 that the MM2 method is not appropriate for the study of hydrogen 
bonds, as the calculated bonds are not sufficiently strong and are usually too 
long, and this could account for some discrepancies in the results. (Entropy 
and solvation effects are also not considered by such calculations216). Note 
that the energy differences between these conformations were not large and 
some contribution to the error may also have been caused by limitations in the 
model structures themselves. Whatever the reason, it was clear that the size 
of the H1 0-H11 coupling constant could not be studied, nor the absolute 
energies used to weight the coupling constants between the two chair 
structures. However, the H11-H12 and H12-H13 coupling constants were 
similar over the range of conformers within each structure, as expected with 
the protons being located on a ring, so these represented useful results. A 
complete discussion and analysis of this work is presented following the 
. second part of this investigation. 
5.3.4.2 GRID SEARCH FOR CONFORMATIONS OF THE C15-C18 
SIDECHAIN 
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Grid search methods have found only limited use for large molecules, 
due mainly to the many degrees of freedom of such structures, but this has 
sometimes been circumvented by the use of 'build-up' procedures124. These 
procedures use the approximation that the conformation of a molecule is 
largely dependent on short range interactions, so that small segments can be 
minimised in grid searches. and the lowest energy conformations pieced 
together. A similar approach was used here to study conformations of the 
C 15-C18 side chain of mycalamide A trans oxazolidinone (5.3) for the two 
possible chair conformations of the C11-C15 ring. The lowest energy 
conformer of each of the structures 5.5A and 5.5B was modified to include 
the full sidechain of mycalamide A, and then the resulting structures (5.5C 
and 5.50) were subjected to a full grid search, allowing 1200 rotations about 
the C15-C16, C16-C17, C17-0, C17-C18 and C18-0 bonds. 
The results of the two searches are shown in Table 5.7. It is readily 
apparent that all the lowest energy conformations have the C14-C15-C16-C17 
dihedral angle in an anti conformation, and this strong preference is well 
known for C-glycosides116. This result is reflected in the calculated coupling 
constants between the H15 and the two H16 protons, which were similar for all 
conformers of both starting structures. (Note that, for the purposes of this 
analysis, the H16 protons have been designated as pro-R (gauche to H15) 
and pro-S (anti to H15). These prochirality assignments are opposite to those 
stated for pederin and pederin dibenzoate (1.2) due to the difference in the 
C17 substituent100,112). Amongst the remaining dihedral angles, there was 
about equal preference for anti and (+) gauche conformations with few (-) 
gauche conformations observed for the angles specified. The coupling 
constants for the rest of the sidechain therefore varied considerably over the 
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various conformations. However, for structure 5.5C, there were three low 
energy conformations which represented about 72% of the total calculated 
population, while for structure 5.50, there were only two low energy 
conformations which represented about 82% of the total calculated 
population. The best three sidechain conformers were the same in both 
searches, and two were found to have hydrogen bonds between C17-0H and 
C15-0 and between C18-0H and C17-0, and a third had a hydrogen bond 
between C17-0H and C18-0, with four of the five dihedral angles in an anti 
~ 
conformation. These conformations are depicted in Figure 5.3. There were 
also many other low energy conformations, which have been included in 
Table 5.6 to give some understanding of the appearance of these higher 
energy conformations, which vary between the two structures. An analysis of 
the average coupling constants is presented below. 
Figure 5.3 Major conformations of the C16-C18 sidechain of mycalamide A 
trans oxazolidinone (5.3), as calculated by molecular modelling. 
5.3.4.3 COMPARISON OF EXPERIMENTAL AND CALCULATED COUPLING 
CONSTANTS 
The average proton-proton coupling constants for each structure have 
been calculated by weighting the individual values for each conformer 
according to its relative population, as estimated by applying a Boltzmann 
distribution to the individual energies. These results have been presented in a 
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combined format in Table 5.7 and compared with, primarily, experimental 
values for the mycalamide A cis and trans oxazolidinones (5.2, 5.3) 
measured in CDCI3 solution, rather than those measured in CD30D. This is 
because the molecular modelling program considers the molecule in the gas 
phase, or in a non-polar solvent215, where intramolecular hydrogen bonds are 
important, whereas CD30D is a solvent which disrupts such bonds, being 
itself a good hydrogen bond acceptor. There are situations where the 
presence or absence of hydrogen bonds makes less difference to the 
. 
conformation, such as within the C11-C15 tetrahydropyran ring, so 
comparisons of the calculated and experimental data in both solvents are 
probably justified in this case (H11-H12 and H12-H13 coupling constants). 
The first part of Table 5.7 shows the calculated average coupling 
constants for H1 O-H11, H11-H12 and H12-H13, derived from grid searches on 
structures 5.4A, 5.48, 5.5A and 5.58. (These values represent an average 
of the calculated values for each conformer, weighted by the Boltzmann 
distribution of their energies). It is clear that there is only reasonable 
agreement between experimental values for the cis isomer (5.2) and 
calculated average values for conformers of the 5.4A structure, but any 
contribution to the.calculated values from conformers derived from structure 
5.48 would result in poorer agreement. Clearly, only the H11-H12 and H12-
H13 coupling constants can be compared, for reasons discussed above 
involving the contribution of other C1 O-C11 rotamers. Thus, if only these 
coupling constants are considered, then this analysis correctly predicts that 
the C11-C15 ring of mycalamide A cis oxazolidinone (5.2) must be almost 
completely in one chair conformation. For the trans isomer (5.3), the 
experimental values for these two coupling constants lay between the average 
values for a single chair conformation (structures 5.5A and 5.58) so that 
some combination of the two is required. As stated earlier, this could not be 
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done by applying a Boltzmann distribution over the two sets of conformers for 
the model structures 5.5A and 5.58 because of the much lower energy of the 
5.58 conformers, giving a result close to that shown for a 100% contribution 
of the latter, in marked contrast to the experimental results. The calculation of 
intermediate ratios of the two averaged results for conformers of structures 
5.5A and 5.58 could be justified only because of the small variance of the 
individual values for each structure (Table 5.5), so that this approximates an 
interleaving of the two sets of results. Within the limited accuracy of this 
. 
approach, it appears that an overall contribution of about 80% and 20%, 
respectively, of conformers from structures 5.5A and 5.58 could satisfy both 
the coupling constants and earlier NOE results for the trans isomer (5.3) in 
CDCI3 solution (with the relative contributions in CD30D being closer to 70% 
and 30%, respectively). 
The remainder of Table 5.7 shows the calculated average coupling 
constants between protons on the C15-C18 portion of conformers derived 
from the modified structures 5.5C and 5.50. There were only small 
differences between these values for the two structures, representing the two 
chair conformations of the C11-C15 ring, and comparison with experimental 
values in CDCI3 solution was surprisingly good, apart from a larger calculated 
H 15-H16S coupling constant than observed. This suggests that the three 
major solution conformations of the sidechain stated above, which have the 
most influence on the size of the average coupling constant, are also the 
major solution conformations in CDCI3. These conformations also agree with 
partial NOE data for this portion (Table 5.3). Since there was little difference 
between the results for conformers of the two structures 5.5C and 5.50, the 
relative contributions of conformers from the two structures was not important. 
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The experimental coupling constants measured in CD30D for this 
portion of the structure were rather different, although the H15-H16 coupling 
constants were similar, suggesting that the same preference for the C14-C15-
C16-C17 dihedral angle to be in an anti conformation still existed. The 
differences here can be rationalised by the lower preference for conformations 
having intramolecular hydrogen bonds, such bonds being disrupted in this 
solvent. No attempt was made to investigate this further. 
5.4 BASE CATALYSED REACTIONS OF MYCALAMIDES A AND 8 
IN OTHER SOLVENTS 
The above sections have described the products obtained from the 
reaction of mycalamide A with sodium methoxide in dry methanol. If the 
observed reaction were simply base catalysed, as expected, then it should 
occur for a range of other base and solvent systems. Indeed, it was found 
subsequently that the reaction of mycalamide A in DMSO with either barium 
oxide or potassium hydroxide gave the same oxazolidinone isomers {Table 
5.8 and Experimental). However, there was a significant increase in the 
proportion of the cis isomer in the product mixtures from these latter reactions, 
a point which will be discussed further in a later section. 
Under more forcing conditions, the reaction of mycalamide A with 
potassium hydroxide in DMSO gave a single rearranged oxazolidinone 
derivative in lower yield. HRFABMS showed that it was an isomer of the 
earlier compounds. The 1 H NMR spectrum of this product was similar to that 
of mycalamide A cis oxazolidinone (5.2), but the C4 exocyclic methylene 
signals and two H5 resonances had been replaced by new signals for an 
allylic methyl and methine, at 61.77 and 5.33 ppm, respectively, having a long 
range coupling104 of 1.5 Hz. This suggested the formation of a t:\4(5) isomer 
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(5.6) by a base catalysed rearrangement of the exocyclic double bond into the 
01-C6 ring196. This compound had the C6 acetal group in an allylic position, 
so it was not expected to be very stable and was therefore not investigated 
further. 
• CH3 H3C A -i CH3 
CHa • OCHa 
OH 
OH 
A4(5) Mycalamide A cis oxazolidinone (5.6) 
The reaction of mycalamide A with sodium hydroxide in mixed aqueous 
solvents was slower and gave two new products in addition to the mycalamide 
A cis and trans oxazolidinones by HPLC. These products were separated by 
HPLC and shown by HRFABMS to be isomers of the original products (5.2, 
5.3), although they coeluted with residual mycalamide A, and this represented 
about a 25% impurity in both samples. The 1 H NMR spectra of these products 
were similar to those of the earlier isomers, and were assigned by a 
combination of NOE and COSY experiments (Table 5.1 ). However, there 
were large changes in the chemical shift of the H5 protons (0.2-0.6 ppm), and 
smaller shifts in the positions of the 6-0CHa, H7 and NH proton resonances. 
There were long range couplings between H7 and H1 0 of 1.3 and 2.1 Hz, 
signifying new cis and trans oxazolidinone isomers209, respectively. NOE 
interactions were observed between the H7 and H1 0 protons and between 
both H5 protons and H7 for the new cis isomer. (Table 5.1 0), and this isomer 
showed averaged coupling constants for the C1 0 to C13 portion and chemical 
shifts from NH9 onwards which were similar to those obseiVed for the·original 
trans isomer (5.3). The new trans isomer had coupling constants and 
chemical shifts from NH9 onwards which were more similar to those for the 
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original cis isomer (5.2). These results could best be explained if these new 
isomers were C7 epimers of the mycalamide A cis and trans oxazolidinones, 
as in structures 5.7 and 5.8. Such an epimerisation would require the base 
catalysed removal of the H7 proton, which is a to the amide carbonyl group, to 
give an enolate ion intermediate154,155, as discussed for various mycalamide 
methyl ethers in Chapter 2. 
0 
i CH3 
OCH3 
OR3 CH3 
R1=R2=R3=R4=H: 7S Mycalamide A cis oxazolidinone (5.7) 
R1=R2=R3=R4=CH3: 12,17,18-tri-0-Methyl, N-methyi7S A cis oxazo.(5.15) 
H 
H 
_ CH3 
OCH3 
OR3 CH3 
R1=R2=R3=R4=H: 7S Mycalamide A trans oxazolidinone (5.8) 
R1=R2=R3=R4=CH3: 12,17,18-tri-0-Methyl, N-methyi7S A trans oxazo.(5.16) 
The reaction of mycalamide B with potassium hydroxide in DMSO also 
gave oxazolidinone derivatives (TLC), as expected. The isomers were not 
separable by reverse phase HPLC but were just resolved by TLC on silica gel. 
Preparative TLC gave two fractions, which contained isomers of mycalamide B 
oxazolidinone by HRFABMS, having molecular formulae indicating the same 
loss of CH20 from mycalamide B. The 1 H NMR spectra were consistent with 
the formation of cis and trans oxazolidinone isomers (5.9, 5.10), analogous to 
those obtained from mycalamide A. These were assigned by COSY 
experiments and by an NOE experiment to give the data in Table 5.9. 
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The reaction of mycalamide B with sodium methoxide in methanol also 
gave a mixture of several oxazolidinones (TLC). These were also not 
resolved by reverse phase HPLC and careful preparative TLC was required to 
separate two fractions. The 1 H NMR spectrum of the first fraction showed one 
major component, mycalamide B cis oxazolidinone (5.9), and a second, minor 
component, which was probably a 7 S cis oxazolidinone derivative. The latter 
assumption ·was based on the observations of a small H7-H1 0 coupling 
constant209 (-1 Hz) and widely separated H5 methylene resonances (o3.1 
and 2.1 ppm), which were characteristic in the mycalamide A examples (Table 
5.1 ). The 1 H NMR spectrum of the second fraction was more complex, as it 
showed that mycalamide B trans oxazolidinone (5.1 0) was the major 
component of a mixture including two minor components. One was a 75 trans 
oxazolidinone derivative, based on the larger H7-H1 0 coupling constant209 
(2.5 Hz) and the same spread in the H5 resonances (o2.9 and 2.1 ppm). The 
remaining component was not an oxazolidinone derivative since the 1 O-OCH2 
methylene signals were present in the 1 H NMR spectrum, but nor was it 
mycalamide B, and was at this point too minor to consider further. 
Subsequent purification and characterisation of this component will, however, 
be described in Chapter 6, where the identity of a mycalamide A equivalent 
from another base catalysed reaction is determined. 
5.5 MECHANISM OF FORMATION OF THE MYCALAMIDE A AND B 
OXAZOLIDINONES 
The base catalysed formation of an oxazolidinone ring system from 
mycalamides A and B would require that an intramolecular substitution-
elimination reaction occur at the C1 0 aza acetal site. This must involve both 
an attack of the C7 hydroxy anion at C1 0 and the cleavage of the C1 0-0 bond 
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of the C 1 O-C12 dioxan ring. The latter evidently results in the facile loss of 
formaldehyde from this C12-0 hemiacetal chain to leave a C12 hydroxyl 
group. This process is summarised in Scheme 5.1. 
Scheme 5.1 Proposed mechanisms to account for the formation of the 
oxazolidinone derivatives from mycalamides A and B. 
a) Reaction via SN2 pathway 
b) Reaction via imine intermediate 
The absolute configurations of mycalamides A and 8 have recently 
been verified by synthesis91. The NMR spectroscopic evidence described 
above is consistent with the cis and trans isomerism of 5.2 and 5.3 being 
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caused by a difference in stereochemistry at C1 0. Therefore the cis isomer, 
5.2, represents a product with an inversion of configuration at C1 0, relative to 
mycalamide A, and the trans isomer, 5.3, represents a retention of the C1 0 
configuration. An SN2-type mechanism 141, as described in Scheme 5.1 a, 
would therefore give the cis isomer exclusively (Figure 5.4). Thus, in order to 
obtain two isomers at C1 0, there must be some involvement of another 
reaction intermediate. 
Figure 5.4 Stereochemistry Qf a proposed intramolecular SN2 reaction in 
mycalamide A to form oxazolidinone derivatives. 
Experimentally, it was found that the cis isomer was favoured in most 
reactions (Table 5.8), and the reactions in DMSO consistently gave a higher 
proportion of this isomer than those in methanol. Further experiments 
established that there was no inclusion of deuterium in the products with 
reactions in d4-methanol and no significant interconversion of the isomers, 
although prolonged reactions gave poor yields of further new oxazolidinone 
compounds by TLC and 1 H NMR spectroscopy whose identities were not 
determined. With mixed aqueous solvents there was some C7 isomerisation, 
and the trans isomer (5.3) was partially converted into the cis isomer (5.2), to 
the extent of about 60% of the reaction mixture. These results suggested that 
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more than one mechanism could be involved in the reaction and that the 
extent of involvement of each could depend on the polarity of the solvent. 
A common synthesis of 2,5-substituted 4-oxazolidinones involves the 
condensation of a-hydroxy amides or cyanohydrins with carbonyl compounds 
in the presence of an acid catalyst208,210,217,218 and two equilibrium steps 
involving a hemiacetal intermediate have been proposed to account for yields 
favouring the more thermodynamically stable cis product209. In particular, an 
imine intermediate, described below, was disfavoured due to the "low basicity 
of the amide nitrogen and because of an unfavourable geometry of the imine 
intermediate to undergo cyclisation"209. 
In the mycalamide A reaction, if intermediates involving direct 
participation of the base or solvent are excluded, then the only alternative is to 
propose the involvement of some ionic intermediate at C1 0, probably 
involving stabilisation from the amide nitrogen. It has been established from 
earlier work on the methylation of mycalamide A (Chapter 2) that there is some 
formation of the amide anion 156 under these strongly basic conditions, since 
N-methylation was achieved readily in the presence of methyl iodide. Such 
an anion could stabilise the cleavage of the C1 0-0 bond by the donation of 
electron density to C10, to form a (delocalised) imine intermediate (Scheme 
5.1 b). Note that this appears more likely under these basic conditions than an 
iminium ion formed directly from the amide, since amides are very weak 
bases219. Such an intermediate would allow an attack of the C7 hydroxy 
anion on either face of the double bond at C1 0 to give the two isomers. Note 
that there is some precedence for the involvement of such intermediates in 
various reactions of amides155,220. 
For the reactions in DMSO, it would appear that there is a strong 
contribution from an SN2-Iike mechanism, in order to account for the high 
proportion of inversion141 at C10. (Alternatively an imine intermediate with 
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tight ion-pairing158 could explain this result). In solvents which favour 
ionisation to a greater extent140, such as methanol and particularly aqueous 
solvents, there was a much lower preference for inversion. This is interpreted 
as suggesting that a mechanism which involves an ionic intermediate, such as 
the imine intermediate discussed above, would be the favoured mechanism 
under more polar conditions. This is supported by the observed formation of 
C7 epimers only under the more polar conditions, which certainly requires the 
involvement of an ionic intermediate154,155. Also, the step involving attack of 
. 
the C7 hydroxy anion on the imine intermediate to form the oxazolidinone ring 
must be reversible under aqueous conditions since the racemisation of the 
trans isomer at C1 0 was observed. However, this barely occured in DMSO, 
and this is taken as further evidence for the proposals above. 
5.6 ACID CATALYSED DECOMPOSITION OF MYCALAMIDE A 
OXAZOLIDINONES 
The synthesis of oxazolidinones by condensing a-hydroxy amides with 
carbonyl compounds in the presence of an acid catalyst relies on the removal 
of water from the reaction208,209, which is often done azeotropically218. 
Consequently, it is known that the products can be hydrolysed by dilute acids 
to give the starting compounds217. In the present case, mycalamide A trans 
oxazolidinone (5.3) was dissolved in CDCI3 with no pyridine added and 
monitored with time. After one day the compound had undergone elimination 
of methanol across C6-C7 and the exocyclic double bond had rearranged into 
the C4-C5 positions of the 01-C6 ring to give a Z neomycalamide A 
oxazolidinone derivative (5.11 ). This was shown by the presence of a new 
allylic system at o1.9 and 6.9 ppm, as discussed in Chapter 3. The same 
occurred for the cis isomer (5.2), to give structure 5.12, and the 1 H NMR data 
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for these products are recorded in the Experimental section. This facile 
reaction in CDCia could not be reproduced, and the starting compound 
degraded slowly to a mixture in which the major fragment was pederolactone 
(3.6). The mycalamide structure was clearly too acid sensitive to isolate other 
products, as expected. 
NH 
~ CH3 
OCH3 
OH 
10S Neomycalamide A oxazolidinone (5.11) 
H 
~ CH3 
OCH3 
OH 
CH3 
OH 
1 OR Neomycalamide A oxazolidinone (5.12) 
One recent review221 stated that little was known about the chemistry of 
4-oxazolidinones, apart from this acid catalysed hydrolysis and their 
methylation218. An earlier review217 was more extensive, reporting these 
reactions, together with their acetylation and hydrogenation. More recently 
there has been a systematic investigation of the formation and behaviour of 
these compounds by some Romanian investigators222-226. The following 
section describes the preparation of some simple derivatives of the 
mycalamide oxazolidinones, which provided some interesting results. 
5.7 DERIVATIVES OF MYCALAMIDE A OXAZOLIDINONES 
5.7.1 PREPARATION AND CHARACTERISATION OFA TETRAACETYL 
DERIVATIVE 
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Mycalamide A trans oxazolidinone (5.3) was acetylated with pyridine 
and acetic anhydride in the usual manner until there was a single product 
(TLC). HRFABMS showed that the product had a molecular formula of 
Ca1 H47N013, which required the replacement of the four exchangeable 
protons in 5.3 by acetyl groups. A 1 H NMR spectrum showed the presence of 
at least three 0-acetyl methyl resonances, corresponding to the esters at C12, 
C17 and C18, as demonstrated by the large downfield shifts in the a-proton 
signals (0.5-1.3 ppm, Table 5.9), which were assigned by a COSY experiment. 
It also showed an acetyl methyl resonance at <52.46 ppm, which would arise 
from an acetyl group on the oxazolidinone ring. 
The acetylation of oxazolidinones is known to occur, but there was 
some doubt as to the structure of the product in at least one report217. The 
most likely position for acetylation would appear to be at the nitrogen atom, to 
give an imide (structure 5.13), since this nitrogen in 5.3 may be more reactive 
than its counterpart in the predominantly trans open chain amide of 
mycalamide A, due to its greater accessibility. The alternative reaction site is 
the carbonyl oxygen, to give a derivative having a double bond between CB 
and the nitrogen, with an 0-acetyl group at ca. This would represent a vinyl 
acetate, the structure being an 0-acyl imidate, which would have a 
characteristic band in the IR spectrum96 (compare results for the 
neomycalamide A triacetate isomers, 3.12 and 3.13, in Chapter 3). No 
evidence seemed to be observed for this in the FTIR spectrum, suggesting that 
the former structure was correct. Furthermore, the H7-H1 0 coupling constant 
was smaller in this derivative, whereas a double bond between CS and the 
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amide N would be predicted to increase the size of this coupling209. The 
deshielding of these acetyl methyl protons would be consistent with their 
being close to another carbonyl group123 and the ca carbonyl is probably 
almost in the plane of the N-acetyl group due to the delocalisation of electron 
density over the complete imide system (Figure 5.5). The carbonyl group of 
amides is also usually only reactive in the presence of silver salts or with 
strong alkylating reagents under almost neutral conditions156. 
Figure 5.5 1 H-1 H NOE interq.ctions and partial solution conformation for 
N-acetyl mycalamide A trans oxazolidinone triacetate (5.13). 
Further evidence for an N-acetyl group was obtained from an analysis 
of chemical shifts observed in a 13C NMR spectrum of this compound, as 
assigned by an HMQC experiment (Table 5.2). There were significant 
downfield shifts in the C1 0 and C12 resonances (+6.1, + 1.6 ppm respectively), 
and upfield shifts in the ~ carbon resonances, ca (-1.0), C11 (-2.2) and C13 (-
2.9), which were consistent with expected substituent effects117 for acetylation 
at C1 O-N and C12-0. (The C7 and C8 resonances could be expected to show 
different shifts for acetylation of the C8 oxygen). There were also other minor 
shifts in the C11-C15 tetrahydropyran ring carbon resonances which were 
indicative of a change to the average solution conformation of this ring, as 
discussed below. 
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5.7.2 SOLUTION CONFORMATIONS OF N-ACETYL MYCALAMIDE A TRANS 
OXAZOLIDINONE 12,17,18-TRIACETATE 
The C11-C15 ring proton-proton coupling constants for 5.13 did not 
show the same averaged behaviour as those for the non-acetylated 
compound (5.3}, and were more consistent with the presence of 
predominantly one chair conformation, as found in mycalamide A and the cis 
oxazolidinone isomer (5.2). Similarly, the carbon resonances for this ring 
were less broad and the ch~mical shift of the C14, 14-CH3R and 14-CH3S 
resonances were also closer to those obseNed for mycalamide A. The results 
of difference NOE experiments, detailed in Table 5.1 0, required that there still 
be a small proportion of the alternate chair as well as the normal chair 
conformation, but such interactions, such as between H216 and H11 and H12 
and H13, were weaker than those in the non-acetylated trans isomer (5.3}. 
The H1 O-H11 coupling constant was only 1.4 Hz in this derivative 
(5.13), suggesting a predominantly gauche relationship between these 
protons98 in solution. There were strong NOE interactions between the H7 
and H13, H10 and H11, and H10 and H15 protons, but not between H10 and 
H 13. These data required that the oxazolidinone and C11-C15 rings have the 
major solution conformation shown in Figure 5.5. The large downfield shift in 
the H11 resonance (+0.6 ppm) is consistent with deshielding by the N-acetyl 
carbonyl group98, 123 in this conformation. Also, the downfield shifts in the H7, 
H13 and H15 resonances are explained by a combination of steric 
interactions and dipolar anisotropic effects associated with the C1 0 
oxygen 123. Similar interactions may also contribute to the shielding117 of the 
C13 and C15 carbon resonances, and to the deshielding of the C1 0 
resonance in this conformation. 
A molecular mechanics minimisation of this conformation showed that it 
was a local minimum but that other C1 O-C11 rotamers were also energetically 
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favourable. However, the absence of NOE evidence for these other 
conformations would suggest that the conformation shown in Figure 5.5 is 
predominant in CDCI3 solution. This illustrates the point that hydrogen 
bonding involving the C12 hydroxyl group may be an important factor in the 
favouring of an anti relationship between H1 0 and H11 in the original trans 
isomer (5.3), despite such a conformation being poorly represented in the 
earlier molecular mechanics calculations. Note that acetylation at the C12-0 
and N positions would not appear to introduce unfavourable steric interactions 
. 
to destabilise a conformation having H1 0 and H11 anti (see Figure 5.1 b). 
However, it does appear to have favoured the normal chair conformation of 
the C11-C15 ring, possibly because the addition of a more bulky substituent at 
C 12 could introduce more unfavourable steric interactions in the minor 
alternate chair conformation where this substituent is axial (see Figure 5.1 c). 
5.7.3 PREPARATION, CHARACTERISATION AND PARTIAL SOLUTION 
CONFORMATIONS OF A SERIES OF METHYLATED DERIVATIVES 
Methylation of mycalamide A trans oxazolidinone (5.3), using 
potassium hydroxide and methyl iodide in DMS0151, as in Chapter 2, gave 
one less polar product, initially, by TLC. On standing overnight, this reaction 
mixture became about a 1 :1 mixture of two major products, and subsequent 
workup and preparative TLC separated these, together with a third minor 
fraction. HRFABMS showed that all the products were isomers, of molecular 
formulae C31 H 4 7N 013, which required the replacement of the four 
exchangeable protons in the starting compound by methyl groups. An NMR 
spectroscopic characterisation and an analysis of the major solution 
conformation is described for each product below. 
5.7.3.1 12, 17, 18-TRI-Q..METHYL, N-METHYL MYCALAMIDE A TRANS 
OXAZOLIDINONE 
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The 1 H NMR spectrum of the product which was of lowest R1 on silica 
gel TLC and was initially major showed that this was 12, 17, 18-tri-O..methyl, N-
methyl mycalamide A trans oxazolidinone (5.14), having one N-methyl and 
five methoxyl resonances. There were upfield shifts in the signals 
corresponding to the a.-protons, H1 0, H12, H17 and both H18's, consistent 
with this methylation101, as assigned by a COSY experiment (Table 5.9). A 
partial assignment of the methoxyl resonances was achieved using results 
from various NOE experiments (Table 5.1 0). A 13C NMR spectrum was also 
recorded for this isomer, and this was partially assigned to give the data in 
Table 5.2. 
NOE experiments were performed to examine the solution 
conformations of this derivative (Table 5.1 0). The strong NOE interactions 
observed between the H7 and H13, H1 0 and H11, and H1 0 and H15, but not 
the H1 0 and H13 protons, indicated that this derivative has the same major 
solution conformation as the acetylated derivative {5.13) above (see Figure 
5.5). The H1 O-H11 coupling constant was also small, as above, and the H11 
resonance was slightly deshielded in this conformation. The observed NOE 
interactions between the H16 and H11 and the H13 and 14-CH3S protons 
suggested the presence of a small population of the alternate chair 
conformation, which was further supported by the observation of slightly 
averaged H11-H12 and H12-H13 coupling constants and the broadening of 
some resonances in the 13C NMR spectrum. 
5.7.3.2 12, 17, 18-TRI-0-METHYL, N-METHYL 7S MYCALAMIDE A CIS 
OXAZOLIDINONE 
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The 1 H NMR spectrum of the other major product, of highest Rt on TLC, 
which appeared to have been formed from the methylated derivative above, 
showed that it was probably a cis isomer, based on the less than 1 Hz 
coupling between the H7 and H1 0 protons209. Furthermore, it was likely to be 
a C7 epimer (structure 5.15), since the two H5 resonances were well 
separated in chemical shift.. This would account for its formation from the 
methylated trans oxazolidinone derivative (5.14) above, since this represents 
an epimerisation at C7, via the enolate, under the basic reaction 
conditions 155. The five methoxyl resonances were all clustered within 0.1 
ppm in the 1 H NMR spectrum, and there were substantial differences in the 
chemical shifts and coupling constants for the central tetrahydropyran ring 
protons and its substituents, as assigned by COSY and NOE experiments 
(Tables 5.9 and 5.1 0). In particular, the chemical shifts of signals assigned to 
the H13, 13-0CH3, 14-CH3R, 14-CH3S, H15 and H16S protons, and the 
coupling constants between H11 and H12 and H12 and H13, were consistent 
with the C11-C15 tetrahydropyran ring being mostly in the alternate chair 
conformation, as found for a tribenzyl derivative (2.47) in Chapter 2. This was 
also reflected in the chemical shifts of signals in a 13C NMR spectrum, as 
assigned by an HMQC experiment (Table 5.2), particularly the 13-0CH3, C14, 
14-CH3R, and 14-CH3S resonances. 
NOE experiments were performed to further examine the solution 
conformations (Table 5.1 0). NOE interactions were observed between the 
H10 and H12, H11 and H16S, H12 and H13 protons, and between both C14 
methyl groups and the H13 and H15 protons, consistent with this alternate 
chair conformation. The NOE interactions between the H7 and H1 0 and 
between the two H5 and both the H11 and H 12 protons were indicative of a 
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cis substitution of the oxazolidinone ring and a mostly anti relationship 
between the H1 0 and H11 protons (see Figure 5.1 a). The latter was also 
consistent with the observed H1 O-H11 coupling constant98 (7.5 Hz). The NOE 
interactions between both H5 protons and H7 were also indicative of the 
epimerisation at C7, as above. 
The two major products from the methylation of mycalamide A trans 
oxazolidinon·e (5.14 and 5.15) therefore have quite different major solution 
conformations, but differ only in the stereochemistry at C7. However, this 
. 
epimerisation could introduce unfavourable steric interactions between the 
two tetrahydropyran ring systems in the new cis isomer. These would be 
reduced by having the alternate chair conformation for the C11-C15 ring, 
since C1 0 would then be an equatorial rather than an axial substituent of this 
ring (see Figure 5.1 c). It is interesting that mycalamide A cis oxazolidinone 
(5.2) does not show a significant proportion of this alternate chair 
conformation. However, this structure does not have the extra 0-methyl and 
N-methyl groups and has an opposite configuration at two centers (C7 and 
C10). 
5.7.3.3 12,17,18-TRI-Q-METHYL, N-METHYL 78 MYCALAMIDE A TRANS 
OXAZOLIDINONE 
The 1 H NMR spectrum of the remaining minor product, of intermediate 
Rt on TLC, showed that it was a trans isomer, based on the size of the H7-H10 
coupling constant209 (2.3 Hz), and that it was probably a C7 epimer, based on 
the large spread in chemical shift of the two H5 resonances. The spectrum 
was comparable to that of 7 S mycalamide A trans oxazolidinone (5.8), but 
showed an N-methyl and five methoxyl resonances, along with shifts in the 
signals for the a-protons, consistent with methylation 1 o 1. This derivative 
(5.16) must therefore arise from an epimerisation at both C7 and C1 0, which 
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would require an opening of the oxazolidinone ring, presumably to give an 
imine intermediate 155. 
Figure 5.6 1 H-1 H NOE interactions and partial solution conformation for 
12,17,18-tri-Q-methyl, N-methyl 7S mycalamide A trans 
oxazolidinone (5.16). 
There was insufficient sample to perform a full NMR characterisation so 
the reaction was repeated on mixed mycalamide B cis and trans 
oxazolidinone isomers (5.9, 5.1 0). The four products were separated by a 
combination of preparative TLC and HPLC, as described for the new product 
below. This allowed the 1 H NMR spectrum of the present derivative to be fully 
assigned (Table 5.9) by using a combination of results from COSY and NOE 
experiments (Table 5.1 0), which also gave an indication of the major solution 
conformations of this derivative. In particular, strong NOE interactions 
between the H7 and H15, N-CH3 and H11, H10 and H11, H10 and H13, but 
not the H1 0 and H15 protons, showed that this compound must have the 
major partial solution conformation shown in Figure 5.6 (above). The H1 0 and 
H11 protons are in a gauche relationship in this conformation, which is 
consistent with the small H10-H11 coupling constant98, but this was a different 
C1 O-C11 rotamer from that observed for the acetylated and methylated 
mycalamide A trans oxazolidinone derivatives (5.13, 5.14) above. The 
conformation of the C11-C15 ring was predominantly the usual chair 
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conformation as shown by NOE interactions between H 13 and H15, and H 12 
and 14-CH3S, and by the size of the H11-H12 and H12-H13 coupling 
constants. There was insufficient sample to record a 13C NMR spectrum. 
5.7.3.4 8,12,17,18-TETRA-0-METHYL MYCALAMIDE A CIS 
OXAZOLIDINONE 
There was a fourth product from the repeated methylation reaction, 
which was formed in low yield and was coincident on silica gel TLC with the 
. 
methylated 7 S mycalamide A cis oxazolidinone derivative (5.15). Separation 
of these two derivatives was achieved by reverse phase HPLC to give a fourth 
isomer by HRFABMS. The 1 H NMR spectrum of this new product suggested 
that it was not N-methylated but 0-methylated at the amide functionality. This 
was inferred from the presence of a new methoxyl resonance at 83.94 ppm, 
which was more consistent with an 0-methyl imidate functionality101 (structure 
5.17). The presence of a full double bond between C8 and the amide 
nitrogen was also suggested by the larger long range coupling constant 
between H7 and H10 of 3.0 Hz209. Unfortunately there was insufficient 
sample to observe longer range NOE interactions to verify the proposed cis 
stereochemistry of the oxazolidinone ring, or to record a 13C NMR spectrum. 
However, this was the only C7-C1 0 configuration not represented above and 
so this would seem to be a likely product. 
H 
CH3 
CH2 OCH3 
OCH3 CH3 
8, 12, 17, 18-tetra-0-Methyl, mycalamide A cis oxazolidinone (5.17) 
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The 1 H NMR spectrum was assigned by using the results obtained from 
a COSY experiment. NOE interactions were observed between H1 0 and both 
H13 and H15, suggesting that H1 0 and H11 were predominantly in an anti 
relationship, which agreed with the observed H1 0-H11 coupling constant9B 
(8.3 Hz). This result also implied that the C11-C15 ring was mainly in the 
usual chair conformation, which was required by the size of the H11-H12 and 
H12-H13 coupling constants, which were close to those recorded for 
mycalamide A trans oxazolidinone (5.3}. 
The fact that alkylation of the amide oxygen was preferred to alkylation 
of the amide nitrogen under reaction conditions which did not favour the 
former156,157, suggested that the amide nitrogen in the cis isomer was too 
hindered to undergo competitive reaction, or that an N-alkylated product was 
less stable. These proposals would seem reasonable on steric grounds, since 
methylation of the C12 hydroxyl group could hinder a reaction of the nearby 
amide nitrogen (Figure 5.1 }. Alternatively, there is some precedent for 
compounds having strong intramolecular hydrogen bonds to be difficult to 
methylate227. 
5. 7.4 CONCLUSIONS 
This methylation study has given derivatives with different C1 O-C11 
rotamers as major solution conformations, which also had different relative 
populations of the two possible chair conformations of the C11-C15 
tetrahydropyran ring. The coupling constant data for these derivatives could 
be compared with those calculated by molecular modelling. The observed 
products from methylation and acetylation of the mycalamide oxazolidinones 
have illustrated the reactivity of this new ring system and further confirmed the 
structure and stereochemistry of the original isomers and the reaction 
mechanisms. Some attempt has been made to show the influence of 
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hydrogen bonding and steric factors in the observed solution conformations of 
the various oxazolidinones. It was apparent that molecular modelling could 
not accurately predict which were the favoured solution conformations, 
possibly due to inadequacies in both the program and the model structures, 
but was still a useful tool for conformational analysis. 
5.8 BIOLOGICAL ASSAY RESULTS 
The assay results for ~all the compounds in this chapter are shown in 
Table 5.11. As expected on the basis of earlier results (Chapter 2) these 
derivatives were not active, having a derivatised C7 hydroxyl group, and any 
activity indicated by the results could be due to the presence of residual 
amounts of unresolved mycalamide A or B. This confirms earlier findings that 
the central portion of mycalamide A is very important for the expression of its 
activity. This work did not achieve the desired amide hydrolysis or yield 
biologically active compounds, but the unusual base reactivity of the C1 0 aza 
acetal was a useful result, which suggested further possibilities for the study of 
this important region of the molecule. 
Table 5.1 1 H NMR dataa for mycalamide A oxazolidinones 
H2 
2-CH3 
H3 
3-CH3 
4:CHZ 
4:CHE 
H5a 
H5e 
6-0CH3 
H7 
NH9 
H10 
H 11 
H12 
H13 
13-0CH3 
14-CH3R 
14-CH3S 
H15 
H16 
H16 
H17 
H18 
H18 
Myc.Acis 
oxazolidinone 
(5.2) 
3.95 (2.5,6.6) 
1.20 (6.6) 
2.21 (2.2,7.0) 
1.05 (6.9) 
4.83 (1.9) 
4.73 {1.9) 
2.40 (2.0, 13.8) 
2.28 (13.9) 
3.30 
4.39 (1.5) 
6.58 
5.59 (1.6,8.9) 
3.88 (6.8,8.9) 
3.97 (6.7,9.8) 
2.96 (9.6) 
3.61 
0.98 
0.89 
3.60 (2.5,9.8) 
1.60 (2.5,4.2, 14.6) 
1.51 {6.9,9.7, 14.6) 
3.91 {m) 
3.62 (6.5, 11.1) 
3.56 (4.1,11.2) 
Myc.A trans 
oxazolidinone 
(5,3) 
3.95 (2.6,6.5) 
1.19 (6.6) 
2.22 (2.8,7.0) 
1.04 (6.9) 
4.85 (2.0) 
4.74 (1.9) 
2.48 (1.9,13.7) 
2.32 (13.7) 
3.31 
4.45 (2.4) 
7.87 
5.62 (2.3,5.3) 
3.93 (5.4,5.4) 
4.00 (5.6,7.4) 
2.98 (7.5) 
3.56 
1.03 
0.88 
3.54 (2.2,8.4) 
1.71 {1.2,8.4,15.2) 
1.58 {2.3,4.1,15.2) 
3.89 {m) 
3.59 {3.8,11.2) 
3.54 (6.7,11.2) 
Myc.Acis 
oxazolidinone 
(CDm) 
3.91 {2.7,6.5) 
1.17 {6.6) 
2.19 (2.7,7.1) 
1.02 {7.0) 
4.80 {2.0) 
4.66 {2.1) 
2.37 {2.0,13.8) 
2.32 {14.0) 
3.27 
4.39 {1.7) 
5.65 (1.8,8.5) 
3.73 {6.6,8.6) 
3.89 (6.6,9.6) 
3.04 {9.5) 
3.58 . 
0.97 
0.86 
3.60 (1.7,10.0) 
1.74 {1.7,5.3,14.6) 
1.48 (6.9,10.1,14.7) 
3.89 (m) 
3.59 (3.8,11.2) 
3.51 { 4.8,11.3) 
Myc.A trans 
oxazolidinone 
(CDj)O) 
3.91 (2.6,6.5) 
1.17 (6.6) 
2.21 (2.6,7.0) 
1.01 {7 .0) 
4.82 (1.9) 
4.67 {2.0) 
2.41 (2.0 ,13.9) 
2.28 (13.8) 
3.28 
4.45 {2.6) 
5.51 (2.6,3.4) 
3.85 (3.6,5.0) 
3.92 (5.1,6.5) 
3.10 (6.6) 
3.51 
1.06 
0.87 
3.62 (2.9,1 0.2) 
1.81 (5.7,9.9,14.5) 
1.68 (2.9,6.6,14.7) 
3.78 (m) 
3.54 (4.3,11.2) 
3.49 (4.8,11.3) 
7SMyc.A cis 
oxazolidinone 
(§.7) 
3.95 (2.6,6.6) 
1.15 (6.5) 
2.19 (2.3,6.7) 
0.99 (6.7) 
4.82 (2.1) 
4.70 (2.0) 
3.05 (2.1,14.3) 
2.1~ (14.2) 
3.36 
4.33 (1.3) 
8.04 
5.6 (1.4,6.9) 
4.06 (6.0,6.7) 
4.01 (6.1 ,8.3) 
3.04 (8.1) 
3.59 
0.98 
0.86 
3.47 (3.1,9.5) 
1.62 (m) 
1.55 (m) 
3.88 (m) 
3.59 (m) 
3.59 (m) 
7 S Myc.A trans 
oxazolidinone 
(5&) 
3.94 (2.4,6.6) 
1.17 (6.5) 
2.20 (2.4,6.7) 
1.02 (7.0) 
4.83 {2.0) 
4.71 {2.1) 
2.92 (2.0,14.4) 
2.13 (14.3) 
3.43 
4.28 (2.1) 
6.67 
5.67 (2.2,8.6) 
3.84 (6.9,8.7) 
3.97 {6.9,9.7) 
2.95 (9.7) 
3.60 
0.97 
0.88 
3.61 (m) 
1.55 (m) 
1.55 (m) 
3.86 (m) 
3.57 (m) 
3.50 (6.3,11.2) 
aAn data were recorded in CDCI3, unless otherwise specified, with chemical shifts in ppm relative to CHCIJ, 67.25 or CHD20D, 63.30 {coupling 
constants in Hz). 
Table 5.2 13C NMR dataa for mycalamide A and B oxazolidinones and derivatives and selected linewidthsa. 
Myc.A cis Myc.A trans N-Acetyl A trans Myc.B cis 12, 17, 18-tri-0-Me, 12, 17, 18-tri-0-Me, 
oxazolidinone oxazolidinone oxazolidinone oxazolidinone N-methyl A trans N-methyl 7 SA cis 
(5.2) ~Jl ldacetate (~.l Jl ~.9} Q~azQ,(~.H) Q~i.lZQ,(~.l~) 
C2 69.31 (2.3) 69.29 (2.5) 69.51 69.18 69.08 69.39 
2-CH3 17.87 (2.3) 17.86 (2.3) 17.82 17.89 17.96 17.46 
C3 41.72 (2.2) 41.61 (2.3) 41.41 41.77 41.76 41.60 
3·CH3 11.70 (2.3) 11.80 (2.2) 11.67 11.77 11.84 11.80 
C4 146.07 (2.2) 146.37 (2.2) 145.60 ? 146.94 146.93 
4:CH2 110.03 (2.7) 109.75 (2.9) 110.39 109.64 109.30 109.26 
C5 33.76 (2.4) 33.65 (2.7) 33.53 33.81 33.64 32.80 
C6 98.82 (1.9) 99.28 (1.8) 99.44 98.32 99.30 98.61 
6-0CH3 48.54 (1.9) 48.81 (2.7) 48.68 48.62 48A1 50.87 
C7 75.68 (2.4) 77.12 (3.0) 78.09 74.96 78.21 80.87 
ca 170.02 (2.1) 171 .63 (2.2) 170.61 ? 168.46 168.89 
N-CH3 27.53 28.96 
C1 0 80.83 (2.6) 86.41 (2.8) 92.49 80.84 94.70 89.67 
C11 77.58 (2.8) 74.12 (10.2) 71.90 ? 70.50 71.75 
C12 68.89 (2.1) 68.89 (3.6) 70.49 69.04 79.53 74.89 
12-0CH3 59.20 57.28 
C13 88.02 (2.1) 86.88 (2.6) 83.97 88.02 85.06 81.21 
13-0CH3 63.09 (2.0) 61.73 (2.9) 61.88 63.00 61.31 59.34 
C14 41.50 (2.4) 39.81 (4.3) 41.50 ? ? 36.35 
14-CH3R 23.42 (2.2) 24.43 (4.0) 23.53 23.41 24.01 27.27 
14-CH3S 13.78 (2.7) 16.28 (8.4) 14.06 13.67 15.40 22.69 
C15 78.58 (2.3) 79.56 (5.0) 77.22 75.63 76.69 78.18 
C16 31.44 (2.5) 31.01 (3.4) 29.95 29.45 29.88 29.45 
C17 72.04 (2.1) 72.48 (2.4) 70.14 78.92 76.89 78.18 
11-0CH3 56.94 57.11 57.62 
C18 66.74 (2.2) 66.76 64.93 62.94 70.72 72.61 
18-0CH3 59.23 58.80 
NCOCH3 24.52 
3x-OCOCH3 21.12,20.99 
20.76 
1\.) 
(J) 
aAII data were recorded in CDCI3, with chemical shifts in ppm relative to CDCI3, o77.01 (linewidths in Hz). ()1 
Table 5.3 2JcH and 3JcH HMBC correlationsa for mycalamide A trans 
oxazolidinone {5.3). 
2-CHs 
3-CHs 
2x4=CH 
2xH5 
6-0CH3 
H7 
H13 
13-0CH3 
14-CH3R 
14-CH3S 
aAII data were recorded in CDCI3 • 
Carbon signal correlated 
C2,C3 
C2, C3, C4 
C3,C5 
C4, 4=CH2, C6 
C6 
C6 
C12, 13-0CH3, C14 
C13 
C13, C14, 14-CH3S, C15 
C13, C14, 14-CH3R, C15 
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Table 5.4 1 H-1 H NOE interactionsa for compounds in Sections 5.2-5.6. 
Slgnal(s) Signals enhanced 
CQmllQI.ID~ lrra~lale~ COt:~ eobaocemenn 
Myc.A cis oxazol. HSa 3-CHs(0.6), H5e(10}, H7(1) 
(5.2) HSe 4=CHE(3), H5a(12}, H11 (1), H7(0.4} 
H7 6-0CHs(2), H10(1) 
H10 H7(2), H11(2), H13(7), H15(6) 
H11 (H17) H5a(1), H5e(1), H10(2}, H16d(1}b,c 
H13 H10(8), 13-0CH3 (2), 14-CHsR(1), H15(2) 
14-CHsR H13(4), 13-0CHs(1), 14-CH3S(1), H15(3), H16d(2)0 
14-CHsS H12(5), H16d(2)0 , H16u(3}c 
H15 (13-0CHs. H10(7}, H13(10)b, 14-CH3R(2), 14-CH3S(0.4)b, 
H218) 2xH16(2)b, H17(4)b 
H216 14-CH3R(1), 14-CH3S(1), H15/H218(2), H17(4) 
Myc.A trans oxazol. H5a 3-CH3(0.5}, H5e(8), H7(1), H10(0.4) (5.3) H5e 4=CHE(2), H5a(9), H7(0.4), H1 0(1} 
H7 H5a(1), 6-0CH3(2), H11(0.5), H13(0.9) 
H10 H5a(0.4), H5e(0.8), H11(2), H12(1), H13(3), H15(2) 
H11 (H2, H17) 2-CHs(1}b, H3(2)b, H5a(0.4)b, 6-0CHs(O.G)b, H7(0.8), 
H10(3), H16d(1}b,c 
H13 H10(4), H12(2), 13-0CH3(2), 14-CHsS(0.4), 
14-CH3R(1}, H15(2) 
14-CHsR {3-CHs} H3(4)b, H13(4), 13-0CH3(1), 14-CH38(1), H15(3), 
H16u(3)0 
14-CH3S H12(4), H13(1), H16d(2)c, H16u(1)c 
H15 (13-0CHs, H10(4), H13(7), 14-CH3R(1), 14-CH3S(0.4), 
H218) 2xH16(2)b, H17(5)b 
H216 H11(2), 13-0CHs(1}, 14-CH3R(1}, 14-CHsS{1), 
H15/H18u(2}0 , H17(3) 
Myc.A trans oxazol. H10 H5e(1}, H11(4), H12{1), H13(2}, H15(2} 
(5.3) in CD30D H13 H10(2}, H12(2), 13-0CH3(2), 14-CH3R(1), H15{3) 
14-CHsS H12{4), H13 (1 ), 14-CH3R(1) 
H15 (13-0CHs) H10(3), H13(3), 14-CH3S{0.3), 14-CHsR(1) 
7SMyc.A cis H5a (H13) 3-CH3{0.8}, H5e(16), H7{2}, H10(4)b, 13-0CH3{1}b, 
oxazolidinone 14-CH3R{1)b, H15{2}b 
(5.7) H5e 4=CHE(4), H5a(16), H7(2} 
H7 H5e(1), 6-0CHs(1) 
H10 H7(1), H13(3), H15(3) 
Myc.B cis oxazol. H7 6-0CHs(2) 
(5.9) H10 H13(5), H15(5) 
aAII data were recorded in CDCis, unless otherwise specified. 
bEnhancement interpreted as being due to the irradiation of an overlapping signal 
0u and d have been used to designate the upfield and downfield resonances of a geminal pair 
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Table 5.5 Molecular modelling results for structures 5.4A, 5.48, 5.5A 
and 5.58. 
Dihedral VIcinal coupling 
%a MM2b Conf.C anglesd constants 9 (dlhed.angle) H-Bonds 
~o~rg~ c~ul~ a} bl kl JH1·:1 :1 J:l:l-:12 J:l2-la (~fjlQtt-Ql 
5.4A 
57.7 139.4 +A- 51 165 -112 8.8(176) 5.6(47) 9.1 (-175) 9-12 
24.3 141.5 -A- -80 164 -111 1.9(49} 6.2(42) 8.9(-173) 
5.9 145.1 ++- 47 59 -99 8.9(172} 5.6(47) 9.0(-174) 9-12 
4.0 146.1 A+- 153 54 -97 2.0(-75) 6.5(40) 8.6(-170) 12-10 
3.7 146.3 
-+- -82 69 -99 2.1(47) 6.2(43) 8.7(-171) 
2.8 146.9 AA- 152 166 -113 1.9(-76) 6.4(41) 8.8(-172} 
1.1 149.4 -88 -71 -99 2.7(42) 6.6(39) 8.4(-168} 12-10 
0.5 151.1 +AA 48 171 -155 8.9(172) 5.7(47) 8. 7(-171} 9-12,12-13 
5.4B 
49.0 130.3 A+- -177 89 -88 4.4(-52) 1.2(-54) 2.3(-73) 
19.1 132.7 A+- -179 119 -88 4.2(-54) 1.1(-54) 2.3(-72) 
12.4 133.8 AA- -177 144 -88 4.4{-52) 1.2(-54) 2.2(-74) 
9.4 134.4 -60 -14 -88 0.8{64) 1.0(-57) 2.3(-73) 12-10 
6.8 135.3 -+- -67 56 -87 1.2(58) 0.8(-59) 2.4(-72) 12-10 
2.1 138.2 +-- 66 -36 -88 8.0(-171) 1.0(-56) 2.3(-73) 
0.7 140.9 A-- -175 -36 -87 4.5(-51) 0.9(-58) 2.4(-72) 
0.5 142.0 +A- 66 179 -89 8.0(-170) 1.4( -52} 2.1(-75) 
S.SA 
48.9 142.6 -A- -83 163 -113 1.4(-75) 6.5(40) 8.7(-171) 
17.0 145.2 -+- -83 66 -99 1.4(-76) 6.6(40} 8.4(-169) 
12.0 146.1 +A- 54 165 -116 2.2(57) . 6.7(39) 8.8(-172) 
10.3 146.5 AA- 163 164 -111 8.5(169) 5.7(47) 9.0(-174) 
9.6 146.7 A+- 161 43 -97 8.5(167) 6.0(44) 8.7(-171) 12-10 
1.6 151.1 ++- 51 64 -100 2.5(54) 6.6(39) 8.6(-170) 
0.6 153.7 A-- 166 -49 -102 8.6(171) 5.5(49) 9.0(-174) 12-10 
5.5B 
40.6 138.2 A+- 174 87 -58 8.7(177) 0.7(-59) 2.8(-69) 
29.1 139.0 +A- 68 -180 -64 1.3(69) 1.0(-57) 2.4(-72) 9-12 
12.2 141.2 AA- 172 152 -57 8.7(176) 0.7(-60) 2.7{-70) 
8.9 142.0 A-- 172 -29 -55 8.7(175) 0.5(-63) 3.0(-67} 12-11 
5.4 143.2 -62 -18 -55 2.7(-59) 0.5(-63) 2.8(-68} 12-10,12-11 
2.8 144.9 +-- 62 -38 -55 1.9(61) 0.3(-65) 3.0(-67) 9-12,12-11 
1.1 147.1 
-+- -70 70 -60 2.1 (-65) 0.4(-64) 2.9(-68) 12-10 
aRelative population (Boltzmann distribution) bin kJ mol-1 °Code for dihedral angles a)-e) 
where 'A'=anti, '+'=(+)gauche,'-'=(-) gauche conformations doihedral angles:- a) O-C10-C11-0 
b) C11-C12-0-H c) C12-C13-0-CHg 9 Calculated coupling constants in Hz. 
Table 5.6 Molecular modelling results for structures 5.5C and 5.50. 
MM2b Conf.c Dihedral anglesd VIcinal coupling constants {dihedral angle}e H·Bonds 
~a ~n~rgl£ "Qtl~ ~l t!l "l til ~l ,11 ~-HHl ,11 ~-12~ ,J12fl-17 !.112S-17 !.117-HHi !il17·1~~ {QH-Q} 
35.3 146.9 AAA+- 179 164 179 63 -55 2.2(60) 11.6(177) 1.0(-78) 10.4(167) 10.5(-178) 3.1 (60) 17-15;18-17 
23.8 147.8 AA+++ 179 164 62 59 53 2.2(59) 11.6(177) 1.0(-79) 10.3(166) 0.6(65) 3.2(-57) 1 7-15; 18-17 
12.7 149.4 A+AAA -179 61 174 -178 -180 2.0(62) 11.6(179) 11.3(175) 4.2(59) 1 0.8(179) 3.5(56) 17-18 
5.7 151.4 A+A+- -177 64 175 69 -55 1.8(64) 11.4(-179) 11.4(178) 3.8(62) 1 0.7(180) 3.3(58) 18-17 
5.1 151.7 A++++ -179 60 58 64 55 1.9(63) 11.5(180) 11.1(173) 4.4(58) 0.8(61) 2.9(-60) 18-17 
3.9 152.4 A++-A -180 59 57 -70 175 2.0(62) 11.6(179) 11.1 (173) 4.5(58) 0.9(60) 2.8(-61) 17-18 
3.2 152.8 AA-+A -179 165 -66 62 -176 2.0(61) 11.6(178) 1.0(-78) 1 0.4(167) 4.7(-62) 10.6{177) 17-15 
2.5 153.5 A+AA+ -180 62 178 -175 83 2.1(61) 11.6(179) 11.3(176} 4.1 {60) 1 0.4(-177) 3.0(61) 17-18 
2.2 153.8 A-AAA -168 -70 -171 177 -177 1.2(72) 10.9(-171) 5.6(49) 1.4(;66) 9.4(-169) 2.3(68) 17-18 
0.9 156.0 AA++A 179 162 53 59 175 2.2(60) 11.6(177) 1.0(-79) 10.2(165) 1.3{56) 2.3(-65) 17-15 
0.9 156.0 AAA+A -180 164 -172 65 -176 2.1(61) 11.6(178) 1.0(-78) 10.4{167) 9.6{-170) 2.2(68) 17-15 
0.8 156.4 AAAAA -169 171 179 -172 -178 1.3(71) 11.0(-172) 1.2(-71) 11.1(174) 10.6(-179) 3.2(59) 17-18 
0.7 156.7 AA+-A -161 -178 60 -42 170 1.0(80) 10.0(-163) 2.2(-60) 11.7(-175) 0.8(61) 2.8(-60) 
0.6 157.0 AA-+- 180 164 -69 58 -77 2.1(61) 11.6(178) 1.0(-79) 1 0.3{166) 4.1 (-66) 10.5{173) 17-15 
0.6 157.2 A+++A -178 59 49 65 175 1.8(64) 11.5(-179) 11.2(174) 4.4(58) 1.6{52) 2.1 {-68) 
49.4 136.6 AAA+- -176 168 180 73 -55 2.2(60) 11.6{176) 1.1 (-73) 11.1{173) 10.4{-177) 3.0(61) 17-10, 15;18-17 
32.8 137.6 AA+++ -176 165 64 72 52 2.2(59) 11.7(175) 1.0(-76) 10.8(171) 0.6(66) 3.4(-55)17-1 0, 15;18-17 
4.1 142.8 A+AAA 175 59 175 -177 179 3.0(53) 11.6(169) 11.2(175) 4.0(61) 1 0.7(179) 3.5(57) 17-18 
3.5 143.1 AA-+A -176 165 -66 73 -176 2.2{60) 11.7(176) 1.0(-75) 10.9(171) 4.6{-63) 10.6(176) 17-10,15 
2.2 144.3 A+AA- 175 58 170 156 -82 3.0(53) 11.6(169) 11.2(174) 4.1 (60) 11.1(173) 4.2(51) 
1.3 145.6 A+AA+ 175 60 180 -175 82 3.1 (52) 11.6{168) 11.3(175) 3.9(61) 10.3{-176) 2.8(62) 17-18 
1.1 146.0 AA++A -176 163 55 72 175 2.3(59) 11.7{175) 1.0(-76) 10.8(170) 1.2{56) 2.4(-64) 17-10,15 
1.0 146.2 AAA+A -176 166 -171 75 -178 2.2(60) 11.7(176) 1.1(-75) 10.9(172) 9.6(-170) 2.2(69} 17-10,15 
1.0 146.4 A++-A 177 60 58 -70 175 2.7(55) 11.7(171) 11.3(175) 3.9(61) 0.8(61) 2.9(-59) 17-18 
0.8 146.7 A+A+- 178 62 176 70 -55 2.8{55} 11.7{171) 11.4(177) 3.7(63) 10.6(180) 3.3(58) 18-17 
0.8 146.8 A++++ 179 61 59 65 55 2.5(57) 11.7(173) 11.3(176) 3.8(62) 0.8(62) 3.0(-58) 18-17 
0.7 147.3 AA-+- -175 166 -70 71 -76 2.1 (60) 11.6(176) 1.0(-75) 10.9(171) 4.1 (-66) 1 0.5(173) 17-10,15 
0.6 147.5 A-AAA -162 -61 -172 178 -176 1.1 (73) 10.9(-172) 4.3(57) 2.6{-55) 9.5(-169) 2.3(68) 17-18 
aRelative population (Boltzmann distribution) bJn kJ mol-1 ccode for dihedral angles a)-e) where 'A'=anti, '+'=(+)gauche,·-·= H gauche conformations 1\) 
dDihedral angles:- a) C14-C15-C16-C17 b) C15-C16-C17-C18 c) C16-C17-C18-0 d) C16-C17-0-H e) C17-C18-0-H 6 Calculated couplings in Hz. 0) 
(.0 
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Table 5.7 Comparison of experimental coupling constants for compounds 
5.2 and 5.3 with calculated average values for conformers of 
structures 5.4A, 5.48, 5.5A, 5.58, 5.5C and 5.50. 
Structures Coup. 
VIcinal coupling constantsa 
Experimental Calculated average valuesb 
con st. CDCia CDaOD A( C) B(D) Ratlosc {5.5A/5.5B) 
§tr §tr !lUl% §5% 80°& 75% 7Q 0& 
5.2, 5.4A/B J1 0-11 8.9 8.5 6.4 3.9 
J11-12 6.8 6.6 5.8 1.1 
J12-13 9.7 9.6 9.0 2.3 
5.3, 5.5A/B J1 0-11 5.3 3.5 3.0 6.0 3.3 3.5 3.6 3.8 3.9 
J11-12 5.6 5.1 6.4 0.7 5.8 5.5 5.3 5.0 4.7 
J12-13 7.5 6.6 8.7 2.7 8.1 7.8 7.5 7.2 6.9 
5.3, 5.5C/D J15-16R 2.2 2.9 2.1 2.2 
J15-16S 9.6 10.1 11.6 11.6 
J16R-17 4.1 6.6 4.2 1.8 
J16S-17 8.4 5.7 8.3 10.4 
J17-18R 6.7 4.8 6.8 7.8 
J17-18S 3.8 4.3 3.5 3.3 
acoupling constants in Hz bcalculated constants were averaged over all conformers using a 
Boltzmann distribution on the energies cRatios of the calculated average values for structure 
5.5A over those for structure 5.58. 
Table 5.8 Summary of syntheses and reactions of mycalamide 
oxazolidinones for various bases and solventsa. 
Compound Base Solvent Temp. Time Product§ C% of totall 
Mycalamide A NaOH (2M) 50% H20/MeOH 55 10 5.2(35),5.3(35),5.7(15),5.8(15) 
NaOMe (1M) MeOH 20 24 5.2(55),5.3(45) 
NaOCD3 (3M) CD30D 20+50 24+2 5.2(40),5.3(30}, (mixed prods) 
BaO DMSO 50 16 5.2(70),5.3(30) 
KOH DMSO 20 96 5.2(>90) 
KOH DMSO 80+ 105 24+24 5.6(>90} 
Mycalamide B NaOMe (1M) MeOH 20+40 24+24 5.9(35},5.10(35), (C7-epimers + ?) 
KOH DMSO 40 24 5.9(65),5.10{35} 
A cis ox. (5.2) NaOCD3 (4M) CD30D 70 2 5.2(50), (mixed prods - no 5.3) 
A trans {5.3) NaOH (1M) 40% H20/MeOH 60 24 5.2(60), (5.3 +decamp.) 
KOH DMSO 20 96 5.3(>90, no reaction} 
aremperature in °C, reaction time in hours. 
Table 5.9 1 H NMR dataa for mycalamide A and B oxazolidinone derivatives 
Myc.B cis Myc.B trans N-Acetyl A 12, 17, 18-tri-0-Me, 12, 17, 18-tri-0-Me, 12, 17, 18-tri-0-Me, 8, 12, 17, 18-tetra-
oxazolidinone oxazolidinone trans oxazo. N-Me 7SA cis N-Me A trans N-Me 7 SA trans 0-Me, myc.A cis 
(5.9) (5JO) lda~~l.£5,13) ~~Q.(5.15) ~~.(5.H) Ql!;azQ,£5,16) Ql!iazQ,(5.1Z) 
H2 3.93 (2.3,6.6) 3.94 (2.6,6.6) 3.95 (2.6,6.5) 3.86 (2.5,6.7) 3.93 (2.5,6.6) 3.80 (2.7,6.5) 3.94 (2.6,6.6) 
2-CH3 1.19 (6.6) 1.18 (6.2) 1.19 (6.6) 1.15(6.7) 1.19 (6.6) 1.08 (6.5) 1.17 (6.6) 
H3 2.19 (2.4,7.0) 2.21 (2.6,6.6) 2.20 (2.5,7.0) 2.17 (2.7,7.0) 2.20 (2.6,7.1) 2.16 (2.5,6.9) 2.19 (2.5,7.1) 
3-CH3 1.04 (7.0) 1.04 (6.8) 1.00 (7.0) 0.96 (7.0) 1.05 (7.0) 0.96 (7.0) 1.00 (7.0) 
4:CHZ 4.82 (1.8) 4.84 (2.0) 4.86 (1.8) 4.80 (2.0) 4.82 (1.9) 4.80 (2.1) 4.81 (2.0) 
4:CHE 4.70 (1.9) 4.72 (1.8) 4.75 (1.8) 4.68 (2.0) 4.68 (1.9) 4.69 (2.0) 4.65 (2.0) 
H5a 2.39 (1.8, 13.7) 2.47 (2.0, 13.7) 2.21 (1.8, 13.8) 3.20 (2.0,14.2) 2.29 (1.9, 13.8) 3.19 (2.1,14.0) 2.07 (2.0, 14.0) 
H5e 2.33 (13.8) 2.32 (13.8) 2.37 (13.8) 2.00 (14.1) 2.20 (13.6) 1.99 (13.9) 2.30 (14.0) 
6-0CH3 3.30 3.30 3.32 3.40 3.31 • 3.33 3.25 
H7 4.34 (1.9) 4.38 (2.2) 4.63 (1.5) 4.26 4.51 (2.5) 4.20 (2.3) 4.63 (3.2) 
8-0CH3 3.94 
NH9 6.65 
N-CH3 3.00 2.95 2.87 
H10 5.52 (1.6,8.8) 5.57 (2.2,6.1) 6.00 (1.4, 1.4) 5.16 (7.5) 5.28 (2.4) 5.44 (2.1) 5.69 (3.0,8.3) 
H11 3.84 (6.6,8.7) 3.80 (5.1 ,6.1) 4.50 (1.4,6.8) 4.01 (2.3,7.6) 4.07 (2.0,6.1) 4.15 (1.9,7.4) 3.76 (5.8,8.3) 
H12 3.94 (6.7,9;6) 3.97 (5.1 ,7.4) 5.02 (6.7,9.5) 3.52 (2.3,2.7) 3.51 (5.8,7.8) 3.63 (7.5,9.7) 3.51 (5.8,8.0) 
12-0CH3 3.41 3.37 3.49 3.46 
H13 2.95 (9.8) 2.93 (7.3) 3.39 (9.4) 2.97 (2.7) 3.27 (8.0) 3.47 (9.7) 3.04 (8.0) 
13-0CH3 3.59 3.54 3.48 3.35 3.48 3.52 3.53 
14-CH3R 0.97 1.03 0.94 1.16 0.96 0.89 0.99 
14-CH3S 0.89 0.88 0.88 0.91 0.86 0.84 0.89 
H15 3.46 (3.9,8.3) 3.40 (2.6, 1 0 .5) 3.77 (5.0,7.5) 3.45 (3.6, 12.0) 3.62 (2.4,9.6) 3.72 (1.5, 10.4) 3.27 (m) 
H16 1.67 (m) 1.85 (m) 1.73 (m) 2.29 (7 .4, 11 .6, 14.3) 1.74 (4.4,9.6, 14.2) 1.68 (1.4,8.2,14.7) 1.75 (m) 
H16 1.67 (m) 1.70 (m) 1.73 (m) 1.64 (3.4,9.9, 14. 7) 1.63 (2.4,8.0, 14.2) 1.44 (2.6, 1 0.3, 14.5) 1.75 (m) 
H17 3.64 (m) 3.50 (m) 5.23 (m) 3.26 (m) 3.43 (m) 3.30 (m) 3.71 (m) 
17-0CH3 3.38 3.43 3.34 3.38 3.32 3.36 
H18 3.79 (4.6, 11.7) 3.78 (4.5, 11.2) 4.26 (3.3, 12.1) 3.51 (2.7,9.1) 3.48 (m) 3.37 (m) 3.53 (m) 
H18 3.69 (5.1 '11.7) 3.62 (6.5, 11.2) 4.12 (6.7,12.1) 3.40 (m) 3.43 (m) 3.31 (m) 3.45 (m) 
18-0CH3 3.35 3.38 3.49 3.38 
aAII data were recorded in CDCJs, with chemical shifts in ppm relative to CHCIJ, o7.25 (coupling constants in Hz). 1"\) 
"' ...... 
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Table 5.10 1 H-1 H NOE interactionsa for compounds in Section 5.7. 
Signal(s) Signals enhanced 
Compound irradiated C% enhancement> 
N-Acetyl myc.A HSa (H3) H2(9)b, 2-CH3(0.5)b, 3-CH3(3), 4=CHZ(5)b, 
trans oxazo.triacet. H5e(21), H7(2), H10(1) 
(5.13) HSe 4=CHE(6), H5a(14), H7(0.7), H10(2) 
H7 6-0CH3(2), H13(4), 13-0CH3(0.3) 
NCOCH3 H10(0.8) 
H10 H5e(1), NCOCHs(0.4), H11(6), H15(3) 
H11 H10(8), H12(11) 
H12 H11(10), H13(1), 13-0CH3(0.3), 14-CH3S(2) 
H13 H7(7), H12(1), 13-0CH3 (2), 14-CH3R(1), 
H15(7) 
H15 H10(5), H13(5), 14-CH3R(1), H17(4), H18d(2)c 
H216 (OAc) H11(3)b, 14-CH3S(2), 14-CH3 R(1), H15(6), H17(9), 
2xH18(2) 
H17 H10(0.9), H15(3), H216(2), H18d(3)c, H18u(2)c 
H18dC H10(0.5), H15(0.8), H17(5), H18u(11)c 
H18uc H10(2), H17(2), H18d{17)c 
12,17, 18-tri-0-Me, HSa 3-CHs(1), H5e(7), H7(1), H10(0.7) 
N-Me myc.A trans HSe (H3) H2(5)b, 2-CH3(0.7)b, 3-CH3(2)b, 4=CHE(3), 
oxazo. (5.14) 4=CHZ(4)b, N-CH3(0.2), H10 (1) 
H7 6-0CH3 (2), H13(2) 
N-CHs H1 0(4), H11 (5), 12-0CH3 (0.9) 
H10 H5e(0.7), N-CH3(1), H11(4), H15(2), H17/H18(1) 
H11 H7(0.9), N-CH3 (2), H1 0(6), H12(6), 12-0CH3 (0.5) 
H12 (13-0CHs) H11(8), 12/18-0CH3(1), H13(4), 14-CH3S(1) 
H13 (6-0CHs) H7(6)b, 13-0CH3(2), 14-CH3R(1), H15(4) 
14-CHsR H13(5), 13-0CH3(0.8), H15(4) 
14-CHsS H12(4), 14-CH3 R(0.7), H16(3) 
H15 H10(4), H13(4), 14-CH3R(0.9), H17/H18(1) 
H216 H11(2), 14-CH3 S(1), 14-CH3R(0.8), H15(4), 
H17/H18(6), 17/18-0CH3 (0.4) 
12, 17,18-tri-Q-Me, H2 H3(5), 2-CH3(1 ), 6-0CH3(0.8) 
N-Me 7 S myc.A HSa 3-CH3 (0.8), H5e(22), H7(2), H11 (1 ), H12(0.8) 
cis oxazo. (5.15) HSe 4=CHE(5), H5a(20), H7(5), H12 (1) 
H7 H5a(0.6), H5e(1 ), 6-0CHs(O.S), H1 0(1) 
N-CH3 (H13) H10(7), H12(1), 12-0CH3(0.6), H17(1) 
H10 H7(1), N-CH3 (1}, H11(1), H12(0.8) 
H11 H5a(0.9), N-CH3(0.3), H10(2), H12(5), H16S(5), 
H17(2) 
H12 (H18) H5a(0.9), H5e(0.8), H1 0(2), H11 (6), 12-0CHs(2), 
H13(3), 13/17/18-0CH3(1), H17(2)b 
H13 H12(3), 12-0CH3(1 ), 13-0CH3 (2), 14-CHsS(0.4), 
14-CH3 R(O. 7) 
14-CH3R (2-CH3) H2{S)b, H3(3)b, 3-CH3(0.7), H10(1), 12-0CH3(0.9), 
H13(6), 13/17/18-0CH3(0.5), 14-CH3S(1), H15(4) 
14-CHsS H12(1), H13(4), 14-CH3R(1), H15(4), H16R(2) 
H16S H11(4), H16R(3) 
aAII data were recorded in CDCis 
bEnhancement interpreted as being due to the irradiation of an overlapping signal 
cu and d have been used to designate the upfield and downfield resonances of a geminal pair 
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Table 5.10 cont'd 1 H-1 H NOE interactionsa for compounds in Section 5.7. 
Compound 
12, 17, 18-tri-G-Me, 
N-Me 7 5 myc.A 
trans oxazo. (5.16) 
8, 12, 17, 18-tetra-
0-Me myc.A cis 
oxazo. (5.17) 
Slgnal(s) 
Irradiated 
H2 
H5a 
H5e 
H7 (H11) 
N-CH3 
H10 
H11 
14-CH3R 
14-CH35 
H15 
H7 (4=CHE) 
H10 • 
aAII data were recorded in CDCI3 
Signals enhanced 
(% enhancement) 
H3(3), 2-CH3(0.7), 6-0CH3(0.4) 
3-CH3(1), H5e(18), H7(2) 
4=CHE(4), H5a(21), H7(4) 
H5e(2), 6-0CH3(0.4), H15(4), H17(2) 
H10(2), H11(4) 
N-CH3(0.9), H11(8), 12-0CH3(0.9), H13 (2) 
N-CH3(2), H1 0(1 0), H12(5), 12-0CH3(0.6) 
H13(5), 13-0CH3(1), H15(5) 
H12(5) 
H7(5), H13(5), 14-CH3R(1), H17(3) 
4=CHZ(11)b, 6-0CH3(2) 
H13(7), H15(4) 
bEnhancement interpreted as being due to the irradiation of an overlapping signal 
cu and d have been used to designate the upfield and downfield resonances of a geminal pair 
Table 5.11 Biological assay results for compounds in Chapter 5. 
CQ!I!PQ!.!Dd Paaa ICsoa Antiviral R~sul1sb (ngLdisk) 
Mycalamide A 0.5 WN WN +* 5 + + +* 2 
Mycalamide B 0.1 WN WN +* 2 +++ +++ +* 1 
Myc.A cis oxazolidinone (5.2) 300 WN WN +* 5000 +++ ++ +* 2000 
Myc.A trans oxazolidinone (5.3) 400 WN WN +* 5000 + ++ +* 2000 
Myc.B cis oxazolidinone (5.8) 21 WN WN +* 500 +++ ++ +* 200 
Myc.B trans oxazolidinone (5.9) 95 WN WN +* 4000 +++ +++ +* 2000 
105 Neomyc.A oxazo. (5.11) 600 WN WN +* 10000 ++ +++ +* 2500 
10R Neomyc.A oxazo. (5.12) 800 WN WN +* 10000 2500 
N-acet.A trans oxazo.triacet. 5000 - 40000 
(5;13) 
12,17,18-tri-0-Me, N-Me myc.A 
trans oxazolidinone (5.14) >12500 - 40000 
12,17,18-tri-G-Me, N-Me 75 
myc.A cis oxazo. (5.15) >12500 - 40000 
12,17,18-tri-G-Me, N-Me 75 
myc.A trans oxazo. (5.16) >12500 - 40000 
a In ng/ml. The derivatives are estimated to be better than 95% pure, having been subjected to 
at least two steps of chromatographic purification in most cases. 
b -,+,++,+++,WW=antiviral zone size. Results are listed in the order of Herpes simplex virus, 
Polio virus, cytotoxicity, loaded sample mass. 
CHAPTER 6 
REACTIONS OF MYCALAMIDES A & B 
AND DERIVATIVES UNDER BASIC 
CONDITIONS 
PART 2 
6.1 INTRODUCTION 
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The C1 O-C12 dioxan ·ring, having an a-N-amido group at C1 0, is a 
substructure unique to mycalamides A and B and onnamide A228. The 
possible biological importance of this substructure was postulated in a recent 
paper reporting the synthesis of mycalamides A and B, with the possibility of 
eliminative cleavage of the C1 0-0 bond causing activation of this system91. 
Exchange reactions were performed at the C1 0 aza acetal site in pederin, but 
only acid catalysed conditions were studied, for which protection of the 
exocyclic double bond was required127,130. Pederin was apparently stable to 
. 
refluxing with dilute sodium methoxide in methanol27, but it is still likely that 
base catalysed reactions could occur under more forcing conditions. 
The observed base catalysed reactions of mycalamides A and B in the 
preceding chapter (5) suggested that the C1 0 position could be a general site 
for nucleophilic substitution under basic conditions. In order to study this 
further, and to consider the possibility of base catalysed amide hydrolysis, it 
was clearly necessary to use a base stable protecting group for the C7 
hydroxyl group to prevent formation of the oxazolidinones. Esters and silyl 
ethers were not sufficiently base stable 131.138 but the mycalamide methyl and 
benzyl ethers, whose preparations were described in Chapter 2, were 
expected to be quite stable to such conditions138. The mycalamide methyl 
ether derivatives suffered from the disadvantages of being poorly resolved on 
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various chromatographic systems and that the protecting groups were not 
selectively removable, whereas the benzyl ethers were better suited in both 
respects. Furthermore, the C7 hydroxyl group was the first site to undergo 
alkylation under normal conditions, so that various suitably protected 
derivatives had been synthesised, and these provided a useful starting point 
for further base reactivity studies. 
6.2 PREPARATION AND CHARACTERISATION OF PRODUCTS 
FROM THE REACTION OF 7-0-ALKYL, N-ALKYLATED 
MYCALAMIDE B WITH POTASSIUM HYDROXIDE IN DMSO 
6.2.1 PREPARATION AND PURIFICATION OF PRODUCTS FROM A TRI-
BENZYLATED MYCALAMIDE B DERIVATIVE 
The mycalamide benzyl ether which had been prepared in the largest 
quantity was the fully substituted compound, 7, 18-di-0-benzyl, N-benzyl 
mycalamide B (2.46), which was also readily formed from mycalamide 8 in 
high yield and represented a well protected derivative. This derivative was 
treated with potassium hydroxide in DMSO at sooc until most of the starting 
material had disappeared, as monitored by silica gel TLC. Workup and 
preparative TLC gave a number of fractions, including one of unreacted 
starting material, but, of the remainder, only one, more polar fraction was pure, 
as shown by 1 H NMR spectroscopy, and this fraction represented about half of 
the product mass by weight. The remaining fractions were complex mixtures, 
with no identifiable components apparent, and no attempt was made to purify 
these fractions further. 
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6.2.2 SPECTROSCOPIC CHARACTERISATION OF THE MAJOR PRODUCT 
The starting compound, 7, 18-di-0-benzyl, N-benzyl mycalamide B 
(2.46), had a molecular formula of C4sHs1N01o- HRCIMS of the major 
product indicated a compound of molecular formula C2gHs1N07, so that this 
was clearly a cleavage product. The molecular ion (MH+) also appeared to 
lose CO readily. An FTIR spectrum showed a strong carbonyl stretching band 
at 1689 cm-1, so that the amide functionality was still present. The 1 H NMR 
spectrum contained resonanQes from only the right .hand portion of the starting 
structure, from H1 0 onwards, and two singlets at 88.05 and 8.21 ppm, 
suggestive of a formamide derivative 101. In fact all the signals in the 1 H NMR 
spectrum were duplicated in a ratio of about 1 :1. This was consistent with the 
classical behaviour of N,N-di-substituted formamides, which display slow 
conformational exchange between the two possible geometric forms of the 
amide C-N bond, due to the restricted rotation caused by its partial double 
bond character107,229. (Note that these forms are called 
conformations 1 oo, 107 and the resulting conformational isomers are given the 
designations E and Z. In the following text however, these will be referred to 
as isomers, for sake of brevity, where this refers strictly to conformational 
isomerism). A common example is N,N-dimethylformamide (DMF) in which 
the two methyl peaks do not reach coalescence in the 1 H NMR spectrum until 
about 1230C98. The structure 6.1, including all the atoms from C8 onwards, 
would therefore satisfy all the spectroscopic evidence above for this cleavage 
product. 
The 1 H NMR spectrum of 6.1, containing the two isomers discussed 
above, was assigned by using the results of COSY and NOE experiments, to 
give the data in Table 6.1. The largest difference in chemical shift between 
proton resonances in the two isomers occurred for the H1 0 protons (1.3 ppm). 
This reflects the large dipolar anisotropic shielding effects associated with the 
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amide carbonyl group123. In particular, the downfield H1 0 resonance must be 
associated with the Z isomer of the amide (Figure 6.1) since this would allow 
maximum deshielding. This was confirmed by the results of NOE experiments 
(Table 6.2), since irradiation of the signal at 88.05 ppm gave an enhancement 
of the upfield H1 0 resonance, whereas irradiation of the other H8 resonance 
gave an enhancement of a signal assigned to the amide N-benzyl methylene 
protons. The latter assignment was based on an observed NOE interaction 
between the H11 and N-benzyl protons for both isomers. The H13 and H15 
proton resonances for each isomer were located by the observation of similar 
enhancements on irradiation of the two H1 0 resonances. Note that this 
required that the solution conformation of the trioxadecalin ring system be the 
same in both isomers as for the starting compound, which was consistent with 
the observed chemical shifts and vicinal proton-proton coupling constants. 
These results have been summarised in Figure 6.1. A similar conformational 
equilibration was observed for the parent compound, 2.46, as described in 
Chapter 2, but the more complex structure of the latter compound gave both a 
different ratio of the two amide isomers and probably a different rate of 
interconversion, resulting in an increased line broadening of the proton 
resonances at room temperature107. 
H 
~ CH3 
OCH3 
R=Ph: N-Benzyl, N-formyl fragment (6.1) 
R=H: N-Methyl, N-formyl fragment (6.2) 
A 13C NMR spectrum was also recorded, which showed the same 
doubling of resonances. An HMQC experiment was used to assign most of 
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the resonances to give the data in Table 6.3. The new C8 formyl resonances 
were observed at o164.9 and 164.2 ppm, upfield of their position in the 
starting compound, as expected117, and there were shifts in many other 
resonances also. The C1 0 resonance associated with the Z isomer was more 
shielded than that for the E isomer, by 7.2 ppm, which was due to an 
interaction with the amide carbonyl group117,118. Similarly, the N-CH2 
resonance associated with the E isomer was the more shielded from a similar 
effect. The remaining resonances could not be assigned to a particular 
. 
isomer, but the chemical shift differences between resonances for the two 
isomers were generally small, with the largest for the C17 resonance (1.1 
ppm), suggesting a long range interaction of the amide with the sidechain. 
Figure 6.1 Selected 1 H-1 H NOE interactions and partial solution 
conformations for N-alkyl, N-formyl mycalamide derivatives 
(R=Ph: 6.1, R=H: 6.2). 
Zisomer £isomer 
6.2.3 REACTION OF METHYLATED DERIVATIVES 
Initially, it seemed surprising that a cleavage in the protected 
mycalamide structure had occurred between C7 and C8, rather than at the 
tertiary amide C-N bond. To confirm that this was not an anomalous reaction 
related to the size of the benzyl protecting groups, the reaction of the fully 
methylated compound was also considered. Thus 7,17, 18-tri-0-methyl, N-
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methyl mycalamide A (2.26) was reacted with potassium hydroxide in DMSO 
at 70°C, until TLC showed a complete loss of starting material. After workup, 
1 H NMR spectroscopy showed the presence of a single product, probably an 
N,N~disubstituted formamide derivative, obtained in excellent yield. HRCIMS 
showed the formation of a compound of molecular formula C17Ha1N07, which 
was correct for a formamide derivative of structure 6.2, representing cleavage 
between C7and ca in compound 2.26. An IR spectrum also confirmed the 
presence of the amide functionality in this product. 
The 1 H NMR spectrum showed two formyl proton resonances, at 38.25 
and 8.16 ppm, two N-methyl resonances, at 33.00 and 2.94 ppm, and two H1 0 
resonances, at 36.09 and 5.15 ppm, while most other resonances were also 
doubled (Table 6.1 ). The complete spectrum was assigned using results from 
COSY and NOE experiments. In particular, NOE interactions were observed 
between one H8 and one N~methyl group and between the second H8 and 
one of the H1 0 protons (Table 6.2), confirming the presence of the same two 
amide isomers. The 13C NMR spectrum showed similarly large differences in 
the chemical shifts of the two C1 0 and the two N-methyl resonances (Table 
6.3), as assigned by an HMQC experiment, which were also consistent with 
previous results. 
The observed cleavage reaction betwen C7 and ca in N-alkylated 
derivatives appeared to be more facile for methyl than for benzyl derivatives. 
However, no fragments from the left hand portion of the molecule had been 
isolated from either reaction. A 1 H NMR spectrum of the evaporated aqueous-
OM SO fraction from the above reaction showed no significant resonances 
apart from residual DMSO. It is possible that such a fragment was unstable 
under the reaction conditions, decomposing to a mixture of components. 
This reaction therefore illustrated the comparative base stability of the 
amide functionality under these relatively anhydrous conditions, compared 
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with that of neighbouring functional group systems associated with it. It was 
noteworthy that no reaction occurred at C1 0 for these substrates, a point which 
will be discussed in a later section. Further attempts at base catalysed 
cleavage on the same N-methyl substrate, 2.26, using sodium methoxide in 
methanol, or sodium hydroxide in aqueous methanol at high temperatures, 
gave only slow decomposition, with no single major product being observed 
by 1 H NMR spectroscopy. Therefore the desired base hydrolysis of the amide, 
which could occur under these aqueous alkaline conditions, did not yield 
useful results, whereas the above reaction was both interesting and potentially 
useful. The benzyl protecting groups of the N-formyl fragment in the previous 
subsection could potentially be removed by catalytic hydrogenolysis78,131 to 
ascertain the biological activity of the equivalent mycalamide 8 cleavage 
product. However there was insufficient time to investigate this possibility. 
6.2.4 DISCUSSION OF A POSSIBLE MECHANISM OF CLEAVAGE 
The C6-C8 substructure of mycalamides A and B has certain similarities 
to an a.-hydroxy, P-dicarbonyl system, a system which is often encountered in 
carbohydrate chemistry230, since the C6 acetal is a masked carbonyl group. It 
has been established that enolisation at C7-C8 occurs readily under the basic 
reaction conditions used above, since C7 epimers were isolated from longer 
methylation reactions (Chapter 2). However, the presence of the alkyl ether 
group, protecting the C7 hydroxyl in the substrates above, makes it difficult to 
envisage further reaction. 
It is proposed that the observed cleavage occurs via an intermediate 
formed by a base catalysed 1 ,2-hydride shift231 from C7 to CB, as in Scheme 
6.1. This is the equivalent of an a.-hydroxy carbonyl isomerisation, via the 
enol, but would require the substitution of hydroxide ion at C7. Note that 
traces of water would be present in the reaction mixture from incomplete 
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drying of the solvent, DMSO. This intermediate could then undergo a reverse 
Claisen or aldol-type reaction79,232,233, involving cleavage of the C7-C8 
bond, to give the observed product and some smaller fragment, where the 
latter could undergo further rearrangement and decomposition233 (Scheme 
6.1). 
Scheme 6.1. Proposed mechanism for the base catalysed cleavage of 
7-0..alkyl, N-alkyl mycalamide derivatives (R=CH3: 2.26, 
R=CH2Ph: 2.46). 
further rearrangements 
Reverse aldol reactions are common degradative reactions of ~­
dicarbonyl derivatives230,233. However it is possible that some alternative 
mechanism is involved. It would be difficult to prove a particular mechanism 
with only one product being stable, and deuterium labelling methods would 
not be useful due to the easy exchange of protons at C7 (and C8) via 
enolisation reactions. 
6.3 BASE CATALYSED REACTIONS OF 7-0-BENZYL 
MYCALAMIDE DERIVATIVES 
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It was noted above that the use of N-alkylated mycalamide derivatives 
for reactions in base appeared to protect the C1 0 aza acetal functionality from 
reaction. Although it was possible that steric factors were involved, it 
appeared more likely that the different base reactivities of the secondary and 
tertiary N-amido acetals were related to the presence or absence of an 
exchangeable proton, just as for the case of hemiacetals compared with 
acetals106,170. In particular, the removal of the NH proton to facilitate the 
formation of an imine intermediate220, and thus the cleavage of the aza acetal, 
was postulated in the formation of the mycalamide oxazolidinones in the 
previous chapter. The reactions of mycalamide A ?-benzyl ethers were 
therefore considered to investigate this in more detail. 
6.3.1 THE REACTION OF 7-D-BENZYL MYCALAMIDE A WITH BARIUM 
OXIDE IN DMSO 
7-0-Benzyl mycalamide A (2.39) was treated with barium oxide in 
DMSO at 7ooc for 8 hours to give a mixture of starting material and another 
compound of higher Rt on silica gel TLC. Separation by preparative TLC gave 
a new derivative, which was isomeric with 7-0-benzyl mycalamide A by 
DC I MS. 
The 1 H NMR spectrum of this new isomer showed large changes in the 
chemical shifts and coupling constants for substituents of the trioxadecalin ring 
system, compared with data for 7-0-benzyl mycalamide A, and these data 
were assigned by using the results of COSY and NOE experiments (Table 
6.4). In particular, the observed vicinal proton-proton coupling constants (in 
Hz) for H1 O-H11 (2.0), H11-H12 (1.8) and H12-H13 (2.4), were indicative of 
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the opposite chair-chair conformation being the major solution conformation 
for the trioxadecalin ring system of this derivative, just as for 7,8, 18-tri-0-
benzyl mycalamide B (2.47) (see also Figure 2.2). There were also 
significant changes in the chemical shifts of the NH (+0.5), H1 0 (-0.5), H12 (-
0.5), H13 (-0.6), 13-0CH3 (-0.2), 14-CH3S (+0.3), H16d (+0.7) and H17 (-0.2) 
proton resonances (Table 6.4), compared with data for 2.39, consistent with 
this conformational change. Irradiation of H1 0 in an NOE experiment gave 
enhancements of the upfield 1 0-0CH, H11 and H12 resonances, irradiation of 
. 
the upfield 1 0-0CH resonance gave enhancements of H1 0 and H12, and 
irradiation of H12 caused enhancement of the H1 0 and upfield 1 0-0CH 
resonances (Table 6.2). These data required that the C1 O-C12 dioxan ring be 
in the opposite chair conformation, where the H1 0, 1 0-0CHS and H12 protons 
could all be axial, and that the configuration at C1 0 be opposite to that in 7-0-
benzyl mycalamide A (2.39). Other NOE interactions, such as between H12 
and H13, and between H13 and both of the 14-CH3 groups, required that the 
C11-C15 ring also be in the opposite chair conformation to that normally 
observed, as deduced from the results above. These results are summarised 
in Figure 6.2, for structure 6.3. 
Figure 6.2 Selected 1 H-1 H NOE interactions and partial solution 
conformation for 7-0-benzyl 1 OR mycalamide A derivatives 
(6.3 and 6.4). 
R1=Ra=R4=H, R2=0CH2Ph: 7-0-Benzyi10R mycalamide A (6.3) 
R1=Ra=H, R2=0CH2Ph, R4=CH2Ph: 7,18-di-O-Benzyi10R myc.A (6.4) 
R1=D, R2=0CH2Ph, Ra=R4=H: 7-Deutero, 7-0-benzyl1 OR myc.A (6.10) 
R1=0CH2Ph, R2=D, Ra=R4=H: 7-Deutero, 7S-O-benzyi10R myc.A (6.13) 
R1=Ra=R4=H, R2=0H: 10R Mycalamide A (6.17) 
R1=R4=H, R2=0H, Ra=CHa: :lOR Mycalamide B (6.18) 
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A 13C NMR spectrum was also obtained on a combined sample and the 
data assigned by an HMQC experiment (Table 6.5). The significant shifts 
were in the C1 0 (+3.0), 1 O-OCH2 (+4.8), C11 (-9.9) and C12 (-1.9) 
resonances, since the shifts in the other resonances were similar to those 
observed for 7,8, 18-tri-0-benzyl mycalamide B (2.47) (Section 2.5.2), and 
were related to changes in the populations of the chair-chair conformations of 
this ring system. It is proposed that the main reason for this observed 
conformational change on epimerisation at C1 0 is to minimise steric 
interactions, since the alternate chair-chair conformation allows the bulky 
amide sidechain to remain equatorial to the dioxan ring at C1 0, as in 
mycalamides A and B (compare Figure 1.6). 
This epimerisation at C1 0 under basic conditions was also observed for 
some C7-dimethoxybenzyl ethers of mycalamides A and B during the total 
synthesis of these compounds91. A discussion of the mechanism of this 
unusual reaction is presented in a following subsection. 
6.3.2 FACILE SYNTHESIS OF 7-0-BENZYL 1 OR MYCALAMIDE A AND 
DERIVATIVES 
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In order to prepare a larger quantity of 7-0-benzyl 1 OR mycalamide A 
(6.3) to complete the above characterisations, a more direct synthetic method 
was required. Adaptation of the Kuhn methylation procedure150, using barium 
oxide as the base in DMS077, was an obvious alternative to the Johnstone 
method151 (Chapter 2), since it was expected that the milder base would give 
greater selectivity, yet permit .the epimerisation observed above. 
The reaction of mycalamide A with benzyl bromide and barium oxide in 
DMSO at 600C for 2 hours gave a mixture of four compounds by silica gel 
TLC. Preparative TLC separated these products and 1 H NMR spectroscopy 
showed that these were 7-0-benzyl mycalamide A (2.39), 7, 18-di-0-benzyl 
mycalamide A (2.40) and their C10 epimers (6.3, 6.4), in about equal 
quantities. The new derivative from this synthesis, 7, 18-di-0-benzyl 1 OR 
mycalamide A (6.4) was also fully characterised by NMR and mass 
spectroscopies. In particular, a more complete set of NOE data were recorded 
(Table 6.2) to conclusively assign the stereochemistry associated with the C14 
methyl and C16 methylene resonances. Of significance was the 
enhancement of the downfield H16 resonance on irradiation of H11, and vice 
versa, so that this could be assigned to be pro-S on the basis of the molecular 
modelling work described in Chapter 5. Also, irradiation of the upfield 14-CH3 
resonance gave weak enhancements of the axial 13-0CH3 and H16R proton 
resonances, so that this was assignable to the equatorial pro-S C14 methyl 
group. The 1 H NMR spectral data were fully assigned by comparison with 
data for 7-0-benzyl 1 OR mycalamide A (Table 6.4) and these assignments 
were confirmed by a COSY experiment. A 13C NMR spectrum was also 
recorded and assigned using an HMQC experiment (Table 6.5). 
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It was significant that no amide benzylation was observed under these 
reaction conditions, whereas methylation occurred readily. This may indicate 
that the amide anion was being formed156, but in low concentration, so that 
benzylation of the amide nitrogen was not sufficiently competitive, being also 
hindered by the benzyl ether at C7 and the size of the reagent. However, a C7 
methoxyl group would give less steric hindrance to reactions of the amide 
anion, while the reagent for methylation, methyl iodide, is also smaller, so that 
methylation of both groups is reasonable. For the benzylation reaction, the 
more forcing conditions of potassium hydroxide in DMS0151 probably 
increases the concentration of the amide anion sufficiently to overcome such 
steric factors. 
6.3.3 DISCUSSION OF THE MECHANISM OF EPIMERISATION AT C1 0 
The formation of an epimer at C1 0 requires the cleavage and readdition 
of one of its substituents. The best leaving group under basic conditions is the 
alkoxy oxygen of the C1 O-C12 dioxan ring, as shown by the formation of the 
oxazolidinone derivatives in the previous chapter (5). It is likely that these 
reactions both involve a similar imine intermediate, since they occur under 
essentially the same experimental conditions. Therefore a proposed 
mechanism for this epimerisation would begin with deprotonation of the amide 
to give the amide anion (a known intermediate from alkylation reactions) and, 
subsequently, the formation of an imine intermediate, by cleavage of the C1 0-
0 bond and formation of a second C1 O-N bond (Scheme 6.2a). 
Note that C10 would have some electrophilic character, due to the 
combined electron withdrawing inductive effects of the amide nitrogen and 
alkoxy groups 170, so that the donation of some electron density from the 
amide anion in this reaction is not unreasonable. This is also consistent with 
the known nucleophilicity of the amide nitrogen under basic conditions147, 155. 
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Also, despite alkoxide ions being relatively poor leaving groups140, it is known 
that a-amino ethers react with Grignard reagents234,235, and other basic 
nucleophiles such as hydride ions236, in substitution reactions which involve a 
preferential cleavage of the C-0 bond. Furthermore, the partial breakdown of 
the cis-fused trioxadecalin ring system by C1 0-0 bond cleavage may be 
compensated for by the relief of gauche interactions between C13 and the 12-
0CH2 carbon and between C1 0 and the opposite dioxan ring atoms. 
Scheme 6.2 Possible mechqnisms for the base catalysed epimerisation of 
7-0-benzyl mycalamide derivatives (2.39, 2.40) at C1 0. 
a) Hemiacetal anion mechanism 
VV' H O~NJ1111" 10 
0 
lo 
However, the cleavage of the C1 0-0 bond would give a hemiacetal 
anion from the methylene acetal, C12-0CH2-o-, which must be 
unstable237,238. Such an anion would also be an effective intramolecular 
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nucleophi le 140, so that an immediate reattack of the electrophilic imine 
carbon, C1 0, is likely, resulting in either reformation of the starting compound 
or its C1 0 epimer (Scheme 6.2a). If this is not possible because C1 0 has 
already undergone substitution, such as by C?-O- to give an oxazolidinone 
ring, then this hemiacetal would be likely to lose formaldehyde to give C12-
0(H), as discussed in the previous chapter. The possibility of the involvement 
of such an unstable hemiacetal anion is best summarised by the following 
statement by C. D. Hurd237 :- "Since compounds of these structures 
. 
(hemiacetals) generally are not isolable as such from the simple aldehydes, 
they are sometimes disregarded in chemical reactions, whereas in many 
instances they are the vital intermediates". 
The mechanism of the base catalysed racemisation of a-methyl-a-
acetamidonitriles was elucidated by extensive kinetic studies, and was 
reported to proceed by elimination and readdition of the elements of HCN, i.e. 
via an imine intermediate220. A requirement for this reaction was that the 
amide nitrogen have a hydrogen atom attached. The rate determining step 
was expulsion of the leaving group, cyanide ion, from the amide anion, to yield 
an imine intermediate. Other analogous reaction mechanisms include the 
isomerisation of glycosylamines via an open chain imine 170 (anil), and the 
isomerisation of cyclic hemiacetals via an open chain aldehyde106. 
Additional experimental evidence is presented here in support of the 
above mechanism for epimerisations at C1 0 in 7-0-benzyl mycalamide A 
(2.39) :-
i) no reaction was observed in the absence of base, or with amine bases 
ii) other strong bases such as sodium methoxide in methanol effected the 
same transformation, 
iii) N-methylation could be achieved readily under similar reaction conditions, 
iv) no epimerisation was observed when the amide nitrogen was alkylated, 
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v) there was no incorporation of deuterium at C1 0 when the reaction was 
performed in deuterated methanol, despite more than 80% inclusion at C7, 
vi) the epimerisation reaction was reversible. 
The evidence presented in points ii), v) and vi) will be described in the 
following subsection. 
Two alternatives to the above mechanism include the loss of the H1 0 
substituent as either proton or hydride ion. The former would give an 
amidomethyl carbanion. Such species have been reported155, but only 
where there was an a-carbonyl or a-cyano substituent adjacent for resonance 
stabilisation, and would therefore require a very strong base to obtain from the 
mycalamide structure. This unlikely possibility is refuted experimentally since 
there was no inclusion of deuterium at C1 0 for a reaction in deuterated 
methanol. A second alternative is the loss of H1 0 as hydride ion. Direct 
exchange with the solvent would seem to be unlikely. However, a hydride 
shift mechanism, similar to that which occurs in the Cannizzaro 
reaction237,239, has been outlined in Scheme 6.2b. This involves a shift of 
hydride ion from C10 to 10-0CH2, with cleavage of the CH2-0(-C12) bond 
and formation of a new C1 O-N double bond from the amide anion. However, it 
is difficult to envisage a reverse reaction to reform the dioxan ring, making this 
an unlikely alternative. Furthermore, the intermediate imidate formed would 
probably be unstable, whereas no decomposition products were observed in 
the reaction above. A third possibility is a cleavage of the C-N bond and 
readdition, but the latter would also seem to be rather unlikely. Therefore the 
best mechanism to account for this epimerisation at C1 0 under basic 
conditions appears to be the original proposal. 
6.3.4 CHARACTERISATION OF PRODUCTS FROM THE REACTION OF 
7-Q-BENZYL 10R MYCALAMIDE A WITH SODIUM METHOXIDE IN 
DEUTEROMETHANOL 
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The title reaction was performed in d1-methanol, with the aims of 
checking for deuterium exchange at C1 0 during epimerisation, determining 
the reversibility of this epimerisation, and of examining the influence of a 
nucleophilic base on the reaction products obtained. Thus 7-0-benzyl 1 OR 
mycalamide A (6.3) was reacted with a solution of 1.5M sodium methoxide in 
deuteromethanol at 60°C for 2.5 hours, when TLC showed that most of the 
starting material had been consumed. Analysis by 1 H NMR spectroscopy 
showed that a complex mixture of several compounds had been formed, but 
reverse phase HPLC indicated that most of these components were resolved. 
Preparative HPLC gave eight fractions, of which the first five were most 
significant, although all were less than 0.5 mg in mass. These fractions were 
analysed by 1 H NMR and mass spectroscopies, and are described in order of 
their increasing HPLC retention times. 
6.3.4.1 HPLC FRACTION 1 
The 1 H NMR spectrum of the first, most polar fraction was very weak, 
and the multiplicity and identity of some resonances were difficult to 
determine. However there was also a notable absence of the two 1 0-0CH 
and H7 resonances. Partial data were obtained (Table 6.6), which included 
an H1 0 resonance shifted strongly downfield, at 86.78 ppm (2.0, 10.6 Hz), 
coupled to a multiplet at 84.19 ppm. The latter was further coupled to a 
doublet at 82.74 (9.1 Hz), as shown by a selective proton decoupling 
experiment. The chemical shifts, multiplicities and coupling constants1 01 
suggested that there was a double bond between C1 0 and C11 since the 
resonances at 84.19 and 82.74 ppm must be assigned to the H12 and H13 
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protons. This was supported by small shifts in the resonances of other ring 
substituents, particularly H15 (-0.3), compared to data for 7-0-benzyl 
mycalamide A (2.39). Note that the upfield shift in the H13 resonance (-0. 7) 
would be associated with the loss of the C1 O-C12 methylene acetal to leave 
an hydroxyl group at C12101,123, as shown for the mycalamide oxazolidinone 
derivatives in the previous chapter. The absence of the H7 resonance 
indicated the incorporation of deuterium at C7 by enolisation. 
The sample was too small to perform further NMR spectroscopic 
. 
analyses. However, a HRFABMS result was obtained, which indicated a 
compound of molecular formula C3oH44DNOg, in agreement with the 
proposed structure, 6.5. Further characterisations will be described for a 
similar derivative, obtained from mycalamide A, later in this chapter. However, 
it is useful to note that this enamide structure is the tautomer of the proposed 
imine intermediate and that an analogous minor product was isolated from the 
racemisation of a-methyl-a-acetamidonitriles220. 
OH 
= 
' 
H 
I 
N 
H OH 
CH2 
R1=D, R2=CH2Ph: 7-Deutero, 7-Q.benzyl, Z ~ 10 1 0-deformyl myc.A (6.5) 
R 1 = R2=H: Z ~ 1 o 1 0-Deformyl mycalamide A (6.16) 
6.3.4.2 HPLC FRACTION 2 
The 1 H NMR spectrum of the second HPLC fraction (major) was much 
more informative. It showed a new methoxyl resonance, loss of the two 10-
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OCH and H7 resonances (implying a high incorporation of deuterium at C7), 
but an H1 0 resonance of normal multiplicity and intensity. Irradiation of H1 0 in 
an NOE experiment gave an enhancement of the methoxyl resonance at 83.45 
ppm, whereas irradiation of H13 enhanced a methoxyl resonance at 83.44 
ppm (Table 6.2), so that these methoxyl resonances could be assigned to 
groups at C1 0 and C13, respectively. Thus this derivative was probably a 
C 1 0-0-methyl substitution product, having an hydroxyl group at C12. The 
remainder of the 1 H NMR spectrum was assigned with the assistance of a 
COSY experiment (Table 6.6). There were shifts in the H1 0 (-0.5), H12 (-0.4), 
H13 (-0.4), 13-0CH3 (-0.1), 14-CH3R (+0.1) and H16 (+0.3) proton 
resonances, compared to data for 7-0-benzyl mycalamide A (2.39), and a 
smaller observed H12-H13 coupling constant (5.6 Hz), suggestive of a mixture 
of the two possible chair conformations of the C11-C15 tetrahydropyran ring, 
as described in the previous chapter (5). Irradiation of the H11/H12 multiplet 
in an NOE experiment gave enhancements in the H1 0, H13, 14-CH3S and the 
more downfield H16 resonances (Table 6.2), confirming the presence of both 
these conformations. 
These data were therefore consistent with the structure 6.6, which was 
further supported by a HRFABMS result, indicating a compound of molecular 
formula C31H4aDN01o- Note that the stereochemistry at C10 was not 
conclusive from these data. However, the conformational behaviour of this 
compound was rather different from that observed for pederin (Chapter 1 ), 
which has a similar structure, so that it is proposed that the stereochemistry at 
C1 0 in this derivative is also different (i.e. 1 OR). This assignment was 
consistent both with the conformational behaviour of 7-0-benzyl 1 OR 
mycalamide A (6.3) and with the reportedly higher thermodynamic stability of 
the 1 OR over the 1 OS pederin derivatives, which caused the former (C1 0 
epimers) to predominate in acid catalysed exchange equilibria130. 
OH 
R1=D, R2=0CH2Ph: 7-Deutero, 7-0-benzyl, 10R-0-methyl myc.A (6.6) 
R1=0CH2Ph, R2=D: 7-Deutero, ?S-O-benzyl, 10R-0-methyl myc.A (6.9) 
6.3.4.3 HPLC FRACTION 3 
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The 1 H NMR spectru~ of the third HPLC fraction was again very weak 
and showed a mixture of three main components, in a ratio of about 4:2:1. The 
most minor component of the three was the 7-deutero, 7-0-benzyl, 1 OR-O-
methyl mycalamide A derivative (6.6) above, and the next smallest 
component was 7-deutero, 7-0-benzyl mycalamide A (6.7), representing an 
epimerisation at C1 0 without incorporation of deuterium at this position. The 
major component was a new derivative, but only partial data (Table 6.6) could 
be obtained due to the presence of the other compounds and the small 
sample size. There was a new methoxyl resonance at 83.43 ppm, in addition 
to similar resonances at 83.57 and 3.23 ppm, which were assigned to the 
groups at C1 0, C13 and C6, respectively. Therefore this derivative was 
probably 7-deutero, 7-0-benzyl, 1 0-0-methyl mycalamide A (6.8). The 
chemical shifts of the H1 0, 13-0CH3, 14-CH3R and 14-CH3S resonances 
suggested that the major conformation of the C11-C15 ring of this derivative 
was the same as that for 7-0-benzyl mycalamide A (2.39). Therefore the 
stereochemistry at C1 0 was probably the same as for pederin and 7-0-benzyl 
mycalamide A. 
The HRFABMS spectrum of this fraction showed two dominant MK+ 
ions (m/z 635 and 633), in a ratio of about 4:1, respectively. This suggested 
that the major component of this fraction had a molecular formula of 
C31 H4aDN01o, consistent with this being an isomer of compound 6.6 above, 
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whereas the minor ion implied a molecular formula of C31H4sDN01o. 
consistent with structure 6.7. However there was insufficient material to 
perform further work on this compound. 
OH 
R1=D, R2=0CH2Ph: 7-Deutero, 7-0-benzyl mycalamide A (6.7) 
R1=0CH2Ph, R2=D: 7-Deutero, ?S-O-benzyl mycalamide A (6.11) 
R1=0H, R2=H: 7S Mycalamide A (6.24) 
OH 
R1=D, R2=0CH2Ph: 7-Deutero, 7-0-benzyl, 10S-O-methyl myc.A (6.8) 
R1=0CH2Ph, R2=D: 7-Deutero, ?S-O-benzyl, 10S-O-methyl myc.A (6.12) 
6.3.4.4 HPLC FRACTION 4 
The 1 H NMR spectrum of the fourth HPLC fraction showed that this 
consisted of another pure compound, which was also a 10-0-methyl 
derivative, as indicated by the presence of three methoxyl resonances, at 
o3.45, 3.44 and 3.35 ppm. The chemical shifts of most resonances in this 
spectrum were very similar to those of 7-deutero, 7-0-benzyl 1 OR-O-methyl 
mycalamide A (6.6), but there was a significant difference in the chemical 
shifts of the H5a (+0.2), H5e (-0.3) and 6-0CH3 (+0.2) proton resonances. 
This separation in the chemical shifts of the H5 resonances was earlier shown 
to be indicative of an epimerisation at C7 (Chapters 2 and 5), so that the 
structure was probably 7-deutero, ?S-O-benzyl, 10R-O-methyl mycalamide A 
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(6.9). The 1 H NMR data were readily assigned by comparison with the data 
for compound 6.6 and by selective proton decoupling experiments, including 
the irradiation of H1 0 and H13, which elucidated the chemical shifts and 
coupling constants for the H11 and H12 proton resonances (Table 6.6). The 
vicinal proton-proton coupling constants and chemical shifts for substituents of 
the C11-C15 ring indicated that the same mixture of conformations for this ring 
were present in this derivative as for 7-deutero, 7-0-benzyl 1 OR-O-methyl 
mycalamide A (6.6), as expected. Good HRFABMS data were also obtained 
for this compound, supporting the proposed structure. 
6.3.4.5 HPLC FRACTIONS 5 AND 6 
The 1 H NMR spectrum of the fifth HPLC fraction showed that this 
consisted almost entirely of starting material, 7-0-benzyl 1 OR mycalamide A, 
but with at least 80% incorporation of deuterium at C7 by integration (structure 
6.1 0). This fraction also contained a minor amount of the compound in 
fraction 4 above. 
The 1 H NMR spectrum of the sixth HPLC fraction was rather weak, but 
showed the presence of one reasonably pure component, which had data 
very similar to those of 7-0-benzyl mycalamide A (2.39). However, the two 
H5 resonances were well spread in chemical shift and the C6 methoxyl 
resonance was shifted downfield (Table 6.6). Therefore this was likely to be 7-
deutero, 7 S-O-benzyl mycalamide A (6.11) and the molecular formula for this 
structure was confirmed by HRFABMS. Unfortunately there was insufficient 
sample to perform further studies on this derivative or even to obtain complete 
1 H NMR spectral data. 
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6.3.4.6 HPLC FRACTIONS 7 AND 8 
' 
The 1 H NMR spectrum of the seventh HPLC fraction was also weak, but 
showed that it consisted of a mixture of two major components, of which the 
slightly dominant component was new, but the other was the compound in 
fraction 6 above, arising from incomplete resolution of these peaks during 
separation by HPLC. The resonances for the new component could still be 
distinguished in the mixture, enabling a partial assignment of the data (Table 
6.6). In particular, this compQund was clearly a fourth 1 0-0-methyl derivative, 
and probably the C7 epimer of the isomer in fraction 3, based on the chemical 
shifts of the two H5 and C6 methoxyl resonances and the similarity of data 
relating to H10 and substituents of the C11-C15 ring. These data suggested 
that the major solution conformation of this portion of the structure was similar 
to that of 7-0-benzyl mycalamide A and pederin. Therefore this compound 
was assigned the structure 6.12, but the sample was too small to purify or to 
perform further characterisations on it. 
The 1 H NMR spectrum of the eighth HPLC fraction was very weak, but 
revealed the presence of one major compound retaining the C1 0-C12 
methylene acetal. The spectrum was similar to that obtained for 7-deutero, 7-
0-benzyl 1 OR mycalamide A, 6.10 (fraction 5), where the chemical shifts and 
coupling constants indicated that the major solution conformation of the 
trioxadecalin ring system was an opposite chair-chair conformation to that 
found in mycalamide A. However, there were additional shifts in the two H5 
and C6 methoxyl resonances, which suggested that this was a G7 epimer, 7-
deutero, ?S-O-benzyl 10R mycalamide A (6.13), and partiai1H NMR spectral 
data are listed in Table 6.6. Again this sample was too small to perform further 
characterisations of this derivative. 
6.3.4.7 COMPARISONS WITH PRODUCTS FROM A REACTION ON 7-0-
BENZYL MYCALAMIDE A 
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An additional experiment was performed, involving similar reaction 
conditions to those above, but beginning with 7-0-benzyl mycalamide A 
(2.39), to investigate the possible influence of the C1 0 stereochemistry of the 
substrate on the ratio of products obtained. Thus, after reaction in a 1M 
solution of sodium methoxide in methanol for two hours at 7ooc, the reaction 
was worked up and the crude. mixture examined by 1 H NMR spectroscopy. 
The 1 H NMR spectrum of the mixture was complex, as expected, but 
the methoxyl resonances, in particular, were distinctive for all of the derivatives 
above, enabling them to be easily recognised. All of the above products were 
present so this spectrum was compared directly with that obtained for the 
crude reaction mixture (from 7-0-benzyl 1 OR mycalamide A) above. Ignoring 
deuterium uptake at C7, it was found that the major isomer from the first 
reaction, 7-0-benzyl 1 OR-O-methyl mycalamide A (6.6), was also the major 
product of this reaction, but there was more 7-0-benzyl 1 OR mycalamide A 
(6.3), less of the C7 epimers, and less of the elimination product, 6.5. The 
latter results were probably due to the slightly less basic conditions used in 
this second reaction. The epimerisations at C1 0 and the similarity in the ratios 
of the 1 0-0-methyl substitution products were indicative of the involvement of 
a common imine intermediate in this reaction. However it was not established 
whether epimerisation at C1 0 could occur for the 1 0-0-methyl derivatives via 
the same intermediate. From the work above and the observed reactions of 
the mycalamide oxazolidinones (Chapter 5) this was probable, despite the fact 
that methoxide ion was also a poor leaving group 140. Note that pederin was 
not subjected to such strongly basic reaction conditions27,94, 129,132 
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6.3.4.8 CONCLUSIONS 
It has been shown that, overall, nine compounds were formed from the 
reaction of 7-0-benzyl 10R mycalamide A (6.3) with sodium methoxide in d1-
methanol. These consisted of four isomers of 7-deutero, 7-0-benzyl 
mycalamide A (6.7), involving epimerisations at either or both of the C7 and 
C1 0 positions (fractions 3, 5, 6, 8), four isomers of 7-deutero, 7-0-benzyl, 10-
0-methyl mycalamide A (6.8), arising from a reaction involving substitution of 
methoxide ion at C1 0, loss. of the C1 O-C12 methylene acetal, and similar 
epimerisations at C7 (fractions 2, 3, 4, 7), and an elimination product, 7-
deutero, 7-0-benzyl, !J.1 o 1 0-deformyl mycalamide A (6.5) (fraction 1 ). 
Significantly, deuterium was incorporated only at C7, not C1 0, during the 
epimerisations observed, as stated above. 
These reactions would be very useful for preparing C1 0-0-alkyl 
mycalamide derivatives, analogous to pederin, provided that the benzyl 
protecting group could be removed quantitatively. In particular, such 
derivatives would be increasingly dominant with longer reaction times, since 
the complete loss of the C1 O-C12 methylene acetal to yield C12-0- and 
formaldehyde would almost certainly be irreversible. From shorter reactions, 
isomers at both C7 and C1 0 of mycalamide A could be obtained. 
Unfortunately time did not permit further investigations of these possibilities. 
6.3.5 FURTHER PRODUCTS FROM THE REACTIONS OF 7-MONO- AND 
7, 18-DI-0-BENZYL MYCALAMIDE A WITH BARIUM OXIDE IN DMSO 
Having demonstrated the potential for epimerisation and substitution at 
C1 0 in 7-0-benzyl mycalamide A (2.39), there was still the question of its 
reactivity under more forcing, non-nucleophilic basic conditions. In particular, 
it was of interest to ascertain whether the same cleavage reaction occurred for 
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this derivative as for the N-benzylated compound, 7, 18-di-0-benzyl, N-benzyl 
mycalamide B (2.46), described at the beginning of this chapter. 
Therefore a mixture of 7-0-benzyl mycalamide A (2.39), 7, 18-di-0-
benzyl mycalamide A (2.40) and their C1 0 epimers (6.3, 6.4) was prepared 
according to the method described in Section 6.3.2, and this was then heated 
further with barium oxide in DMSO for 16 hours at 8ooc. The reaction was 
monitored by TLC and this showed the gradual disappearance of all four 
compounds to yield what appeared to be a single product. However, reverse 
. 
phase HPLC showed the presence of two well-resolved components, which 
were therefore separated prior to analysis. DCIMS showed that the two 
products were isomers, of molecular formulae C1sH2sN04, so that these were 
new cleavage products. The FTIR spectra of these isomers both contained a 
strong carbonyl stretch at 1685 cm-1, indicating the presence of the amide 
functionality. 
A 1 H NM R spectrum of the first fraction revealed resonances derived 
from the left hand portion of 7-0-benzyl mycalamide A (2.39) to the amide, but 
there were no resonances from C1 0 onwards. There were two very broad 
singlets at o6.35 and 5.43 ppm, indicative of protons on the nitrogen of a 
primary amide, which were non-equivalent due to the restricted rotation about 
the C-N bond (lnd the shielding effects associated with the amide carbonyl 
group107, as discussed in earlier sections. There were also small shifts in the 
H7 (-0.1) and upfield 7-0CH (-0.1) proton resonances (Table 6.4). A 13C NMR 
spectrum was also recorded, which showed similar chemical shifts to those 
recorded for the left hand portion of 7-0-benzyl mycalamide A (2.39), except 
for minor shifts in the C7 (-1.7) and C8 (+1.5) resonances (Table 6.5). These 
data were therefore consistent with cleavage of the C1 O-N bond in the starting 
compounds to give a primary amide fragment. In fact the underivatised 
primary amide, pederamide (3.4), has been reported as a cleavage fragment 
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from pederin under mildly acidic conditions 12 6 and has been 
synthesised133,240. A comparison of the 1 H NMR data above with those 
reported for pederamide 133 showed good agreement, allowing for some 
differences around C7 due to the presence of the benzyl ether functionality, 
confirming that this was 7-0-benzyl pederamide (6.14). 
CH2 
7-0-Benzyl pederamide (6.14) 
CH2 
7 S-O-Benzyl pede ram ide (6.15) 
The 1 H NMR spectrum of the second fraction was very similar to that of 
the first fraction above but there were shifts in the H5a (+0.3), HSe{-0.3), 6-
0CH3 (+0.3), H7 (+0.1 ), upfield 7-0CH (+0.1) and downfield NH (+0.2) proton 
resonances (Table 6.4), which were indicative of an epimerisation at C7. A 
13C NMR spectrum also showed a shift in the C7 (+1.9) and 1-0CH2 (+1.3) 
resonances, compared to data for 7-0-benzyl pederamide (Table 6.5). 
Therefore this was 7 S-O-benzyl pede ram ide (6.15), obtained from the 
compound above by an enolisation reaction under the basic reaction 
conditions. 
NOE experiments were performed to examine the solution 
conformations of these two derivatives. However, almost identical results 
were obtained for both C7 isomers (Table 6.2), indicating that the C7-N9 chain 
portions were quite flexible. Note that selective irradiation of one NH 
resonance was not possible due to conformational and chemical exchange. 
The observed cleavage of the C1 O-N bond of 7-0-benzyl mycalamide A 
(2.39) and derivatives under these basic conditions represents an hydrolysis 
of the proposed imine intermediate. In this reaction it is proposed that an 
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unstable hemiaminal241,242 is formed by substitution of hydroxide ion at C1 0, 
as shown in Scheme 6.3, which then breaks down to give the corresponding 
primary amide and an aldehyde. This reaction is exactly the reverse of the 
known base catalysed condensation of primary amides with aldehydes to give 
acylated amino alcohols241, which often react further to give alkylidene 
bisamides. That this cleavage did not occur for N-alkylated substrates is 
further evidence for the involvement of an imine intermediate in these base 
catalysed reactions. Evidently the aldehyde formed is unstable under the 
reaction conditions, since rio other products could be isolated. This is 
consistent with the reactivity of aldehydes under alkaline conditions, permitting 
further rearrangements and degradations233. 
Scheme 6.3 Proposed mechanism for the base catalysed cleavage of 
7-0-benzyl mycalamide A derivatives (2.39, 2.40, 6.3, 6.4). 
ly/NH l 
: + 
0 
further rearrangements 
Thus two different cleavages of the mycalamide structure had been 
achieved, using a benzyl protecting group for the C7 hydroxyl, which have 
been shown to depend on the substitution state of the amide nitrogen. 
However, the presence of an ether group at C7 was not favourable for 
determining structure-activity relationships, since such derivatives were 
relatively inactive {Chapter 2). Therefore attention was focused again on 
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mycalamide A as a substrate, since it was possible that substitution reactions 
could be performed at C1 0 under mildly basic conditions at high temperature. 
Note, however, that the nucleophile could not itself be a strong base since this 
would favour the formation of mycalamide A oxazolidinone derivatives. These 
investigations on mycalamide A are described below. 
6.4 REACTIONS OF MYCALAMIDE A IN THE PRESENCE OF 
SODIUM AZIDE IN DMSO 
Azide ion is a good nucleophile in both protic and dipolar aprotic 
solvents153,243. Substitution reactions involving this nucleophile have been 
studied for various substrates, ranging from simple alkyl halides and tosylates 
to more complex sugar derivatives147. Commonly dipolar aprotic solvents, 
such as DMF or DMSO, have been used in these reactions, since the anions 
are much less solvated than in protic solvents but the polarisable charged 
transition states are more solvated, so that bimolecular reactions of anions are 
much faster in these solvents243. Despite these advantages, the reactions of 
various partially protected sugar derivatives, containing tosylate leaving 
groups, with sodium azide in DMF required temperatures of 14ooc for several 
hours to effect substitution147. 
6.4.1 PREPARATION AND PURIFICATION OF PRODUCTS FROM 
MYCALAMIDE A 
The reaction of mycalamide A with sodium azide in DMSO at 130-
1400C was slow, but after four days a number of products were observed by 
silica gel TLC. Preparative TLC gave six fractions (ordered according to 
increasing Rt), which were examined initially by 1 H NMR spectroscopy. This 
showed that three fractions (1, 2 and 6) were pure compounds but fractions 3, 
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4 and 5 were still mixtures. Fraction 3 was a mixture of unreacted mycalamide 
A and mycalamide A cis and trans oxazolidinones (5.2, 5.3) so this was not 
considered further. However, fractions 4 and 5 contained at least three 
different components, including mycalamide A trans oxazolidinone (5.3), so 
these fractions were further examined by reverse phase HPLC. Separation of 
the components by HPLC gave three further fractions containing unknown 
compounds,· so that overall six new products had been isolated from this 
reaction, excluding unreacted mycalamide A and mycalamide A cis and trans 
oxazolidinones. These products were then examined by NMR and mass 
spectroscopies. 
6.4.2 CHARACTERISATION OF THE MAJOR PRODUCT 
The major product from the reaction (from fraction 2) represented about 
half of the purified products by mass. HRFABMS showed that it had a 
molecular formula of C23H3gNOg, corresponding to a loss of CH20 from 
mycalamide A. The 1 H NMR spectrum showed an absence of the two 1 0-0CH 
and H11 resonances, and shifts in the NH (+1.1 ), H1 0 (+0.8), H13 (-0.7), H15 
(-0.2), H216 (+0.2), H17 (+0.2) and two H18 (+0.1) proton resonances, as 
assigned by a COSY experiment (Table 6.7). The observed shifts in the NH-
H15 resonances and the 2Hz coupling constant between H10 and H12 were 
consistent with the presence of a double bond between C1 0 and C11 and an 
hydroxyl group at C12101,104, as proposed for a 7-0-benzyl derivative (6.5) 
earlier in this chapter. The shifts in the C16-C18 sidechain proton resonances 
suggested that the solution conformations of this substructure were 
significantly affected by the elimination, and NOE experiments were performed 
to investigate this and to solve the stereochemistry of the double bond 
substituents at C1 0. 
Figure 6.3 Selected 1 H-1 H NOE interactions and partial solution 
conformations for A 1 o 1 0-deformyl mycalamide A isomers 
(6.16 and 6.19). 
H~ 
a} Zisomer 
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There were NOE interactions between the H1 0 and H12 protons, as 
well as between the N H and H15 and H 17 protons (Table 6.8), which required 
that the double bond stereochemistry be cis, i.e. a Z isomer, as shown in 
Figure 6.3a, so that the structure was Z A 10 1 0-deformyl mycalamide A (6.16). 
There was also a weak interaction between H7 and H10 which suggested the 
presence of a small amount of the E geometry about the C8-N amide bond in 
solution. Other NOE interactions, including H12-14-CH3S and H13-H15, were 
indicative of the normal chair conformation for the C11-C15 ring, albeit slightly 
distorted by the new exocyclic double bond. This was in agreement with the 
chemical shifts for the ring substituents and the 9 Hz coupling constant 
between the H12 and H13 protons, requiring that these protons be in an anti 
relationship98. Also, the geometric relationship between an axial H12 proton 
and the exocyclic H1 0 proton was analogous to that observed between the 
axial H5 proton and the exocyclic 4=CHE proton, in agreement with the 
observed long range proton coupling constants of 2 Hz in each case104. The 
coupling constants between H15 and the two H16 protons were also 
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indicative of a major conformation about C16-C17 having C17 anti to C14, 
which was consistent with the observed long range NOE interaction between 
NH and H17 (Figure 6.3a). 
A 13C NMR spectrum of this derivative was assigned using HMQC and 
HMBC experiments (Tables 6.9 and 6.10). The C10 and C11 resonances 
were located at B104.9 and 141.7 ppm, consistent with the presence of a new 
double bond117. There were also large shifts in the C8 (-4.5), C12 (-4.8), C13 
(+11.6) and C15 (+6.0) resonances associated with this unsaturated enamide 
structure, and with the cleavage of the methylene acetal at C12 to an hydroxyl 
group, as discussed above. 
The formation of this enamide derivative (6.14) provided some support 
for the proposed involvement of its tautomer, the imine intermediate, in this 
reaction also, as implied by the presence of both mycalamide oxazolidinone 
isomers in the product mixture. In particular, it appeared that the azide ion in 
DMSO was behaving as a significantly strong base, to facilitate formation of 
the amide anion and removal of the C11 proton, although this required high 
reaction temperatures where elimination reactions might be expected to be 
more competitive with substitution reactions176. This basicity is consistent 
with the the reported properties of azide ion and even halide ions in dipolar 
aprotic solvents, being much more reactive towards hydrogen than in protic 
solvents, so that they behave as both strong bases and powerful 
nucleophiles243. 
There is some conjugation possible between the C1 0-C11 double bond 
and the amide 1t system which may stabilise this compound. Physical 
evidence for this conjugation is the observed UV absorbance of this 
compound at A-=254 nm on silica gel TLC plates. Some antibiotics244,245 
have also been isolated containing a similar alkoxy enamide structural 
fragment228, and this enabled some comparison of the 13C NMR data. 
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However this substructure was clearly uncommon. The biological activity of 
this derivative will be discussed with other results at the end of this chapter. 
6.4.3 CHARACTERISATION OF THE MINOR PRODUCTS 
6.4.3.1 10R MYCALAMIDE A (AND B) 
The product obtained in the next highest yield (-12%, from HPLC on 
TLC fractions 4 and 5) was much smaller in mass (less than 1 mg). A 1 H NMR 
spectrum was very similar to .that obtained for 7-0-benzyl 1 OR mycalamide A 
(6.3), but without the benzyl resonances and related substituent effects101. 
The data were readily assigned using results from a COSY experiment and 
selective decoupling experiments (Table 6.7). The chemical shifts and vicinal 
proton-proton coupling constants for substituents of the trioxadecalin ring 
system were indicative of the presence of the opposite chair-chair 
conformation to that found for mycalamide A as the major solution 
conformation for this system in this derivative. NOE experiments (Table 6.8) 
gave almost identical results to those for the 7-0-benzyl 1 OR mycalamide A 
derivatives (6.3, 6.4), requiring that there be an inversion of configuration at 
C 1 0 in mycalamide A, accounting for the conformational changes above. 
Partial 13C NMR data were obtained by direct acquisition, and the remaining 
data were obtained indirectly from HMQC and HMBC experiments performed 
at 500 MHz (Tables 6.9 and 6.1 0). These data were similar to those obtained 
for the 7-0-benzyl derivatives, except in the vicinity of C7. HRFABMS 
confirmed that this compound was an isomer of mycalamide A. Therefore all 
the evidence above was consistent with the proposed structure, 1 OR 
mycalamide A (6.17). 
Interestingly, 1 OR mycalamide A (6.17) had a significantly longer 
retention time on reverse phase HPLC than mycalamide A, just as observed 
for the 7-0-benzyl derivatives, but these compounds were not resolved on 
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silica gel TLC. The isolation and characterisation of this derivative prompted a 
review of earlier results from the reactions of mycalamides A and 8 with 
various bases, described in the previous chapter (5). One fraction from a 
reaction of mycalamide 8 with sodium methoxide in methanol had given a 
mixture of mycalamide 8 trans oxazolidinone and an unknown mycalamide 8 
derivative containing the C10-C12 methylene acetal by 1H NMR spectroscopy. 
Reexamination of this spectrum showed that there were resonances 
consistent with a 1 OR mycalamide 8 compound (6.18) and, by using the 
retention time characteristics of such compounds on reverse phase HPLC, this 
was readily purified. The 1 H NMR spectrum of this sample was very similar to 
that of 10R mycalamide A, and was readily assigned with the assistance of a 
COSY experiment (Table 6.7) and NOE experiments to assign the methoxyl 
resonances (Table 6.8). Although the sample was too small to obtain 13C 
NMR data, the molecular formula was readily confirmed by HRFA8MS. 
Therefore the isolation of these compounds was further indication of the 
possible involvement of a common imine intermediate in these reactions. 
6.4.3.2 £ISOMER OF THE ENAMIDE, 1::,.10 10-DEFORMYL MYCALAMIDE A 
The yields of the remaining four products were less than 10%, 
corresponding to sample masses of less than 0.5 mg. The 1 H NMR spectrum 
of one sample (from HPLC on TLC fraction 5) was very similar to that of the 
major product, Z 1::,.1 o 1 0-deformyl mycalamide A (6.16), suggesting that it was 
the isomer of the C1 0-C11 double bond (6.19). There was an absence of 
the two 10-0CH and H11 resonances and a long range coupling (1.7 Hz) was 
observed between H10 and H12104. However, the H12 resonance was 
further split by coupling to a sharp doublet at 82.65 ppm (2.7 Hz), as shown by 
a selective proton decoupling experiment. This new resonance was assigned 
to the C12 hydroxyl proton since it was removed on addition of D20. A COSY 
308 
experiment was recorded to confirm further assignments of the 1 H NMR data 
(Table 6.7). There were shifts in the H5a (-0.3), H5e (-0.1 ), NH {+0.9}, H1 0 
(+0.3), H12 (+0.2) and H13 {+0.2) proton resonances, compared with data for 
the Z isomer, consistent with a different geometry of the C1 O-C11 double 
bond, causing different electronic101 and shielding effects123 between the 
substituents. Of particular note was the observation of the NH resonance at 
59.43 ppm, suggesting that this proton was involved in a strong hydrogen 
bonding interaction 101. The observation of the C12 hydroxyl resonance, not 
normally observed, suggeste·d that the C12 oxygen could be involved in this 
hydrogen bond. In fact the E geometry of the C1 O-C11 double bond allows 
the NH proton to be close to the C12 oxygen, and a 6-membered ring would 
be formed by a hydrogen bond between these atoms (Figure 6.3b). The 
conformation of this new ring could be described as an envelope, since the 
partial conjugation of the enamide would cause the NH proton to be 
approximately in the plane of this 1t system107, with theN, C10, C11 and C12 
atoms. The solution conformation of the C11-C15 ring was the same in both 
isomers, as shown by the chemical shifts, the similarity in the magnitude of the 
H 12-H13 coupling constant, and by the observation of similar NOE 
interactions (Table 6.8). 
0 H 
N 
I 
H OH 
' CHs c~ I c~ 
OCH3 
E A10 10-Deformyl mycalamide A (6.19) 
OH 
It was interesting that, despite the observed hydrogen bonding 
interaction in this isomer and the trans stereochemistry, it was the minor 
product of the two isomers. It is possible that unfavourable steric interactions 
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between the amide nitrogen and the C12 and C12 oxygen atoms, being on 
the same side of the double bond, are a factor in this. The polarity of this 
compound was close to that of mycalamide A on both silica gel and reverse 
phase HPLC and, during an attempt to purify this sample for further biological 
assays, the sample was unfortunately lost. Hence no mass spectroscopy 
measurement was obtained, but the 1 H NMR data discussed above permitted 
little ambiguity about the structure of this product. 
6.4.3.3 PEDERAMIDE 
Another minor product (from TLC fraction 6) was found to be 
pede ram ide (3.4) by 1 H NMR spectroscopy (Table 6.4), FTIR, CIMS and 
HREIMS, there being good agreement with the reported data for this 
derivative126,133. In a further experiment, the major product of this reaction, Z 
A 1 o 1 0-deformyl mycalamide A (6.16), was treated with sodium azide in 
DMSO for six days at 90°C. The major product after workup and preparative 
TLC was found to be pederamide (3.4), although there was also some 
unreacted starting material and a trace amount of some unknown mycalamide 
A oxazolidinone derivatives. Therefore pederamide would be a major 
hydrolysis product from longer reactions of mycalamide A with azide ion. This 
larger sample of pederamide enabled a 13C NMR spectrum to be recorded 
and assigned (Table 6.9), thus adding to the existing data for this derivative, 
and also allowed more reliable biological assay results to be obtained. 
6.4.3.4 11 R MYCALAMIDE A TRANS OXAZOLIDINONE 
The remaining two products were mycalamide A oxazolidinone 
derivatives by their characteristic blue chars on silica gel TLC plates following 
visualisation with anisaldehyde. The major one was the lowest Rt on silica gel 
of all the products (TLC fraction 1 ). A 1 H NMR spectrum showed a coupling 
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constant of 2 Hz between the H7 and H1 0 protons, suggesting the formation of 
' 
a mycalamide A trans oxazolidinone derivative209. However, there were shifts 
in the H1 0 and H13 proton resonances, and the overlap of signals hindered 
further assignments. The sample was therefore reanalysed in C0300 in an 
attempt to simplify the spectrum. 
Irradiation of H1 0 in a selective proton decoupling experiment located 
the H11 resonance in the new 1 H NMR spectrum, at <33.12 ppm, which had the 
unusual coupling constants of 1.1 and 9.9 Hz to HfO and H12 respectively, 
. 
indicative of gauche and anti relationships between these protons 102. 
Irradiation of H11 in an NOE experiment gave enhancements of the H10 and 
H13 resonances (Table 6.8). These results, and the large coupling constant 
between H12 and H13, required that the C11-C15 ring be almost entirely in 
the normal chair conformation (which was different from that observed for 
mycalamide A trans oxazolidinone, 5.3), but that the configuration at C11 be 
inverted, as shown in Figure 6.4 and in structure 6.20. A COSY experiment 
was performed which assigned the remainder of the 1 H NMR data (Table 
6.11). The observed shifts in the H10 (0.1), H11 (-0.7), H12 (-0.2), H13 (-0.3), 
14-CH3R (-0.1) and H15 (-0.4) proton resonances, compared with data for 
mycalamide A trans oxazolidinone (5.3), were also consistent with this 
epimerisation at C11 and the proposed solution conformation. The molecular 
formula for this 11 R mycalamide A trans oxazolidinone derivative (6.20) was 
verified by HRFABMS. 
OH 
11 R Mycalamide A trans oxazolidinone (6.20) 
Figure 6.4 1 H-1 H NOE interactions and partial solution conformation for 
11 R mycalamide A trans oxazolidinone (6.20) 
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The 1 H NMR spectrum in CDCI3 was able to be assigned by 
comparison with the data above, and this is included (Table 6.11) to enable 
further comparisons of this data with those of mycalamide A trans 
oxazolidinone (5.3). The only major difference from the data above was in the 
size of the H1 O-H11 coupling constant, 5.0 Hz, compared with 1.2 Hz above. 
This reflected only a small difference in the relative populations of the various 
rotamers about the C1 0-C11 bond, indicative of the greater importance of 
intramolecular hydrogen bonding interactions in this solvent. In particular, 
hydrogen bonding interactions are possible between C12-0H and C1 O-N or 
C1 0-0, or NH and C12-0 or C11-0, which result in dihedral angles between 
H1 0 and H11 closer to 0 or 1aoo, thus increasing the size of the coupling 
constant according to the Karp Ius equation98. However, the exact 
conformations were not investigated further. 
This product represents an addition of the C7-0-H group across the top 
face of the (Z) C1 O-C11 enamide double bond. The addition of alcohols to 
activated double bonds is well known 110,246, and here C1 0 is electrophilic, 
and therefore more susceptible to nucleophilic attack by the C7 oxygen. 
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6.4.3.5 A11(12) MYCALAMIDE A TRANSOXAZOLIDINONE 
The final fraction (from HPLC on TLC fraction 4) was a very small 
sample, of similar polarity to mycalamide A. The 1H NMR spectrum was weak 
and showed an absence of the two 1 0-0CH doublets, and the presence of 
coupled H1 0 and H7 proton resonances, at o5.41 and 4.42 ppm (2.0 Hz), 
indicative of a mycalamide A trans oxazolidinone derivative, as above. 
However, the H10 resonance appeared only as a doublet, being completely 
decoupled on irradiation of hl7, and was shifted slightly upfield, compared to 
that for mycalamide A trans oxazolidinone (5.3). There was a small downfield 
shift (+0.2 ppm) in the H15 resonance, which was partially decoupled by 
selective irradiation at o1.55 ppm, performed to reduce the intensity of the H20 
resonance, implying the location of one of the H16 resonances at this 
chemical shift. There was also a significant upfield shift (-0.2) in the C13 
methoxyl resonance, whereas the C14 methyl proton resonances were not 
greatly affected. There was a doublet at o5.18 ppm coupled to a second 
doublet at o3.33 ppm (2.6 Hz), as shown by a proton decoupling experiment, 
which were assigned to the H12 and H13 protons, respectively. Note that 
there was no H11 proton, as shown by the multiplicity of the H1 0 resonance, 
so that there must be a double bond between C11 and C12, which would also 
account for the observed chemical shifts101. Therefore the structure was 
6.21, and the remaining 1 H NMR data were readily assigned (Table 6.11 ). 
HRFABMS showed a compound of molecular formula C23H37N Oa, 
representing a loss of H20 from mycalamide A trans oxazolidinone, in 
agreement with the proposed structure. This derivative could arise from a 
substitution of the C7 oxygen at the C1 0 position of the enamide derivative 
(6.16), and migration of the C10-C11 double bond to C11-C12, with 
elimination of the allylic C12 hydroxyl group. 
= CH3 
CH2 OCH3 
OH 
CH3 
OH 
1111 Mycalamide A trans oxazolidinone (6.21) 
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Therefore the products from the reaction of mycalamide A with sodium 
azide had been identified and characterised as much as sample size would 
permit. Some unexpected products were obtained, exemplifying the base 
chemistry of this aza acetal substructure, which could give important structure-
activity correlations. Before describing these results, it is useful to consider the 
results of two further reactions involving basic conditions, also performed on 
mycalamide A. 
6.5 OTHER REACTIONS - REDUCTION AND OXIDATIVE 
CLEAVAGE OF MYCALAMIDE A 
6.5.1 REACTIONS OF MYCALAMIDE A WITH SODIUM BOROHYDRIDE IN 
DMSO 
It was proposed that the reactivity of the C1 0 aza acetal under basic 
conditions could permit the reduction of this system. Sodium borohydride in 
dipolar aprotic solvents is reported to be an effective source of nucleophilic 
hydride ion247, which can be utilised for the reductive displacement of primary 
and secondary alkyl halides and sulphonate esters. In particular, the use of 
dipolar aprotic solvents accelerates the rate of nucleophilic substitution 
reactions (SN2), without greatly enhancing other forms of attack, such as 
carbonyl additions247. The mildness of the borohydride reagent also allows 
more selective reactions to be performed, since carboxylic acids, esters and 
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amides are not affected, whereas lithium aluminium hydride, for example, is 
much less selective. 
Mycalamide A was reacted with a very large excess of sodium 
borohydride in DMSO at 13ooc for two days. After workup, TLC indicated that 
there was a mixture of at least three products, dominated by mycalamide 
oxazolidinone compounds. A 1 H NMR spectrum of this mixture showed that 
the major product was mycalamide A trans oxazolidinone (5.3), with a minor 
amount of the cis isomer (5.2). However, there was also a minor amount of 
some mycalamide derivative 'not containing an oxazolidinone ring and having 
no C1 0 methylene acetal system. Preparative TLC gave five fractions, of 
which three were mixtures of unreacted mycalamide A and mycalamide A cis 
and trans oxazolidinones by 1 H NMR spectroscopy. The remaining two 
fractions (1 and 2) contained new derivatives, which were then analysed by 
N MR and mass spectroscopies. 
6.5.1.1 CHARACTERISATION OF THE COMPOUND IN FRACTION 1 
The first compound (from TLC fraction 1) was more polar than 
mycalamide A and represented almost one quarter of the purified products by 
mass, discounting unreacted mycalamide A. HRFABMS indicated a 
compound of molecular formula C24H41 NOg, corresponding to a loss of CO 
from mycalamide A. An FTIR spectrum included a carbonyl stretching band at 
1660 cm-1, representing a 20 cm-1 shift to lower frequency of the secondary 
amide band. This was consistent with the removal of the electron withdrawing 
acetal oxygen substituent at C1 0, allowing more electron density to be 
donated by the amide nitrogen to the carbonyl group96. 
The 1 H NMR spectrum showed a loss of the two 1 0-0CH doublets of 
the mycalamide A spectrum, and shifts in the NH (-0.4), H1 0 (-2.1 ), H11 (+0.3), 
H12 (-0.3), H13 (-0.6) proton resonances, as assigned by a COSY experiment 
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(Table 6.7). The NH resonance appeared as a triplet (6.7 Hz}, coupled to a 
two proton triplet at 83.75 ppm (6.7 Hz}, which was further coupled to a quartet 
at 84.15 ppm (6. 7 Hz). The latter was coupled to a doublet of doublets at 83.91 
(6.7, 9.6), which was in turn coupled to a doublet at 82.91 ppm, which were the 
H 12 and H 13 resonances, respectively. Therefore these data required that 
there be two protons at C1 0, but these happened to be coincident in the 1 H 
NMR spectrum98, accounting for the multiplicities and chemical shifts of the 
resonances above. Thus hydrogenolysis of the C1 0 aza acetal had been 
achieved to give the structure 6.22, including an hydroxyl group at C12. Note 
that the loss of the acetal group at C12 would explain the observed large 
upfield shift in the H13 proton resonance, as described for earlier derivatives. 
10, 12-0-Dihydro mycalamide A (6.22) 
NOE experiments were performed to examine the solution 
conformations of this central amide chain and C11-C15 ring portion, but these 
investigations were partly restricted by the coincidence of the two H1 0 proton 
resonances. The observed NOE interactions, H12-14-CH3S, H13-H15, and 
H210-H13 were indicative of the normal chair conformation being the major 
solution conformation for the C11-C15 ring. There were also enhancements 
of the NH and H21 0 resonances on irradiation of H11, and enhancements of 
H 210 and H11 on irradiation of the NH resonance. The observed vicinal 
coupling constants between both H1 0 protons and the NH and H11 protons 
were of similar magnitude, 6.7 Hz. This suggested that there were several 
conformations about the C1 O-N and C1 O-C11 bonds, since this value is close 
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to that for a freely rotating fragment248, in which the main factor governing the 
magnitude of the coupling constant is electronegativity102. Interestingly, this 
was in contrast with the analogous system H15-H216-H17 on the other side of 
the ring, where there were two resolved coupling constants from H15 to the 
two H16 protons, although these were also probably averaged values. 
A 13C NMR spectrum was recorded and the data assigned by an 
HMQC experiment (Table 6.9). The C1 0 resonance was substantially upfield, 
at 836.3 ppm, typical of a methylene carbon attached to a heteroatom, and 
there were related shifts in the C11 (+3.3), C12 (-5.0), C13 (+7.6) and C15 (-
1.2) carbon resonances, consistent with the proposed structure117. 
6.5.1.2 CHARACTERISATION OF THE COMPOUND IN FRACTION 2 
The second compound (from TLC fraction 2) was also more polar than 
mycalamide A, but there was less than 0.5 mg in this fraction. The 1 H NMR 
spectrum showed that this was a ~4(5) mycalamide A trans oxazolidinone 
derivative (6.23), analogous to the cis isomer (5.6) described in the previous 
chapter (5). The distinctive features, compared to data for mycalamide A trans 
oxazolidinone (5.3), were loss of the two 4=CH methylene resonances and 
appearance of a new allylic methyl-methine system, involving a long range 
coupling constant of 1.5 Hz104. The 1 H NMR spectrum was partially assigned 
(Table 6.11 ), but the small sample size and the presence of impurities in the 
sample prevented a more complete analysis. This derivative also proved to 
be unstable in CDCI3 solution containing a trace of pyridine. However, a 
H RFABMS result was obtained, confirming the molecular formula of this 
product. 
OH 
A4(5) Mycalamide A trans oxazolidinone (6.23) 
6.5.1.3 ANALYSIS AND COMPARISONS WITH OTHER REDUCTION 
ATTEMPTS 
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The predominance of the mycalamide A oxazolidinone derivatives in 
the product mixture from the above reaction indicated that the reagent was 
behaving as a base as well as a nucleophile, but this associated basicity was 
to be expected with anions in DMS0243, as discussed earlier. Despite this, a 
significant degree of hydrogenolysis of the aza acetal was achieved, although 
it was uncertain whether this represented a direct SN2 displacement at C1 0, or 
the reduction of an imine intermediate. Finally, in other attempts at reduction, 
no reaction was observed between mycalamide A and sodium borohydride in 
ethanol, or between mycalamide A and lithium aluminium hydride in refluxing 
THF, although in the latter case prolonged reaction appeared to give 
decomposition, so these reactions were abandoned. 
6.5.2 REACTIONS OF MYCALAMIDE A WITH BARIUM OXIDE IN BENZENE 
The work described in the previous chapter and the work above has 
concentrated on exploring the base catalysed reactions of mycalamide A in 
protic or dipolar aprotic solvents. However, the results of successful 
methylation reactions in benzene, described in Chapter 2, suggested that the 
base catalysed reactions of mycalamide A in non-polar solvents should also 
be investigated. In particular, it was proposed that a different reactivity would 
be observed because substitution reactions, such as involved in the formation 
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of the mycalamide A oxazolidinones, would be strongly disfavoured140. 
However, the existence of ion pairs was likely158,140,176, which could permit 
some reactions to occur. 
6.5.2.1 ISOLATION AND CHARACTERISATION OF PRODUCTS FROM A 
REACTION AT 1 oooc 
Mycalamide A was reacted with barium oxide in benzene for 20 hours 
at 1 oooc in a sealed vial. Solvent partition of the residue gave two fractions 
. 
containing chloroform and water soluble material respectively. In this case 
most of the product mass was water soluble. 
A 1 H NMR spectrum of the organic fraction showed the presence of 
mycalamide A, 1 OR mycalamide A (6.17), and one other unknown 
mycalamide A derivative which also retained the C1 O-C12 methylene acetal. 
Analysis by reverse phase HPLC further confirmed the presence of 1 OR 
mycalamide A, but the new component was not separable from mycalamide A. 
However, the new component was of higher Rt than mycalamide A and 1 OR 
mycalamide A (6.17) on silica gel TLC, so it was easily purified. The overall 
yield of this new compound was less than 1 0%. 
The 1 H NMR spectrum of this fraction was weak, but very similar to that 
of mycalamide A, and was readily assigned with the assistance of further 
results from proton decoupling experiments and a COSY experiment. There 
were shifts in the HSa (+0.3), HSe (-0.1) and NH (-0.1) proton resonances 
(Table 6.7), which suggested that a C7 epimer of mycalamide A had been 
formed (6.24), based on earlier results. This was also consistent with the 
known base catalysed reactions of mycalamide A and derivatives, given the 
presence of 10R mycalamide A (6.17) in the reaction mixture. An NOE 
experiment showed the typical enhancement of the C6 methoxyl resonance 
on irradiation of H7. However, the small sample size prevented further NMR 
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spectroscopic examination of this important derivative. A low resolution 
FABMS spectrum showed an ion peak at m/z 472, consistent with the 
expected MH+-CH30H ion, but this was weak and it was possible that some 
decomposition of the sample had occurred, so that no high resolution result 
could be obtained. 
A 1 H NMR spectrum of the water soluble material from the reaction 
contained resonances relating to the left hand portion of the mycalamide A 
structure to C7. It was evident that the 01-C6 tetrahydropyran ring was intact 
. 
since the observed coupling constants and chemical shifts of the substituents 
were similar to those for mycalamide A. Furthermore, NOE interactions were 
observed between the the H2 and 6-0CH3 protons and the H5a and 3-CH3 
protons, consistent with the usual chair conformation for this ring. There were 
small shifts in the H2 (-0.2), two H5 (<0.1) and 6-0CH3 (-0.2) resonances 
(Table 6.7}, compared with data for mycalamide A, but there were no H7 or 
other proton resonances related to the structure. 
A 13C NMR spectrum was also recorded which showed shifts in the C4 
(+2.4}, C5 (+3.3}, C6 (+1.2) and 6-0CH3 (+2.1) carbon resonances (Table 
6.9}, but there were no other related signals to suggest a C7 substituent. 
However, the 13C NMR chemical shifts117, the evidence from the 1 H NMR 
spectrum, and the physical evidence that this was a water- and methanol-
soluble salt, were consistent with possibility that the remaining substituent at 
C6 was a carboxylate anion (6.25). This proposal was later verified by 
negative ion HRFABMS, which showed a very intense M- ion peak at m/z 199, 
indicative of a molecular formula of C1oH1s04, and a weaker M--CH30H ion at 
m/z 167, as expected for the C6 acetal system. This structure could possibly 
arise from air oxidation at C7 and cleavage between C7 and C8 under basic 
conditions, although not necessarily in that order. In an attempt to provide 
further evidence for the presence of a carboxylate salt, a methylation reaction 
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was attempted, using barium oxide and methyl iodide in DMS0249. This was 
unsuccessful in that decomposition occurred, as observed by TLC and 1 H 
NMR spectroscopy. Note that diazomethane methylations required the 
presence of an acidic hydrogen to activate the reagent, whereas acidic 
conditions, required to convert the salt into a carboxylic acid, were undesirable 
due to the acid lability of the C6 acetal. Therefore this methylation attempt was 
abandoned. 
H3CQ H,cyo~coo· 
H3C~ 
CH2 
?-Carboxylate fragment (6.25) 
No products from the right hand portion of the mycalamide A structure 
were isolated in this reaction. However, there were a number of low intensity 
resonances present in the 1 H NMR spectrum of the water soluble fraction 
which could have resulted from the decomposition of such a fragment. 
Therefore the initial reaction was repeated at lower temperature in an attempt 
to trace this missing fragment. 
6.5.2.2 ISOLATION AND CHARACTERISATION OF PRODUCTS FROM A 
REACTION AT aooc 
Mycalamide A was reacted with barium oxide in benzene for two hours 
at 80°C, monitoring by TLC. After workup, the evaporated residue was solvent 
partitioned, as above, to give organic and water soluble fractions. 
The 1 H NMR spectrum of the organic soluble fraction showed that the 
major component was unreacted mycalamide A. There were apparently no 
C7 or C10 epimers of mycalamide A present in this mixture, but there were 
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some minor resonances corresponding to at least two unknown mycalamide 
components. Preparative silica gel TLC separated out a fraction containing 
material which was of significantly higher Rt than both mycalamide A and the 
trace amounts of the C7 epimer. A 1 H NMR spectrum of this fraction showed 
that it was a mixture of the two new components, but did not permit conclusive 
identification of their structure, and the sample was too small to attempt further 
purification and characterisations. Note, however, that both components 
appeared to contain the full mycalamide structure, including the normal chair-
. 
chair conformation of the trioxadecalin ring system, except that the H7 
resonances appeared to be absent. The two pairs of H5 resonances were 
well dispersed and shifted downfield from their positions in the mycalamide A 
spectrum, as follows, H5a (+0.6, +0.5) and H5e (+0.2, +0.2). The two 
derivatives differed most in the chemical shifts of the H5a and 6-0CH3 
resonances, and in those of other nearby substituents. From this limited 
evidence it is possible to suggest that these compounds contained a C7 
ketone functionality, arising from air oxidation under basic conditions, and that 
they could be epimeric at C6. The biological activity of such derivatives would 
be most interesting, in view of the proposed importance of the C7 hydroxyl 
group and neighbouring entities. However, there was insufficient time to 
obtain more of these derivatives, which were formed in low yields and could 
be difficult to separate. 
The 1 H NMR spectrum of the water soluble fraction contained 
resonances for the C7 carboxylate fragment (6.25), but also resonances from 
some fragment arising from the right hand portion of mycalamide A. In 
particular, there were two sets of signals, indicative of one or more compounds 
containing the C1 O-C15 trioxadecalin ring system and the C16-C18 sidechain, 
but the substituent at C1 0 was uncertain. The chemical shifts of the two H1 0 
resonances were 85.83 and 5.95 ppm, so that the amide nitrogen and 
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probably CB were likely to be present. There were some rather weak singlets 
between ()8.2 and 8.4 ppm which could suggest that this was the salt of a 
formamide derivative, such as isolated from the base catalysed cleavage of N-
alkylated mycalamides, described earlier in this chapter. However, irradiation 
of these signals in an NOE experiment gave no obvious enhancements, 
whereas irradiation of both H10 resonances enhanced the 10-0CHR and H15 
resonances. An alternative possibility for the structure is an isonitrile250, 
formed by dehydration of the formamide derivative (such a compound could in 
. 
turn be oxidised to an isocyanate or undergo elimination176,251). However no 
conclusive mass spectroscopy measurements were obtained on this latter 
fragment to better establish its structure and it would not be easily purified, so 
work on it was not pursued. 
Thus the main features of the base chemistry of mycalamide A in non-
polar solvents appeared to be oxidative cleavage at C7-C8, with minor 
amounts of epimerisation at C7 and C1 0 at temperatures of 1 oooc, and, 
apparently, the formation of some intact C7 oxidation products at slightly lower 
temperatures. Further oxidation reactions of mycalamides A and B will be 
discussed in the next chapter (7). 
6.6 BIOLOGICAL ACTIVITY RESULTS 
The biological assay results for derivatives in this chapter are listed in 
Table 6.12. None of the 7 -0-benzyl my cal amide derivatives (6.3-6.15) had 
significant activity, as expected, based on results for 7-0-alkyl mycalamide 
derivatives in Chapter 2. The N-formyl fragments (6.1 and 6.2) were also 
inactive. However, the most significant results were for those derivatives 
which had lost the C1 0-C12 methylene acetal. The en amide products (6.16 
and 6.19), containing a double bond between C1 0 and C11 and an hydroxyl 
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group at C12, were both at least 100 times less active than mycalamide A, and 
the major, Z isomer was certainly inactive. Hydrogenolysis of the acetal gave 
a product (6.22) which was about 40 times less active than mycalamide A. 
These results suggested that the conformation of this central portion of the 
mycalamide structure could not be significantly altered without a dramatic loss 
of activity. The C1 0 aza acetal system itself appeared to be less essential than 
the C6 acetal system (Chapter 4) but the presence of some alkoxy group at 
C10, such as in pederin, still appeared to be advantageous for the biological 
activity. 
A further interesting feature was the extremely low activity of the C7 and 
C10 epimers. The biological activity of 10R mycalamide A (6.17) was at least 
500 times less than for mycalamide A, and 1 OR mycalamide B (6.18) was at 
least 100 times less active than mycalamide B. Note that the stated activity of 
1 OR mycalamide B was probably not a true indication, since the sample was 
very small and a 1% impurity of mycalamide B could account for this assay 
result. Similarly, 7 S mycalamide A (6.24) was at least 400 times less active 
than mycalamide A. Therefore this proved that the chirality of the central 
portion of mycalamides A and B was vitally important. Similarly specific 
results were noted for cycloheximide (0.14), emetine (0.13) and related 
compounds, where only structures having the natural configuration at the 
central secondary hydroxyl or amine carbon atom were active49,53, and such 
results are common16. 
The remaining cleavage products were inactive within the limits of 
purity. In particular, pederamide (3.4) was at least 15000 times less active 
than mycalamide A, and the water soluble salts, obtained from a proposed 
cleavage of mycalamide A at C7-C8, were also relatively inactive. Therefore it 
was evident that both halves of the mycalamide structure were required for the 
biological activity. Importantly, the pederamide portion was not an active 
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substructure, and nor was it an ideal derivative for preparing N-alkyl 
analogues, as first considered, since the reactions possible were limited and 
adequate protection for the C7 hydroxyl group would be required. 
These results have demonstrated some important structure-activity 
relationships for mycalamides A and B. Therefore this detailed study of the 
base catalysed reactions of mycalamide A and its derivatives in various 
solvents was worthwhile, having also elucidated some interesting chemistry of 
the central portion of mycalamide A 
Table 6.1 1 H NMR dataa,b for compounds in Section 6.2. 
H8 
N-CH2Ph 
N-CH3 
H10 
10-0CHR 
1 0-0CHS 
H11 
H12 
H13 
13-0CH3 
14·CH3R 
14-CH3S 
H15 
H16 
H16 
H17 
17-0CH3 
H18 
H18 
18-0CH2P h 
18-0CH3 
N-Benzyl, N-formyl fragment (6.1) 
EOOrrer ZISOfTer 
8.05 8.21 
4.53,4.44 (12.0) 4.51 
4.87 (9.3) 6.18 (10.4) 
4.95 (6.9) 5.14 (6. 7) 
4.82 (6.8) 4.86 (6.7) 
4.13 (7 .1,9.4) 4.05 (6.8,1 0.5) 
4.19 (7.0,10.1) 4.21 (6.9,10.8) 
.3.26 (10.0) 3.50 (10.7) 
3.55 3.55 
0.97 0.93 
0.82 0.84 
3.26 (1 0.0) 3.32 (9.8) 
(no geometry assigned below) 
1.72 (m) 1.72 (m) 
1.54 (m) 1.54 (m) 
3.35 (m) 3.20 (m) 
3.35 3.30 
3.57 (2.3,7.7) 3.44 (4.3,10.0) 
3.45 (m) 3.37(3.8,9.9) 
4.59,4.52 (12.0) 4.59,4.44 (12.0) 
N-Methyl, N-formyl fragment (6.2) 
Eroror Z!SOf!l3[ 
8.25 8.16 
2.94 3.00 
5.15 (9.6) 6.09 (10.4) 
5.13 (6.8) 5.16 (6.8) 
4.90 (6.8) 4.88 (6.7) 
4.26 (7.0,9.6) 4.19 (7.0,1 0.6) 
4.30 (7.2,10.2) 4.27 (10.5) 
3.43 (10.4) 3.53 (10.5) 
3.57 3.58 
0.99 0.97 
0.88 0.87 
3.37 (8.9) 3.25 (9.7) 
(no geometry assigned below) 
1.76 (m) 1.76 (m) 
1.50 (m) 1.50 (m) 
3.28 (m) 3.28 (m) 
3.31 3.31 
3.4 (m) 3.4 (m) 
3.3 (m) 3.3 (m) 
3.36 3.32 
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aAn data were recorded in CDCI3, with chemical shifts in ppm relative to CHCI3, o7.25 (coupling 
constants in Hz). bAromatic proton resonances (not listed) appeared as unresolved multiplets 
between o7.5-7.2 ppm. 
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Table 6.2 1 H-1 H NOE interactionsa for compounds in Sections 6.2-6.3. 
Slgnal(s) Signals· enhanced 
CQmgQund ![[adliU~d ( 0£'2 ~otum~~m~nu 
N-Benzyl, N-formyl H8e:l H10£(12), H18£(1)d 
fragment (6.1) HS.zd N-CH2Z(2) 
H10£(2x10- HS£(19), 2x1 O-OCHR(18)b, H13BH15£(1 0), 
OCH6) 13-0CHsZ(O.S) 
H10.zd 10-0CHR(S}, H13Z{4}, H15Z(7) 
H12£ (H11 E)d N-CH2£(0.7}b, 14-CHsS(1) 
H11.zd N-CH2Z(2), H12Z(4) 
N-Methyl, N-formyl H8e:l H10£(7)d 
fragment (6.2) · HS.zd N-CH3Z(1} 
N-CHse:l H11£(4) 
N-CHs.zd H8Z(8), H11Z(4) 
H10£ (2x10- HS£(12), H10Z(5}, 2x10-0CHS(15)b, 
OCH/i H13£(5), H13Z(4), 2x13-0CHs(0.5), H15£(4) 
H10.zd 10-0CHR(S), H13Z(3), 13-0CH3Z(0.5), H15Z(3) 
7-Q-Benzyl, 1 OR 6-0CHs H2(5), H7(4) 
myc.A (6.3) H7 6-0CHs(2), 7-0CHu(4)c, NH(3) 
H10 10-0CHS(S), H11(5), H12(2) 
1 0-0CHS ( 4=CHZ, H3(3}b, 4=CH£(14)b, 7-0CHu(S)b,c, H10(7}, 
7-QCHdC) 10-0CHR(21), H12{5) 
H12 H10(3), 10-0CHS(4), H13(3), 13-0CH3(1) 
H13 H12(4), 13-0CH3(2), 14-CHsR(1 ), 14-CHsS(0.4) 
7, 18-di-0-Benzyl, H7 6-0CH3(2), 7-0CHd(1)c, 7-0CHu(4)C, NH(3) 
1 OR myc.A (6.4) NH 6-0CH3(0.4), H7(5), H11 (2) 
H10 10-0CHS(S), H11(6), H12(3) 
10-0CHR 1 0-0CH S( 17) 
10-0CHS (4=CHZ, H3(3)b, H7(1)b, 7-0CHu(S)b,c, H10(8), 
7-0CHdC) 10-0CHR(25), H12(4) 
H11 H10{4), H16S(4) 
H12 H10(2), 10-0CHS(2), H11(2), H13{2), 
13-0CH3(0.8) 
H13 H12(4), 13-0CH3(2), 14-CH3R(1), 14-CH3S(0.4} 
14-CHsR H13(7), 14-CH3S(0.9), H15(7) 
14-CHsS H13(5), 13-0CH3(0.6}, 14-CH3R(1), H15(4), 
H16R(5), H16S(2) 
H15 14-CHsR(1), 14-CHsS(O.S}, H16R(3) 
H16R 14-CH3S(0.7), H15(4), H16S(10), H17(4) 
H16S (H3) H2(7)b, 3-CH3(1)b, 4=CHZ(3)b, H11 (1 O), 
H16R{10), H17(5} 
H218 (13-0CH3} H12(2}b, H13(5)b, 18-0CH2(2) 
7-D, 7-Q-benzyl, 10-R- H10 10-0CH3(2) 
0-methyl myc.A (6.6) H11/H12 H1 0(2), H13(2}, 14-CH3S(0.5}, H16S(2) 
H13 13-0CH3(2), 14-CHsR(1} 
7-0-Benzyl H2 2-CH3(1), H3(3), 6-0CH3(0.7) 
pederamide (6.14) HSa 3-CH3(0.6), H5e(7), H7(1) 
HSe 4=CH£(2), H5a(8), H7(0.4) 
6-0CHs H2(2), H7(4) 
H7 6-0CH3(1), 7-0CHd(O.S)c, 7-0CHu(2}c 
2xNH H7(2} 
aAII data were recorded in CDCI3 
bEnhancement interpreted as being due to the irradiation of an overlapping resonance 
cu and d have been used to designate the upfield and downfield resonances of a geminal pair 
d £and Z have been used to designate signals for the two conformational isomers of the amide. 
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Table 6.2 cont'd 1 H-1 H NOE interactionsa for compounds in Section 6.3. 
Compound 
7 S-o-Benzyl 
pederamide (6.15) 
Slgnal(s) 
Irradiated 
H2 
H5a 
H5e 
6-0CHs 
H7 
7-0CHdc (4=CHZ) 
2xNH 
aAn data were recorded in CDCis 
Signals enhanced 
(% enhancement) 
2-CHs(1), H3(4), 6-0CHs(1) 
3-CHs(0.5), H5e(12), H7(0.6) 
4=CHE(2), H5a(14), H7(0.4) 
H2(2}, H7(4) 
6-0CHs(1), 7-0CHd(2)c, 7-0CHu(1)c 
H3(3)b, 4=CHE(15)b, H7(2) 
H7(0.7), H5a(0.9) 
bEnhancement interpreted as being due to the irradiation of an overlapping resonance 
cu and d have been used to designate the upfield and downfield resonances of a geminal pair 
Table 6.3 13C NMR dataa,b for compounds in Section 6.2 (no assignment 
has been made to particular conformational isomers, except 
where stated). 
N-Benzyl. N-formyl fragment (6.1) N-Methyl. N-formyl fragment (6.2) 
ca 164.92 164.15 164.10 163.64 
N-CH2Ph 43.68 (E) 46.43 (Z) 
N-CH3 25.17 (E) 29.16 (Z) 
C1 0 82.21 (E) 75.04 (Z) 81.84 (E) 74.42 (Z) 
1 O-OCH2 86.96 86.34 87.12 86.56 
C11 67.37 67.11 66.71 66.71 
C12 74.63 74.37 74.67 74.51 
C13 79.25 78.94 79.18 79.04 
13-0CH3 61.86 61.86 61.86 61.86 
C14 41.86 41.66 41.93 41.81 
14-CH3R 23.11 22.98 23.12 22.90 
14-CH3S 13.09 13.09 13.00 13.00 
C15 75.96 75.22 75.93 75.26 
C16 30.73 30.23 30.70 29.88 
C17 77.97 76.86 77.90 77.58 
11-0CH3 57.05 57.05 57.13 56.76 
C18 70.58 70.58 74.17 73.22 
18-0CH2P h 73.37 73.19 
18-0CH3 59.20 59.12 
aAn data were recorded in CDCis, with chemical shifts in ppm relative to CHCis, 877.01. 
bAromatic carbon resonances are listed in the Experimental section. 
Table 6.4 1 H NMR dataa for compounds in Section 6.3. 
H2 
2-CHa 
H3 
3·CHa 
4:CHZ 
4:CHE 
H5a 
H5e 
6-0CHa 
H7/7-0H 
1-0CH2Ph 
NH9 
NH9 
H10 
10-0CHR 
10-0CHS 
H11 
H12 
H13 
13-0CHa 
14·CH3 R 
14·CH3S 
H15 
H16 
H16 
H17 
H18 
H18 
18-0CH2Ph · 
7-0-Benzyl 
myc.A f2.39) 
3.88 (2.7,6.6) 
1.17(6.6) 
2.19 (2.5,7.0) 
0.97 (7.0) 
4.82 {1.8) 
4.72 (1.9) 
2.48 (1.9, 14.4) 
2.41 {14.3) 
3.14 
4.10 
4. 77,4.68 (11.2) 
7.24 (10.0) 
5.93(10.1) 
5.13 (7.0) 
4.84 {7.0) 
3.80 (6.8, 1 0.0) 
4.23 {6.8,10.5) 
3.49 (10.5} 
3.56 
0.98 
0.88 
3.68 (5.8,6.9) 
1.55 (m) 
1.50 (m) 
3.82 (m) 
3.62 (3.5,11.3) 
3.39 (6.0,11.2} 
7-0-Benzyi10R 
III)'C.A (.6&) 
3.89 (2.7,6.5) 
1.17 (6.6) 
2.19 (2.9,7.0} 
0.99 (7.1) 
4.81 (1.9) 
4.71 (1.9) 
2.45 (1.9,14.4} 
2.32 (14.6) 
3.19 
4.02 
4.80,4.53 (11.3} 
7.77 (9.3) 
7,18-di-0-Benzyl 
1 OR myc,A (6.4) 
3.87 (2.8,6.6) 
1.13 (6.6) 
2.16 (3.0,7.3) 
0.99 (7.1) 
4.78 (1.9) 
4.67 (1.9) 
2.44 (1.9, 14.6) 
2.35 (14.1) 
3.07 
3.99 
4.81 ,4.48 (11.5} 
7.91 (9.5) 
5.46 (2.1 ,9.3) 5.43 (2.1,9.1) 
5.07 (6.6} 5.05 (6.6} 
4.83 (6.9) 4.82 (6.6) 
3.81 (1.9,1.9) 3.78 (2.0,2.0) 
3.75 (1.7,2.4) 3.74 (1.9,2.4) 
2.92 (2.4} 2.91 (2.3) 
3.38 3.37 
1.21 1.20 
0.91 0.91 
3.64 (3.0,12.1) 3.58 (3.2,11.8) 
2.25 (7.1,12.1,15.1) 2.22 (6.7,11.9,15.0) 
1.44 (3.1 ,5.0, 15.4) 1.54 (3.3,5.9,15.2) 
3.65 (m) 3.82 {m} 
3.51 (3.4,11.0} 3.40 {3.6,9.5) 
3.33 (7.5, 11.0} 3.30 (7.1 ,9.4) 
4.50,4.43 (12.0} 
Pederamide 
M 
4.03 (2.8,6.6) 
1.18 (6.6} 
2.25 (2.6,7.3) 
0.98 (7.1) 
4.86 (2.0) 
4.75 (2.0) 
2.14 (2.1 '14.3} 
2.33 (14.0) 
3.32 
4.25/3.88 
6.78 
5.60 
7-0-Benzyl 
ped. (6.14) 
3.90 (2.8,6.6} 
1.13 (6.7) 
2.20 (2.5,7.0} 
0.97 {7.1) 
4.82 (2.0) 
4.72 (2.1) 
2.52 (2.1,14.4) 
2.38 (14.5) 
3.07 • 
3.97 
4.82,4.55 (11.8) 
6.35 
. 5.43 
7 5-0-Benzyl 
ped. (.6.15) 
3.93 (2.7,6.6) 
1.17 (6.6} 
2.20 (2.5,7.1) 
1.03 (7.0} 
4.81 {2.1} 
4.67 (2.1} 
2.78 (2.2,14.1} 
2.08 (14.0) 
3.35 
4.06 
4.78,4.68 (11.5) 
6.50 
5.38 
aAn data were recorded in CDCI3, with chemical shifts in ppm relative to CHCI3, 157.25 (coupling constants in Hz). bAromatic proton resonances (not 
listed) appeared as unresolved multiplets between 157.5-7.2 ppm. 
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Table 6.5 13C NMR dataa,b for compounds in Section 6.3. 
7-Q-Benzyl 
myc.A (2.39} 
C2 
2-CH3 
C3 
3·CH3 
C4 
4:CH2 
C5 
C6 
6-0CH3 
C7 
1-0CH2P h 
C8 
C10 
10-0CH2 
C11 
C12 
C13 
13-0CH3 
C14 
14-CH3R 
14-CH35 
C15 
C16 
C17 
c1 a 
18-0CH2P h 
69.38 
17.80 
41.38 
11.76 
146.48 
109.91 
34.61 
100.09 
. 49.22 
80.81 
73.24 
170.59 
74.19 
86.86 
71.66 
74.56 
79.24 
61.88 
41.82 
22.98 
13.26 
78.98 
32.02 
71.70 
66.74 
7-Q-Benzyl 
10BA (6.2) 
69.66 
17.74 
41.37 
11.82 
146.46 
110.08 
34.39 
99.65 
49.59 
81.28 
73.43 
169.81 
77.'2.0 
91.59 
61.81 
72.69 
83.74 
59.25 
36.65 
27.35 
22.47 
80.92 
30.41 
71.50 
66.31 
7, 18-di-0-Ben. 
10BA (6.4) 
69.46 
17.77 
41.50 
11.81 
146.57 
109.87 
34.18 
99.72 
48.83 
79.95 
73.31 
170.03 
77.26 
91.42 
61.54 
72.71 
83.84 
59.26 
36.64 
27.41 
22.50 
80.48 
30.71 
69.69 
73.85 
73.25 
7-0-Benzyl 
ped. (6.14) 
69.36 
17.83 
41.46 
11.90 
146.25 
109.99 
33.81 
99.74 
48.64 
79.14 
72.98 
172.05 
7 S-O-Benzyl 
ped. (§.15) 
68.99 
17.96 
41.34 
11.79 
146.79 
109.66 
32.90 
100.54 
49.43 
81.03 
74.30 
171.44 
aAu data were recorded in CDCJs, with chemical shifts in ppm relative to CDCI3, o77.01. 
b Aromatic carbon resonances are listed in the Experimental section. 
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Table 6.6 1 H NMR dataa.b for compounds in Section 6.3. 
7-D, 7-D-benzyl 7-D, 7-D-benzyl 7-D, 7-D-benzyl 7-D, 7$-D-benzyl 7-D, 7$-D-benzyl 7-D, 75-D-benzyl 7-D, ?S-o-benzyl 
Li 1 o 1 0-deformyl 10R-D-methyl A 105-D-methyl A 1 OR-o-methyl A myc.A 1 OS-D-methyl A 10Rmyc.A 
o:uc.A (!2.5) (§,§) (!2.6) (!2.9) (6.1]) (!2.]2) (6.13) 
H2 3.88 (2.5,6.6) 3.91 (2.6,6.7) ? 3.94 (2.6,6.6) 3.89 (2.7,6.5) 3.94 (m) 3.91 (2.5,6.5) 
2-CH3 1.13 (6.6) 1.14 (6.7) 1.16 (6.6) 1.17 (6.5) 1.17 (6.5) 1.17 (6.4) 1.17 (6.6) 
H3 2.19 (2.5,7.0) 2.19 (2.5,7.1) 2.21 (m) 2.20 (2.6,7.0) 2.19 (2.6,7.0) 2.19 (m) 2.18 (m) 
3-CH3 0.93 (7.1) 0.98 (7.1) 0.99 (7.2) 1.03 (7.0) 1.03 (7.0) 1.01 (6.9) 1.01 (7.0) 
4:CHZ 4.80 (2.0) 4.81 (1.9) 4.82 (m) 4.83 (1.9) 4.84 (m) 4.82 (m) 4.82 (m) 
4:CHE 4.70 (2.0) 4.71 (1.9) 4.72 (m) 4.67 (2.0) 4.71 (m) 4.68 (m) 4.68 (m) 
H5a 2.66 (2.0,14.2) 2.64 (1.9,14.5) 2.54 (1.9,14.0) 2.85 (2.0 ,13. 7) 2.83 (m,13.9) 2.75 (m,14.0) 2.74 (m,14.5) 
H5e 2.32 (14.2) 2.37 (14.5) 2.47 (13.9) 2.08 (13.7) 2.07 (13.9) . 2.07 (14.2) 2.07 (14.6) 
6-0CH3 3.14 3.18 3.23 3.35 3.37 3.35 3.35 
1-0CH2P h 4.72 (11.7) 4.72 (11.7) 4.75 (11.2) 4.74 (11.4) 4.75 (11.7) 4.77 (m) 4.79 (m) 
1-0CH2P h 4.51 (11.8) 4.59 (11.7) 4.70 (11.3) 4.68 (11.6) 4.70 (11.6) 4.72 (m) 4.75 (m) 
NH9 ? 7.16 (9.0) ? ? ? ? ? 
H10 6.78 (2.0,1 0.6) 5.41 (6.3,9.1) 5.63 ( 4.4, 1 0.2) 5.38 (6.9,9.0) 5.80 (1 0.1) 5.55 (3.4,1 0.5) 5.45 (2.3,8.9) 
10-0CHR 5.12 (6.9) 5.07 (6.6) 
1 O·OCHS 4.85 (6.9) 4.81 (6.6) 
10-0CH3 3.45 3.43 3.45 3.38 
H11 3.85 ? 3.82 (4.4,6.9) 3.82 (7.3,1 0.3) ? 3.81 (m) 
H12 4.19 (2.1,9.2) 3.85 ? 3.77 (4.6,6.1) 4.23 (7.1,10.4) ? 3.75 (m) 
H13 2.74 (9.1) 3.09 (5.6) ? 3.07 (6.1) 3.44 (1 0.6) 3.15 (8.3) 2.91 (2.2) 
13-0CH3 3.63 3.44 3.57 3.44 3.56 3.55 3.37 
14·CH3R 0.93 1.10 0.95 1.08 0.96 0.98 1.19 
14-CH3S 0.91 0.87 0.85 0.87 0.87 0.85 0.90 
H15 3.31 (3.1,8.8) 3.77 (1.9, 11.2) ? 3.73 (2.0,9.2) 3.69 (m) ? 3.59 (m) 
H16 ? 1.84 (4.0, 11.4,15.5) ? 1.78 (m) ? ? ? 
H16 ? 1.43 (1.9,2.7,15.5) ? 1.43 (m,15.5) ? ? ? 
H17 ? 3.77 (m) ? 3.76 (m) ? ? ? 
H18 ? 3.50 (3.8,11.2) ? 3.48 (4.0,11.8) ? ? ? 
H18 ? 3.41 (7.2,11.2) ? 3.38 (7.0, 11.9) ? ? ? 
aAn data were recorded in CDCI3, with chemical shifts in ppm relative to CHCIJ, o7.25 (coupling constants in Hz). bAromatic proton resonances (not listed) w 
w appeared as unresolved multiplets between o7.5-7.2 ppm. 0 
Table 6.7 1 H NMR dataa for compounds described in Sections 6.4 and 6.5. 
E .o.1 o 1 0-Deform. z .o.1 o 1 0-Deform. 10RMyc.A 10RMyc.B 1 o, 12-0-Dihydro 7SMyc.A 7 -Carboxylate 
!:IM:.A £6,19) !Il¥Q, A £6,1 !2l (§.]1) (6.]6) ~.A(!2.22l (6.2g) tragro~ot (!2.2~l 
H2 4.01 (2.6,6.5) 3.96 (2.7,6.6) 4.05 (2.7,6.4) 4.04 (2.7,6.6) 4.00 {2.7,6.5) 3.97 (2.6,6.6) 3.79 (2.7,6.6) 
2·CH3 1.19 (6.6) 1.19 (6.6) 1.22 (6.5) 1.21 (6.5) 1.18 (6.6) 1.18 (6.5) 1.14 (6.6) 
H3 2.20 {2.2,7.0) 2.21 (2.5,7.1) 2.23 (2.5,7.0) 2.22 (2.3,7.0) 2.23 (2.5,7.0) 2.23 (2.5,7.0) 2.25 (2.2,7.1) 
3·CH3 0.94 (7.1) 0.95 {7.0) 1.06 (7.2) 1.05 (7.3) 0.98 (7.0) 1.02 (7.0) 0.98 (7.1) 
4:CHZ 4.82 (1.8) 4.82 (1.8) 4.84 (1.8) 4.83 {1.9) 4.84 (1.9) 4.86 {1.9) 4.86 (2.1) 
4:CHE 4.71 {1.9) 4.72 (1.8) 4.72 (1.9) 4.71 (2.0) 4.73 (2.0) 4.76 (1.9) 4.70 (2.1) 
H5a 2.05 {1.9,14.4) 2.31 {1.9,14.4) 2.14 (2.0,14.2) 2.12 (1.9,14.0) 2.22 {2.0, 14.4} 2.62 (2.0, 14.4} 2.44 (2.1 '14.4} 
H5e 2.28 (14.1) 2.39 (14.3) 2.28 (14.2) . 2.27 (14.0) 2.35 (14.2) 2.28 {14.4) 2.28 (14.2) 
6·0CH3 3.31 3.29 3.32 3.32 3.30 3.32 3.06 
H7 4.21 (4.1) 4.23 4.22 (2.7) 4.22 (3.9) 4.23 4.26 
7·0H 3.96 {4.1) 3.86 (2.9) 3.90 (3.9) 
NH9 9.43 (10.8) 8.56 (10.4) 8.30 (9.4) 8.28 (9.3) 7.13 (6.7) 7.38 (9.8) 
H1 O/H21 0 6.94 (1.7, 1 0.8) 6.69 {2.0,1 0.4) 5.41 (2.2,9.3) 5.42 (2.3,9.6) /3.75 {6.7) 5.85 (9.9) 
10-0CHR 5.02 (6.7) 5.01 (6.6) 5.13 {7.0} 
10-0CHS 4.79 (6.6) 4.78 (6.7) 4.87 (7.0) 
H11 3.78 (1.5,2.0) 3.72 (1.6,2.3) 4.15 {6.7) 3.85 (6.8, 1 0.0) 
H12 4.36 (2.2,9.5) 4.20 (2.1 ,9.0) 3.73 (1.5,2.3) 3.69 ( 1.6,2.3) 3.91 (6.7,9.6) 4.24 (6.9, 10.6) 
12-0H 2.65 (2.7) 
H13 2.91 (9.5) 2.76 (9.0) 2.92 (2.3) 2.92 (2.3) 2.91 (9.6) 3.45 (1 0.5) 
13·0CH3 3.66 3.62 3.38 3.38 3.58 3.56 
14·CH3R 0.97 0.96 1.21 1.20 0.97 0.98 
14·CH3S 0.94 0.93 0.94 0.94 0.87 0.88 
H15 3.42 (4.1,8.6) 3.41 (2.8,9.3) 3.66 (2.9,11.7) 3.53 (3.0,11.9) 3.63 (5.7,7.3) 3.54 (3.8,8.6) 
H16 1.68 {m) 1.72 (m) 2.26 (7.8, 11.7,15.6) 2.38 (4.0,12.3,15.1) 1.60 (m) 1.56 (m) 
H16 1.68 (m) 1.72 (m) 1.53 (2.9,4.7,15.4) 1.59 (3.1 ,8.3, 15.3) 1.60 (m) 1.56 (m) 
H17 3.93 (m) 3.98 (m) 3.65 (m) 3.30 (m) 3.85 (m} 3.73 (m) 
17·0CH3 3.35 
H18 3.65 (3.8, 11.0) 3.70 (3.4, 11.0) 3.65 (3.2,11.0) 3. 75 (3.3, 11.9) 3.58 (3.8, 11.0} 3.62 (3.5, 11.0} 
H18 ·3.51 (6.0,11.1) 3.52 (7.3,11.0) 3.48 (7.0,11.0) 3.54 (5.5, 11.6) 3.47 (6.1, 11.2) 3.32 (6.6,11.2) 
aoata for compound 6.25 were recorded in D20, with chemical shifts in ppm relative to dioxan, 83.70 ppm. All other data were recorded in CDCI3, with (;.) 
chemical shifts relative to CHCI3, o7.25 ppm, (coupling constants in Hz). (;.) ..... 
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Table 6.8 1 H-1 H NOE interactionsa for compounds in Sections 6.4-6.5. 
Slgnal(s) Signals enhanced 
~Qmggun~ lrra~lated ( 0b ~nhan~~menl} 
Z A 1 o 1 0-Deformyl HSa 3-CHs(0.9} 
myc.A (6.16) HSe 4=CHE(2}, H7(0.8) 
H7 (H12} H5a(0.9), H5e(0.6), 6-0CHs(2), NH(2), H10(0.8) 
14-CH3S(0.6)b 
NH H7(4), H10(2), H15(1), H17(2) 
H10 H7(2), H12(2), H13(0.5) 
H12 (H7) 6-0CH3(0.9)b, H10(1), H13(1), 14-CHsS(1) 
H13 13-0CH3(3), 14-CHsR(O.B), H15(6) 
2x14-CHs (3-CHs) H3(6)b, H5a(2)b, H12(5), H13(6), 13-0CHs(1), 
H15(6), H216(3) 
H15 (6-0CHs, H7(2)b, NH(2), H10(1), H12(2), H13(7), 14-CHsR(1) 
H18uC) 
~ 
H17(2) 
H216 14-CHsR(1), 14-CHgS(2), H15(3), H17(6), 2xH18(1) 
H17 (H2) 2-CHs(2)b, H3(5)b, 6-0CHs(1)b, H15(3), H216(1) 
H18d0 (13-0CHs) H7(2), H10(0.8)b, H12(2)b, H13(1)b, H17(1), H18u{8) 
H18uc (13-0CHs) H7(1), H10(0.7)b, H12(1)b, H13(1)b, H17(1), H18d{8) 
E A 1 o 1 0-Deformyl NH H7(5) 
myc.A (6.19) H12 12-0H(B), 14-CH3S(2) 
12-0H H12(6), 13-0CH3(0.6) 
H13 13-0CHs(2), 14-CHsR(1), H15(4) 
1 OR Myc.A (6.17) HSa 3-CHs(1), H5e(21) 
H7 6-0CHs(3) 
NH H7(5) 
H10 10-0CHS{7}, H11(4), H12(3) 
10-0CHS H10(9), 10-0CHR(30), H12(7) 
H13 H12(4), 13-0CH3(2), 14-CHsS(1) 
14-CHsS H13(5), 13-0CHs(O.S), 14-CHsR(1), H15(4) 
H16R(6) 
H15 (H18dc) 14-CHsR(2), 14-CHsS(O.S}, H16R(4), H18u(5)b,c 
H16R 14-CH3S(1 ), H15(4), H16S(8) 
H16S (H3, HSe) H2(6)b, 3-CHs(1)b, 4=CHE(4)b, 4=CHZ(6)b, H11 (6) 
10R Myc.B (6.18) H7 6-0CHs(2) 
H13 H12(5), 13-0CHs(2}, 14-CHsR(2) 
Pederamide (3.4) H2 2-CHs(0.9), H3(3), 6-0CHs(0.4) 
HSa 3-CHs(0.7), H5e(11), H7(0.8) 
H5e 4=CHE(3), H5a(6) 
H7 6-0CHs(1) 
7-0H H7(0.8) 
2xNH H7(4) 
11 R A trans oxazol. H10 H11(8) 
(6.20) H11 H10(12), H13(5) 
10,12-0-Dihydro H7 6-0CHs(2), NH(3) 
(6.22) NH H7(3), H210(2), H11(2) 
H210 NH(2}, H11(2}, H13(4) 
H11 NH(1), H210(1), H12(5) 
H12 H11(4), 14-CH3S(0.7) 
H13 H210(2), 13-0CHs(2), 14-CHsR(O.B), H15(2) 
aoata for compound 6.25 were recorded in D20. All other data were recorded in CDC Is 
bEnhancement interpreted as being due to the irradiation of an overlapping signal 
0u and d have been used to designate the upfleld and downfield resonances of a geminal pair 
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Table 6.8 cont'd 1 H-1 H NOE interactionsa for compounds in Section 6.5. 
Compound 
7 S Myc.A (6.24) 
7 -Carboxylate 
fragment {6.25) 
Slgnal{s) 
Irradiated 
H7 
H2 
H5a 
H5e (H3} 
6-0CH3 
Signals enhanced 
C% enhancement> 
6-0CHs{2) 
2-CH3(2), H3(5), 6-0CHs(2) 
3-CH3(1), H5e(19) 
H2(3}b, 2-CH3 (0.5}b, 3-CHs(0.5)b, 4=CHZ{2)b, 
H5a(14) 
H2(4) 
aoata for compound 6.25 were recorded in 020. All other data were recorded in COCis 
bEnhancement interpreted as being due to the irradiation of an overlapping signal 
0 u and d have been used to designate the upfield and downfield resonances of a geminal pair 
Table 6.9 13C NMR dataa for compounds described in Sections 6.4 and 6.5 
z .6,1 o 1 0-0eform. 1 OR Myc.A 
C2 
2-CH3 
C3 
3-CHa 
C4 
4:CH2 
C5 
CS 
S-OCHa 
C7 
C8 
C10 
10-0CH2 
C11 
C12 
C13 
13-0CHa 
C14 
14-CHaR 
14-CH3S 
C15 
C16 
C17 
C18 
myc.A (6.16) (6. 17) 
69.81 69.70 
18.15 17.96 
41.42 41.55 
11.82 11.84 
145.90 145.80 
11 0. 17 11 0. 64 
33.61 32.88 
99.91 99.80 
48.98 48.47 
73.14 70.45 
167.32 172.30 
104.92 77.30 
141.65 
69.60 
90.72 
62.59 
41.46 
22.89 
13.74 
85.01 
31.79 
71.63 
66.61 
91.25 
61.05 
72.35 
83.51 
59.31 
36.62 
27.08 
22.89 
81.54 
30.00 
70.45 
66.24 
10, 12-0-0ihydro Pederamide ?-Carboxylate 
myc.A (6.22) (3,4) fragment (6.25) 
69.45 69.41 70.69 
17.99 17.97 17.85 
41.41 41.46 41.69 
12.08 12.13 12.20 
145.64 145.22 148.03 
110.52 110.88 110.90 
33.25 32.76 37.48 
99.93 ? 101.06 
48.67 48.34 50.99 
72.05 70.39 
171.66 171.75 
36.25 
74.51 
69.45 
86.78 
62.67 
41.15 
23.70 
14.42 
77.75 
31.41 
71.86 
66.75 
aoata for compound 6.25 were recorded in 020, with chemical shifts in ppm relative to dioxan, 
567.4. All other data were recorded in COCis, with chemical shifts relative to COCis, o77.01. 
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Table 6.10 2JcH and 3JcH HMBC correlationsa for compounds in Chapter 6. 
Z .111 O 1 0-Deformyl myc.A 
(6.16) 
1 OR Myc.A (6.17) 
proton 
H2 
2-CHa 
H3 
3-CHs 
4=CHEIZ 
HSa/e 
6-0CHa 
H7 
H10 
H12 
H13 
13-0CHa 
14-CHaR 
14-CHsS 
H216 
2-CHs 
3-CHs 
4=CHEIZ 
H5e 
6-0CHs 
H7 
10-0CHR'S 
H13 
13-0CHs 
14-CH3R 
14-CHsS 
8 AII data were recorded in CDCis 
Carbon signal correlated 
3-CHs 
C2, C3 
3-CH3,C4, 4=CH2, CS 
C2, C3, C4 
C3,C5 
C3, C4, 4=CH2, C6 
C6 
C6,C8 
C11 
C11,C13 
C12, 13-0CHs, C14, 14-CHsR, 14-CHsS 
C13 
C13, C14, 14-CH3S, C15 
C13, C14, 14-CHsR, C15 
C15, C17, C18 
C2,C3 
C2, C3, C4 
C3,C5 
C3 
C6 
C6,C8 
C10,C12 
13-0CHs 
C13 
C13, C14, 14-CH3S, C15 
C13, C14, 14-CHsR, C15 
335 
Table 6.11 1H NMR dataa for mycalamide A trans oxazolidinone 
derivatives, described in Sections 6.4 and 6.5. 
11 R Myc.A trans 11 R Myc.A trans A11 Myc.A trans A4(5) Myc.A trans 
oxazo.(CDgOD) oxazolidinone oxazolidinone oxazolidinone 
(§.20} (6.20} (6.21) (§23} 
H2 3.90 (2.5,6.6} 3.94 (2.4,6.4) 3.94 (2.6,6.4) 4.18 (2.7,6.5) 
2-CHs 1.16{6.6) 1.17 {6.5) 1.18 (6.6) 1.16 (6.6) 
H3 2.20 (2.3,7.1) 2.18 (2.7,7.0) 2.20 (2.8,6.9) 2.10 (m) 
3-CHa 1.02(7.1) 1.01 (7.1) 1.03 (6.9) 0.95 (7.0} 
4:CHZ 4.80 (1.8) 4.82 (2.0) 4.83 (2.0) 
4:CHE 4.64 (1.9) 4.68 (2.0} 4.71 (2.0} 
4-CHs 1.78 (1.5) 
HSa 2.35 (1.9, 13.8) 2.43 (2.0, 13.8) 2.44 (2.0, 14.2} 
HSe 2.22 (13.7) 2.25 (14.0} 2.30 (14.0) 
HS 5.32 (1.5) 
6-0CH3 3.23 3.27 3.30 3.36 
H7 4.37 (2.1) 4.36 (2.1) 4.42 (2.0} 4.17 (2.5} 
NH9 ? ? ? ? 
H10 5.40 (1.2,2.2) 5.31 (2.2,4.9) 5.41 (2.0} 5.63 (2.6,5.9) 
H11 3.12 (1.1,9.9} 3.22 (5.0,9.4) 3.91 (5.9) 
H12 3.72 (9.6} 3.66 (9.3} 5.18 (2.6) 3.97 (5.7,7.5} 
H13 2.75 (9.3} 2.78 (9.1) 3.33 (2.6) 2.89 (7.5) 
13-0CHa 3.60 3.61 3.34 3.52 
14-CHaR 0.92 0.94 0.95 1.02 
14-CHaS 0.82 0.84 0.90 0.89 
H15 3.25 (m) 3.35 (5.0,7.6) 3.84 (2.5,9.4) ? 
H16 1.75 (2.1,7.5,14.3) 1.65 (m) 1.70 (m) ? 
H16 1.53 (5.0, 1 0.4, 14.3) 1.60 (m) 1.55 (m) ? 
H17 3.79 (m) 3.87 (m) 3.90 (m) ? 
H18 3.55 (3.5, 11.3) 3.59 (m) 3.63 (3.3, 11.5) ? 
H18 3.46 (5.9, 11.5) 3.45 (5.8, 11.1} 3.48 {6.2, 11.6) ? 
aAu data were recorded in CDCI3, unless otherwise specified, with chemical shifts in ppm 
relative to CHCig, o7.25, or CHD20D, 03.30 (coupling constants in Hz). 
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Table 6.12 Biological assay results for compounds in Chapter 6. 
~Qmggund P~aa IQsoa Antiviral R§!§ultsb (ng/disk) 
Mycalamide A 0.5 VWI WN +* 5 + + +* 2 
Mycalamide B 0.1 VWI WN +* 2 +++ +++ +* 1 
N-Benzyl, N-formyl frag.{6.1) > 12500 40000 
N-Methyl, N-formyl frag.(6.2} 800 +++ +* 20000 + ++ +* 10000 
7-0-Benzyl myc.A {2.39) 90 WN WN +* 1000 500 
7-0-Benzyi10R A {6.3) 600 WN WN +* 20000 ++ +++ +* 10000 
7, 18-Di-0-Benzyl 10-R A (6.4} 1300 VWI WN +* 20000 ++ ++ +* 10000 
7-D, 7-0-Bn. A10 10-de.(6.5} 600 2000 
7-D, 7-0-Bn. 10R-O-Me.(6.6} > 1250 2000 
7-D, 7-0-Bn. 10S-O-Me.(6.8} >1250 2000 
7-D, 78-0-Bn. 10R-0-.. {6.9) >1250 2000 
7-D, 7S-O-Benzyl A (6.11) >1250 
7-0-Benzyl ped. {6.14) 800 WN WN +* 5000 2000 
7 S-O-Benzyl ped. (6.15) 8.00 VWI WN +* 5000 2000 
E A10 10-Deformyl A (6.19) >50 
Z A 1 O 1 0-Deformyl A {6.16) 1500 VWI +++ +* 20000 + +* 10000 
10R Myc.A (6.17) 300 VWI WN +* 5000 2000 
1 OR Myc.B (6.18} 7 WN ww +* 200 +++ +++ +* 100 
Pederamide (3.4) 7500 
- 40000 
11 R A trans oxazo (6.20) 120 ww ww +* 4000 + ++ +* 2000 
1 0, 12-0-Dihydro myc.A (6.22) 20 VWI ww +* 500 +++ +++ +* 200 
7 S Myc.A (6.24) 180 
7-Carboxylate fragment (6.25) 110 VWI +++ +* 500 
a In ng/ml. The derivatives are estimated to be better than 95% pure, having been subjected to 
at least two steps of chromatographic purification in most cases. 
b -,+,++,+++,WW=antiviral zone size. Results are listed in the order of Herpes simplex virus, 
Polio virus, cytotoxicity, loaded sample mass. 
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CHAPTER 7 
OXIDATION OF MYCALAMIDES A AND 8 
7.1 INTRODUCTION 
In view of the proposed importance of the C7 hydroxyl group and, to a 
lesser extent, the substituents of the C16-C18 sidechain for the biological 
activity of mycalamides A and B (Chapters 2 and 6), it was of interest to 
. 
consider the oxidation of the hydroxyl groups present in these structures. 
Selective oxidation of the primary hydroxyl group would also generate a 
reactive centre which could then permit further modifications of this portion of 
the structure. Furthermore, reduction of an aldehyde group would represent a 
facile method for the introduction of an isotopic label, such as deuterium, into 
the mycalamide structure, for potential use in mode of action or 
pharmacokinetic studies73. 
Pederone (7 .1 ), a natural product isolated in low yield together with 
pederin and being a C13 ketone pederin derivative, was reported to show 
strong biological activity28, although this was not quantified. Preliminary 
degradative work on pederin and pseudopederin (3.5) included oxidation 
with potassium permanganate, but this gave unsatisfactory results, with a 
large number of products being formed that were difficult to separate27. 
Pederin was reported to be stable to oxidation using lead tetraacetate in 
benzene solution94. However, pseudopederin reacted readily under these 
conditions to give isopederolactone (7 .2), an isomer of pederolactone (3.6), 
and an aqueous carboxylic acid fraction which yielded pede renal (3.1) on 
acid hydrolysis27,94. Various other oxidations were also performed on 
pederin fragments, during its synthesis, including a Collins oxidation240 (see 
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below), and an oxalyl chloride-DMSO-triethylamine reagent129,252,253 at low 
temperature to successfully oxidise the C7 hydroxyl group. 
OH 
' 
0 
Pederone (7.1) 
H,CIOYO 
H3C~ 
CH2 
lsopederolactone (7.2) 
There are a vast number of oxidising agents available for the oxidation 
of alcohols and a cursory survey is presented here254. Strong oxidising 
agents include reagents such as potassium permanganate, acid dichromate, 
magnesium dioxide and ruthenium tetroxide. Several chromium VI reagents 
are commonly used, including the Jones reagent (chromic acid and sulphuric 
acid in water), the Collins reagent (pyridine-chromium trioxide), the Corey 
reagent (pyridinium chlorochromate) and pyridinium dichromate255. Other 
reagents include morpholine-N-oxide and a ruthenium complex256, lead 
tetraacetate-pyridine257 and DMSO based reagents253,258,259. The latter 
include the Moffat reaction (dicyclohexylcarbodiimide (DCC), DMSO and 
anhydrous phosphoric or trifluoroacetic acids), and variations using acetic 
anhydride, sulphur trioxide-triethylamine-pyridine, oxalyl chloride (Swern 
oxidation) and tosyl chloride amongst many. Of these, oxalyl chloride has 
been reported to be the best activator of DMSO, giving good yields, with few 
side reactions253. Most reagents convert primary alcohols to aldehydes and 
secondary alcohols to ketones, but some of the strong oxidants oxidise 
aldehydes further to carboxylic acids. There are also reagents available for 
the selective oxidation of both primary and secondary alcohols, which will be 
discussed in later sections. However, clearly acidic conditions were not 
appropriate for studies on the mycalamides. An alternative to the above 
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reagents is the Oppenauer oxidation254, involving the use of ketones in the 
presence of strong base, but this was also not appropriate for the 
mycalamides. This chapter describes the results of some initial investigations 
on the oxidation of mycalamides A and B, but there is certainly scope for 
further work in this area. 
7.2 OXIDATIONS OF MYCALAMIDE B 
7.2.1 TRIAL OXIDATION USING PYRIDINIUM DICHROMATE 
Pyridinium dichromate has been reported to be a nearly neutral 
oxidising reagent for selectively converting alcohols to aldehydes or ketones 
and is more convenient to prepare and store than the Collins reagent255. It 
was also reported to be very efficient at oxidation and tolerant of acid and 
base sensitive functionalities, including unsaturated alcohols and substrates 
containing acetal groups. Therefore this reagent seemed to be a good choice 
to begin an oxidation study of mycalamides A and B. Mycalamide B was 
chosen for initial investigations since it contained one less hydroxyl group 
than mycalamide A, thus reducing the possibilities for oxidation. The reagent 
was readily prepared according to the literature method255 to give a good 
yield of orange crystals. 
Mycalamide B was reacted with a slight excess of pyridinium 
dichromate in dichloromethane at room temperature and monitored by TLC. 
After three days TLC showed a mixture of starting material and products, so 
the reaction was stopped. A 1 H NMR spectrum of the crude mixture obtained 
after workup indicated a large mixture of components, including four aldehyde 
signals between o9.5-9.8 ppm and resonances that were characteristic of 
pederolactone (3.6). There was very little mycalamide B present, but there 
were resonances requiring the presence of the C1 O-C12 methylene acetal 
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and the H7 proton in some components. Analysis by HPLC showed some 
unresolved components near to the retention time of mycalamide B, and at 
least three minor, more retained components. Therefore this did not appear to 
be a useful oxidation method, since there had been some acid catalysed 
rearrangement and oxidative cleavage, involving the sensitive homoallylic 
acetal, and the resulting components were not able to be separated. 
7.2.2 SELECTIVE OXIDATION OF PRIMARY OR SECONDARY ALCOHOLS 
. 
In considering alternative methods of oxidation it was decided to focus 
on the use of more selective oxidising agents. There are some reagents 
available for the preferential oxidation of secondary over primary hydroxyl 
groups. The combination of chlorine and pyridine, for example, oxidises both 
groups, but the oxidation of secondary hydroxyl groups is substantially 
faster207. Bromine, in the presence of stannoxane or distannoxane, was 
similarly effective260. However neither method would be useful for use on the 
mycalamides due to the presence of the exocyclic double bond. Another 
method, involving sodium bromate and cerium IV ammonium nitrate261, was 
also not effective in the presence of a double bond. Finally, the use of trityl 
tetrafluoroborate as oxidant involved acidic conditions and so was also not 
useful in the present context262. Therefore the selective oxidation of 
secondary hydroxyl groups in mycalamides A or B did not appear to be 
feasible, since each of the methods available involved either the use of 
halogens, or generated acidic conditions. An alternative approach was the 
use of protecting groups, but there was insufficient time to investigate this 
possibility. 
There are few reagents which preferentially oxidise primary over 
secondary hydroxyl groups. Platinum dioxide in the presence of oxygen263 
has a reportedly high selectivity, although it is claimed by some that these 
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results are not easily reproducible264. However, tris-triphenylphosphine 
ruthenium II chloride, a reagent which is useful for hydrogen-deuterium 
exchange of primary alcohols at very high temperature265, for homogeneous 
transfer hydrogenolysis of CCI4266 and for catalytic hydrogenation in the 
presence of alcohols or base267, has been reported to show selectivities of up 
to 50:1 for the preferential oxidation of primary hydroxyl groups at room 
temperature264. This reagent could be used in the presence of anhydrous 
base for acid sensitive compounds, so this method was selected for a trial 
study on mycalamide B. 
7.2.2.1 PREPARATION AND SEPARATION OF PRODUCTS FROM THE 
REACTION OF MYCALAMIDE B WITH A RUTHENIUM II COMPLEX 
Mycalamide B was reacted with tris-triphenylphosphine ruthenium II 
chloride, in the presence of potassium carbonate, in benzene for seven hours 
at 6ooc, to give a mixture of starting material and several products by silica 
gel TLC. A 1 H NMR spectrum of the crude mixture obtained after workup 
indicated a mixture of at least four major components, including unreacted 
mycalamide B, and there were some weak resonances at o8.9-9.0 ppm. 
Preparative TLC gave five fractions, of which two contained only reagent-
derived material, one fraction was almost pure mycalamide B, one fraction 
was a fairly clean mixture of two major components, and the final fraction was 
smaller and contained one major component with many other minor ones, by 
1 H NMR spectroscopy. These latter two fractions were further purified by 
reverse phase HPLC, in an attempt to isolate the three major components 
identified in these fractions. This yielded eight further fractions, but only two 
fractions were of sufficient mass and purity to characterise. Of the remaining 
fractions, which were all of very low mass, three were unresolved mixtures, 
one contained only reagent-derived material, and two were of good purity, but 
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were still too small to enable a conclusive solution of their structures, by 1 H 
NMR spectroscopy. (Subsequently, one of these latter compounds was 
identified as 18-normycalamide A 17-aldehyde (7.5)). 
7.2.2.2 CHARACTERISATION OF THE MAJOR PRODUCTS 
The 1 H NMR spectrum of the first major fraction indicated the presence 
of the C7 hydroxyl and both the C6 and C10 acetal systems, but the C16-C18 
sidechain had certainly been affected. However, surprisingly, there was no 
aldehyde resonance present to indicate oxidation of the primary hydroxyl 
group. There was a doublet at o6.39 ppm (12.8 Hz), coupled to a doublet of 
doublets, at o4.57 ppm, which was further coupled to a doublet at o3.76 ppm 
(8.8 Hz), as shown by selective proton decoupling experiments. These 
resonances were assigned to protons at positions from C15 to the end of the 
sidechain, since the remainder of the 1 H NMR data were relatively unchanged 
from those of mycalamide B and could be readily assigned (Table 6.1 ). 
Significantly there was a downfield shift in the C17 methoxyl resonance ( +0.2 
ppm). The observed chemical shifts, multiplicities and coupling constants for 
the unassigned resonances above were indicative of the presence of a 
double bond between C16 and C17, as in structure 7.3. 
OH 
NH, 
II• 
H 
0 
0 ~ 
0 
E L\16 18-Normycalamide B (7.3) 
A series of NOE experiments were performed to enable conclusive 
assignments of these data, to determine the stereochemistry of the double 
bond, and to investigate the solution conformations of this portion of the 
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structure. The results of these experiments are summarised in Figure 7.1 a 
and listed in Table 7.2. Irradiation of H1 0 enhanced the resonance at 83.76 
ppm, along with the H13 and 1 0-0CHR resonances, so that this new 
resonance could be assigned to the H15 proton. Irradiation of H15 enhanced 
the H1 0 resonance, and the resonance at 86.39 ppm, to which it was not 
coupled, so that this was assigned to the vinyllic H17 proton. Similarly, 
irradiation ofthe H16 resonance (84.57 ppm) caused an enhancement of the 
C17 methoxyl resonance, requiring that the geometry of the double bond be 
. 
E, with the H16 and H17 protons in a trans relationship, in agreement with the 
12.6 Hz vicinal coupling constant observed1 02. Also the H15 and H16 
protons were evidently mostly in an anti relationship, based on the magnitude 
of the observed vicinal coupling constant102 (8.8 Hz), in agreement with the 
observed NOE interaction between the H15 and H17 protons. 
Figure 7.1 Selected 1 H-1 H NOE interactions and partial solution 
conformations of isomers of L\ 16 18-normycalamide B (7.3, 7.4). 
a) Eisomer 
0 
H 
b) Zisomer 
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The sample was too small to record a 13C NMR spectrum directly. 
However, partial 13C NMR data were obtained indirectly from an HMQC 
experiment, recorded at 500 MHz (Table 7.3). The C15 resonance was 
shifted downfield (+3 ppm), compared with data for mycalamide B, consistent 
with the presence of a double bond between C16 and C17. Also the chemical 
shift of the C17 resonance, o147 ppm, was similar to that observed for methyl 
vinyl ether117, o153.2 ppm, consistent with this proposed structure. Further 
evidence was obtained from HRFABMS, which indicated a molecular formula 
of C24H3gNOg, and from an· FTIR spectrum, which showed a band at 1656 
cm-1, assignable to the more intense C=C stretching band of the vinyl ether96. 
The 1 H NMR spectrum of the second fraction was similar to that of the 
first fraction, but there were large changes in the chemical shifts and coupling 
constants of resonances from C15 to C17, suggestive of an alternate 
geometry of the C16-C17 double bond (structure 7.4). In particular, there 
were shifts in the H15 (+0.6), H16 (-0.3), H17 (-0.5) and 17-0CH3 (+0.1) 
proton resonances (Table 7.1 ), compared with the above data, and a smaller 
H16-H17 vicinal coupling constant (6.6 Hz), indicative of a Z isomer102. NOE 
interactions were observed betwen the H16 and H17 protons (Table 7.2), 
consistent with this assignment. The 9 Hz coupling constant between the H15 
and H16 protons was indicative of a mostly anti relationship between these 
protons, as above, so that the only major difference between the solution 
conformations of the two isomers was in the positions of the H17 and 17-
0CH3 substituents. The different chemical shifts of the H16 resonances in the 
two isomers were consistent with standard substituent effects101. The shifts in 
the H15 and H17 resonances were not predicted, but probably represented 
the results of long range anisotropic deshielding effects 123 associated with 
adjacent ether oxygen groups at C17 and C15, respectively, for the two 
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isomers (Figure 7.1 ). These effects were further confirmation of the 
stereochemistry of the C16-C17 double bond in each compound. 
OH 
= ;; 
: NH, ,,, 
0 
0 ~ 
H 
• ,.._ CH3 
,a CH3 
OCH3 
0 
Z A 16 18-Normycalamide 8 (7.4) 
H 
OCH3 
No 13C NMR data were obtained for this compound, but the molecular 
formula was readily confirmed by HRFA8MS. The biological activity of both 
derivatives will be described in a following section. 
7.2.2.3 REACTION MECHANISMS 
The oxidation of alcohols by ruthenium complexes is reported to 
involve the formation of a ruthenium alkoxide (Scheme 7.1 a}, which normally 
undergoes P-elimination, with removal of hydride ion from the a-carbon and 
cleavage of the metal-oxygen bond, to produce the carbonyl compound and 
an hydride-ruthenium complex256,264. This complex was hydrido-chloro-tris-
triphenylphosphine ruthenium in the present case, and was capable of 
oxidising another mole equivalent of an alcohof264. In an alternative 
oxidation procedure, this method could be made catalytic by the presence of 
an amine-N-oxide, which could reoxidise the ruthenium complex, but this 
reportedly resulted in a significant reduction in selectivity256. 
No C18 aldehyde products were isolated from the reaction with 
mycalamide 8, although it is possible that such compounds were formed but 
decomposed, or underwent rearrangement, under the basic reaction 
conditions. It was initially more difficult to account for the formation of the 
observed major products of the reaction, the isomers of A 16 18-
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normycalamide B (7.3, 7.4). However, it is known that tertiary phosphine 
complexes of ruthenium chloride react with alcohols in the presence of base 
to give very stable hydride-carbonyl ruthenium complexes268. In such 
reactions the alcohol is degraded by oxidation then decarbonylation, so that 
ethanol gives methane. The process is called hydridocarbonylation and is 
known to be the predominant reaction under basic conditions. The 
mechanism268 (Scheme 7.1 b) is believed to involve the initial formation of the 
ruthenium alkoxide, followed by a base-promoted hydride transfer to the 
. 
ruthenium to give a metal-aldehyde complex, which in turn breaks down to 
give a ruthenium carbonyl complex, via an isocarbonyl complex, instead of 
eliminating the aldehyde. This decarbonylation of the original alcohol is 
reportedly favoured by the stability of the ruthenium carbonyl complex product 
and the availability of a metal ligand position following the splitting of the 
original halogen bridge. In the present case (Scheme 7.1 b), it is proposed 
that the decarbonylation occurs by a base-promoted ~-elimination, including 
loss of one H16 proton, cleavage of the C17-C18 bond, and loss of hydride 
ion from C18, in the usual manner. A similar decarbonylation of aldehydes 
also occurs with Wilkinsons catalyst, tris-triphenylphosphine rhodium chloride, 
under the influence of heat and light, to give alkanes and a rhodium carbonyl 
complex269. 
The formation of a C17-aldehyde derivative (7.5) as a minor product 
from the oxidation of mycalamide B (as indicated at the end of Section 7.2.2.1 
and characterised in a later section) would probably arise from the breakdown 
of the 1l16 18-normycalamide B isomers (7.3, 7.4) in the presence of traces of 
acid. In particular, acid catalysed addition of H20 to an enol ether172 would 
give a hemiacetal at C17, which would readily lose methanol to yield the 
required aldehyde (Scheme 7.2). 
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Scheme 7.1 Proposed mechanisms for the oxidation and decarbonylation 
reactions of mycalamide B with a ruthenium II complex. 
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Scheme 7.2 Mechanism of formation of 18-normycalamide A 17-aldehyde 
(7.5) from the hydrolysis of~ 16 18-normycalamide B (7.3, 7.4) 
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7.3 OXIDATIONS OF MYCALAMIDE A 
7.3.1 REACTIONS OF MYCALAMIDE A WITH TRIS-TRIPHENYLPHOSPHlNE 
RUTHENIUM II CHLORIDE 
In view of the partial success obtained with using this ruthenium 
complex for the selective oxidation of the sidechain of mycalamide B, it was 
then of interest to consider reactions on mycalamide A. In particular, it was 
expected that an aldehyde pr.oduct could be obtained in this way, which could 
permit further modifications to this portion of the molecule. 
A trial reaction of mycalamide A with tris-triphenylphosphine ruthenium 
II chloride in benzene, in the absence of base, was very slow at room 
temperature, as monitored by TLC. After two days the reaction was stopped 
and crude separation was performed by silica gel column chromatography to 
remove reagents and unreacted mycalamide A. A 1 H NMR spectrum of the 
product fraction showed the presence of one mycalamide A derivative, having 
an aldehyde triplet at o9.55 ppm, although there was also unresolved 
reagent-derived material and traces of decomposition, and the sample was 
not stable, due probably to the presence of trace amounts of acid. (Note that 
the multiplicity of this aldehyde resonance suggested that this product was 
possibly an 18-normycalamide A 17-aldehyde derivative, 7.5). This reaction 
had only proceeded to the extent of about 50% so it was repeated, this time in 
the presence of potassium carbonate, for two hours at sooc. Preliminary 
column chromatography, then preparative TLC gave two fractions, one 
containing only traces of mycalamide A and reagent-derived material, and the 
other consisting of products. However, a 1 H NMR spectrum of this product 
fraction was dominated by reagent-derived material, and the resonances 
relating to the mycalamide products were weak and indicated a complex 
mixture. This decomposition could have been due to heating the products in 
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the presence of base, causing further reactions and rearrangements. This 
method was therefore abandoned in favour of some alternative method which 
would give clean oxidation under mild reaction conditions and would allow 
good separation of the reagents from the products. 
OH 
18-Normycalamide A 17-aldehyde (7.5) 
7.3.2 REACTIONS OF MYCALAMIDES A AND B WITH LEAD 
TETRMCETATE IN BENZENE-PYRIDINE 
The proposed initial product from the above reaction of mycalamide A 
with the ruthenium II complex, 18-normycalamide A 17-aldehyde (7.5), should 
be more easily obtainable by oxidative cleavage of the C17-C18 diol of 
mycalamide A with sodium periodate or lead tetraacetate270. In fact, the 
combination of lead tetraacetate with pyridine has been reported to be 
effective for the oxidation of both primary and secondary alcohols257, and the 
advantage of incorporating an amine base for neutralisation suggested that 
this could be useful for reactions on mycalamides A and B. However, a trial 
reaction of mycalamide B with these reagents for one day at sooc gave no 
reaction by TLC and 1 H NMR spectroscopy. 
Mycalamide A was reacted with lead tetraacetate in a 1 :1 mixture of 
benzene and pyridine for 1.5 hours at room temperature to give one product of 
higher Rf, cleanly, by silica gel TLC. A 1 H NMR spectrum of the product 
obtained after workup showed the presence of a single pure mycalamide A 
derivative, obtained in quantitative yield. This product was found to be the 
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same as that obtained earlier, from the reaction of mycalamide A with the 
ruthenium II complex, and in lower yield from a similar reaction on 
mycalamide B, described above. Some features of this 1 H NMR spectrum 
included the aldehyde triplet at 89.55 ppm, which was coupled to a multiplet at 
82.36 ppm, which in turn was coupled to a doublet of doublets at 84.09 ppm. 
These resonances could be assigned to the H17, H216, and H15 protons, 
respectively, since the assignments of the remaining 1 H NMR data (Table 7.1) 
were obvious from comparisons with data for mycalamide A and were 
confirmed by COSY and NOE experiments. Note that the shifts in the H15 
(+0.5) and H216 (+0.8) proton resonances were entirely consistent with the 
presence of an aldehyde group at C17, involving electronic1 O 1 and 
anisotropic deshielding effects 123. Also the size of the vicinal coupling 
constants between H17 and the two H16 protons, of 2.0 and 2.6 Hz, was 
typical of the coupling between aldehyde protons and adjacent a-protons102, 
since this is reduced in magnitude by the two bonds to the electronegative 
oxygen atom. There were also shifts in the H5a (-0.3) and H11 (-0.1) proton 
resonances, suggestive of the involvement of some longer range effects. 
Therefore the 1 H NMR data for this derivative were consistent with the 
proposed structure, 18-normycalamide A 17-aldehyde (7.5). 
NOE experiments were performed to examine the solution 
conformations of this derivative. There were similar interactions across the 
trioxadecalin ring system to those observed for mycalamide A, including H15-
H1 0, H15-H13, 14-CH3S-H12, indicating that the solution conformation of this 
system was the same, in agreement with the observed chemical shifts and 
coupling constants. There Were other NOE interactions, including H15-H17, 
H 15-H216, and H216-H17, which suggested that this portion of the structure 
was a mixture of several conformations, in agreement with the averaged 
vicinal coupling constants observed. However, there was also a very 
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significant NOE interaction between the H17 and H5a protons, as found 
earlier for mycalamide B, and possibly for mycalamide A (Chapter 1 ). Such 
evidence could account for the anomalous chemical shift of the H5a proton 
resonance, compared to data for mycalamide A, since some anisotropic 
shielding interaction with the C17 carbonyl group 123 could occur. These 
effects are further considered in a molecular modelling study of the 
conformations of this structure, described below. 
A 13C NMR spectrum was recorded for this derivative and the data 
obtained were readily assigned by comparison with data for mycalamide A 
(Table 7.3). There was a resonance at 8200.5 ppm, assignable to the 
aldehyde carbon, and there were shifts in some other resonances, including 
C7 (-1.6), C15 (-4.9) and C16 (+11.4), consistent with this structure117. In 
addition to this NMR evidence, an FTIR spectrum displayed a new carbonyl 
stretching band at 1725 cm-1, indicative of the aldehyde group96, and 
HRFABMS indicated a molecular formula of c23H37NOg, corresponding to a 
loss of CH40 from mycalamide A. 
Scheme 7.3 Mechanism of oxidative cleavage of mycalamide A with lead 
tetraacetate 
---
HOAc 
Pb(OAc)2 
The mechanism for this oxidation, as proposed by Criegee270, involves 
firstly a slow coordination of both oxygens of the dial onto the lead centre, with 
displacement of two molecules of acetic acid, to give a cyclic coordination 
complex (Scheme 7.3 above). This is followed by a series of shifts in the 
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electron pairs, with cleavage of the two metal oxygen bonds and the central 
carbon-carbon bond, to yield two carbonyl compounds and a reduced lead II 
species (lead diacetate). In the present case the two carbonyl compounds are 
18-normycalamide A 17-aldehyde (7.5) and formaldehyde. 
7.3.3 MOLECULAR MODELLING OF 18-NORMYCALAMIDE A 17-ALDEHYDE 
A molecular modelling study was performed with the aim of determining 
the lowest energy conformations for this structure, to compare with evidence 
. 
obtained from the NMR studies above. This was a better structure to analyse 
than mycalamides A and B, having 33 less degrees of freedom214 (17-0, 17-
18, 18-0 fixed or removed), but was still too challenging to consider a full grid 
search involving rotations of all freely rotatable bonds. In order to simplify the 
task, some constraints were imposed, based on existing knowledge from 
previous modelling studies (Chapter 5) and evidence from the NMR studies 
above and in Chapter 1. In particular, it was known that the two methoxyl 
groups, at C6 and C13, both had preferred orientations, and that the C8-N and 
N-C1 0 bonds could be fixed, since the amide conformation was mostly trans 
(Chapters 1 and 2), while the NH and H1 0 protons were mostly in an anti 
relationship, based on the observed 9.5 Hz coupling constant1 02. 
Furthermore, the conformations of the three rings were evidently the same as 
for mycalamide A, so that these could also be fixed. Thus the only remaining 
rotatable bonds were C6-C7, C7-0, C7-C8, C15-C16 and C16-C17. 
The starting structure (7 .5) was obtained from the crystal structure 
coordinates for pederin di-p-bromobenzoate93 (1.1 ), by adjusting the 
substituents at C7, C10, C12, C13 and C17, setting both H-C10-C11-H and N-
C1 O-O-CH2 anti, and introducing the third ring, as for mycalamide A (Chapter 
1 ). In order to accurately determine the conformations about bonds between 
one sp2 centre and an sp3 centre, 3oo rotations were recommended, in 
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contrast to the normal 1200 rotations for bonds between two sp3 
centres124,214. Two of the five rotatable bonds in the present structure were 
affected, so that a full grid search was not feasible with the computing 
resources available. An alternative method was a Monte Carlo statistical 
conformational search124,214,216. This method performed random, rather 
than systematic, dihedral angle rotations to the starting conformer, to generate 
further conformers. These conformers were accepted if their minimised 
energies were lower, or within 14.6 kJ mol-1 of the existing lowest energy 
. 
conformation. A maximum of 200 conformations was set as the criterion for 
stopping the search. Further energy minimisations were performed on this set 
of conformers and equivalent conformers discarded in the usual way. 
This search was thus performed, using the parameters described 
above and the same modified MODEL program 125 described in earlier 
chapters, to generate a set of lowest energy conformations. These MM2-
calculated geometries were analysed213 to give the results in Table 7.4, and 
were weighted according to their minimised energies by applying a 
Boltzmann distribution, to obtain approximate relative populations. Note that 
only conformers within 12 kJ mol-1 of the lowest energy conformer have been 
shown. Also it was necessary to edit the output file since a few structures 
were non-unique, differing in their dihedral angles by less than 5° (such 
problems are known to occur with MM2 minimisations214). 
An examination of the dihedral angles shows that the C5-C6-C7-C8 
angle was most often in a (-) gauche conformation, and that the C14-C15-
C16-C17 angle was anti in all cases except conformer number 4. Distances 
between the H7 proton and the H5a, H5e, 6-0C, and NH atoms have been 
shown, along with the H5a-NH and H5a-H17 distances, for each conformer. 
These results show that in most of the calculated conformers H7 was within 3 
A of the C6 methoxyl carbon, in agreement with the NOE results. Other 
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conformers, with H7 close to H5a and H5e (within 3 A) were also represented, 
but while there was experimental evidence for the former, there was no 
significant NOE interaction between H7 and H5e. Several conformers also 
showed small H5a-NH, H5a-H17 and H7-NH distances, consistent with the 
observed NOE results. All of the conformers contained intramolecular 
hydrogen bonding interactions, in particular between the C7 hydroxyl proton 
and one or more of the C6 acetal, C8 carbonyl, or C17 carbonyl oxygens, and 
between the amide NH proton and one or more of the C6 acetal, C7 hydroxyl, 
or C17 carbonyl oxygens. 
The first four lowest energy conformers together represented about 
79% of the total population of conformations for this structure, and these have 
been examined in more detail. However, the first lowest energy conformer 
(Figure 7.2a) was anomalous in containing H7 close to H5e, suggesting that 
the ordering of these conformers was unreliable (see below). By comparison, 
conformer 2 (Figure 7.2b) satisfied all the major NOE results, having H17 
close to both H5a (2.7 A) and H15, and H7 close to both the C6 methoxyl 
group (2.6 A) and the NH proton (2.5 A). Conformer 3 (Figure 7.2c) 
represented the experimentally second major C6-C7 rotamer, having H7 
close to H5a (2.3 A), while conformer 4 (Figure 7.2d) was a C15-C16 rotamer 
of conformer 2. Note that a combination of conformers 2, 4 and a third C15-
C16 rotamer was required, in order to satisfy the observed vicinal coupling 
constants between H15 and the two H16 protons (5.2, 7.3 Hz), since the 
calculated values (in Hz) for conformers 2 and 4 were (2.0, 11.5) and (5.5, 1.3), 
respectively. Therefore conformers 2,3 and 4, with probably a third C15-C16 
rotamer, would satisfy all the observed NOE and coupling constant data 
obtained on this derivative. 
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Figure 7.2 Major conformations of 18-normycalamide A 17-aldehyde (7.5), 
as calculated by molecular modelling. 
a) 
b) 
c) 
d) 
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Significantly then, this work has linked the major C6-C7 rotamer with a 
low energy C16-C17 sidechain conformation,· such that H5a and H17 are 
close in space. A consideration of other distances further showed that H17 
was reasonably close to H7 in conformer 3 (2.9 A), to C7-0H in conformer 1 
(3.2 A), but not close to the NH proton in any of the conformers. Therefore a 
long range effect from the different C17 substituents in mycalamide A and 18-
normycalamide A 17-aldehyde (7.5) to C7 could account for the observed 
shift in the C7 carbon resonance for the two compounds. Hence this 
modelling work was quite ·successful, but earlier remarks (Chapter 5), 
regarding the limitations of such programs to order various conformations that 
are close in energy when hydrogen bonding effects were involved215, are 
also applicable here. Furthermore, it has also been noted that global energy 
minima found by such methods are unlikely to remain so when entropy and 
solvation effects are included122,216. Thus it is the set of low energy 
conformations that is important. 
7.3.4 SOLUTION CONFORMATIONS OF THE HEMIACETALS OF 18-NOR-
MYCALAMIDE A 17-ALOEHYOE IN 04-METHANOL 
Further to the molecular modelling work above, it was considered of 
interest to examine the solution conformations of this aldehyde derivative in 
C 0300. However, the 1 H NMR spectrum indicated that the aldehyde 
functionality had reacted with the solvent (containing about 0.1% pyridine) to 
give an approximately 1 :1 mixture of two isomeric hemiacetals. This was of 
interest because of the varying effects of this modification on resonances 
throughout the molecule. The 1 H NMR data were assigned (Table 7.1) using 
COSY and NOE experiments. Of particular interest was the unusually large 
effect on the chemical shift of the H7 resonance for the two isomers (0.08 
ppm), and many of the other 01-C6 ring substituents were also significantly 
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affected. The two H15 resonances were most affected, being spread by 0.1 
ppm. 
A 13C NMR spectrum was recorded to further examine these effects, 
and this was assigned by an HMQC experiment (Table 7.3). The chemical 
shifts of the C17 carbon resonances, 897.9 and 98.0 ppm, were consistent 
with the formation of a hemiacetal at this position117. There were also related 
shifts in the C15 (+3.2, 3.0) and C16 (-5.2, -5.8 ppm) carbon resonances, 
compared to data for 18-normycalamide A 17-aldehyde (7.5). Interestingly 
the 14-CH3S and C11 resonances, and to a lesser extent the resonances of 
other carbons belonging to the trioxadecalin ring system, were rather broad, 
indicative of some exchange with an increased population of the alternate 
chair-chair conformation, whereas this was not significant in data for 18-
normycalamide A 17-aldehyde. (This effect was also a factor in the chemical 
shifts of these resonances and the vicinal proton-proton coupling constants, 
as discussed for derivatives in previous chapters). 
Comparing the 13C NMR data for the two isomers, the largest 
differences occurred in the chemical shifts of the C7 (0.5) and C16 (0.6) 
carbon resonances. However, the C7 hydroxyl group was evidently not 
directly involved in these hemiacetals, as initially postulated, since the 
chemical shift of C7 was almost identical to that of mycalamide A in this 
solvent, whereas an ether linkage would cause a large downfield shift in this 
resonance (Chapter 2). Therefore it was likely that the structure of these 
isomers was simply 7.6, representing the base catalysed addition of CD30D 
across the aldehyde carbonyl bond238. Note that when the solvent was 
removed from this sample and it was redissolved in CDCI3 the 1 H NMR 
spectrum indicated that only the aldehyde derivative (7.5) was present. This 
was consistent with the properties of open chain hemiacetals237, which are 
stable only in alcohol solution because they are in rapid kinetic equilibrium 
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with their parent alcohol and aldehydes238, with which they are similar in 
energy. 
OH 
18-Normycalamide A 17-aldehyde hemiacetals (7.6) 
The solution conformations of the hemiacetals (7 .6) were further 
investigated by NOE experiments (Table 7.2). These results confirmed the 
presence of the major conformation of the trioxadecalin ring system and the 
usual C6-C7 rotamers. There was no NOE interaction between H7 and H17, 
but the H5a-H17 interaction was present for one of the hemiacetal isomers. 
Hence from these results the stereochemistry at C17 did appear to have a 
significant effect on the environment of CS and C7, a result which was 
interesting, given the proposed importance of the C6-C1 0 substructure for the 
biological activity of mycalamides A and B (Chapters 2-6 and 8). 
7.4 REACTIONS OF 18-NORMYCALAMIDE A 17-ALDEHYDE 
The quantitative oxidative cleavage of mycalamide A to 18-
normycalamide A 17-aldehyde (7.5), using lead tetraacetate in benzene-
pyridine257, provided a good source of a derivative with a reasonably reactive 
functional group, which could allow further selective modifications of this 
shortened C16-C17 sidechain of mycalamide A. In particular, reactions such 
as reduction, reductive amination, the formation of imines, hydrazones, 
cyanohydrin and bisulphite adducts, were potentially possible238,271 ,272, 
although reaction conditions would be required which would not affect other 
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functional groups in the molecule. Such derivatives were likely to show good 
biological activity, based on results in Chapter 2, so that effects such as 
substituent size and polarity, and the stereochemistry at C17, could potentially 
be studied. 
7.4.1 REDUCTION WITH SODIUM BOROHYDRIDE 
18-Normycalamide A 17-aldehyde (7.5) reacted readily with sodium 
borohydride in methanol at room temperature to give a single product of lower 
Rt on silica gel TLC. HRFABMS of the fraction obtained from workup indicated 
the presence of a compound of molecular formula C23H3gNOg, suggesting 
that this was the corresponding alcohol, 7.7, from reduction. An FTIR 
spectrum confirmed the loss of the carbonyl stretching band at 1725 cm-1, 
assigned to the aldehyde group in the starting material. 
OH 
OH 
18-Normycalamide A (7.7) 
The 1 H NMR spectrum showed no trace of the aldehyde but there was 
a new two-proton multiplet at o3.50 ppm, along with a single-proton triplet (6.5 
Hz) at o2.96 ppm. The latter was assigned to the new C17 hydroxyl proton, 
being coupled to the resonance at o3.50 in a COSY spectrum, and since it 
was removed on addition of D20. The H15 (-0.5), and two H16 (-0.7, -1.0) 
proton resonances were also shifted substantially upfield, compared to data 
for 18-normycalamide A 17-aldehyde (Table 7.1 ), indicative of this 
reduction101. Also H5a was less shielded in this derivative (+0.2). 
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Interestingly, the observed vicinal coupling constants between HiS and 
the two H 16 protons (1.3, 1 0.5) were rather different in this derivative than for 
18-normycalamide A 17-aldehyde, suggesting a different average solution 
conformation for this portion of the structure. These values were in fact 
indicative of an almost fixed anti geometry for the C14-C15-C16-C17 dihedral 
angle (see Chapter 5), so that the downfield H16 proton, having the smaller 
H15-H16 coupling constant, was probably pro-R and the upfield H16-proton 
pro-S in stereochemistry, based on earlier results. The coupling constants 
. 
from these two H16 protons to the two H17 protons were also extracted from 
the 1 H NMR spectrum. The size of these constants, 3.5, 3.5 and 5.7, 8.9 Hz 
from the H16S and H16R protons respectively, suggested that there was 
some preferred conformation about this C16-C17 bond, possibly with H16S 
anti to C17-0, to give the required gauche and anti relationships {Figure 7.3). 
Unfortunately, the overlap of the two H17 and the H13 proton resonances 
restricted a complete analysis of this portion of the structure using NOE 
experiments. 
Figure 7.3 Selected 1 H-1 H NOE interactions and partial solution 
conformation of 18-normycalamide A (7.7). 
H 
Some NOE experiments were performed to examine the solution 
conformations of the remainder of the structure (Table 7.2). NOE effects from 
irradiations of 14-CH3R and 14-CH3S confirmed the stereochemical 
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assignment of the H16R and H16S protons, along with the conformation of the 
trioxadecalin ring system, which could be inferred from the observed chemical 
shifts and coupling constants. Also the same NOE interaction between the 
H5a and H17 protons was observed. The remaining results were similar to 
those obtained for other derivatives above and for mycalamide A. 
A 13C NMR spectrum was also recorded and this contained a new 
resonance at 858.5 ppm, which was assigned to the C17 methylene carbon. 
There were also shifts in the C15 (+1.4) and C16 (-11.5) resonances (Table 
. 
7.3), consistent with the presence of a primary hydroxyl group at C17, rather 
than an aldehyde 117. The remaining data were readily assigned by 
comparison with those of mycalamide A. This structure (7. 7) was equivalent 
to the replacement of the C18 group in mycalamide A by hydrogen, hence the 
name 18-normycalamide A. Biological assay data for this derivative are 
described in a following section. 
7.4.2 ATTEMPTED REACTION OF 18-NORMYCALAMIDE A 17-ALDEHYDE 
WITH SODIUM BISULPHITE AND OTHER REACTIONS 
Most carbonyl addition reactions are reversible238, apart from 
reductions or reactions with Grignard reagents, and the latter would not be 
possible on mycalamides A and B without protection of the C7 hydroxyl and 
amide nitrogen groups (Chapters 5 and 6). Simple aldehydes react 
quantitatively only with sodium bisulphite or hydrogen cyanide, and the 
addition products are sufficiently stable to be isolable. Bisulphite ion (HS03·) 
is a weak acid238 (Pka=7.2) but an excellent sulphur nucleophile. The 
products are ionic salts, which are water soluble and potentially crystalline. In 
a trial reaction, 18-normycalamide A 17-aldehyde (7.5) was reacted with a 
solution of sodium bisulphite in aqueous methanol for 16 hours at room 
temperature, followed by 1.5 hours at 5ooc, monitoring by TLC. The more 
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polar product material streaked on both silica gel and reverse phase TLC, so 
the reaction was worked up and examined by 1 H NMR spectroscopy in 
deuterated methanol. However, the spectrum obtained was of very poor 
signal to noise ratio and indicated decomposition, with few resolved 
resonances relating to the mycalamide skeleton apparent. It was probable 
that the slight acidity of this reagent could have caused breakdown of the 
acetal moeities in mycalamide A, leading to this result. 
A similar problem was likely to be encountered with other acid 
. 
catalysed additions, including the formation of acetals and imines from 
reactions with alcohols and amines respectively272, since the C6 acetal was 
very reactive under such conditions. The formation of a cyanohydrin was not 
explored, but this reaction was base catalysed238, and such reaction 
conditions were probably more favourable with the mycalamides. Reductive 
amination271 ,273 was also a possibility that was not investigated. Another 
alternative was selective oxidation of the aldehyde group, but the reagents 
which effect this transformation, including aqueous bromine solutions258, or 
alkaline silver oxide274, were not favourable for reactions on the 
mycalamides. In fact the most common synthetic methods for the oxidation of 
aldehydes were reported to be the strong oxidising agents, permanganate or 
chromic acid274. 
7.5 BIOLOGICAL ASSAY RESULTS AND CONCLUSIONS 
The biological assay results for the four compounds described in this 
chapter have been listed in Table 7.5, together with results for mycalamides A 
and B, included for reference. The two major compounds derived from the 
oxidation of mycalamide B, which contained a double bond between C16 and 
C17 and no C18 (7.3 and 7.4), were both significantly less active than 
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mycalamide B. The Z isomer was the most active, but was still almost 100 
times less active than mycalamide B, while the E isomer was between 3 to 4 
times less active again. This was an unexpected result, since it was thought 
that this portion of the mycalamide B structure would be less biologically 
sensitive to structural changes. However, the compounds did appear to show 
some genuine biological activity, having been carefully purified through two 
stages of chromatographic separation. 
Of more interest was the potent biological activity of 18-normycalamide 
A 17-aldehyde (7.5) and 18-rlOrmycalamide A (7.7}, which both appeared to 
be more active than mycalamide A itself, but slightly less active than 
mycalamide B. The biological activity of these derivatives should perhaps be 
further evaluated, as these were potentially useful mycalamide analogues. 
There is potential for further studies from this work. Further reactions of 
the aldehyde could be explored, along with the oxidation of the C7 hydroxyl 
group, which could probably best be achieved under conditions involving 
amine bases to avoid acid instability problems. Unfortunately there was not 
time to investigate all these possibilities in the current research. 
Table 7.1 1 H NMR dataa for compounds in Chapter 7. 
E ~ 16 18-Nor- z~1618-Nor- 18-Normyc.A 18-Normyc.A 17 -ald. hemiacetals 18-Normyc.A 
III)&,6 (1.3) fitiC.B (Z.~) lZ-a1d.Cl.5l (isQrmrtc fQnns) (l,§) (]Jj 
H2 4.04 (3.0,6.6) 4.04 (2.9,6.5) 4.02 (2.8,6.6) 3.87 (2.7,6.6) 3.91 (2.7,6.6} 4.03 (2.8,6.5) 
2·CHa 1.17 (6.6) 1.17 (6.7) 1.18 (6.6) 1.18 (6.6) 1.16 (6.6) 1.20 (6.6) 
H3 2.22 (3.2,7.4} 2.22 (2.9,7.3) 2.23 (2.8,7.1) 2.21 (2.7,7.0) 2.19 (2.7,7.0) 2.26 (2.8,7.0) 
3-CHa 0.98 (7.3) 0.98 (7.3) 0.93 (7.1) 0.96 (7.0) 0.97 (7.0) 1.00 {7.1) 
4:CHZ 4.82 (1.8) 4.82 {1.9) 4.85 (1.9) 4.81 (2.0) 4.79 (2.0) 4.86 (1.8) 
4:CHE 4.69 (1.8} 4.70 (1.8) 4.77 (1.9) 4.64 (2.0) 4.64 (2.0) 4.76 (1.8) 
H5a 2.14 (1.9,13.9) 2.16 (1.9,14.0) 2.06 (1.9,14.2) 2.42 (2.1,14.1) 2.39 (2.0,14.2) 2.22 (2.0, 14.2) 
H5e 2.24 (14.0) 2.25 (13.9) 2.36 (14.1) 2.30 (14.3) 2.29 (14.3) 2.41 (14.0) 
6-0CHa 3.30 3.31 3.30 3.26 3.24 3.31 
H7 4.26 (3.2) 4.25 (2.8) 4.27 4.31 4.23 4.31 
7-0H 3.87 (3.3) 3.96 (2.8) 3.71 
NH9 7;33 {9.7) 7.41 (9.3) 7.47 {9.5) 7.51 (9.6) 
H10 5.93 (9.7) 5.95 {9.3) 5.88 (9.5) 5.75 (8.4) 5.72 {8.4) 5.83 (9.6) 
10-0CHR 5.15 (6.8) 5.15 (6.9) 5.14(7.0) 5.16 (6.9) 5.16 (6.9) 5.14 (6.9) 
10-0CHS 4.90 (6.8} 4.87 (7.0) 4.88 (7.0) 4.82 (7.0) 4.78 (7.0) 4.88 (6.9) 
H11 3.74 (6.3;9.8) 3.77 (6.4,9.3) 3.77 (6.6,9.5) 3.93 (6.5,8.4) 3.85 (6.5,8.4) 3.77 (7.1,9.7) 
H12 4.21 (6.3,1 0.2) 4.18 (6.2,9.6) 4.21 (6.6,1 0.1) 4.14 (6.6,9.3) 4.14 (6.6,9.3) 4.24 (7.1,1 0.5) 
H13 3.49 (10.2) 3.51 (9.6) 3.50 (10.1) 3.57 (9.3) 3.57 (9.3) 3.47 (1 0.4) 
13-0CHa 3.56 3.55 3.57 3.54 3.54 3.57 
14-CHaR 0.94 0.95 0.93 1.02 1.00 1.00 
14·CH3S 0.87 0.85 0.87 0.83 0.83 0.85 
H15 3.76 (8.9) 4.39 (9.0) 4.09 (5.2,7.3) 3.61 (2.4,9.4) 3.51 (4.7,8.3) 3.64 (1.3,1 0.5) 
H16 4.57 (8.7,12.5) 4.25 (6.6,8.9) 2.36 (2.6,7.3) 1.61 (m) 1.58 (m) 1.67 (1.4,5. 7,8.9, 14.5) 
H16 2.36 (2.0,5.2) 1.61 (m) 1.58 (m) 1.37 (3.5,3.5, 1 0.6, 14.4) 
H17/H217 6.39 (12.6) 5.89 (6.6) 9.55 (2.0,2.6) 4.52 (m) 4.51 (m) /3.50 (m) 
17·0CH3 3.44 3.52 
17-0H 2.96 (6.5) 
aoata for structure 7.6 were recorded in CDsOD, with chemical shifts in ppm relative to CHD20D, 03.30 ppm. All other data were recorded in CDCI3 
with chemical shifts relative to CHCI3, <57.25 ppm (coupling constants in Hz). 
c.v 
m 
..p.. 
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Table 7.2 1 H~ 1 H NOE interactionsa for compounds in Chapter 7. 
Slgnal(s) Signals enhanced 
~omgound lrradlilli~ ( 0/q inhancemenn 
E L\16, 18-Nor- H10 10-0CHR(4), H13{3), H15(8) 
myc.B (7.3) H15 (H11) H10(13), H12(7)b, 14-CH3R(1), H17(15) 
H16 14-CHsS(1), 17-0CH3(2) 
H17 H15(5), 17-0CH3(0.5) 
Z ll16, 18-Nor- H10 (H17) 10-0CHR(4~ H13{5), H15(10)b, H16(10)b, 
myc.B (7.4) 17-0CHs(2) 
H15 H10(5), H13(3), H17(2) 
H16 (H7) 6-0CHs(3)b, 14-CHsS(2), H 17(7) 
H17 (H10) 10-0CHR(3)b, H13(4)b, H15(8), H16(9), 17-0CHs(2) 
18-Normyc.A 17 -ald. HSa 3-CHs{0.6), H5e(12), H7(0.4), NH(1), H17(1) 
(7.5) H7 6-0CHs(3), NH(3) 
14-CHsR H13(4), 13-0CH3(0.7), 14-CHs$(1), H15(5), H216(2) 
14-CHsS H12(7), 13-0CH3(0.3), 14-CHsR(1), H216(2), 
H17(0.8) 
H15 H10(7), H13(3), 14-CH3R(0.9), H216(2), H17(4) 
H216 (HSe) 4=CHE(2}b, H5a(6)b, 14-CHsR(1), 14-CH3S(1}, 
H15(2), H17(4) 
H17 H5a(0.7), H15{2}, H216(0.9) 
18-Normyc.A 17-ald. HSa 3-CHs(0.8}, H5e(9), H7d(1)0 , H7u{3)0 , H17(2) 
hemiacetals (7 .6) HSe 4=CHE(5), H5a(15), H5a(9), H7d(0.4)0 , H7u(0.4)0 
6-0CHsd0 H2(3), H7d(13)0 , H7u(2)0 
H7d0 6-0CHsd(3)0 
H7u0 6-0CHsu(2)C 
H10 10-0CHR(S), H13(4), H15d(7)c, H15u(7)0 
14-CHsR (3-CHs) H3(1), H13(5), 13-0CH3(0.6}, 14-CH3S(0.7), 
H15d(6)0 , H15u(4)0 , H216(2) 
14-CHsS (3-CHs, H3(1), H12{9), H13(2), 13-0CHs(O.S), H15d(2)0 
14-CHs~ H15u(3)0 , H216(2} 
H15d0 (H13, H10d(12)0 , 10-0CHR(3), 14-CHs$(0.3), 
13-0CHs) 14-CHsRd(1.5)0 , 14-CH3Ru(0.7)0 , H216(0.7), H17(2) 
H15u0 {13-0CHs) H10d(10)C, 10-0CHR(1), 14-CHs$(0.2), 
14-CHsRd{1.5)0 , 14-CH3Ru(0.7)0 , H216(0.7), H17{2) 
H216 2xH11(2), 14-CHsS(2), 2x14-CHsR(1), 2xH15(4), 
H17{13) 
H17 H5a(0.8), 2xH15(2), H216{1) 
18-Normyc.A HSa (H3} H2(5)0 , 3-CHs(2), 4=CHZ(3)b, H5e(23), H7(2), 
(7.7) H217(0.9) 
H5e 4=CHE(5), H5a(21), 6-0CHs(0.2} 
H7 H5a(0.8), 6-0CH3(3), NH(3) 
14-CHsR (3-CHs) 2-CHs(0.7)b, H3/H5a(3)b, H13(4), 13-0CHs(1), 
14-CHs$(2), H15(4), H16R(5) 
14-CHsS H12(8), 14-CH3R(1), H16S(6) 
H15 (13-0CHs) H10(10), H13(5), 14-CHsR(1) 
H16R 14-CH3R(2), H15(4), H16S(11 ), H217(2) 
H16S 14-CH3S(1), H16R(10), H217(2} 
H211 (H13, H5a(2), H10(0.6}b, 10-0CHR(O.?}b, 14-CH3R(0.3)b, 
13-0CHs) H15(1), H16R(S), H16S(5) 
aoata for compound 7.6 were recorded in CDsOD. All other data were recorded in CDCJs 
bEnhancement interpreted as being due to the irradiation of an overlapping signal 
0u and d have been used to designate the more upfield or more downfield resonance, 
associated with one of the two isomeric hemiacetals {not assigned) 
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Table 7.3 13C NMR dataa for compounds in Chapter 7. 
18-Normyc.A 18-Normyc.A 17-ald hemiacet. 18-Normyc.A 18-Nor-
17-a!Q.(l.Sl (iSQ!ll~ric fQrmS) (l.6) (1:1) m~c.B (7.3) 
C2 69.61 71.23 71.20 69.79 69.6 
2-CH3 17.99 18.45 18.41 17.97 17.7 
C3 41.28 43.34 43.25 41.31 41.0 
3-CH3 12.17 12.80 12.62 12.04 12.2 
C4 145.07 148.48 148.23 145.13 ? 
4=CH2 111.01 110.65 11 0.34 111.04 111.0 
C5 33.23 34.79 34.79 33.41 33.0 
C6 100.05 101.66 101.66 99.90 ? 
6-0CH3 .48.54 ? ? 48.76 48.2 
C7 71.31 74.00 73.52 71.76 70.7 
CB 171.91 174.52 174.45 172.35 ? 
C10 74.16 75.42 75.42 74.35 73.7 
1 O·OCH2 86.60 87.B1 87.68 86.59 87.0 
C11 70.78 70.54 70.54 71.66 ? 
C12 74.25 75.75 75.75 74.78 ? 
C13 79.20 81.37 81.37 79.40 ? 
13·0CH3 61.79 62.09 62.02 61.87 61.7 
C14 40.97 ? ? 41.37 ? 
14-CH3R 23.38 24.33 24.18 23.14 23.8 
14·CH3S 14.04 15.40 15.40 13.38 13.9 
C15 74.06 77.29 77.10 75.41 78.5 
C16 43.35 38.11 37.54 31.86 ? 
C17 200.52 97.98 97.92 58.50 147.0 
17-0CH3 55.9 
aoata for structure 7.6 were recorded in CDsOD, with chemical shifts in ppm relative to 
CDsOD, o49.30 ppm. All other data were recorded in CDCis, with chemical shifts relative to 
CHCis, o77.01 ppm. 
Table 7.4 Molecular modelling results for 18-normycalamide A 17-aldehyde (7.5) 
MM2b Dihedral anglesc Dlstancesd H-Bonds 
.%.a Energy al b) C) d) e) f) g) h) I) D k) (QH/NH-Ol 
33.2 224.5 -162 -61 69 -172 -103 3.3 2.8 3.0 3.8 6.1 3.6 70H-170, NH-01 
24.1 225.3 -62 0 -69 -179 -134 3.7 3.9 2.6 3.6 2.7 2.5 70H-80, NH-01 
12.8 226.9 76 -178 129 -176 134 2.3 3.0 4.0 5.2 4.0 3.2 70H-01, NH-70 
8.5 227.8 -55 -7 -67 74 -132 3.8 3.9 2.7 3.4 2.9 2.5 70H-80, NH-01 
4.7 229.3 -57 -64 99 -180 -2 3.7 3.9 2.7 2.6 7.3 3.5 70H-170, NH-70 
2.8 230.6 -58 12 -76 -177 4 3.8 3.9 2.6 3.7 7.2 2.4 70H-80, NH-01,170 
2.7 230.7 49 -63 62 -169 -102 2.5 3.3 4.0 4.2 5.4 3.6 70H-170, NH-60 
2.1 231.3 -63 -58 95 -174 7 3.8 3.9 2.6 2.4 6.9 3.5 70H-170, NH-70 
2.0 231.4 -55 -10 -49 -163 20 3.7 3.9 2.7 3.0 3.2 2.8 70H-80, NH-01 
1.6 232.1 -63 -173 108 -177 -129 3.8 3.9 2.7 2.8 5.7 3.4 70H-60,NH-70 
1.4 232.4 -59 8 -18 -173 10 3.8 3.9 2.6 2.3 4.2 3.2 ?OH-80,170, NH-01 
1.2 232.6 -55 178 121 -175 137 3.7 3.9 2.7 3.4 5.5 3.3 70H-60, NH-70 
0.7 233.9 -58 -2 -71 -84 -7 3.8 3.9 2.7 3.6 4.7 2.5 70H-80, NH-01 
0.7 233.9 73 -176 126 73 -134 2.3 3.1 4.0 5.2 6.4 3.2 70H-01, NH-70 
0.6 234.3 -60 176 -62 -178 -131 3.7 3.9 2.7 3.4 2.7 2.6 70H-60, NH-01 
0.5 234.7 -61 -177 100 -174 135 3.8 3.9 2.7 2.6 5.7 3.4 70H-60, NH-70 
0.3 236.4 -59 21 -84 -83 -8 3.8 3.9 2.6 3.9 4.4 2.4 70H-80 
aRelative population (Boltzmann distribution) bin kJ mor-1 coihedral angles:- a) C5-C6-C7-C8 b) H-O-C7-C8 c) C6-C7-C8-N d) C14-C15-C16-C17 
e) C15-C16-C17-0 dDistances (in A):- f) H5a-H7 g) H5e-H7 h) 60C-H7 i) H5a-NH j) H5a-H17 k) H7-NH 
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Table 7.5 Biological assay results for compounds in Chapter 7. 
Comgound P3BB ICsoa Antiviral Resultsb (ngLdisk) 
Mycalamide A 0.5 WN WN +* 5 + + +* 2 
Mycalamide B 0.1 WN WN +* 2 +++ +++ +* 1 
E il16 18-Normyc.B (7.3) 34 WN VWJ +* 2000 ++ +++ +* 1000 
z il16 18-Normyc.B (7 .4) 10 WN +++ +* 200 100 
18-Normyc.A 17 -ald. (7.5) 0.2 WN VWJ +* 5 +++ +++ +* 2 
18-Normyc.A (7.7) 0.2 WN VWJ +* 5 +++ +++ +* 2 
a In ng/ml. The derivatives are estimated to be better than 95% pure, having been subjected to 
at least two steps of chromatographic purification in most cases. 
b -,+,++,+++,WW=antiviral zone size. Results are listed in the order of Herpes simplex virus, 
Polio virus, cytotoxicity, loaded sample mass. 
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CHAPTER 8 
STRUCTURE-ACTIVITY RELATIONSHIPS IN 
MYCALAMIDES A AND B AND THE 
SYNTHESIS OF A MODEL COMPOUND 
8.1 INTRODUCTION 
The biological assay results for more than one hundred and ten 
derivatives of mycalamides A and 8 have enabled the elucidation of some 
important structure-activity relationships. These results are reviewed in this 
chapter and the most promising analogues highlighted. Some of these 
analogues have been specified in exemplification of a patent on mycalamides 
A and 8 {and their derivatives) as potential antitumour agents68,69. The 
possible correlation between the in vitro antiviral and antileukemic (P388) 
assay results for these mycalamide derivatives is also investigated. 
With such complex molecules as the mycalamides, it was difficult to 
examine thoroughly the importance of all structural features. Most work has 
centred on the modification of particular functional groups, but even this has 
not been exhaustive, as noted in earlier chapters. However, within the 
limitations of the work performed, it has been established that some structural 
features were certainly important for the biological activity, particularly the 
central amide portion of the molecule. 
Aspects of the syntheses of pederin and the mycalamides A and 8 will 
be reviewed as a background to the design of compounds containing some of 
these important structural features. There is much current interest, for 
example, in the development of peptide mimics as new clinical 
agents65,66,275. As increasingly more efficient syntheses of the natural 
products are developed, there is clearly some potential for the further 
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development of simple analogues. The design of active, conformationally 
restricted molecules70,71 ,92 may also enable more information to be obtained 
about the exact nature of the active site with which these compounds interact. 
The work described in this chapter may thus assist in the further development 
of the mycalamides A and 8 and related compounds as potential antitumour 
agents. 
8.2 STRUCTURE-ACTIVITY RELATIONSHIPS IN MYCALAMIDES A 
AND B 
8.2.1 SUMMARY OF BIOLOGICAL ACTIVITY DATA 
The complete set of biological assay results for all the mycalamide 
derivatives presented in previous chapters has been summarised graphically 
in Figure 8.1. This graph illustrates the relationship between the in vitro 
antiviral and P388 antileukemic assay results by expressing the logarithm of 
the P388 ICso value {in ng/ml) versus the logarithm of the minimum antiviral 
loading (in ng/disk) required for a whole-well antiviral response. Note that the 
data set has been edited to exclude those compounds with a P388 ICso value 
in excess of 500 ng/ml for clarity of presentation (such derivatives can safely 
be considered to be inactive within the limits of purity, as discussed below). It 
is apparent that there is a strong correlation between the two sets of biological 
assay results within experimental error (see below). This correlation is 
probably indicative of a common mode of action for all the derivatives as for 
the parent compounds, that is, an inhibition of protein synthesis53,57, as 
expected. In particular, there are no derivatives with significantly more 
selective antiviral or P388 antileukemic activity. 
Figure 8.1 Graph of the logarithm of the P388 ICso (in ng/ml) versus the 
logarithm of the minimum loading (in ng/disk) for a whole-well 
antiviral response for compounds in this thesis. 
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The derivatives displaying the most potent biological activity were found 
to be (no order intended): 18-0-methyl mycalamide A (2.35), 17,18-di-0-
methyl mycalamide A (2.38), 4a-dihydro mycalamides A and B (4.4, 4.6), 4~­
dihydro mycalamides A and B (4.5, 4.7), 18-normycalamide A (7.7), 18-
normycalamide A 17-aldehyde (7.5), and, to a lesser extent, the following 
esters: mycalamide A 18-p-bromobenzoate (2.1 0), mycalamide B 18-
monoacetate (2.20), mycalamide B 7-monoacetate (2.21 ), mycalamide B 18-
mesylate (2.23) and 17, 18-di-Q-methyl mycalamide A 7-monoacetate (2.36). 
Of these derivatives, the compounds 18-0-methyl mycalamide A (2.35), 
17, 18-di-0-methyl mycalamide A (2.38) and 18-normycalamide A (7.7) were 
perhaps the most promising analogues. Note that the 4~-d i hydro 
mycalamides A and B (4.5, 4.7) were also of some interest, but appeared to 
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be more susceptible to acid catalysed hydrolysis. Really, to determine the 
best analogues, the derivatives would need to be tested over a much wider 
range of assay systems1,2,13. 
There are several possible sources of error in these biological assay 
results. The most crucial and difficult to determine source of error was the 
possible contamination of less active derivatives from trace amounts of more 
active derivatives, such as unresolved mycalamides A and B. There were 
significant uncertainties in the sample masses for fractions of less than 1 mg in 
size, which necessarily caused potential errors in the concentrations of 
samples submitted for assay. There were also physical errors involved in the 
preparation of dilution series and minor statistical variations between 
individual assay runs. In particular, part of the error in the P388 assay result 
arose from the calculation of the ICso value from a relatively small number of 
data points (performed by assuming straight line connections between points 
and interpolating a result between these). To counter this, at least two ICso 
values were calculated for each derivative and the results averaged. There 
were generally insufficient measurements performed to present a better 
statistical view of the overall errors in the stated assay results. However, it has 
been found by experience that the uncertainty is up to a factor of two either 
side of the result, which may be considerably higher for compounds having 
stated activities less than one percent of those of mycalamides A and B (P388 
ICso's of greater than 50 and 10, respectively), since chromatographic purity 
may then be in question, as indicated above. 
8.2.2 REVIEW OF RESULTS BY STRUCTURAL CLASS 
The mycalamide TMS ethers had activities similar to the· parent 
compounds, but this result was questionable since these TMS ethers are 
readily hydrolysed138. The mycalamide TBDMS ethers displayed less activity 
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with increasing substitution of the hydroxyl groups of the mycalamides, so that 
the di- or tri-substituted ethers were inactive and even the mono-substituted 
ethers had little activity. Similarly, of the mycalamide p-bromobenzoate esters, 
only mycalamide A 18-p-bromobenzoate (2.1 0) had significant activity and 
the more substituted esters were much less active. Monoacetylation of 
mycalamide B was mildly deactivating (-1 0-fold), whereas complete 
acetylation of mycalamides A or B gave derivatives at least 100 times less 
active. However, mycalamide B 18-mesylate (2.23) seemed to be as active 
as mycalamide B. Analysis of the biological activity of the mycalamide methyl 
ethers showed that methylation of the C7 hydroxyl group was the most 
deactivating, whereas methylation of the C17 or C18 groups was slightly 
activating. Methylation of the amide was also deactivating. Similar results 
were found for benzylation of these groups. 
The C6 acetal seemed to be important since the pseudomycalamides A 
and B (3. 7, 3.8) were significantly less active and the 4a-dihydro, 6-deoxy 
pseudomycalamide A (4.13) and 5,6-dehydromethoxy mycalamide A (3.11) 
derivatives were relatively inactive, whereas 6-ethoxy mycalamide A (3.1 0) 
was of similar activity to mycalamide A. All rearrangement and cleavage 
fragments arising from the acid catalysed hydrolysis of mycalamide A 
triacetate were inactive. Hydrogenation of the double bond of mycalamides A 
and B gave two isomers, where the 4~ isomers were of about equal activity to 
the parent compounds, but the 4a isomers were slightly less active. Similarly, 
comparing the two epoxide isomers of mycalamides A and B, the 4a isomers 
were much less active than the 4~ isomers and even the latter compounds 
were not very active. Rearrangement of the double bond to the C3-C4 
position also resulted in a loss of activity. 
All the derivatives containing an oxazolidinone ring were inactive, since 
the C7 hydroxyl group was substituted. Importantly, all other compounds 
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derived from base catalysed epimerisations or cleavages at C7 and C1 0 were 
inactive. Removal of the C1 O-C12 methylene acetal system to leave a double 
bond between C1 0 and C11 was completely deactivating and hydrogenolysis 
of this system also gave significant loss of activity. By comparison, the 
removal of C18 by oxidative decarbonylation was slightly activating, provided 
that a double bond was not introduced between C16 and C17. 
8.2.3 STRUCTURE-ACTIVITY THEORIES AND ANALYSIS OF RESULTS 
Fundamental to the study of correlations between structure and activity 
is the knowledge that messengers and enzymes of each organism depend 
strongly on small details of their chemical structure, without which their 
characteristic biological activity is lost. Small changes to these details can 
result in large changes to their degree of action. Potential natural and 
synthetic drugs show a similar dependence on minute detail. Current insight 
into structure-activity relationships has come from studies of physical 
properties and the receptor theory15. For example, three characteristics of the 
action of drugs indicate that these are concentrated by cells on specific areas 
known as receptors: the high dilution (1o-9M) at which solutions of drugs are 
potent, the specific recognition of a particular chirality (illustrating the 
importance of shape) and the high biological specificity of some drugs. 
Historically, it was believed that structure-activity relationships 
depended on the presence of particular chemical substituents or nuclei15. 
The importance of physical properties in these correlations is now well 
accepted and can be summarised by three factors15,75: partition coefficients 
(a measure of relative solubility and thus comparative distribution), ionisation 
(and other measurements of electronic distribution) and shape (steric fit for 
interaction with an active receptor site). In this work, considerable emphasis 
has been placed on the study of shape, with the solution conformations of 
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derivatives being extensively investigated by 1 H NMR spectroscopy and, on 
occasions, molecular modelling. Here it was found that the derivatives with 
solution conformations most like those of mycalamides A and 8 displayed the 
most potent biological activity. Attempts to introduce further unsaturation into 
the molecule to reduce the possible solution conformations always gave rise 
to derivatives with little biological activity. However, despite understanding the 
major solution conformations of mycalamides A and B, it is still not known what 
is the 'active' conformation70,71 (at the receptor15), as stated in earlier 
chapters. 
No other direct assessment was made of electronic distribution, 
although it was observed that the C7 hydroxyl and amide NH groups were 
sites for potential ionisation under basic conditions, being readily alkylated 
with concurrent loss of biological activity. Thus it is probable that these groups 
would be directly involved in interactions with the active site and, possibly, 
receptor binding {pederin binds to a site on the ribosome47,49 to inhibit 
translation in protein synthesis46 and mycalamides A and 8 have a similar 
mechanism of action57). Note, however, that some local regions of electronic 
distribution in these compounds could also be estimated by analysing 1 H and 
13C NMR chemical shift data. 
The small scale preparations and lack of a strong UV chromophore in 
mycalamides A and Band derivatives meant that these were not amenable to 
the measurement of partition coefficients15, which are usually measured for 
octanol and water solutions1 ,75. Some crude assessment of the relative 
polarities could possibly be obtained from a study of the retention 
characteristics75 of the various derivatives on C18 reverse phase material or 
silica gel. It was noted, however, that many derivatives which had similar 
retention times to mycalamides A and B displayed vastly differing levels of 
biological activity. Therefore it is proposed that solubility is not a major factor 
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in the above results and a more detailed analysis was not attempted due to 
time constraints. 
The structure-activity correlations discussed above for the mycalamides 
are complex, since it appeared that few changes could be made to the 
structure without substantial loss of biological activity. However, it was clear 
that the region from C6 to C1 0 was most important, since cleavages, 
epimerisations and functional group modifications to elements of this portion 
always resulted in almost completely inactive derivatives. One of the original 
. 
aims of this research was to synthesise a model compound, including some 
biologically important structural features. This proposal stems from an 
established concept that the molecular structure of natural products can often 
be simplified by removing non-essential structural portions, while still retaining 
the desired therapeutic action4. Historically, the simplification of the structure 
of cocaine to give the local anaesthetic procaine was the first of many notable 
successes in this area4. The following section reviews some aspects of the 
syntheses of pederin and mycalamides A and B as a background to this 
synthetic attempt. 
8.3 SYNTHESIS OF A MODEL COMPOUND 
8.3.1 APPROACHES TO THE SYNTHESES OF PEDERIN AND 
MYCALAMIDES A AND B 
Early approaches to the synthesis of pederin concentrated on the 
individual synthesis of the two halves of the molecule 133,240,276,277,278, since 
it was proposed that these could be coupled at the amide linkage, or adjacent 
to it at C1 Q279. The first successful total synthesis of pederin was reported in 
1 979280 and 198290 by a Japanese group, Yanagiya and coworkers. A 
crucial factor in this synthesis was the novel construction of the central N-(1-
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methoxyalkyl) amide bridge, involving the coupling of a carboxylic acid, 
including the left hand structural portion to C8 (activated in situ as the acyl 
chloride), with a methyl imidate, including the right hand portion to C1 0-NH, 
using triethylamine at room temperature (Scheme 8.1a). The acyl chloride 
was easily formed under very mild conditions by a reaction of the carboxylic 
acid with thionyl chloride and excess pyridine at room temperature, while the 
imidate was constructed from a C1 0 amide by treatment with trimethyloxonium 
tetrafluoroborate. The resulting methyl N-acyl imidates were reduced by 
sodium borohydride to generate the N-{1-methoxyalkyl) amide (Scheme 8.1 a). 
During this synthesis90 the hydroxyl groups were protected as benzoate 
esters and the exocyclic double bond was not generated until the penultimate 
step {by oxidation and elimination of a C4 alkyl phenyl selenium group), to 
counter acid instability problems127,133,276. Using this double bond protected 
substrate, kinetically controlled acid catalysed exchange reactions at C1 0 
could be performed to optimise the yield of pederin over its thermodynamically 
favoured C1 0 epimer127,130. The full details of this synthesis were reported in 
1988 by Matsuda, Matsumoto and coworkers127. 
Subsequent syntheses by Nakata, Oishi and coworkers134,135 and by 
Willson and coworkers128,129,252 depended to a large extent on these 
Matsumoto protocols. More recently, an alternative synthesis was reported by 
Willson132, involving the novel coupling of a C6 metallated dihydropyran with 
an oxamate ester of the right hand portion (to C7) to generate the sensitive 
C6-C8 'masked tricarbonyl' system. This approach had the advantage of 
circumventing problems with the stability of the left hand side intermediates in 
the previous syntheses90,129,132. 
Recently, Kishi and coworkers91 reported the total synthesis of 
mycalamides A and B, involving the coupling of isomeric C10 amines {having 
the entire right hand portion constructed) with the left hand side carboxylic 
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acid intermediate used in earlier syntheses of pederin. This total synthesis 
unambiguously established the absolute configuration of mycalamides A and 
B. It was also sufficiently flexible to allow for the future preparation of further 
mycalamide analogues. 
Scheme 8.1 Reaction sequences employed in the synthesis of pederin and 
a model compound (8.3). 
Ph-CN HCI MeOH 
H,c, 1 £' 
~ 'NH Ph 
OH 
8.3.2 SELECTION OF A MODEL STRUCTURE 
I NaBH4 t EtOH 
As indicated above, structure-activity correlations for the mycalamides A 
and B had established the importance of the central portion from C6 to C1 0 for 
the biological activity of these compounds. The original synthesis of pederin, 
involving the construction of the N-(1-methoxyalkyl) amide, led to the patenting 
of this synthesis of acylaminoacetals281 (8.1) and of hydroxypropionyl-
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aminoacetals282 (8.2) as useful intermediates to pederin. The former patent 
description stated that this structure contributed to the physiological activity of 
pederin, and the second patent description claimed potent physiological 
activity for compounds of the form 8.2, although this was not quantified. 
These hydroxypropionyl-aminoacetals (8.2) contained the structural features 
from C? to C1 0 of pederin, so it was decided to synthesise and separate the 
isomers of bne example of this class of compounds and determine the 
possible biological activities in our assay systems. The compound chosen for 
this study was 8.3, whose synthesis was clearly described in the patent282 
and in the later Matsuda paper127. Note that the only other natural product 
containing similar structural features (C7-C1 0, with C1 0 having an OR group), 
was oxypinnatinine283,284 (8.4), having no published biological activity data. 
R1-R3=alkyl,aryl: (8.1) R1=R2=alkyl,aryl: (8.2) 
R1=Ph, R2=CH3: (8.3) 
H~CyylN):( 
H 
CH20H 2N OH 
Oxypinnatinine (8.4) 
8.3.3 SYNTHESIS OF N-(a:-METHOXYBENZYL)-2-HYDROXY 
PROPIONAMIDE 
A detailed account of the synthesis of the four diastereoisomers of this 
compound and their purification is presented in the Experimental section, so 
will be only briefly described here. The synthetic strategy has been illustrated 
in Scheme 8.1 b, starting with benzonitrile and S-lactic acid (AR grade) in the 
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first instance. Unfortunately this grade of lactic acid was impure, containing 
other esters and anhydrides of lactic acid, but was still used for this initial 
study. Acetylation, using pyridine and acetic anhydride, gave the 2-acetyl 
derivative of S-lactic acid (8.5), containing minor amounts of pyridine and 
acetic acid, by 1 H NMR spectroscopy (for NMR data see Experimental). 
0 
H3C, Jl I 'OH 
OAc • 
S-Lactic acid acetate (8.5) 
PhyNH 
OCH3 
Imino ether (8.6) 
The imino ether (8.6) was synthesised from benzonitrile, using acetyl 
chloride and excess dry methanol to generate anhydrous hydrochloric acid in 
situ, which was required to catalyse the addition of methanol across the C-N 
triple bond (Pinner synthesis285). The product was partially purified on 
Florisil, to give a sample which was at least 90% 8.6, containing only traces of 
benzonitrile and methyl benzoate, by 1 H and 13C NMR spectroscopy (see 
Experimental). Purification using silica gel gave a less pure sample having a 
new aromatic impurity which was not determined (it was not benzoic acid). 
Crude S-lactic acid acetate (8.5) was converted into the acid chloride 
using thionyl chloride and pyridine, then this mixture reacted with the imino 
ether (8.6) in the presence of triethylamine to give the coupled N-acyl imino 
ether, which in turn was reduced using sodium borohydride to give the crude 
product mixture (Scheme 8.1 b). This mixture contained the product 
diastereoisomers (8. 7, 8.8), their acetates (8.9, 8.1 0), byproducts and 
reagent derived material by 1 H NMR spectroscopy, so was initially purified by 
silica gel column chromatography. However, neither the two diastereoisomers 
(8.7, 8.8), nor their acetates (8.9, 8.10) were completely resolved by silica 
gel TLC. Preparative HPLC, using a chiral (R) phenyl urea column under 
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normal phase conditions, enabled a removal of impurities but gave no 
resolution of compounds 8. 7 and 8.8, and the yields appeared to be low. 
However, careful preparative silica gel TLC (developing the plate four times) 
of two fractions from the initial column chromatography above gave several 
fractions containing various ratios of 8.7 and 8.8, including one that was at 
least 85°/o rich in one diastereoisomer and another of similar purity that was 
rich in the other. This work did not resolve the acetates of these compounds, 
but did purify a minor reaction product {8.11 ), having an N-acetyl group281 in 
place of the N-(2-hydroxy propionyl) group282, according to its 1 H NMR data 
(see Experimental). This compound would arise from the presence of small 
amounts of acetic acid in the crude lactic acid used for the coupling reaction. 
H,C, 1 .t' H0C, 1 J:' l 'NH Ph l 'NH Ph 
OR OR 
R=H: SR, SS Products {8.7, 8.8) 
R=Ac: SR, SS Product acetates (8.9, 8.1 0) 
0 OCH3 
H3CANH~Ph 
N-{a-Methoxybenzyl) acetamide (8.11) 
8.3.3.2 CHARACTERISATION OF MAJOR PRODUCTS BY NMR AND MASS 
SPECTROSCOPIES 
The 1 H and 13C NMR data obtained for the two mostly separated 
diastereoisomers (8. 7 and 8.8) have been listed in Table 8.1. (Data for the 
mixed acetates of these compounds are listed in the Experimetal section, 
being similar to these, except in the downfield shift of the a-proton resonances 
and characteristic shifts in the 13 C resonances, consistent with 
acetylation98, 117). There was little difference in the 1 H NMR chemical shifts 
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for the two isomers. The largest differences occurred for the exchangeable 
proton resonances C2-0H and NH (around 0.1 ppm) and H2 (0.05 ppm). 
Similarly, the 13C NMR chemical shifts were within 0.15 ppm for the two 
isomers. 
NOE experiments were performed to investigate their solution 
conformations in an attempt to assign the stereochemistry at C5. Note that 
there was some conformational rigidity from C3 to C5, as in mycalamides A 
and Band pederin, since the amide bond would be in a Z conformation107, 
and the NH and H5 protons were in an anti relationship from the magnitude of 
the observed coupling constant98, 102 (9.7 Hz). The NOE results (Table 8.2) 
were found to be similar for both isomers and did not help with the assignment 
of stereochemistry, since there were insufficient long range NOE interactions 
between substituents at C2 and C5. In any case, the likely conformational 
flexibility about the C2-C3 bond (HC-CO) would probably not allow a 
conclusive answer. 
The structure of these diastereoisomers (8. 7 and 8.8) was further 
supported by HREIMS results. A strong peak was observed at m/z 194, 
corresponding to a loss of CH3 from the parent ion (adjacent to the a-hydroxy 
amide), while a base peak at m/z 121 was found, corresponding to an a-
methoxy benzyl ion (Ca H gO), along with a smaller ion at m/z 105, 
corresponding to a loss of CH4 from the latter (to leave a benzoyl ion). The 
HREIMS spectrum of the mixed acetates (8.9 and 8.10) was also consistent 
with their structure, showing similar peaks at m/z 121 and 105, along with a 
strong peak at m/z 191, corresponding to a loss of acetic acid from the parent 
ion, and a weaker ion at m/z 220, corresponding to a loss of CH30 from the 
parent. 
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8.3.3.3 SYNTHESES USING OPTICALLY PURE LACTATE SALTS 
Having successfully obtained two of the four isomers of 8.3, it was then 
desirable to optimise the synthesis of all four by starting with the optically pure 
carboxylate salts, calcium L(+)-lactate and lithium 0(-)-lactate. Therefore 
these salts were first acetylated, using the original reaction conditions, to give 
S lactic acid acetate (8.5) and R lactic acid acetate (8.12). The complete 
synthesis was then repeated for each, as before, except that the final sodium 
borohydride reduction step was performed on an ice cooled solution 127,282, 
rather than at room temperature, where the reaction was too vigorous. This 
modification had the result of giving much higher yields of the acetyl 
derivatives than in the original reaction. (Yields for the three reactions of 
purified acetates or hydroxy products ranged between 70-90%, with the latter 
reactions giving better overall yields, see Experimental). 
0 
H3C~ 
~ OH 
OAc 
R-Lactic acid acetate (8.12) 
The crude products obtained from both these latter syntheses were 
each subjected to a single stage of purification, using silica gel column 
chromatography, to give fractions containing mixtures of the acetates and/or 
hydroxy products. Note that the diastereoisomers derived from R-lactic acid 
are structures 8.13 and 8.14, while their acetates are compounds 8.15 and 
8.16. These products were identical by HREIMS and 1 H NMR spectroscopy 
to those compounds obtained from the first synthesis. Thus it remained only to 
submit these samples for biological testing. 
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OR OR 
R=H: RR, RS Products (8.13, 8.14) 
R=Ac: RR, RS Product acetates (8.15, 8.16) 
8.3.4 BIOLOGICAL ASSAY RESULTS AND CONCLUSIONS 
The crude reaction products from the first two syntheses showed very 
weak cytotoxicity in the P388 assay. However, this cytotoxicity was not 
associated with the diastereomeric products (8.7, 8.8, 8.13, 8.14), nor with 
their acetates, but with some reagent derived material and other, more polar 
impurities. Thus none of the isomers of 8.3 had significant P388 antileukemic 
activity (ICso values greater than 125000 ng/ml). Similarly, no antiviral or 
cytotoxic response was observed in the antiviral assays for loadings of up to 
80000 ng/disk. Therefore this compound did not seem to have any biological 
activity and was certainly not comparable to the mycalamides or pederin. It 
should be noted that this structure did not include an equivalent of the C6 
acetal system, which did appear to be biologically important in these 
compounds. Thus there are certainly other possible structures to consider, 
which may be accessible using this mild synthetic route with more ambitious 
substrates. However, such investigations were beyond the objectives and 
time available for this research. 
It is certainly possible that some simplification of the mycalamide and 
pederin structures could be achieved while retaining significant biological 
activity4. The production of more complex analogues may be readily 
achievable by small modifications to the existing synthetic routes to the natural 
products, as discussed above. The slight differences in the biological 
properties of pederin, mycalamides A and 8 and onnamide A (see 
Introduction) is sufficient evidence to suggest that such modifications may 
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provide compounds with even better therapeutic potential. It is hoped that the 
extensive structural modifications described in this present work, which have 
culminated in a large number of biological assay results and a better 
understanding of the chemical and conformational behaviour of these 
compounds, will provide some basis and stimulus for the ongoing study and 
development of such potential antitumour compounds in the future. 
Table 8.1 1 H and 13C NM R data a for compounds 8. 7 and 8.8 (called 
'isomers 1 and 2' since the stereochemistry at C5 was not 
defined). 
1H NMR data 13c NMR data 
Isomer 1 Isomer 2 Isomer 1 Isomer 2 
CH3 1.46 (d, 6.9} 1.48 (d, 6.8) C1 21.29 21.42 
H2 4.32 (q, 6.9} 4.27 (q, 6.8) C2 68.39 68.51 
2-0H 2.56 (s) 2.66 (s) C3 174.52 174.61 
NH 6.95 (d, 9.8) 7.03 (d, 9.6) C5 81.29 81.19 
H5 6.11 (d, 9.8) 6.10 (d, 9.7) S-OCH3 56.08 55.98 
S-OCH3 3.46 (s) 3.44 (s) Ph 139.01 139.03 
Ph 7.32-7.45 (m} 7.32-7.43 (m) 128.67 128.65 
128.64 128.61 
125.84 125.84 
aAn data were recorded in CDCis, with chemical shifts in ppm relative to CHCI3, o7.25, or to 
CDCI3, 877.01 ppm (muHiplicity, coupling constants in Hz). 
Table 8.2 1 H-1 H NOE interactionsa for compounds 8. 7 and 8.8. 
Compound 
Isomer 1 
(8.7 or 8.8) 
lsomer2 
(8.8 or 8.7) 
Slgnal(s) 
irradiated 
CH3 
H2 
2-0H 
H5 
5-0CHs 
NH 
CH3 
H2 
2-0H 
H5 
5-0CHg 
NH 
aAn data were recorded in CDCI3. 
Signals enhanced 
(% enhancement> 
H2(5), NH(2) 
CHg(0.6), 2-0H(0.6), NH{1) 
H2(2), NH(1) 
S-OCH3(0.8), Ph(0.6} 
H5(3} 
H2{1) 
H2(6), NH(1 ), H5(0.2}, 5-0CH3(0.3) 
CH3(0.9), NH(1) 
CHg(0.3), H2(3), NH{2}, H5{0.3) 
CHg{0.2}, H2(0.3), 5-0CH3(0.9), Ph{0.7) 
CHg(0.5), H2(0.5), NH(1 ), H5(4), Ph(0.4) 
CH3(0.3), H2{2), 5-0CHs(0.3} 
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EXPERIMENTAL 
GENERAL METHODS 
Infrared (IR) spectra were recorded for CHCI3 solutions or smears (film) 
on potassium bromide plates, using a Pye Unicam SP3-300 spectrometer. 
FTIR spectra were all recorded as smears using either a Perkin Elmer 1600 
Series FTIR spectrometer, equipped with a Hewlett Packard Color Pro plotter, 
or a Bio-Rad Digilab Divisio·n FTS-40 FTI R spectrometer, equipped with a 
3240-SPC data terminal, an NEC multisyncll screen and a KDC FPL-2000 
plotter. Ultraviolet-Visible (UV) spectra were recorded as methanol solutions 
on a Varian OMS 100 UVNisible spectrophotometer. Mass spectra were 
recorded on Finnegan 4500 (DCI/DEI), VG7070E or Jeol SX1 02 (high 
resolution) mass spectrometers (USA), or a Kratos MS80RFA mass 
spectrometer (UOC). 
NMR spectra were recorded on a Varian XL300 spectrometer, 
operating at 300 MHz for 1 Hand at 75 MHz for 13C nuclei, except for 500 MHz 
1 H-detected HMQC or HMBC data, which were recorded on a VXR500S 
spectrometer. All samples for examination in CDCI3 were normally prepared 
and stored in the presence of 0.1% pyridine to prevent acid catalysed 
decomposition95,139. Chemical shifts in this thesis have been expressed as 
parts per million (ppm) on the o scale, relative to the following solvent 
reference peaks; 1H: CHCI3 87.25, CHDCI2 o5.33, CHD20D o3.30, 
CHD2SOCD3 o2.60, CsHDs o7.27, or dioxan o3.70 (for spectra in D20) and 
13C: CHCI3 877.01, CD2CI2 o53.60, CD30D 849.30, CD3SOCD3 o40.5, 
CsDs 8128.40 or dioxan 867.40 (for spectra in D20). The 1 H NMR 
resonances in this section are described as: chemical shift, assignment, 
multiplicity (s for singlet, d for doublet, t for triplet, q for quartet, m for multiplet), 
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coupling constant (in Hz). Difference NOE experiments were performed on 
non-degassed solutions in an arrayed experiment, with the decoupler offset 
1 0000 Hz for the control experiment and then low power cycled over the 
multiplet peaks corresponding to the proton or protons being irradiated in the 
experiment82. A 1 s acquisition time (AT) was used, with a delay (D2) of 2 
seconds. The reported percentage enhancements represented the increase 
in intensity of a particular resonance (independent of the power level used for 
irradiation or the degree of saturation obtained). All NOE and 
. 
two-dimensional correlation· experiments were performed using narrowed 
spectral windows. For NOE and COSY experiments this was typically 80.5-8.5 
ppm, but for HMQC or HMBC experiments the 1 H window was usually 
80.5-6.2 ppm and the 13C window 810-110 or 10-80 ppm. Typical acquisition 
parameters were used for COSY experiments (AT of 0.2 s, D1 of 1 s, pulse 
width (PW) = 0.5x P1 (450), number of increments (NI) = 256), with zero-filling, 
pseudo-echo weighting functions, and symmetrisation used in the data 
processing. Acquisition parameters for HMQC experiments included AT's of 
0.07-0.16 s and D1's of 0.7-1 s, with J1 XH either 130 or 140 Hz, a JNXH of 
140Hz and a 'null' value of 0.4 s. For HMBC experiments similar AT and D1 
values were used, but J1 XH was 130 Hz and JNXH 8.3 Hz. Data were 
generally displayed in the absolute value mode. Molecular mechanics 
calculations, using standard MM2 parameters, were performed on a Vax 
computer, using a MODEL program, version KS 2.94125. 
Silica gel column chromatography was performed using Davisil, 35-70 
f.Lm, 170 A, typically 200-300 mg in a pasteur pipette, using solvent gradients 
starting with mixtures of petroleum ether (PE) and ethyl acetate (EtOAc) and 
progressing to mixtures of ethyl acetate and ethanol (EtOH). Analytical and 
preparative silica gel TLC was performed on Merck DG P .K.60 F2s4 plates, of 
0.2 mm thickness, and reverse phase analytical TLC was performed on 
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Whatman MKC1aF plates, of the same thickness. Visualisation of TLC plates 
containing mycalamide derivatives was achieved using an anisaldehyde dip 
reagent (0.1 :1 :100 by volume of anisaldehyde, concentrated sulphuric acid 
and glacial acetic acid) then heating at 12ooc for 3-5 minutes. The yellow, 
orange or brown colour obtained for most derivatives (except cleavage 
fragments from the right hand portion which gave no colour, or those 
containing an oxazolidinone ring, which gave a blue colour) could be 
accentuated by iodine. In general, the mycalamides and derivatives gave no 
UV absorbance at A-=254 nm. Therefore, fully developed preparative TLC 
plates were visualised by removing a vertical strip of 2 mm width from the 
centre of the plate, visualising the strip with anisaldehyde reagent, then 
extrapolating the bands observed onto the remainder of the plate. 
Reverse phase {C18) analytical and preparative HPLC was performed 
on a Shimadzu LC-4A instrument, equipped with a LKB Bromma 2142 
Differential Refractometer (a refractive index recorder for semi-quantitative 
detection), using an Alltech Econosphere C18 column, of dimensions 250 mm 
x 4.6 mm and 5 Jl particle size. A flow rate of 1 ml/min was generally used with 
the stated mixtures of methanol {AR grade, distilled and filtered) and water 
(deionised). Analytical and preparative normal phase HPLC {Chapter 8) was 
performed on the same instrument, using an Alltech Econosphere CN column, 
of dimensions 250 mm x 4.6 mm and 5 Jl particle size, or a 
Supelcosii-LC-(R)-Urea chiral column of the same dimensions, and with UV 
detection (A-=254 nm). Solvents for this work were distilled and filtered (or 
further purified by standard procedures). 
Microscale reactions were performed in either a 1 or 5 ml reactivial and 
stirred magnetically. (Hydrogenation reactions were performed using sealed 
microscale apparatus which permitted the entrance of a small flow of gas over 
the solution and contained an outlet tube vented into a beaker of water). All 
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technical grade solvents having boiling points less than 80°C were distilled 
prior to use, as were pyridine and acetic anhydride. Benzene and DMSO 
were AR grade, and the latter was usually predried over molecular sieves 
(type 4A). All other reagents were CP or AR grades and used without further 
purification, unless stated otherwise. 
BACKGROUND - ISOLATION AND CHARACTERISATION OF 
MYCALAMIDES A AND 818,58 
The active Myca/e sp. was recollected in January 1987 from the Otago 
Harbour (voucher specimen 87P1-1 ). Part of this collection (12.8 kg) was 
freeze-dried (3.9 kg) and extracted by blending with CH2CI2 and CH30H and 
filtering. The solvents were removed from the combined extracts to give an oil 
(409 g), having in vitro antiviral (AV) activity at 10 )lg/disk, which was then 
partitioned between CHCia and H20. Removal of the solvent from the organic 
fraction gave an oil (144 g, AV at 2.5 )lg/disk), which was partitioned between 
4:1 CHaOH:H20 and CCI4. The CCI4 fraction was an oil (137 g, AV at 20 
)lg/disk), largely sterols. The major sterol was identified as 
24-methylenecholesterol by its 13C NMR signals. The CHaOH:H20 fraction 
gave an oil (6.1 g, AV at 0.25 )lg/disk), which was partitioned between 0. 1 M 
aqueous NaOH and CHCia. The organic fraction was an oil (2.24 g, AV at 
0.05 )lg/disk), which was subjected to silica gel chromatography (45 g Davisil), 
developed in steps from CH2CI2 to CH30H, to give a fraction (270 mg) 
containing mycalamide B (1 :29 CH30H:CH2CI2) and one {65 mg) containing 
mostly mycalamide A (1 :9 CH30H:CH2CI2). The fraction rich in mycalamide B 
was subjected to reverse phase liquid chromatography (RPLC) (2 g C18 
material), developed in steps from 1 :1 CH30H:H20 to CH30H. A fraction (20 
mg), which eluted with 6:4 CH30H:H20, was mostly mycalamide B. This was 
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purified by further RPLC (Merck LOBAR RP18, 40-63 ~m. 310 x 25 mm; 3 
ml/min 3:1 MeOH.H20; refractive index detection). Mycalamide A was purified 
by similar RPLC steps. 
Mycatamide A (0.4): an oil; [a]o +340, [a]s65 +110° (c 0.2, CHCb); IR (CHC13) 
'Umax 3600-3200, 3420, 2950, 2900, 2860, 1680, 1380, 1100, 1085, 1065, 
1020 cm-1, (film) 'Dmax 3700-3100, 2960, 2890, 1690, 1540, 1470, 1390, 1100, 
1080, 1040 cm-1; 1 Hand 13C NMR data in Tables 1.1 and 1.3; HREIMS m/z 
503.27220 (M+, -1.7 ppm for C24H41N010), 471.24824 (M+-CHsOH, +3.0 ppm 
for C23H37NOg); DCIMS {NH3) mlz (%) 521 (13, MNH4+), 491 (34), 490 (31 ), 
489 (1 00, MNH4+-CHsOH), 472 (31, MH+-CH30H), 316 (18), 288 (15), 272 
(14), 260 (18); DCIMS (ND3) m/z (%) 530 (22), 529 (66, MND4+), 528 (55), 527 
(27), 498 (34}, 497 (100, MND4+-CH30H), 496 (95), 495 (48); DCIMS (CH4) 
m/z (%) 474 (16), 473 (34), 472 (1 00, MH+-CH30H), 442 (14). 
Mycalamide B (0.5): an oil; [a]o +390 (c 0.2, CHCI3 ); IR (CHCI3) 'Dmax 
3600-3200, 3375, 2935, 2900, 2850, 1680, 1380, 1090, 1070, 1025 cm-1, 
(film) 'Umax 3700-3150, 2985, 2950, 1690, 1535, 1460, 1390, 1100, 1075, 
1035, 750 cm-1; 1 H and 13C NMR data in Tables 1.1 and 1.3; HREIMS m/z 
485.26422 (M+-CHsOH, +3.5 ppm for C24HsgNOg); DCIMS (NH3) m/z (%) 535 
(7, MNH4+}, 505 (28), 504 {38), 503 {1 00, MNH4+-CH30H), 488 (23), 487 (36), 
486 (89, MH+-CHsOH); DCIMS (ND3) m/z (%) 543 (5), 542 (14, MND4+), 541 
(1 0), 513 (17), 512 (19), 511 {34), 510 (1 00, MND4+-CH30H), 509 (82), 508 
(29), 493 (8), 492 (9), 491 (15), 490 (36, MD+-CH30H), 489 (37), 488 (16); 
DCIMS {CH4) m/z (%>) 488 (16%), 487 (32%), 486 (1 00%, MH+-CH30H), 456 
(16%). 
WORK DESCRIBED IN CHAPTER 1 
1.5 CHARACTERISATION OF PEDERIN DIBENZOATE {1.2) BY NMR 
SPECTROSCOPY 
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Pederin dibenzoate (1.2): an oil; 1 H NMR data in Table 1. 7 except the 
following aromatic resonances, (CDCI3) 38.09 {dd, 1.5, 8.6), 8.03 (dd, 1.6, 8.6), 
7.58 {m), 7.45 (t, 8.4) ppm and (CD30D) 38.08 (dd, 1.5, 8.5), 8.05 {dd, 1.5, 8.6), 
7.66 (dd, 1.5, 8.5}, 7.63 (dd, 1..5, 8.5), 7.52 (t, 8.5) ppm; 13C NMR data in Table 
1.3 except the following aromatic resonances, (CDCI3) o133.50, 133.11, 
130.29, 130.05, 129.56, 129.23, 128.51, 128.46 and (CD30D) o135.07, 
134.78, 131.84, 131.17, 130.86, 130.05,130.01 ppm. 
WORK DESCRIBED IN CHAPTER 2 
2.2.1 and 2.2.2 PREPARATION AND CHARACTERISATION OF TMS ETHERS 
Mycalamide A (2.5 mg) was stirred with N, 0-bis-trimethylsilyl 
acetamide (0.1 ml) in pyridine (0.1 ml) at room temperature overnight. H20 
(0.3 ml} was added and the mixture extracted with CH2CI2 (3x 0.2 ml). The 
solvent was removed and the crude organic products then subjected to silica 
gel column chromatography (200 mg Davisil), developed in steps from PE to 
EtOAc. A fraction (3 mg}, which eluted with 4:1 PE:EtOAc, was pure 
mycalamide A tris-TMS ether (2.1). 
2.1: an oil; 1 H and 13C NMR data in Tables 2.1 and 2.2; HREIMS m/z 
687.3651 (M+-CH30H, -0.4 ppm for C32Hs1 NOgSi3). 
Mycalamide 8 (2.6 mg) was stirred with N, 0-bis-trimethylsilyl 
acetamide (0.1 ml} in pyridine (0.1 ml) at room temperature overnight. H20 
(0.3 ml) was added and the mixture extracted with CH2CI2 (3x 0.2 ml). The 
393 
solvent was removed and the crude organic products then subjected to silica 
gel column chromatography (200 mg Davisil), developed in steps from PE to 
EtOAc. A fraction (3.1 mg), which eluted with 4:1 PE:EtOAc, was pure 
mycalamide 8 bis-TMS ether (2.2). 
2.2: an oil, 1 H and 13C NMR data in Tables 2.1 and 2.2; HREIMS m/z 
629.3418 (M+-CH30H, +0.5 ppm for C30H55N09Si2). 
Mycalamide B (2.0 mg) was dissolved in pyridine (0.1 ml) and cooled in 
ice. N, 0-bis-trimethylsilyl acetamide (0.1 ml) was added and the reaction 
. 
stirred in ice for 5 minutes. H20 (0.5 ml) was then added and the mixture 
extracted with CH2CI2 (3x 0.2 ml). The solvent was removed and the crude 
organic products then subjected to silica gel column chromatography (200 mg 
Davisil), developed in steps from PE to EtOAc. A fraction (2.1 mg), which 
eluted with 2:1 PE:EtOAc, was pure mycalamide 8 18-mono-TMS ether (2.3). 
2.3: an oil; 1 H and 13C NMR data in Tables 2.1 and 2.2; HREIMS m/z 
557.3022 (M+-CH30H, +0.4 ppm for C27H47NOsSi). 
Mycalamide A (1 mg) was dissolved in pyridine (0.1 ml) and cooled in 
ice. N, Q-bis-trimethylsilyl acetamide (0.1 ml) was added and the reaction was 
stirred in ice for 4 minutes. H20 (0.5 ml) was then added and the mixture 
extracted with CH2CI2 (3x 0.2 ml). The solvent was removed and the crude 
organic products then subjected to silica gel column chromatography (200 mg 
Davisil), developed in steps from PE to EtOAc. A fraction (1.2 mg), which 
eluted with 2:1 PE:EtOAc, was pure mycalamide A 17,18-bis-TMS ether (2.4). 
2.4: an oil: 1 H NMR data in Table 2.1; HREIMS m/z 615.3263 (M+-CH30H, 
+0.7 ppm for C29Hs3NOgSi2). 
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2.2.3 CLEAVAGE OF TMS ETHERS 
Mycalamide A tris-TMS ether (2.1, 0.5 mg) was stirred with tetra-n-butyl 
ammonium fluoride (1 J!l of a 1M solution) in THF (0.1 ml) at room temperature 
for 20 minutes. H20 (0.5 ml) was added and the mixture extracted with 
CH2CI2 (3x 0.2 ml). The solvent was removed to give the crude organic 
product, which was almost pure mycalamide A by TLC and 1 H NMR 
spectroscopy. 
2.2.4 PREPARATION AND CHARACTERISATION OF TBDMS ETHERS 
Mycalamide A (1 mg), t-butyldimethylchlorosilane (8 mg), dimethyl-
aminopyridine (1 mg) and triethylamine (5 Jll) were stirred in pyridine (0.2 ml) 
at room temperature for 3 hours. H20 (0.5 ml) was added and the mixture 
extracted with CH2CI2 (3x 0.3 ml). The solvent was removed and the crude 
organic product then subjected to silica gel column chromatography (200 mg 
Davisil), developed in steps from PE to EtOAc. A minor fraction (0.4 mg), 
which eluted with 4:1 PE:EtOAc, was pure mycalamide A 17,18-bis-TBDMS 
ether (2.6) while the major fraction (0.8 mg}, which eluted with 2:1 PE:EtOAc, 
was pure mycalamide A 18-mono-TBDMS ether (2.5). 
2.5: an oil; 1 H and 13C NMR data in Tables 2.4 and 2.5; HRFABMS m/z 
656.3214 (MK+, -2.7 ppm for C3oHssN01oSiK}. 
Mycalamide A (2.6 mg), t-butyldimethylchlorosilane (-20mg), dimethyl-
aminopyridine (2 mg) and triethylamine (30 Jll) were stirred in pyridine (0.3 ml) 
at 600C for 2 days. The solution was concentrated under nitrogen, then H20 
(0.5 ml) was added and the mixture extracted with CH2CI2 (3x 0.3 ml). The 
solvent was removed and the crude organic product then subjected to silica 
gel column chromatography (200 mg Davisil), developed in steps from PE to 
EtOAc. A minor fraction (1.5 mg), which eluted with 9:1 PE:EtOAc was 
mycalamide A tris-TBDMS ether (2.7), while the major fraction (2.5 mg}, which 
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eluted with 3:1 PE:EtOAc, was pure mycalamide A 17, 18-bis-TBDMS ether 
(2. 6). 
2.6: an oil; 1 H and 13C NMR data in Tables 2.4 and 2.5; HRFABMS m/z 
770.4145 (MK+, +6.3 ppm for C3sHsgN01oSi2K). 
2.7: an oil; 1 H and 13C NMR data in Tables 2.4 and 2.5; HRFABMS m/z 
814.5145 (MH+-CH30H, +0.5 ppm for C41HaoNOgSi3). 
Mycalamide B (3 mg), t-butyldimethylchlorosilane {12 mg), dimethyl-
aminopyridine (1 mg) and triethylamine (20 J.LI) were stirred in pyridine (0.2 ml) 
at room temperature for 20 hours. H20 {0.5 ml) was added and the mixture 
extracted with CH2CI2 (3x 0.3 ml). The solvent was removed and the crude 
organic product then subjected to silica gel column chromatography (200 mg 
Davisil), developed in steps from PE to EtOH/EtOAc. The first fraction (1.5 mg), 
which eluted with 3:2 PE:EtOAc, was pure mycalamide B 18-mono-TBDMS 
ether (2.8), whereas the second fraction (1.7 mg), which eluted with 1:19 
EtOH :EtOAc, was mycalamide B. 
2.8: an oil; 1 H and 13C NMR data in Tables 2.1 and 2.5; HRFABMS m/z 
600.3535 (MH+-CH30H, -5.4 ppm for C3oHs4NOgSi). 
Mycalamide B (2.8 mg), t-butyldimethylchlorosilane (25 mg), dimethyl-
aminopyridine (6 mg) and triethylamine {40 J.LI) were stirred in pyridine (0.3 ml) 
at 80°C for 2 days. The solution was concentrated under nitrogen, then H20 
(0.5 ml) was added and the mixture extracted with CH2Cl2 (3x 0.3 ml). The 
solvent was removed and the crude organic products then subjected to silica 
gel column chromatography (200 mg Davisil), developed in steps from PE to 
EtOAc. The MeOH soluble portion of the major fraction (2.5 mg), which eluted 
with 7:1 PE:EtOAc, was pure mycalamide B bis-TBDMS ether (2.9). 
2.9: an oil; 1 H and 13C NMR data in Tables 2.1 and 2.5; HRFABMS m/z 
714.4383 (MH+-CH30H, -6.9 ppm for C3sHsaNOgSi2). 
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2.3.1 PREPARATION AND CHARACTERISATION OF P~BROMOBENZOATE 
ESTERS 
Mycalamide A (2. 7 mg), p-bromobenzoyl chloride (5 mg) and 
triethylamine (4 ~I) were stirred in CH2CI2 (0.3 ml) at room temperature for 24 
hours. The solvent was removed and the crude organic products subjected to 
silica gel column chromatography (200 mg Davisil), developed in steps from 
PE to EtOH/EtOAc. Two fractions, which eluted with 1:1 PE:EtOAc and EtOAc 
were a mixture of two products and unresolved reagent (TLC) so these were 
combined (4.2 mg). Preparative reverse phase HPLC (20% H20 in MeOH) 
gave two fractions {1.8 mg, 0.7 mg), which were pure mycalamide A 18-mono~ 
p-bromobenzoate (2.1 0) and mycalamide A 7-mono-p-bromobenzoate 
(2.11 ), respectively. 
2.10: an oil or white solid; UV (CH30H) /..max 244 nm (e~5700); 1 H NMR data 
in Table 2.7; HRFABMS m/z724.1709 (MK+, -3.6 ppm for Cs1H4479BrN011K). 
2.11: an oil or white solid; UV (CH30H) /..max 245 nm (e-6500); 1 H NMR data 
in Table 2.7; HRFABMS m/z 654.1914 (MH+-CH30H, -0.2 ppm for 
C3oH4179BrN01o). 
Mycalamide A (5.0 mg), p-bromobenzoyl chloride (11 mg), dimethyl-
aminopyridine (1 mg) and triethylamine (1 0 ~I) were stirred in pyridine (0.4 ml) 
at 75oc overnight. The solution was concentrated under nitrogen, then H20 
(0.4 ml) was added and the mixture extracted with CH2CI2 (3x 0.4 ml). The 
solvent was removed to give the crude organic product (17 mg), which was a 
mixture of p-bromobenzoate esters and reagent (TLC). Preparative reverse 
phase HPLC (1 0% H20 in MeOH) gave four fractions {2 mg, 1 mg, 1.2 mg, 1.1 
mg), which were pure mycalamide A 18-mono-p-bromobenzoate (2.1 0), 
mycalamide A 7, 18-di-p-bromobenzoate (2.12), mycalamide A 
17, 18-di-p-bromobenzoate (2.13) and mycalamide A tri-p-bromobenzoate 
(2.14), respectively. 
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2.12: an oil or white solid; UV (CHsOH) "-max 245 nm {t:"'21000); 1H NMR data 
in Table 2.7, 13C NMR data in Table 2.2 except the following 
p-bromobenzoate resonances, (CDCis) o165.72 and 164.77 (7- and 18-0CO), 
131.82, 131.74, 131.50, 131.28, 131.14, 129.04, 128.73 and 128.17 (7- and 
1 8-0COC6H4Br) ppm; HRFABMS m/z 908.1109 {MK+, +2.8 ppm for 
CsaH4?79Br81 BrN012K). 
2.13: an oil or white solid; 1 H NMR data in Table 2.7. 
2.14: an oil or white solid; 1 H NMR data in Table 2.7; HRFABMS m/z 
. 
820.1175 (MH+-CH30H-C6H479BrC02H, +2.2 ppm for Cs7H4279Br81BrN01o), 
FABMS m/z (%) 1076 (5, MNa+), 1074 (5, MNa+), 1022 (14, MNa+-CHsOH}, 
1021 (8), 1020 (16, MNa+-CH30H), 823 (27), 822 (51), 821 (37), 820 (100, 
MH+-CHsOH-C6H4798rC02H), 819 (22), 818 (SO). 
Mycalamide 8 (11 mg}, p-bromobenzoyl chloride (26 mg), dimethyl-
aminopyridine (2 mg), and triethylamine (20 ~I) were stirred in pyridine (0.6 
ml) at ssoc for one week. The solution was concentrated under nitrogen (to 
0.1 ml), then H20 (0.3 ml) was added and the mixture extracted with CH2CI2 
(4x 0.4 ml). The solvent was removed to give the crude organic product (SO 
mg), which was a mixture of p-bromobenzoate esters and reagent (TLC). 
Preparative reverse phase HPLC (10% H20 in MeOH, then 18% H20 in 
MeOH) gave four fractions overall (1.2 mg, 0.8 mg, S.2 mg, 2.4 mg), which 
were pure mycalamide 8, mycalamide 8 7-mono-p-bromobenzoate (2.15}, 
mycalamide 8 18-mono-p-bromobenzoate (2.16) and mycalamide B 
di-p-bromobenzoate (2.17), respectively. 
2.15: an oil or white solid; 1 H NMR data in Table 2.4; HRFA8MS m/z 
738.1874 (MK+, -2.4 ppm for Cs2H46798rN011K). 
2.16: an oil or white solid; 1 H NMR data in Table 2.4, 13C NMR data in Table 
2.2 except the following p-bromobenzoate resonances, (CDCI3) o164.S6 
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(18-0CO), 131.78, 131.14, 129.03 and 128.18 (18-0COCeH4Br) ppm; 
HRFABMS m/z 722.2155 (MNa+, +0.4 ppm for C32H4e79BrN011 Na). 
2.17: an oil or white solid; 1 H NMR data in Table 2.4, 13C NMR data in Table 
2.2 except the following p-bromobenzoate resonances, (CDCI3) 8165.51, 
164.71 (7- and 18-0CO), 131.91, 131.69, 131.41, 131.14, 129.16, 128.71, 
128.15, 128.01 (7- and 18-0COCeH4Br) ppm; HRFABMS m/z 852.1414 
(MH+-CH30H, -0.6 ppm for C3sH4e79Br81 BrN011), DCIMS (NHs) m/z (%) 872 
(15), 871 (55), 870 (32), 869 (1 00, MNH4+-CH30H), 868 (16), 867 (51), 854 
. 
(17), 853 (8), 852 (52, MH+-CH30H), 850 (18). 
2.3.2 LARGE SCALE PREPARATION OF MYCALAMIDE B DI-P-BROMO-
BENZOATE 
Mycalamide B (19 mg), p-bromobenzoyl chloride (40 mg), dimethyl-
aminopyridine (4 mg), and triethylamine (0.1 ml) were stirred in pyridine (0.5 
ml) at 55oc for 1 day then at 7ooc for 2 days. The solution was concentrated 
under nitrogen, then H20 (2 ml) was added and the mixture extracted with 
CH2CI2 (4x 2 ml). The solvent was removed and the crude organic product 
then subjected to preparative silica gel TLC (developed in 2:1 PE:EtOAc). Two 
bands of silica were recovered and eluted with EtOAc, to give two fractions (6 
mg, 15 mg), which were mycalamide B 18-mono-p-bromobenzoate (2.16) and 
pure mycalamide B di-p-bromobenzoate (2.17), respectively. 
2.3.3 PREPARATION AND CHARACTERISATION OF ACETATE ESTERS 
Mycalamide A (6.5 mg) was dissolved in pyridine (0.1 ml) and acetic 
anhydride (0.1 ml) and stirred at room temperature overnight. H20 (2 ml) was 
added and the mixture extracted with CH2CI2 (3x 2 ml). The solvent was 
removed to give 8 mg of almost pure mycalamide A triacetate (2.18). 
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2.18: an oil; IR (CHCI3) Umax 3380, 2940, 2870, 1740, 1705, 1570, 1375, 
1110,1100,1030 cm·1, (film)umax3370, 3070,2954,2925,2855,1741,1678, 
1588, 1522, 1463, 1368, 1230, 1145, 1034 cm-1; 1H and 13C NMR data in 
Tables 2.7 and 2.2; HREIMS m/z 597.27536 (M+-CH 30H, -5.3 ppm for 
C29H4sN012), DCIMS (NH3) m/z (%) 647 (13, MNH4+), 617 {29), 616 (37), 615 
(100, MNH4+-CH30H), 542 (35), 318 (42), 317 (44), 299 (30), 286 (58), 285 
(41 ), 270 (28), 269 (60), 257 (30), DCIMS (CH4) m/z (%) 598 (71, 
MH+-CHsOH), 538 (1 00, MH+-CH30H-CH3C02H), 299 {53), 269 (56), 240 (41 ), 
208 (55). 
Mycalamide A (3.7 mg) was dissolved in pyridine (0.1 ml) and acetic 
anhydride (0.1 ml) and stirred at room temperature for 4 hours. H20 (0.3 ml) 
was added and the mixture extracted with CHCI3 (3x 0.3 ml). The solvent was 
removed and the crude organic product subjected to silica gel column 
chromatography (200 mg Davisil), developed in steps from PE to EtOAc. One 
fraction (0.7 mg) which eluted with EtOAc was a 1:1 mixture of mycalamide A 
triacetate (2.18) and, probably, mycalamide A 7, 18-diacetate by 1 H NMR 
spectroscopy. 
Mycalamide B (2.0 mg) was dissolved in pyridine (0.1 ml) and acetic 
anhydride (p.1 ml) and stirred at room temperature for 5 hours. H20 (0.5 ml) 
was added and the mixture extracted with CHCI3 (3x 0.3 ml). The solvent was 
removed to give 2.5 mg of pure mycalamide B diacetate (2.19). 
2.19: an oil; IR (CHC1a)umax3390, 2940,2890,1740,1710,1380,1125, 
1100, 1030, 910 cm-1; 1 H and 13C NMR data in Tables 2.8 and 2.9; HREIMS 
m/z 569.2848 (M+-CHaOH, +2.1 ppm for C28H43N011), HRFABMS m/z 
624.2973 (MNa+, -3.7 ppm for C29H47N012Na), DCIMS (NHs) m/z (%) 619 (22, 
MNH 4+), 589 (16), 588 (32), 587 (100, MNH4+-CH 30H), 570 (25, 
MH+-CH30H), 318 (19), 290 (25), 258 (62), 257 (26), 241 (45). 
2.3.4 DEACETYLATION OF MYCALAMIDE A TRIACETATE AND 
MYCALAMIDE B DIACETATE 
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Mycalamide A triacetate {2.18, 0.5 mg) was stirred with potassium 
carbonate {0.2 mg) in 9:1 MeOH:H20 {0.2 ml) at room temperature for 2 hours. 
Silica gel TLC indicated complete hydrolysis to mycalamide A. 
Mycalamide B diacetate (2.19, 2.2 mg) was stirred with potassium 
carbonate (0.3 mg) in 9:1 MeOH:H20 (0.3 ml) at room temperature for 12 
hours. The solution was co[lcentrated under nitrogen (to 0.1 ml), then H20 
(0.5 ml) was added and the mixture extracted with CH2CI2 (3x 0.4 ml). The 
solvent was removed to give 2 mg of about 90% mycalamide B by TLC and 1 H 
NMR spectroscopy, containing a small amount of a mycalamide B 
monoacetate. 
Mycalamide B diacetate (2.19, 2.5 mg) was stirred with potassium 
carbonate (0.5 mg) in 9:1 MeOH:H20 {0.3 ml) at room temperature for 1 hour. 
H20 (2.5 ml) was added and the mixture extracted with CH2CI2 (3x 2 ml). The 
solvent was removed and the crude organic products subjected to preparative 
silica gel TLC (developed in EtOAc}. Two bands of silica were recovered 
(Rf=0.2 and 0.7) and eluted with 1:3 EtOH:EtOAc, to give two fractions (0.5 mg, 
1.7 mg), which were pure mycalamide Band mycalamide B 18-monoacetate 
(2.20), respectively. 
2.20: an oil; 1 H and 13C NMR data in Tables 2.8 and 2.9; HREIMS m/z 
527.2749 (M+-CH30H, +3.6 ppm for C2sH41N01o), DCIMS (NH3) m/z (%) 577 
(1, MNH4+), 560 {1, MH+), 547 (15), 546 (35), 545 (100, MNH4+-CH30H}, 530 
(16), 529 (27), 528 (88, MH+-CH30H). 
2.3.5 PREPARATION AND CHARACTERISATION OF MYCALAMIDE 8 7-
MONOACETATE 
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Mycalamide 8 18-mono-TMS ether (2.3, 1.2 mg) was dissolved in 
pyridine (0.1 ml) and acetic anhydride (0.1 ml) and stirred for 3 hours at room 
temperature. H20 {0.4 ml) was added and the mixture extracted with CH2CI2 
(3x 0.3 ml). The solvent was removed to give the crude organic product (1.2 
mg), which was a 3:1 mixture of mycalamide 8 7-monoacetate (2.21) and 
mycalamide 8 diacetate (2\19) by TLC and 1 H NMR spectroscopy. This 
sample was then subjected to silica gel column chromatography (200 mg 
Davisil), developed in steps from PE to EtOAc. The major fraction (0.8 mg), 
which eluted with EtOAc, was pure mycalamide 8 7-monoacetate (2.21). 
2.21: an oil; 1 H and 13C NMR data in Tables 2.8 and 2.9; HRFA8MS m/z 
528.2836 (MH+-CH30H, +5.3 ppm for C26H42N010), DCIMS (NHa) m/z (%) 577 
(15, MNH4+), 547 (28), 546 (30), 545 (100, MNH4+-CH30H), 530 (10), 529 
(11 ), 528 (34, MH+-CH30H). 
2.3.6 PREPARATION AND CHARACTERISATION OF OTHER ESTERS 
Mycalamide A (2.8 mg) was dissolved in pyridine (0.1 ml) and propionic 
anhydride (0.1 ml) and stirred at room temperature overnight. H20 (0.4 ml) 
was added and the mixture extracted with CHCI3 (3x 0.4 ml). The solvent was 
removed to give 3. 7 mg of pure mycalamide A tripropanoate (2.22). 
2.22: an oil; 1 H NMR data in Table 2.8, except the following propanoate 
resonances, (CDCI3) o2.50, 2.48 (7-0COCH2, 2xqd, 7.5, 16.5), 2.32 and 2.25 
(17- and 18-0COCH2, 2xq, 7.5), 1.19, 1.12 and 1.07 (7-, 17- and 
18-0COCH2CH3), 13C NMR data in Table 2.2, except the following 
propanoate resonances, (CDCI3) <5173.95, 173.21 and 173.12 (7-, 17- and 
18-0CO), 27.55, 27.46 and 27.34 (7-, 17- and 18-0COCH2), 9.11, 9.02 and 
8.90 (7-, 17- and 18-0COCH2CH3) ppm; HRFA8MS m/z (%) 694.3356 (MNa+, 
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-8.4 ppm for CssHssN01sNa), DCIMS (NH3) m/z (%) 689 (20, MNH4+), 657 (24, 
MNH4+-CH30H), 404 (23), 346 (52), 331 (44), 314 (28), 244 (85). 
Mycalamide B (1.4 mg), methanesulphonyl chloride (i Jll) and 
triethylamine (3 Jll) were stirred in pyridine {0.2 ml) at room temperature for 1 
day, then at 40°C for 2 hours. The solution was concentrated under nitrogen 
(to 1 ml), then H20 (2 ml) was added and the mixture extracted with CH2CI2 
(3x 2 ml). The solvent was removed and the crude organic products subjected 
to preparative silica gel TLC (developed in EtOAc). Two bands of silica were 
recovered and eluted with 1 :9 EtOH:EtOAc, to give two fractions (0.3 mg, 1.0 
mg), which were mycalamide B and pure mycalamide B 18-monomesylate 
(2.23), respectively. 
2.23: an oil; 1 H and 13C NMR data in Tables 2.8 and 2.9; HRFABMS mlz 
618.2576 (MNa+, +2.6 ppm for C2sH4sN012SNa). 
2.4.2 PREPARATION AND CHARACTERISATION OF N,O-METHYL 
DERIVATIVES 
Mycalamide A (3 mg), powdered potassium hydroxide {3 mg) and 
methyl iodide (3 Jll) were stirred in DMSO (0.2 ml) at room temperature for 4 
hours. H20 (2 ml) was added and the mixture extracted with CH2CI2 (3x 2 ml). 
The solvent was removed to give the crude organic product (3.5 mg), which 
was a mixture of at least two components (TLC). Preparative reverse phase 
HPLC (30% H20 in MeOH) gave two fractions (1.9 mg, 1 mg), which were pure 
7-0-methyl, N-methyl mycalamide A (2.24) and a 4:1 mixture of 
7, 18-di-0-methyl, N-methyl mycalamide A (2.25) and 7, 17-di-0-methyl, 
N-methyl mycalamide A (2.27), respectively. 
2.24: an oil; 1 H and 13C NMR data in Tables 2.10 and 2.11; HREIMS m/z 
499.2798 (M+-CHsOH, +3.2 ppm for C2sH41NOg), DCIMS (NHs) m/z (%) 549 
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{3, MNH4+), 519 (6}, 518 (20), 517 (66, MNH4+-CH30H), 502 (1 0), 501 (29}, 
500 (1 00, MH+-CHsOH). 
Mycalamide A (5.5 mg), powdered potassium hydroxide (14 mg) and 
methyl iodide (1 0 fll) were stirred in DMSO {0.3 ml) at room temperature for 
3.5 hours. H20 was added (0.5 ml) and the mixture transferred onto a reverse 
phase pipette column (200 mg C18, equilibrated to H20), which was then 
flushed with H20 (6 ml) and eluted with MeOH (6 ml). The MeOH fraction was 
evaporated to dryness (5.5 mg), then subjected to preparative silica gel TLC 
(developed in EtOAc). Two bands of silica were recovered and eluted with 1 :9 
EtOH:EtOAc {4 ml) to give two fractions (1 mg, 3.5 mg), which were 
7,18-di-0-methyl, N-methyl mycalamide A {2.25) and 7,17,18-tri-0-methyl, 
N-methyl mycalamide A {2.26), respectively. 
2.25: an oil; 1H and 13C NMR data in Tables 2.10 and 2.11; HREIMS m/z 
513.2928 (M+-CHsOH, -1.8 ppm for C2sH43NOg), DCIMS {NHs) m/z (%) 563 
(1 0, MNH4+), 533 (19), 532 (37), 531 (1 00, MNH4+-CH30H), 516 {17), 515 (32), 
514 (95, MH+-CHsOH). 
2.26: an oil; 1 H and 13C NMR data in Tables 2.10 and 2.11; HREIMS m/z 
527.3068 (M+-CHsOH, -5.1 ppm for C27H4sNOg), DCIMS (NHs) m/z (%) 577 
(1, MNH4+), 547 (4), 546 (6), 545 (19, MNH4+-CH30H), 531 (5), 530 (19), 529 
(30), 528 (100, MH+-CH30H). 
Mycalamide 8 (2 mg), powdered potassium hydroxide {2 mg) and 
methyl iodide (2 J.tl) were stirred in DMSO (0.3 ml) at room temperature for 24 
hours. H20 was added (0.5 ml) and the mixture extracted with CH2CI2 (3x 0.3 
ml). The solvent was removed to give the crude organic product (3 mg), which 
was a mixture of 2 components (TLC). Preparative reverse phase HPLC {30% 
H 20 in MeOH) gave two fractions (1.2 mg, 0.6 mg), which were pure 
7,17-di-0-methyl, N-methyl mycalamide A (2.27) and 7,17,18-tri-0-methyl, 
N-methyl mycalamide A (2.26), respectively. 
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2.27: an oil; 1H and 13C NMR data in Tables 2.10 and 2.11; HREIMS m/z 
513.2945 {M+-CH30H, +1.4 ppm for C2sH4aNOg), DCIMS {NH3) m/z (%) 563 
{2, MNH4+), 533 {9), 531 (34, MNH4+-C H30H), 516 (25), 514 (1 00, 
MH+-CH30H). 
2.4.3 CONFORMATIONAL EXCHANGE OF 7,17,18-TRI-0-METHYL, N-
METHYL MYCALAMIDE A 
2.26: 1 H NMR data at 6°C, (CDCI3) o6.27 (H1 0, d, 9.8}, 5.15 (1 0-0CHR, d, 
6.7), 4.85 (1 0-0CHS, d, 6.7): 4.82 (4=CHZ, t, 1.9), 4.70 (4=CHE, t, 1.9}, 4.26 
(H7, s), 4.26 (H12, dd, 7.1, 1 0.4), 4.16 (H11, dd, 7.2, 9.9), 3.91 (H2, dq, 2.6, 
6.5), 3.55 (13-0CHa, s), 3.49 (H13, d, 1 0.5), 3.43 (7-0CH3, s), 3.38 (H15, m), 
3.29 (6-0CHa, s), 3.20 (N-CH3, s), 2.61 (HSa, dd, 1.9, 14.4), 2.26 {HSe, d, 
14.4), 2.18 (H3, dq, 2.6, 7.1 ), 1.68 (H16, ddd, 1.1, 10.1, 14.0), 1.47 (H16, ddd, 
3.3, 9.6, 14.0), 1.11 (2-CH3, d, 6.6), 0.96 (14-CH3R, s), 0.95 {3-CH3, d, 7.0), 
0.86 (14-CH3S, s) ppm. 
2.4.4 FURTHER METHYLATED DERIVATIVES 
Mycalamide A (4 mg), powdered potassium hydroxide (7.2 mg) and 
methyl iodide (5 Jll) were stirred in DMSO (0.3 ml) at room temperature for 20 
hours, then at 4ooc for 4 hours. H20 (0.5 ml) was added and the mixture 
transferred onto a reverse phase pipette column (200 mg C18, equilibrated to 
H20), which was then flushed with H20 (6 ml) and eluted with MeOH (6 ml). 
The MeOH fraction was evaporated to dryness (4.3 mg), then subjected to 
preparative silica gel TLC (developed in EtOAc). Three bands of silica were 
recovered and eluted with 1 :9 EtOH:EtOAc (4 ml) to give three fractions (0.5 
mg, 1.5 mg, 1 mg), which were 7, 18-di-0-methyl, N-methyl mycalamide A 
(2.25), 7,17,18-tri-0-methyl, N-methyl mycalamide A (2.26) and 
7 S, 17, 18-tri-0-methyl, N-methyl mycalamide A (2.28), respectively. 
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2.28: an oil; 1H and 13C NMR data in Tables 2.10 and 2.11; HREIMS m/z 
527.3078 (M+~CH30H, -3.0 ppm for C27H4sNOg), DCIMS (NH3) m/z (%) 577 
(8, MNH4+), 547 (15), 546 (30), 545 (88, MNH4+-CH30H), 530 (19), 529 (37), 
528 (1 00, MH+-CH30H). 
7,17-Di-O~methyl, N-methyl mycalamide A (2.27, 1.2 mg) was 
dissolved in a solution of sodium methoxide in MeOH (1M, 0.3 ml) and stirred 
at 90°C for three days. The solvent was removed and the residue partitioned 
in 1 :1 H20:CHCI3 (4 ml) and extracted in CHCI3 (3x 1 ml). The solvent was 
. 
removed and the crude organic product then subjected to silica gel column 
chromatography (200 mg Davisil), developed in steps from PE to EtOH/EtOAc. 
The major fraction (0.9 mg), which eluted with 1:19 EtOH:EtOAc, was a 1:3 
mixture of starting material and its epimer at C7 by 1 H NMR spectroscopy. 
Further mixtures of the two epimers were combined (2 mg), reacted as above, 
then subjected to preparative silica gel TLC (developed twice in EtOAc). Two 
bands of silica were recovered and eluted with ethyl acetate to give two 
fractions (0.6 mg, 1.2 mg), which were 7, 17-di-G-methyl, N-methyl mycalamide 
A (2.27) and 78,17-di-G-methyl, N-methyl mycalamide A (2.29), respectively. 
2.29: an oil; 1H and 13C NMR data in Tables 2.10 and 2.11; HREIMS m/z 
513.2960 (M+-CH30H, +4.3 ppm for C2sH43NOg), DCIMS (NH3) m/z (%) 563 
(3, MNH4+), 533 (5), 532 (13), 531 (45, MNH4+-CH30H), 516 (14), 515 (28), 
514 (1 00, MH+-CH30H). 
7-0-Methyl, N-methyl mycalamide A (2.24, 1.2mg) was dissolved in a 
solution of NaOCD3 in C030D (3M, 0.3 ml) and stirred at 700C for 2 days. The 
crude mixture was then subjected directly to preparative silica gel TLC 
(developed twice in 1 :19 EtOH:EtOAc). Two bands of silica were recovered 
and eluted with 1 :3 EtOH:EtOAc to give two fractions (0.4 mg, 0.7 mg), where 
the second (major) fraction was pure 7-deutero, 7S-O-Methyl, N-methyl 
mycalamide A (2.30). 
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2.30: an oil; 1 H NMR data in Table 2.1 0; HREIMS m/z 500.2834 (M+-CH30H, 
-2.0 ppm for C2sH4oDNOg), DCIMS (NH3) m/z (%) 550 {3, MNH4+), 520 (1 0), 
518 {61, MNH4+-CHsOH), 503 {23), 502 {9), 501 (1 00, MH+-CH30H). 
Mycalamide A {1.8 mg), anhydrous barium oxide {20 mg) and methyl 
iodide (6 Jll) were stirred in DMSO (0.3 ml) at 6ooc for 40 minutes. H20 (0.5 
ml) was added and the mixture transferred onto a reverse phase pipette 
column (200 · mg C18, equilibrated to H20), which was then flushed with H20 
(6 ml) and eluted with MeOH (6 ml). The MeOH fraction was evaporated to 
dryness to give the cru.de organic product (1.5 mg) which was 
7, 17, 18-tri-0-methyl, N-methyl mycalamide A (2.26) by TLC and 1 H NMR 
spectroscopy. 
Mycalamide B {1.1 mg), powdered potassium hydroxide (2 mg) and 
methyl iodide (0.8 Jll) were stirred in DMSO (0.3 ml) at room temperature for 7 
hours. H20 (0.4 ml) was added and the mixture extracted with CH2CI2 {3x 0.3 
ml). The solvent was removed to give the crude organic product (1.1 mg), 
which was a mixture of at least 2 components (TLC and 1 H NMR 
spectroscopy). Preparative reverse phase HPLC (40% H20 in MeOH) gave 
two fractions (0.5 mg, 0.5 mg), where the first was possibly 7, 17-di-0-methyl 
mycalamide A (2.33) and the second was pure 7,17-di-0-methyl, N-methyl 
mycalamide A (2.27) by 1 H NMR spectroscopy. 
2.4.5 PREPARATION AND CHARACTERISATION OF Q-METHYL 
DERIVATIVES USING SILVER(!) OXIDE IN BENZENE 
Mycalamide A (4.2 mg), silver(!) oxide (25 mg) and methyl iodide (8 J.!l) 
were stirred in benzene (0.3 ml) at 8QOC for .3 days. The solution was then 
filtered over celite and the solvent removed to give the crude organic product 
(4.6 mg). Preparative silica gel TLC (developed in EtOAc) gave three fractions 
(0.5 mg, 1.2 mg, 2.0 mg), which were 7,17-di-Q-methyl mycalamide A (2.33), 
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7, 18-di-0-methyl mycalamide A (2.32) and 7, 17, 18-tri-0-methyl mycalamide A 
(2.31 ), respectively. (These were individually rechromatographed by 
preparative silica gel TLC to give the pure compounds). 
2.31: an oil; 1 H and 13C NMR data in Tables 2.12 and 2.14; HREIMS m/z 
513.2916 (M+-CHaOH, -4.3 ppm for C26H43N09), DCIMS (NH3) m/z (%) 563 
(1 0, MNH4+), 533 (18), 532 (37), 531 (1 00, MNH4+-CH30H), 516 (11 ), 515 (22), 
514 (74, MH+-CH30H). 
2.32: an oil; 1 H and 13C NMR data in Tables 2.12 and 2.14; HREIMS m/z 
499.2779 (M+-CHaOH, -0.6 ppm for C25H41 N09), DCIMS (NH3) m/z (%) 549 (7, 
MNH4+), 519 (22), 518 (30), 517 (1 00, MNH4+-CH30H), 502 (11 ), 501 (16), 500 
(53, MH+-CH30H). 
Mycalamide A (7 mg), silver(l) oxide (55 mg) and methyl iodide (9 Jll) 
were stirred in benzene (0.4 ml) in a sealed vial at 95oc for 1.5 hours. The 
solution was then filtered over celite and the solvent removed to give the crude 
organic product (7.3 mg). Preparative silica gel TLC (developed twice in 1 :7 
PE:EtOAc) gave four fractions (0.8 mg, 1.4 mg, 2.0 mg, 2.8 mg), which were 
mycalamide A, 7-0-methyl mycalamide A (2.34), 3:2 17-0-methyl mycalamide 
A:18-0-methyl mycalamide A (2.35), and pure 18-0-methyl mycalamide A 
(2.35), respectively. Subsequently, 7-0-methyl mycalamide A (2.34) was 
subjected to further preparative silica gel TLC (developed 3 times in 1 :5 
PE:EtOAc) to give the pure compound (1.2 mg). 
2.34: an oil; 1H and 13C NMR data in Tables 2.12 and 2.14; HREIMS m/z 
485.2618 (M+-CHaOH, -1.4 ppm for C24H3gNOg), DCIMS (NH3) m/z (%) 535 
(1 0, MNH4+), 505 (28), 504 (28), 503 (1 00, MNH4+-CH30H), 488 (12), 487 (9), 
486 (30, MH+-CHaOH). 
2.35: an oil; 1 H and 13C NMR data in Tables 2.12 and 2.14; HREIMS m/z 
485.2617 (M+-CHaOH, -1.6 ppm for C24H3gNOg), DCIMS (NH3) m/z (%) 535 
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{16, MNH4+), 505 {24), 504 (33), 503 {100, MNH4+-CH30H), 487 (19), 486 (66, 
MH+-CH30H). 
Mycalamide 8 (6 mg), silver(!) oxide (40 mg) and methyl iodide (12 J.LI) 
were stirred in benzene (0.4 ml) in a sealed vial at 9ooc for 2 hours. The 
solution was then filtered over celite and the solvent removed to give the crude 
organic product. Pyridine (0.1 ml) and acetic anhydride (0.1 ml) were added 
and the mixture stirred at room temperature for 16 hours. H20 {2.5 ml} was 
added and the mixture extracted with CH2CI2 (3x 2 ml). The solvent was 
removed and the product subjected to preparative silica gel TLC (developed in 
3:1 EtOAc:PE) to give three fractions (1.7 mg, 2.0 mg, 2.4 mg), which were 
pure 7, 17-di-0-methyl mycalamide A 18-monoacetate (2. 37), 
17, 18-di-0-methyl mycalamide A 7-monoacetate (2.36), and mycalamide 8 
diacetate (2.19), respectively. 
2.36: an oil; 1 H and 13C NMR data in Tables 2.8 and 2.9; HREIMS m/z 
541.2866 (M+-CH30H, -3.9 ppm for C27H4sN01o), DCIMS (NHs) m/z (%) 592 
(1 0), 591 (32, MNH4+), 561 (26), 560 (33), 559 (1 00, MNH4+-CH30H), 544 
(1 0), 543 (14), 542 (43, MH+-CH30H). 
2.37: an oil; 1 H and 13C NMR data in Tables 2.8 and 2.9; HREIMS m/z 
541.2881 (M+-CH30H, -1.1 ppm for C27H4sN01o), DCIMS (NHs) m/z (%) 591 
(2, MNH4+), 562 (9), 561 (34), 560 (32), 559 (1 00, MNH4+-CH30H), 545 (11 ), 
544 (36), 543 (30), 542 (99, MH+-CH30H). 
7,17-Di-0-methyl mycalamide A 18-monoacetate (2.37, 1.8 mg) was 
stirred with potassium carbonate (1.2 mg) in 9:1 MeOH:H20 (0.4 ml) at room 
temperature for 5 hours. The solution was concentrated under nitrogen (to 0.1 
ml), then H20 (2.5 ml) was added and the mixture extracted with CH2CI2 (3x 2 
ml). The solvent was removed and the crude organic product then subjected 
to preparative silica gel TLC (developed twice in 1:5 PE:EtOAc) to give 1.2 mg 
of pure 7, 17-di-Q-methyl mycalamide A (2.33). 
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2.33: an oil; 1 H and 13C NMR data in Tables 2.12 and 2.14; HREIMS m/z 
499.2794 (M+-CH30H, +2.6 ppm for C25H41 N09), DCIMS (NH3) m/z (%) 549 
(6, MNH4+), 520 (4), 519 (20), 518 (40), 517 (1 00, MNH4+-CH30H), 502 (13), 
501 (29), 500 (79, MH+-CH30H). 
17, 18-Di-0-methyl mycalamide A 7-monoacetate (2.36, 2 mg) was 
stirred with potassium carbonate (0.4 mg) in 9:1 MeOH:H20 (0.4 ml) at room 
temperature for 1.5 hours. The solution was concentrated under nitrogen (to 
0.1 ml), then H20 (2.5 ml) was added and the mixture extracted with CH2CI2 
. 
(3x 2 ml). The solvent was removed to give 1.8 mg of pure 17, 18-di-0-methyl 
mycalamide A (2.38). 
2.38: an oil; 1 H and 13C NMR data in Tables 2.12 and 2.14; HREIMS m/z 
499.2773 (M+-CH30H, -0.8 ppm for C25H41 N09), DCIMS (NH3) m/z (%) 549 (7, 
MNH4+), 520 (6), 519 (23), 518 (29), 517 (99, MNH4+-CH30H), 503 (5), 502 
(19), 501 (29), 500 (1 00, MH+-CH30H). 
2.5.1-2.5.2 PREPARATION AND CHARACTERISATION OF BENZYL 
DERIVATIVES 
Mycalamide A (5 mg), powdered potassium hydroxide (8 mg) and 
benzyl bromide (12 Jll) were stirred in DMSO (0.3 ml) at room temperature for 
3 minutes. H20 (2 ml) was added and the mixture extracted with CH2CI2 (3x 2 
ml). The solvent was removed to give the crude organic product (7.5 mg), 
which was a mixture of at least 4 components (TLC, HPLC). Preparative 
reverse phase HPLC (15% H20 in MeOH) gave four fractions (1 mg, 0.7 mg, 2 
mg, 2 mg) but the third fraction was a mixture of the second component and 
another component (TLC). Preparative silica gel TLC (developed in 1 :1 
PE:EtOAc) and an appropriate combination of samples gave overall four pure 
products (1 mg, 1.3 mg, 1 mg, 2 mg), which were 7-0-benzyl mycalamide A 
(2.39), 7, 18-di-0-benzyl mycalamide A (2.40), 7-0-benzyl, N-benzyl 
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mycalamide A (2.41) and 7, 18-di-0-benzyl N-benzyl mycalamide A (2.42), 
respectively. 
2.39: an oil; 1 H NMR data in Table 2.15, 13C NMR data in Table 2.16 except 
the following aromatic resonances, (CDCb) o128.55, 128.38 and 128.19 ppm; 
HREIMS mlz 561.2919 (M+-CH30H, -3.4 ppm for C3oH43NOg), DCIMS (NH3) 
m/z (%) 611 (7, MNH4 + }, 582 (8), 581 (26), 580 (34), 579 (1 00, 
MNH4+-CH30H), 564 (5), 563 (6), 562 (17, MH+-CH30H). 
2.40: an oil; 1 H NMR data in Table 2.15, 13C NMR data in Table 2.16 except 
. 
the following aromatic resonances, (CDCI3) o138.36, 137.15, 128.46, 128.41, 
128.34, 128.07, 127.64 and 127.53 ppm; HRFABMS m/z 652.3510 
(MH+-CH30H, +3.7 ppm for Ca7HsoNOg), DCIMS (NH3) m/z (%) 703 (7), 702 
(12), 701 (28, MNH4+), 672 (9), 671 (27), 670 (41), 669 (100, MNH4+-CH30H), 
654 (5), 653 (8), 652 (19, MH+-CH30H). 
2.41: an oil; 1 H NMR data in Table 2.15; HRFABMS m/z 652.3486 
(MH+-CH30H, +2.8 ppm for C37HsoNOg), DCIMS (NH3) mlz (%) 701 {12, 
MNH4+), 672 (17), 671 (46), 670 (44), 669 (1 00, MNH4+-CH30H), 654 (19), 
653 (20), 652 (45, MH+-CH30H). 
2.42: an oil; 1 H NMR data in Table 2.15, 13C NMR data in Table 2.16 except 
the following aromatic resonances, (CDCI3) o138.45, 128.68, 128.32, 128.15, 
127.70, 127.60, 127.48, 127.35 and 126.95 ppm; HRFABMS mlz 742.3991 
(MH+-CH30H, +4.8 ppm for C44HssNOg), DCIMS (NHs) m/z (%) 791 {8, 
MNH4+), 761 {19), 760 (49), 759 {100, MNH4+-CH30H), 743 (13), 742 (24, 
MH+-CH30H). 
Mycalamide B (4.4 mg), powdered potassium hydroxide (7 mg) and 
benzyl bromide (8 Jll) were stirred in DMSO (0.3 ml) at room temperature for 4 
minutes. H20 (2 ml) was added and the mixture extracted with CHCia (3x 2 
ml). The solvent was removed and the crude organic product subjected to 
preparative silica gel TLC (developed in 1 :1 PE:EtOAc). Three bands of silica 
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were recovered and eluted with EtOAc to give three fractions (1.8 mg, 0.8 mg, 
0.9 mg), which were 7-0-benzyl mycalamide B (2.43), 7-0-benzyl, N-benzyl 
mycalamide B (2.45) and 7,18-di-0-benzyl mycalamide B (2.44), 
respectively. 
2.43: an oil; 1H NMR data in Table 2.17, 13C NMR data in Table 2.16 except 
the following aromatic resonances, (CDCI3) 8136.98, 128.57, 128.24 and 
128.20 ppm; HRFABMS m/z 630.3202 (MNa+, -8.3 ppm for C32H4gN010Na), 
FABMS m/z (%) 631 (9), 630 (100, MNa+), 598 (7, MNa+-CH30H), 577 (8), 
576 (20, MH+-CH30H). 
2.44: an oil; 1 H NMR data in Table 2.17, 13C NMR data in Table 2.16 except 
the following aromatic resonances, (CDCI3) 8138.58, 137.06, 128.51, 128.28, 
128.10,127.79 and 127.39 ppm; HRFABMS m/z666.3647 (MH+-CH30H, +0.8 
ppm for C3aHs2NOg), DCIMS (NH3) m/z (%) 716 (9), 715 (19, MNH4+), 686 
(1 0), 685 (28), 684 (45), 683 (1 00, MNH4+-CH30H), 668 (1 0), 667 (16), 666 
(36, MH+-CH30H). 
2.45: an oil; 1 H NMR data in Table 2.17; HRFABMS m/z 666.3612 
(MH+-CH30H, -4.5 ppm for C3aHs2NOg), DCIMS (NH3) m/z (%) 715 (9, 
MNH4+), 686 (13), 685 (33), 684 {45), 683 (100, MNH4+-CH30H), 668 (22), 
667 (27), 666 (63, MH+-CH30H). 
Mycalamide B (7 mg), powdered potassium hydroxide (22 mg) and 
benzyl bromide (26 J.LI) were stirred in DMSO (0.3 ml) at room temperature for 
3 hours. H20 (2 ml) was added and the mixture transferred onto a reverse 
phase pipette column (200 mg C18, equilibrated to H20), which was then 
flushed with H20 (8 ml} and eluted with MeOH (6 ml). The MeOH fraction was 
evaporated to dryness, then subjected to preparative silica gel TLC 
(developed in 5:2 PE:EtOAc). Two bands of silica (Rt=0.6, 0.7) were recovered 
and eluted with EtOAc to give two fractions (2.2 mg, 5.2 mg}, which were 
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7 ,8, 18-tri-0-benzyl mycalamide B (2.47) and 7, 18-di-0-benzyl, N-benzyl 
mycalamide B (2.46), respectively. 
2.46: an oil; IR (CHCI3) t>max 3064, 3029, 2965, 2929, 2879, 2855, 1660, 
1454, 1379, 1104, 1043, 1030 cm-1; 1H NMR data in Table 2.17, 13C NMR 
data in Table 2.16 except the following aromatic resonances, (CDCI3) 
8139.01, 138.30, 138.17, 128.63, 128.28, 128.14, 127.88, 127.51, 127.26 and 
126.67 ppm; HRFABMS m/z 756.4136 (MH+-C H30H, +3.2 ppm for 
C4sHsaNOg), DCIMS (NH3) m/z (%) 805 (17, MNH4+), 775 (22), 774 (49), 773 
. 
(1 00, MNH4+-CH30H), 758 (8), 757 (18), 756 (35, MH+-CH30H). 
2.47: an oil; IR (CHCI3) t>max 3064, 3030, 2930, 2877, 1725, 1665, 1454, 
1378, 1255, 1120, 1100, 1041, 1028, 997 cm-1; 1 H NMR data in Table 2.17, 
13C NMR data in Table 2.16 except the following aromatic resonances, 
(CDCI3) 8128.41, 128.34, 128.25, 128.01, 127.87, 127.69, 127.56 and 127.31 
ppm; HRFABMS m/z 810.4231 (MNa+, +4.7 ppm for C46H61N01oNa), FABMS 
m/z (%) 826 (5, MK+), 812 (8), 811 (25), 810 (48, MNa+), 788 (5, MH+) 757 (5), 
756 (9, MH+-CH30H). 
2.5.2 CONFORMATIONAL EXCHANGE OF 7,18-DI-0-BENZYL, N-BENZYL 
MYCALAMIDE B 
2.46: 1H NMR data at -1ooc, (CDCI3) 86.17 (H10, d, 8.2), 5.17 (10-0CHR, d, 
6.6), 5.11 (N-CHPh, d, 17.6), 4.88 (1 0-0CHS, d, 6.6), 4.78 (4=CHZ, m), 4.66 
(4=CHE, m), 4.63 (N-CHPh, d, 17.5), 4.56 (18-0CH2Ph, s), 4.36 (7-0CHPh, d, 
11.8), 4.24 (H12, dd, 6.9, 9.2), 4.19 (H7, s), 4.03 (H11, dd, 6.9, 8.3), 3.86 (H2, 
dq, 2.4, 6.4), 3.82 (7-0CHPh, d, 11.6), 3.75 (H18, dd, 1.3, 1 0.6), 3.58 (H18, dd, 
2.3, 1 0.6), 3.52 (13-0CH3, s), 3.45 (13'-0CH3, s), 3.35 (1?'-0CH3, s), 3.32 
(H13, d, 9.4), 3.26 (17-0CH3, s), 3.17 (6'-0CH3, s), 3.10 (H13', d, 9.8), 2.82 
(6-0CH3, s), 2.80 (H5a, d, 14.7), 2.38 (H5e', d, 14.8), 2.27 (H5e, d, 14.7), 2.17 
(H3, dq, 2.4, 7.0), 1.90 (H16, m), 1.57 (H16, m), 1.15 (2-CH3, d, 6.5), 1.09 
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(2'-CH3, d, 6.5), 0.97 (3-CH3, d, 7.0), 0.96 (14-CH3R, s), 0.87 (3'-CH3, d, 7.0), 
0.84 (14-CH3S, s), 0.83 (14'-CH3S, s) ppm. 
2.5.3 FURTHER ALKVLATIONS- REACTION OF MYCALAMIDE A WITH DDQ 
AND TRITYLATlON ATTEMPTS 
Mycalamide A {1 mg) was dissolved in CDCI3 {0.6 ml), containing 0.1% 
pyridine, and placed in an NMR sample tube. 2,3-Dichloro-
5,6-dicyanobenzoquinone (DDQ, 2 mg) was added and the sample monitored 
. 
by 1 H NMR spectroscopy. Slow decomposition was observed over a period of 
several hours at room temperature. 
Mycalamide A (1.9 mg), trityl chloride (4 mg), dimethylaminopyridine 
(0.1 mg) and triethylamine (2.5 fll) were stirred at room temperature for 24 
hours. H20 (0.4 ml) was added and the mixture extracted with CHCI3 (3x 0.4 
ml). The solvent was removed to give the crude organic product but TLC and 
1 H NMR spectroscopy indicated that substantial decomposition had occurred. 
The reaction was repeated, but this time, after 1 day, no reaction was 
observed by TLC. A third reaction with pyridine as solvent also gave some 
decomposition but no other apparent reaction, and the use of DMF as solvent 
was equally unsuccessful. 
WORK DESCRIBED IN CHAPTER 3 
3.2 ACID CATALYSED DECOMPOSITIONS 
3.2.2 REACTIONS MONITORED BY HPLC 
Mycalamide A (0.5 mg) was reacted with a solution of hydrochloric acid 
in 90% H20:MeOH (0.1 M, 0.5 ml) at room temperature, monitoring by reverse 
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phase HPLC. After 4 hours there was a mixture of a more polar derivative 
(major) and unreacted mycalamide A. 
This reaction was repeated on a larger scale (1 0-fold) for 1 hour, then 
dilute sodium hydroxide was added (until neutralised} and the solvent 
removed. The residue was extracted in CHCI3, filtered over celite and the 
solvent removed, to give a mixture of pederolactone (3.6), mycalamide A and 
decomposition products (1 H NMR spectroscopy). This was subjected to silica 
gel column chromatography (200 mg Davisil}, developed in steps from PE to 
EtOH/EtOAc. One fraction (1 mg), which eluted with 1:1 PE:EtOAc, was a 
crude sample of pederolactone (3.6), essentially free from mycalamide A, but 
with other alkyl impurities. Pederolactone could not be recovered from further 
silica gel column chromatography or preparative reverse phase HPLC. 
3.6: an oil; FTIR (film) Umax 2956, 2926, 2853, 1720, 1645, 1461, 1377, 1260, 
1166,1096,1072,1031 cm-1; 1H NMR (CDC13)o5.74 (H5, q, 1.5), 4.54 (H2, 
dq, 3.1, 6.6), 2.08 (H3, dq, 3.2, 7.2), 1.98 (4-CH3, d, 1.5), 1.35 {2-CH3, d, 6.6), 
1.06 (3-CH3, d, 7.2) ppm. 
3.3.1 PREPARATION AND CHARACTERISATION OF PSEUDO-
MYCALAMIDES A AND B 
Mycalamide A (2.7 mg) was dissolved in CH2CI2 (0.2 ml) and stirred with an 
aqueous solution of p-toluene sulphonic acid (0.05M, 0.2 ml) at room 
temperature for 4 hours. H20 (2 ml) was added and the mixture neutralised 
with dilute sodium hydroxide then extracted with CH2CI2 (3x 2 ml). The 
solvent was removed to give 2.3 mg of pure pseudomycalamide A (3.7). 
3.7: an oil; 1 H and 13C NMR data in Tables 3.1 and 3.2; HREIMS m/z 
471.2477 (M+-H20, +1.9 ppm for C23H37NOg), HRFABMS m/z 472.2560 
(MH+-H20, +2.8 ppm for C23H3aNOg), DCIMS (NH3) m/z (%) 508 (27), 507 
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(1 00, MNH4+), 491 (34), 490 (26), 489 (72, MNH4+-H20), 474 (14), 473 (29), 
472 (90, MH+-H20). 
Mycalamide B (5.5 mg) was dissolved in CH2CI2 (0.5 ml) and stirred 
with an aqueous solution of p-toluene sulphonic acid (0.05M, 0.2 ml) at room 
temperature for 48 hours. The aqueous layer was removed and the organic 
layer washed with H20 (3x 0.3 ml). The mixture was then extracted with 
C H2CI2 (3x ·o.3 ml) and the solvent removed to give 5.1 mg of 90% pure 
pseudomycalamide B (3.8), containing a small amount of mycalamide B . 
. 
Preparative reverse phase HPLC (20%> H20 in MeOH) on a 1.2 mg subsample 
gave 0.9 mg of pseudomycalamide B (3.8). 
3.8: an oil; 1 H and 13C NMR data in Tables 3.1 and 3.2; HREIMS m/z 
485.2614 (M+-H20, -2.3 ppm for C24H3gNOg ), HRFABMS m/z 486.2717 
(MH+-H20, +2.9 ppm for C24H4oNOg ), DCIMS (NHs) m/z (%) 522 (20), 521 
(64, MNH4+), 504 (51, MH+}, 503 (72, MNH4+-H20), 487 (42), 486 (100, 
MH+-H20). 
3.3.5 REARRANGEMENT AND DECOMPOSITION OF PSEUDO-
MYCALAMIDES 
A sample of crude pseudomycalamide B (3.8, 3 mg), which had been in 
cold storage for several months, was found to contain a new component by 
TLC, so it was subjected to preparative silica gel TLC (developed twice in 1 :9 
PE:EtOAc). Three bands of silica were recovered and eluted with 1:4 
EtOH:EtOAc to give three fractions (0.4 mg, 1.1 mg, 1.2 mg), which were 
mycalamide B and two identical mixtures of pseudomycalamide B (3.8) and, 
possibly, a C6 epimer of pseudomycalamide B. 
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3.3.6 METHANOL YSIS OF PSEUDOMYCALAMIDES A AND 8 
Pseudomycalamide A (3. 7, 0.1 mg) was stirred with a solution of 
p-toluene sulphonic acid in methanol (5x1 o-4M, 0.1 ml) at room temperature, 
monitoring by reverse phase HPLC. After 1 day, HPLC showed that there was 
no pseudomycalamide A present, but there was a single peak at the retention 
time of mycalamide A. 
Pseudomycalamide 8 (3.8, 0.5 mg) was reacted under analogous 
conditions for 4 hours to give .pure mycalamide 8 (TLC, HPLC). 
3.4 1-3.4.3 ALKOXY EXCHANGE REACTIONS AT C6 
Mycalamide A (1.1 mg) was reacted with a solution of trifluoroacetic 
acid in CD30D (0.01 M, 0.6 ml) in an NMR sample tube at room temperature 
overnight, to give almost pure 6-trideuteromethoxy mycalamide A (3.9). 
3.9: an oil; HRFABMS m/z 529.2808 (MNa+, -1.6 ppm for C24H3aD3N01oNa), 
DCIMS (NH3 ) m/z (%) 524 (16, MNH4+), 491 (14), 490 (22), 489 (81, 
MNH4+-CD30H), 472 (16, MH+-CD30H), 278 (16), 245 (19), 244 {96). 
Mycalamide A (1.3 mg) was stirred with a solution of trifluoroacetic acid 
in ethanol (0.01 M, 0.5 ml) at room temperature overnight. The solution was 
neutralised and the solvent removed to give the crude organic product, which 
was a mixture of pseudomycalamide A (3.7), 6-ethoxy mycalamide A (3.10) 
and mycalamide A. 
Mycalamide A (3.3 mg) was stirred with a solution of pyridinium 
p-toluene sulphonate in dry ethanol (1x1 o-3M, 0.3 ml, dried over molecular 
sieves) at room temperature for 4 days. The solution was concentrated under 
nitrogen (to 0.1 ml), then dilute sodium hydroxide was added (2 ml, pH~9) and 
the mixture extracted in CH2CI2 (3x 2 ml). The solvent was removed to give 
the crude organic product (3.2 mg), which was a mixture of unreacted 
mycalamide A and a less polar product (TLC, HPLC). Preparative reverse 
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phase HPLC (40% H20 in MeOH) gave two major fractions (1 mg, 2 mg}, 
which were mycalamide A and 6-ethoxy mycalamide A (3.10) respectively. 
3.10: an oil; 1 H and 13C NMR data in Tables 3.1 and 3.2; HRFABMS m/z 
540.2785 (MNa+, 0.0 ppm for C2sH43N01oNa), 472.2525 (MH+-CHgCH20H, 
-4.4 ppm for C23H3aNOg), DCIMS (NHs) m/z (%) 535 {6, MNH4+), 491 (4), 490 
(6), 489 (100, MNH4+-CHgCH20H), 474 (5), 473 (5), 472 (65, 
MH+-CHsCH20H). 
Mycalamide A (2.2 mg) was stirred with a solution of pyridinium 
p-toluene sulphonate in dry. isopropyl alcohol {1 x1 o-3M, 0.3 ml, dried over 
molecular sieves) at room temperature for 16 hours, then at 55oc for 1 hour. 
The solution was concentrated under nitrogen (to 0.1 ml), then dilute sodium 
hydroxide was added (2 ml, pH~1 0) and the mixture extracted in CH2CI2 (3x 2 
ml). The solvent was removed to give the crude organic product (2 mg), which 
was a mixture of at least 4 components by 1 H NMR spectroscopy, including 
mycalamide A, pseudomycalamide A (3.7), pederolactone (3.6) and another 
compound. Preparative reverse phase HPLC (45% H20 in MeOH) gave two 
major fractions (0.5 mg, 0.7 mg), which were 5,6-dehydromethoxy mycalamide 
A (3.11) and mycalamide A, respectively. 
3.4.5 BASE CATAL YSED ELIMINATION 
Mycalamide A (3.8 mg) was reacted with pyridine (1 0 J.LI) in DMSO (0.6 
ml) in a sealed NMR sample tube at 15ooc for 3 hours. 1 H NMR spectroscopy 
showed that the mixture consisted of about 90% 5,6-dehydromethoxy 
mycalamide A (3.11 ), with a small amount of unreacted mycalamide A and 
methanol. The sample was recovered with MeOH, then the solution 
concentrated under nitrogen, mixed with H20 (1 ml) and transferred onto a 
reverse phase pipette column (200 mg C18, equilibrated to H20). The column 
was flushed with H20 {5 ml), then eluted with MeOH (5 ml) and the latter 
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fraction evaporated to dryness, to give 3.6 mg of mostly 5,6-dehydromethoxy 
mycalamide A (3.11 ). 
3.11: an oil; FTIR (film) Umax 2960,2926, 2855, 1679, 1600, 1529, 1454, 1385, 
1266, 1194, 1109, 1074, 1031 cm-1; 1H and 13C NMR data in Tables 3.1 and 
3.2; HRFABMS m/z 510.2132 (MK+, +5.3 ppm for C23H37NOgK). 
3.6 ACID CATALYSED DECOMPOSITIONS OF MYCALAMIDE A 
TRIACETATE 
Mycalamide A triacetate (2.18, 5.5 mg) was reacted with a solution of 
trifluoroacetic acid in CDCls (0.1 M, 0.6 ml) in an NMR sample tube at room 
temperature for 5 days. The sample was recovered in CH2CI2, then H20 (2 
ml) was added and the mixture extracted in CH2CI2 (3x 2 ml). The solvent was 
removed to give the crude organic product (5 mg). Preparative reverse phase 
HPLC (33% H20 in MeOH) gave three fractions (0.8 mg, 1 mg, 2.5 mg) which 
were mycalamide A triacetate (2.18), E neomycalamide A triacetate (3.13) 
and a mixture. The latter was further separated by HPLC (45% H20 in MeOH) 
to give two fractions (0.5 mg, 1 mg), which were an aldehyde fragment (3.14) 
and a mixture, respectively. 
Mycalamide A triacetate (2.18, 8 mg) was dissolved in CH2CI2 (2 ml) 
and stirred with an aqueous solution of p-toluene sulphonic acid (0.1 M, 1 ml) 
in a sealed vial at ?soc for 24 hours, then at 8SOC for 6 hours. Dilute sodium 
hydroxide was added until the mixture was neutralised, then the mixture 
extracted with CH2CI2 (3x 2 ml). The solvent was removed and the crude 
organic products then subjected to preparative silica gel TLC (developed in 
1 :1 PE:EtOAc). Four bands of silica were recovered and eluted with EtOAc to 
give four fractions (3 mg, 1.2 mg, 1.5 mg, 0.8 mg), which were E 
neomycalamide A triacetate (3.13), mostly Z neomycalamide A triacetate 
(3.12) and two mixtures, respectively. Fraction 3 was therefore subjected to 
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preparative reverse phase HPLC (40% H20 in MeOH) to give three fractions 
(0.4 mg, 0.4 mg, 0.5 mg), which were mycalamide A triacetate (2.18), impure 
pseudomycalamide A triacetate (3.15) and 5,6-dehydromethoxy mycalamide 
A 17, 18-diacetate (3.16), respectively. Fraction 4 was also subjected to 
preparative reverse phase HPLC (47% H20 in MeOH) to give two fractions 
(0.2 mg, 0.3 mg), which were a C11 lactone fragment (3.17) and a C1 0 
aldehyde fragment (3.14), respectively. 
3.12: an oil; FTIR (film) Umax 3375, 2956, 2925, 2854, 177 4, 17 40, 1664, 1640, 
1590, 1514, 1460, 1370, 1228, 1108, 1028, 800 cm-1; 1H NMR data in Table 
3.6; HREIMS m/z 555.2682 (M+-CH2CO, +0.4 ppm for C27H41 N011), 
HRFABMS m/z 598.2857 (MH+, -0.9 ppm for C29H44N012). 
3.13: an oil; FTIR (film) Umax 3380, 2960, 2925,2853, 1765, 1740, 1670, 1644, 
1525, 1370, 1225, 1175, 1110, 1030 cm-1; 1 Hand 13C NMR data in Tables 3.6 
and 3.2; HRFABMS m/z 598.2862 (MH+, -0.3 ppm for C29H44N012), DCIMS 
(NH3) m/z (%) 616 (7), 615 (34, MNH4+), 600 (13), 599 (31 ), 598 (1 00, MH+), 
573 (28), 571 (18), 557 (24), 556 (66, MH+-CH2CO), 493 (8), 419 (35). 
3.14: an oil; FTIR (film) Umax 2963,2926,2854, 1741, 1700, 1637, 1450, 1372, 
1230, 1093, 1044, 1027 cm-1; 1H NMR data in Table 3.6; DCIMS (NH3) m/z 
(%) 348 (6), 347 (13), 346 (1 00, MNH4+), 315 (11 ), 314 (27, MNH4+-CH30H). 
3.16: an oil; 1 H NMR data in Table 3.6; HRFABMS m/z 556.2765 (MH+, +0.7 
ppm for C27H42N011 ). 
3.17: an oil; FTIR (film) Umax 2960, 2925, 2853, 1740, 1720, 1665, 1614, 1455, 
1371, 1229, 1095, 1031 cm-1; 1 H NMR data in Table 3.6; HRFABMS m/z 
353.0987 (MK+, -4.4 ppm for C1sH2207K). 
3.6.6 NEOMYCALAMIDE A P-BROMOBENZOATES 
Mycalamide A (11 mg), p-bromobenzoyl chloride (23 mg) and 
triethylamine (14 !J.I) were stirred in CH2CI2 (0.3 ml) at room temperature for 24 
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hours. The solvent was removed to give the crude organic product which was 
a mixture of p-bromobenzoate esters and reagent (TLC}. Preparative reverse 
phase HPLC (15% H20 in MeOH) gave five fractions (0.7 mg, 2.7 mg, 1.2 mg, 
2.5 mg, 2.7 mg), which were mycalamide A 7-mono-p-bromobenzoate (2.11), 
mycalamide A 18-mono-p-bromobenzoate {2.1 0}, a mixture of E and Z 
neomycalamide A 7,18-di-p-bromobenzoates (3.19, 3.18), Z neomycalamide 
A 7,18-di-p-bromobenzoate (3.18) and mycalamide A 
7, 18-di-p-bromobenzoate (2.12), respectively. The Z isomer (3.18) was 
. 
unstable in CDCI3 solution, changing almost quantitatively overnight into the E 
isomer (3.19). 
3.18: an oil or white solid; 1 H NMR (CDCI3 ) 87.99 and 7.91 (7- and 
18-0COCsH4Br, 2xd, 8.5), 7.61 and 7.54 (7- and 18-0COCsH4Br, 2xd, 8.6}, 
7.35 (H5, q, 1.5), 6.39 (NH9, d, 9.3), 5.94 (H10, t, 9.8), 5.18 (1 0-0CHR, d, 7.0), 
4.86 (1 0-0CHS, d, 6.8), 4.23 (H218, m), 4.21 (H12, dd, 6.6, 1 0.5), 4.13 (H2, dq, 
3.1, 6.5), 4.00 {H17, m), 3.86 (H11, dd, 6.7, 10.2), 3.56 (H15, dd, 2.3, 10.1), 
3.56 (13-0CHs, s), 3.51 (H13, d, 1 0.5), 2.01 (H3, dq, 2.8, 7.1 ), 1.92 (4-CH3, d, 
1.4), 1.70 (H16, m), 1.55 (H16, m), 1.07 (2-CH3, d, 6.5), 0.96 (14-CH3R, s), 0.87 
(3-CH3, d, 7.0), 0.86 (14-CH3S, s) ppm. 
3.19: an oil or white solid; UV (CH30H) A.max 245 nm (e-23000), 285 nm 
(e-7700); 1 H NMR {CDCI3) 88.09 (NH9, d, 9.0), 7.95 and 7.87 (7- and 
18-0COCsH4Br, 2xd, 8.6), 7.56 and 7.50 (7- and 18-0COCsH4Br, 2xd, 8.6), 
5.99 (H1 0, t, 9.7}, 5.97 (H5, q, 1.5}, 5.15 (1 0-0CHR, d, 6.8), 4.88 (1 0-0CHS, d, 
7.0), 4.33 (H2, dq, 2.8, 6.4), 4.26 {H218, m), 4.25 (H12, m), 4.07 (H17, m), 3.89 
(H11, dd, 6.7, 10.2), 3.67 (H15, broad d, 9.6), 3.55 (13-0CH3 , s), 3.48 (H13, d, 
10.6), 2.06 (H3, dq, 2.8, 7.2), 1.83 (4-CH3, d, 1.5}, 1.70 (H16, m), 1.55 (H16, 
m), 1.41 (2-CHs, d, 6.5), 0.99 (3-CH3 , d, 7.0), 0.95 (14-CHsR, s), 0.89 
( 14-C H3 S, s) ppm; HRFABMS m/z 838.1307 (MH+, +5.3 ppm for 
C37H4379Br81 BrN011). 
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WORK DESCRIBED IN CHAPTER 4 
4.2.1 PREPARATION AND CHARACTERISATION OF DIHYDRO EPIMERS 
Mycalamide A (5 mg) was stirred with Adams catalyst (Pt02, 2 mg) in 
MeOH (0.8 ml) under hydrogen at room temperature (and atmospheric 
pressure) for 1 hour. The resulting solution was filtered over celite and the 
solvent removed to give the crude organic product (4.8 mg), which was a 2:1 
mixture of the two dihydrom)!calamide A isomers at C4. Preparative reverse 
phase HPLC (35% H20 in MeOH) gave three fractions (0.9 mg, 1.3 mg, 1.9 
mg), which were -90% 4a-dihydro mycalamide A (4.4), a mixture and -85% 
4j3-dihydro mycalamide A (4.5), respectively. Further HPLC of the combined 
second fraction and the residues gave three further fractions (0.5 mg, 0.5 mg, 
0.6 mg) in the same manner to give overall yields of 1.4 mg 4a-dihydro 
mycalamide A (4.4) and 2.5 mg 4j3-dihydro mycalamide A (4.5). 
4.4: an oil; 1 H and 13C NMR data in Tables 4.1 and 4.4; HRFABMS m/z 
528.2751 (MNa+, -6.4 ppm for C24H43N01oNa). 
4.5: an oil; 1 H and 13C NMR data in Tables 4.1 and 4.4; HRFABMS m/z 
528.2813 (MNa+, +5.3 ppm for C24H43N010Na). 
Mycalamide B (5.5 mg) was stirred with Adams catalyst (Pt02, 3 mg) in 
MeOH (0.8 ml) under hydrogen at room temperature (and atmospheric 
pressure) for 1 hour. The resulting solution was filtered over celite and the 
solvent removed to give the crude organic product (5.5 mg), which was a 3:2 
mixture of the two dihydromycalamide B isomers at C4. Preparative reverse 
phase HPLC (35% H20 in MeOH) gave three fractions (1.8 mg, 0.9 mg, 2.2 
mg), which were -90% 4a-dihydro mycalamide B (4.6), a mixture and -90% 
4j3-dihydro mycalamide B (4.7), respectively. Further HPLC of the combined 
second fraction and the residues gave two further fractions (0.5 mg, 0.5 mg), 
which were a mixture and -90% 4j3-dihydro mycalamide B (4.7), respectively, 
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to give overall yields of 1.8 mg 4a-dihydro mycalamide B (4.6) and 2.7 mg 
4P-dihydro mycalamide B (4.7). 
4.6: an oil; 1 H and 13C NMR data in Tables 4.1 and 4.4; HRFABMS m/z 
510.2725 (MNa+-CHaOH, +9.1 ppm for C24H41NOgNa). 
4.7: an oil; 1 H and 13C NMR data in Tables 4.1 and 4.4; HREIMS m/z 
487.2765 (M+-CHaOH, -3.3 ppm for C24H41NOg), DCIMS (NHa) m/z (%) 537 
(4, MNH4+), '507 (7), 506 (34), 505 (1 00, MNH4+-CH30H), 490 (6), 489 (27), 
488 (90, MH+-CHaOH). 
4.3 ACID CATAL YSED HYDROLYSIS OF DIHYDRO EPIMERS 
4a-Dihydro mycalamide A (4.4) was dissolved in CDCia only (0.6 ml), 
for NMR studies, but hydrolysis occurred within minutes at room temperature to 
give 4a-dihydro pseudomycalamide A (4.10). 
4.10: an oil; 1 H and 13C NMR data in Tables 4.1 and 4.4; HRFABMS m/z 
514.2655 (MNa+, +5.2 ppm for C23H41N010Na), DCIMS (NH3) m/z (%) 509 (9, 
MNH4+), 492 (36), 491 (83, MNH4+-H20), 474 (16, MH+-H20), 292 (17), 262 
(23). 
4P-Dihydro mycalamide A (4.5) was dissolved in CD2CI2 (0.6 ml) but 
hydrolysis occurred within minutes at room temperature to give mostly 
4P-dihydro 6S pseudomycalamide A (4.11 ). 
4.11: an oil; 1 H and 13C NMR data in Tables 4.1 and 4.4; HRFABMS m/z 
514.2585 (MNa+, -8.4 ppm for C23H41 N01oNa). 
4.4.1 HYDROGENATION OVER PALLADIUM ON CARBON 
Mycalamide A (4.5 mg) was stirred with 10% palladium on carbon (4.5 
mg) in MeOH (0.8 ml) under hydrogen at room temperature (and atmospheric 
pressure) for 5 hours. The resulting solution was filtered over celite and the 
solvent removed to give the crude organic product, which was a mixture of at 
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least 5 components (HPLC). Preparative reverse phase HPLC (40% H20 in 
MeOH) gave six fractions (0.7 mg, 0.5 mg, 0.7 mg, 0.8 mg, 0.4 mg, 0.9 mg), 
which were ~3 mycalamide A (4.12), mycalamide A, mostly 4a-dihydro, 
6-deoxy pseudomycalamide A (4.13), 4a-dihydro mycalamide A (4.4), a . 
mixture and 4P-dihydro mycalamide A (4.5). 
4.12: an oil; 1 H NMR data in Table 4.5; HRFABMS m/z 472.2548 
(MH+-CHaOH, +0.3 ppm for C2aHaaNOg). 
4.13: an oil; 1 H and 13C NMR data in Tables 4.5 and 4.4 (on larger sample-
see below); HRFABMS m/z 476.2854 (MH+, -1.1 ppm for C23H42NOg). 
4a-Dihydro, 6-deoxy pseudomycalamide A (4.13, 0.7 mg) was 
dissolved in pyridine (0.1 ml) and acetic anhydride (0.1 ml) and stirred at room 
temperature overnight. The solution was concentrated under nitrogen, then 
H20 (2 ml) was added and the mixture extracted with CH2CI2 (2x 2 ml). The 
solvent was removed to give 0.8 mg of mostly 4a-dihydro, 6-deoxy 
pseudomycalamide A triacetate (4.15). 
4.15: an oil; 1 H NMR data in Table 4.5. 
4.5.1 HYDROGENATION OF 5,6-DEHYDROMETHOXY MYCALAMIDE A 
5,6-Dehydromethoxy mycalamide A (3.11, 3.8 mg) was stirred with 
Adams catalyst (Pt02, 4 mg) in MeOH (0.8 ml) under hydrogen at room 
temperature (and atmospheric pressure) for 8 hours. The resulting solution 
was filtered over celite and the solvent removed to give the crude organic 
product, which was a mixture of at least 5 components (HPLC). Preparative 
reverse phase HPLC (43% H20 in MeOH) gave five fractions (0.7 mg, 0.5 mg, 
0.6 mg, 0.3 mg, 0.5 mg), which were 4a-dihydro, 5,6-dehydromethoxy 
mycalamide A (4.16), a mixture, 4a-dihydro, 6-deoxy pseudomycalamide A 
(4.13), mostly 4a-dihydro mycalamide A (4.4) and mostly 4P-di hydro 
mycalamide A (4.5), respectively. 
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4.16: an oil; 1H NMR data in Table 4.5; HRFABMS m/z 474.2721 (MH+, +3.8 
ppm for C23H4oNOg). 
4.7 ATTEMPTS AT OTHER DOUBLE BOND REARRANGEMENTS 
Mycalamide A (1 mg) was stirred with rhodium trichloride (0.5 mg) in 
EtOH (0.2 ml) at room temperature for 2 hours. The solvent was removed and 
the crude organic residue washed with H20 (2 ml) and extracted in CH2CI2 
(3x 2 ml). The solvent was removed to give the crude organic product, which 
was a mixture of a large number of products by silica gel TLC and 1 H NMR 
spectroscopy indicated complete decomposition. 
Mycalamide A (1 mg) was stirred with freshly prepared bis-benzonitrile 
palladium(ll) chloride (1 mg) in benzene (0.5 ml) at room temperature for 3.5 
hours. Silica gel TLC indicated decomposition, which was confirmed by 1 H 
NMR spectroscopy on the material obtained after workup of the reaction. 
4.9.1 PREPARATION AND CHARACTERISATION OF EPOXIDE ISOMERS 
Mycalamide A (4.5 mg) and m-chloroperbenzoic acid (4.5 mg) were 
stirred in CH2CI2 (0.3 ml) at room temperature for 1 day. The solvent was 
removed and the crude organic product subjected to preparative silica gel TLC 
(developed twice in 1 :19 EtOH:EtOAc). Three bands of silica were recovered 
and eluted with 1 :4 EtOH:EtOAc to give three fractions (1.8 mg, 0.6 mg, 1.7 
mg), which were pure mycalamide A 4a-epoxide (4.17), mostly mycalamide A 
4a-epoxide, and mycalamide A 4p-epoxide (4.18), respectively. 
4.17: an oil; 1 H and 13C NMR data in Tables 4.7 and 4.9; HRFABMS m/z 
542.2594 (MNa+, +3.1 ppm for C24H41 N011 Na), DCIMS (NHs) m/z (%) 537 
(1 0, MNH4+), 505 (22, MNH4+-CH30H), 488 (17, MH+-CH30H), 487 (15), 335 
(34), 262 (16), 231 (24), 230 (34). 
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4.18: an oil; 1H and 13C NMR data in Tables 4.7 and 4.9; HRFABMS m/z 
542.2599 (MNa+, +4.0 ppm for C24H41 N011 Na), DCIMS (NH3) m/z (%) 537 
(24, MNH4+), 505 (23, MNH4+-CH30H), 488 (15, MH+-CH30H), 292 (22), 291 
(34), 278 (23), 264 (31 ). 
Mycalamide B (4.0 mg) and m-chloroperbenzoic acid (6 mg) were 
stirred in CH2CI2 (0.3 ml) at room temperature for 20 hours. The solvent was 
removed and the crude organic product subjected to preparative silica gel TLC 
(developed twice in 1:19 EtOH:EtOAc). Two bands of silica were recovered 
. 
and eluted with 1:4 EtOH:EtOAc to give two fractions (2.2 mg, 1.3 mg), which 
were pure mycalamide B 4a-epoxide (4.19) and mycalamide B 4f3-epoxide 
(4.20), respectively. 
4.19: an oil; 1H and 13C NMR data in Tables 4.7 and 4.9; HRFABMS m/z 
556.2714 (MNa+, -3.6 ppm for C2sH43N011 Na), DCIMS (NH3) m/z (%) 551 
(14, MNH4+), 519 (23, MNH4+-CH30H), 502 (36, MH+-CH30H), 409 (12), 386 
(15), 351 (15), 349 (15), 306 (23), 294 (22), 276 (20), 264 (80). 
4.20: an oil; 1 H and 13C NMR data in Tables 4.7 and 4.9; HRFABMS m/z 
556.2756 (MNa+, +4.0 ppm for C2sH43N011 Na), DCIMS (NH3) m/z (%) 551 
(17, MNH4+), 542 (16), 528 (50), 519 (32, MNH4+-CH30H), 503 (23), 502 (75, 
MH+-CH30H), 408 (16), 406 (16), 400 (27), 391 (18), 386 (58), 373 (22), 372 
(1 00). 
4.10 OTHER DOUBLE BOND ADDITIONS 
Mycalamide B (2.5 mg), potassium carbonate (8.5 mg) and ethyl 
chloroformate (4 Jll) were stirred in benzene (0.3 ml) at room temperature for 
20 hours. The solution was filtered over celite and the solvent removed to give 
the crude organic product (2.5 mg), which was then subjected to preparative 
silica gel TLC (developed in 3:2 PE:EtOAc). A single band of silica was 
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recovered and eluted with EtOAc to give 0.8 mg of 4',4-hydrochloro, 
5,6-dehydromethoxy mycalamide B bis-ethylcarbonate (4.21 ). 
4.21: an oil; 1 H NMR data in Table 4.5. 
Mycalamide A (1 mg) was reacted with a solution of bromine in CCI4 
(0.01 M, 1 ml) at room temperature for 15 minutes. The solvent was removed to 
give the crude organic product which was a 1 :1 mixture of mycalamide A and 
one major bromination product (TLC, 1 H NMR spectroscopy). 
The reaction was repeated with a more concentrated solution of 
. 
bromine in CCI4 (0.1 M, 0.3 ml) at room temperature for 0.5 minutes, but this 
gave decomposition (TLC, 1 H NMR spectroscopy). Similarly mycalamide A 
was reacted with a solution of bromine in 1:1 CH2CI2:CCI4 (0.02M, 0.3 ml), 
containing triethylamine (50 J.tl) at room temperature for 1 minute. The solvent 
was removed to give the crude organic product which was a mixture of several 
components (TLC), but 1 H NMR spectroscopy indicated only decomposition. 
WORK DESCRIBED IN CHAPTER 5 
5.2.2 INITIAL BASE CATAL YSED REACTION STUDIES 
Mycalamide A (0.2 mg) was stirred in a solution of sodium methoxide in 
MeOH (1M, 0.1 ml) at room temperature for 1 day. The reaction mixture was 
found to consist of at least one more polar component (HPLC) which gave a 
blue char on visualisation with anisaldehyde. 
5.3.1 PREPARATION AND CHARACTERISATION OF MYCALAMIDE A 
OXAZOLIDINONES 
Mycalamide A (3.8 mg) was stirred in a solution of sodium methoxide in 
MeOH (1M, 0.3 ml) at sooc for 8 hours. The solvent was removed and the 
crude residue extracted with CHCI3 (3x 1 ml) and filtered to give the crude 
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organic product (3.3 mg). Preparative reverse phase HPLC (45% H20 in 
MeOH) gave two fractions (1.0 mg, 1.3 mg), which were pure mycalamide A cis 
oxazolidinone (5.2) and mycalamide A trans oxazolidinone (5.3), 
respectively. 
5.2: an oil; FTIR (film) Umax 3700-3100, 3073, 2964, 2926, 2855, 1718, 1430, 
1380, 1260, 1102, 1071, 1045, 1018, 800 cm-1; 1H and 13C NMR data in 
Tables 5.1 ·and 5.2; HRFABMS m/z 496.2527 (MNa+, +0.9 ppm for 
C23H3gNOgNa), DCIMS (NH3) m/z (%) 491 (5, MNH4+), 461 (6), 460 (30), 459 
. (1 00, MNH4+-CH30H), 443 (17), 442 (63, MH+-CH30H). 
5.3: an oil; IR (CHCI3) Umax 3600-3200, 2920, 1715, 1600, 1400, 1100-1020 
cm-1; 1 H and 13C NMR data in Tables 5.1 and 5.2; HRFABMS m/z 496.2539 
(MNa+, +3.3 ppm for C23H3gNOgNa), DCIMS (NH3) m/z (%) 461 (6), 460 (29), 
459 (1 00, MNH4+-CH30H), 443 (7), 442 (41, MH+-CH30H). 
5.4 FURTHER REACTIONS 
Mycalamide A (0.2 mg) was stirred with barium oxide (9 mg) in DMSO 
(0.2 ml) at 5ooc for 16 hours. H20 (0.5 ml) was added and the mixture 
transferred onto a reverse phase pipette column (200 mg C18, equilibrated to 
H20), which was then flushed with H20 (5 ml) and eluted with MeOH (6 ml). 
The MeOH fraction was evaporated to dryness to give the crude organic 
product, which was a 2:1 mixture of the two isomers, mycalamide A cis 
oxazolidinone (5.2) and mycalamide A trans oxazolidinone (5.3), respectively 
by HPLC and 1H NMR spectroscopy. 
Mycalamide A (1 mg) was stirred with powdered potassium hydroxide 
(3 mg) in DMSO (0.2 ml) at room temperature for 4 days. H20 (0.5 ml) was 
added and the mixture extracted with CHCI3 (3x 0.3 ml). The solvent was 
removed to give the crude organic product which was mostly mycalamide A cis 
oxazolidinone (5.2). 
428 
Mycalamide A (1.5 mg) was stirred with powdered potassium hydroxide 
{7 mg) in DMSO (0.3 ml) at 800C for 1 day, then at 105oc for 1 day. H20 (0.6 
ml) was added and the mixture transferred onto a reverse phase pipette 
column {200 mg C18, equilibrated to H20), which was then flushed with H20 
(5 ml) and eluted with MeOH (6 ml). The MeOH fraction was evaporated to 
dryness to give the crude organic product, which was mostly A4(5) mycalamide 
A cis oxazolidinone (5.6). 
5.6: an oil; HRFABMS m/z 442.2471 (MH+-CHaOH, +6.8 ppm for 
C22HasNOa). 
Mycalamide A (7 mg) was stirred in a solution of sodium hydroxide in 
3:2 H20:Me0H (2M, 0.3 ml) at 55oc for 10 hours. The solution was 
concentrated (to 1 ml), then H20 (0.6 ml) was added. The mixture was 
transferred onto a reverse phase pipette column (200 mg C18, equilibrated to 
H20), which was then flushed with H20 {5 ml) and eluted with MeOH (5 ml). 
The MeOH fraction was evaporated to dryness to give the crude organic 
product, which was a mixture of at least 4 components (HPLC). Preparative 
reverse phase HPLC (45% H20 in MeOH) gave 4 fractions (1.4 mg, 1.8 mg, 
0.7 mg, 0.8 mg), which were mycalamide A cis oxazolidinone (5.2), 
mycalamide A trans oxazolidinone (5.3), mostly 75 mycalamide A trans 
oxazolidinone (5.8) and mostly 75 mycalamide A cis oxazolidinone (5.7), 
respectively. Note that the latter two fractions contained up to 25% unresolved 
mycalamide A by FABMS and 1H NMR spectroscopy. 
5.7: an oil; 1 H NMR data in Table 5.1; HRFABMS m/z 442.2410 (MH+-CHaOH, 
-6.9 ppm for C22H3sNOa). 
5.8: an oil; 1 H NMR data in Table 5.1; HRFABMS m/z 442.2430 (MH+-CHaOH, 
-2.4 ppm for C22H3sNOa). 
Mycalamide B (2.5 mg) was stirred with powdered potassium hydroxide 
(5 mg) in DMSO (0.2 ml) at 4ooc for 1 day. H20 (0.5 ml) was added and the 
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mixture extracted with CHCI3 (3x 0.3 ml). The solvent was removed and the 
crude organic product subjected to preparative silica gel TLC (developed 
twice in 1:19 EtOH:EtOAc). Two bands of silica were recovered and eluted 
with 1 :3 EtOH:EtOAc to give mycalamide B cis oxazolidinone (5.9) and 
mycalamide B trans oxazolidinone (5.1 0), respectively (although the latter 
fraction also contained traces of mycalamide B). 
5.9: an oil; 1H and 13C NMR data in Tables 5.1 and 5.2; HRFABMS m/z 
456.2587 (MH+-CH30H, -2.3 ppm for C23H3aNOa). 
5.10: an oil; 1 H NMR data in Table 5.1; HRFABMS m/z 510.26340 (MNa+, -8.8 
ppm for C24H41NOgNa). 
Mycalamide B (2.5 mg) was stirred in a solution of sodium methoxide in 
MeOH (1M, 0.3 ml) at room temperature for 1 day, then at sooc for 1 day. The 
solvent was removed and the crude residue partitioned in 1 :1 CHCI3:H20 (5 
ml), then extracted with CHCI3 (3x 2 ml). The solvent was removed and the 
crude organic product subjected to preparative silica gel TLC (developed 
twice in 1 :19 EtOH:EtOAc). Two bands of silica were recovered and eluted 
with 1 :3 EtOH:EtOAc to give two fractions (1 mg, 1 mg), which were both 
mixtures, containing as major components mycalamide B cis oxazolidinone 
(5.9) and mycalamide B trans oxazolidinone (5.10), respectively. 
5.5 REACTION MECHANISMS 
Mycalamide A (1.5 mg) was stirred in a solution of sodium 
trideuteromethoxide in CD30D {3M, 0.2 ml) at room temperature for 1 day, 
then at 5ooc for 2 hours. The solvent was removed and the crude residue 
extracted with CHCI3 (3x 1 ml). The solvent was removed to give the crude 
organic product which was a mixture of mycalamide A cis oxazolidinone (5.2), 
mycalamide A trans oxazolidinone (5.3) and minor products, but there was no 
incorporation of deuterium by 1 H NMR spectroscopy. 
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Mycalamide A cis oxazolidinone (5.2, 1 mg) was stirred in a solution of 
sodium trideuteromethoxide in CD30D (4M, 0.4 ml) at ?ooc for 2 hours. The 
solvent was removed and the crude residue extracted with CHCI3 (3x 1 ml). 
This solution was filtered and the solvent removed to give the crude organic 
product, which was a mixture of mycalamide A cis oxazolidinone (5.2) and 
minor products. There was no mycalamide A trans oxazolidinone (5.3) 
present and no incorporation of deuterium. 
Mycalamide A trans oxazolidinone (5.3, 1.7 mg) was stirred with 
powdered potassium hydroxide (1 0 mg) in DMSO (0.3 ml) at room 
temperature for 4 days. H20 (0.5 ml) was added and the mixture transferred 
onto a reverse phase pipette column (200 mg C18, equilibrated to H20), which 
was then flushed with H20 (8 ml) and eluted with MeOH (8 ml). The MeOH 
fraction was evaporated to dryness to give 1.3 mg of almost pure mycalamide 
A trans oxazolidinone (5.3). 
Mycalamide A trans oxazolidinone (5.3, 1.3 mg) was stirred in a 
solution of sodium hydroxide in 40% H20/MeOH (1M, 0.4 ml) at 6QOC for 1 
day. The solution was concentrated under nitrogen (to 0.2 ml), then H20 (1 
ml) was added and the mixture transferred onto a reverse phase pipette 
column (200 mg C18, equilibrated to H20), which was then flushed with H20 
· (6 ml) and eluted with MeOH (6 ml). The MeOH fraction was evaporated to 
dryness to give a mixture consisting of at least 60% mycalamide A cis 
oxazolidinone (5.2), with some decomposition. 
5.6 ACID DECOMPOSITION 
Mycalamide A trans oxazolidinone (5.3, 1.2 mg) in CDCb only (0.6 ml) 
reacted overnight at 4°C to give Z neomycalamide A 1 OS oxazolidinone 
(5.11) cleanly. Similarly, mycalamide A cis oxazolidinone (5.2, 1 mg) in 
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CDCI3 only (0.6 ml) reacted overnight at 4oc to give Z neomycalamide A 10R 
oxazolidinone (5.12) cleanly. These reactions could not be reproduced. 
5.11: an oil; 1 H NMR (CDCI3) 88.06 (NH9, broad s), 6.94 (H5, q, 1.7), 5.86 
(H1 0, d, 6.4), 4.16 (H2, dq, 2.9, 6.5), 4.05 (H12, dd, 6.1, 8.3), 3.98 (H11, t, 5.9), 
3.91 (H17, m), 3.59 (H218, m), 3.59 (13-0CH3 , s), 3.54 (H15, m), 3.03 (H13, d, 
8.2), 2.03 (H3, dq, 2.5, 7.2), 1.89 (4-CH3, d, 1.3), 1.6-1.7 (H216, m), 1.32 
(2-CH3 , d, 6.5), 1.00 (3-CH3 , d, 7.0), 1.00 (14-CH3 R, s), 0.87 (14-CH3 S, s) ppm. 
5.12: an oil; 1H NMR (CDCI3) o 6.89 (H5, q, 1.5), 6.54 (NH9, broads), 5.86 
. 
(H1 0, d, 7.5), 4.15 (H2, dq, 2.8, 6.6), 4.01 (H12, dd, 7.2, 9.5), 3.95 (H17, m), 
3.94 (H11, t, 7.4), 3.65 (H18, m), 3.63 (13-0CH3 , s), 3.60 (H18, dd, 5.2, 12.7), 
3.6 (H15, m), 3.09 (H13, d, 9.5), 2.02 (H3, dq, 2.6, 7.3), 1.89 (4-CH3, d, 1.6), 
1.5-1.7 (H216, m), 1.35 (2-CH3 , d, 6.5), 1.01 (3-CH3 , d, 7.0), 0.96 (14-CH3R, s), 
0.88 (14-CH3S, s) ppm. 
5.7 ACETYLATION AND METHYLATION OF OXAZOLIDINONES 
Mycalamide A trans oxazolidinone (5.3, 1.7 mg) was dissolved in 
pyridine (0.15 ml) and acetic anhydride (0.15 ml) and stirred at room 
temperature for 2 days. The solution was concentrated under nitrogen, then 
H20 (2 ml) was added and the mixture extracted with CH2CI2 (3x 2 ml). The 
solvent was removed to give 1.8 mg of pure N-acetyl mycalamide A trans 
oxazolidinone 12,17, 18-triacetate (5.13). 
5.13: an oil; FTIR (film) t>max 3075,2968, 2925,2850, 1745, 1715, 1657, 1438, 
1373, 1295, 1264, 1228, 1144, 1094, 1047 cm-1; 1 H and 13C NMR data in 
Tables 5.9 and 5.2; HRFABMS m/z 664.2982 (MNa+, +6.0 ppm for 
C31 H47N013Na). 
Mycalamide A trans oxazolidinone (5.3, 2 mg), powdered potassium 
hydroxide (12 mg) and methyl iodide (5 ~-tl) were stirred in DMSO (0.3 ml) at 
3ooc for 20 hours. H20 (0.6 ml) was added and the mixture transferred onto a 
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reverse phase pipette column (200 mg C18, equilibrated to H20), which was 
then flushed with H20 (6 ml) and eluted with MeOH (6 ml). The MeOH fraction 
was evaporated to dryness to give the crude organic product (2.2 mg) which 
was then subjected to preparative silica gel TLC (developed in 5:2 EtOAc:PE). 
Three bands of silica were recovered and eluted with 3:1 CH2CI2:MeOH to 
give three fractions {0.9 mg, 0.1 mg, 1.1 mg), which were 
12,17,18-tri-0-methyl, N-methyl mycalamide A trans oxazolidinone (5.14), 
12,17, 18-tri-0-methyl, N-methyl 7 S my cal amide A trans oxazolidinone (5.16), 
. 
and 12,17,18-tri-0-methyl, N-methyl 7S mycalamide A cis oxazolidinone 
(5.15), respectively. 
Mycalamide 8 (2.5 mg) and powdered potassium hydroxide (1 0 mg) 
were stirred in DMSO (0.3 ml) at room temperature overnight to give a mixture 
of mycalamide 8 cis and trans oxazolidinones (5.9, 5.1 0) by TLC. Methyl 
iodide (4 ~-tl) was added and the reaction stirred at room temperature for 1 day. 
H 20 (0.5 ml) was added and the mixture transferred onto a reverse phase 
pipette column (200 mg C18, equilibrated to H20), which was then flushed 
with H20 {6 ml) and eluted with MeOH (6 ml). The MeOH fraction was 
evaporated to dryness to give the crude organic product (2.2 mg) which was 
then subjected to preparative silica gel TLC (developed in 5:2 EtOAc:PE). 
Three bands of silica were recovered and eluted with 1:5 EtOH:EtOAc to give 
three fractions (0.8 mg, 0.8 mg, 0.8 mg), which were mostly 5.14 (containing a 
small amount of 7,17, 18-tri-0-methyl, N-methyl mycalamide A, 2.26), pure 
5.16, and a mixture of 5.15 and another component. Preparative reverse 
phase HPLC (25% H20 in MeOH) gave two fractions (0.5 mg, 0.2 mg), which 
were 5.15 and 8, 12, 17, 18-tetra-0-methyl mycalamide A cis oxazolidinone 
(5.17), respectively. 
5.14: an oil; 1 H and 13C NMR data in Tables 5.9 and 5.2; HRFA8MS m/z 
498.3067 (MH+-CH30H, +0.1 ppm for C2sH44NOa). 
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5.15: an oil; 1 H and 13C NMR data in Tables 5.9 and 5.2; HRFABMS m/z 
568.2847 (MK+, -7.1 ppm for C27H47NOgK). 
5.16: an oil; 1 H NMR data in Table 5.9; HRFABMS m/z 498.3083 
(MH+-CH30H, +3.3 ppm for C2sH44NOa). 
5.17: an oil; 1 H NMR data in Table 5.9; HRFABMS m/z 498.3066 
(MH+-CH30H, -0.1 ppm for C2sH44NOa). 
WORK DESCRIBED IN CHAPTER 6 
6.2 BASE CATAL YSED REACTIONS OF N-ALKYL DERIVATIVES 
7, 18-Di-Q-benzyl, N-benzyl mycalamide B (2.46, 5 mg) was stirred with 
powdered potassium hydroxide (6 mg) in DMSO (0.3 ml) at 600C for 5 hours. 
H20 (0.6 ml) was added and the mixture transferred onto a reverse phase 
pipette column (200 mg C18, equilibrated to H20), which was then flushed 
with H20 (5 ml) and eluted with MeOH (5 ml). The MeOH fraction was 
evaporated to dryness to give the crude organic product, which was then 
subjected to preparative silica gel TLC (developed in 2:1 PE:EtOAc). Seven 
bands of silica were recovered and eluted with EtOAc, to give seven fractions 
(<0.5 mg, 1.5 mg, <0.5 mg, 1.8 mg, <0.5 mg, 1 mg, <0.5 mg), but all except 
fraction 4 contained only complex mixtures or alkyl impurities. Fraction 4 was 
a pure N-benzyl, N-formyl fragment (6.1 ). 
6.1: an oil; FTIR (film) Umax 3089, 3063, 3031, 2961, 2928, 2880, 2855, 2825, 
1689, 1454, 1386, 1365, 1260, 1188, 1166, 1107, 1085, 1030 cm-1; 1H NMR 
data in Table 6.1, 13C NMR data in Table 6.3 except the following aromatic 
resonances, (CDCI3) <5128.76, 128.44, 128.31, 128.26, 128.21, 127.95, 
127.85, 127.65, 127.58, 127.39, 127.23 ppm; HRCIMS (C4H1o) m/z 514.2802 
(MH+, -0.5 ppm for C29H4oN07). 
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Mycalamide B (3.6 mg), powdered potassium hydroxide (6 mg) and 
methyl iodide (4 Jll) were stirred in DMSO {0.2 ml) at room temperature for one 
day to give 7,17, 18-tri-0-methyl, N-methyl mycalamide A (2.26) by TLC. 
Powdered potassium hydroxide (2 mg) was added and the mixture stirred at 
7ooc for 5 hours. H20 (0.5 ml) was added and the mixture extracted with 
C H Cl3 (3x 0.3 ml). The solvent was removed to give 1.8 mg of a pure 
N-methyl N-formyl fragment (6.2). 
6.2: an oil; IR (CHCI3)Umax2900, 2860,1680,1600,1380,1080-1020 cm-1; 
1H and 13C NMR data in Tables 6.1 and 6.3; HRCIMS (C4H10} m/z 362.2179 
(MH+, +0.1 ppm for C17H32N07). 
6.3 BASE CATALYSED REACTIONS OF 7-0-BENZYL DERIVATIVES 
7-0-Benzyl mycalamide A (2.39, 2 mg) was stirred with barium oxide 
(11 mg) in DMSO (0.3 ml) at 600C for 4 hours, then at 75oc for 4 hours. H20 
(0.5 ml) was added and the mixture transferred onto a reverse phase pipette 
column (200 mg C18, equilibrated to H20), which was then flushed with H20 
(6 ml) and eluted with MeOH (6 ml). The MeOH fraction was evaporated to 
dryness to give the crude organic product, which was then subjected to 
preparative silica gel TLC (developed in EtOAc). Two bands of silica were 
recovered and eluted with 1 :9 EtOH:EtOAc to give two fractions (0.8 mg, 0.8 
mg), which were 7-0-benzyl mycalamide A (2.39) and 7-0-benzyl 10R 
mycalamide A (6.3), respectively. 
6.3: an oil; 1 H NMR data in Table 6.4, 13C NMR data in Table 6.5 except the 
following aromatic resonances, (CDCI3) o137.26, 128.49, 128.38, 127.98 
ppm; HREIMS m/z 561.3149 (M+-CH30H, 0.0 ppm for C3oH43NOg), DCIMS 
(NH3) m/z (%) 611 (2, MNH4+), 594 (3, MH+), 582 (9), 581 (26), 580 (28), 579 
(80, MNH4+-CH30H}, 565 (12), 564 (37), 563 (33), 562 (100, MH+-CH30H). 
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Mycalamide A (6 mg), barium oxide (26 mg) and benzyl bromide (1 0 J.LI) 
were stirred in DMSO (0.3 ml) at 6ooc for 2 hours. H20 was added (0.5 ml) 
and the mixture transferred onto a reverse phase pipette column (200 mg C18, 
equilibrated to H20), which was then flushed with H20 (8 ml), then eluted with 
MeOH (6 ml). The resulting MeOH fraction was evaporated to dryness, then 
this crude organic product was subjected to preparative silica gel TLC (1 :2 
PE:EtOAc). Four bands of silica were recovered and eluted with EtOAc to give 
four fractions (1 mg, 1 mg, 1.5 mg, 1.5 mg), which were 7-0-benzyl 
mycalamide A (2.39), 7-0-benzyl 1 OR mycalamide A (6.3), 7,18-di-0-benzyl 
1 OR mycalamide A (6.4) and 7,18-di-0-benzyl mycalamide A (2.40), 
respectively. 
6.4: an oil; 1 H NMR data in Table 6.4, 13C NMR data in Table 6.5 except the 
following aromatic resonances, (CDCI3) o137.31, 128.53, 128.40, 128.33, 
127.89, 127.72, 127.66 ppm; HRFABMS m/z 652.3495 (MH+-CH30H, +1.4 
ppm for C37HsoNOg), DCIMS (NH3) m/z (%) 701 (4, MNH4+), 672 (5), 671 
(18), 670 (42), 669 (1 00, MNH4+-C H30H), 654 (11 ), 653 (21 ), 652 (53, 
MH+-CH30H). 
7-0-Benzyl mycalamide A (2.39, 2 mg) was stirred in a solution of 
sodium methoxide in MeOD (1.5M, 0.4 ml) at 6ooc for 2.5 hours. The solvent 
was removed and the crude residue partitioned in 1 :1 CHCI3:H20 (5 ml), then 
extracted in CHCI3 (3x 2 ml). The solvent was removed to give the crude 
organic product, which was a mixture of at least eight components (HPLC). 
Preparative reverse phase HPLC gave eight fractions (0.2 mg, 0.4 mg, 0.3 mg, 
0.3 mg, 0.2 mg, 0.1 mg, 0.1 mg, 0.1 mg), which were 7-deutero, 7-Q-benzyl, Z 
~ 1 o, 1 0-deformyl mycalamide A (6.5), 7-deutero, 7-0-benzyl, 1 OR-O-methyl 
mycalamide A (6.6), a 2:1 mixture of 7-deutero, 7-0-benzyl, 108-0·methyl 
mycalamide A (6.8) and 7-deutero, 7-0-benzyl mycalamide A (6. 7), 
7-deutero, 7 S-O-benzyl 1 OR-O-methyl mycalamide A (6.9), 7-deutero, 
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7~0-benzyl 10R mycalamide A (6.10), 7-deutero, ?S-O-benzyl mycalamide A 
(6.11 ), 7-deutero, 7 S-O-benzyl 1 OS-0-methyl mycalamide A (6.12) and 
7-deutero, ?S-O-benzyl 10R mycalamide A (6.13), respectively. 
6.5: an oil; 1H NMR data in Table 6.7; HRFABMS m/z 603.2770 (MK+, -4.0 
ppm for CaoH44DNOgK). 
6.6: an oil; 1 H NMR data in Table 6.7; HRFABMS m/z 635.3059 (MK+, +0.4 
ppm for Ca1 H4sDN01oK). 
6.7: an oil; HRFABMS m/z 633.2890 (MK+, -1.5 ppm for C31 H4sDN01oK). 
6.8: an oil; 1H NMR data in Table 6.7; HRFABMS m/z 635.3023 (MK+, -5.2 
ppm for Ca1H4sDN01oK). 
6.9: an oil; 1 H NMR data in Table 6.7; HRFABMS m/z 635.3111 (MK+, +8.9 
ppm for Ca1 H4sDNO 1 oK). 
6.11: an oil; 1 H NMR data in Table 6.7; HRFABMS m/z 617.3203 (MNa+, +6.9 
ppm for Ca1 H4sDN01oNa). 
6.12: an oil; 1 H NMR data in Table 6.7. 
6.13: an oil; 1 H NMR data in Table 6.7. 
7-0-Benzyl mycalamide A {2.39, 1 mg) was stirred with sodium 
methoxide in MeOH (1M, 0.3 ml) at 7ooc for 2 hours. The solvent was 
removed and the crude residue partitioned in 1 :1 CHCia:H20 (5 ml), then 
extracted in CHCia (3x 2 ml). The solvent was removed to give the crude 
organic product, which was a mixture of several components, as above (TLC, 
1 H NMR spectroscopy). 
Mycalamide A (4 mg), barium oxide (20 mg) and benzyl bromide (9 Jll) 
were stirred in DMSO (0.3 ml) at 650C overnight. Barium oxide (1 0 mg) was 
then added and the reaction stirred at 800C overnight. H20 (0.6 ml) was 
added and the mixture transferred onto a reverse phase pipette column (200 
mg C18, equilibrated to H20), which was then flushed with H20 (7 ml) and 
eluted with MeOH (7 ml). The MeOH fraction was evaporated to dryness to 
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give the crude organic product, which was a mixture of 2 major components 
(HPLC). Preparative reverse phase HPLC (25% H20 in MeOH) gave two 
fractions (1 mg, 1 mg), which were 7-0-benzyl pede ram ide (6.14) and 
7 S-O-benzyl pede ram ide (6.15), respectively. 
6.14: an oil; FTIR (film) Umax 3700-3100, (3464, 3338, 3203), 3070, 3031, 
2972, 2927, 2855, 1685, 1607, 1490, 1455, 1379, 1325, 1228, 1146, 1102, 
1075, 1048, 1015, 876, 740, 700 cm-1; 1H NMR data in Table 6.4, 13C NMR 
data in Table 6.5 except the following aromatic resonances, (CDCb) 3137.06, 
128.48, 128.44, 128.09 ppm; HREIMS m/z 319.1788 (M+, +1.6 ppm for 
C1aH2sN04), 287.1536 (M+-CH30H, +4.9 ppm for C17H21 N04). 
6.15: an oil; FTIR (film) Umax 3700-3100, (3474, 3360), 3069, 3031, 2972, 
2922,2851, 1686, 1587, 1456, 1378, 1325, 1231, 1144, 1077, 1041, 1028, 
892, 791, 735, 698 cm-1; 1 H NMR data in Table 6.4, 13C NMR data in Table 
6.5 except the following aromatic resonances, (CDCI3) 3128.48, 128.01 ppm; 
HREIMS m/z319.1797 (M+, +4.1 ppm for C1aH2sN04), 287.1518 (M+-CH30H, 
-1.4 ppm for C17H21 N04). 
6.4 REACTION OF MYCALAMIDE A WITH SODIUM AZIDE 
Mycalamide A (6 mg) was stirred with sodium azide (26 mg) in DMSO 
(0.3 ml) at 13SOC for 4 days. H20 (0.6 ml) was added and the mixture 
transferred onto a reverse phase pipette column (200 mg C18, equilibrated to 
H20), which was then flushed with H20 (6 ml) and eluted with MeOH (6 ml). 
The MeOH fraction was evaporated to dryness and the crude organic products 
subjected to preparative silica gel TLC (developed twice in EtOAc). Six bands 
of silica were recovered and eluted with 1 :3 EtOH:EtOAc to give six fractions 
(0.4 mg, 2.8 mg, 0.7 mg, 0.7 mg, 1.0 mg, 0.2 mg), which were 11 R mycalamide 
A trans oxazolidinone (6.20), Z il1 o 1 0-deformyl mycalamide A (6.16), a 
mixture consisting of mycalamide A and mycalamide A cis and trans 
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oxazolidinones (5.2, 5.3), two more mixtures and crude pede ram ide (3.4), 
respectively. Preparative reverse phase HPLC (35% H20 in MeOH) on TLC 
fraction 4 gave three fractions (0.1 mg, 0.2 mg, 0.3 mg), which were 
mycalamide A trans oxazolidinone (5.3), !!.. 11 mycalamide A trans 
oxazolidinone (6.21) and 1 OR mycalamide A (6.17), respectively. 
Preparative reverse phase HPLC (45% H20 in MeOH) on TLC fraction 5 gave 
three fractions (0.2 mg, 0.3 mg, 0.4 mg), which were mycalamide A trans 
oxazolidinone (5.3), E f!..1 O 1 0-deformyl mycalamide A (6.19) and 1 OR 
. 
mycalamide A (6.17), respectively. 
6.16: an oil; FTIR (film) Umax 3600-3100, (3400), 3073, 2971, 2929, 2855, 
1670, 1512, 1380, 1295, 1228, 1092, 1074, 1043, 1015, 910, 880, 735, 704 
cm-1, IR (CHCI3) Umax 3600-3300,2900, 1670, 1380, 1080-1020, 905 cm-1; 1H 
and 13C NMR data in Tables 6.8 and 6.9; HRFABMS m/z 442.2444 
(MH+-CH30H, +0.8 ppm for C22H3sNOa). 
6.17: an oil; FTIR (film) Umax 3600-3100, (3357), 2923, 2853, 1688, 1531, 
1460, 1380, 1197, 1140, 1099, 1075, 1035, 1018 cm-1; 1H and 13C NMR data 
in Tables 6.8 and 6.9; HRFABMS m/z 542.2339 (MK+, -5.2 ppm for 
C24H41N01oK). 
(PURIFICATION AND CHARACTERISATION OF 1 OR MYCALAMIDE B) 
Mycalamide B reacted with sodium methoxide in MeOH, as described in 
Section 5.4, and preparative TLC gave two fractions which were mixtures. In 
particular, fraction 2 (1 mg) contained mycalamide B trans oxazolidinone 
(5.1 0) and a second significant component (1 H NMR spectroscopy). 
Preparative reverse phase HPLC (25% H20 in MeOH) gave three fractions 
(0.6 mg, 0.1 mg, 0.2 mg), which were a mixture of mycalamide B trans 
oxazolidinone (5.1 0) and its C7 epimer, a mixture and pure 1 OR mycalamide 
B (6.18), respectively. 
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6.18: an oil; 1 H NMR data in Table 6.8; HRFABMS m/z 556.2562 (MK+, +6.9 
ppm for C2sH43N01oK). 
6.19: an oil; 1H NMR data in Table 6.8. 
6.20: an oil; 1 H NMR data in Table 6.11; HRFABMS m/z 512.2248 (MK+, -2.7 
ppm for C23H3gNOgK). 
6.21: an oil; 1 H NMR data in Table 6.11; HRFABMS m/z 494.2194 (MK+, +7.7 
ppm for C23H37NOaK). 
Z il10, 10-Deformyl mycalamide A (6.16, 2 mg) was stirred with sodium 
. 
azide (23 mg) in DMSO (0.3 ml) at 900C for 6 days. H20 (0.5 ml) was added 
and the solution transferred onto a reverse phase pipette column (200 mg 
C18, equilibrated to H20), which was then flushed with H20 (6 ml) and eluted 
with MeOH (6 ml). The MeOH fraction was evaporated to dryness and the 
crude organic product then subjected to preparative silica gel TLC (developed 
twice in EtOAc). Three bands of silica were recovered and eluted with 1 :4 
EtOH:EtOAc to give three fractions (0.2 mg, 0.5 mg, 0.6 mg), which were an 
unknown mycalamide A oxazolidinone derivative, Z il 1 o, 1 0-deformyl 
mycalamide A (6.16) and pure pederamide (3.4), respectively. 
3.4: an oil; FTIR (film) Umax 3484, 3358 (br), 3068, 2979, 2914, 2851, 1683, 
1573,1417,1375, 1323, 1230, 1139, 1124, 1103, 1071, 1039, 1015,999,886 
cm-1; 1H and 13C NMR data in Tables 6.4 and 6.9; HREIMS m/z 197.1049 
(M+-CH30H, -1.6 ppm for C10H1sN03), ElMS m/z (%) 197 (32), 155 (71), 153 
(76), 151 (80), 143 (77), 134 (57), 123 (55), 109 (33), 107 (21 ), 96 (22), 95 
(1 00), 93 (23), 91 (22), 81 (78), CIMS (NH3) m/z (%) 199 (11 ), 198 (1 00, 
M H+-CH30H), 180 (22), 155 (83), 153 (57), 152 (36), 134 (40), 125 (16), 123 
(49), 109 (17), 96 (18), 95 (47), 81 (34). 
440 
6.5.1 REACTION OF MYCALAMIDE A WITH SODIUM BOROHYDRIDE 
Mycalamide A (6 mg) was stirred with sodium borohydride (24 mg) in 
DMSO (0.3 ml) at 13ooc for 2 days. H20 (0.6 ml) and formaldehyde (40%, 0.2 
ml) were added (the latter to destroy excess sodium borohydride), then the 
mixture was transferred onto a reverse phase pipette column (200 mg C18, 
equilibrated to H20), which was then flushed with H20 (6 ml) and eluted with 
MeOH (6 ml). The MeOH fraction was evaporated to dryness and the crude 
organic product (1 0 mg) then subjected to preparative silica gel TLC 
(developed twice in 1:25 EtOH:EtOAc). Five bands of silica were recovered 
and eluted with 1:3 EtOH:EtOAc to give five fractions (0.9 mg, 0.3 mg, 1.2 mg, 
1.2 mg, 1 mg), which were 10,12-0-dihydro mycalamide A (6.22), ~4(5) 
mycalamide A trans oxazolidinone (6.23), a mixture of mycalamide A and 
mycalamide A cis oxazolidinone (5.2), a mixture of mycalamide A and 
mycalamide A trans oxazolidinone (5.3) and mycalamide A trans 
oxazolidinone (5.3), respectively. 
6.22: an oil; FTIR (film) Umax3700-3100, 2961,2925,2874, 1660, 1548,1458, 
1382, 1262, 1101, 1073, 1044, 1014, 735 cm-1; 1H and 13C NMR data in 
Tables 6.8 and 6.9; HRFABMS m/z 444.2614 (MH+-CH30H, +3.8 ppm for 
C22H3sNOs). 
6.23: an oil; 1 H NMR data in Table 6.11; HRFABMS m/z 442.2426 
(MH+-CH30H, -3.3 ppm for C22H3sNOs). 
Mycalamide A (1 mg) was stirred with sodium borohydride (1.5 mg) in 
EtOH (0.3 ml) for 4 hours at room temperature. No reaction was observed by 
TLC or 1 H NMR spectroscopy of the product obtained after standard workup 
procedures. 
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6.5.1.3 REDUCTION ATTEMPTS USING LITHIUM ALUMINIUM HYDRIDE 
Mycalamide A (1 mg) was stirred with lithium aluminium hydride (0.3 
mg} in dry THF (0.8 ml) at reflux temperature for 4 hours. The resulting 
solution was filtered over celite and the solvent removed to give the crude 
organic product, which was unreacted mycalamide A by TLC and 1 H NMR 
spectroscopy. 
Mycalamide A (1 mg) was stirred with lithium aluminium hydride (5 mg) 
in dry THF (0.5 ml) in a sealed vial at ?ooc for 2 days. The resulting solution 
was filtered over celite, washing with CH2CI2. The solvent was removed to 
give the crude organic product, a mixture of at least 4 components by TLC, so 
this was then subjected to preparative silica gel TLC (developed in EtOAc). 
Four bands of silica were recovered and eluted with 1 :9 EtOH :EtOAc to give 
four fractions (0.1 mg, 0.3 mg, 0.1 mg, 0.2 mg), where fraction 2 was 
mycalamide A, but the remaining fractions had decomposed by TLC and 1 H 
NMR spectroscopy. 
6.5.2.1 REACTION OF MYCALAMIDE A WITH BARIUM OXIDE IN BENZENE 
Mycalamide A (3 mg) was stirred with barium oxide (20 mg) in benzene 
(0.4 ml) in a sealed vial at 1 oooc for 20 hours. The solvent was removed and 
the crude residue partitioned in 1 :1 CHCia:H20 (5 ml), then extracted in CHCI3 
(3x 2 ml). The solvents were removed to give two fractions (1 mg, 14 mg), 
representing organic and water soluble material respectively, but the former 
was a mixture (TLC, 1 H NMR spectroscopy}. Preparative reverse phase HPLC 
on this organic fraction (32% H20 in MeOH) gave two new fractions (0.5 mg, 
0.3 mg), which were a mixture of mycalamide A and another component, and 
pure 1 OR mycalamide A (6.17}, respectively. HPLC fraction 1 was then 
subjected to preparative silica gel TLC (developed twice in EtOAc) to give two 
further fractions {0.2 mg, 0.2 mg), which were mycalamide A and 7 S 
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mycalamide A (6.24), respectively. The water soluble fraction above 
consisted of inorganic barium salts and the barium salt of a C7 carboxylate 
fragment (6.25). 
6.24: an oil; 1 H NMR data in Table 6.7; FABMS m/z (%) 473 (3), 472 (8, 
MH+-CH30H), 460 (10), 391 (15), 355 {10), 308 {24), 307 (83), 289 {65). 
6.25: a salt; 1H and 13C NMR data in Tables 6.7 and 6.9; HRFABMS {-ve ion) 
m/z 199.0970 (M·, -3.0 ppm for C1oH1s04). 
Mycalamide A (3 mg) was stirred with barium oxide (20 mg) in benzene 
(0.3 ml) at 80°C for 2 hours. ·The solvent was removed and the crude residue 
partitioned in 1 :1 CHCI3:H20 (4 ml), then extracted in CHCI3 (3x 2 ml). The 
solvents were removed to give two fractions (1.9 mg, 10 mg), representing 
organic and water soluble material respectively, as above. The crude organic 
fraction was a mixture of mycalamide A and at least 2 minor components, so it 
was subjected to preparative silica gel TLC (developed twice in EtOAc). Three 
bands of silica were recovered and eluted with 1:5 MeOH:CH2CI2 to give three 
fractions (1.1 mg, 0.1 mg, 0.4 mg), which were mycalamide A, impure 7S 
mycalamide A (6.24) and a mixture of two unknown derivatives, possibly C7 
ketones. The water soluble fraction above consisted of inorganic barium salts, 
the barium salt of a C7 carboxylate fragment (6.25) and a mixture of at least 
two minor mycalamide fragments derived from the right hand portion of the 
molecule. 
The C7 carboxylate fragment (6.25, 0.5 mg), barium oxide (6 mg) and 
methyl iodide (3 J.LI) were stirred in DMSO (0.3 ml) at 7ooc for 3 days. H20 
(0.5 ml) was added and the mixture transferred onto a reverse phase pipette 
column (200 mg C18, equilibrated to H20), which was then flushed with H20 
(8 ml) and eluted with MeOH (8 ml). The solvent was removed from the latter 
fraction to give the crude product which was a complex mixture by 1 H NMR 
spectroscopy. 
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WORK DESCRIBED IN CHAPTER 7 
7.2.1 OXIDATION OF MYCALAMIDE B WITH PYRIDINIUM DICHROMATE 
Reagent preparation: Chromium trioxide (1 g) was dissolved in H20 (1 ml} and 
cooled in ice. Pyridine {0.8 ml) was added slowly, then acetone (4 ml) and the 
mixture set aside in a freezer for 2 hours. The orange crystals of pyridinium 
dichromate were collected by vacuum filtration, washed with acetone and 
dried under vacuum {1.5 g). • 
Mycalamide B (1.5 mg) was stirred with pyridinium dichromate (3.4 mg) 
in CH2CI2 (0.3 ml) at room temperature for 3 days, then at 5ooc for 1 hour. 
The resulting solution was filtered over celite and the solvent removed to give 
the crude organic product, which was a mixture of several components by TLC 
and 1H NMR spectroscopy, including pederolactone (3.6), mycalamide Band 
other oxidation products. These were either not resolved or had decomposed 
by reverse phase HPLC and TLC, so this was abandoned. 
7.2.2 REACTION OF MYCALAMIDE B WITH A RUTHENIUM(II) COMPLEX 
Mycalamide B (3.5 mg), potassium carbonate (6 mg) and 
tris-triphenylphosphine ruthenium(ll) chloride (12 mg) were stirred in dry 
benzene (0.4 ml, dried over molecular sieves) at sooc for 7 hours. The 
solvent was removed and the crude residue subjected to preliminary silica gel 
column chromatography (200 mg Davisil), eluting with EtOAc. The solvent 
was removed to give the crude organic product (13 mg), which was then 
subjected to preparative silica gel TLC (developed in 1 :1 PE:EtOAc). Five 
bands of silica were recovered and eluted with EtOAc to give five fractions 
(1-5) (1 mg, 8 mg, 2 mg, 0.5 mg, 1 mg), which were, a mixture of reagent 
derived material and mycalamide B, a mixture of reagent derived material and 
minor oxidation products, a mixture of two oxidation products, and two 
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mixtures of reagent derived material only, respectively. TLC fraction 3 was 
further purified by preparative reverse phase HPLC (35% H20 in MeOH) to 
give four fractions (0.4 mg, 0.5 mg, 0.5 mg, 0.3 mg), which were, reagent 
derived, E ,L\16 18-normycalamide B (7.3), Z A16 18-normycalamide B (7.4) 
and an unknown derivative, respectively. TLC fraction 2 was also further 
purified, using the same HPLC system, to give four fractions (0.1 mg, 0.3 mg, 4 
mg, 3 mg), which were 18-normycalamide A 17-aldehyde (7.5) and three 
complex mixtures, respectively . 
. 
7.3: an oil; FTIR {film) Umax 3500-3200, (3353), 3065, 2954, 2921, 2849, 1678, 
1656, 1529, 1462, 1438, 1378, 1261, 1102, 1072, 1031, 1012 cm-1; 1H and 
13C NMR data in Tables 7.1 and 7.3; HRFABMS m/z 454.2410 (MH+-CH30H, 
-6.8 ppm for C23H36NOs). 
7.4: an oil; 1 H NMR data in Table 7.1; HRFABMS m/z 454.2401 (MH+-CH30H, 
-8.7 ppm for C23H36NOs). 
7.3.1 REACTION OF MYCALAMIDE A WITH A RUTHENIUM(II} COMPLEX 
Mycalamide A (3.5 mg) was stirred with tris-triphenylphosphine 
ruthenium(ll) chloride (5 mg) in benzene (0.5 ml) at room temperature for 2 
days. The solvent was removed and the crude products subjected to silica gel 
column chromatography (200 mg Davisil), developed in steps from PE to 
EtOAc. The major two fractions (6 mg combined), which eluted with 1 :1 
PE:EtOAc and EtOAc, were mixtures of reagent derived material and 
18-normycalamide A 17-aldehyde (7.5), while a minor fraction (1.5 mg), which 
eluted in 1:19 EtOH:EtOAc, was a mixture of reagent derived material and 
mycalamide A. 
Mycalamide A (3. 7 mg}, potassium carbonate (4.2 mg) and 
tris-triphenylphosphine ruthenium(ll) chloride {14 mg) were stirred in benzene 
(0.3 ml) at 5ooc for 2 hours. The solvent was removed and the crude residue 
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subjected to preliminary silica gel column chromatography (200 mg Davisil), 
eluting with EtOAc, then 1:9 EtOH:EtOAc, to give two fractions (11 mg, 3 mg), 
which were a mixture of reagent derived material and oxidation products, and 
a mixture of reagent derived material and mycalamide A, respectively. 
Fraction 1 was then subjected to preparative silica gel TLC (developed in 
EtOAc) to give one major fraction {9 mg), which was a complex mixture of 
reagent derived material and mycalamide A oxidation products in low yield. 
7.3.2 REACTIONS WITH LEAD TETRAACETATE 
Mycalamide B (2.3 mg) was stirred with lead tetraacetate (-8 mg) in 
pyridine (0.2 ml) and benzene (0.2 ml) at 3ooc for 18 hours. The solution was 
concentrated (to 0.1 ml), then H20 (2 ml) was added and the mixture extracted 
with CH2CI2 (3x 2 ml). The solvent was removed to give the crude organic 
product, which was unreacted mycalamide B. 
Mycalamide A (4 mg) was stirred with lead tetraacetate {1 0 mg) in 
pyridine (0.2 ml) and benzene (0.2 ml) at room temperature for 1.5 hours. The 
solution was concentrated (to 0.1 ml), then H20 (2 ml) was added and the 
mixture extracted with CH2CI2 (3x 2 ml). This extract was filtered and the 
solvent removed to give 3.8 mg of pure 18-normycalamide A 17-aldehyde 
(7.5). 
7.5: an oil; FTIR (film) umax 3600-3100 (3350), 3065, 2968, 2924, 2852, 1725, 
1678, 1527, 1454, 1380, 1260, 1100, 1033,798,734 cm-1; 1H and 13C NMR 
data in Tables 7.1 and 7.3; HRFABMS m/z 440.2305 (MH+-CH30H, +4.8 ppm 
for C22H34NOa). 
7.6: 1 Hand 13C NMR data in Tables 7.1 and 7.3. 
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7.4 REACTIONS OF 18-NORMYCALAMIDE A 17-ALDEHYDE 
18-Normycalamide A 17 -aldehyde (7 .5, 1.5 mg) was stirred with 
sodium borohydride {1.2 mg) in MeOH (0.3 ml) at room temperature for 15 
minutes. The solution was concentrated (to 0.1 ml), then H20 (2 ml) was 
added and the mixture extracted with CH2CI2 (3x 2 ml). The solvent was 
removed to give 1.5 mg of pure 18-normycalamide A (7.7). 
7.7: an oil; FTIR (film) Umax 3600-3100 (3348), 3072, 2969, 2928, 2882, 1676, 
1529, 1453, 1382, 1263, 11.07, 1074, 1035 cm-1; 1H and 13C NMR data in 
Tables 7.1 and 7.3; HRFABMS m/z 442.2426 (MH+-CH30H, -3.4 ppm for 
C22H3aNOa). 
18-Normycalamide A 17-aldehyde (7.5, 0.8 mg) was stirred with 
sodium metabisulphite (4 mg) in 1 :1 H20:MeOH (0.4 ml) at room temperature 
for 16 hours, then at 5ooc for 1.5 hours. The solvent was removed to give the 
crude product, which was a mixture of decomposition products by TLC and 1 H 
NMR spectroscopy. 
WORK DESCRIBED IN CHAPTER 8 
SYNTHESIS OF PhC(OCH3)=NH 
Benzonitrile {PhCN, 7.5 ml, 7 g) and dry MeOH (7 ml, 5.5 g) were 
sealed in a flask under nitrogen and cooled in ice. Acetyl chloride {6.5 ml, 7.2 
g) was added and the solution stirred at 4oc for 14 hours. The resulting 
mixture was poured into aqueous sodium carbonate (5%, 200 ml), and this 
solution stirred for 5 minutes, then extracted with CH2CI2 (3x 200 ml). The 
solvent was removed to give the crude organic product (7.46 g), which was a 
mixture of PhC(OCH3)=NH (8.6) and unreacted PhCN. Chromatography in 
two portions on Florisil (60 g), developed in CH2CI2, gave 0.9 g pure PhCN 
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and 1.2 g 90% PhC(OCHa)=NH (8.6) (containing traces of PhCOOCHa and 
PhCN), with the remainder representing combined mixtures (5.3 g). The latter 
fraction was then subjected to silica gel column chromatography (60 g 
Davisil), developed in steps from CH2CI2 to MeOH/CH2CI2. Two fractions (3.1 
g, 0.8 g), which eluted with CH2CI2, were pure PhCN, and a mixture, 
respectively, while a third fraction {1.2 g), which eluted with 1:9 MeOH:CH2CI2, 
was at least" 80% pure PhC(OCHa)=NH (8.6), containing small amounts of 
PhCOOCHa and another phenyl component (not benzoic acid). Thus the 
. 
overall purified yield of PhC(OCHa)=NH (8.6) was approximately 35%. 
PhC(OCHa)=NH (8.6): an oil; 1H NMR (CDC13) 57.71 (Ph, broad d, 7.0}, 7.41 
{Ph, m), 3.91 (OCHa, s) ppm, 13C NMR (CDCI3) 5168.20 (C=N), 132.52, 
130.75, 128.33 and 126.59 (Ph), 53.29 {OCH3) ppm. 
SYNTHESIS OF $-LACTIC ACID ACETATE (CRUDE) 
S-Lactic acid (AR grade, "'80%, 316 mg) was heated with H20 (1 00 !ll) 
at 7ooc for 30 minutes to remove anhydrides. The solution was then 
concentrated under nitrogen and pumped under vacuum for 5 minutes to give 
the crude starting material {240 mg). Pyridine (1 ml) and acetic anhydride (1 
ml) were added and the mixture allowed to stand at room temperature for 1 
day. This solution was then concentrated under nitrogen (to 0.5 ml), then 
partitioned in 1 :1 CHCJa:H20 {1 0 ml) and extracted with CHCI3 (3x 6 ml). The 
solvent was removed under nitrogen and the sample pumped under vacuum 
to give 215 mg of viscous liquid, which was mostly S-lactic acid acetate (8.5), 
containing no more than 26 mg of pyridine and 17 mg of acetic acid by 1 H 
NMR spectroscopy. 
S-Lactic acid acetate (8.5): a viscous liquid; 1 H NMR (CDCI3) 55.10 (CH, q, 
7.1), 2.13 (OCOCHa, s), 1.52 (CH3, d, 7.1} ppm, 13C NMR (CDCI3) 5170.48 
(C=O}, 68.65 (CH}, 20.72 (COCH3), 16.92 (CH3) ppm. 
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SYNTHESIS OF (SR, SS)-CH3CHOH(C=O)NHCH(OCH3)Ph 
S-Lactic acid acetate (8.5, 215 mg crude, 1 mole equiv.) was dissolved 
in pyridine (300 J.LI) and CH2CI2 (1 ml) and sealed under nitrogen. Thionyl 
chloride (140 J.LI, 1.5 mole equiv.) was added and the mixture stirred for 10 
minutes at room temperature. To this was added a solution of 90% 
PhC(OCH3)=NH (8.6, 135 mg, 0.7 mole equiv.), triethylamine (215 J.LI) and 
C H2CI2 (0 .1 ml) and the resulting mixture was stirred at room temperature for 
70 minutes. This solution vxas concentrated under nitrogen (to 0.5 ml) and 
reacted with a suspension of sodium borohydride (600 mg) in EtOH (5 ml) for 
1 0 minutes. The reaction was quenched with brine (150 ml) then this mixture 
extracted with CHCI3 (3x 1 00 ml). The solvent was removed to give 270 mg of 
a crude organic product, which was then subjected to silica gel column 
chromatography (3 g Davisil), developed in steps from CH2CI2 to 
MeOH/CHCI3, in two portions and the results combined. One fraction (76 mg), 
which eluted with CHCI3, was an approximately 3:1 mixture of the two 
diastereomeric products (8. 7, 8.8) and their acetates (8.9, 8.1 0), while a 
second fraction (63 mg), which eluted with 1 :19 MeOH:CHCI3, was a 2:1 
mixture of the two diastereomeric products only (8.7, 8.8). Thus the overall 
yield of 8.7 and 8.8 was about 63%, with a further 9% yield of the acetates 
8.9 and 8.1 0. 
These fractions were further analysed and purified by preparative TLC 
and HPLC. Firstly, a subsample of Fraction 2 (15 mg) was subjected to 
preparative normal phase HPLC (55% EtOAc in Hexane), using a chiral (R) 
phenyl urea column, to give two major fractions (6 mg, 3 mg), which were a 
mixture of the two diastereomeric products (8.7, 8.8), and mostly an unknown 
phenyl derivative, respectively. Secondly, preparative silica gel TLC 
(developed four times in CHCI3) on a subsample of Fraction 1 (30 mg) gave 
seven fractions (7 mg, 7 mg, 2 mg, 3 mg, 2 mg, 3 mg, 0.5 mg), which were a 
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1 :1 mixture of the two diastereomeric products (8.7, 8.8), a 1:6 mixture of the 
two diastereomeric products (8.7, 8.8), a mixture of one product diastereomer 
and an N-acetyl compound (8.11 ), this N-acetyl compound (8.11 ), and three 
mixtures of the diastereomeric product acetates (8.9, 8.1 0). Finally, 
preparative silica gel TLC (developed four times in CHCis) on a subsample of 
Fraction 2 (15 mg) gave five fractions (5 mg, 5 mg, 2.5 mg, 1 mg, 0.5 mg), of 
which the first four fractions were approximately 9:1, 6:1, 3:1 and 1 :4 mixtures 
of the diastereomeric products (8.7, 8.8) respectively, but the fifth fraction 
consisted only of impurities. 
N-Acetyl compound (8.11 ): an oil; 1 H NMR (CDC Is) 87.37 (Ph, m), 6.11 (CH, 
d, 9.5), 5.92 (NH, broad d, 9.5), 3.46 (OCHs, s), 2.05 (OCOCHs, s) ppm. 
Diastereomeric products (8. 7, 8.8): oils; 1 H and 13C NMR data in Table 8.1; 
H REIMS m/z 194.0820 (M+-CHs, + 1.5 ppm for C1 oH 12NOs), ElMS m/z (%) 
195 (8), 194 (59), 178 (8), 177 (12), 176 (17), 133 (8), 122 (19), 121 (100), 106 
(21 ), 105 (33), 104 (22), 91 (13), 78 (1 0), 77 (32) 
Mixed diastereomeric product acetates (8.9, 8.10): an oil; 1H NMR (CDCis) 
o7.38 (Ph, m), 6.51 (NH, broad d, 9.6), 6.15 and 6.14 (HS, 2xd, 9.6), 5.23 and 
5.19 (H2, 2xq, 6.9), 3.47 and 3.45 (5-0CHs, 2xs), 2.10 and 2.07 (OCOCHs, 
2xs), 1.52 and 1.49 (CHs, 2xd, 6.8) ppm, 13C NMR (CDCis) 8170.84, 170.80 
(C=O), 169.46, 169.43 (C3), 138.94, 138.91, 128.64, 128.59, 125.77 and 
125.74 (Ph), 81.04 (CS), 70.62, 70.55 (C2), 56.20, 56.12 (5-0CH3), 20.99, 
20.96 (COCHs), 17.91, 17.88 (CHs) ppm; HREIMS m/z 220.0972 (M+-CHsO, 
-0.9 ppm for C12H 14NOs), ElMS m/z (%) 220 (1 0), 192 (21 ), 191 (83), 190 
(41), 176 (13), 162 (14), 159 (11), 136 (49), 132 (62), 131 (19), 122 (42), 121 
(1 00), 115 (30), 106 (73), 105 (75), 104 (46), 91 (34), 87 (78), 78 (23), 77 (81 ). 
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SYNTHESIS OF S-LACTIC ACID ACETATE 
Calcium L(+)-lactate (352 mg) was slurried with acetic anhydride (1 ml) 
and pyridine (1 ml) for 3 minutes at room temperature, until crystallisation 
occurred, then allowed to stand for 10 minutes. H20 (8 ml) was added and the 
solution extracted with CHCI3 (3x 6 ml). The solvent was removed under 
nitrogen and the sample pumped under vacuum to give 165 mg of viscous 
liquid, which was mostly S-lactic acid acetate (8.5), containing no more than 
28 mg of pyridine and 9 mg of acetic acid by 1H NMR spectroscopy. 
S-Lactic acid acetate (8.5): a viscous liquid; 1 H NMR (CDCI3) o5.09 (CH, q, 
7.1), 2.11 (OCOCH3, s), 1.50 (CH3, d, 7.2) ppm, 13C NMR (CDCI3) o174.94, 
170.60 (C=O), 68.85 (CH), 20.70 (COCH3), 16.97 (CH3) ppm. 
SYNTHESIS OF (SR, SS)-CH3CHOH(C=O)NHCH(OCH3)Ph 
S-Lactic acid acetate (8.5, 165 mg crude) was dissolved in pyridine 
(280 J.LI) and CH2CI2 (1 ml) and sealed under nitrogen. Thionyl chloride (123 
J.LI) was added and the mixture stirred for 10 minutes at room temperature. To 
this was added a solution of 90% PhC(OCH3)=NH (8.6, 118 mg), 
triethylamine (187 J.LI) and CH2CI2 (0.1 ml) and the resulting mixture was 
stirred at room temperature for 70 minutes. This solution was concentrated 
under nitrogen (to 1 ml), cooled in ice, and reacted with a suspension of 
sodium borohydride (500 mg) in EtOH (5 ml) for 30 minutes. The reaction was 
quenched with brine (50 ml) then this mixture extracted with CHCI3 (3x 50 ml). 
The solvent was removed to give 285 mg of a crude organic product, which 
was then subjected to silica gel column chromatography (1 0 g Davisil), 
developed in steps from CH2CI2 to MeOH/CHCI3. Three fractions (60 mg 
combined), which eluted with CHCI3, were all mixtures of the diastereomeric 
product acetates (8.9, 8.10), while two further fractions (46 mg, 30 mg), which 
also eluted with CHCI3, were an impure mixture of the diastereomeric acetates 
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(8.9, 8.10), and a 1:1 mixture of the diastereomeric products (8.7, 8.8), 
respectively. A sixth fraction (1 0 mg), which eluted with 1% MeOH/CHCis, was 
a 9:1 mixture of the two diastereomeric products (8.7, 8.8). (1H and 13C NMR 
spectroscopy and mass spectroscopy results as above). Thus the overall yield 
of acetates 8.9 and 8.10 was about 53%, with a 24% yield of 8.7 and 8.8. 
SYNTHESIS OF R-LACTIC ACID ACETATE 
Lithium 0(-)-lactate (1 00 mg) was stirred with acetic anhydride (1 ml) 
. 
and pyridine (1 ml) for 18 hours at room temperature. H20 (8 ml) was added 
and the mixture extracted with CHCis (4x 7 ml). The aqueous portion was also 
acidified and reextracted. The solvent was removed from this combined 
extract under nitrogen and the sample pumped under vacuum to give 94 mg of 
viscous liquid, which was mostly R-lactic acid acetate (8.12), containing no 
more than 14 mg of pyridine and 5 mg of acetic acid by 1H NMR spectroscopy. 
R-Lactic acid acetate (8.12): a viscous liquid; 1 H NMR (CDCis) 85.10 (CH, q, 
7.1 ), 2.12 (OCOCHs, s), 1.52 (CHs, d, 7.2) ppm. 
SYNTHESIS OF (RR, RS)-CHsCHOH(C=O)NHCH(OCH3)Ph 
R-Lactic acid acetate (8.12, 94 mg crude) was dissolved in pyridine 
(160 J.LI) and CH2CI2 (1 ml) and sealed under nitrogen. Thionyl chloride (71 
J.LI) was added and the mixture stirred for 20 minutes at room temperature. To 
this was added a solution of 90% PhC(OCHs)=NH (8.6, 70 mg), triethylamine 
(11 0 J.LI) and CH2CI2 (0.1 ml) and the resulting mixture was stirred at room 
temperature for 80 minutes. This solution was concentrated under nitrogen (to 
1 ml), cooled in ice, and reacted with a suspension of sodium borohydride 
(300 mg) in EtOH (3 ml) for 4 hours. The reaction was quenched with brine 
(50 ml) then this mixture extracted with CHCis (3x 50 ml). The solvent was 
removed to give 165 mg of a crude organic product, which was then subjected 
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to silica gel column chromatography (1 0 g Davisil), developed in steps from 
CH2CI2 to MeOH/CHCI3. Two fractions (22 mg, 60 mg), which eluted with 
CHCI3, were both mixtures of the diastereomeric product acetates (8.15, 
8.16) and a third fraction (15 mg), which also eluted with CHCI3, was a 1 :3 
mixture of these acetates and the diastereomeric products (8.13, 8.14). A 
fourth fraction (4 mg), which eluted with 1% MeOH/CHCI3, was a 4:1 mixture of 
the two diastereomeric products only (8.13, 8.14 ). (1 H and 13C NMR 
spectroscopy results were almost identical to those for the products from 
. 
S-lactic acid). Thus the overall yield of acetates 8.15 and 8.16 was about 
73%, with a 15 % yield of 8.13 and 8.14. 
Mixed diastereomeric products (8.13, 8.14): an oil; HREIMS m/z 194.0816 
(M+-CH3, -0.7 ppm for C10H12N03), ElMS m/z (%) 195 (6), 194 (49), 178 (7), 
177 (11), 176 (16), 133 (8), 122 (15), 121 (100), 106 (21), 105 (38), 104 (20), 
91 (11 ), 78 (1 0), 77 (27). 
Mixed diastereomeric product acetates (8.15, 8.16): an oil; HREIMS m/z 
220.0977 (M+-CH30, +1.7 ppm for C12H14N03), ElMS m/z (%) 220 (4), 192 
(9), 191 (57), 190 (15), 179 (4), 176 (6), 162 (6), 159 (5), 136 (14), 133 (4), 132 
(22), 122 (12), 121 (100), 115 (8), 106 (23), 105 (24), 104 (13), 91 (10), 87 
(27), 78 (6), 77 (28), 73 (6). 
453 
REFERENCES 
1. Ferguson, L. N. Chern. Soc. Rev. 1975, 4, 289. 
2. Albert, A. Selective Toxicity, 7th ed.; Chapman and Hall Ltd.: London, 
1985; pp 3-20. 
3. Albert, A. Selective Toxicity, 7th ed.; Chapman and Hall Ltd.: London, 
1985; pp 206-237. 
4. Albert, A. Selective Toxicity, 7th ed.; Chapman and Hall Ltd: London, 
1985; pp 271-281. 
5. Copp, B. R. Ph. D. Thesis; University of Canterbury, 1989; pp 3-8. 
6. Munro, M. H. G.; Blunt, J. W.; Barns, G.; Battershill, C, N.; Lake, R. J.; 
Perry, N. B. Pure Appl. Chern. 1989, 61, 529. 
7. Faulkner, D. J. Nat. Prod. Rep. 1984, 1, 251. 
8. Faulkner, D. J. Nat. Prod. Rep. 1984, 1, 551. 
9. Faulkner, D. J. Nat. Prod. Rep. 1986, 3, 1. 
10. Faulkner, D. J. Nat. Prod. Rep. 1987, 4, 539. 
1 1. Faulkner, D. J. Nat. Prod. Rep. 1988, 5, 613. 
12. Faulkner, D. J. Nat. Prod. Rep. 1990, 7, 269. 
13. Munro, M. H. G.; Luibrand, R. T.; Blunt, J. W. in Biorganic Marine 
Chemistry, edited by P. J. Scheuer; Springer-Verlag: Berlin, 1987; Vol. 
1' pp 93-176. 
14. World Health Organisation Rapid Laboratory Techniques for the 
Diagnosis of Viral Infections; WHO: Geneva, Switzerland, 1981; pp 6, 
17-25. (Technical Reports Series 661) 
15. Albert, A. Selective Toxicity, 7th ed.; Chapman and Hall Ltd.: London, 
1985; pp 21-55. 
16. Albert, A. Selective Toxicity, 7th ed.; Chapman and Hall Ltd.: London, 
1985; pp 491-509. 
454 
17. Blunt, J. W.; Munro, M. H. G.; Battershill, C.N.; Copp, B. A.; McCombs, J. 
D.; Perry, N. B.; Prinsep, M.; Thompson, A. M. New J. Chern. 1990, 14, 
761. 
18. Perry, N. B.; Blunt, J. W.; Munro, M. H. G.; Pannell, L. K. J. Am. Chern. 
Soc. 1988, 110, 4850. 
19. Perry, N. B.; Blunt, J. W.; Munro, M. H. G.; Thompson, A. M. J. Org. 
Chern. 1990, 55, 223. 
20. Carriero, G.; Madaio, A.; Mayol, L.; Piccialli, V.; Sica, D. Tetrahedron 
1989, 45, 277. 
21. Kato, Y.; Fusetani, N.; Matsunaga, S.; Hashimoto, K. Tetrahedron Lett 
1985, 26, 3483. 
22. Fusetani, N.; Yasumuro, K.; Matsunaga, S.; Hashimoto, K. Tetrahedron 
Lett. 1989, 30, 2809. 
23. Capon, R. J.; Macleod, J. K. Tetrahedron 1985, 41, 3391. 
24. Capon, A. J.; Macleod, J. K. J. Nat. Prod. 1987, 50, 225. 
25. Stonik, V. A.; Makar'eva, T. N.; Antanov, A. S.; Elyakov, G. B. Khim. Prir. 
Soedin. 1981 , 1 04. 
26. Dr. P. T. Northcote, personal communication. 
27. Cardani, C.; Ghiringhelli, D.; Mondelli, R.; Quilico, A. Tetrahedron Lett. 
1965, 2537. 
28. Cardani, C.; Ghiringhelti, D.; Quilico, A.; Selva, A. Tetrahedron Lett. 
1967, 4023. 
29. Societa Farmaceutici ltalia Brit. 932,875, July 31 1963. (CA59:11194f) 
30. Quilico, A.; Cardani, C.; Ghiringhelli, D.; Pavan, M. Chim. Ind. 1961, 43, 
1434. 
31. Sakemi, S.; lchiba, T.; Kohmoto, S.; Saucy, G.; Higa, T. J. Am. Chern. 
Soc. 1988, 110, 4851. 
32. Anon. Chern. Br. 1982, 18, 696. 
455 
33. Pavan, M.; Bo, G. Physiol. Comparata et Oecol. 1953, 3, 307. 
34. Furusaki, A.; Watanabe, T. Tetrahedron Lett. 1968, 6301. 
35. Pavan, M. Atti. Accad. Nazi. Ita/. Entomol. Rend. 1962, 10, 119. 
36. Leigheb, G.; Moroni, P.; Pavan, M. Chron. Derm.1983, 14, 357. 
37. Pavan, M. Chron. Derm.1983, 14,301. 
38. Boggio, P.; Davalli, R.; Leigheb, G.; Moroni, P.; Pavan, M. Chron. Derm. 
1985, 16, 249. 
39. Brega, A.; Falaschi, A.; De Carli, L; Pavan, M. J. Cell Bioi. 1968, 36, 
485. 
40. Soldati, M.; Fioretti, A.; Ghione, M. Experientia 1966,22, 176. 
41. Sentein, P. Caryologia, 1975, 28, 163. 
42. Jacobs-Lorena, M.; Braga, A.; Baglioni, C. Biochim. Biophys. Acta 
1971 J 240, 263. 
43. Carrasco, L.; Vazquez, D. J. Antibiotics 1972, 25, 732. 
44. Barbacid, M.; Fresno, M.; Vazquez, D. J. Antibiotics 1975, 28, 453. 
45. Carrasco, L; Battaner, E.; Vazquez, .D. Methods Enzymol. 1974, 30, 
282. 
46. Vazquez, D. Inhibitors of Protein Biosynthesis; Springer-Verlag: Berlin, 
1979; pp 1-14. 
47. Vazquez, D. Inhibitors of Protein Biosynthesis; Springer-Verlag: Berlin, 
1979; pp 155-163. 
48. Stryer, L. Biochemistry; W. H. Freeman and Co.: San Francisco, 1975; 
pp 675-6. 
49. Albert, A. Selective Toxicity, 7th ed.; Chapman and Hall Ltd.: London, 
1985; pp 143-7, 198-9. 
SO. Baglioni, C.; Jacobs-Lorena, M.; Meade, H. Biochim. Biophys. Acta 
1972, 277, 188. 
456 
51. Carrasco, L.; Fernandez-Puentes, C.; Vazquez, D. Mol. Cell. Biochem. 
1976, 10, 97. 
52. Jimenez, A.; Carrasco, L.; Vazquez, D. Biochemistry 1977, 16, 4727. 
53. GroHman, A. P.; Jarkovsky, Z. in Antibiotics Vo/111: Mechanism of Action 
of Antimicrobial and Antitumor Agents, edited by J. W. Corcoran and F. 
Hahn; Springer-Verlag: Berlin, 1975; pp 420-435. 
54. Levine, M. R.; Dancis, J.; Pavan, M.; Cox, R. P. Pediat. Res. 1974, 8, 
606. 
. 
55. Carollo-Cusimano, T. Acta Embr. Exp. 1979, 335. 
56. Bernocchi, G.; Garagna, S.; Manfredi-Romanini, M. G.; Arrigoni, E.; 
Benzi, G.; Pavan, M. Chron. Derm. 1983, 14, 353. 
57. Burres, N. S.; Clement, J. J. Cancer Res. 1989, 49, 2935. 
58. Dr. N. B. Perry, personal communication. 
59. Jennings, L., Christchurch Hospital Board, personal communication. 
60. Stryer, L. Biochemistry; W. H. Freeman and Co.: San Francisco, 1975; 
pp 726-7. 
61. Ogawara, H.; Higashi, K.; Perry, N. B. Camp. Biochim. Biophys. 1991 
(in press). 
62. Ogawara, H.; Hasumi, Y.; Higashi, K.; Ishii, Y.; Saito, T.; Watanabe, S.; 
Suzuki, K.; Kobori, M.; Tanaka, K.; Akiyama, T. J. Antibiotics 1989, 42, 
1530. 
63. Tanaka, H.; Kuroda, A.; Manusawa, H.; Hatanaka, H.; Kino, T.; Goto, T.; 
Hashimoto, M. J. Am. Chern. Soc. 1990, 109, 5031. 
64. Rosen, M. K.; Standaert, R. F.; Galat, A.; Nakatsuka, M.; Schreiber, S. L. 
Science 1990, 248, 863. 
65. Albers, M. W.; Walsh, C. T.; Schreiber, S. L J. Org. Chern. 1990, 55, 
4984. 
457 
66. Harding, M. W.; Galat, A.; Uehling, D. E.; Schreiber, S. L Nature 1989, 
341, 758. 
67. Heischkeil, R. Z. Tropenmed. Parasitol. 1973, 24, 505. (CA80:115961 h) 
68. Munro, M. H. G.; Perry, N. B.; Blunt, J. W. Eur. Pat. Appl. EP 289203, 2 
Nov 1988. (CA 110:8861 Ox) 
69. Blunt, J. W.; Munro, M. H. G.; Perry, N. B.; Thompson, A. M. U. S. US 
4868204, 19 Sep 1989. (CA 113:114949y) 
70. Kessler, H. Angew. Chern. Int. Ed. Eng. 1982, 512. 
71. Kaminski, J. J.; Puchalski, C.; Solomon, D. M.; Rizvi, R. K.; Conn, D. J.; 
Elliott, A. J.; Lovey, R. G.; Guzik, H.; Chiu, P. J. S.; Long, J. F.; McPhail, 
A. T. J. Med. Chern. 1989, 32, 1686. 
72. Loosli, H.; Kessler, H.; Oschkinat, H.; Weber, H.; Petcher, T. J.; Widmer, 
A. Helv. Chim. Acta 1985, 68, 682. 
73. lssaq, H. J.; Muschik, G. M. Int. Lab. 1988, 18. 
74. Deeg, M.; Hagenmaier, H.; Kretschmer, A. J. Antibiotics 1987, 40, 320. 
75. van den Brook, L.A. G. M.; Lazaro, E.; Zylicz, Z.; Fennis, P. J.; Missler, F. 
A. N.; Lelieveld, P.; Garzotto, M.; Wagener, D. J. T.; Ballesta, J. P. G.; 
Ottenheijm, H. C. J. J. Med. Chern. 1989, 32, 2002. 
76. Flowers, H. M in The Chemistry of the Hydroxyl Group, edited by S. 
Patai; lnterscience: London, 1971; pp 1001~1015. 
77. Ferrier, R. J.; Collins, P. M. Monosaccharide Chemistry; Penguin Books 
Ltd.: England, 1972; pp 184-195. 
78. Greene, T. W. Protective Groups in Organic Synthesis; J. Wiley and 
Sons: New York, 1981 ; pp 1 0-86. 
79. Findlay, J. A; Radics, L. Can. J. Chern 1980, 58, 579. 
80. Bax, A.; Freeman, R. J. Magn. Reson. 1981,44,542. 
81. Bax, A; Freeman, R.; Morris, G. J. Magn. Reson. 1981,42, 164. 
82. Kinns, M.; Sanders, J. K. M. J. Magn. Reson. 1984, 56, 518. 
458 
83. Perry, N. B.; Blunt, J. W.; Munro, M. H. G. Magn. Reson. Chern. 1989, 
27, 624. 
84. Perry, N. B.; Blunt, J. W.; Munro, M. H. G.; Thompson, A. M. (manuscript 
yet to be submitted for publication). 
85. Muller, L. J. Am. Chern. Soc. 1979, 101, 4481. 
86. Bax, A.; Summers, M. F. J. Am. Chern. Soc. 1986, 108, 2093. 
87. Martin, G. E.; Zektzer, A. S. Magn. Reson. Chern. 1988, 26, 631. 
88. Bax, A.; Morris, G. A. J. Magn. Reson. 1981, 42, 501. 
89. Reynolds, W. F.; Hughes, D. W.; Perpick~Dumont, M. J. Magn. Reson. 
1985, 63, 413. 
90. Matsuda, F.; Yanagiya, M.; Matsumoto, T. Tetrahedron Lett. 1982, 23, 
4043. 
91. Hong, C. Y.; Kishi, Y. J. Org. Chern. 1990, 55, 4242. 
92. Veber, D. F.; Holly, F. W.; Nutt, R. F.; Bergstrand, S. J.; Brady, S. F.; 
Hirschmann, R.; Glitzer, M.S.; Saperstein, R. Nature 1979, 280, 512. 
93. Bonamartini Corradi, A.; Mangia, A.; Nardelli, M.; Pelizzi, G. Gazz. Chim. 
/ta/.1971, 101,591. 
94. Cardani, C.; Ghiringhelli, D.; Mondelli, R.; Quilico, A. Gazz. Chirn. Ita/. 
1966, 96, 3. 
95. Matsumoto, T.; Tsutsui, S.; Yanagiya, M.; Yasuda, S.; Maeno, S.; 
Kawashima, J.; Ueta, A.; Murakami, M. Bull. Chern. Soc. Japan 1964, 
37, 1892. 
96. Silverstein, R. M.; Bassler, G. C.; Morrill, T. C. Spectrometric 
Identification of Organic Compounds, 4th ed.; J. Wiley and Sons: New 
York, 1981; pp 106-127. 
97. Selva, A. Gazz. Chirn. /tal. 1968, 98, 1464. 
459 
98. Silverstein, R. M.; Bassler, G. C.; Morrill, T. C. Spectrometric 
Identification of Organic Compounds, 4th ed.; J. Wiley and Sons: New 
York, 1981; pp 188-210. 
99. Wagner, G. J. Magn. Reson.1983, 55, 151. 
100. IUPAC Commission on the Nomenclature of Organic Chemistry Pure 
Appl. Chern. 1976, 45, 13. 
101. Silverstein, R. M.; Bassler, G. C.; Morrill, T. C. Spectrometric 
Identification of Organic Compounds, 4th ed.; J. Wiley and Sons: New 
York, 1981; pp 220-237. 
102. Sternhell, S. Quart. Rev. Chern. Soc. 1969, 23, 236. 
103. Haasnoot, C. A. G.; de Leeuw, F. A.M. M.; Altona, C. Tetrahedron 1980, 
36, 2783. 
104. Jackman, L. M.; Stern hell, S. Applications of Nuclear Magnetic 
Resonance Spectroscopy in Organic Chemistry, 2nd ed.; Pergamon 
Press Ltd.: Oxford, 1969; pp 316-344. 
105. Booth, H.; Khedhair, K. A.; Readshaw, S. A. Tetrahedron 1987, 43, 
4699. 
106. Ferrier, R. J.; Collins, P.M. Monosaccharide Chemistry; Penguin Books 
Ltd.: England, 1972; pp 32-49. 
107. Robin, M. B.; Bovey, F. A.; Basch, H. in The Chemistry of Amides, edited 
by J. Zabicky (S. Patai series editor); lnterscience: New York, 1970; pp 
1-37. 
108. Bystrov, V. F.; Ivanov, V. T.; Portnova, S. L.; Balashova, T. A.; 
Ovchinnikov, Y. A. Tetrahedron 1973, 29, 873. 
109. Mattinen, J.; Pihlaja, K.; Czombos, J.; Bartok, M. Tetrahedron 1987,43, 
2761. 
11 0. Ferrier, R. J.; Collins, P. M. Monosaccharide Chemistry; Penguin Books 
Ltd.: England, 1972; pp 214-221. 
460 
111. Swaelens, G.; Anteunis, M. Tetrahedron Lett. 1970, 561. 
112. Cahn, R. S.; Ingold, C.; Prelog, V. Angew. Chern. Int. Ed. Eng. 1966, 5, 
385. 
113. Bhatti, A. K.; Anteunis, M. Tetrahedron Lett. 1973, 71. 
114. Dalling, D. K.; Grant, D. M.; Johnson, L. F. J. Am. Chern. Soc.1971, 93, 
3678. 
115. Blunt, J. W.; Coxon, J. M.; Lindley, N. B.; Lane, G. A. Aust. J. Chern. 
1976, 29, 967. 
1 i 6. Wu, T.; Goekjian, P. G:; Kishi, Y. J. Org. Chern. 1987, 52, 4819. 
117. Silverstein, R. M.; Bassler, G. C.; Morrill, T. C. Spectrometric 
Identification of Organic Compounds, 4th ed.; J. Wiley and Sons: New 
York, i 981; pp 258-272. 
i 18. Stothers, J. B. Carbon-13 NMR Spectroscopy, (Organic Chemistry: A 
Series of Monographs, Vol. 24, edited by A. T. Blomquist and H. 
Wasserman); Academic Press: New York, 1972; pp 144-151, 295-301. 
119. Eliel, E. L.; Manoharan, M.; Pietrusiewicz, R. M.; Hargrave, K. D. Org. 
Magn. Reson. 1983, 21, 94. 
120. Dalling, D. K.; Grant, D. M. J. Am. Chern. Soc. 1972, 94, 5318. 
121. Stothers, J. B. Carbon-13 NMR Spectroscopy, (Organic Chemistry: A 
Series of Monographs, Vol. 24, edited by A. T. Blomquist and H. 
Wasserman); Academic Press: New York, 1972; pp 420-3. 
122. Cohen, N.C.; Blaney, J. M.; Humblet, C.; Gund, P.; Barry, D. C. J. Med. 
Chern. 1990, 33, 885. 
123. Jackman, L. M.; Sternhell, S. Applications of Nuclear Magnetic 
Resonance Spectroscopy in Organic Chemistry, 2nd ed.; Pergamon 
Press Ltd.: Oxford, 1969; pp 61-95. 
124. Howard, A. E.; Kollman, P. A. J. Med. Chern. 1988, 31, 1669. 
461 
125. A copy of the extensively rewritten MODEL program of C. Still (version 
KS 2.94) was provided by Professor Kosta Steliou of the University of 
Montreal. 
126. Matsumoto, T.; Yanagiya, M.; Maeno, S.; Yasuda, S. Tetrahedron Lett. 
1968, 6297. 
127. Matsuda, F.; Tomiyoshi, N.; Yanagiya, M.; Matsumoto, T. Tetrahedron 
1988,. 44, 7063. 
128. Willson, T. M.; Kocienski, P.; Jarowicki, K.; Isaac, K.; Hitchcock, P. M.; 
. 
Faller, A.; Campbell, S. F. Tetrahedron 1990, 46, 1767. 
129. Willson, T.; Kocienski, P.; Faller, A.; Campbell, S. J. Chern. Soc. Chern. 
Commun. 1987, 1 06. 
130. Matsuda, F.; Tomiyoshi, N.; Yanagiya, M.; Matsumoto, T. Tetrahedron 
Lett. 1983, 24, 1277. 
131. Greene, T. W. Protective Groups in Organic Synthesis; J. Wiley and 
Sons: New York, 1981; pp 1-9. 
132. Jarowicki, K.; Kocienski, P.; Marczak, S.; Willson, T. Tetrahedron Lett. 
1990, 31, 3433. 
133. Adams, M. A.; Duggan, A. J.; Smolanoff, J.; Meinwald, J. J. Am. Chern. 
Soc. 1979, 101, 5364. 
134. Nakata, T.; Nagao, S.; Mori, N.; Oishi, T. Tetrahedron Lett. 1985, 26, 
6461. 
135. Nakata, T.; Nagao, S.; Oishi, T. Tetrahedron Lett. 1985, 26, 6465. 
136. Corey, E. J.; Venkateswarlu, A. J. Am. Chern. Soc. 1972, 94,6190. 
137. Hurst, D. T.; Mcinnes, A. G. Can. J. Chern. 1965, 43, 2004. 
138. Greene, T. W. Protective Groups in Organic Synthesis; J. Wiley and 
Sons: New York, 1981; pp 296-314. 
139. Chapman, A. T. J. Am. Chern. Soc. 1935, 57, 419. 
462 
140. March, J. Advanced Organic Chemistry, 3rd ed.; J. Wiley and Sons: 
New York, 1985; pp 298~321. 
141. March, J. Advanced Organic Chemistry, 3rd ed.; J. Wiley and Sons: 
New York, 1985; pp 256-262. 
142. Chaudhary, S. K.; Hernandez, 0. Tetrahedron Lett. 1979, 99. 
143. Scriven, E. F. V. Chern. Soc. Rev. 1983, 12, 129. 
144. Calvo, K. C. J. Am. Chern. Soc. 1985, 107, 3690. 
145. Schneider, H.; Happen, V. J. Org. Chern. 1978, 43, 3866. 
146. March, J. Advanced Organic Chemistry, 3rd ed.; J. Wiley and Sons: 
New York, 1985; pp 290~295. 
147. Ferrier, R. J.; Collins, P.M. Monosaccharide Chemistry; Penguin Books 
Ltd.: England, 1972; pp 108-115, 124, 140. 
148. Duddeck, H. Org. Magn. Reson. 1975, 7, 151. 
149. Merz, A Angew. Chern. Int. Ed. Eng. 1973, 12, 846. 
150. Wallenfels, K.; Bechtler, G.; Kuhn, R.; Trischmann, H.; Egge, H. Angew. 
Chern. Int. Ed. Eng. 1963, 2, 515. 
151. Johnstone, R. A. W.; Rose, M. E. Tetrahedron, 1979, 35, 2169. 
152. Ley, S. V.; Neuhaus, D.; Williams, D. J. Tetrahedron Lett. 1982, 23, 
1207. 
153. Parker, A J. Chern. Rev. 1969, 69, 1. 
154. March, J. Advanced Organic Chemistry, 3rd ed.; J. Wiley and Sons: 
New York, 1985; pp 527-9. 
155. Shafer, J. A. in The Chemistry of Amides, edited by J. Zabicky (S. Patai 
series editor); lnterscience: New York, 1970; pp 697-705. 
156. Challis, B. C.; Challis, J. A in The Chemistry of Amides, edited by J. 
Zabicky (S. Patai series editor); lnterscience: New York, 1970; pp 731-
757. 
463 
157. Hopkins, G. C.; Janak, J. P.; Minnemeyer, H. J.; Tieckelmann H. J. Org. 
Chern. 1987, 32, 4040. 
158. March, J. Advanced Organic Chemistry, 3rd ed.; J. Wiley and Sons: 
New York, 1985; pp 263-5, 517. 
159. Oikawa, Y.; Yoshioka, T.; Yonemitsu, 0. Tetrahedron Lett. 1982, 23, 
885. 
160. Jackman, L. M.; Stern hell, S. Applications of Nuclear Magnetic 
Resonance Spectroscopy in Organic Chemistry, 2nd ed.; Pergamon 
Press Ltd.: Oxford, 1969; pp 270-279. 
161. Walker, D.; Hiebert, J. D. Chern. Rev. 1967, 67, 153. 
162. Chaudhary, S. K.; Hernandez, 0. Tetrahedron Lett. 1979, 95. 
163. Wratten, S. J.; Meinwald, J. Tetrahedron Lett.1980, 21,3163. 
164. Cardani, C.; Ghiringhelli, D.; Mondelli, R.; Selva, A. Gazz. Chim. Ita/. 
1973, 103, 247. 
165. Cardani, C.; Ghiringhelli, D.; Mondelli, R.; Pavan, M.; Quilico, A. Ann. 
Soc. Entomol. France 1965, 1, 813. 
166. Cardani, C.; Fuganti, C.; Ghiringhelli, D. Gazz. Chim. Ita/. 1968, 98, 
474. 
167. Miyashita, N.; Yoshikoshi, A.; Grieco, P. A. J. Org. Chern. 1977, 42, 
3772. 
168. Seebach, D.; Chow, H.; Jackson, R. F. W.; Lawson, K.; Sutter, M. A.; 
Thaisrivongs, S.; Zimmermann, J. J. Am. Chern. Soc.1985, 107,5292. 
169. Baker, G. H.; Brown, P. J.; Dorgan, R. J. J.; Everett, J. R.; Ley, S. V.; 
Slawin, A.M. Z.; Williams, D. J. Tetrahedron Lett. 1987, 28, 5565. 
170. Ferrier, R. J.; Collins, P. M. Monosaccharide Chemistry; Penguin Books 
Ltd.: England, 1972; pp 50-72. 
171. Cordes, E. H.; Bull, H. G. Chern. Rev. 1974, 74, 581. 
464 
172. March, J. Advanced Organic Chemistry, 3rd ed.; J. Wiley and Sons: 
New York, 1 985; pp 329-32. 
173. Sterzycki, R. Synthesis 1979, 724. 
174. Marshall, J. A; Conrow, R. E. J. Am. Chern. Soc. 1983, 105, 5679. 
175. Polonsky, J.; Beloeil, J.; Prange, T.; Pascard, C.; Jacquemin, H.; 
Donnelly, D. M. X.; Kenny, P. T. M. Tetrahedron, 1983, 39, 2647. 
176. March, J. Advanced Organic Chemistry, 3rd ed.; J. Wiley and Sons: 
New York, 1985; pp 873-896. 
177. March, J. Advanced Organic Chemistry, 3rd ed.; J. Wiley and Sons: 
New York, 1 985; pp 234-6. 
178. Dauben, W. G.; Michna, D. M. J. Am. Chern. Soc. 1981, 103, 2284. 
179. Kemp, D. S.; Vellaccio, F. Organic Chemistry; Worth Publishers, Inc.: 
New York, 1980; pp 850-1. 
180. Societa Farmaceutici ltalia Brit. 1 ,078,049, 2 Aug 1967. (CA68:95687v) 
181. Societa Farmaceutici ltalia Brit. 1,1 i 3,829, 15 May 1968. 
(CA69:33079k) 
182. IUPAC Commission on the Nomenclature of Organic Chemistry Pure 
Appl. Chern. 1972, 31, 285. 
183. Rylander, P. N. Hydrogenation Methods; Academic Press: London, 
1985; pp 29-52. 
184. Rylander, P. N. Hydrogenation Methods; Academic Press: London, 
1985; pp 4-11 . 
185. Rylander, P. N. Catalytic Hydrogenation over Platinum Metals; 
Academic Press: London, 1967; pp 91-107. 
186. Briggs, A J.; Glenn, R.; Jones, P. G.; Kirby, A J.; Ramaswamy, P. J. Am. 
Chern. Soc. 1984, 106, 6200. 
187. Kruse, C. G.; Jonkers, F. L.; Dert, V.; van der Gen, A. Rec. Trav. Chim. 
Pays-Bas 1979, 98, 371. 
465 
188. Kotsuki, H.; Ushio, Y.; Yoshimura, N.; Ochi, M. J. Org. Chern. 1987, 52, 
2594. 
189. Tsunoda, T.; Suzuki, M.; Noyori, R. Tetrahedron Lett. 1979, 4679. 
190. Eliel, E. L; Nowak, B. E.; Daignault, R. A; Badding, V. G. J. Org. Chern. 
1965, 30, 2441. 
191. Rylander, P. N. Hydrogenation Methods; Academic Press: London, 
1985; pp 165-168. 
192. March, J. Advanced Organic Chemistry, 3rd ed.; J. Wiley and Sons: 
New York, 1985; pp 691-9. 
193. Cocker, W.; Shannon, P. V. R.; Staniland, P. A J. Chern. Soc. C 1966, 
41. 
194. Davies, N. R. Rev. Pure Appl. Chern. 1967, 17, 83. 
195. March, J. Advanced Organic Chemistry, 3rd ed.; J. Wiley and Sons: 
New York, 1985; pp 389-394. 
196. March, J. Advanced Organic Chemistry, 3rd ed.; J. Wiley and Sons: 
New York, 1985; pp 524-7. 
197. Harrod, J. F.; Chalk, A J. J. Am. Chern. Soc. 1966, 88, 3491. 
198. March, J. Advanced Organic Chemistry, 3rd ed.; J. Wiley and Sons: 
New York, 1985; pp 735-7. 
199. Andrews, L. J. T.; Coxon, J. M.; Hartshorn, M. P. J. Org. Chern. 1969, 
34, 1126. 
200. Grant, P. K.; Weavers, R. T. Tetrahedron 1974, 30, 2385. 
201. Bastard, J.; Due, D. K.; Fetizon, M.; Francis, M. J.; Grant, P. K.; Weavers, 
R. T.; Kaneko, C.; Baddeley, G. V.; Bernassau, J.; Burfitt, I. R.; Wovkulich, 
P. M.; Wenkert, E. J. Nat. Prod. 1984, 47, 592. 
202. Berti, G. in Topics in Stereochemistry, edited by N. L. Allinger and E. L. 
Eliel; lnterscience (J. Wiley and Sons): New York, 1973; Vol. 7, pp 118-
162. 
466 
203. Fieser, L. F.; Fieser, M. Reagents for Organic Synthesis; J. Wiley and 
Sons: New York, 1967; VoL 1, pp 364-7. 
204. Fieser, M.; Fieser, L. F. Reagents for Organic Synthesis; J. Wiley and 
Sons: New York, 1974; Vol. 4, p 228. 
205. Kemp, D. S.; Vellaccio, F. Organic Chemistry; Worth Publishers, Inc.: 
New York, 1980; pp 261. 
206. Wolinsky, J.; Novak, R. W.; Erickson, K. L. J. Org. Chern. 1969, 34, 490. 
207. Wicha, J.; Zorecki, A. Tetrahedron Lett. 1974, 3059. 
208. Pilgram, K.; Pollard, G:E. J. Heterocycl. Chern. 1977, 14, 1029. 
209. Deavenport, D. L.; Harrison, C. H.; Rathburn, D. W. Org. Magn. Reson. 
1973, 5, 285. 
210. Bowman, R. E.; Campbell, A.; Tanner, E. M. J. Chern. Soc. 1963, 692. 
211 . Cort, L. A.; Stewart, R. A. J. Chern. Soc. C 1971 , 1386. 
212. Baron, M.; Hollis, D.P. Rec. Trav. Chim. Pays-Bas1965, 84, 1109. 
213. A copy of a program for the analysis of MODEL files was provided by D. 
Q. McDonald of the University of Canterbury. 
214. Saunders, M.; Houk, K. N.; Wu, Y.; Still, W. C.; Lipton, M.; Chang, G.; 
Guida, W. C. J. Am. Chern. Soc.1990, 112, 1419. 
215. Lopez-Herrera, F. J.; Pine-Gonzalez, M.S.; Planas-Ruiz, F. Tetrahedron 
Asymmetry 1990, 1, 465. 
216. Chang, G.; Guida, W. C.; Still, W. C. J. Am. Chern. Soc.1989, 111, 
4379. 
217. Cornforth, J. W. in Heterocyclic Compounds, edited by R. C. Elderiield; 
J. Wiley and Sons: New York, 1957; Vol. 5, pp· 402-3. 
218. Bishop, D. C.; Bowman, R. E.; Campbell, A.; Jones, W. A. J. Chern. Soc. 
1963, 2381. 
467 
219. Homer, R. B.; Johnson, C. D. in The Chemistry of Amides, edited by J. 
Zabicky (S. Patai series editor); lnterscience: New York, 1970; pp 187-
191' 238-240. 
220. Firestone, R. A.; Reinhold, D. F.; Gaines, W. A.; Chemerda, J. M.; 
Sletzinger, M. J. Org. Chern. 1968, 33, 1213. 
221. Boyd, G. V. in Comprehensive Heterocyclic Chemistry, edited by A. R. 
Katritzky and C. W. Rees; Pergamon Press: Oxford, 1984; Vol 6, p 213. 
222. lonescu, M.; Makkay, C. Stud. Univ. Babes-Bolyai, Ser. Chern. 1966, 
11,115. 
223. lonescu, M.; Makkay, C. Stud. Univ. Babes-Bolyai, Ser. Chern. 1968, 
13, 89. 
224. lonescu, M.; Makkay, C. Stud. Univ. Babes-Bolyai, Ser. Chern. 1968, 
13, 5. 
225. lonescu, M.; Makkay, C. Rev. Roum. Chim. 1970, 15, 265. 
226. lonescu, M.; Makkay, C. Stud. Univ. Babes-Bolyai, Ser. Chern. 1971, 
16, 61. 
227. Ferrier, R. J.; Collins, P.M. Monosaccharide Chemistry; Penguin Books 
Ltd.: England, 1972; p 75. 
228. Registry file, CAS ONLINE search. 
229. Kernan, M. R.; Malinski, T. F.; Faulkner, D. J. J. Org. Chern. 1988, 53, 
5014-20. 
230. Kemp, D. S.; Vellaccio, F. Organic Chemistry; Worth Publishers, Inc.: 
New York, 1980; pp 879-890. 
231. Kemp, D. S.; Vellaccio, F. Organic Chemistry; Worth Publishers, Inc.: 
New York, 1980; pp 1141, 1149. 
232. Kemp, D. S.; Vellaccio, F. Organic Chemistry; Worth Publishers, Inc.: 
New York, 1980; pp 839-844, 859-861. 
468 
233. Ferrier, R. J.; Collins, P. M. Monosaccharide Chemistry; Penguin Books 
Ltd.: England, 1972; pp 88-93, 173-183. 
234. Eisele, G.; Simchen, G. Synthesis 1978, 757. 
235. Kapnang, H.; Charles, G. Tetrahedron Lett. 1983, 24, 1597. 
236. Barluenga, J.; Bayon, A. M.; Campos, P.; Asensio, G.; Gonzalez-Nunez, 
E.; Molina, Y. J. Chern. Soc. Perkins Trans. 11988, 1631. 
237. Hurd, C. D. J. Chern. Educ. 1966, 43, 527. 
238. Kemp, D. S.; Vellaccio, F. Organic Chemistry; Worth Publishers, Inc.: 
New York, 1980; pp 283-306. 
239. March, J. Advanced Organic Chemistry, 3rd ed.; J. Wiley and Sons: 
New York, 1985; pp 1117-9. 
240. Tsuzuki, K.; Watanabe, T.; Yanagiya, M.; Matsumoto, T. Tetrahedron 
Lett. 1976, 4745. 
241. March, J. Advanced Organic Chemistry, 3rd ed.; J. Wiley and Sons: 
New York, 1985; pp 796-8. 
242. March, J. Advanced Organic Chemistry, 3rd ed.; J. Wiley and Sons: 
New York, 1985; pp 784-6. 
243. Parker, A. J. Quart. Rev. Chern. Soc. 1962, 16, 163. 
244. lsono, F.; lnukai, M.; Takahashi, S.; Haneishi, T. J. Antibiotics 1989, 42, 
667. 
245. Chen, R. H.; Buko, A. M.; Whittern, D. N.; McAlpine, J. B. J. Antibiotics 
1989, 42, 512. 
246. March, J. Advanced Organic Chemistry, 3rd ed.; J. Wiley and Sons: 
New York, 1985; pp 664-681, 684-5. 
247. Hutchins, R. 0.; Kandasamy, D.; Dux Ill, F.; Maryanoff, C. A.; Rotstein, D.; 
Goldsmith, B.; Burgoyne, W.; Cistone, F.; Dalessandro, J.; Puglis, J. J. 
Org. Chem.1978, 43, 2259. 
469 
248. Abraham, R. J.; Loftus, P. Proton and Carbon-13 NMR Spectroscopy; 
Heydon: London, 1978; pp 42-45. 
249. Pfeffer, P. E.; Silbert, L. S. J. Org. Chern. 1976, 41, 1373. 
250. March, J. Advanced Organic Chemistry, 3rd ed.; J. Wiley and Sons: 
New York, 1985; pp 932-4. 
251. March, J. Advanced Organic Chemistry, 3rd ed.; J. Wiley and Sons: 
New York, 1985; pp 1076-7. 
252. Willson, T. M.; Kocienski, P.; Jarowicki, K.; Isaac, K.; Faller, A.; 
. 
Campbell, S. F.; Borner, J. Tetrahedron 1990, 46, 1757. 
253. Mancuso, A. J.; Swern, D. Synthesis 1981, 165. 
254. March, J. Advanced Organic Chemistry, 3rd ed.; J. Wiley and Sons: 
New York, 1985; pp 1057-60. 
255. Corey, E. J.; Schmidt, G. Tetrahedron Lett. 1979, 399. 
256. Sharpless, K. B.; Akashi. K.; Oshima, K. Tetrahedron Lett. 1976, 2503. 
257. Partch, R. E. Tetrahedron Lett. 1964, 3071. 
258. Ferrier, R. J.; Collins, P. M. Monosaccharide Chemistry; Penguin Books 
Ltd: England, 1972; pp 82-87, 162-6, 223-5. 
259. March, J. Advanced Organic Chemistry, 3rd ed.; J. Wiley and Sons: 
New York, 1985; pp 1081-83. 
260. Ueno, Y.; Okawara, M. Tetrahedron Lett. 1976, 4597. 
261. Tomioka, H.; Oshima, K.; Nozaki, H. Tetrahedron Lett. 1982, 23, 539. 
262. Jung, M. E.; Brown, R. W. Tetrahedron Lett. 1978, 2771. 
263. Fried, J.; Sih, J. C. Tetrahedron Lett. 1973, 3899. 
264. Tomioka, H.; Takai, K.; Oshima, K.; Nozaki, H. Tetrahedron Lett. 1981, 
22, 1605. 
265. Regen, S. L. J. Org. Chern. 1974, 39, 260. 
266. Sasson, Y.; Rempel, G. L. Tetrahedron Lett. 1974, 3221. 
470 
267. Hallman, P. S.; McGarvey, B. R.; Wilkinson, G. J. Chern. Soc. A 1968, 
3143. 
268. Chatt, J.; Shaw, B. L.; Field, A. E. J. Chern. Soc. 1964, 3466. 
269. March, J. Advanced Organic Chemistry, 3rd ed.; J. Wiley and Sons: 
New York, 1985; pp 655-6. 
270. March, J. Advanced Organic Chemistry, 3rd ed.; J. Wiley and Sons: 
New York, 1985; pp 1063-5. 
271. Morrison, R. T.; Boyd, R. N. Organic Chemistry, 3rd ed.; Allyn and Bacon 
Inc.: Boston, 1973; pp 628-43, 740-1. 
272. Greene, T. W. Protective Groups in Organic Synthesis; J. Wiley and 
Sons: New York, 1981; pp 114-128. 
273. Lane, C. F. Synthesis 1975, 135. 
274. March, J. Advanced Organic Chemistry, 3rd ed.; J. Wiley and Sons: 
New York, 1985; pp 629-31. 
275. Kempf, D. J.; de Lara, E.; Stein, H. H.; Cohen, J.; Egor, D. A.; Plattner, J. 
J. J. Med. Chern. 1990, 33, 371. 
276. Isaac, K.; Kocienski, P.; Campbell, S. J. Chern. Soc. Chern. Commun. 
1983, 249. 
277. Yanagiya, M.; Matsuda, F.; Hasegawa, K.; Matsumoto, T. Tetrahedron 
Le~1982,23, 4039. 
278. Isaac, K.; Kocienski, P. J. Chern. Soc. Chern. Commun. 1982, 460. 
279. Meinwald, J. Pure Appl. Chern. 1977, 49, 1275. 
280. Yanagiya, M.; Tsuzuki, K.; Watanabe, T.; Nakajima, Y.; Matsuda, F.; 
Hasegawa, K.; Matsumoto, T. Koen Yoshishu-Tennen Yuki Kagobutsu 
Toronkai 22nd. 1979, 635. 
281. Matsumoto, T.; Yanagiya, M.; Tsuzuki, K.; Watanabe, T.; Nakajima, Y. 
Jpn. Kokai Tokkyo Koho 79,145,609, 14 Nov 1979. (CA92:146456z) 
471 
282. Mitsubishi Chemical Industries Co. Ltd. Jpn. Kokai Tokkyo Koho 80 
53,252, 18 Apr 1980. {CA93:185793x) 
283. Grove, M. D.; Weisleder, D.; Daxenbichler, M. E. Tetrahedron 1973,29, 
2715. 
284. Kruger, G. J.; du Plessis, L. M.; Grobbelaar, N. J. S. Afr. Chern. lnst. 
1976, 29, 24. 
285. March, J. Advanced Organic Chemistry, 3rd ed.; J. Wiley and Sons: 
New York, 1985; pp 792~3. 
0 
HO 
0 CH30 
Discorhabdin A {0.1) ~-Carboline (0.2) Trithiane A (0.3) 
H 
OH 
R=H: Mycalamide A {0.4) 
R=CH3: Mycalamide B (0.5) 
H 
H 
H3CO OH 
Rotalin A (0.6) Mycalisine A (0.7) 
OAc 
Mycalolide A (0.8) 
H 
Cyclic peroxide (0.9) 
Pateamine (0.1 0) 
OH 
OH 
Pederin (0.11) 
Onnamide A (0.12) 
0 
OCH3 CH3 
Emetine (0.13) Cycloheximide (0.14) 
OR 
H 
OCH3 
= 
CH3 
OR 
R=COC6H48r: Pederin di~p~bromobenzoate (1.1) 
R=COC6Hs: Pederin dibenzoate (1.2) 
0 
R;=R3=R4=Si(CH3)3, R2=H:.Mycalamide A tris~TMS ether (2.1) 
R;=R4=Si(CH3)3, R2=H, R3=CHs: Mycalamide 8 bis~TMS ether (2.2) 
R;=R2=H, R3=CH3, R4=Si(CH3)3: Mycalamide 8 18~mono~TMS ether (2.3) 
R;=R2=H, Rs=R4=Si(CH3)3: Mycalamide A 17,18-bis-TMS ether (2.4) 
R1=R2=R3=H, R4=Si(CH3)2C(CH3)3: Myc.A 18-mono-T8DMS ether (2.5) 
R1 =R2=H, R3=R4=Si(CH3)2C(CH3)3: Myc.A 17, 18-bis-T8DMS ether (2.6) 
R;=Rs=R4=Si(CHs)2C(CH3)3, R2=H: Mycalamide A tris-T8DMS ether (2.7) 
R1=R2=H, R3=CHs, R4=Si(CHs)2C(CHs)3: Myc.8 18-mono-T8DMS ... (2.8) 
R1=R4=Si(CH3)2C(CHs)3, R2=H, R3=CH3: Myc.8 bis-T8DMS ether (2.9) 
R1=R2=R3=H, R4=COCsH4Br: Myc.A 18-mono-p~bromobenzoate (2.10) 
R1 =COC6H48r, R2=R3=R4=H: Myc.A 7~mono-p-bromobenzoate (2.11) 
R1=R4=COC6H48r, R2=R3=H: Myc.A 7,18-di-p-bromobenzoate (2.12) 
R 1 =R2=H, Rs=R4=COCsH4Br: Myc.A 17, 18-di-p-bromobenzoate (2.13) 
R 1 =Rs=R4=COCsH4Br, R2=H: Mycalamide A tri-p-bromo benzoate (2.14) 
R1=COC5H4Br, R2=R4=H, Rs=CHs: Myc.B 7-mono-p-bromobenzoate (2.15) 
R1=R2=H, Rs=CHs, R4=COCsH4Br: Myc.B 18-mon~-p-bromobenzoate (2.16) 
R1=R4=COC0H4Br, R2=H, R3=CHs: Myc.B di-p-bromobenzoate (2.17) 
R1=Rs=R4=COCHs, R2=H: Mycalamide A triacetate (2.18) 
R1=R4=COCHs, R2=H, Rs=CHs: Mycalamide B diacetate (2.19) 
R1=R2=H, Rs=CHs, R4=COCHs: Mycalamide B 18-monoacetate (2.20) 
R1=COCH3, R2=R4=H, Rs=CHs: Mycalamide B 7-monoacetate (2.21) 
Ri=Rs=R4=COCH2CHs, R2=H: Mycalamide A tripropanoate (2.22) 
R1=R2=H, Rs=CHs, R4=S02CHs: Mycalamide B 18-monomesylate (2.23) 
R1=R2=CHs, Rs=R4=H: 7-Q-Methyl, N-methyl myca!amide A (2.24) 
R1=R2=R4=CHs, Rs=H: 7, 18-di-Q-Methyl, N-methyl mycalamide A (2.25) 
R1=R2=Rs=R4=CHs: 7,17,18-tri-Q-Methy!, N-methyl mycalamide A (2.26) 
R1=R2=Rs=CHs, R4=H: 7,17-di-0-Methyl, N-methyl mycalamide A (2.27) 
R1=Rs=R4=CHs, R2=H: 7,17,18-tri-0-Methyl mycalamide A (2.31) 
R1=R4=CHs, R2=Rs=H: 7, 18-di-Q-Methyl mycalamide A (2.32} 
R1=Rs=CHs, R2=R4=H: 7,17-di-0-Methyl mycalamide A (2.33) 
R1=CHs, R2=Rs=R4=H: 7-Q-Methyl mycalamide A (2.34} 
R1=R2=Rs=H, R4=CHs: 18-Q-Methyl mycalamide A (2.35) 
R1=COCH3, R2=H, Rs=R4=CHs: 17, i 8-di-0-Methyl myc.A 7-monoacet. (2.36) 
R1=Rs=CHs, R2=H, R4=COCHs: 7,17-di-0-Methyl myc.A 18-monoacet. (2.37) 
R1=R2=H, Rs=R4=CHs: i 7, 18-di-0-Methyl mycalamide A (2.38} 
R1=CH2Ph, R2=Rs=R4=H: 7-Q-Benzyl mycalamide A (2.39) 
R1=R4=CH2Ph, R2=Rs=H: 7, i 8-di-0-Benzyl mycalamide A (2.40) 
R1=R2=CH2Ph, Rs=R4=H: 7,18-di-0-Benzyl mycalamide A (2.41) 
R1=R2=R4=CH2Ph, Rs=H: 7, 18-di-0-8enzyl, N-benzyl mycalamide A (2.42) 
R1=CH2Ph, R2=R4=H, Rs=CHs: 7-0-8enzyl mycalamide 8 (2.43} 
R1=R4=CH2Ph, R2=H, Rs=CHs: 7,18-di-0-Benzyl mycalamide 8 (2.44) 
R1=R2=CH2Ph, Rs=CHs, R4=H: 7-0-Benzyl, N-benzyl mycalamide 8 (2.45) 
R1=R2=R4=CH2Ph, Rs=CHs: 7, 18-di-Q-Benzyl, N-benzyl myc.B (2.46) 
R1=H, R2=Rs=CHs: 78,17,18-tri-0-Methyl N-methyl mycalamide A (2.28) 
R1=R3=H, R2:=.CH3: 78,17-di-0-Methyl N-methyl mycalamide A (2.29) 
R1=D, R2=Rs=H: 7-Deutero, ?S-O-methyl N-methyl mycalamide A (2.30) 
H 
_ CH3 
OCH3 
7,8, 18-tri-0-Benzyl r.1ycalamide B (2.47) 
0 
H3C 
H OCH3 0 
H3C 
CH3 CH3 OH 
Pederenal (3.1) Pederinolactone (3.2) 
OH 
NH2 
OCH3 
Meropederinacetal (3.3) Pederamide (3.4) 
. OH 
OH 
Pseudopederin (3.5) 
NH~.~, 
0 
0 ~ 
H 
0 
Pederolactor:te. (3.6) R1=R2=Rs=R4=H: Pseudomycalamide A (3.7) 
R1=R2=R4=H, A3=CHs: Pseudomycalamide B (3.8) 
R1=CDs, R2=As=R4=H: 6-Trideuteromethoxy A (3.9) 
A1=CH2CH3, R2=R3=R4=H: 6-Ethoxy myc.A (3.10) 
R1=H, R2=R3=A4=COCH3: Pseudo A triacetate (3.15) 
OH 
NH 
"'·· 
H 
R 1 =R2=H: 5,6-Dehydromethoxy mycalamide A (3.11) 
R1=R2=COCH3: 5,6-Dehydromethoxy A 17,18-diacetate (3.16) 
NH 
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H 
R1=R2=R3=COCH3: ZNeomycalamide A triacetate {3.12} 
R1=Rs=COCeH4Br, R2=H: Z Neomyc.A 7,18-di-p-bromobenzoate (3.18) 
R1=R2=R3=COCH3: E Neomycalamide A triacetate (3.13) 
R 1 =R3=COC6H4Br, R2=H: E Neomyc.A 7, 18-di-p-bromobenzoate (3.19) 
OAc 
1 a-Aldehyde trag ment (3.14) 
H 
0 
OAc 
H 
11-Lactone fragment (3.17) 
R1=0CH3, R2=R3=H: Dihydro pederin (4.1) 
R1 =OH, R2=R3=H: Dihydro pseudopederin {4.2) 
R1=H, R2=R3=H: Dihydro deoxy pseudopederin (4.3) 
R1 =OCH3, R2=R3=Ac: Dihydro pederin diacetate (4.8) 
R1=H, R2=R3=Ac: Dihydro deoxy pseudopederin diacetate (4.14) 
R1=0CH3, R2=R3=R4=H: 4u-Dihydro mycalamide A (4.4) 
R1=0CH3, R2=R4=H, R3=CHs: 4a-Dihydro mycalamide B {4.6) 
R1=0H, R2=R3=R4=H: 4a.-Dihydro pseudomycalamide A (4.10) 
R1=H, R2=Rs=R4=H: 4a.-Dihydro, 6-deoxy pseudomycalamide A (4.13) 
R1=H, R2=R3=R4=Ac: 4a-Dihydro, 6-deoxy pseudomyc.A triacetate (4.15) 
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~ CH3 
OCH3 
OR 
CH3 
R=H: 4~-Dihydro mycalamide A (4.5) 
R=CH3: 4~-Dihydro mycalamide B (4.7) 
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Pederin diacetate (4.9) 
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4~-Dihydro 6S pseudomycalamide A (4.11) 
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63 Mycalamide A (4.12) 
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4a-Dihydro, 5,6-dehydromethoxy mycalamide A (4.16) 
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R=H: Mycalamide A 4a-epoxide (4.17) 
R=CH3: Mycalamide 8 4a-epoxide (4.19) 
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R=H: Mycalamide A 4~-epoxide (4.18) 
R=CH3: Mycalamide 8 4~-epoxide (4.20) 
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4-Hydrochloro, 5,6-dehydromethoxy mycalamide 8 bis-ethylcarbonate (4.21) 
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Meropederoic acid (5.1) 
R1=R2=Rs=H: Mycalamide A cis oxazolidinone (5.2) 
. R1=Rs=H, R2=CHs: Mycalamide 8 cis oxazolidinone (5.9) 
CH2 
R1=R2=Rs=R4=H: Mycalamide A trans oxazo!idinone (5.3) 
R1=R2=R4=H, Rs::::CHs: Mycalamide 8 trans oxazolidinone (5.10) 
R1 =R2=Rs=R4=COCHs: N-Acetyl myc.A trans oxazolidinone triacetate (5.13) 
R 1 =R2=Rs::::R4=CHs: 12,17,18-tri-0-Methyl, N-methyl myc.A trans oxaz. {5.14) 
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L\.4(5) Mycalamide A cis oxazolidinone (5.6) 
R1=R2=R3=R4=H: 7S Mycalamide A Cis oxazolidinone (5.7) 
R1=R2=R3=R4=CH3: 12,17,18-tri-0-Methyl, N-methyi7S A cis oxazo.(5.15) 
R 1 =R2=R3=R4=H: 7 S Mycalamide A trans oxazolidinone (5.8) 
R1=R2=R3=R4=CH3: 12,17,18-tri-0-Methyl, N-methyl 7S A trans oxazo.(5.16) 
OH 
1 OS Neomycalamide A oxazolidinone (5.11) 
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1 OR Neomycalamide A oxazolidinone (5.12) 
8,12,17,18-tetra-0-Methyl, mycalamide A cis oxazolidinone (5.17) 
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R=Ph: N-Benzyl, N-formyl fragment (6.1) 
R=H: N-Methyl, N-formyl fragment (6.2) 
R1=R3=R4=H, R2=0CH2Ph: 7-0-Benzyl 1 OR mycalamide A (6.3) 
R1=R3=H, R2=0CH2Ph, R4=CH2Ph: 7,18-di-0-Benzyi10R myc.A (6.4) 
R1=D, R2=0CH2Ph, R3=R4=H: 7-Deutero, 7-0-benzyi10R myc.A (6.10) 
R1=0CH2Ph, R2=D, R3=R4=H: 7-Deutero, 7S-Q..benzyi10R myc.A (6.13) 
R1=Rs=R4=H, R2==0H: 10R Mycalamide A (6.17) 
R1=R4=H, R2==0H, Rs=CH3: 10RMycalamide 8 (6.18) 
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R1=D, R2=CH2Ph: 7-Deutero, 7-0-benzyl, Z ii10 1 0-deformyl myc.A (6.5) 
R1=R2=H: Zii10 10-Deformyl mycalamide A (6.16) 
OH 
R1=D, R2=0CH2Ph: 7-Deutero, 7-Q-benzyl, 10R-Q-methyl myc.A (6.6) 
R1=0CH2Ph, R2=D: 7-Deutero, 7S-Q-benzyl, 10R-Q-methyl myc.A (6.9) 
OH 
R1=D, R2=0CH2Ph: 7-Deutero, 7-Q-benzyl mycalamide A (6.7) 
R1=0CH2Ph, R2=D: 7-Deutero, ?S-O-benzyl mycalamide A (6.11) 
R1=0H, R2=H: 7S Mycalamide A (6.24) 
OH 
R1=D, R2=0CH2Ph: 7-Deutero, 7-Q-benzyl, 10S-Q-methyl myc.A (6.8) 
R1=0CH2Ph, R2=D: 7-Deutero, 7S-Q-benzyl, 10S-O-methyl myc.A (6.12) 
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7-Q-Benzyl pederamide (6.14) ?S-O-Benzyl pederamide (6.15) 
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.!l1 o 1 0-Deformyl mycalamide A (6.19) 
OH 
11 R Mycalamide A trans oxazolidinone (6.20) 
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.!l11 Mycalamide A trans oxazolidinone (6.21) 
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10, i 2-0-Dihydro mycalamide A (6.22) 
OH 
H 
~ CH3 
CH:~ OCH3 
OH 
CH3 
OH 
~4(5) Mycalamide A trans oxazolidinone (6.23) 
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Pederone (7.1) 
OH 
H,cY~lcoo· 
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7 -Carboxylate 
fragment (6.25) 
H3CIOYO 
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lsopederolactone (7.2) 
E~16 18-Normycalamide B (7.3) 
OH 
Z ~ 16 1 8-Normycalamide B (7.4) 
OH 
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18-Normycalamide A 17 -aldehyde (7 .5) 
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i 8-Normycalamide A 17 -aldehyde hemiacetals (7.6) 
OH 
OH 
i 8-Normycalamide A (7.7) 
R1-R3=alkyl,aryl: (8.1) R1=R2=alkyl,aryl: (8.2) 
R1=Ph, R2=CH3: (8.3) 
Oxypinnatinine (8.4) 
0 H,C00H 
OAc 
S-Lactic acid acetate (8.5) 
PhyNH 
OCH3 
Imino ether (8.6) 
OR OR 
R=H: SR, SS Products (8.7, 8.8) 
R=Ac: SR, SS Product acetates (8.9, 8.1 0) 
0 OCH3 
H3CANH~Ph 
N-(a-Methoxybenzyl) acetamide (8.11) 
OAc 
R-Lactic acid acetate (8.12) 
OR OR 
R=H: RR, RS Products (8.13, 8.14) 
R=Ac: RR, RS Product acetates (8.15, 8.16) 
